{"text":"Among the anti-herpesvirus agents , aciclovir , valaciclovir , penciclovir , famciclovir , idoxuridine , trifluridine and brivudin are used in the treatment of herpes simplex virus and varicella-zoster virus infections , and ganciclovir , foscarnet , cidofovir , fomivirsen and maribavir ( the latter in the developmental stage ) are used in the treatment of cytomegalovirus infections .","paragraph":"<h3><u>Antiviral drugs: current state of the art.</u></h3>The chemotherapy of virus infections has definitely come of age. There are now 15 antiviral agents that have been formally licensed for the treatment of human immunodeficiency virus infections (<b style='color:Tomato;'><i>zidovudine</i></b>, <b style='color:Tomato;'><i>didanosine</i></b>, <b style='color:Tomato;'><i>zalcitabine</i></b>, <b style='color:Tomato;'><i>stavudine</i></b>, <b style='color:Tomato;'><i>lamivudine</i></b>, <b style='color:Tomato;'><i>abacavir</i></b>, <b style='color:Tomato;'><i>nevirapine</i></b>, <b style='color:Tomato;'><i>delavirdine</i></b>, <b style='color:Tomato;'><i>efavirenz</i></b>, <b style='color:Tomato;'><i>saquinavir</i></b>, <b style='color:Tomato;'><i>ritonavir</i></b>, <b style='color:Tomato;'><i>indinavir</i></b>, <b style='color:Tomato;'><i>nelfinavir</i></b>, <b style='color:Tomato;'><i>amprenavir</i></b>, <b style='color:Tomato;'><i>lopinavir</i></b>) and several others, such as <b style='color:Tomato;'><i>tenofovir</i></b> disoproxil, <b style='color:Tomato;'><i>emtricitabine</i></b>, capravirine, emivirine, T-20 (pentafuside) and AMD3100 (bicyclam) are under clinical development. Lamivudine has been approved, and several other compounds (such as <b style='color:Tomato;'><i>adefovir</i></b> dipivoxil, <b style='color:Tomato;'><i>emtricitabine</i></b> and <b style='color:Tomato;'><i>entecavir</i></b>) are under clinical development, for the treatment of hepatitis B virus infections. <b style='color:DodgerBlue;'><i>Among</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>anti-herpesvirus</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>aciclovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>valaciclovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>penciclovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>famciclovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>idoxuridine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>trifluridine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>brivudin</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>herpes</i></b> <b style='color:DodgerBlue;'><i>simplex</i></b> <b style='color:DodgerBlue;'><i>virus</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>varicella-zoster</i></b> <b style='color:DodgerBlue;'><i>virus</i></b> <b style='color:DodgerBlue;'><i>infections</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ganciclovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>foscarnet</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cidofovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>fomivirsen</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>maribavir</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>latter</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>developmental</i></b> <b style='color:DodgerBlue;'><i>stage</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cytomegalovirus</i></b> <b style='color:DodgerBlue;'><i>infections</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Following <b style='color:Tomato;'><i>amantadine</i></b> and <b style='color:Tomato;'><i>rimantadine</i></b>, the neuraminidase inhibitors, <b style='color:Tomato;'><i>zanamivir</i></b> and <b style='color:Tomato;'><i>oseltamivir</i></b>, have now become available for the therapy and prophylaxis of influenza virus infections, and so is <b style='color:Tomato;'><i>ribavirin</i></b> for the treatment of respiratory syncytial virus infections and the combination of <b style='color:Tomato;'><i>ribavirin</i></b> with interferon-alpha for the treatment of hepatitis C virus infections.","tokens":[{"text":"Among","start":0,"end":5,"id":0,"ws":true},{"text":"the","start":6,"end":9,"id":1,"ws":true},{"text":"anti-herpesvirus","start":10,"end":26,"id":2,"ws":true},{"text":"agents","start":27,"end":33,"id":3,"ws":true},{"text":",","start":34,"end":35,"id":4,"ws":true},{"text":"aciclovir","start":36,"end":45,"id":5,"ws":true},{"text":",","start":46,"end":47,"id":6,"ws":true},{"text":"valaciclovir","start":48,"end":60,"id":7,"ws":true},{"text":",","start":61,"end":62,"id":8,"ws":true},{"text":"penciclovir","start":63,"end":74,"id":9,"ws":true},{"text":",","start":75,"end":76,"id":10,"ws":true},{"text":"famciclovir","start":77,"end":88,"id":11,"ws":true},{"text":",","start":89,"end":90,"id":12,"ws":true},{"text":"idoxuridine","start":91,"end":102,"id":13,"ws":true},{"text":",","start":103,"end":104,"id":14,"ws":true},{"text":"trifluridine","start":105,"end":117,"id":15,"ws":true},{"text":"and","start":118,"end":121,"id":16,"ws":true},{"text":"brivudin","start":122,"end":130,"id":17,"ws":true},{"text":"are","start":131,"end":134,"id":18,"ws":true},{"text":"used","start":135,"end":139,"id":19,"ws":true},{"text":"in","start":140,"end":142,"id":20,"ws":true},{"text":"the","start":143,"end":146,"id":21,"ws":true},{"text":"treatment","start":147,"end":156,"id":22,"ws":true},{"text":"of","start":157,"end":159,"id":23,"ws":true},{"text":"herpes","start":160,"end":166,"id":24,"ws":true},{"text":"simplex","start":167,"end":174,"id":25,"ws":true},{"text":"virus","start":175,"end":180,"id":26,"ws":true},{"text":"and","start":181,"end":184,"id":27,"ws":true},{"text":"varicella-zoster","start":185,"end":201,"id":28,"ws":true},{"text":"virus","start":202,"end":207,"id":29,"ws":true},{"text":"infections","start":208,"end":218,"id":30,"ws":true},{"text":",","start":219,"end":220,"id":31,"ws":true},{"text":"and","start":221,"end":224,"id":32,"ws":true},{"text":"ganciclovir","start":225,"end":236,"id":33,"ws":true},{"text":",","start":237,"end":238,"id":34,"ws":true},{"text":"foscarnet","start":239,"end":248,"id":35,"ws":true},{"text":",","start":249,"end":250,"id":36,"ws":true},{"text":"cidofovir","start":251,"end":260,"id":37,"ws":true},{"text":",","start":261,"end":262,"id":38,"ws":true},{"text":"fomivirsen","start":263,"end":273,"id":39,"ws":true},{"text":"and","start":274,"end":277,"id":40,"ws":true},{"text":"maribavir","start":278,"end":287,"id":41,"ws":true},{"text":"(","start":288,"end":289,"id":42,"ws":true},{"text":"the","start":290,"end":293,"id":43,"ws":true},{"text":"latter","start":294,"end":300,"id":44,"ws":true},{"text":"in","start":301,"end":303,"id":45,"ws":true},{"text":"the","start":304,"end":307,"id":46,"ws":true},{"text":"developmental","start":308,"end":321,"id":47,"ws":true},{"text":"stage","start":322,"end":327,"id":48,"ws":true},{"text":")","start":328,"end":329,"id":49,"ws":true},{"text":"are","start":330,"end":333,"id":50,"ws":true},{"text":"used","start":334,"end":338,"id":51,"ws":true},{"text":"in","start":339,"end":341,"id":52,"ws":true},{"text":"the","start":342,"end":345,"id":53,"ws":true},{"text":"treatment","start":346,"end":355,"id":54,"ws":true},{"text":"of","start":356,"end":358,"id":55,"ws":true},{"text":"cytomegalovirus","start":359,"end":374,"id":56,"ws":true},{"text":"infections","start":375,"end":385,"id":57,"ws":true},{"text":".","start":386,"end":387,"id":58,"ws":false}],"spans":[{"start":36,"end":45,"token_start":5,"token_end":5,"label":"DRUG"},{"start":48,"end":60,"token_start":7,"token_end":7,"label":"DRUG"},{"start":63,"end":74,"token_start":9,"token_end":9,"label":"DRUG"},{"start":77,"end":88,"token_start":11,"token_end":11,"label":"DRUG"},{"start":91,"end":102,"token_start":13,"token_end":13,"label":"DRUG"},{"start":105,"end":117,"token_start":15,"token_end":15,"label":"DRUG"},{"start":225,"end":236,"token_start":33,"token_end":33,"label":"DRUG"},{"start":239,"end":248,"token_start":35,"token_end":35,"label":"DRUG"},{"start":251,"end":260,"token_start":37,"token_end":37,"label":"DRUG"}],"_input_hash":1265321677,"_task_hash":1758490147,"_session_id":"drug_drug_pilot_shared-yosi","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The present study examined the efficacy of single and combined treatment with an anticholinesterase , tetrahydroaminoacridine ( i.p . ) , and a glycine-B site partial agonist , D-cycloserine ( i.p . ; a positive allosteric modulator of NMDA receptors ) , in alleviating the deficit in water maze spatial navigation induced by electrolytic lesion of the medial septum or lidocaine infusion into the dorsal hippocampi .","paragraph":"<h3><u>Tetrahydroaminoacridine and D-cycloserine fail to alleviate the water maze spatial navigation defect induced by hippocampal inactivation.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>examined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>anticholinesterase</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>tetrahydroaminoacridine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>i.p</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>glycine-B</i></b> <b style='color:DodgerBlue;'><i>site</i></b> <b style='color:DodgerBlue;'><i>partial</i></b> <b style='color:DodgerBlue;'><i>agonist</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>D-cycloserine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>i.p</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>positive</i></b> <b style='color:DodgerBlue;'><i>allosteric</i></b> <b style='color:DodgerBlue;'><i>modulator</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>NMDA</i></b> <b style='color:DodgerBlue;'><i>receptors</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>alleviating</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>deficit</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>water</i></b> <b style='color:DodgerBlue;'><i>maze</i></b> <b style='color:DodgerBlue;'><i>spatial</i></b> <b style='color:DodgerBlue;'><i>navigation</i></b> <b style='color:DodgerBlue;'><i>induced</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>electrolytic</i></b> <b style='color:DodgerBlue;'><i>lesion</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>medial</i></b> <b style='color:DodgerBlue;'><i>septum</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>lidocaine</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>dorsal</i></b> <b style='color:DodgerBlue;'><i>hippocampi</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In medial septum-lesioned rats, a combination of tetrahydroaminoacridine 3 mg kg(-1) and D-cycloserine 10 mg kg(-1) facilitated acquisition of the water maze test more effectively than either of the drugs alone. Single or combined treatment with tetrahydroaminoacridine 3 mg kg(-1) and D-cycloserine 10 mg kg(-1) had no effect on the water maze deficit induced by hippocampal <b style='color:Tomato;'><i>lidocaine</i></b> infusion. These results suggest that combined treatment with tetrahydroaminoacridine and D-cycloserine can effectively stimulate water maze spatial navigation, and that functioning of the hippocampus is a prerequisite for this effect.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"present","start":4,"end":11,"id":1,"ws":true},{"text":"study","start":12,"end":17,"id":2,"ws":true},{"text":"examined","start":18,"end":26,"id":3,"ws":true},{"text":"the","start":27,"end":30,"id":4,"ws":true},{"text":"efficacy","start":31,"end":39,"id":5,"ws":true},{"text":"of","start":40,"end":42,"id":6,"ws":true},{"text":"single","start":43,"end":49,"id":7,"ws":true},{"text":"and","start":50,"end":53,"id":8,"ws":true},{"text":"combined","start":54,"end":62,"id":9,"ws":true},{"text":"treatment","start":63,"end":72,"id":10,"ws":true},{"text":"with","start":73,"end":77,"id":11,"ws":true},{"text":"an","start":78,"end":80,"id":12,"ws":true},{"text":"anticholinesterase","start":81,"end":99,"id":13,"ws":true},{"text":",","start":100,"end":101,"id":14,"ws":true},{"text":"tetrahydroaminoacridine","start":102,"end":125,"id":15,"ws":true},{"text":"(","start":126,"end":127,"id":16,"ws":true},{"text":"i.p","start":128,"end":131,"id":17,"ws":true},{"text":".","start":132,"end":133,"id":18,"ws":true},{"text":")","start":134,"end":135,"id":19,"ws":true},{"text":",","start":136,"end":137,"id":20,"ws":true},{"text":"and","start":138,"end":141,"id":21,"ws":true},{"text":"a","start":142,"end":143,"id":22,"ws":true},{"text":"glycine-B","start":144,"end":153,"id":23,"ws":true},{"text":"site","start":154,"end":158,"id":24,"ws":true},{"text":"partial","start":159,"end":166,"id":25,"ws":true},{"text":"agonist","start":167,"end":174,"id":26,"ws":true},{"text":",","start":175,"end":176,"id":27,"ws":true},{"text":"D-cycloserine","start":177,"end":190,"id":28,"ws":true},{"text":"(","start":191,"end":192,"id":29,"ws":true},{"text":"i.p","start":193,"end":196,"id":30,"ws":true},{"text":".","start":197,"end":198,"id":31,"ws":true},{"text":";","start":199,"end":200,"id":32,"ws":true},{"text":"a","start":201,"end":202,"id":33,"ws":true},{"text":"positive","start":203,"end":211,"id":34,"ws":true},{"text":"allosteric","start":212,"end":222,"id":35,"ws":true},{"text":"modulator","start":223,"end":232,"id":36,"ws":true},{"text":"of","start":233,"end":235,"id":37,"ws":true},{"text":"NMDA","start":236,"end":240,"id":38,"ws":true},{"text":"receptors","start":241,"end":250,"id":39,"ws":true},{"text":")","start":251,"end":252,"id":40,"ws":true},{"text":",","start":253,"end":254,"id":41,"ws":true},{"text":"in","start":255,"end":257,"id":42,"ws":true},{"text":"alleviating","start":258,"end":269,"id":43,"ws":true},{"text":"the","start":270,"end":273,"id":44,"ws":true},{"text":"deficit","start":274,"end":281,"id":45,"ws":true},{"text":"in","start":282,"end":284,"id":46,"ws":true},{"text":"water","start":285,"end":290,"id":47,"ws":true},{"text":"maze","start":291,"end":295,"id":48,"ws":true},{"text":"spatial","start":296,"end":303,"id":49,"ws":true},{"text":"navigation","start":304,"end":314,"id":50,"ws":true},{"text":"induced","start":315,"end":322,"id":51,"ws":true},{"text":"by","start":323,"end":325,"id":52,"ws":true},{"text":"electrolytic","start":326,"end":338,"id":53,"ws":true},{"text":"lesion","start":339,"end":345,"id":54,"ws":true},{"text":"of","start":346,"end":348,"id":55,"ws":true},{"text":"the","start":349,"end":352,"id":56,"ws":true},{"text":"medial","start":353,"end":359,"id":57,"ws":true},{"text":"septum","start":360,"end":366,"id":58,"ws":true},{"text":"or","start":367,"end":369,"id":59,"ws":true},{"text":"lidocaine","start":370,"end":379,"id":60,"ws":true},{"text":"infusion","start":380,"end":388,"id":61,"ws":true},{"text":"into","start":389,"end":393,"id":62,"ws":true},{"text":"the","start":394,"end":397,"id":63,"ws":true},{"text":"dorsal","start":398,"end":404,"id":64,"ws":true},{"text":"hippocampi","start":405,"end":415,"id":65,"ws":true},{"text":".","start":416,"end":417,"id":66,"ws":false}],"spans":[{"start":177,"end":190,"token_start":28,"token_end":28,"label":"DRUG"},{"start":370,"end":379,"token_start":60,"token_end":60,"label":"DRUG"}],"_input_hash":1944915333,"_task_hash":1724675945,"_session_id":"drug_drug_pilot_shared-yosi","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"He was initially treated with combination chemotherapy regimen of vincristine , actinomycin-D and cyclophosphamide ( VAC therapy ) .","paragraph":"<h3><u>[Rhabdomyosarcoma of the bladder: a case report].</u></h3>A 15-year-old man with the chief complaint of general fatigue was referred to our hospital on November 11, 1993. Bilateral percutaneous nephrostomy was performed for postrenal anuria. X-ray examinations revealed a huge intrapelvic tumor, and it was histopathologically diagnosed as rhabdomyosarcoma by transrectal needle biopsy. <b style='color:DodgerBlue;'><i>He</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>initially</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>actinomycin-D</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>VAC</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Pelvic exenteration was performed on December 15, 1993. Histopathological findings were alveolar rhabdomyosarcoma with degenerative change and partial necrosis. After the operation, he was given two course of VAC therapy. In May, 1994, brain metastasis occurred, so 4 courses of VAC therapy were administered. For a very short period, neurological symptoms improved, but he died of pneumonia on November 15, 1994.","tokens":[{"text":"He","start":0,"end":2,"id":0,"ws":true},{"text":"was","start":3,"end":6,"id":1,"ws":true},{"text":"initially","start":7,"end":16,"id":2,"ws":true},{"text":"treated","start":17,"end":24,"id":3,"ws":true},{"text":"with","start":25,"end":29,"id":4,"ws":true},{"text":"combination","start":30,"end":41,"id":5,"ws":true},{"text":"chemotherapy","start":42,"end":54,"id":6,"ws":true},{"text":"regimen","start":55,"end":62,"id":7,"ws":true},{"text":"of","start":63,"end":65,"id":8,"ws":true},{"text":"vincristine","start":66,"end":77,"id":9,"ws":true},{"text":",","start":78,"end":79,"id":10,"ws":true},{"text":"actinomycin-D","start":80,"end":93,"id":11,"ws":true},{"text":"and","start":94,"end":97,"id":12,"ws":true},{"text":"cyclophosphamide","start":98,"end":114,"id":13,"ws":true},{"text":"(","start":115,"end":116,"id":14,"ws":true},{"text":"VAC","start":117,"end":120,"id":15,"ws":true},{"text":"therapy","start":121,"end":128,"id":16,"ws":true},{"text":")","start":129,"end":130,"id":17,"ws":true},{"text":".","start":131,"end":132,"id":18,"ws":false}],"spans":[{"start":66,"end":77,"token_start":9,"token_end":9,"label":"DRUG"},{"start":98,"end":114,"token_start":13,"token_end":13,"label":"DRUG"}],"_input_hash":1557412523,"_task_hash":-2119098685,"_session_id":"drug_drug_pilot_shared-yosi","_view_id":"blocks","relations":[{"head":9,"child":13,"head_span":{"start":66,"end":77,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":98,"end":114,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":11,"child":13,"head_span":{"start":80,"end":93,"token_start":11,"token_end":11,"label":null},"child_span":{"start":98,"end":114,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"However , when a lung mass was noted two months later , he started to receive combination chemotherapy consisting of cyclophosphamide , adriamycin , vincristine , and prednisolone every three months .","paragraph":"<h3><u>[Lymphomatoid granulomatosis (LYG) occurring in a patient with follicular lymphoma during remission].</u></h3>A 49 years-old man presented with dry cough, low grade fever, and abnormal shadow on a chest X-ray. He had suffered from follicular lymphoma of the liver 5 years previously. He received irradiation therapy in combination with chemotherapy for approximately three years and had been in complete remission. Physical and radiological examination revealed pleural effusion and softly dense masses in the right lung. The laboratory data were within normal limits. He was diagnosed as having lymphomatoid granulomatosis (LYG) by open lung biopsy. The lung lesion was mainly infiltrated with T cells. The patient received <b style='color:Tomato;'><i>prednisolone</i></b> and the lung lesions disappeared. <b style='color:DodgerBlue;'><i>However</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>lung</i></b> <b style='color:DodgerBlue;'><i>mass</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>noted</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>later</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>he</i></b> <b style='color:DodgerBlue;'><i>started</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>receive</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>consisting</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>adriamycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>prednisolone</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>three</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>.</i></b> He has not shown relapse of LYG so far. To investigate the association between the preceding follicular lymphoma and subsequent LYG at this time, DNA analysis using the PCR technique was carried out. The LYG lesion did not show a rearranged band for the JH probe, while the paraffin-embedded specimen of the preceding follicular lymphoma had shown rearranged band for the JH band. Southern blot analysis of the LYG lesion, showed no rearrangement for TCR beta, gamma or JH probe. These findings indicate that the LYG was different from the preceding follicular lymphoma in terms of origin. LYG is considered to be induced in the immunosuppressive state due to lymphoma.","tokens":[{"text":"However","start":0,"end":7,"id":0,"ws":true},{"text":",","start":8,"end":9,"id":1,"ws":true},{"text":"when","start":10,"end":14,"id":2,"ws":true},{"text":"a","start":15,"end":16,"id":3,"ws":true},{"text":"lung","start":17,"end":21,"id":4,"ws":true},{"text":"mass","start":22,"end":26,"id":5,"ws":true},{"text":"was","start":27,"end":30,"id":6,"ws":true},{"text":"noted","start":31,"end":36,"id":7,"ws":true},{"text":"two","start":37,"end":40,"id":8,"ws":true},{"text":"months","start":41,"end":47,"id":9,"ws":true},{"text":"later","start":48,"end":53,"id":10,"ws":true},{"text":",","start":54,"end":55,"id":11,"ws":true},{"text":"he","start":56,"end":58,"id":12,"ws":true},{"text":"started","start":59,"end":66,"id":13,"ws":true},{"text":"to","start":67,"end":69,"id":14,"ws":true},{"text":"receive","start":70,"end":77,"id":15,"ws":true},{"text":"combination","start":78,"end":89,"id":16,"ws":true},{"text":"chemotherapy","start":90,"end":102,"id":17,"ws":true},{"text":"consisting","start":103,"end":113,"id":18,"ws":true},{"text":"of","start":114,"end":116,"id":19,"ws":true},{"text":"cyclophosphamide","start":117,"end":133,"id":20,"ws":true},{"text":",","start":134,"end":135,"id":21,"ws":true},{"text":"adriamycin","start":136,"end":146,"id":22,"ws":true},{"text":",","start":147,"end":148,"id":23,"ws":true},{"text":"vincristine","start":149,"end":160,"id":24,"ws":true},{"text":",","start":161,"end":162,"id":25,"ws":true},{"text":"and","start":163,"end":166,"id":26,"ws":true},{"text":"prednisolone","start":167,"end":179,"id":27,"ws":true},{"text":"every","start":180,"end":185,"id":28,"ws":true},{"text":"three","start":186,"end":191,"id":29,"ws":true},{"text":"months","start":192,"end":198,"id":30,"ws":true},{"text":".","start":199,"end":200,"id":31,"ws":false}],"spans":[{"start":117,"end":133,"token_start":20,"token_end":20,"label":"DRUG"},{"start":149,"end":160,"token_start":24,"token_end":24,"label":"DRUG"},{"start":167,"end":179,"token_start":27,"token_end":27,"label":"DRUG"}],"_input_hash":8987266,"_task_hash":528717002,"_session_id":"drug_drug_pilot_shared-yosi","_view_id":"blocks","relations":[{"head":20,"child":24,"head_span":{"start":117,"end":133,"token_start":20,"token_end":20,"label":"DRUG"},"child_span":{"start":149,"end":160,"token_start":24,"token_end":24,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":24,"child":27,"head_span":{"start":149,"end":160,"token_start":24,"token_end":24,"label":"DRUG"},"child_span":{"start":167,"end":179,"token_start":27,"token_end":27,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":22,"child":24,"head_span":{"start":136,"end":146,"token_start":22,"token_end":22,"label":null},"child_span":{"start":149,"end":160,"token_start":24,"token_end":24,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T1"],"answer":"accept"}
{"text":"Three patients treated initially with propranolol alone have required substitution of amiodarone due to refractory congestive heart failure .","paragraph":"<h3><u>The role of beta-blockade therapy for ventricular tachycardia induced with isoproterenol: a prospective analysis.</u></h3>Isoproterenol is sometimes required for ventricular tachycardia (VT) induction. However, the role of beta-blockade for treatment of such VT has not been critically assessed. The use of beta-blockade was evaluated prospectively in 14 consecutive patients who required isoproterenol 2.4 +/- 1.3 (+/- S.D.) micrograms/min to induce sustained monomorphic VT (greater than 30 seconds, or requiring termination due to hemodynamic collapse) after a negative baseline study. The VT mechanisms were enhanced automaticity (group A, six patients), triggered automaticity (group B, three patients), and reentry (group C, five patients). Groups A and B had serial intravenous electropharmacologic tests with <b style='color:Tomato;'><i>propranolol</i></b> alone (0.2 mg/kg), <b style='color:Tomato;'><i>verapamil</i></b> alone (0.15 mg/kg), and <b style='color:Tomato;'><i>propranolol</i></b> plus <b style='color:Tomato;'><i>verapamil</i></b>, and group C had serial tests with <b style='color:Tomato;'><i>propranolol</i></b> alone, <b style='color:Tomato;'><i>procainamide</i></b> or <b style='color:Tomato;'><i>quinidine</i></b> (class Ia drug) alone, and <b style='color:Tomato;'><i>propranolol</i></b> plus a class Ia drug until VT could no longer be induced. All six patients in group A responded to <b style='color:Tomato;'><i>propranolol</i></b> alone. In group B, one patient responded to <b style='color:Tomato;'><i>verapamil</i></b> alone, and two patients responded to <b style='color:Tomato;'><i>propranolol</i></b> plus <b style='color:Tomato;'><i>verapamil</i></b>. In group C, three patients responded to <b style='color:Tomato;'><i>propranolol</i></b> alone, one patient responded to a class Ia drug alone, and one patient responded to <b style='color:Tomato;'><i>propranolol</i></b> plus a class Ia drug. During a follow-up of 7 to 37 (17.9 +/- 10.7) (+/- S.D.) months, VT has not recurred in any patient. <b style='color:DodgerBlue;'><i>Three</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>initially</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>propranolol</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>required</i></b> <b style='color:DodgerBlue;'><i>substitution</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>amiodarone</i></b> <b style='color:DodgerBlue;'><i>due</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>refractory</i></b> <b style='color:DodgerBlue;'><i>congestive</i></b> <b style='color:DodgerBlue;'><i>heart</i></b> <b style='color:DodgerBlue;'><i>failure</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In patients requiring isoproterenol for VT induction, beta-blockade alone appears to be effective in preventing reinduction of VT caused by enhanced automaticity. A heterogeneous response occurs when the VT mechanisms are triggered automaticity or reentry.","tokens":[{"text":"Three","start":0,"end":5,"id":0,"ws":true},{"text":"patients","start":6,"end":14,"id":1,"ws":true},{"text":"treated","start":15,"end":22,"id":2,"ws":true},{"text":"initially","start":23,"end":32,"id":3,"ws":true},{"text":"with","start":33,"end":37,"id":4,"ws":true},{"text":"propranolol","start":38,"end":49,"id":5,"ws":true},{"text":"alone","start":50,"end":55,"id":6,"ws":true},{"text":"have","start":56,"end":60,"id":7,"ws":true},{"text":"required","start":61,"end":69,"id":8,"ws":true},{"text":"substitution","start":70,"end":82,"id":9,"ws":true},{"text":"of","start":83,"end":85,"id":10,"ws":true},{"text":"amiodarone","start":86,"end":96,"id":11,"ws":true},{"text":"due","start":97,"end":100,"id":12,"ws":true},{"text":"to","start":101,"end":103,"id":13,"ws":true},{"text":"refractory","start":104,"end":114,"id":14,"ws":true},{"text":"congestive","start":115,"end":125,"id":15,"ws":true},{"text":"heart","start":126,"end":131,"id":16,"ws":true},{"text":"failure","start":132,"end":139,"id":17,"ws":true},{"text":".","start":140,"end":141,"id":18,"ws":false}],"spans":[{"start":38,"end":49,"token_start":5,"token_end":5,"label":"DRUG"},{"start":86,"end":96,"token_start":11,"token_end":11,"label":"DRUG"}],"_input_hash":-632828286,"_task_hash":-1526074177,"_session_id":"drug_drug_pilot_shared-yosi","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"We used MCF-7 and MDA-MB231 breast cancer cells incubated with Curcumin and Quercetin for 24h , in the absence and presence of Somatostatin , at their EC50 concentrations , to evaluate membrane fatty acid-based functional lipidomics together with the follow-up of EGFR and MAPK signaling pathways .","paragraph":"<h3><u>Effects of Somatostatin, Curcumin and Quercetin on the fatty acid profile of breast cancer cell membranes.</u></h3> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>MCF-7</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>MDA-MB231</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>incubated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>Curcumin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Quercetin</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>24h</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>absence</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>presence</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>Somatostatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>EC50</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>membrane</i></b> <b style='color:DodgerBlue;'><i>fatty</i></b> <b style='color:DodgerBlue;'><i>acid-based</i></b> <b style='color:DodgerBlue;'><i>functional</i></b> <b style='color:DodgerBlue;'><i>lipidomics</i></b> <b style='color:DodgerBlue;'><i>together</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>follow-up</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>EGFR</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>MAPK</i></b> <b style='color:DodgerBlue;'><i>signaling</i></b> <b style='color:DodgerBlue;'><i>pathways</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The two cell lines gave different membrane free fatty acid reorganization: in MCF-7 cells, the following changes observed: increase of omega-6 linoleic acid in the cells incubated with Somatostatin+Quercetin and Quercetin and decrease of omega-3 acids in the cells incubated with Somatostatin+Curcumin compared to Somatostatin, and significant increases of monounsaturated fatty acid (MUFA), mono-trans arachidonic acid levels and docosapentaenoic acid for the cells incubated with Somatostatin+Quercetin compared to the control cells. In MDA-MB231 cells, incubations with Curcumin, Quercetin and Somatostatin+Quercetin induced the most significant membrane remodeling with the increase of stearic acid, diminution of omega-6 linoleic, arachidonic acids and omega-3 (docosapentaenoic and docosahexaenoic acids). Distinct signaling pathway changes were found for these cell lines. In MCF-7 cells, separate or combined incubations with Somatostatin and Quercetin, significantly decreased EGFR and incubation with Curcumin decreased MAPK signaling. In MDA-MB231 cells, incubation with Curcumin decreased AKT1 and p-AKT1(Thr308) levels. Incubation with Curcumin and Quercetin decreased the EGFR levels.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"used","start":3,"end":7,"id":1,"ws":true},{"text":"MCF-7","start":8,"end":13,"id":2,"ws":true},{"text":"and","start":14,"end":17,"id":3,"ws":true},{"text":"MDA-MB231","start":18,"end":27,"id":4,"ws":true},{"text":"breast","start":28,"end":34,"id":5,"ws":true},{"text":"cancer","start":35,"end":41,"id":6,"ws":true},{"text":"cells","start":42,"end":47,"id":7,"ws":true},{"text":"incubated","start":48,"end":57,"id":8,"ws":true},{"text":"with","start":58,"end":62,"id":9,"ws":true},{"text":"Curcumin","start":63,"end":71,"id":10,"ws":true},{"text":"and","start":72,"end":75,"id":11,"ws":true},{"text":"Quercetin","start":76,"end":85,"id":12,"ws":true},{"text":"for","start":86,"end":89,"id":13,"ws":true},{"text":"24h","start":90,"end":93,"id":14,"ws":true},{"text":",","start":94,"end":95,"id":15,"ws":true},{"text":"in","start":96,"end":98,"id":16,"ws":true},{"text":"the","start":99,"end":102,"id":17,"ws":true},{"text":"absence","start":103,"end":110,"id":18,"ws":true},{"text":"and","start":111,"end":114,"id":19,"ws":true},{"text":"presence","start":115,"end":123,"id":20,"ws":true},{"text":"of","start":124,"end":126,"id":21,"ws":true},{"text":"Somatostatin","start":127,"end":139,"id":22,"ws":true},{"text":",","start":140,"end":141,"id":23,"ws":true},{"text":"at","start":142,"end":144,"id":24,"ws":true},{"text":"their","start":145,"end":150,"id":25,"ws":true},{"text":"EC50","start":151,"end":155,"id":26,"ws":true},{"text":"concentrations","start":156,"end":170,"id":27,"ws":true},{"text":",","start":171,"end":172,"id":28,"ws":true},{"text":"to","start":173,"end":175,"id":29,"ws":true},{"text":"evaluate","start":176,"end":184,"id":30,"ws":true},{"text":"membrane","start":185,"end":193,"id":31,"ws":true},{"text":"fatty","start":194,"end":199,"id":32,"ws":true},{"text":"acid-based","start":200,"end":210,"id":33,"ws":true},{"text":"functional","start":211,"end":221,"id":34,"ws":true},{"text":"lipidomics","start":222,"end":232,"id":35,"ws":true},{"text":"together","start":233,"end":241,"id":36,"ws":true},{"text":"with","start":242,"end":246,"id":37,"ws":true},{"text":"the","start":247,"end":250,"id":38,"ws":true},{"text":"follow-up","start":251,"end":260,"id":39,"ws":true},{"text":"of","start":261,"end":263,"id":40,"ws":true},{"text":"EGFR","start":264,"end":268,"id":41,"ws":true},{"text":"and","start":269,"end":272,"id":42,"ws":true},{"text":"MAPK","start":273,"end":277,"id":43,"ws":true},{"text":"signaling","start":278,"end":287,"id":44,"ws":true},{"text":"pathways","start":288,"end":296,"id":45,"ws":true},{"text":".","start":297,"end":298,"id":46,"ws":false}],"spans":[{"start":63,"end":71,"token_start":10,"token_end":10,"label":"DRUG"},{"start":127,"end":139,"token_start":22,"token_end":22,"label":"DRUG"}],"_input_hash":-1803484576,"_task_hash":288010961,"_session_id":"drug_drug_pilot_shared-yosi","_view_id":"blocks","relations":[{"head":10,"child":12,"head_span":{"start":63,"end":71,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":76,"end":85,"token_start":12,"token_end":12,"label":null},"color":"#96e8ce","label":"COMB1"},{"head":22,"child":12,"head_span":{"start":127,"end":139,"token_start":22,"token_end":22,"label":"DRUG"},"child_span":{"start":76,"end":85,"token_start":12,"token_end":12,"label":null},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"Following corneal scrapings and culture , topical 0.5 % moxifloxacin and 0.5 % tobramycin were administered hourly .","paragraph":"<h3><u>A case of Stenotrophomonas maltophilia keratitis effectively treated with moxifloxacin.</u></h3>A 70-year-old man with a long history of diabetes mellitus presented to our hospital (Department of Ophthalmology, Sahm Yook Medical Center, Seoul, Korea) complaining of severe ocular pain and visual disturbance in his left eye that had started three days prior to admission. A round 3.7 \u00d7 5.0 mm dense central stromal infiltrate with an overlying epithelial defect was noted on slit-lamp examination. <b style='color:DodgerBlue;'><i>Following</i></b> <b style='color:DodgerBlue;'><i>corneal</i></b> <b style='color:DodgerBlue;'><i>scrapings</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>culture</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>topical</i></b> <b style='color:DodgerBlue;'><i>0.5</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:MediumOrchid;'><i>moxifloxacin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>0.5</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:MediumOrchid;'><i>tobramycin</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>hourly</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A few days later, Stenotrophomonas maltophilia was isolated in a bacterial culture from a corneal specimen. According to the results of susceptibility tests, topical 0.5% <b style='color:Tomato;'><i>moxifloxacin</i></b> was given every hour and 0.5% <b style='color:Tomato;'><i>tobramycin</i></b> was stopped. The patient's clinical features improved steadily with treatment. The corneal epithelium healed rapidly, and the infiltrate resolved within four weeks of the initiation of treatment. The patient's best corrected visual acuity improved from hand motion to 20 / 25.","tokens":[{"text":"Following","start":0,"end":9,"id":0,"ws":true},{"text":"corneal","start":10,"end":17,"id":1,"ws":true},{"text":"scrapings","start":18,"end":27,"id":2,"ws":true},{"text":"and","start":28,"end":31,"id":3,"ws":true},{"text":"culture","start":32,"end":39,"id":4,"ws":true},{"text":",","start":40,"end":41,"id":5,"ws":true},{"text":"topical","start":42,"end":49,"id":6,"ws":true},{"text":"0.5","start":50,"end":53,"id":7,"ws":true},{"text":"%","start":54,"end":55,"id":8,"ws":true},{"text":"moxifloxacin","start":56,"end":68,"id":9,"ws":true},{"text":"and","start":69,"end":72,"id":10,"ws":true},{"text":"0.5","start":73,"end":76,"id":11,"ws":true},{"text":"%","start":77,"end":78,"id":12,"ws":true},{"text":"tobramycin","start":79,"end":89,"id":13,"ws":true},{"text":"were","start":90,"end":94,"id":14,"ws":true},{"text":"administered","start":95,"end":107,"id":15,"ws":true},{"text":"hourly","start":108,"end":114,"id":16,"ws":true},{"text":".","start":115,"end":116,"id":17,"ws":false}],"spans":[{"start":56,"end":68,"token_start":9,"token_end":9,"label":"DRUG"},{"start":79,"end":89,"token_start":13,"token_end":13,"label":"DRUG"}],"_input_hash":1332991430,"_task_hash":1426603318,"_session_id":"drug_drug_pilot_shared-yosi","_view_id":"blocks","relations":[{"head":9,"child":13,"head_span":{"start":56,"end":68,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":79,"end":89,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T1"],"answer":"accept"}
{"text":"Combination treatment with cetuximab and nystatin selectively increased cetuximab uptake by tumor tissues , translating into potentiated antitumor efficacy of cetuximab in vivo ( A431 and A549 tumors ) .","paragraph":"<h3><u>Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration.</u></h3>Cetuximab, a monoclonal antibody (mAb) targeting the epidermal growth factor receptor (EGFR), has been intensively investigated as a promising cancer treatment strategy. The specific mechanism of <b style='color:Tomato;'><i>cetuximab</i></b> endocytosis and its influence on <b style='color:Tomato;'><i>cetuximab</i></b> uptake, biodistribution and efficacy still remain elusive. Recently, statins have been reported to synergize with EGFR-targeting agents. Our prior work established that <b style='color:Tomato;'><i>nystatin</i></b>, a cholesterol-sequestering antifungal drug, facilitates endocytosis via the clathrin-dependent pathway. This study aimed to investigate whether <b style='color:Tomato;'><i>nystatin</i></b> regulates the uptake and efficacy of <b style='color:Tomato;'><i>cetuximab</i></b> and <b style='color:Tomato;'><i>cetuximab</i></b>-based antibody-drug conjugates (<b style='color:Tomato;'><i>cetuximab</i></b>-ADCs). In vitro and in vivo efficacies of <b style='color:Tomato;'><i>nystatin</i></b> on the uptake and activity of <b style='color:Tomato;'><i>cetuximab</i></b>/<b style='color:Tomato;'><i>cetuximab</i></b>-ADCs were studied in multiple human carcinoma cell lines and xenograft models, respectively. We identified that cholesterol sequestration by <b style='color:Tomato;'><i>nystatin</i></b> enhanced <b style='color:Tomato;'><i>cetuximab</i></b> internalization in EGFR-positive carcinoma cells by regulating EGFR trafficking/turnover and facilitating a switch from lipid rafts to clathrin-mediated endocytosis. <b style='color:DodgerBlue;'><i>Combination</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>nystatin</i></b> <b style='color:DodgerBlue;'><i>selectively</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>uptake</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>tumor</i></b> <b style='color:DodgerBlue;'><i>tissues</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>translating</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>potentiated</i></b> <b style='color:DodgerBlue;'><i>antitumor</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vivo</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>A431</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>A549</i></b> <b style='color:DodgerBlue;'><i>tumors</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Nystatin-enhanced internalization of <b style='color:Tomato;'><i>cetuximab</i></b> further improved the uptake and potency of <b style='color:Tomato;'><i>cetuximab</i></b>-<b style='color:Tomato;'><i>doxorubicin</i></b> and <b style='color:Tomato;'><i>cetuximab</i></b>-<b style='color:Tomato;'><i>methotrexate</i></b> conjugates in EGFR-positive <b style='color:Tomato;'><i>cetuximab</i></b>-resistant tumors. Combination therapy with <b style='color:Tomato;'><i>nystatin</i></b> plus either <b style='color:Tomato;'><i>cetuximab</i></b> or <b style='color:Tomato;'><i>cetuximab</i></b>-ADC further prolonged animal survival and significantly suppressed tumor growth, as compared with single-agent <b style='color:Tomato;'><i>cetuximab</i></b> or <b style='color:Tomato;'><i>cetuximab</i></b>-ADC. In summary, our results identify a novel mechanism whereby cholesterol sequestration enhances the uptake of EGFR-targeting mAb and ADCs, therefore providing preclinical proof-of-concept that combination with <b style='color:Tomato;'><i>nystatin</i></b> can potentiate the delivery and efficacy of these EGFR-targeted agents. ","tokens":[{"text":"Combination","start":0,"end":11,"id":0,"ws":true},{"text":"treatment","start":12,"end":21,"id":1,"ws":true},{"text":"with","start":22,"end":26,"id":2,"ws":true},{"text":"cetuximab","start":27,"end":36,"id":3,"ws":true},{"text":"and","start":37,"end":40,"id":4,"ws":true},{"text":"nystatin","start":41,"end":49,"id":5,"ws":true},{"text":"selectively","start":50,"end":61,"id":6,"ws":true},{"text":"increased","start":62,"end":71,"id":7,"ws":true},{"text":"cetuximab","start":72,"end":81,"id":8,"ws":true},{"text":"uptake","start":82,"end":88,"id":9,"ws":true},{"text":"by","start":89,"end":91,"id":10,"ws":true},{"text":"tumor","start":92,"end":97,"id":11,"ws":true},{"text":"tissues","start":98,"end":105,"id":12,"ws":true},{"text":",","start":106,"end":107,"id":13,"ws":true},{"text":"translating","start":108,"end":119,"id":14,"ws":true},{"text":"into","start":120,"end":124,"id":15,"ws":true},{"text":"potentiated","start":125,"end":136,"id":16,"ws":true},{"text":"antitumor","start":137,"end":146,"id":17,"ws":true},{"text":"efficacy","start":147,"end":155,"id":18,"ws":true},{"text":"of","start":156,"end":158,"id":19,"ws":true},{"text":"cetuximab","start":159,"end":168,"id":20,"ws":true},{"text":"in","start":169,"end":171,"id":21,"ws":true},{"text":"vivo","start":172,"end":176,"id":22,"ws":true},{"text":"(","start":177,"end":178,"id":23,"ws":true},{"text":"A431","start":179,"end":183,"id":24,"ws":true},{"text":"and","start":184,"end":187,"id":25,"ws":true},{"text":"A549","start":188,"end":192,"id":26,"ws":true},{"text":"tumors","start":193,"end":199,"id":27,"ws":true},{"text":")","start":200,"end":201,"id":28,"ws":true},{"text":".","start":202,"end":203,"id":29,"ws":false}],"spans":[{"start":27,"end":36,"token_start":3,"token_end":3,"label":"DRUG"},{"start":41,"end":49,"token_start":5,"token_end":5,"label":"DRUG"},{"start":72,"end":81,"token_start":8,"token_end":8,"label":"DRUG"},{"start":159,"end":168,"token_start":20,"token_end":20,"label":"DRUG"}],"_input_hash":-1277491604,"_task_hash":-1965461189,"_session_id":"drug_drug_pilot_shared-yosi","_view_id":"blocks","relations":[{"head":3,"child":5,"head_span":{"start":27,"end":36,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":41,"end":49,"token_start":5,"token_end":5,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T0"],"answer":"accept"}
{"text":"The effects of combination therapy with chenodeoxycholic acid ( CDCA ) and simvastatin on serum cholestanol , low-density lipoprotein ( LDL ) cholesterol , and lathosterol levels were investigated in seven adult patients with cerebrotendinous xanthomatosis ( CTX ) who were on long-term treatment with CDCA .","paragraph":"<h3><u>Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>chenodeoxycholic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CDCA</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>simvastatin</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>serum</i></b> <b style='color:DodgerBlue;'><i>cholestanol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>low-density</i></b> <b style='color:DodgerBlue;'><i>lipoprotein</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>LDL</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>cholesterol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>lathosterol</i></b> <b style='color:DodgerBlue;'><i>levels</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>investigated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>seven</i></b> <b style='color:DodgerBlue;'><i>adult</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>cerebrotendinous</i></b> <b style='color:DodgerBlue;'><i>xanthomatosis</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CTX</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>long-term</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>CDCA</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The patients were treated with a combination of CDCA 750 mg daily and an increasing dose of <b style='color:Tomato;'><i>simvastatin</i></b> from 10 mg to 40 mg daily for a period of 6 months. We found a significant effect of this combination therapy compared with CDCA alone in terms of decreasing the serum cholestanol and LDL cholesterol levels, particularly with a daily dose of 40 mg <b style='color:Tomato;'><i>simvastatin</i></b>. The mean cholestanol level decreased from 9.27 micromol/L (baseline) to 6.69 micromol/L (40 mg <b style='color:Tomato;'><i>simvastatin</i></b>), while the mean LDL cholesterol level decreased from 5.08 mmol/L (baseline) to 3.04 mmol/L (40 mg <b style='color:Tomato;'><i>simvastatin</i></b>). No side effects were reported, and there were no effects on the clinical condition, cerebral magnetic resonance imaging (MRI), visual evoked potentials, and electroencephalographic features. We conclude that a combination of 750 mg CDCA and 40 mg <b style='color:Tomato;'><i>simvastatin</i></b> daily is effective to further reduce serum cholestanol, LDL cholesterol, and lathosterol in adult CTX patients treated with long-term CDCA. Whether this combination treatment will be effective for the long-term prevention of neurological deterioration and atherosclerosis remains to be established.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"effects","start":4,"end":11,"id":1,"ws":true},{"text":"of","start":12,"end":14,"id":2,"ws":true},{"text":"combination","start":15,"end":26,"id":3,"ws":true},{"text":"therapy","start":27,"end":34,"id":4,"ws":true},{"text":"with","start":35,"end":39,"id":5,"ws":true},{"text":"chenodeoxycholic","start":40,"end":56,"id":6,"ws":true},{"text":"acid","start":57,"end":61,"id":7,"ws":true},{"text":"(","start":62,"end":63,"id":8,"ws":true},{"text":"CDCA","start":64,"end":68,"id":9,"ws":true},{"text":")","start":69,"end":70,"id":10,"ws":true},{"text":"and","start":71,"end":74,"id":11,"ws":true},{"text":"simvastatin","start":75,"end":86,"id":12,"ws":true},{"text":"on","start":87,"end":89,"id":13,"ws":true},{"text":"serum","start":90,"end":95,"id":14,"ws":true},{"text":"cholestanol","start":96,"end":107,"id":15,"ws":true},{"text":",","start":108,"end":109,"id":16,"ws":true},{"text":"low-density","start":110,"end":121,"id":17,"ws":true},{"text":"lipoprotein","start":122,"end":133,"id":18,"ws":true},{"text":"(","start":134,"end":135,"id":19,"ws":true},{"text":"LDL","start":136,"end":139,"id":20,"ws":true},{"text":")","start":140,"end":141,"id":21,"ws":true},{"text":"cholesterol","start":142,"end":153,"id":22,"ws":true},{"text":",","start":154,"end":155,"id":23,"ws":true},{"text":"and","start":156,"end":159,"id":24,"ws":true},{"text":"lathosterol","start":160,"end":171,"id":25,"ws":true},{"text":"levels","start":172,"end":178,"id":26,"ws":true},{"text":"were","start":179,"end":183,"id":27,"ws":true},{"text":"investigated","start":184,"end":196,"id":28,"ws":true},{"text":"in","start":197,"end":199,"id":29,"ws":true},{"text":"seven","start":200,"end":205,"id":30,"ws":true},{"text":"adult","start":206,"end":211,"id":31,"ws":true},{"text":"patients","start":212,"end":220,"id":32,"ws":true},{"text":"with","start":221,"end":225,"id":33,"ws":true},{"text":"cerebrotendinous","start":226,"end":242,"id":34,"ws":true},{"text":"xanthomatosis","start":243,"end":256,"id":35,"ws":true},{"text":"(","start":257,"end":258,"id":36,"ws":true},{"text":"CTX","start":259,"end":262,"id":37,"ws":true},{"text":")","start":263,"end":264,"id":38,"ws":true},{"text":"who","start":265,"end":268,"id":39,"ws":true},{"text":"were","start":269,"end":273,"id":40,"ws":true},{"text":"on","start":274,"end":276,"id":41,"ws":true},{"text":"long-term","start":277,"end":286,"id":42,"ws":true},{"text":"treatment","start":287,"end":296,"id":43,"ws":true},{"text":"with","start":297,"end":301,"id":44,"ws":true},{"text":"CDCA","start":302,"end":306,"id":45,"ws":true},{"text":".","start":307,"end":308,"id":46,"ws":false}],"spans":[{"start":40,"end":56,"token_start":6,"token_end":6,"label":"DRUG"},{"start":75,"end":86,"token_start":12,"token_end":12,"label":"DRUG"}],"_input_hash":-475065306,"_task_hash":-2052397739,"_session_id":"drug_drug_pilot_shared-yosi","_view_id":"blocks","relations":[{"head":6,"child":12,"head_span":{"start":40,"end":56,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":75,"end":86,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T0"],"answer":"accept"}
{"text":"Paclitaxel ( Taxol ; Bristol-Myers Squibb Company , Princeton , NJ ) has been demonstrated to be highly effective in treating patients with advanced breast cancer , including those with anthracycline-resistant breast cancer , a fact that has led to efforts to combine paclitaxel and anthracyclines .","paragraph":"<h3><u>Paclitaxel and doxorubicin in metastatic breast cancer.</u></h3>For the past decades the anthracyclines have been regarded as among the most active drugs for the treatment of metastatic breast cancer. However, the 5-year survival rate in patients with stage IV breast cancer continues to be below 20%, and new active drugs and drug combinations clearly must be explored. <b style='color:MediumOrchid;'><i>Paclitaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Taxol</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>Bristol-Myers</i></b> <b style='color:DodgerBlue;'><i>Squibb</i></b> <b style='color:DodgerBlue;'><i>Company</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Princeton</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>NJ</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>highly</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>treating</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>anthracycline-resistant</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>fact</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>led</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>efforts</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>combine</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>anthracyclines</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Several studies aiming to define the optimal dose and schedule of combination <b style='color:Tomato;'><i>paclitaxel</i></b>/<b style='color:Tomato;'><i>doxorubicin</i></b> have now been completed or are ongoing. Phase I/II studies have yielded encouraging preliminary response rates but quite variable toxicity profiles depending on the schedule used. These clinical trials involving combination <b style='color:Tomato;'><i>paclitaxel</i></b>/<b style='color:Tomato;'><i>doxorubicin</i></b> are reviewed, with special emphasis on the short-infusion trials.","tokens":[{"text":"Paclitaxel","start":0,"end":10,"id":0,"ws":true},{"text":"(","start":11,"end":12,"id":1,"ws":true},{"text":"Taxol","start":13,"end":18,"id":2,"ws":true},{"text":";","start":19,"end":20,"id":3,"ws":true},{"text":"Bristol-Myers","start":21,"end":34,"id":4,"ws":true},{"text":"Squibb","start":35,"end":41,"id":5,"ws":true},{"text":"Company","start":42,"end":49,"id":6,"ws":true},{"text":",","start":50,"end":51,"id":7,"ws":true},{"text":"Princeton","start":52,"end":61,"id":8,"ws":true},{"text":",","start":62,"end":63,"id":9,"ws":true},{"text":"NJ","start":64,"end":66,"id":10,"ws":true},{"text":")","start":67,"end":68,"id":11,"ws":true},{"text":"has","start":69,"end":72,"id":12,"ws":true},{"text":"been","start":73,"end":77,"id":13,"ws":true},{"text":"demonstrated","start":78,"end":90,"id":14,"ws":true},{"text":"to","start":91,"end":93,"id":15,"ws":true},{"text":"be","start":94,"end":96,"id":16,"ws":true},{"text":"highly","start":97,"end":103,"id":17,"ws":true},{"text":"effective","start":104,"end":113,"id":18,"ws":true},{"text":"in","start":114,"end":116,"id":19,"ws":true},{"text":"treating","start":117,"end":125,"id":20,"ws":true},{"text":"patients","start":126,"end":134,"id":21,"ws":true},{"text":"with","start":135,"end":139,"id":22,"ws":true},{"text":"advanced","start":140,"end":148,"id":23,"ws":true},{"text":"breast","start":149,"end":155,"id":24,"ws":true},{"text":"cancer","start":156,"end":162,"id":25,"ws":true},{"text":",","start":163,"end":164,"id":26,"ws":true},{"text":"including","start":165,"end":174,"id":27,"ws":true},{"text":"those","start":175,"end":180,"id":28,"ws":true},{"text":"with","start":181,"end":185,"id":29,"ws":true},{"text":"anthracycline-resistant","start":186,"end":209,"id":30,"ws":true},{"text":"breast","start":210,"end":216,"id":31,"ws":true},{"text":"cancer","start":217,"end":223,"id":32,"ws":true},{"text":",","start":224,"end":225,"id":33,"ws":true},{"text":"a","start":226,"end":227,"id":34,"ws":true},{"text":"fact","start":228,"end":232,"id":35,"ws":true},{"text":"that","start":233,"end":237,"id":36,"ws":true},{"text":"has","start":238,"end":241,"id":37,"ws":true},{"text":"led","start":242,"end":245,"id":38,"ws":true},{"text":"to","start":246,"end":248,"id":39,"ws":true},{"text":"efforts","start":249,"end":256,"id":40,"ws":true},{"text":"to","start":257,"end":259,"id":41,"ws":true},{"text":"combine","start":260,"end":267,"id":42,"ws":true},{"text":"paclitaxel","start":268,"end":278,"id":43,"ws":true},{"text":"and","start":279,"end":282,"id":44,"ws":true},{"text":"anthracyclines","start":283,"end":297,"id":45,"ws":true},{"text":".","start":298,"end":299,"id":46,"ws":false}],"spans":[{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},{"start":268,"end":278,"token_start":43,"token_end":43,"label":"DRUG"}],"_input_hash":702583470,"_task_hash":1770101995,"_session_id":"drug_drug_pilot_shared-yosi","_view_id":"blocks","relations":[{"head":43,"child":45,"head_span":{"start":268,"end":278,"token_start":43,"token_end":43,"label":"DRUG"},"child_span":{"start":283,"end":297,"token_start":45,"token_end":45,"label":null},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"However , anastrozole , exemestane and letrozole are associated with significantly fewer endometrial cancers , as well as venous and arterial vascular events , when compared with tamoxifen [ 9 , 10 ] .","paragraph":"<h3><u>Erythema nodosum secondary to aromatase inhibitor use in breast cancer patients: case reports and review of the literature.</u></h3>Aromatase inhibitors (AI's) are increasingly being incorporated in the treatment strategy for hormone receptor positive breast cancer either alone or in combination with chemotherapy, biologics in both the adjuvant and metastatic setting [1]. They markedly suppress plasma estrogen levels by inhibiting or inactivating aromatase, the enzyme responsible for the synthesis of estrogens from androgenic substrates [1]. Currently, the three selective aromatase inhibitors that are available are <b style='color:Tomato;'><i>anastrozole</i></b>, <b style='color:Tomato;'><i>letrozole</i></b> and <b style='color:Tomato;'><i>exemestane</i></b> which reduce circulating estrogen to 1 to 10% of pretreatment levels [2]. For advanced breast cancer, aromatase inhibitors appear to be at a minimum, equivalent and perhaps even better than <b style='color:Tomato;'><i>tamoxifen</i></b> in the first line setting [3, 4]. In primary breast cancer, adjuvant therapy with <b style='color:Tomato;'><i>anastrozole</i></b> or <b style='color:Tomato;'><i>letrozole</i></b> appears to be superior to <b style='color:Tomato;'><i>tamoxifen</i></b> in reducing the risk of relapse [5, 6]. Common adverse effects associated with AI's include arthralgias (21%), myalgias (12%), other musculoskeletal disorders (28%) and an up to 60% increased risk of bone fracture [7, 8]. <b style='color:DodgerBlue;'><i>However</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>anastrozole</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>exemestane</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>letrozole</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>fewer</i></b> <b style='color:DodgerBlue;'><i>endometrial</i></b> <b style='color:DodgerBlue;'><i>cancers</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>venous</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>arterial</i></b> <b style='color:DodgerBlue;'><i>vascular</i></b> <b style='color:DodgerBlue;'><i>events</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>9</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Very rarely <b style='color:Tomato;'><i>letrozole</i></b> and <b style='color:Tomato;'><i>anastrozole</i></b> can cause a skin rash; the frequency of its occurrence has not been quantified(. )However, <b style='color:Tomato;'><i>exemestane</i></b> has not been reported to cause a skin rash [11]. To date, erythema nodosum (EN) has not been reported as a dermatologic side effect of AI's. Here, we report three cases of EN which developed in postmenopausal breast cancer patients on AI's.","tokens":[{"text":"However","start":0,"end":7,"id":0,"ws":true},{"text":",","start":8,"end":9,"id":1,"ws":true},{"text":"anastrozole","start":10,"end":21,"id":2,"ws":true},{"text":",","start":22,"end":23,"id":3,"ws":true},{"text":"exemestane","start":24,"end":34,"id":4,"ws":true},{"text":"and","start":35,"end":38,"id":5,"ws":true},{"text":"letrozole","start":39,"end":48,"id":6,"ws":true},{"text":"are","start":49,"end":52,"id":7,"ws":true},{"text":"associated","start":53,"end":63,"id":8,"ws":true},{"text":"with","start":64,"end":68,"id":9,"ws":true},{"text":"significantly","start":69,"end":82,"id":10,"ws":true},{"text":"fewer","start":83,"end":88,"id":11,"ws":true},{"text":"endometrial","start":89,"end":100,"id":12,"ws":true},{"text":"cancers","start":101,"end":108,"id":13,"ws":true},{"text":",","start":109,"end":110,"id":14,"ws":true},{"text":"as","start":111,"end":113,"id":15,"ws":true},{"text":"well","start":114,"end":118,"id":16,"ws":true},{"text":"as","start":119,"end":121,"id":17,"ws":true},{"text":"venous","start":122,"end":128,"id":18,"ws":true},{"text":"and","start":129,"end":132,"id":19,"ws":true},{"text":"arterial","start":133,"end":141,"id":20,"ws":true},{"text":"vascular","start":142,"end":150,"id":21,"ws":true},{"text":"events","start":151,"end":157,"id":22,"ws":true},{"text":",","start":158,"end":159,"id":23,"ws":true},{"text":"when","start":160,"end":164,"id":24,"ws":true},{"text":"compared","start":165,"end":173,"id":25,"ws":true},{"text":"with","start":174,"end":178,"id":26,"ws":true},{"text":"tamoxifen","start":179,"end":188,"id":27,"ws":true},{"text":"[","start":189,"end":190,"id":28,"ws":true},{"text":"9","start":191,"end":192,"id":29,"ws":true},{"text":",","start":193,"end":194,"id":30,"ws":true},{"text":"10","start":195,"end":197,"id":31,"ws":true},{"text":"]","start":198,"end":199,"id":32,"ws":true},{"text":".","start":200,"end":201,"id":33,"ws":false}],"spans":[{"start":10,"end":21,"token_start":2,"token_end":2,"label":"DRUG"},{"start":24,"end":34,"token_start":4,"token_end":4,"label":"DRUG"},{"start":39,"end":48,"token_start":6,"token_end":6,"label":"DRUG"},{"start":179,"end":188,"token_start":27,"token_end":27,"label":"DRUG"}],"_input_hash":155070717,"_task_hash":-411756935,"_session_id":"drug_drug_pilot_shared-dana_a","_view_id":"blocks","relations":[{"head":2,"child":4,"head_span":{"start":10,"end":21,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":24,"end":34,"token_start":4,"token_end":4,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"},{"head":6,"child":4,"head_span":{"start":39,"end":48,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":24,"end":34,"token_start":4,"token_end":4,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"},{"head":27,"child":6,"head_span":{"start":179,"end":188,"token_start":27,"token_end":27,"label":"DRUG"},"child_span":{"start":39,"end":48,"token_start":6,"token_end":6,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG11","NEG1T0"],"answer":"accept"}
{"text":"Additivity , synergy , or competition was observed with MIS and rapamycin , AzadC , doxorubicin , cisplatin , and paclitaxel , suggesting that MIS in combination with selective targeted therapies might achieve greater activity against ovarian cancer than the use of each individual agent alone .","paragraph":"<h3><u>Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.</u></h3>Mullerian Inhibiting Substance (MIS), a biological modifier that causes regression of Mullerian ducts in male embryos, is effective as a single agent in vitro and in vivo against human and mouse ovarian cancer cell lines expressing MIS type II receptor; however, little is known about how recombinant human MIS (rhMIS), now being scaled for preclinical trials, could be used in combination with cytotoxic or targeted chemotherapeutic agents. Mouse serous and endometrioid ovarian carcinoma cell lines were tested in vitro against rhMIS alone and with <b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>paclitaxel</i></b>, or cisplatin as agents in clinical use. Because MIS releases FK506 binding protein (FKBP12), which activates the mammalian target of <b style='color:Tomato;'><i>rapamycin</i></b> (mTOR) downstream of Akt, rhMIS and <b style='color:Tomato;'><i>rapamycin</i></b> combinations were tested. MIS increases p16 protein levels, and 5'-Aza-2'-deoxycytidine (AzadC) induces p16 mRNA; therefore, they were used in combination in vitro and in vivo with a human ovarian cancer cell line. A <b style='color:Tomato;'><i>paclitaxel</i></b>-resistant human ovarian cancer cell line and its parental line both respond to rhMIS in vitro. <b style='color:DodgerBlue;'><i>Additivity</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>synergy</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>competition</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>observed</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>MIS</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rapamycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>AzadC</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>suggesting</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>MIS</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>selective</i></b> <b style='color:DodgerBlue;'><i>targeted</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>might</i></b> <b style='color:DodgerBlue;'><i>achieve</i></b> <b style='color:DodgerBlue;'><i>greater</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>ovarian</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>each</i></b> <b style='color:DodgerBlue;'><i>individual</i></b> <b style='color:DodgerBlue;'><i>agent</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> These assays and statistical analyses could be useful in selecting rhMIS and chemotherapeutic agent combinations that enhance clinical efficacy and reduce toxicity.","tokens":[{"text":"Additivity","start":0,"end":10,"id":0,"ws":true},{"text":",","start":11,"end":12,"id":1,"ws":true},{"text":"synergy","start":13,"end":20,"id":2,"ws":true},{"text":",","start":21,"end":22,"id":3,"ws":true},{"text":"or","start":23,"end":25,"id":4,"ws":true},{"text":"competition","start":26,"end":37,"id":5,"ws":true},{"text":"was","start":38,"end":41,"id":6,"ws":true},{"text":"observed","start":42,"end":50,"id":7,"ws":true},{"text":"with","start":51,"end":55,"id":8,"ws":true},{"text":"MIS","start":56,"end":59,"id":9,"ws":true},{"text":"and","start":60,"end":63,"id":10,"ws":true},{"text":"rapamycin","start":64,"end":73,"id":11,"ws":true},{"text":",","start":74,"end":75,"id":12,"ws":true},{"text":"AzadC","start":76,"end":81,"id":13,"ws":true},{"text":",","start":82,"end":83,"id":14,"ws":true},{"text":"doxorubicin","start":84,"end":95,"id":15,"ws":true},{"text":",","start":96,"end":97,"id":16,"ws":true},{"text":"cisplatin","start":98,"end":107,"id":17,"ws":true},{"text":",","start":108,"end":109,"id":18,"ws":true},{"text":"and","start":110,"end":113,"id":19,"ws":true},{"text":"paclitaxel","start":114,"end":124,"id":20,"ws":true},{"text":",","start":125,"end":126,"id":21,"ws":true},{"text":"suggesting","start":127,"end":137,"id":22,"ws":true},{"text":"that","start":138,"end":142,"id":23,"ws":true},{"text":"MIS","start":143,"end":146,"id":24,"ws":true},{"text":"in","start":147,"end":149,"id":25,"ws":true},{"text":"combination","start":150,"end":161,"id":26,"ws":true},{"text":"with","start":162,"end":166,"id":27,"ws":true},{"text":"selective","start":167,"end":176,"id":28,"ws":true},{"text":"targeted","start":177,"end":185,"id":29,"ws":true},{"text":"therapies","start":186,"end":195,"id":30,"ws":true},{"text":"might","start":196,"end":201,"id":31,"ws":true},{"text":"achieve","start":202,"end":209,"id":32,"ws":true},{"text":"greater","start":210,"end":217,"id":33,"ws":true},{"text":"activity","start":218,"end":226,"id":34,"ws":true},{"text":"against","start":227,"end":234,"id":35,"ws":true},{"text":"ovarian","start":235,"end":242,"id":36,"ws":true},{"text":"cancer","start":243,"end":249,"id":37,"ws":true},{"text":"than","start":250,"end":254,"id":38,"ws":true},{"text":"the","start":255,"end":258,"id":39,"ws":true},{"text":"use","start":259,"end":262,"id":40,"ws":true},{"text":"of","start":263,"end":265,"id":41,"ws":true},{"text":"each","start":266,"end":270,"id":42,"ws":true},{"text":"individual","start":271,"end":281,"id":43,"ws":true},{"text":"agent","start":282,"end":287,"id":44,"ws":true},{"text":"alone","start":288,"end":293,"id":45,"ws":true},{"text":".","start":294,"end":295,"id":46,"ws":false}],"spans":[{"start":56,"end":59,"token_start":9,"token_end":9,"label":"DRUG"},{"start":64,"end":73,"token_start":11,"token_end":11,"label":"DRUG"},{"start":76,"end":81,"token_start":13,"token_end":13,"label":"DRUG"},{"start":84,"end":95,"token_start":15,"token_end":15,"label":"DRUG"},{"start":98,"end":107,"token_start":17,"token_end":17,"label":"DRUG"},{"start":114,"end":124,"token_start":20,"token_end":20,"label":"DRUG"}],"_input_hash":1387497584,"_task_hash":991977050,"_session_id":"drug_drug_pilot_shared-dana_a","_view_id":"blocks","relations":[{"head":9,"child":11,"head_span":{"start":56,"end":59,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":64,"end":73,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":9,"child":13,"head_span":{"start":56,"end":59,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":76,"end":81,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":9,"child":15,"head_span":{"start":56,"end":59,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":84,"end":95,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":9,"child":17,"head_span":{"start":56,"end":59,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":98,"end":107,"token_start":17,"token_end":17,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":9,"child":20,"head_span":{"start":56,"end":59,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":114,"end":124,"token_start":20,"token_end":20,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T0"],"answer":"accept"}
{"text":"There was no cytotoxic effect of cisplatin , ifosfamide , and etoposide .","paragraph":"<h3><u>Overcoming Chemoresistance of Pediatric Ependymoma by Inhibition of STAT3 Signaling.</u></h3>The long-term clinical outcome of pediatric intracranial epepdymoma is poor with a high rate of recurrence. One of the main reasons for this poor outcome is the tumor's inherent resistance to chemotherapy. Signal transducer and activator of transcription 3 (STAT3) is overactive in many human cancers, and inhibition of STAT3 signaling is an emerging area of interest in oncology. In this study, the possibility of STAT3 inhibition as a treatment was investigated in pediatric intracranial ependymoma tissues and cell lines. STAT3 activation status was checked in ependymoma tissues. The responses to conventional chemotherapeutic agents and a STAT3 inhibitor WP1066 in primarily cultured ependymoma cells were measured by cell viability assay. Apoptosis assays were conducted to reveal the cytotoxic mechanism of applied agents. Knockdown of STAT3 was tried to confirm the effects of STAT3 inhibition in ependymoma cells. High levels of phospho-STAT3 (p-STAT3) expression were observed in ependymoma tissue, especially in the anaplastic histology group. <b style='color:DodgerBlue;'><i>There</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>cytotoxic</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Both brain tumor-initiating cells (BTICs) and bulk tumor cells (BCs) showed considerably decreased viability after WP1066 treatment. However, BTICs had fewer responses than BCs. No additive or synergistic effect was observed for combination therapy of WP1066 and cisplatin. WP1066 effectively abrogated p-STAT3 expression. An increased apoptosis and decreased Survivin expression were observed after WP1066 treatment. Knockdown of STAT3 also decreased cell survival, supporting the critical role of STAT3 in sustaining ependymoma cells. In this study, we observed a cytotoxic effect of STAT3 inhibitor on ependymoma BTICs and BCs. There is urgent need to develop new therapeutic agents for pediatric ependymoma. STAT3 inhibitors may be a new group of drugs for clinical application. ","tokens":[{"text":"There","start":0,"end":5,"id":0,"ws":true},{"text":"was","start":6,"end":9,"id":1,"ws":true},{"text":"no","start":10,"end":12,"id":2,"ws":true},{"text":"cytotoxic","start":13,"end":22,"id":3,"ws":true},{"text":"effect","start":23,"end":29,"id":4,"ws":true},{"text":"of","start":30,"end":32,"id":5,"ws":true},{"text":"cisplatin","start":33,"end":42,"id":6,"ws":true},{"text":",","start":43,"end":44,"id":7,"ws":true},{"text":"ifosfamide","start":45,"end":55,"id":8,"ws":true},{"text":",","start":56,"end":57,"id":9,"ws":true},{"text":"and","start":58,"end":61,"id":10,"ws":true},{"text":"etoposide","start":62,"end":71,"id":11,"ws":true},{"text":".","start":72,"end":73,"id":12,"ws":false}],"spans":[{"start":33,"end":42,"token_start":6,"token_end":6,"label":"DRUG"},{"start":45,"end":55,"token_start":8,"token_end":8,"label":"DRUG"},{"start":62,"end":71,"token_start":11,"token_end":11,"label":"DRUG"}],"_input_hash":-1352726798,"_task_hash":-274527523,"_session_id":"drug_drug_pilot_shared-dana_a","_view_id":"blocks","relations":[{"head":6,"child":8,"head_span":{"start":33,"end":42,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":45,"end":55,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"},{"head":8,"child":11,"head_span":{"start":45,"end":55,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":62,"end":71,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG10","NEG1T0"],"answer":"accept"}
{"text":"Several first-line phase III trials , as well as ongoing trials for which only preliminary results have been published , have fueled debates on the optimal dose and schedule ; these have focused not only on weekly vs q3-weeks paclitaxel , but also on other modifications and the advisability of adding bevacizumab .","paragraph":"<h3><u>Carboplatin/Paclitaxel Induction in Ovarian Cancer: The Finer Points.</u></h3>The <b style='color:Tomato;'><i>carboplatin</i></b>/<b style='color:Tomato;'><i>paclitaxel</i></b> doublet remains the chemotherapy backbone for the initial treatment of ovarian cancer. This two-drug regimen, with <b style='color:Tomato;'><i>carboplatin</i></b> dosed using the Calvert formula, yielded convincing noninferior outcomes when compared with the prior, more toxic, regimen of cisplatin/<b style='color:Tomato;'><i>paclitaxel</i></b>. Carboplatin's dose-limiting toxicity is thrombocytopenia; however, when this drug is properly dosed and combined with <b style='color:Tomato;'><i>paclitaxel</i></b>, the doublet's cycle 1 dose in chemotherapy-naive women is generally safe. Carboplatin (unlike cisplatin) contributes minimally to the cumulative sensory neuropathy of <b style='color:Tomato;'><i>paclitaxel</i></b>, thus ensuring noticeable reversibility of neuropathy symptoms following completion of 6 cycles and only occasionally requiring cessation or substitution of the taxane. Paclitaxel is responsible for the hair loss associated with the <b style='color:Tomato;'><i>carboplatin</i></b>/<b style='color:Tomato;'><i>paclitaxel</i></b> doublet; preventive measures must be considered for patients who would otherwise refuse treatment. <b style='color:DodgerBlue;'><i>Several</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>III</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>ongoing</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>which</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>preliminary</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>published</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>fueled</i></b> <b style='color:DodgerBlue;'><i>debates</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>optimal</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>schedule</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>focused</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>weekly</i></b> <b style='color:DodgerBlue;'><i>vs</i></b> <b style='color:DodgerBlue;'><i>q3-weeks</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>also</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>modifications</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>advisability</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>adding</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Our view is that results of this doublet in the first-line treatment of ovarian cancer are driven primarily by <b style='color:Tomato;'><i>carboplatin</i></b>, given that ovarian cancer is a platinum-sensitive disease. Consequently, the roles of the accompanying <b style='color:Tomato;'><i>paclitaxel</i></b> dose and schedule and the addition of <b style='color:Tomato;'><i>bevacizumab</i></b> are currently unsettled, and questions regarding these issues should be decided based on patient tolerance and comorbidities until additional data are available.","tokens":[{"text":"Several","start":0,"end":7,"id":0,"ws":true},{"text":"first-line","start":8,"end":18,"id":1,"ws":true},{"text":"phase","start":19,"end":24,"id":2,"ws":true},{"text":"III","start":25,"end":28,"id":3,"ws":true},{"text":"trials","start":29,"end":35,"id":4,"ws":true},{"text":",","start":36,"end":37,"id":5,"ws":true},{"text":"as","start":38,"end":40,"id":6,"ws":true},{"text":"well","start":41,"end":45,"id":7,"ws":true},{"text":"as","start":46,"end":48,"id":8,"ws":true},{"text":"ongoing","start":49,"end":56,"id":9,"ws":true},{"text":"trials","start":57,"end":63,"id":10,"ws":true},{"text":"for","start":64,"end":67,"id":11,"ws":true},{"text":"which","start":68,"end":73,"id":12,"ws":true},{"text":"only","start":74,"end":78,"id":13,"ws":true},{"text":"preliminary","start":79,"end":90,"id":14,"ws":true},{"text":"results","start":91,"end":98,"id":15,"ws":true},{"text":"have","start":99,"end":103,"id":16,"ws":true},{"text":"been","start":104,"end":108,"id":17,"ws":true},{"text":"published","start":109,"end":118,"id":18,"ws":true},{"text":",","start":119,"end":120,"id":19,"ws":true},{"text":"have","start":121,"end":125,"id":20,"ws":true},{"text":"fueled","start":126,"end":132,"id":21,"ws":true},{"text":"debates","start":133,"end":140,"id":22,"ws":true},{"text":"on","start":141,"end":143,"id":23,"ws":true},{"text":"the","start":144,"end":147,"id":24,"ws":true},{"text":"optimal","start":148,"end":155,"id":25,"ws":true},{"text":"dose","start":156,"end":160,"id":26,"ws":true},{"text":"and","start":161,"end":164,"id":27,"ws":true},{"text":"schedule","start":165,"end":173,"id":28,"ws":true},{"text":";","start":174,"end":175,"id":29,"ws":true},{"text":"these","start":176,"end":181,"id":30,"ws":true},{"text":"have","start":182,"end":186,"id":31,"ws":true},{"text":"focused","start":187,"end":194,"id":32,"ws":true},{"text":"not","start":195,"end":198,"id":33,"ws":true},{"text":"only","start":199,"end":203,"id":34,"ws":true},{"text":"on","start":204,"end":206,"id":35,"ws":true},{"text":"weekly","start":207,"end":213,"id":36,"ws":true},{"text":"vs","start":214,"end":216,"id":37,"ws":true},{"text":"q3-weeks","start":217,"end":225,"id":38,"ws":true},{"text":"paclitaxel","start":226,"end":236,"id":39,"ws":true},{"text":",","start":237,"end":238,"id":40,"ws":true},{"text":"but","start":239,"end":242,"id":41,"ws":true},{"text":"also","start":243,"end":247,"id":42,"ws":true},{"text":"on","start":248,"end":250,"id":43,"ws":true},{"text":"other","start":251,"end":256,"id":44,"ws":true},{"text":"modifications","start":257,"end":270,"id":45,"ws":true},{"text":"and","start":271,"end":274,"id":46,"ws":true},{"text":"the","start":275,"end":278,"id":47,"ws":true},{"text":"advisability","start":279,"end":291,"id":48,"ws":true},{"text":"of","start":292,"end":294,"id":49,"ws":true},{"text":"adding","start":295,"end":301,"id":50,"ws":true},{"text":"bevacizumab","start":302,"end":313,"id":51,"ws":true},{"text":".","start":314,"end":315,"id":52,"ws":false}],"spans":[{"start":226,"end":236,"token_start":39,"token_end":39,"label":"DRUG"},{"start":302,"end":313,"token_start":51,"token_end":51,"label":"DRUG"}],"_input_hash":1252988243,"_task_hash":322511723,"_session_id":"drug_drug_pilot_shared-dana_a","_view_id":"blocks","relations":[{"head":39,"child":51,"head_span":{"start":226,"end":236,"token_start":39,"token_end":39,"label":"DRUG"},"child_span":{"start":302,"end":313,"token_start":51,"token_end":51,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T1"],"answer":"accept"}
{"text":"The primary goal was achieve the correct estimation of the target plasma area against the topotecan concentration-time curve ( AUC ) in a 5 day course of cladribine followed by monitored topotecan in pediatric patients with recurrent/refractory AML .","paragraph":"<h3><u>Topotecan exposure estimation in pediatric acute myeloid leukemia supported by LC-MS-based drug monitoring and pharmacokinetic analysis.</u></h3>Individualization of the <b style='color:Tomato;'><i>topotecan</i></b> dosing can reduce inter-patient variability, toxicity, and at the same time increases chemotherapy efficacy. Topotecan dosing based on simultaneous drug monitoring and pharmacokinetic analysis can yield more accurate and precise estimation of the <b style='color:Tomato;'><i>topotecan</i></b> systemic exposure than that attainable with the fixed dosing approach. Therefore, a combined approach could provide a tool assisting the clinicians in individualization of the <b style='color:Tomato;'><i>topotecan</i></b> dosing. The aim of the study was to estimate the <b style='color:Tomato;'><i>topotecan</i></b> exposure in pediatric patients with acute myeloid leukemia (AML) based on the plasma concentration-time data and using the pharmacokinetic analysis. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>primary</i></b> <b style='color:DodgerBlue;'><i>goal</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>achieve</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>correct</i></b> <b style='color:DodgerBlue;'><i>estimation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>target</i></b> <b style='color:DodgerBlue;'><i>plasma</i></b> <b style='color:DodgerBlue;'><i>area</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:MediumOrchid;'><i>topotecan</i></b> <b style='color:DodgerBlue;'><i>concentration-time</i></b> <b style='color:DodgerBlue;'><i>curve</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AUC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>course</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cladribine</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>monitored</i></b> <b style='color:MediumOrchid;'><i>topotecan</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>pediatric</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>recurrent/refractory</i></b> <b style='color:DodgerBlue;'><i>AML</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A sensitive and selective reversed-phase liquid chromatographic-mass spectrometry (LC-MS) assay was developed to quantify total <b style='color:Tomato;'><i>topotecan</i></b> in the human plasma samples. This method, with its lower quantification limit of 1 ng/ml, was validated over a linear range of 1-150 ng/ml. Under the proposed approach, the <b style='color:Tomato;'><i>topotecan</i></b> dosing was selected so as to achieve the final AUC value of 140\u00b120 ng/ml h. The presented analytical and pharmacokinetic data demonstrate that the proposed approach can be a practical, useful, efficient, and accurate tool for individualizing the <b style='color:Tomato;'><i>topotecan</i></b> dosing in children with AML.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"primary","start":4,"end":11,"id":1,"ws":true},{"text":"goal","start":12,"end":16,"id":2,"ws":true},{"text":"was","start":17,"end":20,"id":3,"ws":true},{"text":"achieve","start":21,"end":28,"id":4,"ws":true},{"text":"the","start":29,"end":32,"id":5,"ws":true},{"text":"correct","start":33,"end":40,"id":6,"ws":true},{"text":"estimation","start":41,"end":51,"id":7,"ws":true},{"text":"of","start":52,"end":54,"id":8,"ws":true},{"text":"the","start":55,"end":58,"id":9,"ws":true},{"text":"target","start":59,"end":65,"id":10,"ws":true},{"text":"plasma","start":66,"end":72,"id":11,"ws":true},{"text":"area","start":73,"end":77,"id":12,"ws":true},{"text":"against","start":78,"end":85,"id":13,"ws":true},{"text":"the","start":86,"end":89,"id":14,"ws":true},{"text":"topotecan","start":90,"end":99,"id":15,"ws":true},{"text":"concentration-time","start":100,"end":118,"id":16,"ws":true},{"text":"curve","start":119,"end":124,"id":17,"ws":true},{"text":"(","start":125,"end":126,"id":18,"ws":true},{"text":"AUC","start":127,"end":130,"id":19,"ws":true},{"text":")","start":131,"end":132,"id":20,"ws":true},{"text":"in","start":133,"end":135,"id":21,"ws":true},{"text":"a","start":136,"end":137,"id":22,"ws":true},{"text":"5","start":138,"end":139,"id":23,"ws":true},{"text":"day","start":140,"end":143,"id":24,"ws":true},{"text":"course","start":144,"end":150,"id":25,"ws":true},{"text":"of","start":151,"end":153,"id":26,"ws":true},{"text":"cladribine","start":154,"end":164,"id":27,"ws":true},{"text":"followed","start":165,"end":173,"id":28,"ws":true},{"text":"by","start":174,"end":176,"id":29,"ws":true},{"text":"monitored","start":177,"end":186,"id":30,"ws":true},{"text":"topotecan","start":187,"end":196,"id":31,"ws":true},{"text":"in","start":197,"end":199,"id":32,"ws":true},{"text":"pediatric","start":200,"end":209,"id":33,"ws":true},{"text":"patients","start":210,"end":218,"id":34,"ws":true},{"text":"with","start":219,"end":223,"id":35,"ws":true},{"text":"recurrent/refractory","start":224,"end":244,"id":36,"ws":true},{"text":"AML","start":245,"end":248,"id":37,"ws":true},{"text":".","start":249,"end":250,"id":38,"ws":false}],"spans":[{"start":90,"end":99,"token_start":15,"token_end":15,"label":"DRUG"},{"start":154,"end":164,"token_start":27,"token_end":27,"label":"DRUG"},{"start":187,"end":196,"token_start":31,"token_end":31,"label":"DRUG"}],"_input_hash":796298966,"_task_hash":-199747777,"_session_id":"drug_drug_pilot_shared-dana_a","_view_id":"blocks","relations":[{"head":27,"child":31,"head_span":{"start":154,"end":164,"token_start":27,"token_end":27,"label":"DRUG"},"child_span":{"start":187,"end":196,"token_start":31,"token_end":31,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T1"],"answer":"accept"}
{"text":"The management of EP is challenging : no standardized guidelines exist with literature suggesting cyclosporine or infliximab as first-line therapy .","paragraph":"<h3><u>Erythrodermic psoriasis successfully and rapidly treated with brodalumab: Report of two cases.</u></h3>Erythrodermic psoriasis (EP) is a rare form of the disease clinically characterized by a generalized erythema covering \u226590% of the body surface area (BSA). <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>management</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>EP</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>challenging</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>standardized</i></b> <b style='color:DodgerBlue;'><i>guidelines</i></b> <b style='color:DodgerBlue;'><i>exist</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>literature</i></b> <b style='color:DodgerBlue;'><i>suggesting</i></b> <b style='color:MediumOrchid;'><i>cyclosporine</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>infliximab</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, a recent systematic review showed a positive response in EP patients treated with biologic agents. The most common biologic used for EP up until now has been <b style='color:Tomato;'><i>ustekinumab</i></b>, whereas <b style='color:Tomato;'><i>infliximab</i></b> might represent a first-line option in case of complicated EP (acute, severe, or unstable). Up until now, no case of <b style='color:Tomato;'><i>brodalumab</i></b> (a monoclonal antibody blocking IL-17 receptor) treatment for EP in real-life has ever been described. Here, we report the first two cases of efficacy and safety of <b style='color:Tomato;'><i>brodalumab</i></b> in real-life cases of EP.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"management","start":4,"end":14,"id":1,"ws":true},{"text":"of","start":15,"end":17,"id":2,"ws":true},{"text":"EP","start":18,"end":20,"id":3,"ws":true},{"text":"is","start":21,"end":23,"id":4,"ws":true},{"text":"challenging","start":24,"end":35,"id":5,"ws":true},{"text":":","start":36,"end":37,"id":6,"ws":true},{"text":"no","start":38,"end":40,"id":7,"ws":true},{"text":"standardized","start":41,"end":53,"id":8,"ws":true},{"text":"guidelines","start":54,"end":64,"id":9,"ws":true},{"text":"exist","start":65,"end":70,"id":10,"ws":true},{"text":"with","start":71,"end":75,"id":11,"ws":true},{"text":"literature","start":76,"end":86,"id":12,"ws":true},{"text":"suggesting","start":87,"end":97,"id":13,"ws":true},{"text":"cyclosporine","start":98,"end":110,"id":14,"ws":true},{"text":"or","start":111,"end":113,"id":15,"ws":true},{"text":"infliximab","start":114,"end":124,"id":16,"ws":true},{"text":"as","start":125,"end":127,"id":17,"ws":true},{"text":"first-line","start":128,"end":138,"id":18,"ws":true},{"text":"therapy","start":139,"end":146,"id":19,"ws":true},{"text":".","start":147,"end":148,"id":20,"ws":false}],"spans":[{"start":98,"end":110,"token_start":14,"token_end":14,"label":"DRUG"},{"start":114,"end":124,"token_start":16,"token_end":16,"label":"DRUG"}],"_input_hash":-575753313,"_task_hash":-166345926,"_session_id":"drug_drug_pilot_shared-dana_a","_view_id":"blocks","relations":[],"radio": [],"answer":"accept"}
{"text":"As single agents , curcumin and metformin are reported to exhibit chemopreventive properties , in vitro as well as in patients with oral cancer .","paragraph":"<h3><u>Curcumin and metformin-mediated chemoprevention of oral cancer is associated with inhibition of cancer stem cells.</u></h3>Effective chemoprevention is critical for improving outcomes of oral cancer. <b style='color:DodgerBlue;'><i>As</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>curcumin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>metformin</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>reported</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>exhibit</i></b> <b style='color:DodgerBlue;'><i>chemopreventive</i></b> <b style='color:DodgerBlue;'><i>properties</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In this study, the chemopreventive efficacy of this drug combination was tested in a 4-nitro quinoline-1-oxide (4NQO) induced mice oral carcinogenesis model. Molecular analysis revealed a cancer stem cell (CSC)-driven oral carcinogenic progression in this model, wherein a progressive increase in the expression of CSC-specific markers (CD44 and CD133) was observed from 8th to 25th week, at transcript (40-100-fold) and protein levels (P\u2009\u2264\u20090.0001). Chemopreventive treatment of the animals at 17th week with <b style='color:Tomato;'><i>curcumin</i></b> and <b style='color:Tomato;'><i>metformin</i></b> indicated that the combination regimen decreased tumor volume when compared to the control arm (0.69+0.03 vs 6.66+2.4\u2009mm","tokens":[{"text":"As","start":0,"end":2,"id":0,"ws":true},{"text":"single","start":3,"end":9,"id":1,"ws":true},{"text":"agents","start":10,"end":16,"id":2,"ws":true},{"text":",","start":17,"end":18,"id":3,"ws":true},{"text":"curcumin","start":19,"end":27,"id":4,"ws":true},{"text":"and","start":28,"end":31,"id":5,"ws":true},{"text":"metformin","start":32,"end":41,"id":6,"ws":true},{"text":"are","start":42,"end":45,"id":7,"ws":true},{"text":"reported","start":46,"end":54,"id":8,"ws":true},{"text":"to","start":55,"end":57,"id":9,"ws":true},{"text":"exhibit","start":58,"end":65,"id":10,"ws":true},{"text":"chemopreventive","start":66,"end":81,"id":11,"ws":true},{"text":"properties","start":82,"end":92,"id":12,"ws":true},{"text":",","start":93,"end":94,"id":13,"ws":true},{"text":"in","start":95,"end":97,"id":14,"ws":true},{"text":"vitro","start":98,"end":103,"id":15,"ws":true},{"text":"as","start":104,"end":106,"id":16,"ws":true},{"text":"well","start":107,"end":111,"id":17,"ws":true},{"text":"as","start":112,"end":114,"id":18,"ws":true},{"text":"in","start":115,"end":117,"id":19,"ws":true},{"text":"patients","start":118,"end":126,"id":20,"ws":true},{"text":"with","start":127,"end":131,"id":21,"ws":true},{"text":"oral","start":132,"end":136,"id":22,"ws":true},{"text":"cancer","start":137,"end":143,"id":23,"ws":true},{"text":".","start":144,"end":145,"id":24,"ws":false}],"spans":[{"start":19,"end":27,"token_start":4,"token_end":4,"label":"DRUG"},{"start":32,"end":41,"token_start":6,"token_end":6,"label":"DRUG"}],"_input_hash":-1095827099,"_task_hash":-240223432,"_session_id":"drug_drug_pilot_shared-dana_a","_view_id":"blocks","relations":[{"head":4,"child":6,"head_span":{"start":19,"end":27,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":32,"end":41,"token_start":6,"token_end":6,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T0"],"answer":"accept"}
{"text":"Withdrawal rates were comparable to drug survival rates of other biological therapies and rates of adverse events were similar between brodalumab and ustekinumab .","paragraph":"<h3><u>Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.</u></h3>As part of the National Institute for Health and Care Excellence single technology appraisal process, <b style='color:Tomato;'><i>brodalumab</i></b> was assessed to determine the clinical and cost effectiveness of its use in the treatment of moderate-to-severe plaque psoriasis. The Centre for Reviews and Dissemination and the Centre for Health Economics Technology Assessment Group at the University of York were commissioned to act as the independent Evidence Review Group. This article provides a summary of the Evidence Review Group's review of the company's submission, the Evidence Review Group report and the National Institute for Health and Care Excellence Appraisal Committee's subsequent guidance issued in March 2018. The main clinical effectiveness data were derived from three well-conducted, multicentre, double-blind randomised controlled trials. The trials demonstrated that <b style='color:Tomato;'><i>brodalumab</i></b> statistically significantly reduced the severity of psoriasis and its impact on health-related quality of life, compared with placebo, at 12\u00a0weeks. In comparison with <b style='color:Tomato;'><i>ustekinumab</i></b>, statistically significantly more patients taking <b style='color:Tomato;'><i>brodalumab</i></b> had reduced psoriasis severity at 12\u00a0weeks. Psoriasis severity and quality of life also appeared improved at 52\u00a0weeks, although statistical significance was not assessed. <b style='color:DodgerBlue;'><i>Withdrawal</i></b> <b style='color:DodgerBlue;'><i>rates</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>comparable</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>rates</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>biological</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>rates</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>adverse</i></b> <b style='color:DodgerBlue;'><i>events</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>similar</i></b> <b style='color:DodgerBlue;'><i>between</i></b> <b style='color:MediumOrchid;'><i>brodalumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ustekinumab</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A network meta-analysis was presented, comparing <b style='color:Tomato;'><i>brodalumab</i></b> with other therapies available at the same point in the treatment pathway (i.e. in patients for whom standard systemic therapy or phototherapy is inadequately effective, not tolerated or contraindicated). The network meta-analysis ranked treatments in order of effectiveness, in terms of achieving different levels of Psoriasis Area and Severity Index response. The results indicated that <b style='color:Tomato;'><i>brodalumab</i></b> had a similar probability of response to <b style='color:Tomato;'><i>ixekizumab</i></b>, <b style='color:Tomato;'><i>secukinumab</i></b> and <b style='color:Tomato;'><i>infliximab</i></b> and a higher probability of response than <b style='color:Tomato;'><i>ustekinumab</i></b>, <b style='color:Tomato;'><i>adalimumab</i></b>, <b style='color:Tomato;'><i>etanercept</i></b>, <b style='color:Tomato;'><i>apremilast</i></b>, <b style='color:Tomato;'><i>dimethyl fumarate</i></b> and placebo. The company's economic model compared nine treatment sequences that included three lines of active therapy, consisting of <b style='color:Tomato;'><i>brodalumab</i></b> and other comparators recommended by the National Institute for Health and Care Excellence, followed by best supportive care. The sequence with <b style='color:Tomato;'><i>brodalumab</i></b> in the first-line position dominated sequences that started with <b style='color:Tomato;'><i>adalimumab</i></b>, <b style='color:Tomato;'><i>infliximab</i></b>, <b style='color:Tomato;'><i>secukinumab</i></b> and <b style='color:Tomato;'><i>ustekinumab</i></b>. The incremental cost-effectiveness ratio of the <b style='color:Tomato;'><i>brodalumab</i></b> sequence compared to less effective and non-dominated sequences ranged from \u00a37145 (vs. the <b style='color:Tomato;'><i>etanercept</i></b> sequence) to \u00a313,353 (vs. the <b style='color:Tomato;'><i>dimethyl fumarate</i></b> sequence) per quality-adjusted life-year gained. The incremental cost-effectiveness ratio for the more costly and effective <b style='color:Tomato;'><i>ixekizumab</i></b> sequence was \u00a3894,010 per quality-adjusted life-year gained compared to the <b style='color:Tomato;'><i>brodalumab</i></b> sequence. At a threshold of \u00a320,000 per quality-adjusted life-year gained, the <b style='color:Tomato;'><i>brodalumab</i></b> sequence had the highest probability of being cost effective (96%). The main limitation of the company's economic model was the restrictive nature of the sequences compared. Twelve separate scenarios based on key uncertainties were explored by the Evidence Review Group. The only scenarios where <b style='color:Tomato;'><i>brodalumab</i></b> was ranked lower than first were not considered to be more appropriate or plausible than the assumptions or scenarios included in the company's base case. The treatment rankings identified in the Evidence Review Group's alternative base case were identical to those derived from the company's base case model. At the first National Institute for Health and Care Excellence Appraisal Committee meeting, the Committee concluded that <b style='color:Tomato;'><i>brodalumab</i></b> appears to be as effective as other anti-interleukin-17 agents and is cost effective, based on the discount agreed in the patient access scheme. Brodalumab is recommended as an option for treating adults with severe plaque psoriasis (defined by a total Psoriasis Area and Severity Index score of 10 or more and a Dermatology Life Quality Index score of more than 10) who have not responded to other systemic non-biological therapies. Brodalumab should be stopped at 12\u00a0weeks if the psoriasis has not responded adequately.","tokens":[{"text":"Withdrawal","start":0,"end":10,"id":0,"ws":true},{"text":"rates","start":11,"end":16,"id":1,"ws":true},{"text":"were","start":17,"end":21,"id":2,"ws":true},{"text":"comparable","start":22,"end":32,"id":3,"ws":true},{"text":"to","start":33,"end":35,"id":4,"ws":true},{"text":"drug","start":36,"end":40,"id":5,"ws":true},{"text":"survival","start":41,"end":49,"id":6,"ws":true},{"text":"rates","start":50,"end":55,"id":7,"ws":true},{"text":"of","start":56,"end":58,"id":8,"ws":true},{"text":"other","start":59,"end":64,"id":9,"ws":true},{"text":"biological","start":65,"end":75,"id":10,"ws":true},{"text":"therapies","start":76,"end":85,"id":11,"ws":true},{"text":"and","start":86,"end":89,"id":12,"ws":true},{"text":"rates","start":90,"end":95,"id":13,"ws":true},{"text":"of","start":96,"end":98,"id":14,"ws":true},{"text":"adverse","start":99,"end":106,"id":15,"ws":true},{"text":"events","start":107,"end":113,"id":16,"ws":true},{"text":"were","start":114,"end":118,"id":17,"ws":true},{"text":"similar","start":119,"end":126,"id":18,"ws":true},{"text":"between","start":127,"end":134,"id":19,"ws":true},{"text":"brodalumab","start":135,"end":145,"id":20,"ws":true},{"text":"and","start":146,"end":149,"id":21,"ws":true},{"text":"ustekinumab","start":150,"end":161,"id":22,"ws":true},{"text":".","start":162,"end":163,"id":23,"ws":false}],"spans":[{"start":135,"end":145,"token_start":20,"token_end":20,"label":"DRUG"},{"start":150,"end":161,"token_start":22,"token_end":22,"label":"DRUG"}],"_input_hash":-2044054306,"_task_hash":40529012,"_session_id":"drug_drug_pilot_shared-dana_a","_view_id":"blocks","relations":[],"radio": [],"answer":"accept"}
{"text":"In patients with NPSLE , the use of high-dose corticosteroids is recommended in combination with immunosuppressants , such as mycophenolate mofetil and intravenous cyclophosphamide pulse therapy .","paragraph":"<h3><u>[Neuropsychiatric Systemic Lupus Erythematosus].</u></h3>Central nervous system damage, a major organ manifestation of systemic lupus erythematosus (SLE), causes significant morbidity and mortality. Designating this condition as neuropsychiatric SLE (NPSLE), the American College of Rheumatology defines it as involving the central and peripheral nervous systems and being characterized by various manifestations including stroke, seizures, and psychosis. NPSLE treatment mainly seeks to reduce damage accrual. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>NPSLE</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:DodgerBlue;'><i>corticosteroids</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>recommended</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>immunosuppressants</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>mycophenolate</i></b> <b style='color:DodgerBlue;'><i>mofetil</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>pulse</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> This can be accomplished by controlling the activity of the disease, minimizing the use of corticosteroids, and optimizing the management of comorbidities, including cardiovascular risk factors. An international task force analysis of a treat-to-target strategy for SLE (T2T/SLE) recommended targeting remission, preventing damage, and improving quality of life. Thus, more effective and less toxic treatments, such as those using biologics or kinase inhibitors, are still being developed for the treatment of SLE/NPSLE.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"patients","start":3,"end":11,"id":1,"ws":true},{"text":"with","start":12,"end":16,"id":2,"ws":true},{"text":"NPSLE","start":17,"end":22,"id":3,"ws":true},{"text":",","start":23,"end":24,"id":4,"ws":true},{"text":"the","start":25,"end":28,"id":5,"ws":true},{"text":"use","start":29,"end":32,"id":6,"ws":true},{"text":"of","start":33,"end":35,"id":7,"ws":true},{"text":"high-dose","start":36,"end":45,"id":8,"ws":true},{"text":"corticosteroids","start":46,"end":61,"id":9,"ws":true},{"text":"is","start":62,"end":64,"id":10,"ws":true},{"text":"recommended","start":65,"end":76,"id":11,"ws":true},{"text":"in","start":77,"end":79,"id":12,"ws":true},{"text":"combination","start":80,"end":91,"id":13,"ws":true},{"text":"with","start":92,"end":96,"id":14,"ws":true},{"text":"immunosuppressants","start":97,"end":115,"id":15,"ws":true},{"text":",","start":116,"end":117,"id":16,"ws":true},{"text":"such","start":118,"end":122,"id":17,"ws":true},{"text":"as","start":123,"end":125,"id":18,"ws":true},{"text":"mycophenolate","start":126,"end":139,"id":19,"ws":true},{"text":"mofetil","start":140,"end":147,"id":20,"ws":true},{"text":"and","start":148,"end":151,"id":21,"ws":true},{"text":"intravenous","start":152,"end":163,"id":22,"ws":true},{"text":"cyclophosphamide","start":164,"end":180,"id":23,"ws":true},{"text":"pulse","start":181,"end":186,"id":24,"ws":true},{"text":"therapy","start":187,"end":194,"id":25,"ws":true},{"text":".","start":195,"end":196,"id":26,"ws":false}],"spans":[{"start":126,"end":139,"token_start":19,"token_end":19,"label":"DRUG"},{"start":164,"end":180,"token_start":23,"token_end":23,"label":"DRUG"}],"_input_hash":438186251,"_task_hash":1532533663,"_session_id":"drug_drug_pilot_shared-dana_a","_view_id":"blocks","relations":[{"head":19,"child":23,"head_span":{"start":126,"end":139,"token_start":19,"token_end":19,"label":"DRUG"},"child_span":{"start":164,"end":180,"token_start":23,"token_end":23,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T0"],"answer":"accept"}
{"text":"Thirty-three women diagnosed with metastatic breast cancer participated in a phase 1 clinical trial of a new combination of cyclophosphamide ( CTX ) and mitoxantrone ( MXT ) , with dose escalation of paclitaxel .","paragraph":"<h3><u>Longitudinal effects of high-dose chemotherapy and autologous stem cell transplantation on quality of life in the treatment of metastatic breast cancer.</u></h3>This study determined the effects of high-dose chemotherapy (HDCT) with autologous blood stem cell transplantation (ASCT) on quality of life (QL) in women with metastatic breast cancer prior to, and during treatment, and up to 1-year post-ASCT. <b style='color:DodgerBlue;'><i>Thirty-three</i></b> <b style='color:DodgerBlue;'><i>women</i></b> <b style='color:DodgerBlue;'><i>diagnosed</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>participated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>new</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CTX</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>mitoxantrone</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>MXT</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>escalation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Longitudinal QL data were collected using the functional living index-cancer (FLIC) and symptom scales at seven time periods: pre-induction chemotherapy (CT), post-induction CT, post-high dose CT (HDCT), and at 3, 6, 9 and 12 months post-ASCT. FLIC scores indicated that the worst problems for patients were feelings of hardship on themselves and their families, followed by psychological functioning and physical functioning problems. The time around diagnosis of the metastatic disease and following HDCT were the worst times for all levels of quality of life, but anxiety and depression symptoms continued to increase in severity across the entire follow-up period. The symptoms that were most problematic were worry about the future, loss of sexual interest, anxiety about the treatment, general worrying, and joint pain. These data highlight the problems that women with metastatic breast cancer encounter at different stages of the disease and treatment process, and can be used to tailor psychosocial interventions appropriate for treating the relevant issues at different points in time.","tokens":[{"text":"Thirty-three","start":0,"end":12,"id":0,"ws":true},{"text":"women","start":13,"end":18,"id":1,"ws":true},{"text":"diagnosed","start":19,"end":28,"id":2,"ws":true},{"text":"with","start":29,"end":33,"id":3,"ws":true},{"text":"metastatic","start":34,"end":44,"id":4,"ws":true},{"text":"breast","start":45,"end":51,"id":5,"ws":true},{"text":"cancer","start":52,"end":58,"id":6,"ws":true},{"text":"participated","start":59,"end":71,"id":7,"ws":true},{"text":"in","start":72,"end":74,"id":8,"ws":true},{"text":"a","start":75,"end":76,"id":9,"ws":true},{"text":"phase","start":77,"end":82,"id":10,"ws":true},{"text":"1","start":83,"end":84,"id":11,"ws":true},{"text":"clinical","start":85,"end":93,"id":12,"ws":true},{"text":"trial","start":94,"end":99,"id":13,"ws":true},{"text":"of","start":100,"end":102,"id":14,"ws":true},{"text":"a","start":103,"end":104,"id":15,"ws":true},{"text":"new","start":105,"end":108,"id":16,"ws":true},{"text":"combination","start":109,"end":120,"id":17,"ws":true},{"text":"of","start":121,"end":123,"id":18,"ws":true},{"text":"cyclophosphamide","start":124,"end":140,"id":19,"ws":true},{"text":"(","start":141,"end":142,"id":20,"ws":true},{"text":"CTX","start":143,"end":146,"id":21,"ws":true},{"text":")","start":147,"end":148,"id":22,"ws":true},{"text":"and","start":149,"end":152,"id":23,"ws":true},{"text":"mitoxantrone","start":153,"end":165,"id":24,"ws":true},{"text":"(","start":166,"end":167,"id":25,"ws":true},{"text":"MXT","start":168,"end":171,"id":26,"ws":true},{"text":")","start":172,"end":173,"id":27,"ws":true},{"text":",","start":174,"end":175,"id":28,"ws":true},{"text":"with","start":176,"end":180,"id":29,"ws":true},{"text":"dose","start":181,"end":185,"id":30,"ws":true},{"text":"escalation","start":186,"end":196,"id":31,"ws":true},{"text":"of","start":197,"end":199,"id":32,"ws":true},{"text":"paclitaxel","start":200,"end":210,"id":33,"ws":true},{"text":".","start":211,"end":212,"id":34,"ws":false}],"spans":[{"start":124,"end":140,"token_start":19,"token_end":19,"label":"DRUG"},{"start":153,"end":165,"token_start":24,"token_end":24,"label":"DRUG"},{"start":200,"end":210,"token_start":33,"token_end":33,"label":"DRUG"}],"_input_hash":1782132717,"_task_hash":189034633,"_session_id":"drug_drug_pilot_shared-dana_a","_view_id":"blocks","relations":[{"head":19,"child":24,"head_span":{"start":124,"end":140,"token_start":19,"token_end":19,"label":"DRUG"},"child_span":{"start":153,"end":165,"token_start":24,"token_end":24,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":24,"child":33,"head_span":{"start":153,"end":165,"token_start":24,"token_end":24,"label":"DRUG"},"child_span":{"start":200,"end":210,"token_start":33,"token_end":33,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T1"],"answer":"accept"}
{"text":"However , anastrozole , exemestane and letrozole are associated with significantly fewer endometrial cancers , as well as venous and arterial vascular events , when compared with tamoxifen [ 9 , 10 ] .","paragraph":"<h3><u>Erythema nodosum secondary to aromatase inhibitor use in breast cancer patients: case reports and review of the literature.</u></h3>Aromatase inhibitors (AI's) are increasingly being incorporated in the treatment strategy for hormone receptor positive breast cancer either alone or in combination with chemotherapy, biologics in both the adjuvant and metastatic setting [1]. They markedly suppress plasma estrogen levels by inhibiting or inactivating aromatase, the enzyme responsible for the synthesis of estrogens from androgenic substrates [1]. Currently, the three selective aromatase inhibitors that are available are <b style='color:Tomato;'><i>anastrozole</i></b>, <b style='color:Tomato;'><i>letrozole</i></b> and <b style='color:Tomato;'><i>exemestane</i></b> which reduce circulating estrogen to 1 to 10% of pretreatment levels [2]. For advanced breast cancer, aromatase inhibitors appear to be at a minimum, equivalent and perhaps even better than <b style='color:Tomato;'><i>tamoxifen</i></b> in the first line setting [3, 4]. In primary breast cancer, adjuvant therapy with <b style='color:Tomato;'><i>anastrozole</i></b> or <b style='color:Tomato;'><i>letrozole</i></b> appears to be superior to <b style='color:Tomato;'><i>tamoxifen</i></b> in reducing the risk of relapse [5, 6]. Common adverse effects associated with AI's include arthralgias (21%), myalgias (12%), other musculoskeletal disorders (28%) and an up to 60% increased risk of bone fracture [7, 8]. <b style='color:DodgerBlue;'><i>However</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>anastrozole</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>exemestane</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>letrozole</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>fewer</i></b> <b style='color:DodgerBlue;'><i>endometrial</i></b> <b style='color:DodgerBlue;'><i>cancers</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>venous</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>arterial</i></b> <b style='color:DodgerBlue;'><i>vascular</i></b> <b style='color:DodgerBlue;'><i>events</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>9</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Very rarely <b style='color:Tomato;'><i>letrozole</i></b> and <b style='color:Tomato;'><i>anastrozole</i></b> can cause a skin rash; the frequency of its occurrence has not been quantified(. )However, <b style='color:Tomato;'><i>exemestane</i></b> has not been reported to cause a skin rash [11]. To date, erythema nodosum (EN) has not been reported as a dermatologic side effect of AI's. Here, we report three cases of EN which developed in postmenopausal breast cancer patients on AI's.","tokens":[{"text":"However","start":0,"end":7,"id":0,"ws":true},{"text":",","start":8,"end":9,"id":1,"ws":true},{"text":"anastrozole","start":10,"end":21,"id":2,"ws":true},{"text":",","start":22,"end":23,"id":3,"ws":true},{"text":"exemestane","start":24,"end":34,"id":4,"ws":true},{"text":"and","start":35,"end":38,"id":5,"ws":true},{"text":"letrozole","start":39,"end":48,"id":6,"ws":true},{"text":"are","start":49,"end":52,"id":7,"ws":true},{"text":"associated","start":53,"end":63,"id":8,"ws":true},{"text":"with","start":64,"end":68,"id":9,"ws":true},{"text":"significantly","start":69,"end":82,"id":10,"ws":true},{"text":"fewer","start":83,"end":88,"id":11,"ws":true},{"text":"endometrial","start":89,"end":100,"id":12,"ws":true},{"text":"cancers","start":101,"end":108,"id":13,"ws":true},{"text":",","start":109,"end":110,"id":14,"ws":true},{"text":"as","start":111,"end":113,"id":15,"ws":true},{"text":"well","start":114,"end":118,"id":16,"ws":true},{"text":"as","start":119,"end":121,"id":17,"ws":true},{"text":"venous","start":122,"end":128,"id":18,"ws":true},{"text":"and","start":129,"end":132,"id":19,"ws":true},{"text":"arterial","start":133,"end":141,"id":20,"ws":true},{"text":"vascular","start":142,"end":150,"id":21,"ws":true},{"text":"events","start":151,"end":157,"id":22,"ws":true},{"text":",","start":158,"end":159,"id":23,"ws":true},{"text":"when","start":160,"end":164,"id":24,"ws":true},{"text":"compared","start":165,"end":173,"id":25,"ws":true},{"text":"with","start":174,"end":178,"id":26,"ws":true},{"text":"tamoxifen","start":179,"end":188,"id":27,"ws":true},{"text":"[","start":189,"end":190,"id":28,"ws":true},{"text":"9","start":191,"end":192,"id":29,"ws":true},{"text":",","start":193,"end":194,"id":30,"ws":true},{"text":"10","start":195,"end":197,"id":31,"ws":true},{"text":"]","start":198,"end":199,"id":32,"ws":true},{"text":".","start":200,"end":201,"id":33,"ws":false}],"spans":[{"start":10,"end":21,"token_start":2,"token_end":2,"label":"DRUG"},{"start":24,"end":34,"token_start":4,"token_end":4,"label":"DRUG"},{"start":39,"end":48,"token_start":6,"token_end":6,"label":"DRUG"},{"start":179,"end":188,"token_start":27,"token_end":27,"label":"DRUG"}],"_input_hash":155070717,"_task_hash":-411756935,"_session_id":"drug_drug_pilot_shared-yosi","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Additivity , synergy , or competition was observed with MIS and rapamycin , AzadC , doxorubicin , cisplatin , and paclitaxel , suggesting that MIS in combination with selective targeted therapies might achieve greater activity against ovarian cancer than the use of each individual agent alone .","paragraph":"<h3><u>Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.</u></h3>Mullerian Inhibiting Substance (MIS), a biological modifier that causes regression of Mullerian ducts in male embryos, is effective as a single agent in vitro and in vivo against human and mouse ovarian cancer cell lines expressing MIS type II receptor; however, little is known about how recombinant human MIS (rhMIS), now being scaled for preclinical trials, could be used in combination with cytotoxic or targeted chemotherapeutic agents. Mouse serous and endometrioid ovarian carcinoma cell lines were tested in vitro against rhMIS alone and with <b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>paclitaxel</i></b>, or cisplatin as agents in clinical use. Because MIS releases FK506 binding protein (FKBP12), which activates the mammalian target of <b style='color:Tomato;'><i>rapamycin</i></b> (mTOR) downstream of Akt, rhMIS and <b style='color:Tomato;'><i>rapamycin</i></b> combinations were tested. MIS increases p16 protein levels, and 5'-Aza-2'-deoxycytidine (AzadC) induces p16 mRNA; therefore, they were used in combination in vitro and in vivo with a human ovarian cancer cell line. A <b style='color:Tomato;'><i>paclitaxel</i></b>-resistant human ovarian cancer cell line and its parental line both respond to rhMIS in vitro. <b style='color:DodgerBlue;'><i>Additivity</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>synergy</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>competition</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>observed</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>MIS</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rapamycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>AzadC</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>suggesting</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>MIS</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>selective</i></b> <b style='color:DodgerBlue;'><i>targeted</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>might</i></b> <b style='color:DodgerBlue;'><i>achieve</i></b> <b style='color:DodgerBlue;'><i>greater</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>ovarian</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>each</i></b> <b style='color:DodgerBlue;'><i>individual</i></b> <b style='color:DodgerBlue;'><i>agent</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> These assays and statistical analyses could be useful in selecting rhMIS and chemotherapeutic agent combinations that enhance clinical efficacy and reduce toxicity.","tokens":[{"text":"Additivity","start":0,"end":10,"id":0,"ws":true},{"text":",","start":11,"end":12,"id":1,"ws":true},{"text":"synergy","start":13,"end":20,"id":2,"ws":true},{"text":",","start":21,"end":22,"id":3,"ws":true},{"text":"or","start":23,"end":25,"id":4,"ws":true},{"text":"competition","start":26,"end":37,"id":5,"ws":true},{"text":"was","start":38,"end":41,"id":6,"ws":true},{"text":"observed","start":42,"end":50,"id":7,"ws":true},{"text":"with","start":51,"end":55,"id":8,"ws":true},{"text":"MIS","start":56,"end":59,"id":9,"ws":true},{"text":"and","start":60,"end":63,"id":10,"ws":true},{"text":"rapamycin","start":64,"end":73,"id":11,"ws":true},{"text":",","start":74,"end":75,"id":12,"ws":true},{"text":"AzadC","start":76,"end":81,"id":13,"ws":true},{"text":",","start":82,"end":83,"id":14,"ws":true},{"text":"doxorubicin","start":84,"end":95,"id":15,"ws":true},{"text":",","start":96,"end":97,"id":16,"ws":true},{"text":"cisplatin","start":98,"end":107,"id":17,"ws":true},{"text":",","start":108,"end":109,"id":18,"ws":true},{"text":"and","start":110,"end":113,"id":19,"ws":true},{"text":"paclitaxel","start":114,"end":124,"id":20,"ws":true},{"text":",","start":125,"end":126,"id":21,"ws":true},{"text":"suggesting","start":127,"end":137,"id":22,"ws":true},{"text":"that","start":138,"end":142,"id":23,"ws":true},{"text":"MIS","start":143,"end":146,"id":24,"ws":true},{"text":"in","start":147,"end":149,"id":25,"ws":true},{"text":"combination","start":150,"end":161,"id":26,"ws":true},{"text":"with","start":162,"end":166,"id":27,"ws":true},{"text":"selective","start":167,"end":176,"id":28,"ws":true},{"text":"targeted","start":177,"end":185,"id":29,"ws":true},{"text":"therapies","start":186,"end":195,"id":30,"ws":true},{"text":"might","start":196,"end":201,"id":31,"ws":true},{"text":"achieve","start":202,"end":209,"id":32,"ws":true},{"text":"greater","start":210,"end":217,"id":33,"ws":true},{"text":"activity","start":218,"end":226,"id":34,"ws":true},{"text":"against","start":227,"end":234,"id":35,"ws":true},{"text":"ovarian","start":235,"end":242,"id":36,"ws":true},{"text":"cancer","start":243,"end":249,"id":37,"ws":true},{"text":"than","start":250,"end":254,"id":38,"ws":true},{"text":"the","start":255,"end":258,"id":39,"ws":true},{"text":"use","start":259,"end":262,"id":40,"ws":true},{"text":"of","start":263,"end":265,"id":41,"ws":true},{"text":"each","start":266,"end":270,"id":42,"ws":true},{"text":"individual","start":271,"end":281,"id":43,"ws":true},{"text":"agent","start":282,"end":287,"id":44,"ws":true},{"text":"alone","start":288,"end":293,"id":45,"ws":true},{"text":".","start":294,"end":295,"id":46,"ws":false}],"spans":[{"start":64,"end":73,"token_start":11,"token_end":11,"label":"DRUG"},{"start":84,"end":95,"token_start":15,"token_end":15,"label":"DRUG"},{"start":114,"end":124,"token_start":20,"token_end":20,"label":"DRUG"}],"_input_hash":1387497584,"_task_hash":991977050,"_session_id":"drug_drug_pilot_shared-yosi","_view_id":"blocks","relations":[{"head":9,"child":11,"head_span":{"start":56,"end":59,"token_start":9,"token_end":9,"label":null},"child_span":{"start":64,"end":73,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":9,"child":13,"head_span":{"start":56,"end":59,"token_start":9,"token_end":9,"label":null},"child_span":{"start":76,"end":81,"token_start":13,"token_end":13,"label":null},"color":"#ffd882","label":"POS2"},{"head":15,"child":9,"head_span":{"start":84,"end":95,"token_start":15,"token_end":15,"label":"DRUG"},"child_span":{"start":56,"end":59,"token_start":9,"token_end":9,"label":null},"color":"#d9fbad","label":"POS3"}],"radio":["POS10","POS1T0","POS20","POS2T0","POS30","POS3T0"],"answer":"accept"}
{"text":"There was no cytotoxic effect of cisplatin , ifosfamide , and etoposide .","paragraph":"<h3><u>Overcoming Chemoresistance of Pediatric Ependymoma by Inhibition of STAT3 Signaling.</u></h3>The long-term clinical outcome of pediatric intracranial epepdymoma is poor with a high rate of recurrence. One of the main reasons for this poor outcome is the tumor's inherent resistance to chemotherapy. Signal transducer and activator of transcription 3 (STAT3) is overactive in many human cancers, and inhibition of STAT3 signaling is an emerging area of interest in oncology. In this study, the possibility of STAT3 inhibition as a treatment was investigated in pediatric intracranial ependymoma tissues and cell lines. STAT3 activation status was checked in ependymoma tissues. The responses to conventional chemotherapeutic agents and a STAT3 inhibitor WP1066 in primarily cultured ependymoma cells were measured by cell viability assay. Apoptosis assays were conducted to reveal the cytotoxic mechanism of applied agents. Knockdown of STAT3 was tried to confirm the effects of STAT3 inhibition in ependymoma cells. High levels of phospho-STAT3 (p-STAT3) expression were observed in ependymoma tissue, especially in the anaplastic histology group. <b style='color:DodgerBlue;'><i>There</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>cytotoxic</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Both brain tumor-initiating cells (BTICs) and bulk tumor cells (BCs) showed considerably decreased viability after WP1066 treatment. However, BTICs had fewer responses than BCs. No additive or synergistic effect was observed for combination therapy of WP1066 and cisplatin. WP1066 effectively abrogated p-STAT3 expression. An increased apoptosis and decreased Survivin expression were observed after WP1066 treatment. Knockdown of STAT3 also decreased cell survival, supporting the critical role of STAT3 in sustaining ependymoma cells. In this study, we observed a cytotoxic effect of STAT3 inhibitor on ependymoma BTICs and BCs. There is urgent need to develop new therapeutic agents for pediatric ependymoma. STAT3 inhibitors may be a new group of drugs for clinical application. ","tokens":[{"text":"There","start":0,"end":5,"id":0,"ws":true},{"text":"was","start":6,"end":9,"id":1,"ws":true},{"text":"no","start":10,"end":12,"id":2,"ws":true},{"text":"cytotoxic","start":13,"end":22,"id":3,"ws":true},{"text":"effect","start":23,"end":29,"id":4,"ws":true},{"text":"of","start":30,"end":32,"id":5,"ws":true},{"text":"cisplatin","start":33,"end":42,"id":6,"ws":true},{"text":",","start":43,"end":44,"id":7,"ws":true},{"text":"ifosfamide","start":45,"end":55,"id":8,"ws":true},{"text":",","start":56,"end":57,"id":9,"ws":true},{"text":"and","start":58,"end":61,"id":10,"ws":true},{"text":"etoposide","start":62,"end":71,"id":11,"ws":true},{"text":".","start":72,"end":73,"id":12,"ws":false}],"spans":[{"start":45,"end":55,"token_start":8,"token_end":8,"label":"DRUG"},{"start":62,"end":71,"token_start":11,"token_end":11,"label":"DRUG"}],"_input_hash":-1352726798,"_task_hash":-274527523,"_session_id":"drug_drug_pilot_shared-yosi","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Several first-line phase III trials , as well as ongoing trials for which only preliminary results have been published , have fueled debates on the optimal dose and schedule ; these have focused not only on weekly vs q3-weeks paclitaxel , but also on other modifications and the advisability of adding bevacizumab .","paragraph":"<h3><u>Carboplatin/Paclitaxel Induction in Ovarian Cancer: The Finer Points.</u></h3>The <b style='color:Tomato;'><i>carboplatin</i></b>/<b style='color:Tomato;'><i>paclitaxel</i></b> doublet remains the chemotherapy backbone for the initial treatment of ovarian cancer. This two-drug regimen, with <b style='color:Tomato;'><i>carboplatin</i></b> dosed using the Calvert formula, yielded convincing noninferior outcomes when compared with the prior, more toxic, regimen of cisplatin/<b style='color:Tomato;'><i>paclitaxel</i></b>. Carboplatin's dose-limiting toxicity is thrombocytopenia; however, when this drug is properly dosed and combined with <b style='color:Tomato;'><i>paclitaxel</i></b>, the doublet's cycle 1 dose in chemotherapy-naive women is generally safe. Carboplatin (unlike cisplatin) contributes minimally to the cumulative sensory neuropathy of <b style='color:Tomato;'><i>paclitaxel</i></b>, thus ensuring noticeable reversibility of neuropathy symptoms following completion of 6 cycles and only occasionally requiring cessation or substitution of the taxane. Paclitaxel is responsible for the hair loss associated with the <b style='color:Tomato;'><i>carboplatin</i></b>/<b style='color:Tomato;'><i>paclitaxel</i></b> doublet; preventive measures must be considered for patients who would otherwise refuse treatment. <b style='color:DodgerBlue;'><i>Several</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>III</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>ongoing</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>which</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>preliminary</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>published</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>fueled</i></b> <b style='color:DodgerBlue;'><i>debates</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>optimal</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>schedule</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>focused</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>weekly</i></b> <b style='color:DodgerBlue;'><i>vs</i></b> <b style='color:DodgerBlue;'><i>q3-weeks</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>also</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>modifications</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>advisability</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>adding</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Our view is that results of this doublet in the first-line treatment of ovarian cancer are driven primarily by <b style='color:Tomato;'><i>carboplatin</i></b>, given that ovarian cancer is a platinum-sensitive disease. Consequently, the roles of the accompanying <b style='color:Tomato;'><i>paclitaxel</i></b> dose and schedule and the addition of <b style='color:Tomato;'><i>bevacizumab</i></b> are currently unsettled, and questions regarding these issues should be decided based on patient tolerance and comorbidities until additional data are available.","tokens":[{"text":"Several","start":0,"end":7,"id":0,"ws":true},{"text":"first-line","start":8,"end":18,"id":1,"ws":true},{"text":"phase","start":19,"end":24,"id":2,"ws":true},{"text":"III","start":25,"end":28,"id":3,"ws":true},{"text":"trials","start":29,"end":35,"id":4,"ws":true},{"text":",","start":36,"end":37,"id":5,"ws":true},{"text":"as","start":38,"end":40,"id":6,"ws":true},{"text":"well","start":41,"end":45,"id":7,"ws":true},{"text":"as","start":46,"end":48,"id":8,"ws":true},{"text":"ongoing","start":49,"end":56,"id":9,"ws":true},{"text":"trials","start":57,"end":63,"id":10,"ws":true},{"text":"for","start":64,"end":67,"id":11,"ws":true},{"text":"which","start":68,"end":73,"id":12,"ws":true},{"text":"only","start":74,"end":78,"id":13,"ws":true},{"text":"preliminary","start":79,"end":90,"id":14,"ws":true},{"text":"results","start":91,"end":98,"id":15,"ws":true},{"text":"have","start":99,"end":103,"id":16,"ws":true},{"text":"been","start":104,"end":108,"id":17,"ws":true},{"text":"published","start":109,"end":118,"id":18,"ws":true},{"text":",","start":119,"end":120,"id":19,"ws":true},{"text":"have","start":121,"end":125,"id":20,"ws":true},{"text":"fueled","start":126,"end":132,"id":21,"ws":true},{"text":"debates","start":133,"end":140,"id":22,"ws":true},{"text":"on","start":141,"end":143,"id":23,"ws":true},{"text":"the","start":144,"end":147,"id":24,"ws":true},{"text":"optimal","start":148,"end":155,"id":25,"ws":true},{"text":"dose","start":156,"end":160,"id":26,"ws":true},{"text":"and","start":161,"end":164,"id":27,"ws":true},{"text":"schedule","start":165,"end":173,"id":28,"ws":true},{"text":";","start":174,"end":175,"id":29,"ws":true},{"text":"these","start":176,"end":181,"id":30,"ws":true},{"text":"have","start":182,"end":186,"id":31,"ws":true},{"text":"focused","start":187,"end":194,"id":32,"ws":true},{"text":"not","start":195,"end":198,"id":33,"ws":true},{"text":"only","start":199,"end":203,"id":34,"ws":true},{"text":"on","start":204,"end":206,"id":35,"ws":true},{"text":"weekly","start":207,"end":213,"id":36,"ws":true},{"text":"vs","start":214,"end":216,"id":37,"ws":true},{"text":"q3-weeks","start":217,"end":225,"id":38,"ws":true},{"text":"paclitaxel","start":226,"end":236,"id":39,"ws":true},{"text":",","start":237,"end":238,"id":40,"ws":true},{"text":"but","start":239,"end":242,"id":41,"ws":true},{"text":"also","start":243,"end":247,"id":42,"ws":true},{"text":"on","start":248,"end":250,"id":43,"ws":true},{"text":"other","start":251,"end":256,"id":44,"ws":true},{"text":"modifications","start":257,"end":270,"id":45,"ws":true},{"text":"and","start":271,"end":274,"id":46,"ws":true},{"text":"the","start":275,"end":278,"id":47,"ws":true},{"text":"advisability","start":279,"end":291,"id":48,"ws":true},{"text":"of","start":292,"end":294,"id":49,"ws":true},{"text":"adding","start":295,"end":301,"id":50,"ws":true},{"text":"bevacizumab","start":302,"end":313,"id":51,"ws":true},{"text":".","start":314,"end":315,"id":52,"ws":false}],"spans":[{"start":226,"end":236,"token_start":39,"token_end":39,"label":"DRUG"},{"start":302,"end":313,"token_start":51,"token_end":51,"label":"DRUG"}],"_input_hash":1252988243,"_task_hash":322511723,"_session_id":"drug_drug_pilot_shared-yosi","_view_id":"blocks","relations":[{"head":39,"child":51,"head_span":{"start":226,"end":236,"token_start":39,"token_end":39,"label":"DRUG"},"child_span":{"start":302,"end":313,"token_start":51,"token_end":51,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"The primary goal was achieve the correct estimation of the target plasma area against the topotecan concentration-time curve ( AUC ) in a 5 day course of cladribine followed by monitored topotecan in pediatric patients with recurrent/refractory AML .","paragraph":"<h3><u>Topotecan exposure estimation in pediatric acute myeloid leukemia supported by LC-MS-based drug monitoring and pharmacokinetic analysis.</u></h3>Individualization of the <b style='color:Tomato;'><i>topotecan</i></b> dosing can reduce inter-patient variability, toxicity, and at the same time increases chemotherapy efficacy. Topotecan dosing based on simultaneous drug monitoring and pharmacokinetic analysis can yield more accurate and precise estimation of the <b style='color:Tomato;'><i>topotecan</i></b> systemic exposure than that attainable with the fixed dosing approach. Therefore, a combined approach could provide a tool assisting the clinicians in individualization of the <b style='color:Tomato;'><i>topotecan</i></b> dosing. The aim of the study was to estimate the <b style='color:Tomato;'><i>topotecan</i></b> exposure in pediatric patients with acute myeloid leukemia (AML) based on the plasma concentration-time data and using the pharmacokinetic analysis. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>primary</i></b> <b style='color:DodgerBlue;'><i>goal</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>achieve</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>correct</i></b> <b style='color:DodgerBlue;'><i>estimation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>target</i></b> <b style='color:DodgerBlue;'><i>plasma</i></b> <b style='color:DodgerBlue;'><i>area</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:MediumOrchid;'><i>topotecan</i></b> <b style='color:DodgerBlue;'><i>concentration-time</i></b> <b style='color:DodgerBlue;'><i>curve</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AUC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>course</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cladribine</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>monitored</i></b> <b style='color:MediumOrchid;'><i>topotecan</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>pediatric</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>recurrent/refractory</i></b> <b style='color:DodgerBlue;'><i>AML</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A sensitive and selective reversed-phase liquid chromatographic-mass spectrometry (LC-MS) assay was developed to quantify total <b style='color:Tomato;'><i>topotecan</i></b> in the human plasma samples. This method, with its lower quantification limit of 1 ng/ml, was validated over a linear range of 1-150 ng/ml. Under the proposed approach, the <b style='color:Tomato;'><i>topotecan</i></b> dosing was selected so as to achieve the final AUC value of 140\u00b120 ng/ml h. The presented analytical and pharmacokinetic data demonstrate that the proposed approach can be a practical, useful, efficient, and accurate tool for individualizing the <b style='color:Tomato;'><i>topotecan</i></b> dosing in children with AML.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"primary","start":4,"end":11,"id":1,"ws":true},{"text":"goal","start":12,"end":16,"id":2,"ws":true},{"text":"was","start":17,"end":20,"id":3,"ws":true},{"text":"achieve","start":21,"end":28,"id":4,"ws":true},{"text":"the","start":29,"end":32,"id":5,"ws":true},{"text":"correct","start":33,"end":40,"id":6,"ws":true},{"text":"estimation","start":41,"end":51,"id":7,"ws":true},{"text":"of","start":52,"end":54,"id":8,"ws":true},{"text":"the","start":55,"end":58,"id":9,"ws":true},{"text":"target","start":59,"end":65,"id":10,"ws":true},{"text":"plasma","start":66,"end":72,"id":11,"ws":true},{"text":"area","start":73,"end":77,"id":12,"ws":true},{"text":"against","start":78,"end":85,"id":13,"ws":true},{"text":"the","start":86,"end":89,"id":14,"ws":true},{"text":"topotecan","start":90,"end":99,"id":15,"ws":true},{"text":"concentration-time","start":100,"end":118,"id":16,"ws":true},{"text":"curve","start":119,"end":124,"id":17,"ws":true},{"text":"(","start":125,"end":126,"id":18,"ws":true},{"text":"AUC","start":127,"end":130,"id":19,"ws":true},{"text":")","start":131,"end":132,"id":20,"ws":true},{"text":"in","start":133,"end":135,"id":21,"ws":true},{"text":"a","start":136,"end":137,"id":22,"ws":true},{"text":"5","start":138,"end":139,"id":23,"ws":true},{"text":"day","start":140,"end":143,"id":24,"ws":true},{"text":"course","start":144,"end":150,"id":25,"ws":true},{"text":"of","start":151,"end":153,"id":26,"ws":true},{"text":"cladribine","start":154,"end":164,"id":27,"ws":true},{"text":"followed","start":165,"end":173,"id":28,"ws":true},{"text":"by","start":174,"end":176,"id":29,"ws":true},{"text":"monitored","start":177,"end":186,"id":30,"ws":true},{"text":"topotecan","start":187,"end":196,"id":31,"ws":true},{"text":"in","start":197,"end":199,"id":32,"ws":true},{"text":"pediatric","start":200,"end":209,"id":33,"ws":true},{"text":"patients","start":210,"end":218,"id":34,"ws":true},{"text":"with","start":219,"end":223,"id":35,"ws":true},{"text":"recurrent/refractory","start":224,"end":244,"id":36,"ws":true},{"text":"AML","start":245,"end":248,"id":37,"ws":true},{"text":".","start":249,"end":250,"id":38,"ws":false}],"spans":[{"start":90,"end":99,"token_start":15,"token_end":15,"label":"DRUG"},{"start":154,"end":164,"token_start":27,"token_end":27,"label":"DRUG"},{"start":187,"end":196,"token_start":31,"token_end":31,"label":"DRUG"}],"_input_hash":796298966,"_task_hash":-199747777,"_session_id":"drug_drug_pilot_shared-yosi","_view_id":"blocks","relations":[{"head":27,"child":31,"head_span":{"start":154,"end":164,"token_start":27,"token_end":27,"label":"DRUG"},"child_span":{"start":187,"end":196,"token_start":31,"token_end":31,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T1"],"answer":"accept"}
{"text":"The management of EP is challenging : no standardized guidelines exist with literature suggesting cyclosporine or infliximab as first-line therapy .","paragraph":"<h3><u>Erythrodermic psoriasis successfully and rapidly treated with brodalumab: Report of two cases.</u></h3>Erythrodermic psoriasis (EP) is a rare form of the disease clinically characterized by a generalized erythema covering \u226590% of the body surface area (BSA). <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>management</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>EP</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>challenging</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>standardized</i></b> <b style='color:DodgerBlue;'><i>guidelines</i></b> <b style='color:DodgerBlue;'><i>exist</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>literature</i></b> <b style='color:DodgerBlue;'><i>suggesting</i></b> <b style='color:MediumOrchid;'><i>cyclosporine</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>infliximab</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, a recent systematic review showed a positive response in EP patients treated with biologic agents. The most common biologic used for EP up until now has been <b style='color:Tomato;'><i>ustekinumab</i></b>, whereas <b style='color:Tomato;'><i>infliximab</i></b> might represent a first-line option in case of complicated EP (acute, severe, or unstable). Up until now, no case of <b style='color:Tomato;'><i>brodalumab</i></b> (a monoclonal antibody blocking IL-17 receptor) treatment for EP in real-life has ever been described. Here, we report the first two cases of efficacy and safety of <b style='color:Tomato;'><i>brodalumab</i></b> in real-life cases of EP.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"management","start":4,"end":14,"id":1,"ws":true},{"text":"of","start":15,"end":17,"id":2,"ws":true},{"text":"EP","start":18,"end":20,"id":3,"ws":true},{"text":"is","start":21,"end":23,"id":4,"ws":true},{"text":"challenging","start":24,"end":35,"id":5,"ws":true},{"text":":","start":36,"end":37,"id":6,"ws":true},{"text":"no","start":38,"end":40,"id":7,"ws":true},{"text":"standardized","start":41,"end":53,"id":8,"ws":true},{"text":"guidelines","start":54,"end":64,"id":9,"ws":true},{"text":"exist","start":65,"end":70,"id":10,"ws":true},{"text":"with","start":71,"end":75,"id":11,"ws":true},{"text":"literature","start":76,"end":86,"id":12,"ws":true},{"text":"suggesting","start":87,"end":97,"id":13,"ws":true},{"text":"cyclosporine","start":98,"end":110,"id":14,"ws":true},{"text":"or","start":111,"end":113,"id":15,"ws":true},{"text":"infliximab","start":114,"end":124,"id":16,"ws":true},{"text":"as","start":125,"end":127,"id":17,"ws":true},{"text":"first-line","start":128,"end":138,"id":18,"ws":true},{"text":"therapy","start":139,"end":146,"id":19,"ws":true},{"text":".","start":147,"end":148,"id":20,"ws":false}],"spans":[{"start":98,"end":110,"token_start":14,"token_end":14,"label":"DRUG"},{"start":114,"end":124,"token_start":16,"token_end":16,"label":"DRUG"}],"_input_hash":-575753313,"_task_hash":-166345926,"_session_id":"drug_drug_pilot_shared-yosi","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"As single agents , curcumin and metformin are reported to exhibit chemopreventive properties , in vitro as well as in patients with oral cancer .","paragraph":"<h3><u>Curcumin and metformin-mediated chemoprevention of oral cancer is associated with inhibition of cancer stem cells.</u></h3>Effective chemoprevention is critical for improving outcomes of oral cancer. <b style='color:DodgerBlue;'><i>As</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>curcumin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>metformin</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>reported</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>exhibit</i></b> <b style='color:DodgerBlue;'><i>chemopreventive</i></b> <b style='color:DodgerBlue;'><i>properties</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In this study, the chemopreventive efficacy of this drug combination was tested in a 4-nitro quinoline-1-oxide (4NQO) induced mice oral carcinogenesis model. Molecular analysis revealed a cancer stem cell (CSC)-driven oral carcinogenic progression in this model, wherein a progressive increase in the expression of CSC-specific markers (CD44 and CD133) was observed from 8th to 25th week, at transcript (40-100-fold) and protein levels (P\u2009\u2264\u20090.0001). Chemopreventive treatment of the animals at 17th week with <b style='color:Tomato;'><i>curcumin</i></b> and <b style='color:Tomato;'><i>metformin</i></b> indicated that the combination regimen decreased tumor volume when compared to the control arm (0.69+0.03 vs 6.66+2.4\u2009mm","tokens":[{"text":"As","start":0,"end":2,"id":0,"ws":true},{"text":"single","start":3,"end":9,"id":1,"ws":true},{"text":"agents","start":10,"end":16,"id":2,"ws":true},{"text":",","start":17,"end":18,"id":3,"ws":true},{"text":"curcumin","start":19,"end":27,"id":4,"ws":true},{"text":"and","start":28,"end":31,"id":5,"ws":true},{"text":"metformin","start":32,"end":41,"id":6,"ws":true},{"text":"are","start":42,"end":45,"id":7,"ws":true},{"text":"reported","start":46,"end":54,"id":8,"ws":true},{"text":"to","start":55,"end":57,"id":9,"ws":true},{"text":"exhibit","start":58,"end":65,"id":10,"ws":true},{"text":"chemopreventive","start":66,"end":81,"id":11,"ws":true},{"text":"properties","start":82,"end":92,"id":12,"ws":true},{"text":",","start":93,"end":94,"id":13,"ws":true},{"text":"in","start":95,"end":97,"id":14,"ws":true},{"text":"vitro","start":98,"end":103,"id":15,"ws":true},{"text":"as","start":104,"end":106,"id":16,"ws":true},{"text":"well","start":107,"end":111,"id":17,"ws":true},{"text":"as","start":112,"end":114,"id":18,"ws":true},{"text":"in","start":115,"end":117,"id":19,"ws":true},{"text":"patients","start":118,"end":126,"id":20,"ws":true},{"text":"with","start":127,"end":131,"id":21,"ws":true},{"text":"oral","start":132,"end":136,"id":22,"ws":true},{"text":"cancer","start":137,"end":143,"id":23,"ws":true},{"text":".","start":144,"end":145,"id":24,"ws":false}],"spans":[{"start":19,"end":27,"token_start":4,"token_end":4,"label":"DRUG"},{"start":32,"end":41,"token_start":6,"token_end":6,"label":"DRUG"}],"_input_hash":-1095827099,"_task_hash":-240223432,"_session_id":"drug_drug_pilot_shared-yosi","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Withdrawal rates were comparable to drug survival rates of other biological therapies and rates of adverse events were similar between brodalumab and ustekinumab .","paragraph":"<h3><u>Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.</u></h3>As part of the National Institute for Health and Care Excellence single technology appraisal process, <b style='color:Tomato;'><i>brodalumab</i></b> was assessed to determine the clinical and cost effectiveness of its use in the treatment of moderate-to-severe plaque psoriasis. The Centre for Reviews and Dissemination and the Centre for Health Economics Technology Assessment Group at the University of York were commissioned to act as the independent Evidence Review Group. This article provides a summary of the Evidence Review Group's review of the company's submission, the Evidence Review Group report and the National Institute for Health and Care Excellence Appraisal Committee's subsequent guidance issued in March 2018. The main clinical effectiveness data were derived from three well-conducted, multicentre, double-blind randomised controlled trials. The trials demonstrated that <b style='color:Tomato;'><i>brodalumab</i></b> statistically significantly reduced the severity of psoriasis and its impact on health-related quality of life, compared with placebo, at 12\u00a0weeks. In comparison with <b style='color:Tomato;'><i>ustekinumab</i></b>, statistically significantly more patients taking <b style='color:Tomato;'><i>brodalumab</i></b> had reduced psoriasis severity at 12\u00a0weeks. Psoriasis severity and quality of life also appeared improved at 52\u00a0weeks, although statistical significance was not assessed. <b style='color:DodgerBlue;'><i>Withdrawal</i></b> <b style='color:DodgerBlue;'><i>rates</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>comparable</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>rates</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>biological</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>rates</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>adverse</i></b> <b style='color:DodgerBlue;'><i>events</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>similar</i></b> <b style='color:DodgerBlue;'><i>between</i></b> <b style='color:MediumOrchid;'><i>brodalumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ustekinumab</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A network meta-analysis was presented, comparing <b style='color:Tomato;'><i>brodalumab</i></b> with other therapies available at the same point in the treatment pathway (i.e. in patients for whom standard systemic therapy or phototherapy is inadequately effective, not tolerated or contraindicated). The network meta-analysis ranked treatments in order of effectiveness, in terms of achieving different levels of Psoriasis Area and Severity Index response. The results indicated that <b style='color:Tomato;'><i>brodalumab</i></b> had a similar probability of response to <b style='color:Tomato;'><i>ixekizumab</i></b>, <b style='color:Tomato;'><i>secukinumab</i></b> and <b style='color:Tomato;'><i>infliximab</i></b> and a higher probability of response than <b style='color:Tomato;'><i>ustekinumab</i></b>, <b style='color:Tomato;'><i>adalimumab</i></b>, <b style='color:Tomato;'><i>etanercept</i></b>, <b style='color:Tomato;'><i>apremilast</i></b>, <b style='color:Tomato;'><i>dimethyl fumarate</i></b> and placebo. The company's economic model compared nine treatment sequences that included three lines of active therapy, consisting of <b style='color:Tomato;'><i>brodalumab</i></b> and other comparators recommended by the National Institute for Health and Care Excellence, followed by best supportive care. The sequence with <b style='color:Tomato;'><i>brodalumab</i></b> in the first-line position dominated sequences that started with <b style='color:Tomato;'><i>adalimumab</i></b>, <b style='color:Tomato;'><i>infliximab</i></b>, <b style='color:Tomato;'><i>secukinumab</i></b> and <b style='color:Tomato;'><i>ustekinumab</i></b>. The incremental cost-effectiveness ratio of the <b style='color:Tomato;'><i>brodalumab</i></b> sequence compared to less effective and non-dominated sequences ranged from \u00a37145 (vs. the <b style='color:Tomato;'><i>etanercept</i></b> sequence) to \u00a313,353 (vs. the <b style='color:Tomato;'><i>dimethyl fumarate</i></b> sequence) per quality-adjusted life-year gained. The incremental cost-effectiveness ratio for the more costly and effective <b style='color:Tomato;'><i>ixekizumab</i></b> sequence was \u00a3894,010 per quality-adjusted life-year gained compared to the <b style='color:Tomato;'><i>brodalumab</i></b> sequence. At a threshold of \u00a320,000 per quality-adjusted life-year gained, the <b style='color:Tomato;'><i>brodalumab</i></b> sequence had the highest probability of being cost effective (96%). The main limitation of the company's economic model was the restrictive nature of the sequences compared. Twelve separate scenarios based on key uncertainties were explored by the Evidence Review Group. The only scenarios where <b style='color:Tomato;'><i>brodalumab</i></b> was ranked lower than first were not considered to be more appropriate or plausible than the assumptions or scenarios included in the company's base case. The treatment rankings identified in the Evidence Review Group's alternative base case were identical to those derived from the company's base case model. At the first National Institute for Health and Care Excellence Appraisal Committee meeting, the Committee concluded that <b style='color:Tomato;'><i>brodalumab</i></b> appears to be as effective as other anti-interleukin-17 agents and is cost effective, based on the discount agreed in the patient access scheme. Brodalumab is recommended as an option for treating adults with severe plaque psoriasis (defined by a total Psoriasis Area and Severity Index score of 10 or more and a Dermatology Life Quality Index score of more than 10) who have not responded to other systemic non-biological therapies. Brodalumab should be stopped at 12\u00a0weeks if the psoriasis has not responded adequately.","tokens":[{"text":"Withdrawal","start":0,"end":10,"id":0,"ws":true},{"text":"rates","start":11,"end":16,"id":1,"ws":true},{"text":"were","start":17,"end":21,"id":2,"ws":true},{"text":"comparable","start":22,"end":32,"id":3,"ws":true},{"text":"to","start":33,"end":35,"id":4,"ws":true},{"text":"drug","start":36,"end":40,"id":5,"ws":true},{"text":"survival","start":41,"end":49,"id":6,"ws":true},{"text":"rates","start":50,"end":55,"id":7,"ws":true},{"text":"of","start":56,"end":58,"id":8,"ws":true},{"text":"other","start":59,"end":64,"id":9,"ws":true},{"text":"biological","start":65,"end":75,"id":10,"ws":true},{"text":"therapies","start":76,"end":85,"id":11,"ws":true},{"text":"and","start":86,"end":89,"id":12,"ws":true},{"text":"rates","start":90,"end":95,"id":13,"ws":true},{"text":"of","start":96,"end":98,"id":14,"ws":true},{"text":"adverse","start":99,"end":106,"id":15,"ws":true},{"text":"events","start":107,"end":113,"id":16,"ws":true},{"text":"were","start":114,"end":118,"id":17,"ws":true},{"text":"similar","start":119,"end":126,"id":18,"ws":true},{"text":"between","start":127,"end":134,"id":19,"ws":true},{"text":"brodalumab","start":135,"end":145,"id":20,"ws":true},{"text":"and","start":146,"end":149,"id":21,"ws":true},{"text":"ustekinumab","start":150,"end":161,"id":22,"ws":true},{"text":".","start":162,"end":163,"id":23,"ws":false}],"spans":[{"start":135,"end":145,"token_start":20,"token_end":20,"label":"DRUG"},{"start":150,"end":161,"token_start":22,"token_end":22,"label":"DRUG"}],"_input_hash":-2044054306,"_task_hash":40529012,"_session_id":"drug_drug_pilot_shared-yosi","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"In patients with NPSLE , the use of high-dose corticosteroids is recommended in combination with immunosuppressants , such as mycophenolate mofetil and intravenous cyclophosphamide pulse therapy .","paragraph":"<h3><u>[Neuropsychiatric Systemic Lupus Erythematosus].</u></h3>Central nervous system damage, a major organ manifestation of systemic lupus erythematosus (SLE), causes significant morbidity and mortality. Designating this condition as neuropsychiatric SLE (NPSLE), the American College of Rheumatology defines it as involving the central and peripheral nervous systems and being characterized by various manifestations including stroke, seizures, and psychosis. NPSLE treatment mainly seeks to reduce damage accrual. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>NPSLE</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:DodgerBlue;'><i>corticosteroids</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>recommended</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>immunosuppressants</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>mycophenolate</i></b> <b style='color:DodgerBlue;'><i>mofetil</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>pulse</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> This can be accomplished by controlling the activity of the disease, minimizing the use of corticosteroids, and optimizing the management of comorbidities, including cardiovascular risk factors. An international task force analysis of a treat-to-target strategy for SLE (T2T/SLE) recommended targeting remission, preventing damage, and improving quality of life. Thus, more effective and less toxic treatments, such as those using biologics or kinase inhibitors, are still being developed for the treatment of SLE/NPSLE.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"patients","start":3,"end":11,"id":1,"ws":true},{"text":"with","start":12,"end":16,"id":2,"ws":true},{"text":"NPSLE","start":17,"end":22,"id":3,"ws":true},{"text":",","start":23,"end":24,"id":4,"ws":true},{"text":"the","start":25,"end":28,"id":5,"ws":true},{"text":"use","start":29,"end":32,"id":6,"ws":true},{"text":"of","start":33,"end":35,"id":7,"ws":true},{"text":"high-dose","start":36,"end":45,"id":8,"ws":true},{"text":"corticosteroids","start":46,"end":61,"id":9,"ws":true},{"text":"is","start":62,"end":64,"id":10,"ws":true},{"text":"recommended","start":65,"end":76,"id":11,"ws":true},{"text":"in","start":77,"end":79,"id":12,"ws":true},{"text":"combination","start":80,"end":91,"id":13,"ws":true},{"text":"with","start":92,"end":96,"id":14,"ws":true},{"text":"immunosuppressants","start":97,"end":115,"id":15,"ws":true},{"text":",","start":116,"end":117,"id":16,"ws":true},{"text":"such","start":118,"end":122,"id":17,"ws":true},{"text":"as","start":123,"end":125,"id":18,"ws":true},{"text":"mycophenolate","start":126,"end":139,"id":19,"ws":true},{"text":"mofetil","start":140,"end":147,"id":20,"ws":true},{"text":"and","start":148,"end":151,"id":21,"ws":true},{"text":"intravenous","start":152,"end":163,"id":22,"ws":true},{"text":"cyclophosphamide","start":164,"end":180,"id":23,"ws":true},{"text":"pulse","start":181,"end":186,"id":24,"ws":true},{"text":"therapy","start":187,"end":194,"id":25,"ws":true},{"text":".","start":195,"end":196,"id":26,"ws":false}],"spans":[{"start":126,"end":139,"token_start":19,"token_end":19,"label":"DRUG"},{"start":164,"end":180,"token_start":23,"token_end":23,"label":"DRUG"}],"_input_hash":438186251,"_task_hash":1532533663,"_session_id":"drug_drug_pilot_shared-yosi","_view_id":"blocks","relations":[{"head":9,"child":19,"head_span":{"start":46,"end":61,"token_start":9,"token_end":9,"label":null},"child_span":{"start":126,"end":139,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":9,"child":23,"head_span":{"start":46,"end":61,"token_start":9,"token_end":9,"label":null},"child_span":{"start":164,"end":180,"token_start":23,"token_end":23,"label":"DRUG"},"color":"#ffd882","label":"POS2"},{"head":9,"child":20,"head_span":{"start":46,"end":61,"token_start":9,"token_end":9,"label":null},"child_span":{"start":140,"end":147,"token_start":20,"token_end":20,"label":null},"color":"#d9fbad","label":"POS3"}],"radio":["POS10","POS1T0","POS20","POS2T0","POS30","POS3T0"],"answer":"accept"}
{"text":"Thirty-three women diagnosed with metastatic breast cancer participated in a phase 1 clinical trial of a new combination of cyclophosphamide ( CTX ) and mitoxantrone ( MXT ) , with dose escalation of paclitaxel .","paragraph":"<h3><u>Longitudinal effects of high-dose chemotherapy and autologous stem cell transplantation on quality of life in the treatment of metastatic breast cancer.</u></h3>This study determined the effects of high-dose chemotherapy (HDCT) with autologous blood stem cell transplantation (ASCT) on quality of life (QL) in women with metastatic breast cancer prior to, and during treatment, and up to 1-year post-ASCT. <b style='color:DodgerBlue;'><i>Thirty-three</i></b> <b style='color:DodgerBlue;'><i>women</i></b> <b style='color:DodgerBlue;'><i>diagnosed</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>participated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>new</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CTX</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>mitoxantrone</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>MXT</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>escalation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Longitudinal QL data were collected using the functional living index-cancer (FLIC) and symptom scales at seven time periods: pre-induction chemotherapy (CT), post-induction CT, post-high dose CT (HDCT), and at 3, 6, 9 and 12 months post-ASCT. FLIC scores indicated that the worst problems for patients were feelings of hardship on themselves and their families, followed by psychological functioning and physical functioning problems. The time around diagnosis of the metastatic disease and following HDCT were the worst times for all levels of quality of life, but anxiety and depression symptoms continued to increase in severity across the entire follow-up period. The symptoms that were most problematic were worry about the future, loss of sexual interest, anxiety about the treatment, general worrying, and joint pain. These data highlight the problems that women with metastatic breast cancer encounter at different stages of the disease and treatment process, and can be used to tailor psychosocial interventions appropriate for treating the relevant issues at different points in time.","tokens":[{"text":"Thirty-three","start":0,"end":12,"id":0,"ws":true},{"text":"women","start":13,"end":18,"id":1,"ws":true},{"text":"diagnosed","start":19,"end":28,"id":2,"ws":true},{"text":"with","start":29,"end":33,"id":3,"ws":true},{"text":"metastatic","start":34,"end":44,"id":4,"ws":true},{"text":"breast","start":45,"end":51,"id":5,"ws":true},{"text":"cancer","start":52,"end":58,"id":6,"ws":true},{"text":"participated","start":59,"end":71,"id":7,"ws":true},{"text":"in","start":72,"end":74,"id":8,"ws":true},{"text":"a","start":75,"end":76,"id":9,"ws":true},{"text":"phase","start":77,"end":82,"id":10,"ws":true},{"text":"1","start":83,"end":84,"id":11,"ws":true},{"text":"clinical","start":85,"end":93,"id":12,"ws":true},{"text":"trial","start":94,"end":99,"id":13,"ws":true},{"text":"of","start":100,"end":102,"id":14,"ws":true},{"text":"a","start":103,"end":104,"id":15,"ws":true},{"text":"new","start":105,"end":108,"id":16,"ws":true},{"text":"combination","start":109,"end":120,"id":17,"ws":true},{"text":"of","start":121,"end":123,"id":18,"ws":true},{"text":"cyclophosphamide","start":124,"end":140,"id":19,"ws":true},{"text":"(","start":141,"end":142,"id":20,"ws":true},{"text":"CTX","start":143,"end":146,"id":21,"ws":true},{"text":")","start":147,"end":148,"id":22,"ws":true},{"text":"and","start":149,"end":152,"id":23,"ws":true},{"text":"mitoxantrone","start":153,"end":165,"id":24,"ws":true},{"text":"(","start":166,"end":167,"id":25,"ws":true},{"text":"MXT","start":168,"end":171,"id":26,"ws":true},{"text":")","start":172,"end":173,"id":27,"ws":true},{"text":",","start":174,"end":175,"id":28,"ws":true},{"text":"with","start":176,"end":180,"id":29,"ws":true},{"text":"dose","start":181,"end":185,"id":30,"ws":true},{"text":"escalation","start":186,"end":196,"id":31,"ws":true},{"text":"of","start":197,"end":199,"id":32,"ws":true},{"text":"paclitaxel","start":200,"end":210,"id":33,"ws":true},{"text":".","start":211,"end":212,"id":34,"ws":false}],"spans":[{"start":124,"end":140,"token_start":19,"token_end":19,"label":"DRUG"},{"start":153,"end":165,"token_start":24,"token_end":24,"label":"DRUG"},{"start":200,"end":210,"token_start":33,"token_end":33,"label":"DRUG"}],"_input_hash":1782132717,"_task_hash":189034633,"_session_id":"drug_drug_pilot_shared-yosi","_view_id":"blocks","relations":[{"head":19,"child":24,"head_span":{"start":124,"end":140,"token_start":19,"token_end":19,"label":"DRUG"},"child_span":{"start":153,"end":165,"token_start":24,"token_end":24,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":19,"child":33,"head_span":{"start":124,"end":140,"token_start":19,"token_end":19,"label":"DRUG"},"child_span":{"start":200,"end":210,"token_start":33,"token_end":33,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"These studies suggest a slight advantage to the combined approaches that contain flutamide and bicalutamide , but the lack of dramatic differences in outcome makes monotherapy reasonable , especially in patients with more indolent disease .","paragraph":"<h3><u>The selection of hormonal therapy in prostate cancer: who, when, and for how long?</u></h3>Androgen deprivation is the foundation for the systemic therapy of advanced prostate cancer. Multiple trials have tested combined androgen blockade versus androgen deprivation alone in patients with advanced disease. <b style='color:DodgerBlue;'><i>These</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>suggest</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>slight</i></b> <b style='color:DodgerBlue;'><i>advantage</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>approaches</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>contain</i></b> <b style='color:MediumOrchid;'><i>flutamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>bicalutamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>lack</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>dramatic</i></b> <b style='color:DodgerBlue;'><i>differences</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>outcome</i></b> <b style='color:DodgerBlue;'><i>makes</i></b> <b style='color:DodgerBlue;'><i>monotherapy</i></b> <b style='color:DodgerBlue;'><i>reasonable</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>especially</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>indolent</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Intermittent androgen deprivation is an alternative that may allow patients to reduce the total time on androgen suppression as well as possibly delay the onset of androgen independence. A number of secondary hormonal therapies, including deferred and secondary antiandrogens, <b style='color:Tomato;'><i>ketoconazole</i></b>, and estrogens have shown modest response proportions. Patients with less advanced disease such as a rising prostate-specific antigen have varied outcomes, and no standard approach exists. In this group, noncastrating forms of hormonal therapy are being evaluated. Patients undergoing definitive local therapy who have high-risk features may benefit from early, as opposed to deferred, androgen deprivation. This review examines the evidence for the current state of the art in hormonal therapy in patients with prostate cancer and focuses, in particular, on treatment composition and timing as well as the rationale for the use of hormonal therapy in early stage disease.","tokens":[{"text":"These","start":0,"end":5,"id":0,"ws":true},{"text":"studies","start":6,"end":13,"id":1,"ws":true},{"text":"suggest","start":14,"end":21,"id":2,"ws":true},{"text":"a","start":22,"end":23,"id":3,"ws":true},{"text":"slight","start":24,"end":30,"id":4,"ws":true},{"text":"advantage","start":31,"end":40,"id":5,"ws":true},{"text":"to","start":41,"end":43,"id":6,"ws":true},{"text":"the","start":44,"end":47,"id":7,"ws":true},{"text":"combined","start":48,"end":56,"id":8,"ws":true},{"text":"approaches","start":57,"end":67,"id":9,"ws":true},{"text":"that","start":68,"end":72,"id":10,"ws":true},{"text":"contain","start":73,"end":80,"id":11,"ws":true},{"text":"flutamide","start":81,"end":90,"id":12,"ws":true},{"text":"and","start":91,"end":94,"id":13,"ws":true},{"text":"bicalutamide","start":95,"end":107,"id":14,"ws":true},{"text":",","start":108,"end":109,"id":15,"ws":true},{"text":"but","start":110,"end":113,"id":16,"ws":true},{"text":"the","start":114,"end":117,"id":17,"ws":true},{"text":"lack","start":118,"end":122,"id":18,"ws":true},{"text":"of","start":123,"end":125,"id":19,"ws":true},{"text":"dramatic","start":126,"end":134,"id":20,"ws":true},{"text":"differences","start":135,"end":146,"id":21,"ws":true},{"text":"in","start":147,"end":149,"id":22,"ws":true},{"text":"outcome","start":150,"end":157,"id":23,"ws":true},{"text":"makes","start":158,"end":163,"id":24,"ws":true},{"text":"monotherapy","start":164,"end":175,"id":25,"ws":true},{"text":"reasonable","start":176,"end":186,"id":26,"ws":true},{"text":",","start":187,"end":188,"id":27,"ws":true},{"text":"especially","start":189,"end":199,"id":28,"ws":true},{"text":"in","start":200,"end":202,"id":29,"ws":true},{"text":"patients","start":203,"end":211,"id":30,"ws":true},{"text":"with","start":212,"end":216,"id":31,"ws":true},{"text":"more","start":217,"end":221,"id":32,"ws":true},{"text":"indolent","start":222,"end":230,"id":33,"ws":true},{"text":"disease","start":231,"end":238,"id":34,"ws":true},{"text":".","start":239,"end":240,"id":35,"ws":false}],"spans":[{"start":81,"end":90,"token_start":12,"token_end":12,"label":"DRUG"},{"start":95,"end":107,"token_start":14,"token_end":14,"label":"DRUG"}],"_input_hash":137769162,"_task_hash":410888998,"_session_id":"drug_drug_pilot_shared-yosi","_view_id":"blocks","relations":[{"head":12,"child":14,"head_span":{"start":81,"end":90,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":95,"end":107,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T0"],"answer":"accept"}
{"text":"We examined the feasibility and safety of using paclitaxel and trastuzumab as maintenance therapy after high-dose chemotherapy ( HDC ) with autologous hematopoietic stem cell transplantation ( AHST ) for patients with HER2-positive metastatic breast cancer .","paragraph":"<h3><u>Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation.</u></h3> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>examined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>feasibility</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>maintenance</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>HDC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>autologous</i></b> <b style='color:DodgerBlue;'><i>hematopoietic</i></b> <b style='color:DodgerBlue;'><i>stem</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>transplantation</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AHST</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>HER2-positive</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Ten patients (9 women and 1 man) were enrolled in the study. The median age was 46.5 years (range, 27-65 years). The median follow-up time was 1003 days (range, 216-2526 days). All patients had metastatic disease, but 2 had only bone metastasis. One patient had complete response, 6 had partial response and 3 had stable disease to the standard-dose chemotherapy prior to transplantation. The conditioning regimen consisted of <b style='color:Tomato;'><i>cyclophosphamide</i></b>, <b style='color:Tomato;'><i>carmustine</i></b>, and <b style='color:Tomato;'><i>thiotepa</i></b>. After AHST, patients received weekly <b style='color:Tomato;'><i>paclitaxel</i></b> for 12 doses and <b style='color:Tomato;'><i>trastuzumab</i></b> every 3 weeks for 1 year as maintenance therapy. All patients experienced successful engraftment. The only grade 4 toxic effects observed were leukopenia and thrombocytopenia. The most common grade 3 toxic effect was neutropenic fever. No treatment-related deaths were observed. The median progression-free survival time was 441 days, and the median overall survival time was 955 days. Two patients died in accidents while their disease remained in remission. Five patients died with disease progression. At the time of this report, 3 patients are alive with stable disease, 1 of whom has remained free of disease progression for 2526 days since transplantation. Our findings indicate that <b style='color:Tomato;'><i>paclitaxel</i></b> plus <b style='color:Tomato;'><i>trastuzumab</i></b> as maintenance therapy after HDC with AHST for patients with HER2-positive metastatic breast cancer not only is feasible and safe but also results in survival outcomes similar to historical results. ","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"examined","start":3,"end":11,"id":1,"ws":true},{"text":"the","start":12,"end":15,"id":2,"ws":true},{"text":"feasibility","start":16,"end":27,"id":3,"ws":true},{"text":"and","start":28,"end":31,"id":4,"ws":true},{"text":"safety","start":32,"end":38,"id":5,"ws":true},{"text":"of","start":39,"end":41,"id":6,"ws":true},{"text":"using","start":42,"end":47,"id":7,"ws":true},{"text":"paclitaxel","start":48,"end":58,"id":8,"ws":true},{"text":"and","start":59,"end":62,"id":9,"ws":true},{"text":"trastuzumab","start":63,"end":74,"id":10,"ws":true},{"text":"as","start":75,"end":77,"id":11,"ws":true},{"text":"maintenance","start":78,"end":89,"id":12,"ws":true},{"text":"therapy","start":90,"end":97,"id":13,"ws":true},{"text":"after","start":98,"end":103,"id":14,"ws":true},{"text":"high-dose","start":104,"end":113,"id":15,"ws":true},{"text":"chemotherapy","start":114,"end":126,"id":16,"ws":true},{"text":"(","start":127,"end":128,"id":17,"ws":true},{"text":"HDC","start":129,"end":132,"id":18,"ws":true},{"text":")","start":133,"end":134,"id":19,"ws":true},{"text":"with","start":135,"end":139,"id":20,"ws":true},{"text":"autologous","start":140,"end":150,"id":21,"ws":true},{"text":"hematopoietic","start":151,"end":164,"id":22,"ws":true},{"text":"stem","start":165,"end":169,"id":23,"ws":true},{"text":"cell","start":170,"end":174,"id":24,"ws":true},{"text":"transplantation","start":175,"end":190,"id":25,"ws":true},{"text":"(","start":191,"end":192,"id":26,"ws":true},{"text":"AHST","start":193,"end":197,"id":27,"ws":true},{"text":")","start":198,"end":199,"id":28,"ws":true},{"text":"for","start":200,"end":203,"id":29,"ws":true},{"text":"patients","start":204,"end":212,"id":30,"ws":true},{"text":"with","start":213,"end":217,"id":31,"ws":true},{"text":"HER2-positive","start":218,"end":231,"id":32,"ws":true},{"text":"metastatic","start":232,"end":242,"id":33,"ws":true},{"text":"breast","start":243,"end":249,"id":34,"ws":true},{"text":"cancer","start":250,"end":256,"id":35,"ws":true},{"text":".","start":257,"end":258,"id":36,"ws":false}],"spans":[{"start":48,"end":58,"token_start":8,"token_end":8,"label":"DRUG"},{"start":63,"end":74,"token_start":10,"token_end":10,"label":"DRUG"}],"_input_hash":-1578970086,"_task_hash":304060663,"_session_id":"drug_drug_pilot_shared-yosi","_view_id":"blocks","relations":[{"head":8,"child":10,"head_span":{"start":48,"end":58,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":63,"end":74,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T0"],"answer":"accept"}
{"text":"Dual antiplatelet therapy with aspirin and clopidogrel ( the preferred thienopyridine because of its superior hematologic safety ) is recommended for at least 4 weeks to prevent subacute stent thrombosis with bare-metal stents and 3 to 6 months to prevent late-stent thrombosis with drug-eluting stents .","paragraph":"<h3><u>Long-term care after percutaneous coronary intervention: focus on the role of antiplatelet therapy.</u></h3>Arterial wall injury caused by percutaneous coronary intervention (PCI) triggers transient platelet activation and mural thrombosis; these effects are superimposed on the preexisting platelet hyperreactivity associated with underlying atherothrombosis. Platelet activation has been implicated in the major complications of PCI: acute and subacute thrombosis and restenosis. Antithrombotic and anticoagulant therapy minimizes thrombotic complications after PCI. Aspirin plus a thienopyridine (<b style='color:Tomato;'><i>ticlopidine</i></b> or <b style='color:Tomato;'><i>clopidogrel</i></b>) is more effective than <b style='color:Tomato;'><i>aspirin</i></b> plus <b style='color:Tomato;'><i>heparin</i></b> and extended <b style='color:Tomato;'><i>warfarin</i></b> therapy in preventing periprocedural ischemic events and subsequent stent thrombosis and results in less major and minor bleeding. <b style='color:DodgerBlue;'><i>Dual</i></b> <b style='color:DodgerBlue;'><i>antiplatelet</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>aspirin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>clopidogrel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>preferred</i></b> <b style='color:DodgerBlue;'><i>thienopyridine</i></b> <b style='color:DodgerBlue;'><i>because</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>its</i></b> <b style='color:DodgerBlue;'><i>superior</i></b> <b style='color:DodgerBlue;'><i>hematologic</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>recommended</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>least</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>prevent</i></b> <b style='color:DodgerBlue;'><i>subacute</i></b> <b style='color:DodgerBlue;'><i>stent</i></b> <b style='color:DodgerBlue;'><i>thrombosis</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>bare-metal</i></b> <b style='color:DodgerBlue;'><i>stents</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>prevent</i></b> <b style='color:DodgerBlue;'><i>late-stent</i></b> <b style='color:DodgerBlue;'><i>thrombosis</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>drug-eluting</i></b> <b style='color:DodgerBlue;'><i>stents</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Coronary atherothrombosis is a diffuse vascular disease, and reduction of the risk of future ischemic events requires strategies that extend beyond the focal treatment of stenotic lesions. Optimal long-term care after PCI requires aggressive systemic pharmacotherapy (antiplatelet agents, statins, beta-blockers, and angiotensin-converting enzyme Inhibitors) in conjunction with therapeutic lifestyle changes (smoking cessation, weight reduction, dietary measures, and exercise). In this context, dual antiplatelet therapy (<b style='color:Tomato;'><i>aspirin</i></b> plus <b style='color:Tomato;'><i>clopidogrel</i></b>) is recommended for at least 12 months after PCI for prophylaxis of future atherothrombotic events.","tokens":[{"text":"Dual","start":0,"end":4,"id":0,"ws":true},{"text":"antiplatelet","start":5,"end":17,"id":1,"ws":true},{"text":"therapy","start":18,"end":25,"id":2,"ws":true},{"text":"with","start":26,"end":30,"id":3,"ws":true},{"text":"aspirin","start":31,"end":38,"id":4,"ws":true},{"text":"and","start":39,"end":42,"id":5,"ws":true},{"text":"clopidogrel","start":43,"end":54,"id":6,"ws":true},{"text":"(","start":55,"end":56,"id":7,"ws":true},{"text":"the","start":57,"end":60,"id":8,"ws":true},{"text":"preferred","start":61,"end":70,"id":9,"ws":true},{"text":"thienopyridine","start":71,"end":85,"id":10,"ws":true},{"text":"because","start":86,"end":93,"id":11,"ws":true},{"text":"of","start":94,"end":96,"id":12,"ws":true},{"text":"its","start":97,"end":100,"id":13,"ws":true},{"text":"superior","start":101,"end":109,"id":14,"ws":true},{"text":"hematologic","start":110,"end":121,"id":15,"ws":true},{"text":"safety","start":122,"end":128,"id":16,"ws":true},{"text":")","start":129,"end":130,"id":17,"ws":true},{"text":"is","start":131,"end":133,"id":18,"ws":true},{"text":"recommended","start":134,"end":145,"id":19,"ws":true},{"text":"for","start":146,"end":149,"id":20,"ws":true},{"text":"at","start":150,"end":152,"id":21,"ws":true},{"text":"least","start":153,"end":158,"id":22,"ws":true},{"text":"4","start":159,"end":160,"id":23,"ws":true},{"text":"weeks","start":161,"end":166,"id":24,"ws":true},{"text":"to","start":167,"end":169,"id":25,"ws":true},{"text":"prevent","start":170,"end":177,"id":26,"ws":true},{"text":"subacute","start":178,"end":186,"id":27,"ws":true},{"text":"stent","start":187,"end":192,"id":28,"ws":true},{"text":"thrombosis","start":193,"end":203,"id":29,"ws":true},{"text":"with","start":204,"end":208,"id":30,"ws":true},{"text":"bare-metal","start":209,"end":219,"id":31,"ws":true},{"text":"stents","start":220,"end":226,"id":32,"ws":true},{"text":"and","start":227,"end":230,"id":33,"ws":true},{"text":"3","start":231,"end":232,"id":34,"ws":true},{"text":"to","start":233,"end":235,"id":35,"ws":true},{"text":"6","start":236,"end":237,"id":36,"ws":true},{"text":"months","start":238,"end":244,"id":37,"ws":true},{"text":"to","start":245,"end":247,"id":38,"ws":true},{"text":"prevent","start":248,"end":255,"id":39,"ws":true},{"text":"late-stent","start":256,"end":266,"id":40,"ws":true},{"text":"thrombosis","start":267,"end":277,"id":41,"ws":true},{"text":"with","start":278,"end":282,"id":42,"ws":true},{"text":"drug-eluting","start":283,"end":295,"id":43,"ws":true},{"text":"stents","start":296,"end":302,"id":44,"ws":true},{"text":".","start":303,"end":304,"id":45,"ws":false}],"spans":[{"start":31,"end":38,"token_start":4,"token_end":4,"label":"DRUG"},{"start":43,"end":54,"token_start":6,"token_end":6,"label":"DRUG"}],"_input_hash":1471340217,"_task_hash":-1789027077,"_session_id":"drug_drug_pilot_shared-yosi","_view_id":"blocks","relations":[{"head":4,"child":6,"head_span":{"start":31,"end":38,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":43,"end":54,"token_start":6,"token_end":6,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T1"],"answer":"accept"}
{"text":"Furthermore , in non-metastatic castration-resistant prostate cancer ( M0 CRPC ) , two second-generation anti-androgens , apalutamide and enzalutamide , when used in combination with ADT , have demonstrated a significant benefit in metastasis-free survival .","paragraph":"<h3><u>Recent trends in the management of advanced prostate cancer.</u></h3>Advanced prostate cancer includes a wide spectrum of disease ranging from hormone na\u00efve or hormone sensitive to castration resistant, both containing populations of men who have demonstrable metastatic and non-metastatic states. The mainstay of treatment for metastatic hormone-sensitive prostate cancer is androgen deprivation therapy (ADT). However, recent level 1 evidence demonstrates that the addition of chemotherapy or <b style='color:Tomato;'><i>abiraterone</i></b> acetate to ADT results in significant survival advantage as compared with ADT alone. <b style='color:DodgerBlue;'><i>Furthermore</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>non-metastatic</i></b> <b style='color:DodgerBlue;'><i>castration-resistant</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>M0</i></b> <b style='color:DodgerBlue;'><i>CRPC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>second-generation</i></b> <b style='color:DodgerBlue;'><i>anti-androgens</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>apalutamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>enzalutamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>ADT</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>significant</i></b> <b style='color:DodgerBlue;'><i>benefit</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>metastasis-free</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Here, we review the most recent studies leading to these significant changes in the treatment of advanced prostate cancer.","tokens":[{"text":"Furthermore","start":0,"end":11,"id":0,"ws":true},{"text":",","start":12,"end":13,"id":1,"ws":true},{"text":"in","start":14,"end":16,"id":2,"ws":true},{"text":"non-metastatic","start":17,"end":31,"id":3,"ws":true},{"text":"castration-resistant","start":32,"end":52,"id":4,"ws":true},{"text":"prostate","start":53,"end":61,"id":5,"ws":true},{"text":"cancer","start":62,"end":68,"id":6,"ws":true},{"text":"(","start":69,"end":70,"id":7,"ws":true},{"text":"M0","start":71,"end":73,"id":8,"ws":true},{"text":"CRPC","start":74,"end":78,"id":9,"ws":true},{"text":")","start":79,"end":80,"id":10,"ws":true},{"text":",","start":81,"end":82,"id":11,"ws":true},{"text":"two","start":83,"end":86,"id":12,"ws":true},{"text":"second-generation","start":87,"end":104,"id":13,"ws":true},{"text":"anti-androgens","start":105,"end":119,"id":14,"ws":true},{"text":",","start":120,"end":121,"id":15,"ws":true},{"text":"apalutamide","start":122,"end":133,"id":16,"ws":true},{"text":"and","start":134,"end":137,"id":17,"ws":true},{"text":"enzalutamide","start":138,"end":150,"id":18,"ws":true},{"text":",","start":151,"end":152,"id":19,"ws":true},{"text":"when","start":153,"end":157,"id":20,"ws":true},{"text":"used","start":158,"end":162,"id":21,"ws":true},{"text":"in","start":163,"end":165,"id":22,"ws":true},{"text":"combination","start":166,"end":177,"id":23,"ws":true},{"text":"with","start":178,"end":182,"id":24,"ws":true},{"text":"ADT","start":183,"end":186,"id":25,"ws":true},{"text":",","start":187,"end":188,"id":26,"ws":true},{"text":"have","start":189,"end":193,"id":27,"ws":true},{"text":"demonstrated","start":194,"end":206,"id":28,"ws":true},{"text":"a","start":207,"end":208,"id":29,"ws":true},{"text":"significant","start":209,"end":220,"id":30,"ws":true},{"text":"benefit","start":221,"end":228,"id":31,"ws":true},{"text":"in","start":229,"end":231,"id":32,"ws":true},{"text":"metastasis-free","start":232,"end":247,"id":33,"ws":true},{"text":"survival","start":248,"end":256,"id":34,"ws":true},{"text":".","start":257,"end":258,"id":35,"ws":false}],"spans":[{"start":122,"end":133,"token_start":16,"token_end":16,"label":"DRUG"},{"start":138,"end":150,"token_start":18,"token_end":18,"label":"DRUG"}],"_input_hash":236482726,"_task_hash":-1620523265,"_session_id":"drug_drug_pilot_shared-yosi","_view_id":"blocks","relations":[{"head":16,"child":25,"head_span":{"start":122,"end":133,"token_start":16,"token_end":16,"label":"DRUG"},"child_span":{"start":183,"end":186,"token_start":25,"token_end":25,"label":null},"color":"#c5bdf4","label":"POS1"},{"head":18,"child":25,"head_span":{"start":138,"end":150,"token_start":18,"token_end":18,"label":"DRUG"},"child_span":{"start":183,"end":186,"token_start":25,"token_end":25,"label":null},"color":"#ffd882","label":"POS2"}],"radio":["POS10","POS1T0","POS20","POS2T0"],"answer":"accept"}
{"text":"A screening method based on liquid chromatography-electrospray mass spectrometry for the simultaneous determination of six corticosteroids ( betamethasone 17-valerate BM 17-V , beclomethasone BC , beclomethasone dipropionate BCDP , methylprednisolone MP , budesonide BD , flunisolide FN ) was developed in order to control their illegal use in cosmetic and natural products .","paragraph":"<h3><u>LC-MS method for the simultaneous determination of six glucocorticoids in pharmaceutical formulations and counterfeit cosmetic products.</u></h3> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>screening</i></b> <b style='color:DodgerBlue;'><i>method</i></b> <b style='color:DodgerBlue;'><i>based</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>liquid</i></b> <b style='color:DodgerBlue;'><i>chromatography-electrospray</i></b> <b style='color:DodgerBlue;'><i>mass</i></b> <b style='color:DodgerBlue;'><i>spectrometry</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>simultaneous</i></b> <b style='color:DodgerBlue;'><i>determination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>six</i></b> <b style='color:DodgerBlue;'><i>corticosteroids</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>betamethasone</i></b> <b style='color:DodgerBlue;'><i>17-valerate</i></b> <b style='color:DodgerBlue;'><i>BM</i></b> <b style='color:DodgerBlue;'><i>17-V</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>beclomethasone</i></b> <b style='color:DodgerBlue;'><i>BC</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>beclomethasone</i></b> <b style='color:DodgerBlue;'><i>dipropionate</i></b> <b style='color:DodgerBlue;'><i>BCDP</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>methylprednisolone</i></b> <b style='color:DodgerBlue;'><i>MP</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>budesonide</i></b> <b style='color:DodgerBlue;'><i>BD</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>flunisolide</i></b> <b style='color:DodgerBlue;'><i>FN</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>developed</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>order</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>control</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>illegal</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>cosmetic</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>natural</i></b> <b style='color:DodgerBlue;'><i>products</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Indeed, despite corticosteroids are banned in cosmetics, counterfeit products might be present on the market, representing a health hazard. Therefore, effective analytical methods are required to rapidly screen over the counter products in health care shops for counterfeit corticosteroids. The analytical method involves the employment of a Waters Synergy C18 column (150mm\u00d72.0mm I.D.) by using the following mobile phase: A (0.1% formic acid in acetonitrile), B (0.1% formic acid in water) in a linear gradient (from A-B 25:75, v/v to A-B 95:5, v/v in 30min) at the flow rate of 0.3mL/min. The detection was performed with an ion trap (IT) mass spectrometer in positive polarity, total ion current (TIC) and tandem mass modalities for qualitative purpose; single ion monitoring (SIM) mode was used for quantitative analysis on the ESI generated most abundant ion for each steroid. The method was fully validated in terms of precision, detection and quantification limits, linearity, recovery, and it was applied to the identification and quantification of corticosteroids in pharmaceutical formulations and cosmetic products. The mean recovery of BM 17-V, BC, BCDP, MP, BD and FN were found to be 101.3, 101.5, 98.8, 98.9, 98.1, 99.0%, respectively. Limits of quantitation (LOQ) were comprised in the range 29-95ng/mL. To the best of our knowledge, for the first time this mix of glucocorticoids were simultaneously determined in cosmetic products by using a fully validated method. BMV, in its two isomeric forms BM 17-V and BM 21-V, was found to be illegally present in one cream sample (A) with the total concentration level of 0.036% (w/w). ","tokens":[{"text":"A","start":0,"end":1,"id":0,"ws":true},{"text":"screening","start":2,"end":11,"id":1,"ws":true},{"text":"method","start":12,"end":18,"id":2,"ws":true},{"text":"based","start":19,"end":24,"id":3,"ws":true},{"text":"on","start":25,"end":27,"id":4,"ws":true},{"text":"liquid","start":28,"end":34,"id":5,"ws":true},{"text":"chromatography-electrospray","start":35,"end":62,"id":6,"ws":true},{"text":"mass","start":63,"end":67,"id":7,"ws":true},{"text":"spectrometry","start":68,"end":80,"id":8,"ws":true},{"text":"for","start":81,"end":84,"id":9,"ws":true},{"text":"the","start":85,"end":88,"id":10,"ws":true},{"text":"simultaneous","start":89,"end":101,"id":11,"ws":true},{"text":"determination","start":102,"end":115,"id":12,"ws":true},{"text":"of","start":116,"end":118,"id":13,"ws":true},{"text":"six","start":119,"end":122,"id":14,"ws":true},{"text":"corticosteroids","start":123,"end":138,"id":15,"ws":true},{"text":"(","start":139,"end":140,"id":16,"ws":true},{"text":"betamethasone","start":141,"end":154,"id":17,"ws":true},{"text":"17-valerate","start":155,"end":166,"id":18,"ws":true},{"text":"BM","start":167,"end":169,"id":19,"ws":true},{"text":"17-V","start":170,"end":174,"id":20,"ws":true},{"text":",","start":175,"end":176,"id":21,"ws":true},{"text":"beclomethasone","start":177,"end":191,"id":22,"ws":true},{"text":"BC","start":192,"end":194,"id":23,"ws":true},{"text":",","start":195,"end":196,"id":24,"ws":true},{"text":"beclomethasone","start":197,"end":211,"id":25,"ws":true},{"text":"dipropionate","start":212,"end":224,"id":26,"ws":true},{"text":"BCDP","start":225,"end":229,"id":27,"ws":true},{"text":",","start":230,"end":231,"id":28,"ws":true},{"text":"methylprednisolone","start":232,"end":250,"id":29,"ws":true},{"text":"MP","start":251,"end":253,"id":30,"ws":true},{"text":",","start":254,"end":255,"id":31,"ws":true},{"text":"budesonide","start":256,"end":266,"id":32,"ws":true},{"text":"BD","start":267,"end":269,"id":33,"ws":true},{"text":",","start":270,"end":271,"id":34,"ws":true},{"text":"flunisolide","start":272,"end":283,"id":35,"ws":true},{"text":"FN","start":284,"end":286,"id":36,"ws":true},{"text":")","start":287,"end":288,"id":37,"ws":true},{"text":"was","start":289,"end":292,"id":38,"ws":true},{"text":"developed","start":293,"end":302,"id":39,"ws":true},{"text":"in","start":303,"end":305,"id":40,"ws":true},{"text":"order","start":306,"end":311,"id":41,"ws":true},{"text":"to","start":312,"end":314,"id":42,"ws":true},{"text":"control","start":315,"end":322,"id":43,"ws":true},{"text":"their","start":323,"end":328,"id":44,"ws":true},{"text":"illegal","start":329,"end":336,"id":45,"ws":true},{"text":"use","start":337,"end":340,"id":46,"ws":true},{"text":"in","start":341,"end":343,"id":47,"ws":true},{"text":"cosmetic","start":344,"end":352,"id":48,"ws":true},{"text":"and","start":353,"end":356,"id":49,"ws":true},{"text":"natural","start":357,"end":364,"id":50,"ws":true},{"text":"products","start":365,"end":373,"id":51,"ws":true},{"text":".","start":374,"end":375,"id":52,"ws":false}],"spans":[{"start":141,"end":154,"token_start":17,"token_end":17,"label":"DRUG"},{"start":177,"end":191,"token_start":22,"token_end":22,"label":"DRUG"},{"start":197,"end":211,"token_start":25,"token_end":25,"label":"DRUG"},{"start":232,"end":250,"token_start":29,"token_end":29,"label":"DRUG"},{"start":256,"end":266,"token_start":32,"token_end":32,"label":"DRUG"}],"_input_hash":782553464,"_task_hash":-1744775723,"_session_id":"drug_drug_pilot_shared-yosi","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Among the anti-herpesvirus agents , aciclovir , valaciclovir , penciclovir , famciclovir , idoxuridine , trifluridine and brivudin are used in the treatment of herpes simplex virus and varicella-zoster virus infections , and ganciclovir , foscarnet , cidofovir , fomivirsen and maribavir ( the latter in the developmental stage ) are used in the treatment of cytomegalovirus infections .","paragraph":"<h3><u>Antiviral drugs: current state of the art.</u></h3>The chemotherapy of virus infections has definitely come of age. There are now 15 antiviral agents that have been formally licensed for the treatment of human immunodeficiency virus infections (<b style='color:Tomato;'><i>zidovudine</i></b>, <b style='color:Tomato;'><i>didanosine</i></b>, <b style='color:Tomato;'><i>zalcitabine</i></b>, <b style='color:Tomato;'><i>stavudine</i></b>, <b style='color:Tomato;'><i>lamivudine</i></b>, <b style='color:Tomato;'><i>abacavir</i></b>, <b style='color:Tomato;'><i>nevirapine</i></b>, <b style='color:Tomato;'><i>delavirdine</i></b>, <b style='color:Tomato;'><i>efavirenz</i></b>, <b style='color:Tomato;'><i>saquinavir</i></b>, <b style='color:Tomato;'><i>ritonavir</i></b>, <b style='color:Tomato;'><i>indinavir</i></b>, <b style='color:Tomato;'><i>nelfinavir</i></b>, <b style='color:Tomato;'><i>amprenavir</i></b>, <b style='color:Tomato;'><i>lopinavir</i></b>) and several others, such as <b style='color:Tomato;'><i>tenofovir</i></b> disoproxil, <b style='color:Tomato;'><i>emtricitabine</i></b>, capravirine, emivirine, T-20 (pentafuside) and AMD3100 (bicyclam) are under clinical development. Lamivudine has been approved, and several other compounds (such as <b style='color:Tomato;'><i>adefovir</i></b> dipivoxil, <b style='color:Tomato;'><i>emtricitabine</i></b> and <b style='color:Tomato;'><i>entecavir</i></b>) are under clinical development, for the treatment of hepatitis B virus infections. <b style='color:DodgerBlue;'><i>Among</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>anti-herpesvirus</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>aciclovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>valaciclovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>penciclovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>famciclovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>idoxuridine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>trifluridine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>brivudin</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>herpes</i></b> <b style='color:DodgerBlue;'><i>simplex</i></b> <b style='color:DodgerBlue;'><i>virus</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>varicella-zoster</i></b> <b style='color:DodgerBlue;'><i>virus</i></b> <b style='color:DodgerBlue;'><i>infections</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ganciclovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>foscarnet</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cidofovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>fomivirsen</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>maribavir</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>latter</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>developmental</i></b> <b style='color:DodgerBlue;'><i>stage</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cytomegalovirus</i></b> <b style='color:DodgerBlue;'><i>infections</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Following <b style='color:Tomato;'><i>amantadine</i></b> and <b style='color:Tomato;'><i>rimantadine</i></b>, the neuraminidase inhibitors, <b style='color:Tomato;'><i>zanamivir</i></b> and <b style='color:Tomato;'><i>oseltamivir</i></b>, have now become available for the therapy and prophylaxis of influenza virus infections, and so is <b style='color:Tomato;'><i>ribavirin</i></b> for the treatment of respiratory syncytial virus infections and the combination of <b style='color:Tomato;'><i>ribavirin</i></b> with interferon-alpha for the treatment of hepatitis C virus infections.","tokens":[{"text":"Among","start":0,"end":5,"id":0,"ws":true},{"text":"the","start":6,"end":9,"id":1,"ws":true},{"text":"anti-herpesvirus","start":10,"end":26,"id":2,"ws":true},{"text":"agents","start":27,"end":33,"id":3,"ws":true},{"text":",","start":34,"end":35,"id":4,"ws":true},{"text":"aciclovir","start":36,"end":45,"id":5,"ws":true},{"text":",","start":46,"end":47,"id":6,"ws":true},{"text":"valaciclovir","start":48,"end":60,"id":7,"ws":true},{"text":",","start":61,"end":62,"id":8,"ws":true},{"text":"penciclovir","start":63,"end":74,"id":9,"ws":true},{"text":",","start":75,"end":76,"id":10,"ws":true},{"text":"famciclovir","start":77,"end":88,"id":11,"ws":true},{"text":",","start":89,"end":90,"id":12,"ws":true},{"text":"idoxuridine","start":91,"end":102,"id":13,"ws":true},{"text":",","start":103,"end":104,"id":14,"ws":true},{"text":"trifluridine","start":105,"end":117,"id":15,"ws":true},{"text":"and","start":118,"end":121,"id":16,"ws":true},{"text":"brivudin","start":122,"end":130,"id":17,"ws":true},{"text":"are","start":131,"end":134,"id":18,"ws":true},{"text":"used","start":135,"end":139,"id":19,"ws":true},{"text":"in","start":140,"end":142,"id":20,"ws":true},{"text":"the","start":143,"end":146,"id":21,"ws":true},{"text":"treatment","start":147,"end":156,"id":22,"ws":true},{"text":"of","start":157,"end":159,"id":23,"ws":true},{"text":"herpes","start":160,"end":166,"id":24,"ws":true},{"text":"simplex","start":167,"end":174,"id":25,"ws":true},{"text":"virus","start":175,"end":180,"id":26,"ws":true},{"text":"and","start":181,"end":184,"id":27,"ws":true},{"text":"varicella-zoster","start":185,"end":201,"id":28,"ws":true},{"text":"virus","start":202,"end":207,"id":29,"ws":true},{"text":"infections","start":208,"end":218,"id":30,"ws":true},{"text":",","start":219,"end":220,"id":31,"ws":true},{"text":"and","start":221,"end":224,"id":32,"ws":true},{"text":"ganciclovir","start":225,"end":236,"id":33,"ws":true},{"text":",","start":237,"end":238,"id":34,"ws":true},{"text":"foscarnet","start":239,"end":248,"id":35,"ws":true},{"text":",","start":249,"end":250,"id":36,"ws":true},{"text":"cidofovir","start":251,"end":260,"id":37,"ws":true},{"text":",","start":261,"end":262,"id":38,"ws":true},{"text":"fomivirsen","start":263,"end":273,"id":39,"ws":true},{"text":"and","start":274,"end":277,"id":40,"ws":true},{"text":"maribavir","start":278,"end":287,"id":41,"ws":true},{"text":"(","start":288,"end":289,"id":42,"ws":true},{"text":"the","start":290,"end":293,"id":43,"ws":true},{"text":"latter","start":294,"end":300,"id":44,"ws":true},{"text":"in","start":301,"end":303,"id":45,"ws":true},{"text":"the","start":304,"end":307,"id":46,"ws":true},{"text":"developmental","start":308,"end":321,"id":47,"ws":true},{"text":"stage","start":322,"end":327,"id":48,"ws":true},{"text":")","start":328,"end":329,"id":49,"ws":true},{"text":"are","start":330,"end":333,"id":50,"ws":true},{"text":"used","start":334,"end":338,"id":51,"ws":true},{"text":"in","start":339,"end":341,"id":52,"ws":true},{"text":"the","start":342,"end":345,"id":53,"ws":true},{"text":"treatment","start":346,"end":355,"id":54,"ws":true},{"text":"of","start":356,"end":358,"id":55,"ws":true},{"text":"cytomegalovirus","start":359,"end":374,"id":56,"ws":true},{"text":"infections","start":375,"end":385,"id":57,"ws":true},{"text":".","start":386,"end":387,"id":58,"ws":false}],"spans":[{"start":36,"end":45,"token_start":5,"token_end":5,"label":"DRUG"},{"start":48,"end":60,"token_start":7,"token_end":7,"label":"DRUG"},{"start":63,"end":74,"token_start":9,"token_end":9,"label":"DRUG"},{"start":77,"end":88,"token_start":11,"token_end":11,"label":"DRUG"},{"start":91,"end":102,"token_start":13,"token_end":13,"label":"DRUG"},{"start":105,"end":117,"token_start":15,"token_end":15,"label":"DRUG"},{"start":225,"end":236,"token_start":33,"token_end":33,"label":"DRUG"},{"start":239,"end":248,"token_start":35,"token_end":35,"label":"DRUG"},{"start":251,"end":260,"token_start":37,"token_end":37,"label":"DRUG"}],"_input_hash":1265321677,"_task_hash":1758490147,"_session_id":"drug_drug_pilot_shared-dana_a","_view_id":"blocks","relations":[],"radio": [],"answer":"accept"}
{"text":"The present study examined the efficacy of single and combined treatment with an anticholinesterase , tetrahydroaminoacridine ( i.p . ) , and a glycine-B site partial agonist , D-cycloserine ( i.p . ; a positive allosteric modulator of NMDA receptors ) , in alleviating the deficit in water maze spatial navigation induced by electrolytic lesion of the medial septum or lidocaine infusion into the dorsal hippocampi .","paragraph":"<h3><u>Tetrahydroaminoacridine and D-cycloserine fail to alleviate the water maze spatial navigation defect induced by hippocampal inactivation.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>examined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>anticholinesterase</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>tetrahydroaminoacridine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>i.p</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>glycine-B</i></b> <b style='color:DodgerBlue;'><i>site</i></b> <b style='color:DodgerBlue;'><i>partial</i></b> <b style='color:DodgerBlue;'><i>agonist</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>D-cycloserine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>i.p</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>positive</i></b> <b style='color:DodgerBlue;'><i>allosteric</i></b> <b style='color:DodgerBlue;'><i>modulator</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>NMDA</i></b> <b style='color:DodgerBlue;'><i>receptors</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>alleviating</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>deficit</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>water</i></b> <b style='color:DodgerBlue;'><i>maze</i></b> <b style='color:DodgerBlue;'><i>spatial</i></b> <b style='color:DodgerBlue;'><i>navigation</i></b> <b style='color:DodgerBlue;'><i>induced</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>electrolytic</i></b> <b style='color:DodgerBlue;'><i>lesion</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>medial</i></b> <b style='color:DodgerBlue;'><i>septum</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>lidocaine</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>dorsal</i></b> <b style='color:DodgerBlue;'><i>hippocampi</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In medial septum-lesioned rats, a combination of tetrahydroaminoacridine 3 mg kg(-1) and D-cycloserine 10 mg kg(-1) facilitated acquisition of the water maze test more effectively than either of the drugs alone. Single or combined treatment with tetrahydroaminoacridine 3 mg kg(-1) and D-cycloserine 10 mg kg(-1) had no effect on the water maze deficit induced by hippocampal <b style='color:Tomato;'><i>lidocaine</i></b> infusion. These results suggest that combined treatment with tetrahydroaminoacridine and D-cycloserine can effectively stimulate water maze spatial navigation, and that functioning of the hippocampus is a prerequisite for this effect.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"present","start":4,"end":11,"id":1,"ws":true},{"text":"study","start":12,"end":17,"id":2,"ws":true},{"text":"examined","start":18,"end":26,"id":3,"ws":true},{"text":"the","start":27,"end":30,"id":4,"ws":true},{"text":"efficacy","start":31,"end":39,"id":5,"ws":true},{"text":"of","start":40,"end":42,"id":6,"ws":true},{"text":"single","start":43,"end":49,"id":7,"ws":true},{"text":"and","start":50,"end":53,"id":8,"ws":true},{"text":"combined","start":54,"end":62,"id":9,"ws":true},{"text":"treatment","start":63,"end":72,"id":10,"ws":true},{"text":"with","start":73,"end":77,"id":11,"ws":true},{"text":"an","start":78,"end":80,"id":12,"ws":true},{"text":"anticholinesterase","start":81,"end":99,"id":13,"ws":true},{"text":",","start":100,"end":101,"id":14,"ws":true},{"text":"tetrahydroaminoacridine","start":102,"end":125,"id":15,"ws":true},{"text":"(","start":126,"end":127,"id":16,"ws":true},{"text":"i.p","start":128,"end":131,"id":17,"ws":true},{"text":".","start":132,"end":133,"id":18,"ws":true},{"text":")","start":134,"end":135,"id":19,"ws":true},{"text":",","start":136,"end":137,"id":20,"ws":true},{"text":"and","start":138,"end":141,"id":21,"ws":true},{"text":"a","start":142,"end":143,"id":22,"ws":true},{"text":"glycine-B","start":144,"end":153,"id":23,"ws":true},{"text":"site","start":154,"end":158,"id":24,"ws":true},{"text":"partial","start":159,"end":166,"id":25,"ws":true},{"text":"agonist","start":167,"end":174,"id":26,"ws":true},{"text":",","start":175,"end":176,"id":27,"ws":true},{"text":"D-cycloserine","start":177,"end":190,"id":28,"ws":true},{"text":"(","start":191,"end":192,"id":29,"ws":true},{"text":"i.p","start":193,"end":196,"id":30,"ws":true},{"text":".","start":197,"end":198,"id":31,"ws":true},{"text":";","start":199,"end":200,"id":32,"ws":true},{"text":"a","start":201,"end":202,"id":33,"ws":true},{"text":"positive","start":203,"end":211,"id":34,"ws":true},{"text":"allosteric","start":212,"end":222,"id":35,"ws":true},{"text":"modulator","start":223,"end":232,"id":36,"ws":true},{"text":"of","start":233,"end":235,"id":37,"ws":true},{"text":"NMDA","start":236,"end":240,"id":38,"ws":true},{"text":"receptors","start":241,"end":250,"id":39,"ws":true},{"text":")","start":251,"end":252,"id":40,"ws":true},{"text":",","start":253,"end":254,"id":41,"ws":true},{"text":"in","start":255,"end":257,"id":42,"ws":true},{"text":"alleviating","start":258,"end":269,"id":43,"ws":true},{"text":"the","start":270,"end":273,"id":44,"ws":true},{"text":"deficit","start":274,"end":281,"id":45,"ws":true},{"text":"in","start":282,"end":284,"id":46,"ws":true},{"text":"water","start":285,"end":290,"id":47,"ws":true},{"text":"maze","start":291,"end":295,"id":48,"ws":true},{"text":"spatial","start":296,"end":303,"id":49,"ws":true},{"text":"navigation","start":304,"end":314,"id":50,"ws":true},{"text":"induced","start":315,"end":322,"id":51,"ws":true},{"text":"by","start":323,"end":325,"id":52,"ws":true},{"text":"electrolytic","start":326,"end":338,"id":53,"ws":true},{"text":"lesion","start":339,"end":345,"id":54,"ws":true},{"text":"of","start":346,"end":348,"id":55,"ws":true},{"text":"the","start":349,"end":352,"id":56,"ws":true},{"text":"medial","start":353,"end":359,"id":57,"ws":true},{"text":"septum","start":360,"end":366,"id":58,"ws":true},{"text":"or","start":367,"end":369,"id":59,"ws":true},{"text":"lidocaine","start":370,"end":379,"id":60,"ws":true},{"text":"infusion","start":380,"end":388,"id":61,"ws":true},{"text":"into","start":389,"end":393,"id":62,"ws":true},{"text":"the","start":394,"end":397,"id":63,"ws":true},{"text":"dorsal","start":398,"end":404,"id":64,"ws":true},{"text":"hippocampi","start":405,"end":415,"id":65,"ws":true},{"text":".","start":416,"end":417,"id":66,"ws":false}],"spans":[{"start":102,"end":125,"token_start":15,"token_end":15,"label":"DRUG"},{"start":177,"end":190,"token_start":28,"token_end":28,"label":"DRUG"},{"start":370,"end":379,"token_start":60,"token_end":60,"label":"DRUG"}],"_input_hash":1944915333,"_task_hash":1724675945,"_session_id":"drug_drug_pilot_shared-dana_a","_view_id":"blocks","relations":[],"radio": [],"answer":"accept"}
{"text":"He was initially treated with combination chemotherapy regimen of vincristine , actinomycin-D and cyclophosphamide ( VAC therapy ) .","paragraph":"<h3><u>[Rhabdomyosarcoma of the bladder: a case report].</u></h3>A 15-year-old man with the chief complaint of general fatigue was referred to our hospital on November 11, 1993. Bilateral percutaneous nephrostomy was performed for postrenal anuria. X-ray examinations revealed a huge intrapelvic tumor, and it was histopathologically diagnosed as rhabdomyosarcoma by transrectal needle biopsy. <b style='color:DodgerBlue;'><i>He</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>initially</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>actinomycin-D</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>VAC</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Pelvic exenteration was performed on December 15, 1993. Histopathological findings were alveolar rhabdomyosarcoma with degenerative change and partial necrosis. After the operation, he was given two course of VAC therapy. In May, 1994, brain metastasis occurred, so 4 courses of VAC therapy were administered. For a very short period, neurological symptoms improved, but he died of pneumonia on November 15, 1994.","tokens":[{"text":"He","start":0,"end":2,"id":0,"ws":true},{"text":"was","start":3,"end":6,"id":1,"ws":true},{"text":"initially","start":7,"end":16,"id":2,"ws":true},{"text":"treated","start":17,"end":24,"id":3,"ws":true},{"text":"with","start":25,"end":29,"id":4,"ws":true},{"text":"combination","start":30,"end":41,"id":5,"ws":true},{"text":"chemotherapy","start":42,"end":54,"id":6,"ws":true},{"text":"regimen","start":55,"end":62,"id":7,"ws":true},{"text":"of","start":63,"end":65,"id":8,"ws":true},{"text":"vincristine","start":66,"end":77,"id":9,"ws":true},{"text":",","start":78,"end":79,"id":10,"ws":true},{"text":"actinomycin-D","start":80,"end":93,"id":11,"ws":true},{"text":"and","start":94,"end":97,"id":12,"ws":true},{"text":"cyclophosphamide","start":98,"end":114,"id":13,"ws":true},{"text":"(","start":115,"end":116,"id":14,"ws":true},{"text":"VAC","start":117,"end":120,"id":15,"ws":true},{"text":"therapy","start":121,"end":128,"id":16,"ws":true},{"text":")","start":129,"end":130,"id":17,"ws":true},{"text":".","start":131,"end":132,"id":18,"ws":false}],"spans":[{"start":66,"end":77,"token_start":9,"token_end":9,"label":"DRUG"},{"start":98,"end":114,"token_start":13,"token_end":13,"label":"DRUG"}],"_input_hash":1557412523,"_task_hash":-2119098685,"_session_id":"drug_drug_pilot_shared-dana_a","_view_id":"blocks","relations":[{"head":9,"child":11,"head_span":{"start":66,"end":77,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":80,"end":93,"token_start":11,"token_end":11,"label":null},"color":"#96e8ce","label":"COMB1"},{"head":11,"child":13,"head_span":{"start":80,"end":93,"token_start":11,"token_end":11,"label":null},"child_span":{"start":98,"end":114,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"However , when a lung mass was noted two months later , he started to receive combination chemotherapy consisting of cyclophosphamide , adriamycin , vincristine , and prednisolone every three months .","paragraph":"<h3><u>[Lymphomatoid granulomatosis (LYG) occurring in a patient with follicular lymphoma during remission].</u></h3>A 49 years-old man presented with dry cough, low grade fever, and abnormal shadow on a chest X-ray. He had suffered from follicular lymphoma of the liver 5 years previously. He received irradiation therapy in combination with chemotherapy for approximately three years and had been in complete remission. Physical and radiological examination revealed pleural effusion and softly dense masses in the right lung. The laboratory data were within normal limits. He was diagnosed as having lymphomatoid granulomatosis (LYG) by open lung biopsy. The lung lesion was mainly infiltrated with T cells. The patient received <b style='color:Tomato;'><i>prednisolone</i></b> and the lung lesions disappeared. <b style='color:DodgerBlue;'><i>However</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>lung</i></b> <b style='color:DodgerBlue;'><i>mass</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>noted</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>later</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>he</i></b> <b style='color:DodgerBlue;'><i>started</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>receive</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>consisting</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>adriamycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>prednisolone</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>three</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>.</i></b> He has not shown relapse of LYG so far. To investigate the association between the preceding follicular lymphoma and subsequent LYG at this time, DNA analysis using the PCR technique was carried out. The LYG lesion did not show a rearranged band for the JH probe, while the paraffin-embedded specimen of the preceding follicular lymphoma had shown rearranged band for the JH band. Southern blot analysis of the LYG lesion, showed no rearrangement for TCR beta, gamma or JH probe. These findings indicate that the LYG was different from the preceding follicular lymphoma in terms of origin. LYG is considered to be induced in the immunosuppressive state due to lymphoma.","tokens":[{"text":"However","start":0,"end":7,"id":0,"ws":true},{"text":",","start":8,"end":9,"id":1,"ws":true},{"text":"when","start":10,"end":14,"id":2,"ws":true},{"text":"a","start":15,"end":16,"id":3,"ws":true},{"text":"lung","start":17,"end":21,"id":4,"ws":true},{"text":"mass","start":22,"end":26,"id":5,"ws":true},{"text":"was","start":27,"end":30,"id":6,"ws":true},{"text":"noted","start":31,"end":36,"id":7,"ws":true},{"text":"two","start":37,"end":40,"id":8,"ws":true},{"text":"months","start":41,"end":47,"id":9,"ws":true},{"text":"later","start":48,"end":53,"id":10,"ws":true},{"text":",","start":54,"end":55,"id":11,"ws":true},{"text":"he","start":56,"end":58,"id":12,"ws":true},{"text":"started","start":59,"end":66,"id":13,"ws":true},{"text":"to","start":67,"end":69,"id":14,"ws":true},{"text":"receive","start":70,"end":77,"id":15,"ws":true},{"text":"combination","start":78,"end":89,"id":16,"ws":true},{"text":"chemotherapy","start":90,"end":102,"id":17,"ws":true},{"text":"consisting","start":103,"end":113,"id":18,"ws":true},{"text":"of","start":114,"end":116,"id":19,"ws":true},{"text":"cyclophosphamide","start":117,"end":133,"id":20,"ws":true},{"text":",","start":134,"end":135,"id":21,"ws":true},{"text":"adriamycin","start":136,"end":146,"id":22,"ws":true},{"text":",","start":147,"end":148,"id":23,"ws":true},{"text":"vincristine","start":149,"end":160,"id":24,"ws":true},{"text":",","start":161,"end":162,"id":25,"ws":true},{"text":"and","start":163,"end":166,"id":26,"ws":true},{"text":"prednisolone","start":167,"end":179,"id":27,"ws":true},{"text":"every","start":180,"end":185,"id":28,"ws":true},{"text":"three","start":186,"end":191,"id":29,"ws":true},{"text":"months","start":192,"end":198,"id":30,"ws":true},{"text":".","start":199,"end":200,"id":31,"ws":false}],"spans":[{"start":117,"end":133,"token_start":20,"token_end":20,"label":"DRUG"},{"start":149,"end":160,"token_start":24,"token_end":24,"label":"DRUG"},{"start":167,"end":179,"token_start":27,"token_end":27,"label":"DRUG"}],"_input_hash":8987266,"_task_hash":528717002,"_session_id":"drug_drug_pilot_shared-dana_a","_view_id":"blocks","relations":[{"head":20,"child":22,"head_span":{"start":117,"end":133,"token_start":20,"token_end":20,"label":"DRUG"},"child_span":{"start":136,"end":146,"token_start":22,"token_end":22,"label":null},"color":"#96e8ce","label":"COMB1"},{"head":22,"child":24,"head_span":{"start":136,"end":146,"token_start":22,"token_end":22,"label":null},"child_span":{"start":149,"end":160,"token_start":24,"token_end":24,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":24,"child":27,"head_span":{"start":149,"end":160,"token_start":24,"token_end":24,"label":"DRUG"},"child_span":{"start":167,"end":179,"token_start":27,"token_end":27,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T1"],"answer":"accept"}
{"text":"Three patients treated initially with propranolol alone have required substitution of amiodarone due to refractory congestive heart failure .","paragraph":"<h3><u>The role of beta-blockade therapy for ventricular tachycardia induced with isoproterenol: a prospective analysis.</u></h3>Isoproterenol is sometimes required for ventricular tachycardia (VT) induction. However, the role of beta-blockade for treatment of such VT has not been critically assessed. The use of beta-blockade was evaluated prospectively in 14 consecutive patients who required isoproterenol 2.4 +/- 1.3 (+/- S.D.) micrograms/min to induce sustained monomorphic VT (greater than 30 seconds, or requiring termination due to hemodynamic collapse) after a negative baseline study. The VT mechanisms were enhanced automaticity (group A, six patients), triggered automaticity (group B, three patients), and reentry (group C, five patients). Groups A and B had serial intravenous electropharmacologic tests with <b style='color:Tomato;'><i>propranolol</i></b> alone (0.2 mg/kg), <b style='color:Tomato;'><i>verapamil</i></b> alone (0.15 mg/kg), and <b style='color:Tomato;'><i>propranolol</i></b> plus <b style='color:Tomato;'><i>verapamil</i></b>, and group C had serial tests with <b style='color:Tomato;'><i>propranolol</i></b> alone, <b style='color:Tomato;'><i>procainamide</i></b> or <b style='color:Tomato;'><i>quinidine</i></b> (class Ia drug) alone, and <b style='color:Tomato;'><i>propranolol</i></b> plus a class Ia drug until VT could no longer be induced. All six patients in group A responded to <b style='color:Tomato;'><i>propranolol</i></b> alone. In group B, one patient responded to <b style='color:Tomato;'><i>verapamil</i></b> alone, and two patients responded to <b style='color:Tomato;'><i>propranolol</i></b> plus <b style='color:Tomato;'><i>verapamil</i></b>. In group C, three patients responded to <b style='color:Tomato;'><i>propranolol</i></b> alone, one patient responded to a class Ia drug alone, and one patient responded to <b style='color:Tomato;'><i>propranolol</i></b> plus a class Ia drug. During a follow-up of 7 to 37 (17.9 +/- 10.7) (+/- S.D.) months, VT has not recurred in any patient. <b style='color:DodgerBlue;'><i>Three</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>initially</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>propranolol</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>required</i></b> <b style='color:DodgerBlue;'><i>substitution</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>amiodarone</i></b> <b style='color:DodgerBlue;'><i>due</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>refractory</i></b> <b style='color:DodgerBlue;'><i>congestive</i></b> <b style='color:DodgerBlue;'><i>heart</i></b> <b style='color:DodgerBlue;'><i>failure</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In patients requiring isoproterenol for VT induction, beta-blockade alone appears to be effective in preventing reinduction of VT caused by enhanced automaticity. A heterogeneous response occurs when the VT mechanisms are triggered automaticity or reentry.","tokens":[{"text":"Three","start":0,"end":5,"id":0,"ws":true},{"text":"patients","start":6,"end":14,"id":1,"ws":true},{"text":"treated","start":15,"end":22,"id":2,"ws":true},{"text":"initially","start":23,"end":32,"id":3,"ws":true},{"text":"with","start":33,"end":37,"id":4,"ws":true},{"text":"propranolol","start":38,"end":49,"id":5,"ws":true},{"text":"alone","start":50,"end":55,"id":6,"ws":true},{"text":"have","start":56,"end":60,"id":7,"ws":true},{"text":"required","start":61,"end":69,"id":8,"ws":true},{"text":"substitution","start":70,"end":82,"id":9,"ws":true},{"text":"of","start":83,"end":85,"id":10,"ws":true},{"text":"amiodarone","start":86,"end":96,"id":11,"ws":true},{"text":"due","start":97,"end":100,"id":12,"ws":true},{"text":"to","start":101,"end":103,"id":13,"ws":true},{"text":"refractory","start":104,"end":114,"id":14,"ws":true},{"text":"congestive","start":115,"end":125,"id":15,"ws":true},{"text":"heart","start":126,"end":131,"id":16,"ws":true},{"text":"failure","start":132,"end":139,"id":17,"ws":true},{"text":".","start":140,"end":141,"id":18,"ws":false}],"spans":[{"start":38,"end":49,"token_start":5,"token_end":5,"label":"DRUG"},{"start":86,"end":96,"token_start":11,"token_end":11,"label":"DRUG"}],"_input_hash":-632828286,"_task_hash":-1526074177,"_session_id":"drug_drug_pilot_shared-dana_a","_view_id":"blocks","relations":[{"head":5,"child":11,"head_span":{"start":38,"end":49,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":86,"end":96,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG10","NEG1T0"],"answer":"accept"}
{"text":"These studies suggest a slight advantage to the combined approaches that contain flutamide and bicalutamide , but the lack of dramatic differences in outcome makes monotherapy reasonable , especially in patients with more indolent disease .","paragraph":"<h3><u>The selection of hormonal therapy in prostate cancer: who, when, and for how long?</u></h3>Androgen deprivation is the foundation for the systemic therapy of advanced prostate cancer. Multiple trials have tested combined androgen blockade versus androgen deprivation alone in patients with advanced disease. <b style='color:DodgerBlue;'><i>These</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>suggest</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>slight</i></b> <b style='color:DodgerBlue;'><i>advantage</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>approaches</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>contain</i></b> <b style='color:MediumOrchid;'><i>flutamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>bicalutamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>lack</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>dramatic</i></b> <b style='color:DodgerBlue;'><i>differences</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>outcome</i></b> <b style='color:DodgerBlue;'><i>makes</i></b> <b style='color:DodgerBlue;'><i>monotherapy</i></b> <b style='color:DodgerBlue;'><i>reasonable</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>especially</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>indolent</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Intermittent androgen deprivation is an alternative that may allow patients to reduce the total time on androgen suppression as well as possibly delay the onset of androgen independence. A number of secondary hormonal therapies, including deferred and secondary antiandrogens, <b style='color:Tomato;'><i>ketoconazole</i></b>, and estrogens have shown modest response proportions. Patients with less advanced disease such as a rising prostate-specific antigen have varied outcomes, and no standard approach exists. In this group, noncastrating forms of hormonal therapy are being evaluated. Patients undergoing definitive local therapy who have high-risk features may benefit from early, as opposed to deferred, androgen deprivation. This review examines the evidence for the current state of the art in hormonal therapy in patients with prostate cancer and focuses, in particular, on treatment composition and timing as well as the rationale for the use of hormonal therapy in early stage disease.","tokens":[{"text":"These","start":0,"end":5,"id":0,"ws":true},{"text":"studies","start":6,"end":13,"id":1,"ws":true},{"text":"suggest","start":14,"end":21,"id":2,"ws":true},{"text":"a","start":22,"end":23,"id":3,"ws":true},{"text":"slight","start":24,"end":30,"id":4,"ws":true},{"text":"advantage","start":31,"end":40,"id":5,"ws":true},{"text":"to","start":41,"end":43,"id":6,"ws":true},{"text":"the","start":44,"end":47,"id":7,"ws":true},{"text":"combined","start":48,"end":56,"id":8,"ws":true},{"text":"approaches","start":57,"end":67,"id":9,"ws":true},{"text":"that","start":68,"end":72,"id":10,"ws":true},{"text":"contain","start":73,"end":80,"id":11,"ws":true},{"text":"flutamide","start":81,"end":90,"id":12,"ws":true},{"text":"and","start":91,"end":94,"id":13,"ws":true},{"text":"bicalutamide","start":95,"end":107,"id":14,"ws":true},{"text":",","start":108,"end":109,"id":15,"ws":true},{"text":"but","start":110,"end":113,"id":16,"ws":true},{"text":"the","start":114,"end":117,"id":17,"ws":true},{"text":"lack","start":118,"end":122,"id":18,"ws":true},{"text":"of","start":123,"end":125,"id":19,"ws":true},{"text":"dramatic","start":126,"end":134,"id":20,"ws":true},{"text":"differences","start":135,"end":146,"id":21,"ws":true},{"text":"in","start":147,"end":149,"id":22,"ws":true},{"text":"outcome","start":150,"end":157,"id":23,"ws":true},{"text":"makes","start":158,"end":163,"id":24,"ws":true},{"text":"monotherapy","start":164,"end":175,"id":25,"ws":true},{"text":"reasonable","start":176,"end":186,"id":26,"ws":true},{"text":",","start":187,"end":188,"id":27,"ws":true},{"text":"especially","start":189,"end":199,"id":28,"ws":true},{"text":"in","start":200,"end":202,"id":29,"ws":true},{"text":"patients","start":203,"end":211,"id":30,"ws":true},{"text":"with","start":212,"end":216,"id":31,"ws":true},{"text":"more","start":217,"end":221,"id":32,"ws":true},{"text":"indolent","start":222,"end":230,"id":33,"ws":true},{"text":"disease","start":231,"end":238,"id":34,"ws":true},{"text":".","start":239,"end":240,"id":35,"ws":false}],"spans":[{"start":81,"end":90,"token_start":12,"token_end":12,"label":"DRUG"},{"start":95,"end":107,"token_start":14,"token_end":14,"label":"DRUG"}],"_input_hash":137769162,"_task_hash":410888998,"_session_id":"drug_drug_pilot_shared-dana_a","_view_id":"blocks","relations":[{"head":12,"child":14,"head_span":{"start":81,"end":90,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":95,"end":107,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T0"],"answer":"accept"}
{"text":"We examined the feasibility and safety of using paclitaxel and trastuzumab as maintenance therapy after high-dose chemotherapy ( HDC ) with autologous hematopoietic stem cell transplantation ( AHST ) for patients with HER2-positive metastatic breast cancer .","paragraph":"<h3><u>Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation.</u></h3> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>examined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>feasibility</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>maintenance</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>HDC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>autologous</i></b> <b style='color:DodgerBlue;'><i>hematopoietic</i></b> <b style='color:DodgerBlue;'><i>stem</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>transplantation</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AHST</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>HER2-positive</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Ten patients (9 women and 1 man) were enrolled in the study. The median age was 46.5 years (range, 27-65 years). The median follow-up time was 1003 days (range, 216-2526 days). All patients had metastatic disease, but 2 had only bone metastasis. One patient had complete response, 6 had partial response and 3 had stable disease to the standard-dose chemotherapy prior to transplantation. The conditioning regimen consisted of <b style='color:Tomato;'><i>cyclophosphamide</i></b>, <b style='color:Tomato;'><i>carmustine</i></b>, and <b style='color:Tomato;'><i>thiotepa</i></b>. After AHST, patients received weekly <b style='color:Tomato;'><i>paclitaxel</i></b> for 12 doses and <b style='color:Tomato;'><i>trastuzumab</i></b> every 3 weeks for 1 year as maintenance therapy. All patients experienced successful engraftment. The only grade 4 toxic effects observed were leukopenia and thrombocytopenia. The most common grade 3 toxic effect was neutropenic fever. No treatment-related deaths were observed. The median progression-free survival time was 441 days, and the median overall survival time was 955 days. Two patients died in accidents while their disease remained in remission. Five patients died with disease progression. At the time of this report, 3 patients are alive with stable disease, 1 of whom has remained free of disease progression for 2526 days since transplantation. Our findings indicate that <b style='color:Tomato;'><i>paclitaxel</i></b> plus <b style='color:Tomato;'><i>trastuzumab</i></b> as maintenance therapy after HDC with AHST for patients with HER2-positive metastatic breast cancer not only is feasible and safe but also results in survival outcomes similar to historical results. ","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"examined","start":3,"end":11,"id":1,"ws":true},{"text":"the","start":12,"end":15,"id":2,"ws":true},{"text":"feasibility","start":16,"end":27,"id":3,"ws":true},{"text":"and","start":28,"end":31,"id":4,"ws":true},{"text":"safety","start":32,"end":38,"id":5,"ws":true},{"text":"of","start":39,"end":41,"id":6,"ws":true},{"text":"using","start":42,"end":47,"id":7,"ws":true},{"text":"paclitaxel","start":48,"end":58,"id":8,"ws":true},{"text":"and","start":59,"end":62,"id":9,"ws":true},{"text":"trastuzumab","start":63,"end":74,"id":10,"ws":true},{"text":"as","start":75,"end":77,"id":11,"ws":true},{"text":"maintenance","start":78,"end":89,"id":12,"ws":true},{"text":"therapy","start":90,"end":97,"id":13,"ws":true},{"text":"after","start":98,"end":103,"id":14,"ws":true},{"text":"high-dose","start":104,"end":113,"id":15,"ws":true},{"text":"chemotherapy","start":114,"end":126,"id":16,"ws":true},{"text":"(","start":127,"end":128,"id":17,"ws":true},{"text":"HDC","start":129,"end":132,"id":18,"ws":true},{"text":")","start":133,"end":134,"id":19,"ws":true},{"text":"with","start":135,"end":139,"id":20,"ws":true},{"text":"autologous","start":140,"end":150,"id":21,"ws":true},{"text":"hematopoietic","start":151,"end":164,"id":22,"ws":true},{"text":"stem","start":165,"end":169,"id":23,"ws":true},{"text":"cell","start":170,"end":174,"id":24,"ws":true},{"text":"transplantation","start":175,"end":190,"id":25,"ws":true},{"text":"(","start":191,"end":192,"id":26,"ws":true},{"text":"AHST","start":193,"end":197,"id":27,"ws":true},{"text":")","start":198,"end":199,"id":28,"ws":true},{"text":"for","start":200,"end":203,"id":29,"ws":true},{"text":"patients","start":204,"end":212,"id":30,"ws":true},{"text":"with","start":213,"end":217,"id":31,"ws":true},{"text":"HER2-positive","start":218,"end":231,"id":32,"ws":true},{"text":"metastatic","start":232,"end":242,"id":33,"ws":true},{"text":"breast","start":243,"end":249,"id":34,"ws":true},{"text":"cancer","start":250,"end":256,"id":35,"ws":true},{"text":".","start":257,"end":258,"id":36,"ws":false}],"spans":[{"start":48,"end":58,"token_start":8,"token_end":8,"label":"DRUG"},{"start":63,"end":74,"token_start":10,"token_end":10,"label":"DRUG"},{"start":193,"end":197,"token_start":27,"token_end":27,"label":"DRUG"}],"_input_hash":-1578970086,"_task_hash":304060663,"_session_id":"drug_drug_pilot_shared-dana_a","_view_id":"blocks","relations":[{"head":8,"child":10,"head_span":{"start":48,"end":58,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":63,"end":74,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"Dual antiplatelet therapy with aspirin and clopidogrel ( the preferred thienopyridine because of its superior hematologic safety ) is recommended for at least 4 weeks to prevent subacute stent thrombosis with bare-metal stents and 3 to 6 months to prevent late-stent thrombosis with drug-eluting stents .","paragraph":"<h3><u>Long-term care after percutaneous coronary intervention: focus on the role of antiplatelet therapy.</u></h3>Arterial wall injury caused by percutaneous coronary intervention (PCI) triggers transient platelet activation and mural thrombosis; these effects are superimposed on the preexisting platelet hyperreactivity associated with underlying atherothrombosis. Platelet activation has been implicated in the major complications of PCI: acute and subacute thrombosis and restenosis. Antithrombotic and anticoagulant therapy minimizes thrombotic complications after PCI. Aspirin plus a thienopyridine (<b style='color:Tomato;'><i>ticlopidine</i></b> or <b style='color:Tomato;'><i>clopidogrel</i></b>) is more effective than <b style='color:Tomato;'><i>aspirin</i></b> plus <b style='color:Tomato;'><i>heparin</i></b> and extended <b style='color:Tomato;'><i>warfarin</i></b> therapy in preventing periprocedural ischemic events and subsequent stent thrombosis and results in less major and minor bleeding. <b style='color:DodgerBlue;'><i>Dual</i></b> <b style='color:DodgerBlue;'><i>antiplatelet</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>aspirin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>clopidogrel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>preferred</i></b> <b style='color:DodgerBlue;'><i>thienopyridine</i></b> <b style='color:DodgerBlue;'><i>because</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>its</i></b> <b style='color:DodgerBlue;'><i>superior</i></b> <b style='color:DodgerBlue;'><i>hematologic</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>recommended</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>least</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>prevent</i></b> <b style='color:DodgerBlue;'><i>subacute</i></b> <b style='color:DodgerBlue;'><i>stent</i></b> <b style='color:DodgerBlue;'><i>thrombosis</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>bare-metal</i></b> <b style='color:DodgerBlue;'><i>stents</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>prevent</i></b> <b style='color:DodgerBlue;'><i>late-stent</i></b> <b style='color:DodgerBlue;'><i>thrombosis</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>drug-eluting</i></b> <b style='color:DodgerBlue;'><i>stents</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Coronary atherothrombosis is a diffuse vascular disease, and reduction of the risk of future ischemic events requires strategies that extend beyond the focal treatment of stenotic lesions. Optimal long-term care after PCI requires aggressive systemic pharmacotherapy (antiplatelet agents, statins, beta-blockers, and angiotensin-converting enzyme Inhibitors) in conjunction with therapeutic lifestyle changes (smoking cessation, weight reduction, dietary measures, and exercise). In this context, dual antiplatelet therapy (<b style='color:Tomato;'><i>aspirin</i></b> plus <b style='color:Tomato;'><i>clopidogrel</i></b>) is recommended for at least 12 months after PCI for prophylaxis of future atherothrombotic events.","tokens":[{"text":"Dual","start":0,"end":4,"id":0,"ws":true},{"text":"antiplatelet","start":5,"end":17,"id":1,"ws":true},{"text":"therapy","start":18,"end":25,"id":2,"ws":true},{"text":"with","start":26,"end":30,"id":3,"ws":true},{"text":"aspirin","start":31,"end":38,"id":4,"ws":true},{"text":"and","start":39,"end":42,"id":5,"ws":true},{"text":"clopidogrel","start":43,"end":54,"id":6,"ws":true},{"text":"(","start":55,"end":56,"id":7,"ws":true},{"text":"the","start":57,"end":60,"id":8,"ws":true},{"text":"preferred","start":61,"end":70,"id":9,"ws":true},{"text":"thienopyridine","start":71,"end":85,"id":10,"ws":true},{"text":"because","start":86,"end":93,"id":11,"ws":true},{"text":"of","start":94,"end":96,"id":12,"ws":true},{"text":"its","start":97,"end":100,"id":13,"ws":true},{"text":"superior","start":101,"end":109,"id":14,"ws":true},{"text":"hematologic","start":110,"end":121,"id":15,"ws":true},{"text":"safety","start":122,"end":128,"id":16,"ws":true},{"text":")","start":129,"end":130,"id":17,"ws":true},{"text":"is","start":131,"end":133,"id":18,"ws":true},{"text":"recommended","start":134,"end":145,"id":19,"ws":true},{"text":"for","start":146,"end":149,"id":20,"ws":true},{"text":"at","start":150,"end":152,"id":21,"ws":true},{"text":"least","start":153,"end":158,"id":22,"ws":true},{"text":"4","start":159,"end":160,"id":23,"ws":true},{"text":"weeks","start":161,"end":166,"id":24,"ws":true},{"text":"to","start":167,"end":169,"id":25,"ws":true},{"text":"prevent","start":170,"end":177,"id":26,"ws":true},{"text":"subacute","start":178,"end":186,"id":27,"ws":true},{"text":"stent","start":187,"end":192,"id":28,"ws":true},{"text":"thrombosis","start":193,"end":203,"id":29,"ws":true},{"text":"with","start":204,"end":208,"id":30,"ws":true},{"text":"bare-metal","start":209,"end":219,"id":31,"ws":true},{"text":"stents","start":220,"end":226,"id":32,"ws":true},{"text":"and","start":227,"end":230,"id":33,"ws":true},{"text":"3","start":231,"end":232,"id":34,"ws":true},{"text":"to","start":233,"end":235,"id":35,"ws":true},{"text":"6","start":236,"end":237,"id":36,"ws":true},{"text":"months","start":238,"end":244,"id":37,"ws":true},{"text":"to","start":245,"end":247,"id":38,"ws":true},{"text":"prevent","start":248,"end":255,"id":39,"ws":true},{"text":"late-stent","start":256,"end":266,"id":40,"ws":true},{"text":"thrombosis","start":267,"end":277,"id":41,"ws":true},{"text":"with","start":278,"end":282,"id":42,"ws":true},{"text":"drug-eluting","start":283,"end":295,"id":43,"ws":true},{"text":"stents","start":296,"end":302,"id":44,"ws":true},{"text":".","start":303,"end":304,"id":45,"ws":false}],"spans":[{"start":31,"end":38,"token_start":4,"token_end":4,"label":"DRUG"},{"start":43,"end":54,"token_start":6,"token_end":6,"label":"DRUG"}],"_input_hash":1471340217,"_task_hash":-1789027077,"_session_id":"drug_drug_pilot_shared-dana_a","_view_id":"blocks","relations":[],"radio": [],"answer":"accept"}
{"text":"Furthermore , in non-metastatic castration-resistant prostate cancer ( M0 CRPC ) , two second-generation anti-androgens , apalutamide and enzalutamide , when used in combination with ADT , have demonstrated a significant benefit in metastasis-free survival .","paragraph":"<h3><u>Recent trends in the management of advanced prostate cancer.</u></h3>Advanced prostate cancer includes a wide spectrum of disease ranging from hormone na\u00efve or hormone sensitive to castration resistant, both containing populations of men who have demonstrable metastatic and non-metastatic states. The mainstay of treatment for metastatic hormone-sensitive prostate cancer is androgen deprivation therapy (ADT). However, recent level 1 evidence demonstrates that the addition of chemotherapy or <b style='color:Tomato;'><i>abiraterone</i></b> acetate to ADT results in significant survival advantage as compared with ADT alone. <b style='color:DodgerBlue;'><i>Furthermore</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>non-metastatic</i></b> <b style='color:DodgerBlue;'><i>castration-resistant</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>M0</i></b> <b style='color:DodgerBlue;'><i>CRPC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>second-generation</i></b> <b style='color:DodgerBlue;'><i>anti-androgens</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>apalutamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>enzalutamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>ADT</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>significant</i></b> <b style='color:DodgerBlue;'><i>benefit</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>metastasis-free</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Here, we review the most recent studies leading to these significant changes in the treatment of advanced prostate cancer.","tokens":[{"text":"Furthermore","start":0,"end":11,"id":0,"ws":true},{"text":",","start":12,"end":13,"id":1,"ws":true},{"text":"in","start":14,"end":16,"id":2,"ws":true},{"text":"non-metastatic","start":17,"end":31,"id":3,"ws":true},{"text":"castration-resistant","start":32,"end":52,"id":4,"ws":true},{"text":"prostate","start":53,"end":61,"id":5,"ws":true},{"text":"cancer","start":62,"end":68,"id":6,"ws":true},{"text":"(","start":69,"end":70,"id":7,"ws":true},{"text":"M0","start":71,"end":73,"id":8,"ws":true},{"text":"CRPC","start":74,"end":78,"id":9,"ws":true},{"text":")","start":79,"end":80,"id":10,"ws":true},{"text":",","start":81,"end":82,"id":11,"ws":true},{"text":"two","start":83,"end":86,"id":12,"ws":true},{"text":"second-generation","start":87,"end":104,"id":13,"ws":true},{"text":"anti-androgens","start":105,"end":119,"id":14,"ws":true},{"text":",","start":120,"end":121,"id":15,"ws":true},{"text":"apalutamide","start":122,"end":133,"id":16,"ws":true},{"text":"and","start":134,"end":137,"id":17,"ws":true},{"text":"enzalutamide","start":138,"end":150,"id":18,"ws":true},{"text":",","start":151,"end":152,"id":19,"ws":true},{"text":"when","start":153,"end":157,"id":20,"ws":true},{"text":"used","start":158,"end":162,"id":21,"ws":true},{"text":"in","start":163,"end":165,"id":22,"ws":true},{"text":"combination","start":166,"end":177,"id":23,"ws":true},{"text":"with","start":178,"end":182,"id":24,"ws":true},{"text":"ADT","start":183,"end":186,"id":25,"ws":true},{"text":",","start":187,"end":188,"id":26,"ws":true},{"text":"have","start":189,"end":193,"id":27,"ws":true},{"text":"demonstrated","start":194,"end":206,"id":28,"ws":true},{"text":"a","start":207,"end":208,"id":29,"ws":true},{"text":"significant","start":209,"end":220,"id":30,"ws":true},{"text":"benefit","start":221,"end":228,"id":31,"ws":true},{"text":"in","start":229,"end":231,"id":32,"ws":true},{"text":"metastasis-free","start":232,"end":247,"id":33,"ws":true},{"text":"survival","start":248,"end":256,"id":34,"ws":true},{"text":".","start":257,"end":258,"id":35,"ws":false}],"spans":[{"start":122,"end":133,"token_start":16,"token_end":16,"label":"DRUG"},{"start":138,"end":150,"token_start":18,"token_end":18,"label":"DRUG"}],"_input_hash":236482726,"_task_hash":-1620523265,"_session_id":"drug_drug_pilot_shared-dana_a","_view_id":"blocks","relations":[{"head":16,"child":18,"head_span":{"start":122,"end":133,"token_start":16,"token_end":16,"label":"DRUG"},"child_span":{"start":138,"end":150,"token_start":18,"token_end":18,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T0"],"answer":"accept"}
{"text":"A screening method based on liquid chromatography-electrospray mass spectrometry for the simultaneous determination of six corticosteroids ( betamethasone 17-valerate BM 17-V , beclomethasone BC , beclomethasone dipropionate BCDP , methylprednisolone MP , budesonide BD , flunisolide FN ) was developed in order to control their illegal use in cosmetic and natural products .","paragraph":"<h3><u>LC-MS method for the simultaneous determination of six glucocorticoids in pharmaceutical formulations and counterfeit cosmetic products.</u></h3> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>screening</i></b> <b style='color:DodgerBlue;'><i>method</i></b> <b style='color:DodgerBlue;'><i>based</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>liquid</i></b> <b style='color:DodgerBlue;'><i>chromatography-electrospray</i></b> <b style='color:DodgerBlue;'><i>mass</i></b> <b style='color:DodgerBlue;'><i>spectrometry</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>simultaneous</i></b> <b style='color:DodgerBlue;'><i>determination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>six</i></b> <b style='color:DodgerBlue;'><i>corticosteroids</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>betamethasone</i></b> <b style='color:DodgerBlue;'><i>17-valerate</i></b> <b style='color:DodgerBlue;'><i>BM</i></b> <b style='color:DodgerBlue;'><i>17-V</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>beclomethasone</i></b> <b style='color:DodgerBlue;'><i>BC</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>beclomethasone</i></b> <b style='color:DodgerBlue;'><i>dipropionate</i></b> <b style='color:DodgerBlue;'><i>BCDP</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>methylprednisolone</i></b> <b style='color:DodgerBlue;'><i>MP</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>budesonide</i></b> <b style='color:DodgerBlue;'><i>BD</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>flunisolide</i></b> <b style='color:DodgerBlue;'><i>FN</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>developed</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>order</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>control</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>illegal</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>cosmetic</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>natural</i></b> <b style='color:DodgerBlue;'><i>products</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Indeed, despite corticosteroids are banned in cosmetics, counterfeit products might be present on the market, representing a health hazard. Therefore, effective analytical methods are required to rapidly screen over the counter products in health care shops for counterfeit corticosteroids. The analytical method involves the employment of a Waters Synergy C18 column (150mm\u00d72.0mm I.D.) by using the following mobile phase: A (0.1% formic acid in acetonitrile), B (0.1% formic acid in water) in a linear gradient (from A-B 25:75, v/v to A-B 95:5, v/v in 30min) at the flow rate of 0.3mL/min. The detection was performed with an ion trap (IT) mass spectrometer in positive polarity, total ion current (TIC) and tandem mass modalities for qualitative purpose; single ion monitoring (SIM) mode was used for quantitative analysis on the ESI generated most abundant ion for each steroid. The method was fully validated in terms of precision, detection and quantification limits, linearity, recovery, and it was applied to the identification and quantification of corticosteroids in pharmaceutical formulations and cosmetic products. The mean recovery of BM 17-V, BC, BCDP, MP, BD and FN were found to be 101.3, 101.5, 98.8, 98.9, 98.1, 99.0%, respectively. Limits of quantitation (LOQ) were comprised in the range 29-95ng/mL. To the best of our knowledge, for the first time this mix of glucocorticoids were simultaneously determined in cosmetic products by using a fully validated method. BMV, in its two isomeric forms BM 17-V and BM 21-V, was found to be illegally present in one cream sample (A) with the total concentration level of 0.036% (w/w). ","tokens":[{"text":"A","start":0,"end":1,"id":0,"ws":true},{"text":"screening","start":2,"end":11,"id":1,"ws":true},{"text":"method","start":12,"end":18,"id":2,"ws":true},{"text":"based","start":19,"end":24,"id":3,"ws":true},{"text":"on","start":25,"end":27,"id":4,"ws":true},{"text":"liquid","start":28,"end":34,"id":5,"ws":true},{"text":"chromatography-electrospray","start":35,"end":62,"id":6,"ws":true},{"text":"mass","start":63,"end":67,"id":7,"ws":true},{"text":"spectrometry","start":68,"end":80,"id":8,"ws":true},{"text":"for","start":81,"end":84,"id":9,"ws":true},{"text":"the","start":85,"end":88,"id":10,"ws":true},{"text":"simultaneous","start":89,"end":101,"id":11,"ws":true},{"text":"determination","start":102,"end":115,"id":12,"ws":true},{"text":"of","start":116,"end":118,"id":13,"ws":true},{"text":"six","start":119,"end":122,"id":14,"ws":true},{"text":"corticosteroids","start":123,"end":138,"id":15,"ws":true},{"text":"(","start":139,"end":140,"id":16,"ws":true},{"text":"betamethasone","start":141,"end":154,"id":17,"ws":true},{"text":"17-valerate","start":155,"end":166,"id":18,"ws":true},{"text":"BM","start":167,"end":169,"id":19,"ws":true},{"text":"17-V","start":170,"end":174,"id":20,"ws":true},{"text":",","start":175,"end":176,"id":21,"ws":true},{"text":"beclomethasone","start":177,"end":191,"id":22,"ws":true},{"text":"BC","start":192,"end":194,"id":23,"ws":true},{"text":",","start":195,"end":196,"id":24,"ws":true},{"text":"beclomethasone","start":197,"end":211,"id":25,"ws":true},{"text":"dipropionate","start":212,"end":224,"id":26,"ws":true},{"text":"BCDP","start":225,"end":229,"id":27,"ws":true},{"text":",","start":230,"end":231,"id":28,"ws":true},{"text":"methylprednisolone","start":232,"end":250,"id":29,"ws":true},{"text":"MP","start":251,"end":253,"id":30,"ws":true},{"text":",","start":254,"end":255,"id":31,"ws":true},{"text":"budesonide","start":256,"end":266,"id":32,"ws":true},{"text":"BD","start":267,"end":269,"id":33,"ws":true},{"text":",","start":270,"end":271,"id":34,"ws":true},{"text":"flunisolide","start":272,"end":283,"id":35,"ws":true},{"text":"FN","start":284,"end":286,"id":36,"ws":true},{"text":")","start":287,"end":288,"id":37,"ws":true},{"text":"was","start":289,"end":292,"id":38,"ws":true},{"text":"developed","start":293,"end":302,"id":39,"ws":true},{"text":"in","start":303,"end":305,"id":40,"ws":true},{"text":"order","start":306,"end":311,"id":41,"ws":true},{"text":"to","start":312,"end":314,"id":42,"ws":true},{"text":"control","start":315,"end":322,"id":43,"ws":true},{"text":"their","start":323,"end":328,"id":44,"ws":true},{"text":"illegal","start":329,"end":336,"id":45,"ws":true},{"text":"use","start":337,"end":340,"id":46,"ws":true},{"text":"in","start":341,"end":343,"id":47,"ws":true},{"text":"cosmetic","start":344,"end":352,"id":48,"ws":true},{"text":"and","start":353,"end":356,"id":49,"ws":true},{"text":"natural","start":357,"end":364,"id":50,"ws":true},{"text":"products","start":365,"end":373,"id":51,"ws":true},{"text":".","start":374,"end":375,"id":52,"ws":false}],"spans":[{"start":141,"end":154,"token_start":17,"token_end":17,"label":"DRUG"},{"start":177,"end":191,"token_start":22,"token_end":22,"label":"DRUG"},{"start":197,"end":211,"token_start":25,"token_end":25,"label":"DRUG"},{"start":232,"end":250,"token_start":29,"token_end":29,"label":"DRUG"},{"start":256,"end":266,"token_start":32,"token_end":32,"label":"DRUG"}],"_input_hash":782553464,"_task_hash":-1744775723,"_session_id":"drug_drug_pilot_shared-dana_a","_view_id":"blocks","relations":[],"radio": [],"answer":"accept"}
{"text":"We used MCF-7 and MDA-MB231 breast cancer cells incubated with Curcumin and Quercetin for 24h , in the absence and presence of Somatostatin , at their EC50 concentrations , to evaluate membrane fatty acid-based functional lipidomics together with the follow-up of EGFR and MAPK signaling pathways .","paragraph":"<h3><u>Effects of Somatostatin, Curcumin and Quercetin on the fatty acid profile of breast cancer cell membranes.</u></h3> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>MCF-7</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>MDA-MB231</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>incubated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>Curcumin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Quercetin</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>24h</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>absence</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>presence</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>Somatostatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>EC50</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>membrane</i></b> <b style='color:DodgerBlue;'><i>fatty</i></b> <b style='color:DodgerBlue;'><i>acid-based</i></b> <b style='color:DodgerBlue;'><i>functional</i></b> <b style='color:DodgerBlue;'><i>lipidomics</i></b> <b style='color:DodgerBlue;'><i>together</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>follow-up</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>EGFR</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>MAPK</i></b> <b style='color:DodgerBlue;'><i>signaling</i></b> <b style='color:DodgerBlue;'><i>pathways</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The two cell lines gave different membrane free fatty acid reorganization: in MCF-7 cells, the following changes observed: increase of omega-6 linoleic acid in the cells incubated with Somatostatin+Quercetin and Quercetin and decrease of omega-3 acids in the cells incubated with Somatostatin+Curcumin compared to Somatostatin, and significant increases of monounsaturated fatty acid (MUFA), mono-trans arachidonic acid levels and docosapentaenoic acid for the cells incubated with Somatostatin+Quercetin compared to the control cells. In MDA-MB231 cells, incubations with Curcumin, Quercetin and Somatostatin+Quercetin induced the most significant membrane remodeling with the increase of stearic acid, diminution of omega-6 linoleic, arachidonic acids and omega-3 (docosapentaenoic and docosahexaenoic acids). Distinct signaling pathway changes were found for these cell lines. In MCF-7 cells, separate or combined incubations with Somatostatin and Quercetin, significantly decreased EGFR and incubation with Curcumin decreased MAPK signaling. In MDA-MB231 cells, incubation with Curcumin decreased AKT1 and p-AKT1(Thr308) levels. Incubation with Curcumin and Quercetin decreased the EGFR levels.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"used","start":3,"end":7,"id":1,"ws":true},{"text":"MCF-7","start":8,"end":13,"id":2,"ws":true},{"text":"and","start":14,"end":17,"id":3,"ws":true},{"text":"MDA-MB231","start":18,"end":27,"id":4,"ws":true},{"text":"breast","start":28,"end":34,"id":5,"ws":true},{"text":"cancer","start":35,"end":41,"id":6,"ws":true},{"text":"cells","start":42,"end":47,"id":7,"ws":true},{"text":"incubated","start":48,"end":57,"id":8,"ws":true},{"text":"with","start":58,"end":62,"id":9,"ws":true},{"text":"Curcumin","start":63,"end":71,"id":10,"ws":true},{"text":"and","start":72,"end":75,"id":11,"ws":true},{"text":"Quercetin","start":76,"end":85,"id":12,"ws":true},{"text":"for","start":86,"end":89,"id":13,"ws":true},{"text":"24h","start":90,"end":93,"id":14,"ws":true},{"text":",","start":94,"end":95,"id":15,"ws":true},{"text":"in","start":96,"end":98,"id":16,"ws":true},{"text":"the","start":99,"end":102,"id":17,"ws":true},{"text":"absence","start":103,"end":110,"id":18,"ws":true},{"text":"and","start":111,"end":114,"id":19,"ws":true},{"text":"presence","start":115,"end":123,"id":20,"ws":true},{"text":"of","start":124,"end":126,"id":21,"ws":true},{"text":"Somatostatin","start":127,"end":139,"id":22,"ws":true},{"text":",","start":140,"end":141,"id":23,"ws":true},{"text":"at","start":142,"end":144,"id":24,"ws":true},{"text":"their","start":145,"end":150,"id":25,"ws":true},{"text":"EC50","start":151,"end":155,"id":26,"ws":true},{"text":"concentrations","start":156,"end":170,"id":27,"ws":true},{"text":",","start":171,"end":172,"id":28,"ws":true},{"text":"to","start":173,"end":175,"id":29,"ws":true},{"text":"evaluate","start":176,"end":184,"id":30,"ws":true},{"text":"membrane","start":185,"end":193,"id":31,"ws":true},{"text":"fatty","start":194,"end":199,"id":32,"ws":true},{"text":"acid-based","start":200,"end":210,"id":33,"ws":true},{"text":"functional","start":211,"end":221,"id":34,"ws":true},{"text":"lipidomics","start":222,"end":232,"id":35,"ws":true},{"text":"together","start":233,"end":241,"id":36,"ws":true},{"text":"with","start":242,"end":246,"id":37,"ws":true},{"text":"the","start":247,"end":250,"id":38,"ws":true},{"text":"follow-up","start":251,"end":260,"id":39,"ws":true},{"text":"of","start":261,"end":263,"id":40,"ws":true},{"text":"EGFR","start":264,"end":268,"id":41,"ws":true},{"text":"and","start":269,"end":272,"id":42,"ws":true},{"text":"MAPK","start":273,"end":277,"id":43,"ws":true},{"text":"signaling","start":278,"end":287,"id":44,"ws":true},{"text":"pathways","start":288,"end":296,"id":45,"ws":true},{"text":".","start":297,"end":298,"id":46,"ws":false}],"spans":[{"start":63,"end":71,"token_start":10,"token_end":10,"label":"DRUG"},{"start":76,"end":85,"token_start":12,"token_end":12,"label":"DRUG"},{"start":127,"end":139,"token_start":22,"token_end":22,"label":"DRUG"}],"_input_hash":-1803484576,"_task_hash":288010961,"_session_id":"drug_drug_pilot_shared-dana_a","_view_id":"blocks","relations":[{"head":10,"child":12,"head_span":{"start":63,"end":71,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":76,"end":85,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":12,"child":22,"head_span":{"start":76,"end":85,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":127,"end":139,"token_start":22,"token_end":22,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"Following corneal scrapings and culture , topical 0.5 % moxifloxacin and 0.5 % tobramycin were administered hourly .","paragraph":"<h3><u>A case of Stenotrophomonas maltophilia keratitis effectively treated with moxifloxacin.</u></h3>A 70-year-old man with a long history of diabetes mellitus presented to our hospital (Department of Ophthalmology, Sahm Yook Medical Center, Seoul, Korea) complaining of severe ocular pain and visual disturbance in his left eye that had started three days prior to admission. A round 3.7 \u00d7 5.0 mm dense central stromal infiltrate with an overlying epithelial defect was noted on slit-lamp examination. <b style='color:DodgerBlue;'><i>Following</i></b> <b style='color:DodgerBlue;'><i>corneal</i></b> <b style='color:DodgerBlue;'><i>scrapings</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>culture</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>topical</i></b> <b style='color:DodgerBlue;'><i>0.5</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:MediumOrchid;'><i>moxifloxacin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>0.5</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:MediumOrchid;'><i>tobramycin</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>hourly</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A few days later, Stenotrophomonas maltophilia was isolated in a bacterial culture from a corneal specimen. According to the results of susceptibility tests, topical 0.5% <b style='color:Tomato;'><i>moxifloxacin</i></b> was given every hour and 0.5% <b style='color:Tomato;'><i>tobramycin</i></b> was stopped. The patient's clinical features improved steadily with treatment. The corneal epithelium healed rapidly, and the infiltrate resolved within four weeks of the initiation of treatment. The patient's best corrected visual acuity improved from hand motion to 20 / 25.","tokens":[{"text":"Following","start":0,"end":9,"id":0,"ws":true},{"text":"corneal","start":10,"end":17,"id":1,"ws":true},{"text":"scrapings","start":18,"end":27,"id":2,"ws":true},{"text":"and","start":28,"end":31,"id":3,"ws":true},{"text":"culture","start":32,"end":39,"id":4,"ws":true},{"text":",","start":40,"end":41,"id":5,"ws":true},{"text":"topical","start":42,"end":49,"id":6,"ws":true},{"text":"0.5","start":50,"end":53,"id":7,"ws":true},{"text":"%","start":54,"end":55,"id":8,"ws":true},{"text":"moxifloxacin","start":56,"end":68,"id":9,"ws":true},{"text":"and","start":69,"end":72,"id":10,"ws":true},{"text":"0.5","start":73,"end":76,"id":11,"ws":true},{"text":"%","start":77,"end":78,"id":12,"ws":true},{"text":"tobramycin","start":79,"end":89,"id":13,"ws":true},{"text":"were","start":90,"end":94,"id":14,"ws":true},{"text":"administered","start":95,"end":107,"id":15,"ws":true},{"text":"hourly","start":108,"end":114,"id":16,"ws":true},{"text":".","start":115,"end":116,"id":17,"ws":false}],"spans":[{"start":56,"end":68,"token_start":9,"token_end":9,"label":"DRUG"},{"start":79,"end":89,"token_start":13,"token_end":13,"label":"DRUG"}],"_input_hash":1332991430,"_task_hash":1426603318,"_session_id":"drug_drug_pilot_shared-dana_a","_view_id":"blocks","relations":[],"radio": [],"answer":"accept"}
{"text":"Combination treatment with cetuximab and nystatin selectively increased cetuximab uptake by tumor tissues , translating into potentiated antitumor efficacy of cetuximab in vivo ( A431 and A549 tumors ) .","paragraph":"<h3><u>Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration.</u></h3>Cetuximab, a monoclonal antibody (mAb) targeting the epidermal growth factor receptor (EGFR), has been intensively investigated as a promising cancer treatment strategy. The specific mechanism of <b style='color:Tomato;'><i>cetuximab</i></b> endocytosis and its influence on <b style='color:Tomato;'><i>cetuximab</i></b> uptake, biodistribution and efficacy still remain elusive. Recently, statins have been reported to synergize with EGFR-targeting agents. Our prior work established that <b style='color:Tomato;'><i>nystatin</i></b>, a cholesterol-sequestering antifungal drug, facilitates endocytosis via the clathrin-dependent pathway. This study aimed to investigate whether <b style='color:Tomato;'><i>nystatin</i></b> regulates the uptake and efficacy of <b style='color:Tomato;'><i>cetuximab</i></b> and <b style='color:Tomato;'><i>cetuximab</i></b>-based antibody-drug conjugates (<b style='color:Tomato;'><i>cetuximab</i></b>-ADCs). In vitro and in vivo efficacies of <b style='color:Tomato;'><i>nystatin</i></b> on the uptake and activity of <b style='color:Tomato;'><i>cetuximab</i></b>/<b style='color:Tomato;'><i>cetuximab</i></b>-ADCs were studied in multiple human carcinoma cell lines and xenograft models, respectively. We identified that cholesterol sequestration by <b style='color:Tomato;'><i>nystatin</i></b> enhanced <b style='color:Tomato;'><i>cetuximab</i></b> internalization in EGFR-positive carcinoma cells by regulating EGFR trafficking/turnover and facilitating a switch from lipid rafts to clathrin-mediated endocytosis. <b style='color:DodgerBlue;'><i>Combination</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>nystatin</i></b> <b style='color:DodgerBlue;'><i>selectively</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>uptake</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>tumor</i></b> <b style='color:DodgerBlue;'><i>tissues</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>translating</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>potentiated</i></b> <b style='color:DodgerBlue;'><i>antitumor</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vivo</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>A431</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>A549</i></b> <b style='color:DodgerBlue;'><i>tumors</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Nystatin-enhanced internalization of <b style='color:Tomato;'><i>cetuximab</i></b> further improved the uptake and potency of <b style='color:Tomato;'><i>cetuximab</i></b>-<b style='color:Tomato;'><i>doxorubicin</i></b> and <b style='color:Tomato;'><i>cetuximab</i></b>-<b style='color:Tomato;'><i>methotrexate</i></b> conjugates in EGFR-positive <b style='color:Tomato;'><i>cetuximab</i></b>-resistant tumors. Combination therapy with <b style='color:Tomato;'><i>nystatin</i></b> plus either <b style='color:Tomato;'><i>cetuximab</i></b> or <b style='color:Tomato;'><i>cetuximab</i></b>-ADC further prolonged animal survival and significantly suppressed tumor growth, as compared with single-agent <b style='color:Tomato;'><i>cetuximab</i></b> or <b style='color:Tomato;'><i>cetuximab</i></b>-ADC. In summary, our results identify a novel mechanism whereby cholesterol sequestration enhances the uptake of EGFR-targeting mAb and ADCs, therefore providing preclinical proof-of-concept that combination with <b style='color:Tomato;'><i>nystatin</i></b> can potentiate the delivery and efficacy of these EGFR-targeted agents. ","tokens":[{"text":"Combination","start":0,"end":11,"id":0,"ws":true},{"text":"treatment","start":12,"end":21,"id":1,"ws":true},{"text":"with","start":22,"end":26,"id":2,"ws":true},{"text":"cetuximab","start":27,"end":36,"id":3,"ws":true},{"text":"and","start":37,"end":40,"id":4,"ws":true},{"text":"nystatin","start":41,"end":49,"id":5,"ws":true},{"text":"selectively","start":50,"end":61,"id":6,"ws":true},{"text":"increased","start":62,"end":71,"id":7,"ws":true},{"text":"cetuximab","start":72,"end":81,"id":8,"ws":true},{"text":"uptake","start":82,"end":88,"id":9,"ws":true},{"text":"by","start":89,"end":91,"id":10,"ws":true},{"text":"tumor","start":92,"end":97,"id":11,"ws":true},{"text":"tissues","start":98,"end":105,"id":12,"ws":true},{"text":",","start":106,"end":107,"id":13,"ws":true},{"text":"translating","start":108,"end":119,"id":14,"ws":true},{"text":"into","start":120,"end":124,"id":15,"ws":true},{"text":"potentiated","start":125,"end":136,"id":16,"ws":true},{"text":"antitumor","start":137,"end":146,"id":17,"ws":true},{"text":"efficacy","start":147,"end":155,"id":18,"ws":true},{"text":"of","start":156,"end":158,"id":19,"ws":true},{"text":"cetuximab","start":159,"end":168,"id":20,"ws":true},{"text":"in","start":169,"end":171,"id":21,"ws":true},{"text":"vivo","start":172,"end":176,"id":22,"ws":true},{"text":"(","start":177,"end":178,"id":23,"ws":true},{"text":"A431","start":179,"end":183,"id":24,"ws":true},{"text":"and","start":184,"end":187,"id":25,"ws":true},{"text":"A549","start":188,"end":192,"id":26,"ws":true},{"text":"tumors","start":193,"end":199,"id":27,"ws":true},{"text":")","start":200,"end":201,"id":28,"ws":true},{"text":".","start":202,"end":203,"id":29,"ws":false}],"spans":[{"start":27,"end":36,"token_start":3,"token_end":3,"label":"DRUG"},{"start":41,"end":49,"token_start":5,"token_end":5,"label":"DRUG"},{"start":72,"end":81,"token_start":8,"token_end":8,"label":"DRUG"},{"start":159,"end":168,"token_start":20,"token_end":20,"label":"DRUG"}],"_input_hash":-1277491604,"_task_hash":-1965461189,"_session_id":"drug_drug_pilot_shared-dana_a","_view_id":"blocks","relations":[{"head":3,"child":5,"head_span":{"start":27,"end":36,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":41,"end":49,"token_start":5,"token_end":5,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T0"],"answer":"accept"}
{"text":"The effects of combination therapy with chenodeoxycholic acid ( CDCA ) and simvastatin on serum cholestanol , low-density lipoprotein ( LDL ) cholesterol , and lathosterol levels were investigated in seven adult patients with cerebrotendinous xanthomatosis ( CTX ) who were on long-term treatment with CDCA .","paragraph":"<h3><u>Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>chenodeoxycholic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CDCA</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>simvastatin</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>serum</i></b> <b style='color:DodgerBlue;'><i>cholestanol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>low-density</i></b> <b style='color:DodgerBlue;'><i>lipoprotein</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>LDL</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>cholesterol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>lathosterol</i></b> <b style='color:DodgerBlue;'><i>levels</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>investigated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>seven</i></b> <b style='color:DodgerBlue;'><i>adult</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>cerebrotendinous</i></b> <b style='color:DodgerBlue;'><i>xanthomatosis</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CTX</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>long-term</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>CDCA</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The patients were treated with a combination of CDCA 750 mg daily and an increasing dose of <b style='color:Tomato;'><i>simvastatin</i></b> from 10 mg to 40 mg daily for a period of 6 months. We found a significant effect of this combination therapy compared with CDCA alone in terms of decreasing the serum cholestanol and LDL cholesterol levels, particularly with a daily dose of 40 mg <b style='color:Tomato;'><i>simvastatin</i></b>. The mean cholestanol level decreased from 9.27 micromol/L (baseline) to 6.69 micromol/L (40 mg <b style='color:Tomato;'><i>simvastatin</i></b>), while the mean LDL cholesterol level decreased from 5.08 mmol/L (baseline) to 3.04 mmol/L (40 mg <b style='color:Tomato;'><i>simvastatin</i></b>). No side effects were reported, and there were no effects on the clinical condition, cerebral magnetic resonance imaging (MRI), visual evoked potentials, and electroencephalographic features. We conclude that a combination of 750 mg CDCA and 40 mg <b style='color:Tomato;'><i>simvastatin</i></b> daily is effective to further reduce serum cholestanol, LDL cholesterol, and lathosterol in adult CTX patients treated with long-term CDCA. Whether this combination treatment will be effective for the long-term prevention of neurological deterioration and atherosclerosis remains to be established.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"effects","start":4,"end":11,"id":1,"ws":true},{"text":"of","start":12,"end":14,"id":2,"ws":true},{"text":"combination","start":15,"end":26,"id":3,"ws":true},{"text":"therapy","start":27,"end":34,"id":4,"ws":true},{"text":"with","start":35,"end":39,"id":5,"ws":true},{"text":"chenodeoxycholic","start":40,"end":56,"id":6,"ws":true},{"text":"acid","start":57,"end":61,"id":7,"ws":true},{"text":"(","start":62,"end":63,"id":8,"ws":true},{"text":"CDCA","start":64,"end":68,"id":9,"ws":true},{"text":")","start":69,"end":70,"id":10,"ws":true},{"text":"and","start":71,"end":74,"id":11,"ws":true},{"text":"simvastatin","start":75,"end":86,"id":12,"ws":true},{"text":"on","start":87,"end":89,"id":13,"ws":true},{"text":"serum","start":90,"end":95,"id":14,"ws":true},{"text":"cholestanol","start":96,"end":107,"id":15,"ws":true},{"text":",","start":108,"end":109,"id":16,"ws":true},{"text":"low-density","start":110,"end":121,"id":17,"ws":true},{"text":"lipoprotein","start":122,"end":133,"id":18,"ws":true},{"text":"(","start":134,"end":135,"id":19,"ws":true},{"text":"LDL","start":136,"end":139,"id":20,"ws":true},{"text":")","start":140,"end":141,"id":21,"ws":true},{"text":"cholesterol","start":142,"end":153,"id":22,"ws":true},{"text":",","start":154,"end":155,"id":23,"ws":true},{"text":"and","start":156,"end":159,"id":24,"ws":true},{"text":"lathosterol","start":160,"end":171,"id":25,"ws":true},{"text":"levels","start":172,"end":178,"id":26,"ws":true},{"text":"were","start":179,"end":183,"id":27,"ws":true},{"text":"investigated","start":184,"end":196,"id":28,"ws":true},{"text":"in","start":197,"end":199,"id":29,"ws":true},{"text":"seven","start":200,"end":205,"id":30,"ws":true},{"text":"adult","start":206,"end":211,"id":31,"ws":true},{"text":"patients","start":212,"end":220,"id":32,"ws":true},{"text":"with","start":221,"end":225,"id":33,"ws":true},{"text":"cerebrotendinous","start":226,"end":242,"id":34,"ws":true},{"text":"xanthomatosis","start":243,"end":256,"id":35,"ws":true},{"text":"(","start":257,"end":258,"id":36,"ws":true},{"text":"CTX","start":259,"end":262,"id":37,"ws":true},{"text":")","start":263,"end":264,"id":38,"ws":true},{"text":"who","start":265,"end":268,"id":39,"ws":true},{"text":"were","start":269,"end":273,"id":40,"ws":true},{"text":"on","start":274,"end":276,"id":41,"ws":true},{"text":"long-term","start":277,"end":286,"id":42,"ws":true},{"text":"treatment","start":287,"end":296,"id":43,"ws":true},{"text":"with","start":297,"end":301,"id":44,"ws":true},{"text":"CDCA","start":302,"end":306,"id":45,"ws":true},{"text":".","start":307,"end":308,"id":46,"ws":false}],"spans":[{"start":40,"end":56,"token_start":6,"token_end":6,"label":"DRUG"},{"start":75,"end":86,"token_start":12,"token_end":12,"label":"DRUG"}],"_input_hash":-475065306,"_task_hash":-2052397739,"_session_id":"drug_drug_pilot_shared-dana_a","_view_id":"blocks","relations":[{"head":6,"child":12,"head_span":{"start":40,"end":56,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":75,"end":86,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T1"],"answer":"accept"}
{"text":"Paclitaxel ( Taxol ; Bristol-Myers Squibb Company , Princeton , NJ ) has been demonstrated to be highly effective in treating patients with advanced breast cancer , including those with anthracycline-resistant breast cancer , a fact that has led to efforts to combine paclitaxel and anthracyclines .","paragraph":"<h3><u>Paclitaxel and doxorubicin in metastatic breast cancer.</u></h3>For the past decades the anthracyclines have been regarded as among the most active drugs for the treatment of metastatic breast cancer. However, the 5-year survival rate in patients with stage IV breast cancer continues to be below 20%, and new active drugs and drug combinations clearly must be explored. <b style='color:MediumOrchid;'><i>Paclitaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Taxol</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>Bristol-Myers</i></b> <b style='color:DodgerBlue;'><i>Squibb</i></b> <b style='color:DodgerBlue;'><i>Company</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Princeton</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>NJ</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>highly</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>treating</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>anthracycline-resistant</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>fact</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>led</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>efforts</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>combine</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>anthracyclines</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Several studies aiming to define the optimal dose and schedule of combination <b style='color:Tomato;'><i>paclitaxel</i></b>/<b style='color:Tomato;'><i>doxorubicin</i></b> have now been completed or are ongoing. Phase I/II studies have yielded encouraging preliminary response rates but quite variable toxicity profiles depending on the schedule used. These clinical trials involving combination <b style='color:Tomato;'><i>paclitaxel</i></b>/<b style='color:Tomato;'><i>doxorubicin</i></b> are reviewed, with special emphasis on the short-infusion trials.","tokens":[{"text":"Paclitaxel","start":0,"end":10,"id":0,"ws":true},{"text":"(","start":11,"end":12,"id":1,"ws":true},{"text":"Taxol","start":13,"end":18,"id":2,"ws":true},{"text":";","start":19,"end":20,"id":3,"ws":true},{"text":"Bristol-Myers","start":21,"end":34,"id":4,"ws":true},{"text":"Squibb","start":35,"end":41,"id":5,"ws":true},{"text":"Company","start":42,"end":49,"id":6,"ws":true},{"text":",","start":50,"end":51,"id":7,"ws":true},{"text":"Princeton","start":52,"end":61,"id":8,"ws":true},{"text":",","start":62,"end":63,"id":9,"ws":true},{"text":"NJ","start":64,"end":66,"id":10,"ws":true},{"text":")","start":67,"end":68,"id":11,"ws":true},{"text":"has","start":69,"end":72,"id":12,"ws":true},{"text":"been","start":73,"end":77,"id":13,"ws":true},{"text":"demonstrated","start":78,"end":90,"id":14,"ws":true},{"text":"to","start":91,"end":93,"id":15,"ws":true},{"text":"be","start":94,"end":96,"id":16,"ws":true},{"text":"highly","start":97,"end":103,"id":17,"ws":true},{"text":"effective","start":104,"end":113,"id":18,"ws":true},{"text":"in","start":114,"end":116,"id":19,"ws":true},{"text":"treating","start":117,"end":125,"id":20,"ws":true},{"text":"patients","start":126,"end":134,"id":21,"ws":true},{"text":"with","start":135,"end":139,"id":22,"ws":true},{"text":"advanced","start":140,"end":148,"id":23,"ws":true},{"text":"breast","start":149,"end":155,"id":24,"ws":true},{"text":"cancer","start":156,"end":162,"id":25,"ws":true},{"text":",","start":163,"end":164,"id":26,"ws":true},{"text":"including","start":165,"end":174,"id":27,"ws":true},{"text":"those","start":175,"end":180,"id":28,"ws":true},{"text":"with","start":181,"end":185,"id":29,"ws":true},{"text":"anthracycline-resistant","start":186,"end":209,"id":30,"ws":true},{"text":"breast","start":210,"end":216,"id":31,"ws":true},{"text":"cancer","start":217,"end":223,"id":32,"ws":true},{"text":",","start":224,"end":225,"id":33,"ws":true},{"text":"a","start":226,"end":227,"id":34,"ws":true},{"text":"fact","start":228,"end":232,"id":35,"ws":true},{"text":"that","start":233,"end":237,"id":36,"ws":true},{"text":"has","start":238,"end":241,"id":37,"ws":true},{"text":"led","start":242,"end":245,"id":38,"ws":true},{"text":"to","start":246,"end":248,"id":39,"ws":true},{"text":"efforts","start":249,"end":256,"id":40,"ws":true},{"text":"to","start":257,"end":259,"id":41,"ws":true},{"text":"combine","start":260,"end":267,"id":42,"ws":true},{"text":"paclitaxel","start":268,"end":278,"id":43,"ws":true},{"text":"and","start":279,"end":282,"id":44,"ws":true},{"text":"anthracyclines","start":283,"end":297,"id":45,"ws":true},{"text":".","start":298,"end":299,"id":46,"ws":false}],"spans":[{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},{"start":268,"end":278,"token_start":43,"token_end":43,"label":"DRUG"},{"start":283,"end":297,"token_start":45,"token_end":45,"label":"DRUG"}],"_input_hash":702583470,"_task_hash":1770101995,"_session_id":"drug_drug_pilot_shared-dana_a","_view_id":"blocks","relations":[{"head":43,"child":45,"head_span":{"start":268,"end":278,"token_start":43,"token_end":43,"label":"DRUG"},"child_span":{"start":283,"end":297,"token_start":45,"token_end":45,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"However , anastrozole , exemestane and letrozole are associated with significantly fewer endometrial cancers , as well as venous and arterial vascular events , when compared with tamoxifen [ 9 , 10 ] .","paragraph":"<h3><u>Erythema nodosum secondary to aromatase inhibitor use in breast cancer patients: case reports and review of the literature.</u></h3>Aromatase inhibitors (AI's) are increasingly being incorporated in the treatment strategy for hormone receptor positive breast cancer either alone or in combination with chemotherapy, biologics in both the adjuvant and metastatic setting [1]. They markedly suppress plasma estrogen levels by inhibiting or inactivating aromatase, the enzyme responsible for the synthesis of estrogens from androgenic substrates [1]. Currently, the three selective aromatase inhibitors that are available are <b style='color:Tomato;'><i>anastrozole</i></b>, <b style='color:Tomato;'><i>letrozole</i></b> and <b style='color:Tomato;'><i>exemestane</i></b> which reduce circulating estrogen to 1 to 10% of pretreatment levels [2]. For advanced breast cancer, aromatase inhibitors appear to be at a minimum, equivalent and perhaps even better than <b style='color:Tomato;'><i>tamoxifen</i></b> in the first line setting [3, 4]. In primary breast cancer, adjuvant therapy with <b style='color:Tomato;'><i>anastrozole</i></b> or <b style='color:Tomato;'><i>letrozole</i></b> appears to be superior to <b style='color:Tomato;'><i>tamoxifen</i></b> in reducing the risk of relapse [5, 6]. Common adverse effects associated with AI's include arthralgias (21%), myalgias (12%), other musculoskeletal disorders (28%) and an up to 60% increased risk of bone fracture [7, 8]. <b style='color:DodgerBlue;'><i>However</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>anastrozole</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>exemestane</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>letrozole</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>fewer</i></b> <b style='color:DodgerBlue;'><i>endometrial</i></b> <b style='color:DodgerBlue;'><i>cancers</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>venous</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>arterial</i></b> <b style='color:DodgerBlue;'><i>vascular</i></b> <b style='color:DodgerBlue;'><i>events</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>9</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Very rarely <b style='color:Tomato;'><i>letrozole</i></b> and <b style='color:Tomato;'><i>anastrozole</i></b> can cause a skin rash; the frequency of its occurrence has not been quantified(. )However, <b style='color:Tomato;'><i>exemestane</i></b> has not been reported to cause a skin rash [11]. To date, erythema nodosum (EN) has not been reported as a dermatologic side effect of AI's. Here, we report three cases of EN which developed in postmenopausal breast cancer patients on AI's.","tokens":[{"text":"However","start":0,"end":7,"id":0,"ws":true},{"text":",","start":8,"end":9,"id":1,"ws":true},{"text":"anastrozole","start":10,"end":21,"id":2,"ws":true},{"text":",","start":22,"end":23,"id":3,"ws":true},{"text":"exemestane","start":24,"end":34,"id":4,"ws":true},{"text":"and","start":35,"end":38,"id":5,"ws":true},{"text":"letrozole","start":39,"end":48,"id":6,"ws":true},{"text":"are","start":49,"end":52,"id":7,"ws":true},{"text":"associated","start":53,"end":63,"id":8,"ws":true},{"text":"with","start":64,"end":68,"id":9,"ws":true},{"text":"significantly","start":69,"end":82,"id":10,"ws":true},{"text":"fewer","start":83,"end":88,"id":11,"ws":true},{"text":"endometrial","start":89,"end":100,"id":12,"ws":true},{"text":"cancers","start":101,"end":108,"id":13,"ws":true},{"text":",","start":109,"end":110,"id":14,"ws":true},{"text":"as","start":111,"end":113,"id":15,"ws":true},{"text":"well","start":114,"end":118,"id":16,"ws":true},{"text":"as","start":119,"end":121,"id":17,"ws":true},{"text":"venous","start":122,"end":128,"id":18,"ws":true},{"text":"and","start":129,"end":132,"id":19,"ws":true},{"text":"arterial","start":133,"end":141,"id":20,"ws":true},{"text":"vascular","start":142,"end":150,"id":21,"ws":true},{"text":"events","start":151,"end":157,"id":22,"ws":true},{"text":",","start":158,"end":159,"id":23,"ws":true},{"text":"when","start":160,"end":164,"id":24,"ws":true},{"text":"compared","start":165,"end":173,"id":25,"ws":true},{"text":"with","start":174,"end":178,"id":26,"ws":true},{"text":"tamoxifen","start":179,"end":188,"id":27,"ws":true},{"text":"[","start":189,"end":190,"id":28,"ws":true},{"text":"9","start":191,"end":192,"id":29,"ws":true},{"text":",","start":193,"end":194,"id":30,"ws":true},{"text":"10","start":195,"end":197,"id":31,"ws":true},{"text":"]","start":198,"end":199,"id":32,"ws":true},{"text":".","start":200,"end":201,"id":33,"ws":false}],"spans":[{"start":10,"end":21,"token_start":2,"token_end":2,"label":"DRUG"},{"start":24,"end":34,"token_start":4,"token_end":4,"label":"DRUG"},{"start":39,"end":48,"token_start":6,"token_end":6,"label":"DRUG"},{"start":179,"end":188,"token_start":27,"token_end":27,"label":"DRUG"}],"_input_hash":155070717,"_task_hash":-411756935,"_session_id":"drug_drug_pilot_shared-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Additivity , synergy , or competition was observed with MIS and rapamycin , AzadC , doxorubicin , cisplatin , and paclitaxel , suggesting that MIS in combination with selective targeted therapies might achieve greater activity against ovarian cancer than the use of each individual agent alone .","paragraph":"<h3><u>Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.</u></h3>Mullerian Inhibiting Substance (MIS), a biological modifier that causes regression of Mullerian ducts in male embryos, is effective as a single agent in vitro and in vivo against human and mouse ovarian cancer cell lines expressing MIS type II receptor; however, little is known about how recombinant human MIS (rhMIS), now being scaled for preclinical trials, could be used in combination with cytotoxic or targeted chemotherapeutic agents. Mouse serous and endometrioid ovarian carcinoma cell lines were tested in vitro against rhMIS alone and with <b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>paclitaxel</i></b>, or cisplatin as agents in clinical use. Because MIS releases FK506 binding protein (FKBP12), which activates the mammalian target of <b style='color:Tomato;'><i>rapamycin</i></b> (mTOR) downstream of Akt, rhMIS and <b style='color:Tomato;'><i>rapamycin</i></b> combinations were tested. MIS increases p16 protein levels, and 5'-Aza-2'-deoxycytidine (AzadC) induces p16 mRNA; therefore, they were used in combination in vitro and in vivo with a human ovarian cancer cell line. A <b style='color:Tomato;'><i>paclitaxel</i></b>-resistant human ovarian cancer cell line and its parental line both respond to rhMIS in vitro. <b style='color:DodgerBlue;'><i>Additivity</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>synergy</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>competition</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>observed</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>MIS</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rapamycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>AzadC</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>suggesting</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>MIS</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>selective</i></b> <b style='color:DodgerBlue;'><i>targeted</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>might</i></b> <b style='color:DodgerBlue;'><i>achieve</i></b> <b style='color:DodgerBlue;'><i>greater</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>ovarian</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>each</i></b> <b style='color:DodgerBlue;'><i>individual</i></b> <b style='color:DodgerBlue;'><i>agent</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> These assays and statistical analyses could be useful in selecting rhMIS and chemotherapeutic agent combinations that enhance clinical efficacy and reduce toxicity.","tokens":[{"text":"Additivity","start":0,"end":10,"id":0,"ws":true},{"text":",","start":11,"end":12,"id":1,"ws":true},{"text":"synergy","start":13,"end":20,"id":2,"ws":true},{"text":",","start":21,"end":22,"id":3,"ws":true},{"text":"or","start":23,"end":25,"id":4,"ws":true},{"text":"competition","start":26,"end":37,"id":5,"ws":true},{"text":"was","start":38,"end":41,"id":6,"ws":true},{"text":"observed","start":42,"end":50,"id":7,"ws":true},{"text":"with","start":51,"end":55,"id":8,"ws":true},{"text":"MIS","start":56,"end":59,"id":9,"ws":true},{"text":"and","start":60,"end":63,"id":10,"ws":true},{"text":"rapamycin","start":64,"end":73,"id":11,"ws":true},{"text":",","start":74,"end":75,"id":12,"ws":true},{"text":"AzadC","start":76,"end":81,"id":13,"ws":true},{"text":",","start":82,"end":83,"id":14,"ws":true},{"text":"doxorubicin","start":84,"end":95,"id":15,"ws":true},{"text":",","start":96,"end":97,"id":16,"ws":true},{"text":"cisplatin","start":98,"end":107,"id":17,"ws":true},{"text":",","start":108,"end":109,"id":18,"ws":true},{"text":"and","start":110,"end":113,"id":19,"ws":true},{"text":"paclitaxel","start":114,"end":124,"id":20,"ws":true},{"text":",","start":125,"end":126,"id":21,"ws":true},{"text":"suggesting","start":127,"end":137,"id":22,"ws":true},{"text":"that","start":138,"end":142,"id":23,"ws":true},{"text":"MIS","start":143,"end":146,"id":24,"ws":true},{"text":"in","start":147,"end":149,"id":25,"ws":true},{"text":"combination","start":150,"end":161,"id":26,"ws":true},{"text":"with","start":162,"end":166,"id":27,"ws":true},{"text":"selective","start":167,"end":176,"id":28,"ws":true},{"text":"targeted","start":177,"end":185,"id":29,"ws":true},{"text":"therapies","start":186,"end":195,"id":30,"ws":true},{"text":"might","start":196,"end":201,"id":31,"ws":true},{"text":"achieve","start":202,"end":209,"id":32,"ws":true},{"text":"greater","start":210,"end":217,"id":33,"ws":true},{"text":"activity","start":218,"end":226,"id":34,"ws":true},{"text":"against","start":227,"end":234,"id":35,"ws":true},{"text":"ovarian","start":235,"end":242,"id":36,"ws":true},{"text":"cancer","start":243,"end":249,"id":37,"ws":true},{"text":"than","start":250,"end":254,"id":38,"ws":true},{"text":"the","start":255,"end":258,"id":39,"ws":true},{"text":"use","start":259,"end":262,"id":40,"ws":true},{"text":"of","start":263,"end":265,"id":41,"ws":true},{"text":"each","start":266,"end":270,"id":42,"ws":true},{"text":"individual","start":271,"end":281,"id":43,"ws":true},{"text":"agent","start":282,"end":287,"id":44,"ws":true},{"text":"alone","start":288,"end":293,"id":45,"ws":true},{"text":".","start":294,"end":295,"id":46,"ws":false}],"spans":[{"start":64,"end":73,"token_start":11,"token_end":11,"label":"DRUG"},{"start":84,"end":95,"token_start":15,"token_end":15,"label":"DRUG"},{"start":114,"end":124,"token_start":20,"token_end":20,"label":"DRUG"}],"_input_hash":1387497584,"_task_hash":991977050,"_session_id":"drug_drug_pilot_shared-yuval","_view_id":"blocks","relations":[{"head":9,"child":11,"head_span":{"start":56,"end":59,"token_start":9,"token_end":9,"label":null},"child_span":{"start":64,"end":73,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":9,"child":13,"head_span":{"start":56,"end":59,"token_start":9,"token_end":9,"label":null},"child_span":{"start":76,"end":81,"token_start":13,"token_end":13,"label":null},"color":"#ffd882","label":"POS2"},{"head":9,"child":15,"head_span":{"start":56,"end":59,"token_start":9,"token_end":9,"label":null},"child_span":{"start":84,"end":95,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#d9fbad","label":"POS3"}],"radio":["POS10","POS1T0","POS20","POS2T0","POS30","POS3T0"],"answer":"accept"}
{"text":"There was no cytotoxic effect of cisplatin , ifosfamide , and etoposide .","paragraph":"<h3><u>Overcoming Chemoresistance of Pediatric Ependymoma by Inhibition of STAT3 Signaling.</u></h3>The long-term clinical outcome of pediatric intracranial epepdymoma is poor with a high rate of recurrence. One of the main reasons for this poor outcome is the tumor's inherent resistance to chemotherapy. Signal transducer and activator of transcription 3 (STAT3) is overactive in many human cancers, and inhibition of STAT3 signaling is an emerging area of interest in oncology. In this study, the possibility of STAT3 inhibition as a treatment was investigated in pediatric intracranial ependymoma tissues and cell lines. STAT3 activation status was checked in ependymoma tissues. The responses to conventional chemotherapeutic agents and a STAT3 inhibitor WP1066 in primarily cultured ependymoma cells were measured by cell viability assay. Apoptosis assays were conducted to reveal the cytotoxic mechanism of applied agents. Knockdown of STAT3 was tried to confirm the effects of STAT3 inhibition in ependymoma cells. High levels of phospho-STAT3 (p-STAT3) expression were observed in ependymoma tissue, especially in the anaplastic histology group. <b style='color:DodgerBlue;'><i>There</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>cytotoxic</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Both brain tumor-initiating cells (BTICs) and bulk tumor cells (BCs) showed considerably decreased viability after WP1066 treatment. However, BTICs had fewer responses than BCs. No additive or synergistic effect was observed for combination therapy of WP1066 and cisplatin. WP1066 effectively abrogated p-STAT3 expression. An increased apoptosis and decreased Survivin expression were observed after WP1066 treatment. Knockdown of STAT3 also decreased cell survival, supporting the critical role of STAT3 in sustaining ependymoma cells. In this study, we observed a cytotoxic effect of STAT3 inhibitor on ependymoma BTICs and BCs. There is urgent need to develop new therapeutic agents for pediatric ependymoma. STAT3 inhibitors may be a new group of drugs for clinical application. ","tokens":[{"text":"There","start":0,"end":5,"id":0,"ws":true},{"text":"was","start":6,"end":9,"id":1,"ws":true},{"text":"no","start":10,"end":12,"id":2,"ws":true},{"text":"cytotoxic","start":13,"end":22,"id":3,"ws":true},{"text":"effect","start":23,"end":29,"id":4,"ws":true},{"text":"of","start":30,"end":32,"id":5,"ws":true},{"text":"cisplatin","start":33,"end":42,"id":6,"ws":true},{"text":",","start":43,"end":44,"id":7,"ws":true},{"text":"ifosfamide","start":45,"end":55,"id":8,"ws":true},{"text":",","start":56,"end":57,"id":9,"ws":true},{"text":"and","start":58,"end":61,"id":10,"ws":true},{"text":"etoposide","start":62,"end":71,"id":11,"ws":true},{"text":".","start":72,"end":73,"id":12,"ws":false}],"spans":[{"start":45,"end":55,"token_start":8,"token_end":8,"label":"DRUG"},{"start":62,"end":71,"token_start":11,"token_end":11,"label":"DRUG"}],"_input_hash":-1352726798,"_task_hash":-274527523,"_session_id":"drug_drug_pilot_shared-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Several first-line phase III trials , as well as ongoing trials for which only preliminary results have been published , have fueled debates on the optimal dose and schedule ; these have focused not only on weekly vs q3-weeks paclitaxel , but also on other modifications and the advisability of adding bevacizumab .","paragraph":"<h3><u>Carboplatin/Paclitaxel Induction in Ovarian Cancer: The Finer Points.</u></h3>The <b style='color:Tomato;'><i>carboplatin</i></b>/<b style='color:Tomato;'><i>paclitaxel</i></b> doublet remains the chemotherapy backbone for the initial treatment of ovarian cancer. This two-drug regimen, with <b style='color:Tomato;'><i>carboplatin</i></b> dosed using the Calvert formula, yielded convincing noninferior outcomes when compared with the prior, more toxic, regimen of cisplatin/<b style='color:Tomato;'><i>paclitaxel</i></b>. <b style='color:Tomato;'><i>carboplatin</i></b>'s dose-limiting toxicity is thrombocytopenia; however, when this drug is properly dosed and combined with <b style='color:Tomato;'><i>paclitaxel</i></b>, the doublet's cycle 1 dose in chemotherapy-naive women is generally safe. <b style='color:Tomato;'><i>carboplatin</i></b> (unlike cisplatin) contributes minimally to the cumulative sensory neuropathy of <b style='color:Tomato;'><i>paclitaxel</i></b>, thus ensuring noticeable reversibility of neuropathy symptoms following completion of 6 cycles and only occasionally requiring cessation or substitution of the taxane. <b style='color:Tomato;'><i>paclitaxel</i></b> is responsible for the hair loss associated with the <b style='color:Tomato;'><i>carboplatin</i></b>/<b style='color:Tomato;'><i>paclitaxel</i></b> doublet; preventive measures must be considered for patients who would otherwise refuse treatment. <b style='color:DodgerBlue;'><i>Several</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>III</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>ongoing</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>which</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>preliminary</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>published</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>fueled</i></b> <b style='color:DodgerBlue;'><i>debates</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>optimal</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>schedule</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>focused</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>weekly</i></b> <b style='color:DodgerBlue;'><i>vs</i></b> <b style='color:DodgerBlue;'><i>q3-weeks</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>also</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>modifications</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>advisability</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>adding</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Our view is that results of this doublet in the first-line treatment of ovarian cancer are driven primarily by <b style='color:Tomato;'><i>carboplatin</i></b>, given that ovarian cancer is a platinum-sensitive disease. Consequently, the roles of the accompanying <b style='color:Tomato;'><i>paclitaxel</i></b> dose and schedule and the addition of <b style='color:Tomato;'><i>bevacizumab</i></b> are currently unsettled, and questions regarding these issues should be decided based on patient tolerance and comorbidities until additional data are available.","tokens":[{"text":"Several","start":0,"end":7,"id":0,"ws":true},{"text":"first-line","start":8,"end":18,"id":1,"ws":true},{"text":"phase","start":19,"end":24,"id":2,"ws":true},{"text":"III","start":25,"end":28,"id":3,"ws":true},{"text":"trials","start":29,"end":35,"id":4,"ws":true},{"text":",","start":36,"end":37,"id":5,"ws":true},{"text":"as","start":38,"end":40,"id":6,"ws":true},{"text":"well","start":41,"end":45,"id":7,"ws":true},{"text":"as","start":46,"end":48,"id":8,"ws":true},{"text":"ongoing","start":49,"end":56,"id":9,"ws":true},{"text":"trials","start":57,"end":63,"id":10,"ws":true},{"text":"for","start":64,"end":67,"id":11,"ws":true},{"text":"which","start":68,"end":73,"id":12,"ws":true},{"text":"only","start":74,"end":78,"id":13,"ws":true},{"text":"preliminary","start":79,"end":90,"id":14,"ws":true},{"text":"results","start":91,"end":98,"id":15,"ws":true},{"text":"have","start":99,"end":103,"id":16,"ws":true},{"text":"been","start":104,"end":108,"id":17,"ws":true},{"text":"published","start":109,"end":118,"id":18,"ws":true},{"text":",","start":119,"end":120,"id":19,"ws":true},{"text":"have","start":121,"end":125,"id":20,"ws":true},{"text":"fueled","start":126,"end":132,"id":21,"ws":true},{"text":"debates","start":133,"end":140,"id":22,"ws":true},{"text":"on","start":141,"end":143,"id":23,"ws":true},{"text":"the","start":144,"end":147,"id":24,"ws":true},{"text":"optimal","start":148,"end":155,"id":25,"ws":true},{"text":"dose","start":156,"end":160,"id":26,"ws":true},{"text":"and","start":161,"end":164,"id":27,"ws":true},{"text":"schedule","start":165,"end":173,"id":28,"ws":true},{"text":";","start":174,"end":175,"id":29,"ws":true},{"text":"these","start":176,"end":181,"id":30,"ws":true},{"text":"have","start":182,"end":186,"id":31,"ws":true},{"text":"focused","start":187,"end":194,"id":32,"ws":true},{"text":"not","start":195,"end":198,"id":33,"ws":true},{"text":"only","start":199,"end":203,"id":34,"ws":true},{"text":"on","start":204,"end":206,"id":35,"ws":true},{"text":"weekly","start":207,"end":213,"id":36,"ws":true},{"text":"vs","start":214,"end":216,"id":37,"ws":true},{"text":"q3-weeks","start":217,"end":225,"id":38,"ws":true},{"text":"paclitaxel","start":226,"end":236,"id":39,"ws":true},{"text":",","start":237,"end":238,"id":40,"ws":true},{"text":"but","start":239,"end":242,"id":41,"ws":true},{"text":"also","start":243,"end":247,"id":42,"ws":true},{"text":"on","start":248,"end":250,"id":43,"ws":true},{"text":"other","start":251,"end":256,"id":44,"ws":true},{"text":"modifications","start":257,"end":270,"id":45,"ws":true},{"text":"and","start":271,"end":274,"id":46,"ws":true},{"text":"the","start":275,"end":278,"id":47,"ws":true},{"text":"advisability","start":279,"end":291,"id":48,"ws":true},{"text":"of","start":292,"end":294,"id":49,"ws":true},{"text":"adding","start":295,"end":301,"id":50,"ws":true},{"text":"bevacizumab","start":302,"end":313,"id":51,"ws":true},{"text":".","start":314,"end":315,"id":52,"ws":false}],"spans":[{"start":226,"end":236,"token_start":39,"token_end":39,"label":"DRUG"},{"start":302,"end":313,"token_start":51,"token_end":51,"label":"DRUG"}],"_input_hash":1252988243,"_task_hash":322511723,"_session_id":"drug_drug_pilot_shared-yuval","_view_id":"blocks","relations":[{"head":39,"child":51,"head_span":{"start":226,"end":236,"token_start":39,"token_end":39,"label":"DRUG"},"child_span":{"start":302,"end":313,"token_start":51,"token_end":51,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"The primary goal was achieve the correct estimation of the target plasma area against the topotecan concentration-time curve ( AUC ) in a 5 day course of cladribine followed by monitored topotecan in pediatric patients with recurrent/refractory AML .","paragraph":"<h3><u>Topotecan exposure estimation in pediatric acute myeloid leukemia supported by LC-MS-based drug monitoring and pharmacokinetic analysis.</u></h3>Individualization of the <b style='color:Tomato;'><i>topotecan</i></b> dosing can reduce inter-patient variability, toxicity, and at the same time increases chemotherapy efficacy. <b style='color:Tomato;'><i>topotecan</i></b> dosing based on simultaneous drug monitoring and pharmacokinetic analysis can yield more accurate and precise estimation of the <b style='color:Tomato;'><i>topotecan</i></b> systemic exposure than that attainable with the fixed dosing approach. Therefore, a combined approach could provide a tool assisting the clinicians in individualization of the <b style='color:Tomato;'><i>topotecan</i></b> dosing. The aim of the study was to estimate the <b style='color:Tomato;'><i>topotecan</i></b> exposure in pediatric patients with acute myeloid leukemia (AML) based on the plasma concentration-time data and using the pharmacokinetic analysis. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>primary</i></b> <b style='color:DodgerBlue;'><i>goal</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>achieve</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>correct</i></b> <b style='color:DodgerBlue;'><i>estimation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>target</i></b> <b style='color:DodgerBlue;'><i>plasma</i></b> <b style='color:DodgerBlue;'><i>area</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:MediumOrchid;'><i>topotecan</i></b> <b style='color:DodgerBlue;'><i>concentration-time</i></b> <b style='color:DodgerBlue;'><i>curve</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AUC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>course</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cladribine</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>monitored</i></b> <b style='color:MediumOrchid;'><i>topotecan</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>pediatric</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>recurrent/refractory</i></b> <b style='color:DodgerBlue;'><i>AML</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A sensitive and selective reversed-phase liquid chromatographic-mass spectrometry (LC-MS) assay was developed to quantify total <b style='color:Tomato;'><i>topotecan</i></b> in the human plasma samples. This method, with its lower quantification limit of 1 ng/ml, was validated over a linear range of 1-150 ng/ml. Under the proposed approach, the <b style='color:Tomato;'><i>topotecan</i></b> dosing was selected so as to achieve the final AUC value of 140\u00b120 ng/ml h. The presented analytical and pharmacokinetic data demonstrate that the proposed approach can be a practical, useful, efficient, and accurate tool for individualizing the <b style='color:Tomato;'><i>topotecan</i></b> dosing in children with AML.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"primary","start":4,"end":11,"id":1,"ws":true},{"text":"goal","start":12,"end":16,"id":2,"ws":true},{"text":"was","start":17,"end":20,"id":3,"ws":true},{"text":"achieve","start":21,"end":28,"id":4,"ws":true},{"text":"the","start":29,"end":32,"id":5,"ws":true},{"text":"correct","start":33,"end":40,"id":6,"ws":true},{"text":"estimation","start":41,"end":51,"id":7,"ws":true},{"text":"of","start":52,"end":54,"id":8,"ws":true},{"text":"the","start":55,"end":58,"id":9,"ws":true},{"text":"target","start":59,"end":65,"id":10,"ws":true},{"text":"plasma","start":66,"end":72,"id":11,"ws":true},{"text":"area","start":73,"end":77,"id":12,"ws":true},{"text":"against","start":78,"end":85,"id":13,"ws":true},{"text":"the","start":86,"end":89,"id":14,"ws":true},{"text":"topotecan","start":90,"end":99,"id":15,"ws":true},{"text":"concentration-time","start":100,"end":118,"id":16,"ws":true},{"text":"curve","start":119,"end":124,"id":17,"ws":true},{"text":"(","start":125,"end":126,"id":18,"ws":true},{"text":"AUC","start":127,"end":130,"id":19,"ws":true},{"text":")","start":131,"end":132,"id":20,"ws":true},{"text":"in","start":133,"end":135,"id":21,"ws":true},{"text":"a","start":136,"end":137,"id":22,"ws":true},{"text":"5","start":138,"end":139,"id":23,"ws":true},{"text":"day","start":140,"end":143,"id":24,"ws":true},{"text":"course","start":144,"end":150,"id":25,"ws":true},{"text":"of","start":151,"end":153,"id":26,"ws":true},{"text":"cladribine","start":154,"end":164,"id":27,"ws":true},{"text":"followed","start":165,"end":173,"id":28,"ws":true},{"text":"by","start":174,"end":176,"id":29,"ws":true},{"text":"monitored","start":177,"end":186,"id":30,"ws":true},{"text":"topotecan","start":187,"end":196,"id":31,"ws":true},{"text":"in","start":197,"end":199,"id":32,"ws":true},{"text":"pediatric","start":200,"end":209,"id":33,"ws":true},{"text":"patients","start":210,"end":218,"id":34,"ws":true},{"text":"with","start":219,"end":223,"id":35,"ws":true},{"text":"recurrent/refractory","start":224,"end":244,"id":36,"ws":true},{"text":"AML","start":245,"end":248,"id":37,"ws":true},{"text":".","start":249,"end":250,"id":38,"ws":false}],"spans":[{"start":90,"end":99,"token_start":15,"token_end":15,"label":"DRUG"},{"start":154,"end":164,"token_start":27,"token_end":27,"label":"DRUG"},{"start":187,"end":196,"token_start":31,"token_end":31,"label":"DRUG"}],"_input_hash":796298966,"_task_hash":-199747777,"_session_id":"drug_drug_pilot_shared-yuval","_view_id":"blocks","relations":[{"head":27,"child":31,"head_span":{"start":154,"end":164,"token_start":27,"token_end":27,"label":"DRUG"},"child_span":{"start":187,"end":196,"token_start":31,"token_end":31,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T1"],"answer":"accept"}
{"text":"The management of EP is challenging : no standardized guidelines exist with literature suggesting cyclosporine or infliximab as first-line therapy .","paragraph":"<h3><u>Erythrodermic psoriasis successfully and rapidly treated with brodalumab: Report of two cases.</u></h3>Erythrodermic psoriasis (EP) is a rare form of the disease clinically characterized by a generalized erythema covering \u226590% of the body surface area (BSA). <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>management</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>EP</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>challenging</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>standardized</i></b> <b style='color:DodgerBlue;'><i>guidelines</i></b> <b style='color:DodgerBlue;'><i>exist</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>literature</i></b> <b style='color:DodgerBlue;'><i>suggesting</i></b> <b style='color:MediumOrchid;'><i>cyclosporine</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>infliximab</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, a recent systematic review showed a positive response in EP patients treated with biologic agents. The most common biologic used for EP up until now has been <b style='color:Tomato;'><i>ustekinumab</i></b>, whereas <b style='color:Tomato;'><i>infliximab</i></b> might represent a first-line option in case of complicated EP (acute, severe, or unstable). Up until now, no case of <b style='color:Tomato;'><i>brodalumab</i></b> (a monoclonal antibody blocking IL-17 receptor) treatment for EP in real-life has ever been described. Here, we report the first two cases of efficacy and safety of <b style='color:Tomato;'><i>brodalumab</i></b> in real-life cases of EP.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"management","start":4,"end":14,"id":1,"ws":true},{"text":"of","start":15,"end":17,"id":2,"ws":true},{"text":"EP","start":18,"end":20,"id":3,"ws":true},{"text":"is","start":21,"end":23,"id":4,"ws":true},{"text":"challenging","start":24,"end":35,"id":5,"ws":true},{"text":":","start":36,"end":37,"id":6,"ws":true},{"text":"no","start":38,"end":40,"id":7,"ws":true},{"text":"standardized","start":41,"end":53,"id":8,"ws":true},{"text":"guidelines","start":54,"end":64,"id":9,"ws":true},{"text":"exist","start":65,"end":70,"id":10,"ws":true},{"text":"with","start":71,"end":75,"id":11,"ws":true},{"text":"literature","start":76,"end":86,"id":12,"ws":true},{"text":"suggesting","start":87,"end":97,"id":13,"ws":true},{"text":"cyclosporine","start":98,"end":110,"id":14,"ws":true},{"text":"or","start":111,"end":113,"id":15,"ws":true},{"text":"infliximab","start":114,"end":124,"id":16,"ws":true},{"text":"as","start":125,"end":127,"id":17,"ws":true},{"text":"first-line","start":128,"end":138,"id":18,"ws":true},{"text":"therapy","start":139,"end":146,"id":19,"ws":true},{"text":".","start":147,"end":148,"id":20,"ws":false}],"spans":[{"start":98,"end":110,"token_start":14,"token_end":14,"label":"DRUG"},{"start":114,"end":124,"token_start":16,"token_end":16,"label":"DRUG"}],"_input_hash":-575753313,"_task_hash":-166345926,"_session_id":"drug_drug_pilot_shared-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"As single agents , curcumin and metformin are reported to exhibit chemopreventive properties , in vitro as well as in patients with oral cancer .","paragraph":"<h3><u>Curcumin and metformin-mediated chemoprevention of oral cancer is associated with inhibition of cancer stem cells.</u></h3>Effective chemoprevention is critical for improving outcomes of oral cancer. <b style='color:DodgerBlue;'><i>As</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>curcumin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>metformin</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>reported</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>exhibit</i></b> <b style='color:DodgerBlue;'><i>chemopreventive</i></b> <b style='color:DodgerBlue;'><i>properties</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In this study, the chemopreventive efficacy of this drug combination was tested in a 4-nitro quinoline-1-oxide (4NQO) induced mice oral carcinogenesis model. Molecular analysis revealed a cancer stem cell (CSC)-driven oral carcinogenic progression in this model, wherein a progressive increase in the expression of CSC-specific markers (CD44 and CD133) was observed from 8th to 25th week, at transcript (40-100-fold) and protein levels (P\u2009\u2264\u20090.0001). Chemopreventive treatment of the animals at 17th week with <b style='color:Tomato;'><i>curcumin</i></b> and <b style='color:Tomato;'><i>metformin</i></b> indicated that the combination regimen decreased tumor volume when compared to the control arm (0.69+0.03 vs 6.66+2.4\u2009mm","tokens":[{"text":"As","start":0,"end":2,"id":0,"ws":true},{"text":"single","start":3,"end":9,"id":1,"ws":true},{"text":"agents","start":10,"end":16,"id":2,"ws":true},{"text":",","start":17,"end":18,"id":3,"ws":true},{"text":"curcumin","start":19,"end":27,"id":4,"ws":true},{"text":"and","start":28,"end":31,"id":5,"ws":true},{"text":"metformin","start":32,"end":41,"id":6,"ws":true},{"text":"are","start":42,"end":45,"id":7,"ws":true},{"text":"reported","start":46,"end":54,"id":8,"ws":true},{"text":"to","start":55,"end":57,"id":9,"ws":true},{"text":"exhibit","start":58,"end":65,"id":10,"ws":true},{"text":"chemopreventive","start":66,"end":81,"id":11,"ws":true},{"text":"properties","start":82,"end":92,"id":12,"ws":true},{"text":",","start":93,"end":94,"id":13,"ws":true},{"text":"in","start":95,"end":97,"id":14,"ws":true},{"text":"vitro","start":98,"end":103,"id":15,"ws":true},{"text":"as","start":104,"end":106,"id":16,"ws":true},{"text":"well","start":107,"end":111,"id":17,"ws":true},{"text":"as","start":112,"end":114,"id":18,"ws":true},{"text":"in","start":115,"end":117,"id":19,"ws":true},{"text":"patients","start":118,"end":126,"id":20,"ws":true},{"text":"with","start":127,"end":131,"id":21,"ws":true},{"text":"oral","start":132,"end":136,"id":22,"ws":true},{"text":"cancer","start":137,"end":143,"id":23,"ws":true},{"text":".","start":144,"end":145,"id":24,"ws":false}],"spans":[{"start":19,"end":27,"token_start":4,"token_end":4,"label":"DRUG"},{"start":32,"end":41,"token_start":6,"token_end":6,"label":"DRUG"}],"_input_hash":-1095827099,"_task_hash":-240223432,"_session_id":"drug_drug_pilot_shared-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Withdrawal rates were comparable to drug survival rates of other biological therapies and rates of adverse events were similar between brodalumab and ustekinumab .","paragraph":"<h3><u>Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.</u></h3>As part of the National Institute for Health and Care Excellence single technology appraisal process, <b style='color:Tomato;'><i>brodalumab</i></b> was assessed to determine the clinical and cost effectiveness of its use in the treatment of moderate-to-severe plaque psoriasis. The Centre for Reviews and Dissemination and the Centre for Health Economics Technology Assessment Group at the University of York were commissioned to act as the independent Evidence Review Group. This article provides a summary of the Evidence Review Group's review of the company's submission, the Evidence Review Group report and the National Institute for Health and Care Excellence Appraisal Committee's subsequent guidance issued in March 2018. The main clinical effectiveness data were derived from three well-conducted, multicentre, double-blind randomised controlled trials. The trials demonstrated that <b style='color:Tomato;'><i>brodalumab</i></b> statistically significantly reduced the severity of psoriasis and its impact on health-related quality of life, compared with placebo, at 12\u00a0weeks. In comparison with <b style='color:Tomato;'><i>ustekinumab</i></b>, statistically significantly more patients taking <b style='color:Tomato;'><i>brodalumab</i></b> had reduced psoriasis severity at 12\u00a0weeks. Psoriasis severity and quality of life also appeared improved at 52\u00a0weeks, although statistical significance was not assessed. <b style='color:DodgerBlue;'><i>Withdrawal</i></b> <b style='color:DodgerBlue;'><i>rates</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>comparable</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>rates</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>biological</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>rates</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>adverse</i></b> <b style='color:DodgerBlue;'><i>events</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>similar</i></b> <b style='color:DodgerBlue;'><i>between</i></b> <b style='color:MediumOrchid;'><i>brodalumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ustekinumab</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A network meta-analysis was presented, comparing <b style='color:Tomato;'><i>brodalumab</i></b> with other therapies available at the same point in the treatment pathway (i.e. in patients for whom standard systemic therapy or phototherapy is inadequately effective, not tolerated or contraindicated). The network meta-analysis ranked treatments in order of effectiveness, in terms of achieving different levels of Psoriasis Area and Severity Index response. The results indicated that <b style='color:Tomato;'><i>brodalumab</i></b> had a similar probability of response to <b style='color:Tomato;'><i>ixekizumab</i></b>, <b style='color:Tomato;'><i>secukinumab</i></b> and <b style='color:Tomato;'><i>infliximab</i></b> and a higher probability of response than <b style='color:Tomato;'><i>ustekinumab</i></b>, <b style='color:Tomato;'><i>adalimumab</i></b>, <b style='color:Tomato;'><i>etanercept</i></b>, <b style='color:Tomato;'><i>apremilast</i></b>, <b style='color:Tomato;'><i>dimethyl fumarate</i></b> and placebo. The company's economic model compared nine treatment sequences that included three lines of active therapy, consisting of <b style='color:Tomato;'><i>brodalumab</i></b> and other comparators recommended by the National Institute for Health and Care Excellence, followed by best supportive care. The sequence with <b style='color:Tomato;'><i>brodalumab</i></b> in the first-line position dominated sequences that started with <b style='color:Tomato;'><i>adalimumab</i></b>, <b style='color:Tomato;'><i>infliximab</i></b>, <b style='color:Tomato;'><i>secukinumab</i></b> and <b style='color:Tomato;'><i>ustekinumab</i></b>. The incremental cost-effectiveness ratio of the <b style='color:Tomato;'><i>brodalumab</i></b> sequence compared to less effective and non-dominated sequences ranged from \u00a37145 (vs. the <b style='color:Tomato;'><i>etanercept</i></b> sequence) to \u00a313,353 (vs. the <b style='color:Tomato;'><i>dimethyl fumarate</i></b> sequence) per quality-adjusted life-year gained. The incremental cost-effectiveness ratio for the more costly and effective <b style='color:Tomato;'><i>ixekizumab</i></b> sequence was \u00a3894,010 per quality-adjusted life-year gained compared to the <b style='color:Tomato;'><i>brodalumab</i></b> sequence. At a threshold of \u00a320,000 per quality-adjusted life-year gained, the <b style='color:Tomato;'><i>brodalumab</i></b> sequence had the highest probability of being cost effective (96%). The main limitation of the company's economic model was the restrictive nature of the sequences compared. Twelve separate scenarios based on key uncertainties were explored by the Evidence Review Group. The only scenarios where <b style='color:Tomato;'><i>brodalumab</i></b> was ranked lower than first were not considered to be more appropriate or plausible than the assumptions or scenarios included in the company's base case. The treatment rankings identified in the Evidence Review Group's alternative base case were identical to those derived from the company's base case model. At the first National Institute for Health and Care Excellence Appraisal Committee meeting, the Committee concluded that <b style='color:Tomato;'><i>brodalumab</i></b> appears to be as effective as other anti-interleukin-17 agents and is cost effective, based on the discount agreed in the patient access scheme. <b style='color:Tomato;'><i>brodalumab</i></b> is recommended as an option for treating adults with severe plaque psoriasis (defined by a total Psoriasis Area and Severity Index score of 10 or more and a Dermatology Life Quality Index score of more than 10) who have not responded to other systemic non-biological therapies. <b style='color:Tomato;'><i>brodalumab</i></b> should be stopped at 12\u00a0weeks if the psoriasis has not responded adequately.","tokens":[{"text":"Withdrawal","start":0,"end":10,"id":0,"ws":true},{"text":"rates","start":11,"end":16,"id":1,"ws":true},{"text":"were","start":17,"end":21,"id":2,"ws":true},{"text":"comparable","start":22,"end":32,"id":3,"ws":true},{"text":"to","start":33,"end":35,"id":4,"ws":true},{"text":"drug","start":36,"end":40,"id":5,"ws":true},{"text":"survival","start":41,"end":49,"id":6,"ws":true},{"text":"rates","start":50,"end":55,"id":7,"ws":true},{"text":"of","start":56,"end":58,"id":8,"ws":true},{"text":"other","start":59,"end":64,"id":9,"ws":true},{"text":"biological","start":65,"end":75,"id":10,"ws":true},{"text":"therapies","start":76,"end":85,"id":11,"ws":true},{"text":"and","start":86,"end":89,"id":12,"ws":true},{"text":"rates","start":90,"end":95,"id":13,"ws":true},{"text":"of","start":96,"end":98,"id":14,"ws":true},{"text":"adverse","start":99,"end":106,"id":15,"ws":true},{"text":"events","start":107,"end":113,"id":16,"ws":true},{"text":"were","start":114,"end":118,"id":17,"ws":true},{"text":"similar","start":119,"end":126,"id":18,"ws":true},{"text":"between","start":127,"end":134,"id":19,"ws":true},{"text":"brodalumab","start":135,"end":145,"id":20,"ws":true},{"text":"and","start":146,"end":149,"id":21,"ws":true},{"text":"ustekinumab","start":150,"end":161,"id":22,"ws":true},{"text":".","start":162,"end":163,"id":23,"ws":false}],"spans":[{"start":135,"end":145,"token_start":20,"token_end":20,"label":"DRUG"},{"start":150,"end":161,"token_start":22,"token_end":22,"label":"DRUG"}],"_input_hash":-2044054306,"_task_hash":40529012,"_session_id":"drug_drug_pilot_shared-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"In patients with NPSLE , the use of high-dose corticosteroids is recommended in combination with immunosuppressants , such as mycophenolate mofetil and intravenous cyclophosphamide pulse therapy .","paragraph":"<h3><u>[Neuropsychiatric Systemic Lupus Erythematosus].</u></h3>Central nervous system damage, a major organ manifestation of systemic lupus erythematosus (SLE), causes significant morbidity and mortality. Designating this condition as neuropsychiatric SLE (NPSLE), the American College of Rheumatology defines it as involving the central and peripheral nervous systems and being characterized by various manifestations including stroke, seizures, and psychosis. NPSLE treatment mainly seeks to reduce damage accrual. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>NPSLE</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:DodgerBlue;'><i>corticosteroids</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>recommended</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>immunosuppressants</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>mycophenolate</i></b> <b style='color:DodgerBlue;'><i>mofetil</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>pulse</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> This can be accomplished by controlling the activity of the disease, minimizing the use of corticosteroids, and optimizing the management of comorbidities, including cardiovascular risk factors. An international task force analysis of a treat-to-target strategy for SLE (T2T/SLE) recommended targeting remission, preventing damage, and improving quality of life. Thus, more effective and less toxic treatments, such as those using biologics or kinase inhibitors, are still being developed for the treatment of SLE/NPSLE.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"patients","start":3,"end":11,"id":1,"ws":true},{"text":"with","start":12,"end":16,"id":2,"ws":true},{"text":"NPSLE","start":17,"end":22,"id":3,"ws":true},{"text":",","start":23,"end":24,"id":4,"ws":true},{"text":"the","start":25,"end":28,"id":5,"ws":true},{"text":"use","start":29,"end":32,"id":6,"ws":true},{"text":"of","start":33,"end":35,"id":7,"ws":true},{"text":"high-dose","start":36,"end":45,"id":8,"ws":true},{"text":"corticosteroids","start":46,"end":61,"id":9,"ws":true},{"text":"is","start":62,"end":64,"id":10,"ws":true},{"text":"recommended","start":65,"end":76,"id":11,"ws":true},{"text":"in","start":77,"end":79,"id":12,"ws":true},{"text":"combination","start":80,"end":91,"id":13,"ws":true},{"text":"with","start":92,"end":96,"id":14,"ws":true},{"text":"immunosuppressants","start":97,"end":115,"id":15,"ws":true},{"text":",","start":116,"end":117,"id":16,"ws":true},{"text":"such","start":118,"end":122,"id":17,"ws":true},{"text":"as","start":123,"end":125,"id":18,"ws":true},{"text":"mycophenolate","start":126,"end":139,"id":19,"ws":true},{"text":"mofetil","start":140,"end":147,"id":20,"ws":true},{"text":"and","start":148,"end":151,"id":21,"ws":true},{"text":"intravenous","start":152,"end":163,"id":22,"ws":true},{"text":"cyclophosphamide","start":164,"end":180,"id":23,"ws":true},{"text":"pulse","start":181,"end":186,"id":24,"ws":true},{"text":"therapy","start":187,"end":194,"id":25,"ws":true},{"text":".","start":195,"end":196,"id":26,"ws":false}],"spans":[{"start":126,"end":139,"token_start":19,"token_end":19,"label":"DRUG"},{"start":164,"end":180,"token_start":23,"token_end":23,"label":"DRUG"}],"_input_hash":438186251,"_task_hash":1532533663,"_session_id":"drug_drug_pilot_shared-yuval","_view_id":"blocks","relations":[{"head":9,"child":19,"head_span":{"start":46,"end":61,"token_start":9,"token_end":9,"label":null},"child_span":{"start":126,"end":139,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":9,"child":23,"head_span":{"start":46,"end":61,"token_start":9,"token_end":9,"label":null},"child_span":{"start":164,"end":180,"token_start":23,"token_end":23,"label":"DRUG"},"color":"#ffd882","label":"POS2"}],"radio":["POS10","POS1T0","POS20","POS2T0"],"answer":"accept"}
{"text":"Thirty-three women diagnosed with metastatic breast cancer participated in a phase 1 clinical trial of a new combination of cyclophosphamide ( CTX ) and mitoxantrone ( MXT ) , with dose escalation of paclitaxel .","paragraph":"<h3><u>Longitudinal effects of high-dose chemotherapy and autologous stem cell transplantation on quality of life in the treatment of metastatic breast cancer.</u></h3>This study determined the effects of high-dose chemotherapy (HDCT) with autologous blood stem cell transplantation (ASCT) on quality of life (QL) in women with metastatic breast cancer prior to, and during treatment, and up to 1-year post-ASCT. <b style='color:DodgerBlue;'><i>Thirty-three</i></b> <b style='color:DodgerBlue;'><i>women</i></b> <b style='color:DodgerBlue;'><i>diagnosed</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>participated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>new</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CTX</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>mitoxantrone</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>MXT</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>escalation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Longitudinal QL data were collected using the functional living index-cancer (FLIC) and symptom scales at seven time periods: pre-induction chemotherapy (CT), post-induction CT, post-high dose CT (HDCT), and at 3, 6, 9 and 12 months post-ASCT. FLIC scores indicated that the worst problems for patients were feelings of hardship on themselves and their families, followed by psychological functioning and physical functioning problems. The time around diagnosis of the metastatic disease and following HDCT were the worst times for all levels of quality of life, but anxiety and depression symptoms continued to increase in severity across the entire follow-up period. The symptoms that were most problematic were worry about the future, loss of sexual interest, anxiety about the treatment, general worrying, and joint pain. These data highlight the problems that women with metastatic breast cancer encounter at different stages of the disease and treatment process, and can be used to tailor psychosocial interventions appropriate for treating the relevant issues at different points in time.","tokens":[{"text":"Thirty-three","start":0,"end":12,"id":0,"ws":true},{"text":"women","start":13,"end":18,"id":1,"ws":true},{"text":"diagnosed","start":19,"end":28,"id":2,"ws":true},{"text":"with","start":29,"end":33,"id":3,"ws":true},{"text":"metastatic","start":34,"end":44,"id":4,"ws":true},{"text":"breast","start":45,"end":51,"id":5,"ws":true},{"text":"cancer","start":52,"end":58,"id":6,"ws":true},{"text":"participated","start":59,"end":71,"id":7,"ws":true},{"text":"in","start":72,"end":74,"id":8,"ws":true},{"text":"a","start":75,"end":76,"id":9,"ws":true},{"text":"phase","start":77,"end":82,"id":10,"ws":true},{"text":"1","start":83,"end":84,"id":11,"ws":true},{"text":"clinical","start":85,"end":93,"id":12,"ws":true},{"text":"trial","start":94,"end":99,"id":13,"ws":true},{"text":"of","start":100,"end":102,"id":14,"ws":true},{"text":"a","start":103,"end":104,"id":15,"ws":true},{"text":"new","start":105,"end":108,"id":16,"ws":true},{"text":"combination","start":109,"end":120,"id":17,"ws":true},{"text":"of","start":121,"end":123,"id":18,"ws":true},{"text":"cyclophosphamide","start":124,"end":140,"id":19,"ws":true},{"text":"(","start":141,"end":142,"id":20,"ws":true},{"text":"CTX","start":143,"end":146,"id":21,"ws":true},{"text":")","start":147,"end":148,"id":22,"ws":true},{"text":"and","start":149,"end":152,"id":23,"ws":true},{"text":"mitoxantrone","start":153,"end":165,"id":24,"ws":true},{"text":"(","start":166,"end":167,"id":25,"ws":true},{"text":"MXT","start":168,"end":171,"id":26,"ws":true},{"text":")","start":172,"end":173,"id":27,"ws":true},{"text":",","start":174,"end":175,"id":28,"ws":true},{"text":"with","start":176,"end":180,"id":29,"ws":true},{"text":"dose","start":181,"end":185,"id":30,"ws":true},{"text":"escalation","start":186,"end":196,"id":31,"ws":true},{"text":"of","start":197,"end":199,"id":32,"ws":true},{"text":"paclitaxel","start":200,"end":210,"id":33,"ws":true},{"text":".","start":211,"end":212,"id":34,"ws":false}],"spans":[{"start":124,"end":140,"token_start":19,"token_end":19,"label":"DRUG"},{"start":153,"end":165,"token_start":24,"token_end":24,"label":"DRUG"},{"start":200,"end":210,"token_start":33,"token_end":33,"label":"DRUG"}],"_input_hash":1782132717,"_task_hash":189034633,"_session_id":"drug_drug_pilot_shared-yuval","_view_id":"blocks","relations":[{"head":19,"child":24,"head_span":{"start":124,"end":140,"token_start":19,"token_end":19,"label":"DRUG"},"child_span":{"start":153,"end":165,"token_start":24,"token_end":24,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":33,"child":24,"head_span":{"start":200,"end":210,"token_start":33,"token_end":33,"label":"DRUG"},"child_span":{"start":153,"end":165,"token_start":24,"token_end":24,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"Among the anti-herpesvirus agents , aciclovir , valaciclovir , penciclovir , famciclovir , idoxuridine , trifluridine and brivudin are used in the treatment of herpes simplex virus and varicella-zoster virus infections , and ganciclovir , foscarnet , cidofovir , fomivirsen and maribavir ( the latter in the developmental stage ) are used in the treatment of cytomegalovirus infections .","paragraph":"<h3><u>Antiviral drugs: current state of the art.</u></h3>The chemotherapy of virus infections has definitely come of age. There are now 15 antiviral agents that have been formally licensed for the treatment of human immunodeficiency virus infections (<b style='color:Tomato;'><i>zidovudine</i></b>, <b style='color:Tomato;'><i>didanosine</i></b>, <b style='color:Tomato;'><i>zalcitabine</i></b>, <b style='color:Tomato;'><i>stavudine</i></b>, <b style='color:Tomato;'><i>lamivudine</i></b>, <b style='color:Tomato;'><i>abacavir</i></b>, <b style='color:Tomato;'><i>nevirapine</i></b>, <b style='color:Tomato;'><i>delavirdine</i></b>, <b style='color:Tomato;'><i>efavirenz</i></b>, <b style='color:Tomato;'><i>saquinavir</i></b>, <b style='color:Tomato;'><i>ritonavir</i></b>, <b style='color:Tomato;'><i>indinavir</i></b>, <b style='color:Tomato;'><i>nelfinavir</i></b>, <b style='color:Tomato;'><i>amprenavir</i></b>, <b style='color:Tomato;'><i>lopinavir</i></b>) and several others, such as <b style='color:Tomato;'><i>tenofovir</i></b> disoproxil, <b style='color:Tomato;'><i>emtricitabine</i></b>, capravirine, emivirine, T-20 (pentafuside) and AMD3100 (bicyclam) are under clinical development. <b style='color:Tomato;'><i>lamivudine</i></b> has been approved, and several other compounds (such as <b style='color:Tomato;'><i>adefovir</i></b> dipivoxil, <b style='color:Tomato;'><i>emtricitabine</i></b> and <b style='color:Tomato;'><i>entecavir</i></b>) are under clinical development, for the treatment of hepatitis B virus infections. <b style='color:DodgerBlue;'><i>Among</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>anti-herpesvirus</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>aciclovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>valaciclovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>penciclovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>famciclovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>idoxuridine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>trifluridine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>brivudin</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>herpes</i></b> <b style='color:DodgerBlue;'><i>simplex</i></b> <b style='color:DodgerBlue;'><i>virus</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>varicella-zoster</i></b> <b style='color:DodgerBlue;'><i>virus</i></b> <b style='color:DodgerBlue;'><i>infections</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ganciclovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>foscarnet</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cidofovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>fomivirsen</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>maribavir</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>latter</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>developmental</i></b> <b style='color:DodgerBlue;'><i>stage</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cytomegalovirus</i></b> <b style='color:DodgerBlue;'><i>infections</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Following <b style='color:Tomato;'><i>amantadine</i></b> and <b style='color:Tomato;'><i>rimantadine</i></b>, the neuraminidase inhibitors, <b style='color:Tomato;'><i>zanamivir</i></b> and <b style='color:Tomato;'><i>oseltamivir</i></b>, have now become available for the therapy and prophylaxis of influenza virus infections, and so is <b style='color:Tomato;'><i>ribavirin</i></b> for the treatment of respiratory syncytial virus infections and the combination of <b style='color:Tomato;'><i>ribavirin</i></b> with interferon-alpha for the treatment of hepatitis C virus infections.","tokens":[{"text":"Among","start":0,"end":5,"id":0,"ws":true},{"text":"the","start":6,"end":9,"id":1,"ws":true},{"text":"anti-herpesvirus","start":10,"end":26,"id":2,"ws":true},{"text":"agents","start":27,"end":33,"id":3,"ws":true},{"text":",","start":34,"end":35,"id":4,"ws":true},{"text":"aciclovir","start":36,"end":45,"id":5,"ws":true},{"text":",","start":46,"end":47,"id":6,"ws":true},{"text":"valaciclovir","start":48,"end":60,"id":7,"ws":true},{"text":",","start":61,"end":62,"id":8,"ws":true},{"text":"penciclovir","start":63,"end":74,"id":9,"ws":true},{"text":",","start":75,"end":76,"id":10,"ws":true},{"text":"famciclovir","start":77,"end":88,"id":11,"ws":true},{"text":",","start":89,"end":90,"id":12,"ws":true},{"text":"idoxuridine","start":91,"end":102,"id":13,"ws":true},{"text":",","start":103,"end":104,"id":14,"ws":true},{"text":"trifluridine","start":105,"end":117,"id":15,"ws":true},{"text":"and","start":118,"end":121,"id":16,"ws":true},{"text":"brivudin","start":122,"end":130,"id":17,"ws":true},{"text":"are","start":131,"end":134,"id":18,"ws":true},{"text":"used","start":135,"end":139,"id":19,"ws":true},{"text":"in","start":140,"end":142,"id":20,"ws":true},{"text":"the","start":143,"end":146,"id":21,"ws":true},{"text":"treatment","start":147,"end":156,"id":22,"ws":true},{"text":"of","start":157,"end":159,"id":23,"ws":true},{"text":"herpes","start":160,"end":166,"id":24,"ws":true},{"text":"simplex","start":167,"end":174,"id":25,"ws":true},{"text":"virus","start":175,"end":180,"id":26,"ws":true},{"text":"and","start":181,"end":184,"id":27,"ws":true},{"text":"varicella-zoster","start":185,"end":201,"id":28,"ws":true},{"text":"virus","start":202,"end":207,"id":29,"ws":true},{"text":"infections","start":208,"end":218,"id":30,"ws":true},{"text":",","start":219,"end":220,"id":31,"ws":true},{"text":"and","start":221,"end":224,"id":32,"ws":true},{"text":"ganciclovir","start":225,"end":236,"id":33,"ws":true},{"text":",","start":237,"end":238,"id":34,"ws":true},{"text":"foscarnet","start":239,"end":248,"id":35,"ws":true},{"text":",","start":249,"end":250,"id":36,"ws":true},{"text":"cidofovir","start":251,"end":260,"id":37,"ws":true},{"text":",","start":261,"end":262,"id":38,"ws":true},{"text":"fomivirsen","start":263,"end":273,"id":39,"ws":true},{"text":"and","start":274,"end":277,"id":40,"ws":true},{"text":"maribavir","start":278,"end":287,"id":41,"ws":true},{"text":"(","start":288,"end":289,"id":42,"ws":true},{"text":"the","start":290,"end":293,"id":43,"ws":true},{"text":"latter","start":294,"end":300,"id":44,"ws":true},{"text":"in","start":301,"end":303,"id":45,"ws":true},{"text":"the","start":304,"end":307,"id":46,"ws":true},{"text":"developmental","start":308,"end":321,"id":47,"ws":true},{"text":"stage","start":322,"end":327,"id":48,"ws":true},{"text":")","start":328,"end":329,"id":49,"ws":true},{"text":"are","start":330,"end":333,"id":50,"ws":true},{"text":"used","start":334,"end":338,"id":51,"ws":true},{"text":"in","start":339,"end":341,"id":52,"ws":true},{"text":"the","start":342,"end":345,"id":53,"ws":true},{"text":"treatment","start":346,"end":355,"id":54,"ws":true},{"text":"of","start":356,"end":358,"id":55,"ws":true},{"text":"cytomegalovirus","start":359,"end":374,"id":56,"ws":true},{"text":"infections","start":375,"end":385,"id":57,"ws":true},{"text":".","start":386,"end":387,"id":58,"ws":false}],"spans":[{"start":36,"end":45,"token_start":5,"token_end":5,"label":"DRUG"},{"start":48,"end":60,"token_start":7,"token_end":7,"label":"DRUG"},{"start":63,"end":74,"token_start":9,"token_end":9,"label":"DRUG"},{"start":77,"end":88,"token_start":11,"token_end":11,"label":"DRUG"},{"start":91,"end":102,"token_start":13,"token_end":13,"label":"DRUG"},{"start":105,"end":117,"token_start":15,"token_end":15,"label":"DRUG"},{"start":225,"end":236,"token_start":33,"token_end":33,"label":"DRUG"},{"start":239,"end":248,"token_start":35,"token_end":35,"label":"DRUG"},{"start":251,"end":260,"token_start":37,"token_end":37,"label":"DRUG"}],"_input_hash":1265321677,"_task_hash":1758490147,"_session_id":"drug_drug_pilot_shared-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The present study examined the efficacy of single and combined treatment with an anticholinesterase , tetrahydroaminoacridine ( i.p . ) , and a glycine-B site partial agonist , D-cycloserine ( i.p . ; a positive allosteric modulator of NMDA receptors ) , in alleviating the deficit in water maze spatial navigation induced by electrolytic lesion of the medial septum or lidocaine infusion into the dorsal hippocampi .","paragraph":"<h3><u>Tetrahydroaminoacridine and D-cycloserine fail to alleviate the water maze spatial navigation defect induced by hippocampal inactivation.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>examined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>anticholinesterase</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>tetrahydroaminoacridine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>i.p</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>glycine-B</i></b> <b style='color:DodgerBlue;'><i>site</i></b> <b style='color:DodgerBlue;'><i>partial</i></b> <b style='color:DodgerBlue;'><i>agonist</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>D-cycloserine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>i.p</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>positive</i></b> <b style='color:DodgerBlue;'><i>allosteric</i></b> <b style='color:DodgerBlue;'><i>modulator</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>NMDA</i></b> <b style='color:DodgerBlue;'><i>receptors</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>alleviating</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>deficit</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>water</i></b> <b style='color:DodgerBlue;'><i>maze</i></b> <b style='color:DodgerBlue;'><i>spatial</i></b> <b style='color:DodgerBlue;'><i>navigation</i></b> <b style='color:DodgerBlue;'><i>induced</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>electrolytic</i></b> <b style='color:DodgerBlue;'><i>lesion</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>medial</i></b> <b style='color:DodgerBlue;'><i>septum</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>lidocaine</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>dorsal</i></b> <b style='color:DodgerBlue;'><i>hippocampi</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In medial septum-lesioned rats, a combination of tetrahydroaminoacridine 3 mg kg(-1) and <b style='color:Tomato;'><i>d-cycloserine</i></b> 10 mg kg(-1) facilitated acquisition of the water maze test more effectively than either of the drugs alone. Single or combined treatment with tetrahydroaminoacridine 3 mg kg(-1) and <b style='color:Tomato;'><i>d-cycloserine</i></b> 10 mg kg(-1) had no effect on the water maze deficit induced by hippocampal <b style='color:Tomato;'><i>lidocaine</i></b> infusion. These results suggest that combined treatment with tetrahydroaminoacridine and <b style='color:Tomato;'><i>d-cycloserine</i></b> can effectively stimulate water maze spatial navigation, and that functioning of the hippocampus is a prerequisite for this effect.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"present","start":4,"end":11,"id":1,"ws":true},{"text":"study","start":12,"end":17,"id":2,"ws":true},{"text":"examined","start":18,"end":26,"id":3,"ws":true},{"text":"the","start":27,"end":30,"id":4,"ws":true},{"text":"efficacy","start":31,"end":39,"id":5,"ws":true},{"text":"of","start":40,"end":42,"id":6,"ws":true},{"text":"single","start":43,"end":49,"id":7,"ws":true},{"text":"and","start":50,"end":53,"id":8,"ws":true},{"text":"combined","start":54,"end":62,"id":9,"ws":true},{"text":"treatment","start":63,"end":72,"id":10,"ws":true},{"text":"with","start":73,"end":77,"id":11,"ws":true},{"text":"an","start":78,"end":80,"id":12,"ws":true},{"text":"anticholinesterase","start":81,"end":99,"id":13,"ws":true},{"text":",","start":100,"end":101,"id":14,"ws":true},{"text":"tetrahydroaminoacridine","start":102,"end":125,"id":15,"ws":true},{"text":"(","start":126,"end":127,"id":16,"ws":true},{"text":"i.p","start":128,"end":131,"id":17,"ws":true},{"text":".","start":132,"end":133,"id":18,"ws":true},{"text":")","start":134,"end":135,"id":19,"ws":true},{"text":",","start":136,"end":137,"id":20,"ws":true},{"text":"and","start":138,"end":141,"id":21,"ws":true},{"text":"a","start":142,"end":143,"id":22,"ws":true},{"text":"glycine-B","start":144,"end":153,"id":23,"ws":true},{"text":"site","start":154,"end":158,"id":24,"ws":true},{"text":"partial","start":159,"end":166,"id":25,"ws":true},{"text":"agonist","start":167,"end":174,"id":26,"ws":true},{"text":",","start":175,"end":176,"id":27,"ws":true},{"text":"D-cycloserine","start":177,"end":190,"id":28,"ws":true},{"text":"(","start":191,"end":192,"id":29,"ws":true},{"text":"i.p","start":193,"end":196,"id":30,"ws":true},{"text":".","start":197,"end":198,"id":31,"ws":true},{"text":";","start":199,"end":200,"id":32,"ws":true},{"text":"a","start":201,"end":202,"id":33,"ws":true},{"text":"positive","start":203,"end":211,"id":34,"ws":true},{"text":"allosteric","start":212,"end":222,"id":35,"ws":true},{"text":"modulator","start":223,"end":232,"id":36,"ws":true},{"text":"of","start":233,"end":235,"id":37,"ws":true},{"text":"NMDA","start":236,"end":240,"id":38,"ws":true},{"text":"receptors","start":241,"end":250,"id":39,"ws":true},{"text":")","start":251,"end":252,"id":40,"ws":true},{"text":",","start":253,"end":254,"id":41,"ws":true},{"text":"in","start":255,"end":257,"id":42,"ws":true},{"text":"alleviating","start":258,"end":269,"id":43,"ws":true},{"text":"the","start":270,"end":273,"id":44,"ws":true},{"text":"deficit","start":274,"end":281,"id":45,"ws":true},{"text":"in","start":282,"end":284,"id":46,"ws":true},{"text":"water","start":285,"end":290,"id":47,"ws":true},{"text":"maze","start":291,"end":295,"id":48,"ws":true},{"text":"spatial","start":296,"end":303,"id":49,"ws":true},{"text":"navigation","start":304,"end":314,"id":50,"ws":true},{"text":"induced","start":315,"end":322,"id":51,"ws":true},{"text":"by","start":323,"end":325,"id":52,"ws":true},{"text":"electrolytic","start":326,"end":338,"id":53,"ws":true},{"text":"lesion","start":339,"end":345,"id":54,"ws":true},{"text":"of","start":346,"end":348,"id":55,"ws":true},{"text":"the","start":349,"end":352,"id":56,"ws":true},{"text":"medial","start":353,"end":359,"id":57,"ws":true},{"text":"septum","start":360,"end":366,"id":58,"ws":true},{"text":"or","start":367,"end":369,"id":59,"ws":true},{"text":"lidocaine","start":370,"end":379,"id":60,"ws":true},{"text":"infusion","start":380,"end":388,"id":61,"ws":true},{"text":"into","start":389,"end":393,"id":62,"ws":true},{"text":"the","start":394,"end":397,"id":63,"ws":true},{"text":"dorsal","start":398,"end":404,"id":64,"ws":true},{"text":"hippocampi","start":405,"end":415,"id":65,"ws":true},{"text":".","start":416,"end":417,"id":66,"ws":false}],"spans":[{"start":177,"end":190,"token_start":28,"token_end":28,"label":"DRUG"},{"start":370,"end":379,"token_start":60,"token_end":60,"label":"DRUG"}],"_input_hash":1944915333,"_task_hash":1724675945,"_session_id":"drug_drug_pilot_shared-yuval","_view_id":"blocks","relations":[{"head":15,"child":28,"head_span":{"start":102,"end":125,"token_start":15,"token_end":15,"label":null},"child_span":{"start":177,"end":190,"token_start":28,"token_end":28,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"He was initially treated with combination chemotherapy regimen of vincristine , actinomycin-D and cyclophosphamide ( VAC therapy ) .","paragraph":"<h3><u>[Rhabdomyosarcoma of the bladder: a case report].</u></h3>A 15-year-old man with the chief complaint of general fatigue was referred to our hospital on November 11, 1993. Bilateral percutaneous nephrostomy was performed for postrenal anuria. X-ray examinations revealed a huge intrapelvic tumor, and it was histopathologically diagnosed as rhabdomyosarcoma by transrectal needle biopsy. <b style='color:DodgerBlue;'><i>He</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>initially</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>actinomycin-D</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>VAC</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Pelvic exenteration was performed on December 15, 1993. Histopathological findings were alveolar rhabdomyosarcoma with degenerative change and partial necrosis. After the operation, he was given two course of VAC therapy. In May, 1994, brain metastasis occurred, so 4 courses of VAC therapy were administered. For a very short period, neurological symptoms improved, but he died of pneumonia on November 15, 1994.","tokens":[{"text":"He","start":0,"end":2,"id":0,"ws":true},{"text":"was","start":3,"end":6,"id":1,"ws":true},{"text":"initially","start":7,"end":16,"id":2,"ws":true},{"text":"treated","start":17,"end":24,"id":3,"ws":true},{"text":"with","start":25,"end":29,"id":4,"ws":true},{"text":"combination","start":30,"end":41,"id":5,"ws":true},{"text":"chemotherapy","start":42,"end":54,"id":6,"ws":true},{"text":"regimen","start":55,"end":62,"id":7,"ws":true},{"text":"of","start":63,"end":65,"id":8,"ws":true},{"text":"vincristine","start":66,"end":77,"id":9,"ws":true},{"text":",","start":78,"end":79,"id":10,"ws":true},{"text":"actinomycin-D","start":80,"end":93,"id":11,"ws":true},{"text":"and","start":94,"end":97,"id":12,"ws":true},{"text":"cyclophosphamide","start":98,"end":114,"id":13,"ws":true},{"text":"(","start":115,"end":116,"id":14,"ws":true},{"text":"VAC","start":117,"end":120,"id":15,"ws":true},{"text":"therapy","start":121,"end":128,"id":16,"ws":true},{"text":")","start":129,"end":130,"id":17,"ws":true},{"text":".","start":131,"end":132,"id":18,"ws":false}],"spans":[{"start":66,"end":77,"token_start":9,"token_end":9,"label":"DRUG"},{"start":98,"end":114,"token_start":13,"token_end":13,"label":"DRUG"}],"_input_hash":1557412523,"_task_hash":-2119098685,"_session_id":"drug_drug_pilot_shared-yuval","_view_id":"blocks","relations":[{"head":9,"child":11,"head_span":{"start":66,"end":77,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":80,"end":93,"token_start":11,"token_end":11,"label":null},"color":"#96e8ce","label":"COMB1"},{"head":13,"child":11,"head_span":{"start":98,"end":114,"token_start":13,"token_end":13,"label":"DRUG"},"child_span":{"start":80,"end":93,"token_start":11,"token_end":11,"label":null},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"However , when a lung mass was noted two months later , he started to receive combination chemotherapy consisting of cyclophosphamide , adriamycin , vincristine , and prednisolone every three months .","paragraph":"<h3><u>[Lymphomatoid granulomatosis (LYG) occurring in a patient with follicular lymphoma during remission].</u></h3>A 49 years-old man presented with dry cough, low grade fever, and abnormal shadow on a chest X-ray. He had suffered from follicular lymphoma of the liver 5 years previously. He received irradiation therapy in combination with chemotherapy for approximately three years and had been in complete remission. Physical and radiological examination revealed pleural effusion and softly dense masses in the right lung. The laboratory data were within normal limits. He was diagnosed as having lymphomatoid granulomatosis (LYG) by open lung biopsy. The lung lesion was mainly infiltrated with T cells. The patient received <b style='color:Tomato;'><i>prednisolone</i></b> and the lung lesions disappeared. <b style='color:DodgerBlue;'><i>However</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>lung</i></b> <b style='color:DodgerBlue;'><i>mass</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>noted</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>later</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>he</i></b> <b style='color:DodgerBlue;'><i>started</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>receive</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>consisting</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>adriamycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>prednisolone</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>three</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>.</i></b> He has not shown relapse of LYG so far. To investigate the association between the preceding follicular lymphoma and subsequent LYG at this time, DNA analysis using the PCR technique was carried out. The LYG lesion did not show a rearranged band for the JH probe, while the paraffin-embedded specimen of the preceding follicular lymphoma had shown rearranged band for the JH band. Southern blot analysis of the LYG lesion, showed no rearrangement for TCR beta, gamma or JH probe. These findings indicate that the LYG was different from the preceding follicular lymphoma in terms of origin. LYG is considered to be induced in the immunosuppressive state due to lymphoma.","tokens":[{"text":"However","start":0,"end":7,"id":0,"ws":true},{"text":",","start":8,"end":9,"id":1,"ws":true},{"text":"when","start":10,"end":14,"id":2,"ws":true},{"text":"a","start":15,"end":16,"id":3,"ws":true},{"text":"lung","start":17,"end":21,"id":4,"ws":true},{"text":"mass","start":22,"end":26,"id":5,"ws":true},{"text":"was","start":27,"end":30,"id":6,"ws":true},{"text":"noted","start":31,"end":36,"id":7,"ws":true},{"text":"two","start":37,"end":40,"id":8,"ws":true},{"text":"months","start":41,"end":47,"id":9,"ws":true},{"text":"later","start":48,"end":53,"id":10,"ws":true},{"text":",","start":54,"end":55,"id":11,"ws":true},{"text":"he","start":56,"end":58,"id":12,"ws":true},{"text":"started","start":59,"end":66,"id":13,"ws":true},{"text":"to","start":67,"end":69,"id":14,"ws":true},{"text":"receive","start":70,"end":77,"id":15,"ws":true},{"text":"combination","start":78,"end":89,"id":16,"ws":true},{"text":"chemotherapy","start":90,"end":102,"id":17,"ws":true},{"text":"consisting","start":103,"end":113,"id":18,"ws":true},{"text":"of","start":114,"end":116,"id":19,"ws":true},{"text":"cyclophosphamide","start":117,"end":133,"id":20,"ws":true},{"text":",","start":134,"end":135,"id":21,"ws":true},{"text":"adriamycin","start":136,"end":146,"id":22,"ws":true},{"text":",","start":147,"end":148,"id":23,"ws":true},{"text":"vincristine","start":149,"end":160,"id":24,"ws":true},{"text":",","start":161,"end":162,"id":25,"ws":true},{"text":"and","start":163,"end":166,"id":26,"ws":true},{"text":"prednisolone","start":167,"end":179,"id":27,"ws":true},{"text":"every","start":180,"end":185,"id":28,"ws":true},{"text":"three","start":186,"end":191,"id":29,"ws":true},{"text":"months","start":192,"end":198,"id":30,"ws":true},{"text":".","start":199,"end":200,"id":31,"ws":false}],"spans":[{"start":117,"end":133,"token_start":20,"token_end":20,"label":"DRUG"},{"start":149,"end":160,"token_start":24,"token_end":24,"label":"DRUG"},{"start":167,"end":179,"token_start":27,"token_end":27,"label":"DRUG"}],"_input_hash":8987266,"_task_hash":528717002,"_session_id":"drug_drug_pilot_shared-yuval","_view_id":"blocks","relations":[{"head":20,"child":22,"head_span":{"start":117,"end":133,"token_start":20,"token_end":20,"label":"DRUG"},"child_span":{"start":136,"end":146,"token_start":22,"token_end":22,"label":null},"color":"#96e8ce","label":"COMB1"},{"head":22,"child":24,"head_span":{"start":136,"end":146,"token_start":22,"token_end":22,"label":null},"child_span":{"start":149,"end":160,"token_start":24,"token_end":24,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":27,"child":24,"head_span":{"start":167,"end":179,"token_start":27,"token_end":27,"label":"DRUG"},"child_span":{"start":149,"end":160,"token_start":24,"token_end":24,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T1"],"answer":"accept"}
{"text":"Three patients treated initially with propranolol alone have required substitution of amiodarone due to refractory congestive heart failure .","paragraph":"<h3><u>The role of beta-blockade therapy for ventricular tachycardia induced with isoproterenol: a prospective analysis.</u></h3>Isoproterenol is sometimes required for ventricular tachycardia (VT) induction. However, the role of beta-blockade for treatment of such VT has not been critically assessed. The use of beta-blockade was evaluated prospectively in 14 consecutive patients who required isoproterenol 2.4 +/- 1.3 (+/- S.D.) micrograms/min to induce sustained monomorphic VT (greater than 30 seconds, or requiring termination due to hemodynamic collapse) after a negative baseline study. The VT mechanisms were enhanced automaticity (group A, six patients), triggered automaticity (group B, three patients), and reentry (group C, five patients). Groups A and B had serial intravenous electropharmacologic tests with <b style='color:Tomato;'><i>propranolol</i></b> alone (0.2 mg/kg), <b style='color:Tomato;'><i>verapamil</i></b> alone (0.15 mg/kg), and <b style='color:Tomato;'><i>propranolol</i></b> plus <b style='color:Tomato;'><i>verapamil</i></b>, and group C had serial tests with <b style='color:Tomato;'><i>propranolol</i></b> alone, <b style='color:Tomato;'><i>procainamide</i></b> or <b style='color:Tomato;'><i>quinidine</i></b> (class Ia drug) alone, and <b style='color:Tomato;'><i>propranolol</i></b> plus a class Ia drug until VT could no longer be induced. All six patients in group A responded to <b style='color:Tomato;'><i>propranolol</i></b> alone. In group B, one patient responded to <b style='color:Tomato;'><i>verapamil</i></b> alone, and two patients responded to <b style='color:Tomato;'><i>propranolol</i></b> plus <b style='color:Tomato;'><i>verapamil</i></b>. In group C, three patients responded to <b style='color:Tomato;'><i>propranolol</i></b> alone, one patient responded to a class Ia drug alone, and one patient responded to <b style='color:Tomato;'><i>propranolol</i></b> plus a class Ia drug. During a follow-up of 7 to 37 (17.9 +/- 10.7) (+/- S.D.) months, VT has not recurred in any patient. <b style='color:DodgerBlue;'><i>Three</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>initially</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>propranolol</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>required</i></b> <b style='color:DodgerBlue;'><i>substitution</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>amiodarone</i></b> <b style='color:DodgerBlue;'><i>due</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>refractory</i></b> <b style='color:DodgerBlue;'><i>congestive</i></b> <b style='color:DodgerBlue;'><i>heart</i></b> <b style='color:DodgerBlue;'><i>failure</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In patients requiring isoproterenol for VT induction, beta-blockade alone appears to be effective in preventing reinduction of VT caused by enhanced automaticity. A heterogeneous response occurs when the VT mechanisms are triggered automaticity or reentry.","tokens":[{"text":"Three","start":0,"end":5,"id":0,"ws":true},{"text":"patients","start":6,"end":14,"id":1,"ws":true},{"text":"treated","start":15,"end":22,"id":2,"ws":true},{"text":"initially","start":23,"end":32,"id":3,"ws":true},{"text":"with","start":33,"end":37,"id":4,"ws":true},{"text":"propranolol","start":38,"end":49,"id":5,"ws":true},{"text":"alone","start":50,"end":55,"id":6,"ws":true},{"text":"have","start":56,"end":60,"id":7,"ws":true},{"text":"required","start":61,"end":69,"id":8,"ws":true},{"text":"substitution","start":70,"end":82,"id":9,"ws":true},{"text":"of","start":83,"end":85,"id":10,"ws":true},{"text":"amiodarone","start":86,"end":96,"id":11,"ws":true},{"text":"due","start":97,"end":100,"id":12,"ws":true},{"text":"to","start":101,"end":103,"id":13,"ws":true},{"text":"refractory","start":104,"end":114,"id":14,"ws":true},{"text":"congestive","start":115,"end":125,"id":15,"ws":true},{"text":"heart","start":126,"end":131,"id":16,"ws":true},{"text":"failure","start":132,"end":139,"id":17,"ws":true},{"text":".","start":140,"end":141,"id":18,"ws":false}],"spans":[{"start":38,"end":49,"token_start":5,"token_end":5,"label":"DRUG"},{"start":86,"end":96,"token_start":11,"token_end":11,"label":"DRUG"}],"_input_hash":-632828286,"_task_hash":-1526074177,"_session_id":"drug_drug_pilot_shared-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"These studies suggest a slight advantage to the combined approaches that contain flutamide and bicalutamide , but the lack of dramatic differences in outcome makes monotherapy reasonable , especially in patients with more indolent disease .","paragraph":"<h3><u>The selection of hormonal therapy in prostate cancer: who, when, and for how long?</u></h3>Androgen deprivation is the foundation for the systemic therapy of advanced prostate cancer. Multiple trials have tested combined androgen blockade versus androgen deprivation alone in patients with advanced disease. <b style='color:DodgerBlue;'><i>These</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>suggest</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>slight</i></b> <b style='color:DodgerBlue;'><i>advantage</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>approaches</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>contain</i></b> <b style='color:MediumOrchid;'><i>flutamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>bicalutamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>lack</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>dramatic</i></b> <b style='color:DodgerBlue;'><i>differences</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>outcome</i></b> <b style='color:DodgerBlue;'><i>makes</i></b> <b style='color:DodgerBlue;'><i>monotherapy</i></b> <b style='color:DodgerBlue;'><i>reasonable</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>especially</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>indolent</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Intermittent androgen deprivation is an alternative that may allow patients to reduce the total time on androgen suppression as well as possibly delay the onset of androgen independence. A number of secondary hormonal therapies, including deferred and secondary antiandrogens, <b style='color:Tomato;'><i>ketoconazole</i></b>, and estrogens have shown modest response proportions. Patients with less advanced disease such as a rising prostate-specific antigen have varied outcomes, and no standard approach exists. In this group, noncastrating forms of hormonal therapy are being evaluated. Patients undergoing definitive local therapy who have high-risk features may benefit from early, as opposed to deferred, androgen deprivation. This review examines the evidence for the current state of the art in hormonal therapy in patients with prostate cancer and focuses, in particular, on treatment composition and timing as well as the rationale for the use of hormonal therapy in early stage disease.","tokens":[{"text":"These","start":0,"end":5,"id":0,"ws":true},{"text":"studies","start":6,"end":13,"id":1,"ws":true},{"text":"suggest","start":14,"end":21,"id":2,"ws":true},{"text":"a","start":22,"end":23,"id":3,"ws":true},{"text":"slight","start":24,"end":30,"id":4,"ws":true},{"text":"advantage","start":31,"end":40,"id":5,"ws":true},{"text":"to","start":41,"end":43,"id":6,"ws":true},{"text":"the","start":44,"end":47,"id":7,"ws":true},{"text":"combined","start":48,"end":56,"id":8,"ws":true},{"text":"approaches","start":57,"end":67,"id":9,"ws":true},{"text":"that","start":68,"end":72,"id":10,"ws":true},{"text":"contain","start":73,"end":80,"id":11,"ws":true},{"text":"flutamide","start":81,"end":90,"id":12,"ws":true},{"text":"and","start":91,"end":94,"id":13,"ws":true},{"text":"bicalutamide","start":95,"end":107,"id":14,"ws":true},{"text":",","start":108,"end":109,"id":15,"ws":true},{"text":"but","start":110,"end":113,"id":16,"ws":true},{"text":"the","start":114,"end":117,"id":17,"ws":true},{"text":"lack","start":118,"end":122,"id":18,"ws":true},{"text":"of","start":123,"end":125,"id":19,"ws":true},{"text":"dramatic","start":126,"end":134,"id":20,"ws":true},{"text":"differences","start":135,"end":146,"id":21,"ws":true},{"text":"in","start":147,"end":149,"id":22,"ws":true},{"text":"outcome","start":150,"end":157,"id":23,"ws":true},{"text":"makes","start":158,"end":163,"id":24,"ws":true},{"text":"monotherapy","start":164,"end":175,"id":25,"ws":true},{"text":"reasonable","start":176,"end":186,"id":26,"ws":true},{"text":",","start":187,"end":188,"id":27,"ws":true},{"text":"especially","start":189,"end":199,"id":28,"ws":true},{"text":"in","start":200,"end":202,"id":29,"ws":true},{"text":"patients","start":203,"end":211,"id":30,"ws":true},{"text":"with","start":212,"end":216,"id":31,"ws":true},{"text":"more","start":217,"end":221,"id":32,"ws":true},{"text":"indolent","start":222,"end":230,"id":33,"ws":true},{"text":"disease","start":231,"end":238,"id":34,"ws":true},{"text":".","start":239,"end":240,"id":35,"ws":false}],"spans":[{"start":81,"end":90,"token_start":12,"token_end":12,"label":"DRUG"},{"start":95,"end":107,"token_start":14,"token_end":14,"label":"DRUG"}],"_input_hash":137769162,"_task_hash":410888998,"_session_id":"drug_drug_pilot_shared-yuval","_view_id":"blocks","relations":[{"head":12,"child":14,"head_span":{"start":81,"end":90,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":95,"end":107,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T0"],"answer":"accept"}
{"text":"We examined the feasibility and safety of using paclitaxel and trastuzumab as maintenance therapy after high-dose chemotherapy ( HDC ) with autologous hematopoietic stem cell transplantation ( AHST ) for patients with HER2-positive metastatic breast cancer .","paragraph":"<h3><u>Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation.</u></h3> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>examined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>feasibility</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>maintenance</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>HDC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>autologous</i></b> <b style='color:DodgerBlue;'><i>hematopoietic</i></b> <b style='color:DodgerBlue;'><i>stem</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>transplantation</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AHST</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>HER2-positive</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Ten patients (9 women and 1 man) were enrolled in the study. The median age was 46.5 years (range, 27-65 years). The median follow-up time was 1003 days (range, 216-2526 days). All patients had metastatic disease, but 2 had only bone metastasis. One patient had complete response, 6 had partial response and 3 had stable disease to the standard-dose chemotherapy prior to transplantation. The conditioning regimen consisted of <b style='color:Tomato;'><i>cyclophosphamide</i></b>, <b style='color:Tomato;'><i>carmustine</i></b>, and <b style='color:Tomato;'><i>thiotepa</i></b>. After AHST, patients received weekly <b style='color:Tomato;'><i>paclitaxel</i></b> for 12 doses and <b style='color:Tomato;'><i>trastuzumab</i></b> every 3 weeks for 1 year as maintenance therapy. All patients experienced successful engraftment. The only grade 4 toxic effects observed were leukopenia and thrombocytopenia. The most common grade 3 toxic effect was neutropenic fever. No treatment-related deaths were observed. The median progression-free survival time was 441 days, and the median overall survival time was 955 days. Two patients died in accidents while their disease remained in remission. Five patients died with disease progression. At the time of this report, 3 patients are alive with stable disease, 1 of whom has remained free of disease progression for 2526 days since transplantation. Our findings indicate that <b style='color:Tomato;'><i>paclitaxel</i></b> plus <b style='color:Tomato;'><i>trastuzumab</i></b> as maintenance therapy after HDC with AHST for patients with HER2-positive metastatic breast cancer not only is feasible and safe but also results in survival outcomes similar to historical results. ","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"examined","start":3,"end":11,"id":1,"ws":true},{"text":"the","start":12,"end":15,"id":2,"ws":true},{"text":"feasibility","start":16,"end":27,"id":3,"ws":true},{"text":"and","start":28,"end":31,"id":4,"ws":true},{"text":"safety","start":32,"end":38,"id":5,"ws":true},{"text":"of","start":39,"end":41,"id":6,"ws":true},{"text":"using","start":42,"end":47,"id":7,"ws":true},{"text":"paclitaxel","start":48,"end":58,"id":8,"ws":true},{"text":"and","start":59,"end":62,"id":9,"ws":true},{"text":"trastuzumab","start":63,"end":74,"id":10,"ws":true},{"text":"as","start":75,"end":77,"id":11,"ws":true},{"text":"maintenance","start":78,"end":89,"id":12,"ws":true},{"text":"therapy","start":90,"end":97,"id":13,"ws":true},{"text":"after","start":98,"end":103,"id":14,"ws":true},{"text":"high-dose","start":104,"end":113,"id":15,"ws":true},{"text":"chemotherapy","start":114,"end":126,"id":16,"ws":true},{"text":"(","start":127,"end":128,"id":17,"ws":true},{"text":"HDC","start":129,"end":132,"id":18,"ws":true},{"text":")","start":133,"end":134,"id":19,"ws":true},{"text":"with","start":135,"end":139,"id":20,"ws":true},{"text":"autologous","start":140,"end":150,"id":21,"ws":true},{"text":"hematopoietic","start":151,"end":164,"id":22,"ws":true},{"text":"stem","start":165,"end":169,"id":23,"ws":true},{"text":"cell","start":170,"end":174,"id":24,"ws":true},{"text":"transplantation","start":175,"end":190,"id":25,"ws":true},{"text":"(","start":191,"end":192,"id":26,"ws":true},{"text":"AHST","start":193,"end":197,"id":27,"ws":true},{"text":")","start":198,"end":199,"id":28,"ws":true},{"text":"for","start":200,"end":203,"id":29,"ws":true},{"text":"patients","start":204,"end":212,"id":30,"ws":true},{"text":"with","start":213,"end":217,"id":31,"ws":true},{"text":"HER2-positive","start":218,"end":231,"id":32,"ws":true},{"text":"metastatic","start":232,"end":242,"id":33,"ws":true},{"text":"breast","start":243,"end":249,"id":34,"ws":true},{"text":"cancer","start":250,"end":256,"id":35,"ws":true},{"text":".","start":257,"end":258,"id":36,"ws":false}],"spans":[{"start":48,"end":58,"token_start":8,"token_end":8,"label":"DRUG"},{"start":63,"end":74,"token_start":10,"token_end":10,"label":"DRUG"}],"_input_hash":-1578970086,"_task_hash":304060663,"_session_id":"drug_drug_pilot_shared-yuval","_view_id":"blocks","relations":[{"head":8,"child":10,"head_span":{"start":48,"end":58,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":63,"end":74,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"Dual antiplatelet therapy with aspirin and clopidogrel ( the preferred thienopyridine because of its superior hematologic safety ) is recommended for at least 4 weeks to prevent subacute stent thrombosis with bare-metal stents and 3 to 6 months to prevent late-stent thrombosis with drug-eluting stents .","paragraph":"<h3><u>Long-term care after percutaneous coronary intervention: focus on the role of antiplatelet therapy.</u></h3>Arterial wall injury caused by percutaneous coronary intervention (PCI) triggers transient platelet activation and mural thrombosis; these effects are superimposed on the preexisting platelet hyperreactivity associated with underlying atherothrombosis. Platelet activation has been implicated in the major complications of PCI: acute and subacute thrombosis and restenosis. Antithrombotic and anticoagulant therapy minimizes thrombotic complications after PCI. <b style='color:Tomato;'><i>aspirin</i></b> plus a thienopyridine (<b style='color:Tomato;'><i>ticlopidine</i></b> or <b style='color:Tomato;'><i>clopidogrel</i></b>) is more effective than <b style='color:Tomato;'><i>aspirin</i></b> plus <b style='color:Tomato;'><i>heparin</i></b> and extended <b style='color:Tomato;'><i>warfarin</i></b> therapy in preventing periprocedural ischemic events and subsequent stent thrombosis and results in less major and minor bleeding. <b style='color:DodgerBlue;'><i>Dual</i></b> <b style='color:DodgerBlue;'><i>antiplatelet</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>aspirin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>clopidogrel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>preferred</i></b> <b style='color:DodgerBlue;'><i>thienopyridine</i></b> <b style='color:DodgerBlue;'><i>because</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>its</i></b> <b style='color:DodgerBlue;'><i>superior</i></b> <b style='color:DodgerBlue;'><i>hematologic</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>recommended</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>least</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>prevent</i></b> <b style='color:DodgerBlue;'><i>subacute</i></b> <b style='color:DodgerBlue;'><i>stent</i></b> <b style='color:DodgerBlue;'><i>thrombosis</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>bare-metal</i></b> <b style='color:DodgerBlue;'><i>stents</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>prevent</i></b> <b style='color:DodgerBlue;'><i>late-stent</i></b> <b style='color:DodgerBlue;'><i>thrombosis</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>drug-eluting</i></b> <b style='color:DodgerBlue;'><i>stents</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Coronary atherothrombosis is a diffuse vascular disease, and reduction of the risk of future ischemic events requires strategies that extend beyond the focal treatment of stenotic lesions. Optimal long-term care after PCI requires aggressive systemic pharmacotherapy (antiplatelet agents, statins, beta-blockers, and angiotensin-converting enzyme Inhibitors) in conjunction with therapeutic lifestyle changes (smoking cessation, weight reduction, dietary measures, and exercise). In this context, dual antiplatelet therapy (<b style='color:Tomato;'><i>aspirin</i></b> plus <b style='color:Tomato;'><i>clopidogrel</i></b>) is recommended for at least 12 months after PCI for prophylaxis of future atherothrombotic events.","tokens":[{"text":"Dual","start":0,"end":4,"id":0,"ws":true},{"text":"antiplatelet","start":5,"end":17,"id":1,"ws":true},{"text":"therapy","start":18,"end":25,"id":2,"ws":true},{"text":"with","start":26,"end":30,"id":3,"ws":true},{"text":"aspirin","start":31,"end":38,"id":4,"ws":true},{"text":"and","start":39,"end":42,"id":5,"ws":true},{"text":"clopidogrel","start":43,"end":54,"id":6,"ws":true},{"text":"(","start":55,"end":56,"id":7,"ws":true},{"text":"the","start":57,"end":60,"id":8,"ws":true},{"text":"preferred","start":61,"end":70,"id":9,"ws":true},{"text":"thienopyridine","start":71,"end":85,"id":10,"ws":true},{"text":"because","start":86,"end":93,"id":11,"ws":true},{"text":"of","start":94,"end":96,"id":12,"ws":true},{"text":"its","start":97,"end":100,"id":13,"ws":true},{"text":"superior","start":101,"end":109,"id":14,"ws":true},{"text":"hematologic","start":110,"end":121,"id":15,"ws":true},{"text":"safety","start":122,"end":128,"id":16,"ws":true},{"text":")","start":129,"end":130,"id":17,"ws":true},{"text":"is","start":131,"end":133,"id":18,"ws":true},{"text":"recommended","start":134,"end":145,"id":19,"ws":true},{"text":"for","start":146,"end":149,"id":20,"ws":true},{"text":"at","start":150,"end":152,"id":21,"ws":true},{"text":"least","start":153,"end":158,"id":22,"ws":true},{"text":"4","start":159,"end":160,"id":23,"ws":true},{"text":"weeks","start":161,"end":166,"id":24,"ws":true},{"text":"to","start":167,"end":169,"id":25,"ws":true},{"text":"prevent","start":170,"end":177,"id":26,"ws":true},{"text":"subacute","start":178,"end":186,"id":27,"ws":true},{"text":"stent","start":187,"end":192,"id":28,"ws":true},{"text":"thrombosis","start":193,"end":203,"id":29,"ws":true},{"text":"with","start":204,"end":208,"id":30,"ws":true},{"text":"bare-metal","start":209,"end":219,"id":31,"ws":true},{"text":"stents","start":220,"end":226,"id":32,"ws":true},{"text":"and","start":227,"end":230,"id":33,"ws":true},{"text":"3","start":231,"end":232,"id":34,"ws":true},{"text":"to","start":233,"end":235,"id":35,"ws":true},{"text":"6","start":236,"end":237,"id":36,"ws":true},{"text":"months","start":238,"end":244,"id":37,"ws":true},{"text":"to","start":245,"end":247,"id":38,"ws":true},{"text":"prevent","start":248,"end":255,"id":39,"ws":true},{"text":"late-stent","start":256,"end":266,"id":40,"ws":true},{"text":"thrombosis","start":267,"end":277,"id":41,"ws":true},{"text":"with","start":278,"end":282,"id":42,"ws":true},{"text":"drug-eluting","start":283,"end":295,"id":43,"ws":true},{"text":"stents","start":296,"end":302,"id":44,"ws":true},{"text":".","start":303,"end":304,"id":45,"ws":false}],"spans":[{"start":31,"end":38,"token_start":4,"token_end":4,"label":"DRUG"},{"start":43,"end":54,"token_start":6,"token_end":6,"label":"DRUG"}],"_input_hash":1471340217,"_task_hash":-1789027077,"_session_id":"drug_drug_pilot_shared-yuval","_view_id":"blocks","relations":[{"head":4,"child":6,"head_span":{"start":31,"end":38,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":43,"end":54,"token_start":6,"token_end":6,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T1"],"answer":"accept"}
{"text":"Furthermore , in non-metastatic castration-resistant prostate cancer ( M0 CRPC ) , two second-generation anti-androgens , apalutamide and enzalutamide , when used in combination with ADT , have demonstrated a significant benefit in metastasis-free survival .","paragraph":"<h3><u>Recent trends in the management of advanced prostate cancer.</u></h3>Advanced prostate cancer includes a wide spectrum of disease ranging from hormone na\u00efve or hormone sensitive to castration resistant, both containing populations of men who have demonstrable metastatic and non-metastatic states. The mainstay of treatment for metastatic hormone-sensitive prostate cancer is androgen deprivation therapy (ADT). However, recent level 1 evidence demonstrates that the addition of chemotherapy or <b style='color:Tomato;'><i>abiraterone</i></b> acetate to ADT results in significant survival advantage as compared with ADT alone. <b style='color:DodgerBlue;'><i>Furthermore</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>non-metastatic</i></b> <b style='color:DodgerBlue;'><i>castration-resistant</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>M0</i></b> <b style='color:DodgerBlue;'><i>CRPC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>second-generation</i></b> <b style='color:DodgerBlue;'><i>anti-androgens</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>apalutamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>enzalutamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>ADT</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>significant</i></b> <b style='color:DodgerBlue;'><i>benefit</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>metastasis-free</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Here, we review the most recent studies leading to these significant changes in the treatment of advanced prostate cancer.","tokens":[{"text":"Furthermore","start":0,"end":11,"id":0,"ws":true},{"text":",","start":12,"end":13,"id":1,"ws":true},{"text":"in","start":14,"end":16,"id":2,"ws":true},{"text":"non-metastatic","start":17,"end":31,"id":3,"ws":true},{"text":"castration-resistant","start":32,"end":52,"id":4,"ws":true},{"text":"prostate","start":53,"end":61,"id":5,"ws":true},{"text":"cancer","start":62,"end":68,"id":6,"ws":true},{"text":"(","start":69,"end":70,"id":7,"ws":true},{"text":"M0","start":71,"end":73,"id":8,"ws":true},{"text":"CRPC","start":74,"end":78,"id":9,"ws":true},{"text":")","start":79,"end":80,"id":10,"ws":true},{"text":",","start":81,"end":82,"id":11,"ws":true},{"text":"two","start":83,"end":86,"id":12,"ws":true},{"text":"second-generation","start":87,"end":104,"id":13,"ws":true},{"text":"anti-androgens","start":105,"end":119,"id":14,"ws":true},{"text":",","start":120,"end":121,"id":15,"ws":true},{"text":"apalutamide","start":122,"end":133,"id":16,"ws":true},{"text":"and","start":134,"end":137,"id":17,"ws":true},{"text":"enzalutamide","start":138,"end":150,"id":18,"ws":true},{"text":",","start":151,"end":152,"id":19,"ws":true},{"text":"when","start":153,"end":157,"id":20,"ws":true},{"text":"used","start":158,"end":162,"id":21,"ws":true},{"text":"in","start":163,"end":165,"id":22,"ws":true},{"text":"combination","start":166,"end":177,"id":23,"ws":true},{"text":"with","start":178,"end":182,"id":24,"ws":true},{"text":"ADT","start":183,"end":186,"id":25,"ws":true},{"text":",","start":187,"end":188,"id":26,"ws":true},{"text":"have","start":189,"end":193,"id":27,"ws":true},{"text":"demonstrated","start":194,"end":206,"id":28,"ws":true},{"text":"a","start":207,"end":208,"id":29,"ws":true},{"text":"significant","start":209,"end":220,"id":30,"ws":true},{"text":"benefit","start":221,"end":228,"id":31,"ws":true},{"text":"in","start":229,"end":231,"id":32,"ws":true},{"text":"metastasis-free","start":232,"end":247,"id":33,"ws":true},{"text":"survival","start":248,"end":256,"id":34,"ws":true},{"text":".","start":257,"end":258,"id":35,"ws":false}],"spans":[{"start":122,"end":133,"token_start":16,"token_end":16,"label":"DRUG"},{"start":138,"end":150,"token_start":18,"token_end":18,"label":"DRUG"}],"_input_hash":236482726,"_task_hash":-1620523265,"_session_id":"drug_drug_pilot_shared-yuval","_view_id":"blocks","relations":[{"head":16,"child":18,"head_span":{"start":122,"end":133,"token_start":16,"token_end":16,"label":"DRUG"},"child_span":{"start":138,"end":150,"token_start":18,"token_end":18,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":25,"child":18,"head_span":{"start":183,"end":186,"token_start":25,"token_end":25,"label":null},"child_span":{"start":138,"end":150,"token_start":18,"token_end":18,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T0"],"answer":"accept"}
{"text":"A screening method based on liquid chromatography-electrospray mass spectrometry for the simultaneous determination of six corticosteroids ( betamethasone 17-valerate BM 17-V , beclomethasone BC , beclomethasone dipropionate BCDP , methylprednisolone MP , budesonide BD , flunisolide FN ) was developed in order to control their illegal use in cosmetic and natural products .","paragraph":"<h3><u>LC-MS method for the simultaneous determination of six glucocorticoids in pharmaceutical formulations and counterfeit cosmetic products.</u></h3> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>screening</i></b> <b style='color:DodgerBlue;'><i>method</i></b> <b style='color:DodgerBlue;'><i>based</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>liquid</i></b> <b style='color:DodgerBlue;'><i>chromatography-electrospray</i></b> <b style='color:DodgerBlue;'><i>mass</i></b> <b style='color:DodgerBlue;'><i>spectrometry</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>simultaneous</i></b> <b style='color:DodgerBlue;'><i>determination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>six</i></b> <b style='color:DodgerBlue;'><i>corticosteroids</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>betamethasone</i></b> <b style='color:DodgerBlue;'><i>17-valerate</i></b> <b style='color:DodgerBlue;'><i>BM</i></b> <b style='color:DodgerBlue;'><i>17-V</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>beclomethasone</i></b> <b style='color:DodgerBlue;'><i>BC</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>beclomethasone</i></b> <b style='color:DodgerBlue;'><i>dipropionate</i></b> <b style='color:DodgerBlue;'><i>BCDP</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>methylprednisolone</i></b> <b style='color:DodgerBlue;'><i>MP</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>budesonide</i></b> <b style='color:DodgerBlue;'><i>BD</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>flunisolide</i></b> <b style='color:DodgerBlue;'><i>FN</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>developed</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>order</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>control</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>illegal</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>cosmetic</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>natural</i></b> <b style='color:DodgerBlue;'><i>products</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Indeed, despite corticosteroids are banned in cosmetics, counterfeit products might be present on the market, representing a health hazard. Therefore, effective analytical methods are required to rapidly screen over the counter products in health care shops for counterfeit corticosteroids. The analytical method involves the employment of a Waters Synergy C18 column (150mm\u00d72.0mm I.D.) by using the following mobile phase: A (0.1% formic acid in acetonitrile), B (0.1% formic acid in water) in a linear gradient (from A-B 25:75, v/v to A-B 95:5, v/v in 30min) at the flow rate of 0.3mL/min. The detection was performed with an ion trap (IT) mass spectrometer in positive polarity, total ion current (TIC) and tandem mass modalities for qualitative purpose; single ion monitoring (SIM) mode was used for quantitative analysis on the ESI generated most abundant ion for each steroid. The method was fully validated in terms of precision, detection and quantification limits, linearity, recovery, and it was applied to the identification and quantification of corticosteroids in pharmaceutical formulations and cosmetic products. The mean recovery of BM 17-V, BC, BCDP, MP, BD and FN were found to be 101.3, 101.5, 98.8, 98.9, 98.1, 99.0%, respectively. Limits of quantitation (LOQ) were comprised in the range 29-95ng/mL. To the best of our knowledge, for the first time this mix of glucocorticoids were simultaneously determined in cosmetic products by using a fully validated method. BMV, in its two isomeric forms BM 17-V and BM 21-V, was found to be illegally present in one cream sample (A) with the total concentration level of 0.036% (w/w). ","tokens":[{"text":"A","start":0,"end":1,"id":0,"ws":true},{"text":"screening","start":2,"end":11,"id":1,"ws":true},{"text":"method","start":12,"end":18,"id":2,"ws":true},{"text":"based","start":19,"end":24,"id":3,"ws":true},{"text":"on","start":25,"end":27,"id":4,"ws":true},{"text":"liquid","start":28,"end":34,"id":5,"ws":true},{"text":"chromatography-electrospray","start":35,"end":62,"id":6,"ws":true},{"text":"mass","start":63,"end":67,"id":7,"ws":true},{"text":"spectrometry","start":68,"end":80,"id":8,"ws":true},{"text":"for","start":81,"end":84,"id":9,"ws":true},{"text":"the","start":85,"end":88,"id":10,"ws":true},{"text":"simultaneous","start":89,"end":101,"id":11,"ws":true},{"text":"determination","start":102,"end":115,"id":12,"ws":true},{"text":"of","start":116,"end":118,"id":13,"ws":true},{"text":"six","start":119,"end":122,"id":14,"ws":true},{"text":"corticosteroids","start":123,"end":138,"id":15,"ws":true},{"text":"(","start":139,"end":140,"id":16,"ws":true},{"text":"betamethasone","start":141,"end":154,"id":17,"ws":true},{"text":"17-valerate","start":155,"end":166,"id":18,"ws":true},{"text":"BM","start":167,"end":169,"id":19,"ws":true},{"text":"17-V","start":170,"end":174,"id":20,"ws":true},{"text":",","start":175,"end":176,"id":21,"ws":true},{"text":"beclomethasone","start":177,"end":191,"id":22,"ws":true},{"text":"BC","start":192,"end":194,"id":23,"ws":true},{"text":",","start":195,"end":196,"id":24,"ws":true},{"text":"beclomethasone","start":197,"end":211,"id":25,"ws":true},{"text":"dipropionate","start":212,"end":224,"id":26,"ws":true},{"text":"BCDP","start":225,"end":229,"id":27,"ws":true},{"text":",","start":230,"end":231,"id":28,"ws":true},{"text":"methylprednisolone","start":232,"end":250,"id":29,"ws":true},{"text":"MP","start":251,"end":253,"id":30,"ws":true},{"text":",","start":254,"end":255,"id":31,"ws":true},{"text":"budesonide","start":256,"end":266,"id":32,"ws":true},{"text":"BD","start":267,"end":269,"id":33,"ws":true},{"text":",","start":270,"end":271,"id":34,"ws":true},{"text":"flunisolide","start":272,"end":283,"id":35,"ws":true},{"text":"FN","start":284,"end":286,"id":36,"ws":true},{"text":")","start":287,"end":288,"id":37,"ws":true},{"text":"was","start":289,"end":292,"id":38,"ws":true},{"text":"developed","start":293,"end":302,"id":39,"ws":true},{"text":"in","start":303,"end":305,"id":40,"ws":true},{"text":"order","start":306,"end":311,"id":41,"ws":true},{"text":"to","start":312,"end":314,"id":42,"ws":true},{"text":"control","start":315,"end":322,"id":43,"ws":true},{"text":"their","start":323,"end":328,"id":44,"ws":true},{"text":"illegal","start":329,"end":336,"id":45,"ws":true},{"text":"use","start":337,"end":340,"id":46,"ws":true},{"text":"in","start":341,"end":343,"id":47,"ws":true},{"text":"cosmetic","start":344,"end":352,"id":48,"ws":true},{"text":"and","start":353,"end":356,"id":49,"ws":true},{"text":"natural","start":357,"end":364,"id":50,"ws":true},{"text":"products","start":365,"end":373,"id":51,"ws":true},{"text":".","start":374,"end":375,"id":52,"ws":false}],"spans":[{"start":141,"end":154,"token_start":17,"token_end":17,"label":"DRUG"},{"start":177,"end":191,"token_start":22,"token_end":22,"label":"DRUG"},{"start":197,"end":211,"token_start":25,"token_end":25,"label":"DRUG"},{"start":232,"end":250,"token_start":29,"token_end":29,"label":"DRUG"},{"start":256,"end":266,"token_start":32,"token_end":32,"label":"DRUG"}],"_input_hash":782553464,"_task_hash":-1744775723,"_session_id":"drug_drug_pilot_shared-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"We used MCF-7 and MDA-MB231 breast cancer cells incubated with Curcumin and Quercetin for 24h , in the absence and presence of Somatostatin , at their EC50 concentrations , to evaluate membrane fatty acid-based functional lipidomics together with the follow-up of EGFR and MAPK signaling pathways .","paragraph":"<h3><u>Effects of Somatostatin, Curcumin and Quercetin on the fatty acid profile of breast cancer cell membranes.</u></h3> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>MCF-7</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>MDA-MB231</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>incubated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>Curcumin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Quercetin</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>24h</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>absence</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>presence</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>Somatostatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>EC50</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>membrane</i></b> <b style='color:DodgerBlue;'><i>fatty</i></b> <b style='color:DodgerBlue;'><i>acid-based</i></b> <b style='color:DodgerBlue;'><i>functional</i></b> <b style='color:DodgerBlue;'><i>lipidomics</i></b> <b style='color:DodgerBlue;'><i>together</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>follow-up</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>EGFR</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>MAPK</i></b> <b style='color:DodgerBlue;'><i>signaling</i></b> <b style='color:DodgerBlue;'><i>pathways</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The two cell lines gave different membrane free fatty acid reorganization: in MCF-7 cells, the following changes observed: increase of omega-6 linoleic acid in the cells incubated with <b style='color:Tomato;'><i>somatostatin</i></b>+Quercetin and Quercetin and decrease of omega-3 acids in the cells incubated with <b style='color:Tomato;'><i>somatostatin</i></b>+<b style='color:Tomato;'><i>curcumin</i></b> compared to <b style='color:Tomato;'><i>somatostatin</i></b>, and significant increases of monounsaturated fatty acid (MUFA), mono-trans arachidonic acid levels and docosapentaenoic acid for the cells incubated with <b style='color:Tomato;'><i>somatostatin</i></b>+Quercetin compared to the control cells. In MDA-MB231 cells, incubations with <b style='color:Tomato;'><i>curcumin</i></b>, Quercetin and <b style='color:Tomato;'><i>somatostatin</i></b>+Quercetin induced the most significant membrane remodeling with the increase of stearic acid, diminution of omega-6 linoleic, arachidonic acids and omega-3 (docosapentaenoic and docosahexaenoic acids). Distinct signaling pathway changes were found for these cell lines. In MCF-7 cells, separate or combined incubations with <b style='color:Tomato;'><i>somatostatin</i></b> and Quercetin, significantly decreased EGFR and incubation with <b style='color:Tomato;'><i>curcumin</i></b> decreased MAPK signaling. In MDA-MB231 cells, incubation with <b style='color:Tomato;'><i>curcumin</i></b> decreased AKT1 and p-AKT1(Thr308) levels. Incubation with <b style='color:Tomato;'><i>curcumin</i></b> and Quercetin decreased the EGFR levels.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"used","start":3,"end":7,"id":1,"ws":true},{"text":"MCF-7","start":8,"end":13,"id":2,"ws":true},{"text":"and","start":14,"end":17,"id":3,"ws":true},{"text":"MDA-MB231","start":18,"end":27,"id":4,"ws":true},{"text":"breast","start":28,"end":34,"id":5,"ws":true},{"text":"cancer","start":35,"end":41,"id":6,"ws":true},{"text":"cells","start":42,"end":47,"id":7,"ws":true},{"text":"incubated","start":48,"end":57,"id":8,"ws":true},{"text":"with","start":58,"end":62,"id":9,"ws":true},{"text":"Curcumin","start":63,"end":71,"id":10,"ws":true},{"text":"and","start":72,"end":75,"id":11,"ws":true},{"text":"Quercetin","start":76,"end":85,"id":12,"ws":true},{"text":"for","start":86,"end":89,"id":13,"ws":true},{"text":"24h","start":90,"end":93,"id":14,"ws":true},{"text":",","start":94,"end":95,"id":15,"ws":true},{"text":"in","start":96,"end":98,"id":16,"ws":true},{"text":"the","start":99,"end":102,"id":17,"ws":true},{"text":"absence","start":103,"end":110,"id":18,"ws":true},{"text":"and","start":111,"end":114,"id":19,"ws":true},{"text":"presence","start":115,"end":123,"id":20,"ws":true},{"text":"of","start":124,"end":126,"id":21,"ws":true},{"text":"Somatostatin","start":127,"end":139,"id":22,"ws":true},{"text":",","start":140,"end":141,"id":23,"ws":true},{"text":"at","start":142,"end":144,"id":24,"ws":true},{"text":"their","start":145,"end":150,"id":25,"ws":true},{"text":"EC50","start":151,"end":155,"id":26,"ws":true},{"text":"concentrations","start":156,"end":170,"id":27,"ws":true},{"text":",","start":171,"end":172,"id":28,"ws":true},{"text":"to","start":173,"end":175,"id":29,"ws":true},{"text":"evaluate","start":176,"end":184,"id":30,"ws":true},{"text":"membrane","start":185,"end":193,"id":31,"ws":true},{"text":"fatty","start":194,"end":199,"id":32,"ws":true},{"text":"acid-based","start":200,"end":210,"id":33,"ws":true},{"text":"functional","start":211,"end":221,"id":34,"ws":true},{"text":"lipidomics","start":222,"end":232,"id":35,"ws":true},{"text":"together","start":233,"end":241,"id":36,"ws":true},{"text":"with","start":242,"end":246,"id":37,"ws":true},{"text":"the","start":247,"end":250,"id":38,"ws":true},{"text":"follow-up","start":251,"end":260,"id":39,"ws":true},{"text":"of","start":261,"end":263,"id":40,"ws":true},{"text":"EGFR","start":264,"end":268,"id":41,"ws":true},{"text":"and","start":269,"end":272,"id":42,"ws":true},{"text":"MAPK","start":273,"end":277,"id":43,"ws":true},{"text":"signaling","start":278,"end":287,"id":44,"ws":true},{"text":"pathways","start":288,"end":296,"id":45,"ws":true},{"text":".","start":297,"end":298,"id":46,"ws":false}],"spans":[{"start":63,"end":71,"token_start":10,"token_end":10,"label":"DRUG"},{"start":127,"end":139,"token_start":22,"token_end":22,"label":"DRUG"}],"_input_hash":-1803484576,"_task_hash":288010961,"_session_id":"drug_drug_pilot_shared-yuval","_view_id":"blocks","relations":[{"head":10,"child":12,"head_span":{"start":63,"end":71,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":76,"end":85,"token_start":12,"token_end":12,"label":null},"color":"#96e8ce","label":"COMB1"},{"head":10,"child":12,"head_span":{"start":63,"end":71,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":76,"end":85,"token_start":12,"token_end":12,"label":null},"color":"#ffd1b2","label":"COMB2"},{"head":22,"child":12,"head_span":{"start":127,"end":139,"token_start":22,"token_end":22,"label":"DRUG"},"child_span":{"start":76,"end":85,"token_start":12,"token_end":12,"label":null},"color":"#ffd1b2","label":"COMB2"}],"radio":["COMB1T1","COMB2T1"],"answer":"accept"}
{"text":"Following corneal scrapings and culture , topical 0.5 % moxifloxacin and 0.5 % tobramycin were administered hourly .","paragraph":"<h3><u>A case of Stenotrophomonas maltophilia keratitis effectively treated with moxifloxacin.</u></h3>A 70-year-old man with a long history of diabetes mellitus presented to our hospital (Department of Ophthalmology, Sahm Yook Medical Center, Seoul, Korea) complaining of severe ocular pain and visual disturbance in his left eye that had started three days prior to admission. A round 3.7 \u00d7 5.0 mm dense central stromal infiltrate with an overlying epithelial defect was noted on slit-lamp examination. <b style='color:DodgerBlue;'><i>Following</i></b> <b style='color:DodgerBlue;'><i>corneal</i></b> <b style='color:DodgerBlue;'><i>scrapings</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>culture</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>topical</i></b> <b style='color:DodgerBlue;'><i>0.5</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:MediumOrchid;'><i>moxifloxacin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>0.5</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:MediumOrchid;'><i>tobramycin</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>hourly</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A few days later, Stenotrophomonas maltophilia was isolated in a bacterial culture from a corneal specimen. According to the results of susceptibility tests, topical 0.5% <b style='color:Tomato;'><i>moxifloxacin</i></b> was given every hour and 0.5% <b style='color:Tomato;'><i>tobramycin</i></b> was stopped. The patient's clinical features improved steadily with treatment. The corneal epithelium healed rapidly, and the infiltrate resolved within four weeks of the initiation of treatment. The patient's best corrected visual acuity improved from hand motion to 20 / 25.","tokens":[{"text":"Following","start":0,"end":9,"id":0,"ws":true},{"text":"corneal","start":10,"end":17,"id":1,"ws":true},{"text":"scrapings","start":18,"end":27,"id":2,"ws":true},{"text":"and","start":28,"end":31,"id":3,"ws":true},{"text":"culture","start":32,"end":39,"id":4,"ws":true},{"text":",","start":40,"end":41,"id":5,"ws":true},{"text":"topical","start":42,"end":49,"id":6,"ws":true},{"text":"0.5","start":50,"end":53,"id":7,"ws":true},{"text":"%","start":54,"end":55,"id":8,"ws":true},{"text":"moxifloxacin","start":56,"end":68,"id":9,"ws":true},{"text":"and","start":69,"end":72,"id":10,"ws":true},{"text":"0.5","start":73,"end":76,"id":11,"ws":true},{"text":"%","start":77,"end":78,"id":12,"ws":true},{"text":"tobramycin","start":79,"end":89,"id":13,"ws":true},{"text":"were","start":90,"end":94,"id":14,"ws":true},{"text":"administered","start":95,"end":107,"id":15,"ws":true},{"text":"hourly","start":108,"end":114,"id":16,"ws":true},{"text":".","start":115,"end":116,"id":17,"ws":false}],"spans":[{"start":56,"end":68,"token_start":9,"token_end":9,"label":"DRUG"},{"start":79,"end":89,"token_start":13,"token_end":13,"label":"DRUG"}],"_input_hash":1332991430,"_task_hash":1426603318,"_session_id":"drug_drug_pilot_shared-yuval","_view_id":"blocks","relations":[{"head":9,"child":13,"head_span":{"start":56,"end":68,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":79,"end":89,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T1"],"answer":"accept"}
{"text":"Combination treatment with cetuximab and nystatin selectively increased cetuximab uptake by tumor tissues , translating into potentiated antitumor efficacy of cetuximab in vivo ( A431 and A549 tumors ) .","paragraph":"<h3><u>Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration.</u></h3><b style='color:Tomato;'><i>cetuximab</i></b>, a monoclonal antibody (mAb) targeting the epidermal growth factor receptor (EGFR), has been intensively investigated as a promising cancer treatment strategy. The specific mechanism of <b style='color:Tomato;'><i>cetuximab</i></b> endocytosis and its influence on <b style='color:Tomato;'><i>cetuximab</i></b> uptake, biodistribution and efficacy still remain elusive. Recently, statins have been reported to synergize with EGFR-targeting agents. Our prior work established that <b style='color:Tomato;'><i>nystatin</i></b>, a cholesterol-sequestering antifungal drug, facilitates endocytosis via the clathrin-dependent pathway. This study aimed to investigate whether <b style='color:Tomato;'><i>nystatin</i></b> regulates the uptake and efficacy of <b style='color:Tomato;'><i>cetuximab</i></b> and <b style='color:Tomato;'><i>cetuximab</i></b>-based antibody-drug conjugates (<b style='color:Tomato;'><i>cetuximab</i></b>-ADCs). In vitro and in vivo efficacies of <b style='color:Tomato;'><i>nystatin</i></b> on the uptake and activity of <b style='color:Tomato;'><i>cetuximab</i></b>/<b style='color:Tomato;'><i>cetuximab</i></b>-ADCs were studied in multiple human carcinoma cell lines and xenograft models, respectively. We identified that cholesterol sequestration by <b style='color:Tomato;'><i>nystatin</i></b> enhanced <b style='color:Tomato;'><i>cetuximab</i></b> internalization in EGFR-positive carcinoma cells by regulating EGFR trafficking/turnover and facilitating a switch from lipid rafts to clathrin-mediated endocytosis. <b style='color:DodgerBlue;'><i>Combination</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>nystatin</i></b> <b style='color:DodgerBlue;'><i>selectively</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>uptake</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>tumor</i></b> <b style='color:DodgerBlue;'><i>tissues</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>translating</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>potentiated</i></b> <b style='color:DodgerBlue;'><i>antitumor</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vivo</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>A431</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>A549</i></b> <b style='color:DodgerBlue;'><i>tumors</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>nystatin</i></b>-enhanced internalization of <b style='color:Tomato;'><i>cetuximab</i></b> further improved the uptake and potency of <b style='color:Tomato;'><i>cetuximab</i></b>-<b style='color:Tomato;'><i>doxorubicin</i></b> and <b style='color:Tomato;'><i>cetuximab</i></b>-<b style='color:Tomato;'><i>methotrexate</i></b> conjugates in EGFR-positive <b style='color:Tomato;'><i>cetuximab</i></b>-resistant tumors. Combination therapy with <b style='color:Tomato;'><i>nystatin</i></b> plus either <b style='color:Tomato;'><i>cetuximab</i></b> or <b style='color:Tomato;'><i>cetuximab</i></b>-ADC further prolonged animal survival and significantly suppressed tumor growth, as compared with single-agent <b style='color:Tomato;'><i>cetuximab</i></b> or <b style='color:Tomato;'><i>cetuximab</i></b>-ADC. In summary, our results identify a novel mechanism whereby cholesterol sequestration enhances the uptake of EGFR-targeting mAb and ADCs, therefore providing preclinical proof-of-concept that combination with <b style='color:Tomato;'><i>nystatin</i></b> can potentiate the delivery and efficacy of these EGFR-targeted agents. ","tokens":[{"text":"Combination","start":0,"end":11,"id":0,"ws":true},{"text":"treatment","start":12,"end":21,"id":1,"ws":true},{"text":"with","start":22,"end":26,"id":2,"ws":true},{"text":"cetuximab","start":27,"end":36,"id":3,"ws":true},{"text":"and","start":37,"end":40,"id":4,"ws":true},{"text":"nystatin","start":41,"end":49,"id":5,"ws":true},{"text":"selectively","start":50,"end":61,"id":6,"ws":true},{"text":"increased","start":62,"end":71,"id":7,"ws":true},{"text":"cetuximab","start":72,"end":81,"id":8,"ws":true},{"text":"uptake","start":82,"end":88,"id":9,"ws":true},{"text":"by","start":89,"end":91,"id":10,"ws":true},{"text":"tumor","start":92,"end":97,"id":11,"ws":true},{"text":"tissues","start":98,"end":105,"id":12,"ws":true},{"text":",","start":106,"end":107,"id":13,"ws":true},{"text":"translating","start":108,"end":119,"id":14,"ws":true},{"text":"into","start":120,"end":124,"id":15,"ws":true},{"text":"potentiated","start":125,"end":136,"id":16,"ws":true},{"text":"antitumor","start":137,"end":146,"id":17,"ws":true},{"text":"efficacy","start":147,"end":155,"id":18,"ws":true},{"text":"of","start":156,"end":158,"id":19,"ws":true},{"text":"cetuximab","start":159,"end":168,"id":20,"ws":true},{"text":"in","start":169,"end":171,"id":21,"ws":true},{"text":"vivo","start":172,"end":176,"id":22,"ws":true},{"text":"(","start":177,"end":178,"id":23,"ws":true},{"text":"A431","start":179,"end":183,"id":24,"ws":true},{"text":"and","start":184,"end":187,"id":25,"ws":true},{"text":"A549","start":188,"end":192,"id":26,"ws":true},{"text":"tumors","start":193,"end":199,"id":27,"ws":true},{"text":")","start":200,"end":201,"id":28,"ws":true},{"text":".","start":202,"end":203,"id":29,"ws":false}],"spans":[{"start":27,"end":36,"token_start":3,"token_end":3,"label":"DRUG"},{"start":41,"end":49,"token_start":5,"token_end":5,"label":"DRUG"},{"start":72,"end":81,"token_start":8,"token_end":8,"label":"DRUG"},{"start":159,"end":168,"token_start":20,"token_end":20,"label":"DRUG"}],"_input_hash":-1277491604,"_task_hash":-1965461189,"_session_id":"drug_drug_pilot_shared-yuval","_view_id":"blocks","relations":[{"head":3,"child":5,"head_span":{"start":27,"end":36,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":41,"end":49,"token_start":5,"token_end":5,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T0"],"answer":"accept"}
{"text":"However , anastrozole , exemestane and letrozole are associated with significantly fewer endometrial cancers , as well as venous and arterial vascular events , when compared with tamoxifen [ 9 , 10 ] .","paragraph":"<h3><u>Erythema nodosum secondary to aromatase inhibitor use in breast cancer patients: case reports and review of the literature.</u></h3>Aromatase inhibitors (AI's) are increasingly being incorporated in the treatment strategy for hormone receptor positive breast cancer either alone or in combination with chemotherapy, biologics in both the adjuvant and metastatic setting [1]. They markedly suppress plasma estrogen levels by inhibiting or inactivating aromatase, the enzyme responsible for the synthesis of estrogens from androgenic substrates [1]. Currently, the three selective aromatase inhibitors that are available are <b style='color:Tomato;'><i>anastrozole</i></b>, <b style='color:Tomato;'><i>letrozole</i></b> and <b style='color:Tomato;'><i>exemestane</i></b> which reduce circulating estrogen to 1 to 10% of pretreatment levels [2]. For advanced breast cancer, aromatase inhibitors appear to be at a minimum, equivalent and perhaps even better than <b style='color:Tomato;'><i>tamoxifen</i></b> in the first line setting [3, 4]. In primary breast cancer, adjuvant therapy with <b style='color:Tomato;'><i>anastrozole</i></b> or <b style='color:Tomato;'><i>letrozole</i></b> appears to be superior to <b style='color:Tomato;'><i>tamoxifen</i></b> in reducing the risk of relapse [5, 6]. Common adverse effects associated with AI's include arthralgias (21%), myalgias (12%), other musculoskeletal disorders (28%) and an up to 60% increased risk of bone fracture [7, 8]. <b style='color:DodgerBlue;'><i>However</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>anastrozole</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>exemestane</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>letrozole</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>fewer</i></b> <b style='color:DodgerBlue;'><i>endometrial</i></b> <b style='color:DodgerBlue;'><i>cancers</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>venous</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>arterial</i></b> <b style='color:DodgerBlue;'><i>vascular</i></b> <b style='color:DodgerBlue;'><i>events</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>9</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Very rarely <b style='color:Tomato;'><i>letrozole</i></b> and <b style='color:Tomato;'><i>anastrozole</i></b> can cause a skin rash; the frequency of its occurrence has not been quantified(. )However, <b style='color:Tomato;'><i>exemestane</i></b> has not been reported to cause a skin rash [11]. To date, erythema nodosum (EN) has not been reported as a dermatologic side effect of AI's. Here, we report three cases of EN which developed in postmenopausal breast cancer patients on AI's.","tokens":[{"text":"However","start":0,"end":7,"id":0,"ws":true},{"text":",","start":8,"end":9,"id":1,"ws":true},{"text":"anastrozole","start":10,"end":21,"id":2,"ws":true},{"text":",","start":22,"end":23,"id":3,"ws":true},{"text":"exemestane","start":24,"end":34,"id":4,"ws":true},{"text":"and","start":35,"end":38,"id":5,"ws":true},{"text":"letrozole","start":39,"end":48,"id":6,"ws":true},{"text":"are","start":49,"end":52,"id":7,"ws":true},{"text":"associated","start":53,"end":63,"id":8,"ws":true},{"text":"with","start":64,"end":68,"id":9,"ws":true},{"text":"significantly","start":69,"end":82,"id":10,"ws":true},{"text":"fewer","start":83,"end":88,"id":11,"ws":true},{"text":"endometrial","start":89,"end":100,"id":12,"ws":true},{"text":"cancers","start":101,"end":108,"id":13,"ws":true},{"text":",","start":109,"end":110,"id":14,"ws":true},{"text":"as","start":111,"end":113,"id":15,"ws":true},{"text":"well","start":114,"end":118,"id":16,"ws":true},{"text":"as","start":119,"end":121,"id":17,"ws":true},{"text":"venous","start":122,"end":128,"id":18,"ws":true},{"text":"and","start":129,"end":132,"id":19,"ws":true},{"text":"arterial","start":133,"end":141,"id":20,"ws":true},{"text":"vascular","start":142,"end":150,"id":21,"ws":true},{"text":"events","start":151,"end":157,"id":22,"ws":true},{"text":",","start":158,"end":159,"id":23,"ws":true},{"text":"when","start":160,"end":164,"id":24,"ws":true},{"text":"compared","start":165,"end":173,"id":25,"ws":true},{"text":"with","start":174,"end":178,"id":26,"ws":true},{"text":"tamoxifen","start":179,"end":188,"id":27,"ws":true},{"text":"[","start":189,"end":190,"id":28,"ws":true},{"text":"9","start":191,"end":192,"id":29,"ws":true},{"text":",","start":193,"end":194,"id":30,"ws":true},{"text":"10","start":195,"end":197,"id":31,"ws":true},{"text":"]","start":198,"end":199,"id":32,"ws":true},{"text":".","start":200,"end":201,"id":33,"ws":false}],"spans":[{"start":10,"end":21,"token_start":2,"token_end":2,"label":"DRUG"},{"start":24,"end":34,"token_start":4,"token_end":4,"label":"DRUG"},{"start":39,"end":48,"token_start":6,"token_end":6,"label":"DRUG"},{"start":179,"end":188,"token_start":27,"token_end":27,"label":"DRUG"}],"_input_hash":155070717,"_task_hash":-411756935,"_session_id":"drug_drug_pilot_shared-dana_n","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Additivity , synergy , or competition was observed with MIS and rapamycin , AzadC , doxorubicin , cisplatin , and paclitaxel , suggesting that MIS in combination with selective targeted therapies might achieve greater activity against ovarian cancer than the use of each individual agent alone .","paragraph":"<h3><u>Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.</u></h3>Mullerian Inhibiting Substance (MIS), a biological modifier that causes regression of Mullerian ducts in male embryos, is effective as a single agent in vitro and in vivo against human and mouse ovarian cancer cell lines expressing MIS type II receptor; however, little is known about how recombinant human MIS (rhMIS), now being scaled for preclinical trials, could be used in combination with cytotoxic or targeted chemotherapeutic agents. Mouse serous and endometrioid ovarian carcinoma cell lines were tested in vitro against rhMIS alone and with <b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>paclitaxel</i></b>, or cisplatin as agents in clinical use. Because MIS releases FK506 binding protein (FKBP12), which activates the mammalian target of <b style='color:Tomato;'><i>rapamycin</i></b> (mTOR) downstream of Akt, rhMIS and <b style='color:Tomato;'><i>rapamycin</i></b> combinations were tested. MIS increases p16 protein levels, and 5'-Aza-2'-deoxycytidine (AzadC) induces p16 mRNA; therefore, they were used in combination in vitro and in vivo with a human ovarian cancer cell line. A <b style='color:Tomato;'><i>paclitaxel</i></b>-resistant human ovarian cancer cell line and its parental line both respond to rhMIS in vitro. <b style='color:DodgerBlue;'><i>Additivity</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>synergy</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>competition</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>observed</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>MIS</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rapamycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>AzadC</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>suggesting</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>MIS</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>selective</i></b> <b style='color:DodgerBlue;'><i>targeted</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>might</i></b> <b style='color:DodgerBlue;'><i>achieve</i></b> <b style='color:DodgerBlue;'><i>greater</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>ovarian</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>each</i></b> <b style='color:DodgerBlue;'><i>individual</i></b> <b style='color:DodgerBlue;'><i>agent</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> These assays and statistical analyses could be useful in selecting rhMIS and chemotherapeutic agent combinations that enhance clinical efficacy and reduce toxicity.","tokens":[{"text":"Additivity","start":0,"end":10,"id":0,"ws":true},{"text":",","start":11,"end":12,"id":1,"ws":true},{"text":"synergy","start":13,"end":20,"id":2,"ws":true},{"text":",","start":21,"end":22,"id":3,"ws":true},{"text":"or","start":23,"end":25,"id":4,"ws":true},{"text":"competition","start":26,"end":37,"id":5,"ws":true},{"text":"was","start":38,"end":41,"id":6,"ws":true},{"text":"observed","start":42,"end":50,"id":7,"ws":true},{"text":"with","start":51,"end":55,"id":8,"ws":true},{"text":"MIS","start":56,"end":59,"id":9,"ws":true},{"text":"and","start":60,"end":63,"id":10,"ws":true},{"text":"rapamycin","start":64,"end":73,"id":11,"ws":true},{"text":",","start":74,"end":75,"id":12,"ws":true},{"text":"AzadC","start":76,"end":81,"id":13,"ws":true},{"text":",","start":82,"end":83,"id":14,"ws":true},{"text":"doxorubicin","start":84,"end":95,"id":15,"ws":true},{"text":",","start":96,"end":97,"id":16,"ws":true},{"text":"cisplatin","start":98,"end":107,"id":17,"ws":true},{"text":",","start":108,"end":109,"id":18,"ws":true},{"text":"and","start":110,"end":113,"id":19,"ws":true},{"text":"paclitaxel","start":114,"end":124,"id":20,"ws":true},{"text":",","start":125,"end":126,"id":21,"ws":true},{"text":"suggesting","start":127,"end":137,"id":22,"ws":true},{"text":"that","start":138,"end":142,"id":23,"ws":true},{"text":"MIS","start":143,"end":146,"id":24,"ws":true},{"text":"in","start":147,"end":149,"id":25,"ws":true},{"text":"combination","start":150,"end":161,"id":26,"ws":true},{"text":"with","start":162,"end":166,"id":27,"ws":true},{"text":"selective","start":167,"end":176,"id":28,"ws":true},{"text":"targeted","start":177,"end":185,"id":29,"ws":true},{"text":"therapies","start":186,"end":195,"id":30,"ws":true},{"text":"might","start":196,"end":201,"id":31,"ws":true},{"text":"achieve","start":202,"end":209,"id":32,"ws":true},{"text":"greater","start":210,"end":217,"id":33,"ws":true},{"text":"activity","start":218,"end":226,"id":34,"ws":true},{"text":"against","start":227,"end":234,"id":35,"ws":true},{"text":"ovarian","start":235,"end":242,"id":36,"ws":true},{"text":"cancer","start":243,"end":249,"id":37,"ws":true},{"text":"than","start":250,"end":254,"id":38,"ws":true},{"text":"the","start":255,"end":258,"id":39,"ws":true},{"text":"use","start":259,"end":262,"id":40,"ws":true},{"text":"of","start":263,"end":265,"id":41,"ws":true},{"text":"each","start":266,"end":270,"id":42,"ws":true},{"text":"individual","start":271,"end":281,"id":43,"ws":true},{"text":"agent","start":282,"end":287,"id":44,"ws":true},{"text":"alone","start":288,"end":293,"id":45,"ws":true},{"text":".","start":294,"end":295,"id":46,"ws":false}],"spans":[{"start":64,"end":73,"token_start":11,"token_end":11,"label":"DRUG"},{"start":84,"end":95,"token_start":15,"token_end":15,"label":"DRUG"},{"start":114,"end":124,"token_start":20,"token_end":20,"label":"DRUG"}],"_input_hash":1387497584,"_task_hash":991977050,"_session_id":"drug_drug_pilot_shared-dana_n","_view_id":"blocks","relations":[{"head":11,"child":15,"head_span":{"start":64,"end":73,"token_start":11,"token_end":11,"label":"DRUG"},"child_span":{"start":84,"end":95,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":15,"child":17,"head_span":{"start":84,"end":95,"token_start":15,"token_end":15,"label":"DRUG"},"child_span":{"start":98,"end":107,"token_start":17,"token_end":17,"label":null},"color":"#c5bdf4","label":"POS1"},{"head":20,"child":17,"head_span":{"start":114,"end":124,"token_start":20,"token_end":20,"label":"DRUG"},"child_span":{"start":98,"end":107,"token_start":17,"token_end":17,"label":null},"color":"#c5bdf4","label":"POS1"}],"answer":"accept","radio":["POS10","POS1T0"]}
{"text":"The effects of combination therapy with chenodeoxycholic acid ( CDCA ) and simvastatin on serum cholestanol , low-density lipoprotein ( LDL ) cholesterol , and lathosterol levels were investigated in seven adult patients with cerebrotendinous xanthomatosis ( CTX ) who were on long-term treatment with CDCA .","paragraph":"<h3><u>Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>chenodeoxycholic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CDCA</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>simvastatin</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>serum</i></b> <b style='color:DodgerBlue;'><i>cholestanol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>low-density</i></b> <b style='color:DodgerBlue;'><i>lipoprotein</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>LDL</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>cholesterol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>lathosterol</i></b> <b style='color:DodgerBlue;'><i>levels</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>investigated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>seven</i></b> <b style='color:DodgerBlue;'><i>adult</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>cerebrotendinous</i></b> <b style='color:DodgerBlue;'><i>xanthomatosis</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CTX</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>long-term</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>CDCA</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The patients were treated with a combination of CDCA 750 mg daily and an increasing dose of <b style='color:Tomato;'><i>simvastatin</i></b> from 10 mg to 40 mg daily for a period of 6 months. We found a significant effect of this combination therapy compared with CDCA alone in terms of decreasing the serum cholestanol and LDL cholesterol levels, particularly with a daily dose of 40 mg <b style='color:Tomato;'><i>simvastatin</i></b>. The mean cholestanol level decreased from 9.27 micromol/L (baseline) to 6.69 micromol/L (40 mg <b style='color:Tomato;'><i>simvastatin</i></b>), while the mean LDL cholesterol level decreased from 5.08 mmol/L (baseline) to 3.04 mmol/L (40 mg <b style='color:Tomato;'><i>simvastatin</i></b>). No side effects were reported, and there were no effects on the clinical condition, cerebral magnetic resonance imaging (MRI), visual evoked potentials, and electroencephalographic features. We conclude that a combination of 750 mg CDCA and 40 mg <b style='color:Tomato;'><i>simvastatin</i></b> daily is effective to further reduce serum cholestanol, LDL cholesterol, and lathosterol in adult CTX patients treated with long-term CDCA. Whether this combination treatment will be effective for the long-term prevention of neurological deterioration and atherosclerosis remains to be established.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"effects","start":4,"end":11,"id":1,"ws":true},{"text":"of","start":12,"end":14,"id":2,"ws":true},{"text":"combination","start":15,"end":26,"id":3,"ws":true},{"text":"therapy","start":27,"end":34,"id":4,"ws":true},{"text":"with","start":35,"end":39,"id":5,"ws":true},{"text":"chenodeoxycholic","start":40,"end":56,"id":6,"ws":true},{"text":"acid","start":57,"end":61,"id":7,"ws":true},{"text":"(","start":62,"end":63,"id":8,"ws":true},{"text":"CDCA","start":64,"end":68,"id":9,"ws":true},{"text":")","start":69,"end":70,"id":10,"ws":true},{"text":"and","start":71,"end":74,"id":11,"ws":true},{"text":"simvastatin","start":75,"end":86,"id":12,"ws":true},{"text":"on","start":87,"end":89,"id":13,"ws":true},{"text":"serum","start":90,"end":95,"id":14,"ws":true},{"text":"cholestanol","start":96,"end":107,"id":15,"ws":true},{"text":",","start":108,"end":109,"id":16,"ws":true},{"text":"low-density","start":110,"end":121,"id":17,"ws":true},{"text":"lipoprotein","start":122,"end":133,"id":18,"ws":true},{"text":"(","start":134,"end":135,"id":19,"ws":true},{"text":"LDL","start":136,"end":139,"id":20,"ws":true},{"text":")","start":140,"end":141,"id":21,"ws":true},{"text":"cholesterol","start":142,"end":153,"id":22,"ws":true},{"text":",","start":154,"end":155,"id":23,"ws":true},{"text":"and","start":156,"end":159,"id":24,"ws":true},{"text":"lathosterol","start":160,"end":171,"id":25,"ws":true},{"text":"levels","start":172,"end":178,"id":26,"ws":true},{"text":"were","start":179,"end":183,"id":27,"ws":true},{"text":"investigated","start":184,"end":196,"id":28,"ws":true},{"text":"in","start":197,"end":199,"id":29,"ws":true},{"text":"seven","start":200,"end":205,"id":30,"ws":true},{"text":"adult","start":206,"end":211,"id":31,"ws":true},{"text":"patients","start":212,"end":220,"id":32,"ws":true},{"text":"with","start":221,"end":225,"id":33,"ws":true},{"text":"cerebrotendinous","start":226,"end":242,"id":34,"ws":true},{"text":"xanthomatosis","start":243,"end":256,"id":35,"ws":true},{"text":"(","start":257,"end":258,"id":36,"ws":true},{"text":"CTX","start":259,"end":262,"id":37,"ws":true},{"text":")","start":263,"end":264,"id":38,"ws":true},{"text":"who","start":265,"end":268,"id":39,"ws":true},{"text":"were","start":269,"end":273,"id":40,"ws":true},{"text":"on","start":274,"end":276,"id":41,"ws":true},{"text":"long-term","start":277,"end":286,"id":42,"ws":true},{"text":"treatment","start":287,"end":296,"id":43,"ws":true},{"text":"with","start":297,"end":301,"id":44,"ws":true},{"text":"CDCA","start":302,"end":306,"id":45,"ws":true},{"text":".","start":307,"end":308,"id":46,"ws":false}],"spans":[{"start":40,"end":56,"token_start":6,"token_end":6,"label":"DRUG"},{"start":75,"end":86,"token_start":12,"token_end":12,"label":"DRUG"}],"_input_hash":-475065306,"_task_hash":-2052397739,"_session_id":"drug_drug_pilot_shared-yuval","_view_id":"blocks","relations":[{"head":6,"child":12,"head_span":{"start":40,"end":56,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":75,"end":86,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"Paclitaxel ( Taxol ; Bristol-Myers Squibb Company , Princeton , NJ ) has been demonstrated to be highly effective in treating patients with advanced breast cancer , including those with anthracycline-resistant breast cancer , a fact that has led to efforts to combine paclitaxel and anthracyclines .","paragraph":"<h3><u>Paclitaxel and doxorubicin in metastatic breast cancer.</u></h3>For the past decades the anthracyclines have been regarded as among the most active drugs for the treatment of metastatic breast cancer. However, the 5-year survival rate in patients with stage IV breast cancer continues to be below 20%, and new active drugs and drug combinations clearly must be explored. <b style='color:MediumOrchid;'><i>Paclitaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Taxol</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>Bristol-Myers</i></b> <b style='color:DodgerBlue;'><i>Squibb</i></b> <b style='color:DodgerBlue;'><i>Company</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Princeton</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>NJ</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>highly</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>treating</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>anthracycline-resistant</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>fact</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>led</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>efforts</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>combine</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>anthracyclines</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Several studies aiming to define the optimal dose and schedule of combination <b style='color:Tomato;'><i>paclitaxel</i></b>/<b style='color:Tomato;'><i>doxorubicin</i></b> have now been completed or are ongoing. Phase I/II studies have yielded encouraging preliminary response rates but quite variable toxicity profiles depending on the schedule used. These clinical trials involving combination <b style='color:Tomato;'><i>paclitaxel</i></b>/<b style='color:Tomato;'><i>doxorubicin</i></b> are reviewed, with special emphasis on the short-infusion trials.","tokens":[{"text":"Paclitaxel","start":0,"end":10,"id":0,"ws":true},{"text":"(","start":11,"end":12,"id":1,"ws":true},{"text":"Taxol","start":13,"end":18,"id":2,"ws":true},{"text":";","start":19,"end":20,"id":3,"ws":true},{"text":"Bristol-Myers","start":21,"end":34,"id":4,"ws":true},{"text":"Squibb","start":35,"end":41,"id":5,"ws":true},{"text":"Company","start":42,"end":49,"id":6,"ws":true},{"text":",","start":50,"end":51,"id":7,"ws":true},{"text":"Princeton","start":52,"end":61,"id":8,"ws":true},{"text":",","start":62,"end":63,"id":9,"ws":true},{"text":"NJ","start":64,"end":66,"id":10,"ws":true},{"text":")","start":67,"end":68,"id":11,"ws":true},{"text":"has","start":69,"end":72,"id":12,"ws":true},{"text":"been","start":73,"end":77,"id":13,"ws":true},{"text":"demonstrated","start":78,"end":90,"id":14,"ws":true},{"text":"to","start":91,"end":93,"id":15,"ws":true},{"text":"be","start":94,"end":96,"id":16,"ws":true},{"text":"highly","start":97,"end":103,"id":17,"ws":true},{"text":"effective","start":104,"end":113,"id":18,"ws":true},{"text":"in","start":114,"end":116,"id":19,"ws":true},{"text":"treating","start":117,"end":125,"id":20,"ws":true},{"text":"patients","start":126,"end":134,"id":21,"ws":true},{"text":"with","start":135,"end":139,"id":22,"ws":true},{"text":"advanced","start":140,"end":148,"id":23,"ws":true},{"text":"breast","start":149,"end":155,"id":24,"ws":true},{"text":"cancer","start":156,"end":162,"id":25,"ws":true},{"text":",","start":163,"end":164,"id":26,"ws":true},{"text":"including","start":165,"end":174,"id":27,"ws":true},{"text":"those","start":175,"end":180,"id":28,"ws":true},{"text":"with","start":181,"end":185,"id":29,"ws":true},{"text":"anthracycline-resistant","start":186,"end":209,"id":30,"ws":true},{"text":"breast","start":210,"end":216,"id":31,"ws":true},{"text":"cancer","start":217,"end":223,"id":32,"ws":true},{"text":",","start":224,"end":225,"id":33,"ws":true},{"text":"a","start":226,"end":227,"id":34,"ws":true},{"text":"fact","start":228,"end":232,"id":35,"ws":true},{"text":"that","start":233,"end":237,"id":36,"ws":true},{"text":"has","start":238,"end":241,"id":37,"ws":true},{"text":"led","start":242,"end":245,"id":38,"ws":true},{"text":"to","start":246,"end":248,"id":39,"ws":true},{"text":"efforts","start":249,"end":256,"id":40,"ws":true},{"text":"to","start":257,"end":259,"id":41,"ws":true},{"text":"combine","start":260,"end":267,"id":42,"ws":true},{"text":"paclitaxel","start":268,"end":278,"id":43,"ws":true},{"text":"and","start":279,"end":282,"id":44,"ws":true},{"text":"anthracyclines","start":283,"end":297,"id":45,"ws":true},{"text":".","start":298,"end":299,"id":46,"ws":false}],"spans":[{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},{"start":268,"end":278,"token_start":43,"token_end":43,"label":"DRUG"}],"_input_hash":702583470,"_task_hash":1770101995,"_session_id":"drug_drug_pilot_shared-yuval","_view_id":"blocks","relations":[{"head":43,"child":45,"head_span":{"start":268,"end":278,"token_start":43,"token_end":43,"label":"DRUG"},"child_span":{"start":283,"end":297,"token_start":45,"token_end":45,"label":null},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"There was no cytotoxic effect of cisplatin , ifosfamide , and etoposide .","paragraph":"<h3><u>Overcoming Chemoresistance of Pediatric Ependymoma by Inhibition of STAT3 Signaling.</u></h3>The long-term clinical outcome of pediatric intracranial epepdymoma is poor with a high rate of recurrence. One of the main reasons for this poor outcome is the tumor's inherent resistance to chemotherapy. Signal transducer and activator of transcription 3 (STAT3) is overactive in many human cancers, and inhibition of STAT3 signaling is an emerging area of interest in oncology. In this study, the possibility of STAT3 inhibition as a treatment was investigated in pediatric intracranial ependymoma tissues and cell lines. STAT3 activation status was checked in ependymoma tissues. The responses to conventional chemotherapeutic agents and a STAT3 inhibitor WP1066 in primarily cultured ependymoma cells were measured by cell viability assay. Apoptosis assays were conducted to reveal the cytotoxic mechanism of applied agents. Knockdown of STAT3 was tried to confirm the effects of STAT3 inhibition in ependymoma cells. High levels of phospho-STAT3 (p-STAT3) expression were observed in ependymoma tissue, especially in the anaplastic histology group. <b style='color:DodgerBlue;'><i>There</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>cytotoxic</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Both brain tumor-initiating cells (BTICs) and bulk tumor cells (BCs) showed considerably decreased viability after WP1066 treatment. However, BTICs had fewer responses than BCs. No additive or synergistic effect was observed for combination therapy of WP1066 and cisplatin. WP1066 effectively abrogated p-STAT3 expression. An increased apoptosis and decreased Survivin expression were observed after WP1066 treatment. Knockdown of STAT3 also decreased cell survival, supporting the critical role of STAT3 in sustaining ependymoma cells. In this study, we observed a cytotoxic effect of STAT3 inhibitor on ependymoma BTICs and BCs. There is urgent need to develop new therapeutic agents for pediatric ependymoma. STAT3 inhibitors may be a new group of drugs for clinical application. ","tokens":[{"text":"There","start":0,"end":5,"id":0,"ws":true},{"text":"was","start":6,"end":9,"id":1,"ws":true},{"text":"no","start":10,"end":12,"id":2,"ws":true},{"text":"cytotoxic","start":13,"end":22,"id":3,"ws":true},{"text":"effect","start":23,"end":29,"id":4,"ws":true},{"text":"of","start":30,"end":32,"id":5,"ws":true},{"text":"cisplatin","start":33,"end":42,"id":6,"ws":true},{"text":",","start":43,"end":44,"id":7,"ws":true},{"text":"ifosfamide","start":45,"end":55,"id":8,"ws":true},{"text":",","start":56,"end":57,"id":9,"ws":true},{"text":"and","start":58,"end":61,"id":10,"ws":true},{"text":"etoposide","start":62,"end":71,"id":11,"ws":true},{"text":".","start":72,"end":73,"id":12,"ws":false}],"spans":[{"start":45,"end":55,"token_start":8,"token_end":8,"label":"DRUG"},{"start":62,"end":71,"token_start":11,"token_end":11,"label":"DRUG"}],"_input_hash":-1352726798,"_task_hash":-274527523,"_session_id":"drug_drug_pilot_shared-dana_n","_view_id":"blocks","relations":[{"head":8,"child":11,"head_span":{"start":45,"end":55,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":62,"end":71,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":6,"child":8,"head_span":{"start":33,"end":42,"token_start":6,"token_end":6,"label":null},"child_span":{"start":45,"end":55,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["POS11","POS1T0","COMB1T0"],"answer":"accept"}
{"text":"Several first-line phase III trials , as well as ongoing trials for which only preliminary results have been published , have fueled debates on the optimal dose and schedule ; these have focused not only on weekly vs q3-weeks paclitaxel , but also on other modifications and the advisability of adding bevacizumab .","paragraph":"<h3><u>Carboplatin/Paclitaxel Induction in Ovarian Cancer: The Finer Points.</u></h3>The <b style='color:Tomato;'><i>carboplatin</i></b>/<b style='color:Tomato;'><i>paclitaxel</i></b> doublet remains the chemotherapy backbone for the initial treatment of ovarian cancer. This two-drug regimen, with <b style='color:Tomato;'><i>carboplatin</i></b> dosed using the Calvert formula, yielded convincing noninferior outcomes when compared with the prior, more toxic, regimen of cisplatin/<b style='color:Tomato;'><i>paclitaxel</i></b>. <b style='color:Tomato;'><i>carboplatin</i></b>'s dose-limiting toxicity is thrombocytopenia; however, when this drug is properly dosed and combined with <b style='color:Tomato;'><i>paclitaxel</i></b>, the doublet's cycle 1 dose in chemotherapy-naive women is generally safe. <b style='color:Tomato;'><i>carboplatin</i></b> (unlike cisplatin) contributes minimally to the cumulative sensory neuropathy of <b style='color:Tomato;'><i>paclitaxel</i></b>, thus ensuring noticeable reversibility of neuropathy symptoms following completion of 6 cycles and only occasionally requiring cessation or substitution of the taxane. <b style='color:Tomato;'><i>paclitaxel</i></b> is responsible for the hair loss associated with the <b style='color:Tomato;'><i>carboplatin</i></b>/<b style='color:Tomato;'><i>paclitaxel</i></b> doublet; preventive measures must be considered for patients who would otherwise refuse treatment. <b style='color:DodgerBlue;'><i>Several</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>III</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>ongoing</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>which</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>preliminary</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>published</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>fueled</i></b> <b style='color:DodgerBlue;'><i>debates</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>optimal</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>schedule</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>focused</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>weekly</i></b> <b style='color:DodgerBlue;'><i>vs</i></b> <b style='color:DodgerBlue;'><i>q3-weeks</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>also</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>modifications</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>advisability</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>adding</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Our view is that results of this doublet in the first-line treatment of ovarian cancer are driven primarily by <b style='color:Tomato;'><i>carboplatin</i></b>, given that ovarian cancer is a platinum-sensitive disease. Consequently, the roles of the accompanying <b style='color:Tomato;'><i>paclitaxel</i></b> dose and schedule and the addition of <b style='color:Tomato;'><i>bevacizumab</i></b> are currently unsettled, and questions regarding these issues should be decided based on patient tolerance and comorbidities until additional data are available.","tokens":[{"text":"Several","start":0,"end":7,"id":0,"ws":true},{"text":"first-line","start":8,"end":18,"id":1,"ws":true},{"text":"phase","start":19,"end":24,"id":2,"ws":true},{"text":"III","start":25,"end":28,"id":3,"ws":true},{"text":"trials","start":29,"end":35,"id":4,"ws":true},{"text":",","start":36,"end":37,"id":5,"ws":true},{"text":"as","start":38,"end":40,"id":6,"ws":true},{"text":"well","start":41,"end":45,"id":7,"ws":true},{"text":"as","start":46,"end":48,"id":8,"ws":true},{"text":"ongoing","start":49,"end":56,"id":9,"ws":true},{"text":"trials","start":57,"end":63,"id":10,"ws":true},{"text":"for","start":64,"end":67,"id":11,"ws":true},{"text":"which","start":68,"end":73,"id":12,"ws":true},{"text":"only","start":74,"end":78,"id":13,"ws":true},{"text":"preliminary","start":79,"end":90,"id":14,"ws":true},{"text":"results","start":91,"end":98,"id":15,"ws":true},{"text":"have","start":99,"end":103,"id":16,"ws":true},{"text":"been","start":104,"end":108,"id":17,"ws":true},{"text":"published","start":109,"end":118,"id":18,"ws":true},{"text":",","start":119,"end":120,"id":19,"ws":true},{"text":"have","start":121,"end":125,"id":20,"ws":true},{"text":"fueled","start":126,"end":132,"id":21,"ws":true},{"text":"debates","start":133,"end":140,"id":22,"ws":true},{"text":"on","start":141,"end":143,"id":23,"ws":true},{"text":"the","start":144,"end":147,"id":24,"ws":true},{"text":"optimal","start":148,"end":155,"id":25,"ws":true},{"text":"dose","start":156,"end":160,"id":26,"ws":true},{"text":"and","start":161,"end":164,"id":27,"ws":true},{"text":"schedule","start":165,"end":173,"id":28,"ws":true},{"text":";","start":174,"end":175,"id":29,"ws":true},{"text":"these","start":176,"end":181,"id":30,"ws":true},{"text":"have","start":182,"end":186,"id":31,"ws":true},{"text":"focused","start":187,"end":194,"id":32,"ws":true},{"text":"not","start":195,"end":198,"id":33,"ws":true},{"text":"only","start":199,"end":203,"id":34,"ws":true},{"text":"on","start":204,"end":206,"id":35,"ws":true},{"text":"weekly","start":207,"end":213,"id":36,"ws":true},{"text":"vs","start":214,"end":216,"id":37,"ws":true},{"text":"q3-weeks","start":217,"end":225,"id":38,"ws":true},{"text":"paclitaxel","start":226,"end":236,"id":39,"ws":true},{"text":",","start":237,"end":238,"id":40,"ws":true},{"text":"but","start":239,"end":242,"id":41,"ws":true},{"text":"also","start":243,"end":247,"id":42,"ws":true},{"text":"on","start":248,"end":250,"id":43,"ws":true},{"text":"other","start":251,"end":256,"id":44,"ws":true},{"text":"modifications","start":257,"end":270,"id":45,"ws":true},{"text":"and","start":271,"end":274,"id":46,"ws":true},{"text":"the","start":275,"end":278,"id":47,"ws":true},{"text":"advisability","start":279,"end":291,"id":48,"ws":true},{"text":"of","start":292,"end":294,"id":49,"ws":true},{"text":"adding","start":295,"end":301,"id":50,"ws":true},{"text":"bevacizumab","start":302,"end":313,"id":51,"ws":true},{"text":".","start":314,"end":315,"id":52,"ws":false}],"spans":[{"start":226,"end":236,"token_start":39,"token_end":39,"label":"DRUG"},{"start":302,"end":313,"token_start":51,"token_end":51,"label":"DRUG"}],"_input_hash":1252988243,"_task_hash":322511723,"_session_id":"drug_drug_pilot_shared-dana_n","_view_id":"blocks","relations":[{"head":51,"child":39,"head_span":{"start":302,"end":313,"token_start":51,"token_end":51,"label":"DRUG"},"child_span":{"start":226,"end":236,"token_start":39,"token_end":39,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"answer":"accept","radio":["COMB1T1"]}
{"text":"The primary goal was achieve the correct estimation of the target plasma area against the topotecan concentration-time curve ( AUC ) in a 5 day course of cladribine followed by monitored topotecan in pediatric patients with recurrent/refractory AML .","paragraph":"<h3><u>Topotecan exposure estimation in pediatric acute myeloid leukemia supported by LC-MS-based drug monitoring and pharmacokinetic analysis.</u></h3>Individualization of the <b style='color:Tomato;'><i>topotecan</i></b> dosing can reduce inter-patient variability, toxicity, and at the same time increases chemotherapy efficacy. <b style='color:Tomato;'><i>topotecan</i></b> dosing based on simultaneous drug monitoring and pharmacokinetic analysis can yield more accurate and precise estimation of the <b style='color:Tomato;'><i>topotecan</i></b> systemic exposure than that attainable with the fixed dosing approach. Therefore, a combined approach could provide a tool assisting the clinicians in individualization of the <b style='color:Tomato;'><i>topotecan</i></b> dosing. The aim of the study was to estimate the <b style='color:Tomato;'><i>topotecan</i></b> exposure in pediatric patients with acute myeloid leukemia (AML) based on the plasma concentration-time data and using the pharmacokinetic analysis. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>primary</i></b> <b style='color:DodgerBlue;'><i>goal</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>achieve</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>correct</i></b> <b style='color:DodgerBlue;'><i>estimation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>target</i></b> <b style='color:DodgerBlue;'><i>plasma</i></b> <b style='color:DodgerBlue;'><i>area</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:MediumOrchid;'><i>topotecan</i></b> <b style='color:DodgerBlue;'><i>concentration-time</i></b> <b style='color:DodgerBlue;'><i>curve</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AUC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>course</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cladribine</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>monitored</i></b> <b style='color:MediumOrchid;'><i>topotecan</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>pediatric</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>recurrent/refractory</i></b> <b style='color:DodgerBlue;'><i>AML</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A sensitive and selective reversed-phase liquid chromatographic-mass spectrometry (LC-MS) assay was developed to quantify total <b style='color:Tomato;'><i>topotecan</i></b> in the human plasma samples. This method, with its lower quantification limit of 1 ng/ml, was validated over a linear range of 1-150 ng/ml. Under the proposed approach, the <b style='color:Tomato;'><i>topotecan</i></b> dosing was selected so as to achieve the final AUC value of 140\u00b120 ng/ml h. The presented analytical and pharmacokinetic data demonstrate that the proposed approach can be a practical, useful, efficient, and accurate tool for individualizing the <b style='color:Tomato;'><i>topotecan</i></b> dosing in children with AML.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"primary","start":4,"end":11,"id":1,"ws":true},{"text":"goal","start":12,"end":16,"id":2,"ws":true},{"text":"was","start":17,"end":20,"id":3,"ws":true},{"text":"achieve","start":21,"end":28,"id":4,"ws":true},{"text":"the","start":29,"end":32,"id":5,"ws":true},{"text":"correct","start":33,"end":40,"id":6,"ws":true},{"text":"estimation","start":41,"end":51,"id":7,"ws":true},{"text":"of","start":52,"end":54,"id":8,"ws":true},{"text":"the","start":55,"end":58,"id":9,"ws":true},{"text":"target","start":59,"end":65,"id":10,"ws":true},{"text":"plasma","start":66,"end":72,"id":11,"ws":true},{"text":"area","start":73,"end":77,"id":12,"ws":true},{"text":"against","start":78,"end":85,"id":13,"ws":true},{"text":"the","start":86,"end":89,"id":14,"ws":true},{"text":"topotecan","start":90,"end":99,"id":15,"ws":true},{"text":"concentration-time","start":100,"end":118,"id":16,"ws":true},{"text":"curve","start":119,"end":124,"id":17,"ws":true},{"text":"(","start":125,"end":126,"id":18,"ws":true},{"text":"AUC","start":127,"end":130,"id":19,"ws":true},{"text":")","start":131,"end":132,"id":20,"ws":true},{"text":"in","start":133,"end":135,"id":21,"ws":true},{"text":"a","start":136,"end":137,"id":22,"ws":true},{"text":"5","start":138,"end":139,"id":23,"ws":true},{"text":"day","start":140,"end":143,"id":24,"ws":true},{"text":"course","start":144,"end":150,"id":25,"ws":true},{"text":"of","start":151,"end":153,"id":26,"ws":true},{"text":"cladribine","start":154,"end":164,"id":27,"ws":true},{"text":"followed","start":165,"end":173,"id":28,"ws":true},{"text":"by","start":174,"end":176,"id":29,"ws":true},{"text":"monitored","start":177,"end":186,"id":30,"ws":true},{"text":"topotecan","start":187,"end":196,"id":31,"ws":true},{"text":"in","start":197,"end":199,"id":32,"ws":true},{"text":"pediatric","start":200,"end":209,"id":33,"ws":true},{"text":"patients","start":210,"end":218,"id":34,"ws":true},{"text":"with","start":219,"end":223,"id":35,"ws":true},{"text":"recurrent/refractory","start":224,"end":244,"id":36,"ws":true},{"text":"AML","start":245,"end":248,"id":37,"ws":true},{"text":".","start":249,"end":250,"id":38,"ws":false}],"spans":[{"start":90,"end":99,"token_start":15,"token_end":15,"label":"DRUG"},{"start":154,"end":164,"token_start":27,"token_end":27,"label":"DRUG"},{"start":187,"end":196,"token_start":31,"token_end":31,"label":"DRUG"}],"_input_hash":796298966,"_task_hash":-199747777,"_session_id":"drug_drug_pilot_shared-dana_n","_view_id":"blocks","relations":[{"head":27,"child":31,"head_span":{"start":154,"end":164,"token_start":27,"token_end":27,"label":"DRUG"},"child_span":{"start":187,"end":196,"token_start":31,"token_end":31,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":15,"child":31,"head_span":{"start":90,"end":99,"token_start":15,"token_end":15,"label":"DRUG"},"child_span":{"start":187,"end":196,"token_start":31,"token_end":31,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T1"],"answer":"accept"}
{"text":"However , anastrozole , exemestane and letrozole are associated with significantly fewer endometrial cancers , as well as venous and arterial vascular events , when compared with tamoxifen [ 9 , 10 ] .","paragraph":"<h3><u>Erythema nodosum secondary to aromatase inhibitor use in breast cancer patients: case reports and review of the literature.</u></h3>Aromatase inhibitors (AI's) are increasingly being incorporated in the treatment strategy for hormone receptor positive breast cancer either alone or in combination with chemotherapy, biologics in both the adjuvant and metastatic setting [1]. They markedly suppress plasma estrogen levels by inhibiting or inactivating aromatase, the enzyme responsible for the synthesis of estrogens from androgenic substrates [1]. Currently, the three selective aromatase inhibitors that are available are <b style='color:Tomato;'><i>anastrozole</i></b>, <b style='color:Tomato;'><i>letrozole</i></b> and <b style='color:Tomato;'><i>exemestane</i></b> which reduce circulating estrogen to 1 to 10% of pretreatment levels [2]. For advanced breast cancer, aromatase inhibitors appear to be at a minimum, equivalent and perhaps even better than <b style='color:Tomato;'><i>tamoxifen</i></b> in the first line setting [3, 4]. In primary breast cancer, adjuvant therapy with <b style='color:Tomato;'><i>anastrozole</i></b> or <b style='color:Tomato;'><i>letrozole</i></b> appears to be superior to <b style='color:Tomato;'><i>tamoxifen</i></b> in reducing the risk of relapse [5, 6]. Common adverse effects associated with AI's include arthralgias (21%), myalgias (12%), other musculoskeletal disorders (28%) and an up to 60% increased risk of bone fracture [7, 8]. <b style='color:DodgerBlue;'><i>However</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>anastrozole</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>exemestane</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>letrozole</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>fewer</i></b> <b style='color:DodgerBlue;'><i>endometrial</i></b> <b style='color:DodgerBlue;'><i>cancers</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>venous</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>arterial</i></b> <b style='color:DodgerBlue;'><i>vascular</i></b> <b style='color:DodgerBlue;'><i>events</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>9</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Very rarely <b style='color:Tomato;'><i>letrozole</i></b> and <b style='color:Tomato;'><i>anastrozole</i></b> can cause a skin rash; the frequency of its occurrence has not been quantified(. )However, <b style='color:Tomato;'><i>exemestane</i></b> has not been reported to cause a skin rash [11]. To date, erythema nodosum (EN) has not been reported as a dermatologic side effect of AI's. Here, we report three cases of EN which developed in postmenopausal breast cancer patients on AI's.","tokens":[{"text":"However","start":0,"end":7,"id":0,"ws":true},{"text":",","start":8,"end":9,"id":1,"ws":true},{"text":"anastrozole","start":10,"end":21,"id":2,"ws":true},{"text":",","start":22,"end":23,"id":3,"ws":true},{"text":"exemestane","start":24,"end":34,"id":4,"ws":true},{"text":"and","start":35,"end":38,"id":5,"ws":true},{"text":"letrozole","start":39,"end":48,"id":6,"ws":true},{"text":"are","start":49,"end":52,"id":7,"ws":true},{"text":"associated","start":53,"end":63,"id":8,"ws":true},{"text":"with","start":64,"end":68,"id":9,"ws":true},{"text":"significantly","start":69,"end":82,"id":10,"ws":true},{"text":"fewer","start":83,"end":88,"id":11,"ws":true},{"text":"endometrial","start":89,"end":100,"id":12,"ws":true},{"text":"cancers","start":101,"end":108,"id":13,"ws":true},{"text":",","start":109,"end":110,"id":14,"ws":true},{"text":"as","start":111,"end":113,"id":15,"ws":true},{"text":"well","start":114,"end":118,"id":16,"ws":true},{"text":"as","start":119,"end":121,"id":17,"ws":true},{"text":"venous","start":122,"end":128,"id":18,"ws":true},{"text":"and","start":129,"end":132,"id":19,"ws":true},{"text":"arterial","start":133,"end":141,"id":20,"ws":true},{"text":"vascular","start":142,"end":150,"id":21,"ws":true},{"text":"events","start":151,"end":157,"id":22,"ws":true},{"text":",","start":158,"end":159,"id":23,"ws":true},{"text":"when","start":160,"end":164,"id":24,"ws":true},{"text":"compared","start":165,"end":173,"id":25,"ws":true},{"text":"with","start":174,"end":178,"id":26,"ws":true},{"text":"tamoxifen","start":179,"end":188,"id":27,"ws":true},{"text":"[","start":189,"end":190,"id":28,"ws":true},{"text":"9","start":191,"end":192,"id":29,"ws":true},{"text":",","start":193,"end":194,"id":30,"ws":true},{"text":"10","start":195,"end":197,"id":31,"ws":true},{"text":"]","start":198,"end":199,"id":32,"ws":true},{"text":".","start":200,"end":201,"id":33,"ws":false}],"spans":[{"start":10,"end":21,"token_start":2,"token_end":2,"label":"DRUG"},{"start":24,"end":34,"token_start":4,"token_end":4,"label":"DRUG"},{"start":39,"end":48,"token_start":6,"token_end":6,"label":"DRUG"},{"start":179,"end":188,"token_start":27,"token_end":27,"label":"DRUG"}],"_input_hash":155070717,"_task_hash":-411756935,"_session_id":"drug_drug_pilot_shared-hagit","_view_id":"blocks","relations":[{"head":2,"child":4,"head_span":{"start":10,"end":21,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":24,"end":34,"token_start":4,"token_end":4,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"},{"head":6,"child":4,"head_span":{"start":39,"end":48,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":24,"end":34,"token_start":4,"token_end":4,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"},{"head":27,"child":6,"head_span":{"start":179,"end":188,"token_start":27,"token_end":27,"label":"DRUG"},"child_span":{"start":39,"end":48,"token_start":6,"token_end":6,"label":"DRUG"},"color":"#ffdaf9","label":"NEG2"},{"head":27,"child":4,"head_span":{"start":179,"end":188,"token_start":27,"token_end":27,"label":"DRUG"},"child_span":{"start":24,"end":34,"token_start":4,"token_end":4,"label":"DRUG"},"color":"#ffdaf9","label":"NEG2"},{"head":27,"child":2,"head_span":{"start":179,"end":188,"token_start":27,"token_end":27,"label":"DRUG"},"child_span":{"start":10,"end":21,"token_start":2,"token_end":2,"label":"DRUG"},"color":"#ffdaf9","label":"NEG2"}],"radio":["NEG10","NEG1T0","NEG20","NEG2T0"],"answer":"accept"}
{"text":"Additivity , synergy , or competition was observed with MIS and rapamycin , AzadC , doxorubicin , cisplatin , and paclitaxel , suggesting that MIS in combination with selective targeted therapies might achieve greater activity against ovarian cancer than the use of each individual agent alone .","paragraph":"<h3><u>Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.</u></h3>Mullerian Inhibiting Substance (MIS), a biological modifier that causes regression of Mullerian ducts in male embryos, is effective as a single agent in vitro and in vivo against human and mouse ovarian cancer cell lines expressing MIS type II receptor; however, little is known about how recombinant human MIS (rhMIS), now being scaled for preclinical trials, could be used in combination with cytotoxic or targeted chemotherapeutic agents. Mouse serous and endometrioid ovarian carcinoma cell lines were tested in vitro against rhMIS alone and with <b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>paclitaxel</i></b>, or cisplatin as agents in clinical use. Because MIS releases FK506 binding protein (FKBP12), which activates the mammalian target of <b style='color:Tomato;'><i>rapamycin</i></b> (mTOR) downstream of Akt, rhMIS and <b style='color:Tomato;'><i>rapamycin</i></b> combinations were tested. MIS increases p16 protein levels, and 5'-Aza-2'-deoxycytidine (AzadC) induces p16 mRNA; therefore, they were used in combination in vitro and in vivo with a human ovarian cancer cell line. A <b style='color:Tomato;'><i>paclitaxel</i></b>-resistant human ovarian cancer cell line and its parental line both respond to rhMIS in vitro. <b style='color:DodgerBlue;'><i>Additivity</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>synergy</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>competition</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>observed</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>MIS</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rapamycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>AzadC</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>suggesting</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>MIS</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>selective</i></b> <b style='color:DodgerBlue;'><i>targeted</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>might</i></b> <b style='color:DodgerBlue;'><i>achieve</i></b> <b style='color:DodgerBlue;'><i>greater</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>ovarian</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>each</i></b> <b style='color:DodgerBlue;'><i>individual</i></b> <b style='color:DodgerBlue;'><i>agent</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> These assays and statistical analyses could be useful in selecting rhMIS and chemotherapeutic agent combinations that enhance clinical efficacy and reduce toxicity.","tokens":[{"text":"Additivity","start":0,"end":10,"id":0,"ws":true},{"text":",","start":11,"end":12,"id":1,"ws":true},{"text":"synergy","start":13,"end":20,"id":2,"ws":true},{"text":",","start":21,"end":22,"id":3,"ws":true},{"text":"or","start":23,"end":25,"id":4,"ws":true},{"text":"competition","start":26,"end":37,"id":5,"ws":true},{"text":"was","start":38,"end":41,"id":6,"ws":true},{"text":"observed","start":42,"end":50,"id":7,"ws":true},{"text":"with","start":51,"end":55,"id":8,"ws":true},{"text":"MIS","start":56,"end":59,"id":9,"ws":true},{"text":"and","start":60,"end":63,"id":10,"ws":true},{"text":"rapamycin","start":64,"end":73,"id":11,"ws":true},{"text":",","start":74,"end":75,"id":12,"ws":true},{"text":"AzadC","start":76,"end":81,"id":13,"ws":true},{"text":",","start":82,"end":83,"id":14,"ws":true},{"text":"doxorubicin","start":84,"end":95,"id":15,"ws":true},{"text":",","start":96,"end":97,"id":16,"ws":true},{"text":"cisplatin","start":98,"end":107,"id":17,"ws":true},{"text":",","start":108,"end":109,"id":18,"ws":true},{"text":"and","start":110,"end":113,"id":19,"ws":true},{"text":"paclitaxel","start":114,"end":124,"id":20,"ws":true},{"text":",","start":125,"end":126,"id":21,"ws":true},{"text":"suggesting","start":127,"end":137,"id":22,"ws":true},{"text":"that","start":138,"end":142,"id":23,"ws":true},{"text":"MIS","start":143,"end":146,"id":24,"ws":true},{"text":"in","start":147,"end":149,"id":25,"ws":true},{"text":"combination","start":150,"end":161,"id":26,"ws":true},{"text":"with","start":162,"end":166,"id":27,"ws":true},{"text":"selective","start":167,"end":176,"id":28,"ws":true},{"text":"targeted","start":177,"end":185,"id":29,"ws":true},{"text":"therapies","start":186,"end":195,"id":30,"ws":true},{"text":"might","start":196,"end":201,"id":31,"ws":true},{"text":"achieve","start":202,"end":209,"id":32,"ws":true},{"text":"greater","start":210,"end":217,"id":33,"ws":true},{"text":"activity","start":218,"end":226,"id":34,"ws":true},{"text":"against","start":227,"end":234,"id":35,"ws":true},{"text":"ovarian","start":235,"end":242,"id":36,"ws":true},{"text":"cancer","start":243,"end":249,"id":37,"ws":true},{"text":"than","start":250,"end":254,"id":38,"ws":true},{"text":"the","start":255,"end":258,"id":39,"ws":true},{"text":"use","start":259,"end":262,"id":40,"ws":true},{"text":"of","start":263,"end":265,"id":41,"ws":true},{"text":"each","start":266,"end":270,"id":42,"ws":true},{"text":"individual","start":271,"end":281,"id":43,"ws":true},{"text":"agent","start":282,"end":287,"id":44,"ws":true},{"text":"alone","start":288,"end":293,"id":45,"ws":true},{"text":".","start":294,"end":295,"id":46,"ws":false}],"spans":[{"start":64,"end":73,"token_start":11,"token_end":11,"label":"DRUG"},{"start":84,"end":95,"token_start":15,"token_end":15,"label":"DRUG"},{"start":114,"end":124,"token_start":20,"token_end":20,"label":"DRUG"}],"_input_hash":1387497584,"_task_hash":991977050,"_session_id":"drug_drug_pilot_shared-hagit","_view_id":"blocks","relations":[{"head":9,"child":11,"head_span":{"start":56,"end":59,"token_start":9,"token_end":9,"label":null},"child_span":{"start":64,"end":73,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":13,"child":9,"head_span":{"start":76,"end":81,"token_start":13,"token_end":13,"label":null},"child_span":{"start":56,"end":59,"token_start":9,"token_end":9,"label":null},"color":"#c5bdf4","label":"POS1"},{"head":9,"child":15,"head_span":{"start":56,"end":59,"token_start":9,"token_end":9,"label":null},"child_span":{"start":84,"end":95,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":17,"child":9,"head_span":{"start":98,"end":107,"token_start":17,"token_end":17,"label":null},"child_span":{"start":56,"end":59,"token_start":9,"token_end":9,"label":null},"color":"#c5bdf4","label":"POS1"},{"head":9,"child":20,"head_span":{"start":56,"end":59,"token_start":9,"token_end":9,"label":null},"child_span":{"start":114,"end":124,"token_start":20,"token_end":20,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T0"],"answer":"accept"}
{"text":"There was no cytotoxic effect of cisplatin , ifosfamide , and etoposide .","paragraph":"<h3><u>Overcoming Chemoresistance of Pediatric Ependymoma by Inhibition of STAT3 Signaling.</u></h3>The long-term clinical outcome of pediatric intracranial epepdymoma is poor with a high rate of recurrence. One of the main reasons for this poor outcome is the tumor's inherent resistance to chemotherapy. Signal transducer and activator of transcription 3 (STAT3) is overactive in many human cancers, and inhibition of STAT3 signaling is an emerging area of interest in oncology. In this study, the possibility of STAT3 inhibition as a treatment was investigated in pediatric intracranial ependymoma tissues and cell lines. STAT3 activation status was checked in ependymoma tissues. The responses to conventional chemotherapeutic agents and a STAT3 inhibitor WP1066 in primarily cultured ependymoma cells were measured by cell viability assay. Apoptosis assays were conducted to reveal the cytotoxic mechanism of applied agents. Knockdown of STAT3 was tried to confirm the effects of STAT3 inhibition in ependymoma cells. High levels of phospho-STAT3 (p-STAT3) expression were observed in ependymoma tissue, especially in the anaplastic histology group. <b style='color:DodgerBlue;'><i>There</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>cytotoxic</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Both brain tumor-initiating cells (BTICs) and bulk tumor cells (BCs) showed considerably decreased viability after WP1066 treatment. However, BTICs had fewer responses than BCs. No additive or synergistic effect was observed for combination therapy of WP1066 and cisplatin. WP1066 effectively abrogated p-STAT3 expression. An increased apoptosis and decreased Survivin expression were observed after WP1066 treatment. Knockdown of STAT3 also decreased cell survival, supporting the critical role of STAT3 in sustaining ependymoma cells. In this study, we observed a cytotoxic effect of STAT3 inhibitor on ependymoma BTICs and BCs. There is urgent need to develop new therapeutic agents for pediatric ependymoma. STAT3 inhibitors may be a new group of drugs for clinical application. ","tokens":[{"text":"There","start":0,"end":5,"id":0,"ws":true},{"text":"was","start":6,"end":9,"id":1,"ws":true},{"text":"no","start":10,"end":12,"id":2,"ws":true},{"text":"cytotoxic","start":13,"end":22,"id":3,"ws":true},{"text":"effect","start":23,"end":29,"id":4,"ws":true},{"text":"of","start":30,"end":32,"id":5,"ws":true},{"text":"cisplatin","start":33,"end":42,"id":6,"ws":true},{"text":",","start":43,"end":44,"id":7,"ws":true},{"text":"ifosfamide","start":45,"end":55,"id":8,"ws":true},{"text":",","start":56,"end":57,"id":9,"ws":true},{"text":"and","start":58,"end":61,"id":10,"ws":true},{"text":"etoposide","start":62,"end":71,"id":11,"ws":true},{"text":".","start":72,"end":73,"id":12,"ws":false}],"spans":[{"start":45,"end":55,"token_start":8,"token_end":8,"label":"DRUG"},{"start":62,"end":71,"token_start":11,"token_end":11,"label":"DRUG"}],"_input_hash":-1352726798,"_task_hash":-274527523,"_session_id":"drug_drug_pilot_shared-hagit","_view_id":"blocks","relations":[{"head":6,"child":8,"head_span":{"start":33,"end":42,"token_start":6,"token_end":6,"label":null},"child_span":{"start":45,"end":55,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":6,"child":11,"head_span":{"start":33,"end":42,"token_start":6,"token_end":6,"label":null},"child_span":{"start":62,"end":71,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"Several first-line phase III trials , as well as ongoing trials for which only preliminary results have been published , have fueled debates on the optimal dose and schedule ; these have focused not only on weekly vs q3-weeks paclitaxel , but also on other modifications and the advisability of adding bevacizumab .","paragraph":"<h3><u>Carboplatin/Paclitaxel Induction in Ovarian Cancer: The Finer Points.</u></h3>The <b style='color:Tomato;'><i>carboplatin</i></b>/<b style='color:Tomato;'><i>paclitaxel</i></b> doublet remains the chemotherapy backbone for the initial treatment of ovarian cancer. This two-drug regimen, with <b style='color:Tomato;'><i>carboplatin</i></b> dosed using the Calvert formula, yielded convincing noninferior outcomes when compared with the prior, more toxic, regimen of cisplatin/<b style='color:Tomato;'><i>paclitaxel</i></b>. <b style='color:Tomato;'><i>carboplatin</i></b>'s dose-limiting toxicity is thrombocytopenia; however, when this drug is properly dosed and combined with <b style='color:Tomato;'><i>paclitaxel</i></b>, the doublet's cycle 1 dose in chemotherapy-naive women is generally safe. <b style='color:Tomato;'><i>carboplatin</i></b> (unlike cisplatin) contributes minimally to the cumulative sensory neuropathy of <b style='color:Tomato;'><i>paclitaxel</i></b>, thus ensuring noticeable reversibility of neuropathy symptoms following completion of 6 cycles and only occasionally requiring cessation or substitution of the taxane. <b style='color:Tomato;'><i>paclitaxel</i></b> is responsible for the hair loss associated with the <b style='color:Tomato;'><i>carboplatin</i></b>/<b style='color:Tomato;'><i>paclitaxel</i></b> doublet; preventive measures must be considered for patients who would otherwise refuse treatment. <b style='color:DodgerBlue;'><i>Several</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>III</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>ongoing</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>which</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>preliminary</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>published</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>fueled</i></b> <b style='color:DodgerBlue;'><i>debates</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>optimal</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>schedule</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>focused</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>weekly</i></b> <b style='color:DodgerBlue;'><i>vs</i></b> <b style='color:DodgerBlue;'><i>q3-weeks</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>also</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>modifications</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>advisability</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>adding</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Our view is that results of this doublet in the first-line treatment of ovarian cancer are driven primarily by <b style='color:Tomato;'><i>carboplatin</i></b>, given that ovarian cancer is a platinum-sensitive disease. Consequently, the roles of the accompanying <b style='color:Tomato;'><i>paclitaxel</i></b> dose and schedule and the addition of <b style='color:Tomato;'><i>bevacizumab</i></b> are currently unsettled, and questions regarding these issues should be decided based on patient tolerance and comorbidities until additional data are available.","tokens":[{"text":"Several","start":0,"end":7,"id":0,"ws":true},{"text":"first-line","start":8,"end":18,"id":1,"ws":true},{"text":"phase","start":19,"end":24,"id":2,"ws":true},{"text":"III","start":25,"end":28,"id":3,"ws":true},{"text":"trials","start":29,"end":35,"id":4,"ws":true},{"text":",","start":36,"end":37,"id":5,"ws":true},{"text":"as","start":38,"end":40,"id":6,"ws":true},{"text":"well","start":41,"end":45,"id":7,"ws":true},{"text":"as","start":46,"end":48,"id":8,"ws":true},{"text":"ongoing","start":49,"end":56,"id":9,"ws":true},{"text":"trials","start":57,"end":63,"id":10,"ws":true},{"text":"for","start":64,"end":67,"id":11,"ws":true},{"text":"which","start":68,"end":73,"id":12,"ws":true},{"text":"only","start":74,"end":78,"id":13,"ws":true},{"text":"preliminary","start":79,"end":90,"id":14,"ws":true},{"text":"results","start":91,"end":98,"id":15,"ws":true},{"text":"have","start":99,"end":103,"id":16,"ws":true},{"text":"been","start":104,"end":108,"id":17,"ws":true},{"text":"published","start":109,"end":118,"id":18,"ws":true},{"text":",","start":119,"end":120,"id":19,"ws":true},{"text":"have","start":121,"end":125,"id":20,"ws":true},{"text":"fueled","start":126,"end":132,"id":21,"ws":true},{"text":"debates","start":133,"end":140,"id":22,"ws":true},{"text":"on","start":141,"end":143,"id":23,"ws":true},{"text":"the","start":144,"end":147,"id":24,"ws":true},{"text":"optimal","start":148,"end":155,"id":25,"ws":true},{"text":"dose","start":156,"end":160,"id":26,"ws":true},{"text":"and","start":161,"end":164,"id":27,"ws":true},{"text":"schedule","start":165,"end":173,"id":28,"ws":true},{"text":";","start":174,"end":175,"id":29,"ws":true},{"text":"these","start":176,"end":181,"id":30,"ws":true},{"text":"have","start":182,"end":186,"id":31,"ws":true},{"text":"focused","start":187,"end":194,"id":32,"ws":true},{"text":"not","start":195,"end":198,"id":33,"ws":true},{"text":"only","start":199,"end":203,"id":34,"ws":true},{"text":"on","start":204,"end":206,"id":35,"ws":true},{"text":"weekly","start":207,"end":213,"id":36,"ws":true},{"text":"vs","start":214,"end":216,"id":37,"ws":true},{"text":"q3-weeks","start":217,"end":225,"id":38,"ws":true},{"text":"paclitaxel","start":226,"end":236,"id":39,"ws":true},{"text":",","start":237,"end":238,"id":40,"ws":true},{"text":"but","start":239,"end":242,"id":41,"ws":true},{"text":"also","start":243,"end":247,"id":42,"ws":true},{"text":"on","start":248,"end":250,"id":43,"ws":true},{"text":"other","start":251,"end":256,"id":44,"ws":true},{"text":"modifications","start":257,"end":270,"id":45,"ws":true},{"text":"and","start":271,"end":274,"id":46,"ws":true},{"text":"the","start":275,"end":278,"id":47,"ws":true},{"text":"advisability","start":279,"end":291,"id":48,"ws":true},{"text":"of","start":292,"end":294,"id":49,"ws":true},{"text":"adding","start":295,"end":301,"id":50,"ws":true},{"text":"bevacizumab","start":302,"end":313,"id":51,"ws":true},{"text":".","start":314,"end":315,"id":52,"ws":false}],"spans":[{"start":226,"end":236,"token_start":39,"token_end":39,"label":"DRUG"},{"start":302,"end":313,"token_start":51,"token_end":51,"label":"DRUG"}],"_input_hash":1252988243,"_task_hash":322511723,"_session_id":"drug_drug_pilot_shared-hagit","_view_id":"blocks","relations":[{"head":39,"child":51,"head_span":{"start":226,"end":236,"token_start":39,"token_end":39,"label":"DRUG"},"child_span":{"start":302,"end":313,"token_start":51,"token_end":51,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"The primary goal was achieve the correct estimation of the target plasma area against the topotecan concentration-time curve ( AUC ) in a 5 day course of cladribine followed by monitored topotecan in pediatric patients with recurrent/refractory AML .","paragraph":"<h3><u>Topotecan exposure estimation in pediatric acute myeloid leukemia supported by LC-MS-based drug monitoring and pharmacokinetic analysis.</u></h3>Individualization of the <b style='color:Tomato;'><i>topotecan</i></b> dosing can reduce inter-patient variability, toxicity, and at the same time increases chemotherapy efficacy. <b style='color:Tomato;'><i>topotecan</i></b> dosing based on simultaneous drug monitoring and pharmacokinetic analysis can yield more accurate and precise estimation of the <b style='color:Tomato;'><i>topotecan</i></b> systemic exposure than that attainable with the fixed dosing approach. Therefore, a combined approach could provide a tool assisting the clinicians in individualization of the <b style='color:Tomato;'><i>topotecan</i></b> dosing. The aim of the study was to estimate the <b style='color:Tomato;'><i>topotecan</i></b> exposure in pediatric patients with acute myeloid leukemia (AML) based on the plasma concentration-time data and using the pharmacokinetic analysis. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>primary</i></b> <b style='color:DodgerBlue;'><i>goal</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>achieve</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>correct</i></b> <b style='color:DodgerBlue;'><i>estimation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>target</i></b> <b style='color:DodgerBlue;'><i>plasma</i></b> <b style='color:DodgerBlue;'><i>area</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:MediumOrchid;'><i>topotecan</i></b> <b style='color:DodgerBlue;'><i>concentration-time</i></b> <b style='color:DodgerBlue;'><i>curve</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AUC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>course</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cladribine</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>monitored</i></b> <b style='color:MediumOrchid;'><i>topotecan</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>pediatric</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>recurrent/refractory</i></b> <b style='color:DodgerBlue;'><i>AML</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A sensitive and selective reversed-phase liquid chromatographic-mass spectrometry (LC-MS) assay was developed to quantify total <b style='color:Tomato;'><i>topotecan</i></b> in the human plasma samples. This method, with its lower quantification limit of 1 ng/ml, was validated over a linear range of 1-150 ng/ml. Under the proposed approach, the <b style='color:Tomato;'><i>topotecan</i></b> dosing was selected so as to achieve the final AUC value of 140\u00b120 ng/ml h. The presented analytical and pharmacokinetic data demonstrate that the proposed approach can be a practical, useful, efficient, and accurate tool for individualizing the <b style='color:Tomato;'><i>topotecan</i></b> dosing in children with AML.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"primary","start":4,"end":11,"id":1,"ws":true},{"text":"goal","start":12,"end":16,"id":2,"ws":true},{"text":"was","start":17,"end":20,"id":3,"ws":true},{"text":"achieve","start":21,"end":28,"id":4,"ws":true},{"text":"the","start":29,"end":32,"id":5,"ws":true},{"text":"correct","start":33,"end":40,"id":6,"ws":true},{"text":"estimation","start":41,"end":51,"id":7,"ws":true},{"text":"of","start":52,"end":54,"id":8,"ws":true},{"text":"the","start":55,"end":58,"id":9,"ws":true},{"text":"target","start":59,"end":65,"id":10,"ws":true},{"text":"plasma","start":66,"end":72,"id":11,"ws":true},{"text":"area","start":73,"end":77,"id":12,"ws":true},{"text":"against","start":78,"end":85,"id":13,"ws":true},{"text":"the","start":86,"end":89,"id":14,"ws":true},{"text":"topotecan","start":90,"end":99,"id":15,"ws":true},{"text":"concentration-time","start":100,"end":118,"id":16,"ws":true},{"text":"curve","start":119,"end":124,"id":17,"ws":true},{"text":"(","start":125,"end":126,"id":18,"ws":true},{"text":"AUC","start":127,"end":130,"id":19,"ws":true},{"text":")","start":131,"end":132,"id":20,"ws":true},{"text":"in","start":133,"end":135,"id":21,"ws":true},{"text":"a","start":136,"end":137,"id":22,"ws":true},{"text":"5","start":138,"end":139,"id":23,"ws":true},{"text":"day","start":140,"end":143,"id":24,"ws":true},{"text":"course","start":144,"end":150,"id":25,"ws":true},{"text":"of","start":151,"end":153,"id":26,"ws":true},{"text":"cladribine","start":154,"end":164,"id":27,"ws":true},{"text":"followed","start":165,"end":173,"id":28,"ws":true},{"text":"by","start":174,"end":176,"id":29,"ws":true},{"text":"monitored","start":177,"end":186,"id":30,"ws":true},{"text":"topotecan","start":187,"end":196,"id":31,"ws":true},{"text":"in","start":197,"end":199,"id":32,"ws":true},{"text":"pediatric","start":200,"end":209,"id":33,"ws":true},{"text":"patients","start":210,"end":218,"id":34,"ws":true},{"text":"with","start":219,"end":223,"id":35,"ws":true},{"text":"recurrent/refractory","start":224,"end":244,"id":36,"ws":true},{"text":"AML","start":245,"end":248,"id":37,"ws":true},{"text":".","start":249,"end":250,"id":38,"ws":false}],"spans":[{"start":90,"end":99,"token_start":15,"token_end":15,"label":"DRUG"},{"start":154,"end":164,"token_start":27,"token_end":27,"label":"DRUG"},{"start":187,"end":196,"token_start":31,"token_end":31,"label":"DRUG"}],"_input_hash":796298966,"_task_hash":-199747777,"_session_id":"drug_drug_pilot_shared-hagit","_view_id":"blocks","relations":[{"head":27,"child":31,"head_span":{"start":154,"end":164,"token_start":27,"token_end":27,"label":"DRUG"},"child_span":{"start":187,"end":196,"token_start":31,"token_end":31,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T1"],"answer":"accept"}
{"text":"The management of EP is challenging : no standardized guidelines exist with literature suggesting cyclosporine or infliximab as first-line therapy .","paragraph":"<h3><u>Erythrodermic psoriasis successfully and rapidly treated with brodalumab: Report of two cases.</u></h3>Erythrodermic psoriasis (EP) is a rare form of the disease clinically characterized by a generalized erythema covering \u226590% of the body surface area (BSA). <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>management</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>EP</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>challenging</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>standardized</i></b> <b style='color:DodgerBlue;'><i>guidelines</i></b> <b style='color:DodgerBlue;'><i>exist</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>literature</i></b> <b style='color:DodgerBlue;'><i>suggesting</i></b> <b style='color:MediumOrchid;'><i>cyclosporine</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>infliximab</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, a recent systematic review showed a positive response in EP patients treated with biologic agents. The most common biologic used for EP up until now has been <b style='color:Tomato;'><i>ustekinumab</i></b>, whereas <b style='color:Tomato;'><i>infliximab</i></b> might represent a first-line option in case of complicated EP (acute, severe, or unstable). Up until now, no case of <b style='color:Tomato;'><i>brodalumab</i></b> (a monoclonal antibody blocking IL-17 receptor) treatment for EP in real-life has ever been described. Here, we report the first two cases of efficacy and safety of <b style='color:Tomato;'><i>brodalumab</i></b> in real-life cases of EP.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"management","start":4,"end":14,"id":1,"ws":true},{"text":"of","start":15,"end":17,"id":2,"ws":true},{"text":"EP","start":18,"end":20,"id":3,"ws":true},{"text":"is","start":21,"end":23,"id":4,"ws":true},{"text":"challenging","start":24,"end":35,"id":5,"ws":true},{"text":":","start":36,"end":37,"id":6,"ws":true},{"text":"no","start":38,"end":40,"id":7,"ws":true},{"text":"standardized","start":41,"end":53,"id":8,"ws":true},{"text":"guidelines","start":54,"end":64,"id":9,"ws":true},{"text":"exist","start":65,"end":70,"id":10,"ws":true},{"text":"with","start":71,"end":75,"id":11,"ws":true},{"text":"literature","start":76,"end":86,"id":12,"ws":true},{"text":"suggesting","start":87,"end":97,"id":13,"ws":true},{"text":"cyclosporine","start":98,"end":110,"id":14,"ws":true},{"text":"or","start":111,"end":113,"id":15,"ws":true},{"text":"infliximab","start":114,"end":124,"id":16,"ws":true},{"text":"as","start":125,"end":127,"id":17,"ws":true},{"text":"first-line","start":128,"end":138,"id":18,"ws":true},{"text":"therapy","start":139,"end":146,"id":19,"ws":true},{"text":".","start":147,"end":148,"id":20,"ws":false}],"spans":[{"start":98,"end":110,"token_start":14,"token_end":14,"label":"DRUG"},{"start":114,"end":124,"token_start":16,"token_end":16,"label":"DRUG"}],"_input_hash":-575753313,"_task_hash":-166345926,"_session_id":"drug_drug_pilot_shared-hagit","_view_id":"blocks","relations":[{"head":14,"child":16,"head_span":{"start":98,"end":110,"token_start":14,"token_end":14,"label":"DRUG"},"child_span":{"start":114,"end":124,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"As single agents , curcumin and metformin are reported to exhibit chemopreventive properties , in vitro as well as in patients with oral cancer .","paragraph":"<h3><u>Curcumin and metformin-mediated chemoprevention of oral cancer is associated with inhibition of cancer stem cells.</u></h3>Effective chemoprevention is critical for improving outcomes of oral cancer. <b style='color:DodgerBlue;'><i>As</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>curcumin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>metformin</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>reported</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>exhibit</i></b> <b style='color:DodgerBlue;'><i>chemopreventive</i></b> <b style='color:DodgerBlue;'><i>properties</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In this study, the chemopreventive efficacy of this drug combination was tested in a 4-nitro quinoline-1-oxide (4NQO) induced mice oral carcinogenesis model. Molecular analysis revealed a cancer stem cell (CSC)-driven oral carcinogenic progression in this model, wherein a progressive increase in the expression of CSC-specific markers (CD44 and CD133) was observed from 8th to 25th week, at transcript (40-100-fold) and protein levels (P\u2009\u2264\u20090.0001). Chemopreventive treatment of the animals at 17th week with <b style='color:Tomato;'><i>curcumin</i></b> and <b style='color:Tomato;'><i>metformin</i></b> indicated that the combination regimen decreased tumor volume when compared to the control arm (0.69+0.03 vs 6.66+2.4\u2009mm","tokens":[{"text":"As","start":0,"end":2,"id":0,"ws":true},{"text":"single","start":3,"end":9,"id":1,"ws":true},{"text":"agents","start":10,"end":16,"id":2,"ws":true},{"text":",","start":17,"end":18,"id":3,"ws":true},{"text":"curcumin","start":19,"end":27,"id":4,"ws":true},{"text":"and","start":28,"end":31,"id":5,"ws":true},{"text":"metformin","start":32,"end":41,"id":6,"ws":true},{"text":"are","start":42,"end":45,"id":7,"ws":true},{"text":"reported","start":46,"end":54,"id":8,"ws":true},{"text":"to","start":55,"end":57,"id":9,"ws":true},{"text":"exhibit","start":58,"end":65,"id":10,"ws":true},{"text":"chemopreventive","start":66,"end":81,"id":11,"ws":true},{"text":"properties","start":82,"end":92,"id":12,"ws":true},{"text":",","start":93,"end":94,"id":13,"ws":true},{"text":"in","start":95,"end":97,"id":14,"ws":true},{"text":"vitro","start":98,"end":103,"id":15,"ws":true},{"text":"as","start":104,"end":106,"id":16,"ws":true},{"text":"well","start":107,"end":111,"id":17,"ws":true},{"text":"as","start":112,"end":114,"id":18,"ws":true},{"text":"in","start":115,"end":117,"id":19,"ws":true},{"text":"patients","start":118,"end":126,"id":20,"ws":true},{"text":"with","start":127,"end":131,"id":21,"ws":true},{"text":"oral","start":132,"end":136,"id":22,"ws":true},{"text":"cancer","start":137,"end":143,"id":23,"ws":true},{"text":".","start":144,"end":145,"id":24,"ws":false}],"spans":[{"start":19,"end":27,"token_start":4,"token_end":4,"label":"DRUG"},{"start":32,"end":41,"token_start":6,"token_end":6,"label":"DRUG"}],"_input_hash":-1095827099,"_task_hash":-240223432,"_session_id":"drug_drug_pilot_shared-hagit","_view_id":"blocks","relations":[{"head":4,"child":6,"head_span":{"start":19,"end":27,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":32,"end":41,"token_start":6,"token_end":6,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"Withdrawal rates were comparable to drug survival rates of other biological therapies and rates of adverse events were similar between brodalumab and ustekinumab .","paragraph":"<h3><u>Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.</u></h3>As part of the National Institute for Health and Care Excellence single technology appraisal process, <b style='color:Tomato;'><i>brodalumab</i></b> was assessed to determine the clinical and cost effectiveness of its use in the treatment of moderate-to-severe plaque psoriasis. The Centre for Reviews and Dissemination and the Centre for Health Economics Technology Assessment Group at the University of York were commissioned to act as the independent Evidence Review Group. This article provides a summary of the Evidence Review Group's review of the company's submission, the Evidence Review Group report and the National Institute for Health and Care Excellence Appraisal Committee's subsequent guidance issued in March 2018. The main clinical effectiveness data were derived from three well-conducted, multicentre, double-blind randomised controlled trials. The trials demonstrated that <b style='color:Tomato;'><i>brodalumab</i></b> statistically significantly reduced the severity of psoriasis and its impact on health-related quality of life, compared with placebo, at 12\u00a0weeks. In comparison with <b style='color:Tomato;'><i>ustekinumab</i></b>, statistically significantly more patients taking <b style='color:Tomato;'><i>brodalumab</i></b> had reduced psoriasis severity at 12\u00a0weeks. Psoriasis severity and quality of life also appeared improved at 52\u00a0weeks, although statistical significance was not assessed. <b style='color:DodgerBlue;'><i>Withdrawal</i></b> <b style='color:DodgerBlue;'><i>rates</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>comparable</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>rates</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>biological</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>rates</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>adverse</i></b> <b style='color:DodgerBlue;'><i>events</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>similar</i></b> <b style='color:DodgerBlue;'><i>between</i></b> <b style='color:MediumOrchid;'><i>brodalumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ustekinumab</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A network meta-analysis was presented, comparing <b style='color:Tomato;'><i>brodalumab</i></b> with other therapies available at the same point in the treatment pathway (i.e. in patients for whom standard systemic therapy or phototherapy is inadequately effective, not tolerated or contraindicated). The network meta-analysis ranked treatments in order of effectiveness, in terms of achieving different levels of Psoriasis Area and Severity Index response. The results indicated that <b style='color:Tomato;'><i>brodalumab</i></b> had a similar probability of response to <b style='color:Tomato;'><i>ixekizumab</i></b>, <b style='color:Tomato;'><i>secukinumab</i></b> and <b style='color:Tomato;'><i>infliximab</i></b> and a higher probability of response than <b style='color:Tomato;'><i>ustekinumab</i></b>, <b style='color:Tomato;'><i>adalimumab</i></b>, <b style='color:Tomato;'><i>etanercept</i></b>, <b style='color:Tomato;'><i>apremilast</i></b>, <b style='color:Tomato;'><i>dimethyl fumarate</i></b> and placebo. The company's economic model compared nine treatment sequences that included three lines of active therapy, consisting of <b style='color:Tomato;'><i>brodalumab</i></b> and other comparators recommended by the National Institute for Health and Care Excellence, followed by best supportive care. The sequence with <b style='color:Tomato;'><i>brodalumab</i></b> in the first-line position dominated sequences that started with <b style='color:Tomato;'><i>adalimumab</i></b>, <b style='color:Tomato;'><i>infliximab</i></b>, <b style='color:Tomato;'><i>secukinumab</i></b> and <b style='color:Tomato;'><i>ustekinumab</i></b>. The incremental cost-effectiveness ratio of the <b style='color:Tomato;'><i>brodalumab</i></b> sequence compared to less effective and non-dominated sequences ranged from \u00a37145 (vs. the <b style='color:Tomato;'><i>etanercept</i></b> sequence) to \u00a313,353 (vs. the <b style='color:Tomato;'><i>dimethyl fumarate</i></b> sequence) per quality-adjusted life-year gained. The incremental cost-effectiveness ratio for the more costly and effective <b style='color:Tomato;'><i>ixekizumab</i></b> sequence was \u00a3894,010 per quality-adjusted life-year gained compared to the <b style='color:Tomato;'><i>brodalumab</i></b> sequence. At a threshold of \u00a320,000 per quality-adjusted life-year gained, the <b style='color:Tomato;'><i>brodalumab</i></b> sequence had the highest probability of being cost effective (96%). The main limitation of the company's economic model was the restrictive nature of the sequences compared. Twelve separate scenarios based on key uncertainties were explored by the Evidence Review Group. The only scenarios where <b style='color:Tomato;'><i>brodalumab</i></b> was ranked lower than first were not considered to be more appropriate or plausible than the assumptions or scenarios included in the company's base case. The treatment rankings identified in the Evidence Review Group's alternative base case were identical to those derived from the company's base case model. At the first National Institute for Health and Care Excellence Appraisal Committee meeting, the Committee concluded that <b style='color:Tomato;'><i>brodalumab</i></b> appears to be as effective as other anti-interleukin-17 agents and is cost effective, based on the discount agreed in the patient access scheme. <b style='color:Tomato;'><i>brodalumab</i></b> is recommended as an option for treating adults with severe plaque psoriasis (defined by a total Psoriasis Area and Severity Index score of 10 or more and a Dermatology Life Quality Index score of more than 10) who have not responded to other systemic non-biological therapies. <b style='color:Tomato;'><i>brodalumab</i></b> should be stopped at 12\u00a0weeks if the psoriasis has not responded adequately.","tokens":[{"text":"Withdrawal","start":0,"end":10,"id":0,"ws":true},{"text":"rates","start":11,"end":16,"id":1,"ws":true},{"text":"were","start":17,"end":21,"id":2,"ws":true},{"text":"comparable","start":22,"end":32,"id":3,"ws":true},{"text":"to","start":33,"end":35,"id":4,"ws":true},{"text":"drug","start":36,"end":40,"id":5,"ws":true},{"text":"survival","start":41,"end":49,"id":6,"ws":true},{"text":"rates","start":50,"end":55,"id":7,"ws":true},{"text":"of","start":56,"end":58,"id":8,"ws":true},{"text":"other","start":59,"end":64,"id":9,"ws":true},{"text":"biological","start":65,"end":75,"id":10,"ws":true},{"text":"therapies","start":76,"end":85,"id":11,"ws":true},{"text":"and","start":86,"end":89,"id":12,"ws":true},{"text":"rates","start":90,"end":95,"id":13,"ws":true},{"text":"of","start":96,"end":98,"id":14,"ws":true},{"text":"adverse","start":99,"end":106,"id":15,"ws":true},{"text":"events","start":107,"end":113,"id":16,"ws":true},{"text":"were","start":114,"end":118,"id":17,"ws":true},{"text":"similar","start":119,"end":126,"id":18,"ws":true},{"text":"between","start":127,"end":134,"id":19,"ws":true},{"text":"brodalumab","start":135,"end":145,"id":20,"ws":true},{"text":"and","start":146,"end":149,"id":21,"ws":true},{"text":"ustekinumab","start":150,"end":161,"id":22,"ws":true},{"text":".","start":162,"end":163,"id":23,"ws":false}],"spans":[{"start":135,"end":145,"token_start":20,"token_end":20,"label":"DRUG"},{"start":150,"end":161,"token_start":22,"token_end":22,"label":"DRUG"}],"_input_hash":-2044054306,"_task_hash":40529012,"_session_id":"drug_drug_pilot_shared-hagit","_view_id":"blocks","relations":[{"head":20,"child":22,"head_span":{"start":135,"end":145,"token_start":20,"token_end":20,"label":"DRUG"},"child_span":{"start":150,"end":161,"token_start":22,"token_end":22,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"In patients with NPSLE , the use of high-dose corticosteroids is recommended in combination with immunosuppressants , such as mycophenolate mofetil and intravenous cyclophosphamide pulse therapy .","paragraph":"<h3><u>[Neuropsychiatric Systemic Lupus Erythematosus].</u></h3>Central nervous system damage, a major organ manifestation of systemic lupus erythematosus (SLE), causes significant morbidity and mortality. Designating this condition as neuropsychiatric SLE (NPSLE), the American College of Rheumatology defines it as involving the central and peripheral nervous systems and being characterized by various manifestations including stroke, seizures, and psychosis. NPSLE treatment mainly seeks to reduce damage accrual. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>NPSLE</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:DodgerBlue;'><i>corticosteroids</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>recommended</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>immunosuppressants</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>mycophenolate</i></b> <b style='color:DodgerBlue;'><i>mofetil</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>pulse</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> This can be accomplished by controlling the activity of the disease, minimizing the use of corticosteroids, and optimizing the management of comorbidities, including cardiovascular risk factors. An international task force analysis of a treat-to-target strategy for SLE (T2T/SLE) recommended targeting remission, preventing damage, and improving quality of life. Thus, more effective and less toxic treatments, such as those using biologics or kinase inhibitors, are still being developed for the treatment of SLE/NPSLE.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"patients","start":3,"end":11,"id":1,"ws":true},{"text":"with","start":12,"end":16,"id":2,"ws":true},{"text":"NPSLE","start":17,"end":22,"id":3,"ws":true},{"text":",","start":23,"end":24,"id":4,"ws":true},{"text":"the","start":25,"end":28,"id":5,"ws":true},{"text":"use","start":29,"end":32,"id":6,"ws":true},{"text":"of","start":33,"end":35,"id":7,"ws":true},{"text":"high-dose","start":36,"end":45,"id":8,"ws":true},{"text":"corticosteroids","start":46,"end":61,"id":9,"ws":true},{"text":"is","start":62,"end":64,"id":10,"ws":true},{"text":"recommended","start":65,"end":76,"id":11,"ws":true},{"text":"in","start":77,"end":79,"id":12,"ws":true},{"text":"combination","start":80,"end":91,"id":13,"ws":true},{"text":"with","start":92,"end":96,"id":14,"ws":true},{"text":"immunosuppressants","start":97,"end":115,"id":15,"ws":true},{"text":",","start":116,"end":117,"id":16,"ws":true},{"text":"such","start":118,"end":122,"id":17,"ws":true},{"text":"as","start":123,"end":125,"id":18,"ws":true},{"text":"mycophenolate","start":126,"end":139,"id":19,"ws":true},{"text":"mofetil","start":140,"end":147,"id":20,"ws":true},{"text":"and","start":148,"end":151,"id":21,"ws":true},{"text":"intravenous","start":152,"end":163,"id":22,"ws":true},{"text":"cyclophosphamide","start":164,"end":180,"id":23,"ws":true},{"text":"pulse","start":181,"end":186,"id":24,"ws":true},{"text":"therapy","start":187,"end":194,"id":25,"ws":true},{"text":".","start":195,"end":196,"id":26,"ws":false}],"spans":[{"start":126,"end":139,"token_start":19,"token_end":19,"label":"DRUG"},{"start":164,"end":180,"token_start":23,"token_end":23,"label":"DRUG"}],"_input_hash":438186251,"_task_hash":1532533663,"_session_id":"drug_drug_pilot_shared-hagit","_view_id":"blocks","relations":[{"head":9,"child":19,"head_span":{"start":46,"end":61,"token_start":9,"token_end":9,"label":null},"child_span":{"start":126,"end":139,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":9,"child":20,"head_span":{"start":46,"end":61,"token_start":9,"token_end":9,"label":null},"child_span":{"start":140,"end":147,"token_start":20,"token_end":20,"label":null},"color":"#ffd882","label":"POS2"},{"head":9,"child":23,"head_span":{"start":46,"end":61,"token_start":9,"token_end":9,"label":null},"child_span":{"start":164,"end":180,"token_start":23,"token_end":23,"label":"DRUG"},"color":"#d9fbad","label":"POS3"}],"radio":["POS10","POS1T0","POS20","POS2T0","POS30","POS3T1"],"answer":"accept"}
{"text":"Thirty-three women diagnosed with metastatic breast cancer participated in a phase 1 clinical trial of a new combination of cyclophosphamide ( CTX ) and mitoxantrone ( MXT ) , with dose escalation of paclitaxel .","paragraph":"<h3><u>Longitudinal effects of high-dose chemotherapy and autologous stem cell transplantation on quality of life in the treatment of metastatic breast cancer.</u></h3>This study determined the effects of high-dose chemotherapy (HDCT) with autologous blood stem cell transplantation (ASCT) on quality of life (QL) in women with metastatic breast cancer prior to, and during treatment, and up to 1-year post-ASCT. <b style='color:DodgerBlue;'><i>Thirty-three</i></b> <b style='color:DodgerBlue;'><i>women</i></b> <b style='color:DodgerBlue;'><i>diagnosed</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>participated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>new</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CTX</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>mitoxantrone</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>MXT</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>escalation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Longitudinal QL data were collected using the functional living index-cancer (FLIC) and symptom scales at seven time periods: pre-induction chemotherapy (CT), post-induction CT, post-high dose CT (HDCT), and at 3, 6, 9 and 12 months post-ASCT. FLIC scores indicated that the worst problems for patients were feelings of hardship on themselves and their families, followed by psychological functioning and physical functioning problems. The time around diagnosis of the metastatic disease and following HDCT were the worst times for all levels of quality of life, but anxiety and depression symptoms continued to increase in severity across the entire follow-up period. The symptoms that were most problematic were worry about the future, loss of sexual interest, anxiety about the treatment, general worrying, and joint pain. These data highlight the problems that women with metastatic breast cancer encounter at different stages of the disease and treatment process, and can be used to tailor psychosocial interventions appropriate for treating the relevant issues at different points in time.","tokens":[{"text":"Thirty-three","start":0,"end":12,"id":0,"ws":true},{"text":"women","start":13,"end":18,"id":1,"ws":true},{"text":"diagnosed","start":19,"end":28,"id":2,"ws":true},{"text":"with","start":29,"end":33,"id":3,"ws":true},{"text":"metastatic","start":34,"end":44,"id":4,"ws":true},{"text":"breast","start":45,"end":51,"id":5,"ws":true},{"text":"cancer","start":52,"end":58,"id":6,"ws":true},{"text":"participated","start":59,"end":71,"id":7,"ws":true},{"text":"in","start":72,"end":74,"id":8,"ws":true},{"text":"a","start":75,"end":76,"id":9,"ws":true},{"text":"phase","start":77,"end":82,"id":10,"ws":true},{"text":"1","start":83,"end":84,"id":11,"ws":true},{"text":"clinical","start":85,"end":93,"id":12,"ws":true},{"text":"trial","start":94,"end":99,"id":13,"ws":true},{"text":"of","start":100,"end":102,"id":14,"ws":true},{"text":"a","start":103,"end":104,"id":15,"ws":true},{"text":"new","start":105,"end":108,"id":16,"ws":true},{"text":"combination","start":109,"end":120,"id":17,"ws":true},{"text":"of","start":121,"end":123,"id":18,"ws":true},{"text":"cyclophosphamide","start":124,"end":140,"id":19,"ws":true},{"text":"(","start":141,"end":142,"id":20,"ws":true},{"text":"CTX","start":143,"end":146,"id":21,"ws":true},{"text":")","start":147,"end":148,"id":22,"ws":true},{"text":"and","start":149,"end":152,"id":23,"ws":true},{"text":"mitoxantrone","start":153,"end":165,"id":24,"ws":true},{"text":"(","start":166,"end":167,"id":25,"ws":true},{"text":"MXT","start":168,"end":171,"id":26,"ws":true},{"text":")","start":172,"end":173,"id":27,"ws":true},{"text":",","start":174,"end":175,"id":28,"ws":true},{"text":"with","start":176,"end":180,"id":29,"ws":true},{"text":"dose","start":181,"end":185,"id":30,"ws":true},{"text":"escalation","start":186,"end":196,"id":31,"ws":true},{"text":"of","start":197,"end":199,"id":32,"ws":true},{"text":"paclitaxel","start":200,"end":210,"id":33,"ws":true},{"text":".","start":211,"end":212,"id":34,"ws":false}],"spans":[{"start":124,"end":140,"token_start":19,"token_end":19,"label":"DRUG"},{"start":153,"end":165,"token_start":24,"token_end":24,"label":"DRUG"},{"start":200,"end":210,"token_start":33,"token_end":33,"label":"DRUG"}],"_input_hash":1782132717,"_task_hash":189034633,"_session_id":"drug_drug_pilot_shared-hagit","_view_id":"blocks","relations":[{"head":19,"child":24,"head_span":{"start":124,"end":140,"token_start":19,"token_end":19,"label":"DRUG"},"child_span":{"start":153,"end":165,"token_start":24,"token_end":24,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":33,"child":24,"head_span":{"start":200,"end":210,"token_start":33,"token_end":33,"label":"DRUG"},"child_span":{"start":153,"end":165,"token_start":24,"token_end":24,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T0"],"answer":"accept"}
{"text":"Among the anti-herpesvirus agents , aciclovir , valaciclovir , penciclovir , famciclovir , idoxuridine , trifluridine and brivudin are used in the treatment of herpes simplex virus and varicella-zoster virus infections , and ganciclovir , foscarnet , cidofovir , fomivirsen and maribavir ( the latter in the developmental stage ) are used in the treatment of cytomegalovirus infections .","paragraph":"<h3><u>Antiviral drugs: current state of the art.</u></h3>The chemotherapy of virus infections has definitely come of age. There are now 15 antiviral agents that have been formally licensed for the treatment of human immunodeficiency virus infections (<b style='color:Tomato;'><i>zidovudine</i></b>, <b style='color:Tomato;'><i>didanosine</i></b>, <b style='color:Tomato;'><i>zalcitabine</i></b>, <b style='color:Tomato;'><i>stavudine</i></b>, <b style='color:Tomato;'><i>lamivudine</i></b>, <b style='color:Tomato;'><i>abacavir</i></b>, <b style='color:Tomato;'><i>nevirapine</i></b>, <b style='color:Tomato;'><i>delavirdine</i></b>, <b style='color:Tomato;'><i>efavirenz</i></b>, <b style='color:Tomato;'><i>saquinavir</i></b>, <b style='color:Tomato;'><i>ritonavir</i></b>, <b style='color:Tomato;'><i>indinavir</i></b>, <b style='color:Tomato;'><i>nelfinavir</i></b>, <b style='color:Tomato;'><i>amprenavir</i></b>, <b style='color:Tomato;'><i>lopinavir</i></b>) and several others, such as <b style='color:Tomato;'><i>tenofovir</i></b> disoproxil, <b style='color:Tomato;'><i>emtricitabine</i></b>, capravirine, emivirine, T-20 (pentafuside) and AMD3100 (bicyclam) are under clinical development. <b style='color:Tomato;'><i>lamivudine</i></b> has been approved, and several other compounds (such as <b style='color:Tomato;'><i>adefovir</i></b> dipivoxil, <b style='color:Tomato;'><i>emtricitabine</i></b> and <b style='color:Tomato;'><i>entecavir</i></b>) are under clinical development, for the treatment of hepatitis B virus infections. <b style='color:DodgerBlue;'><i>Among</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>anti-herpesvirus</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>aciclovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>valaciclovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>penciclovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>famciclovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>idoxuridine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>trifluridine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>brivudin</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>herpes</i></b> <b style='color:DodgerBlue;'><i>simplex</i></b> <b style='color:DodgerBlue;'><i>virus</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>varicella-zoster</i></b> <b style='color:DodgerBlue;'><i>virus</i></b> <b style='color:DodgerBlue;'><i>infections</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ganciclovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>foscarnet</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cidofovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>fomivirsen</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>maribavir</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>latter</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>developmental</i></b> <b style='color:DodgerBlue;'><i>stage</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cytomegalovirus</i></b> <b style='color:DodgerBlue;'><i>infections</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Following <b style='color:Tomato;'><i>amantadine</i></b> and <b style='color:Tomato;'><i>rimantadine</i></b>, the neuraminidase inhibitors, <b style='color:Tomato;'><i>zanamivir</i></b> and <b style='color:Tomato;'><i>oseltamivir</i></b>, have now become available for the therapy and prophylaxis of influenza virus infections, and so is <b style='color:Tomato;'><i>ribavirin</i></b> for the treatment of respiratory syncytial virus infections and the combination of <b style='color:Tomato;'><i>ribavirin</i></b> with interferon-alpha for the treatment of hepatitis C virus infections.","tokens":[{"text":"Among","start":0,"end":5,"id":0,"ws":true},{"text":"the","start":6,"end":9,"id":1,"ws":true},{"text":"anti-herpesvirus","start":10,"end":26,"id":2,"ws":true},{"text":"agents","start":27,"end":33,"id":3,"ws":true},{"text":",","start":34,"end":35,"id":4,"ws":true},{"text":"aciclovir","start":36,"end":45,"id":5,"ws":true},{"text":",","start":46,"end":47,"id":6,"ws":true},{"text":"valaciclovir","start":48,"end":60,"id":7,"ws":true},{"text":",","start":61,"end":62,"id":8,"ws":true},{"text":"penciclovir","start":63,"end":74,"id":9,"ws":true},{"text":",","start":75,"end":76,"id":10,"ws":true},{"text":"famciclovir","start":77,"end":88,"id":11,"ws":true},{"text":",","start":89,"end":90,"id":12,"ws":true},{"text":"idoxuridine","start":91,"end":102,"id":13,"ws":true},{"text":",","start":103,"end":104,"id":14,"ws":true},{"text":"trifluridine","start":105,"end":117,"id":15,"ws":true},{"text":"and","start":118,"end":121,"id":16,"ws":true},{"text":"brivudin","start":122,"end":130,"id":17,"ws":true},{"text":"are","start":131,"end":134,"id":18,"ws":true},{"text":"used","start":135,"end":139,"id":19,"ws":true},{"text":"in","start":140,"end":142,"id":20,"ws":true},{"text":"the","start":143,"end":146,"id":21,"ws":true},{"text":"treatment","start":147,"end":156,"id":22,"ws":true},{"text":"of","start":157,"end":159,"id":23,"ws":true},{"text":"herpes","start":160,"end":166,"id":24,"ws":true},{"text":"simplex","start":167,"end":174,"id":25,"ws":true},{"text":"virus","start":175,"end":180,"id":26,"ws":true},{"text":"and","start":181,"end":184,"id":27,"ws":true},{"text":"varicella-zoster","start":185,"end":201,"id":28,"ws":true},{"text":"virus","start":202,"end":207,"id":29,"ws":true},{"text":"infections","start":208,"end":218,"id":30,"ws":true},{"text":",","start":219,"end":220,"id":31,"ws":true},{"text":"and","start":221,"end":224,"id":32,"ws":true},{"text":"ganciclovir","start":225,"end":236,"id":33,"ws":true},{"text":",","start":237,"end":238,"id":34,"ws":true},{"text":"foscarnet","start":239,"end":248,"id":35,"ws":true},{"text":",","start":249,"end":250,"id":36,"ws":true},{"text":"cidofovir","start":251,"end":260,"id":37,"ws":true},{"text":",","start":261,"end":262,"id":38,"ws":true},{"text":"fomivirsen","start":263,"end":273,"id":39,"ws":true},{"text":"and","start":274,"end":277,"id":40,"ws":true},{"text":"maribavir","start":278,"end":287,"id":41,"ws":true},{"text":"(","start":288,"end":289,"id":42,"ws":true},{"text":"the","start":290,"end":293,"id":43,"ws":true},{"text":"latter","start":294,"end":300,"id":44,"ws":true},{"text":"in","start":301,"end":303,"id":45,"ws":true},{"text":"the","start":304,"end":307,"id":46,"ws":true},{"text":"developmental","start":308,"end":321,"id":47,"ws":true},{"text":"stage","start":322,"end":327,"id":48,"ws":true},{"text":")","start":328,"end":329,"id":49,"ws":true},{"text":"are","start":330,"end":333,"id":50,"ws":true},{"text":"used","start":334,"end":338,"id":51,"ws":true},{"text":"in","start":339,"end":341,"id":52,"ws":true},{"text":"the","start":342,"end":345,"id":53,"ws":true},{"text":"treatment","start":346,"end":355,"id":54,"ws":true},{"text":"of","start":356,"end":358,"id":55,"ws":true},{"text":"cytomegalovirus","start":359,"end":374,"id":56,"ws":true},{"text":"infections","start":375,"end":385,"id":57,"ws":true},{"text":".","start":386,"end":387,"id":58,"ws":false}],"spans":[{"start":36,"end":45,"token_start":5,"token_end":5,"label":"DRUG"},{"start":48,"end":60,"token_start":7,"token_end":7,"label":"DRUG"},{"start":63,"end":74,"token_start":9,"token_end":9,"label":"DRUG"},{"start":77,"end":88,"token_start":11,"token_end":11,"label":"DRUG"},{"start":91,"end":102,"token_start":13,"token_end":13,"label":"DRUG"},{"start":105,"end":117,"token_start":15,"token_end":15,"label":"DRUG"},{"start":225,"end":236,"token_start":33,"token_end":33,"label":"DRUG"},{"start":239,"end":248,"token_start":35,"token_end":35,"label":"DRUG"},{"start":251,"end":260,"token_start":37,"token_end":37,"label":"DRUG"}],"_input_hash":1265321677,"_task_hash":1758490147,"_session_id":"drug_drug_pilot_shared-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The present study examined the efficacy of single and combined treatment with an anticholinesterase , tetrahydroaminoacridine ( i.p . ) , and a glycine-B site partial agonist , D-cycloserine ( i.p . ; a positive allosteric modulator of NMDA receptors ) , in alleviating the deficit in water maze spatial navigation induced by electrolytic lesion of the medial septum or lidocaine infusion into the dorsal hippocampi .","paragraph":"<h3><u>Tetrahydroaminoacridine and D-cycloserine fail to alleviate the water maze spatial navigation defect induced by hippocampal inactivation.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>examined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>anticholinesterase</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>tetrahydroaminoacridine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>i.p</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>glycine-B</i></b> <b style='color:DodgerBlue;'><i>site</i></b> <b style='color:DodgerBlue;'><i>partial</i></b> <b style='color:DodgerBlue;'><i>agonist</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>D-cycloserine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>i.p</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>positive</i></b> <b style='color:DodgerBlue;'><i>allosteric</i></b> <b style='color:DodgerBlue;'><i>modulator</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>NMDA</i></b> <b style='color:DodgerBlue;'><i>receptors</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>alleviating</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>deficit</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>water</i></b> <b style='color:DodgerBlue;'><i>maze</i></b> <b style='color:DodgerBlue;'><i>spatial</i></b> <b style='color:DodgerBlue;'><i>navigation</i></b> <b style='color:DodgerBlue;'><i>induced</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>electrolytic</i></b> <b style='color:DodgerBlue;'><i>lesion</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>medial</i></b> <b style='color:DodgerBlue;'><i>septum</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>lidocaine</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>dorsal</i></b> <b style='color:DodgerBlue;'><i>hippocampi</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In medial septum-lesioned rats, a combination of tetrahydroaminoacridine 3 mg kg(-1) and <b style='color:Tomato;'><i>d-cycloserine</i></b> 10 mg kg(-1) facilitated acquisition of the water maze test more effectively than either of the drugs alone. Single or combined treatment with tetrahydroaminoacridine 3 mg kg(-1) and <b style='color:Tomato;'><i>d-cycloserine</i></b> 10 mg kg(-1) had no effect on the water maze deficit induced by hippocampal <b style='color:Tomato;'><i>lidocaine</i></b> infusion. These results suggest that combined treatment with tetrahydroaminoacridine and <b style='color:Tomato;'><i>d-cycloserine</i></b> can effectively stimulate water maze spatial navigation, and that functioning of the hippocampus is a prerequisite for this effect.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"present","start":4,"end":11,"id":1,"ws":true},{"text":"study","start":12,"end":17,"id":2,"ws":true},{"text":"examined","start":18,"end":26,"id":3,"ws":true},{"text":"the","start":27,"end":30,"id":4,"ws":true},{"text":"efficacy","start":31,"end":39,"id":5,"ws":true},{"text":"of","start":40,"end":42,"id":6,"ws":true},{"text":"single","start":43,"end":49,"id":7,"ws":true},{"text":"and","start":50,"end":53,"id":8,"ws":true},{"text":"combined","start":54,"end":62,"id":9,"ws":true},{"text":"treatment","start":63,"end":72,"id":10,"ws":true},{"text":"with","start":73,"end":77,"id":11,"ws":true},{"text":"an","start":78,"end":80,"id":12,"ws":true},{"text":"anticholinesterase","start":81,"end":99,"id":13,"ws":true},{"text":",","start":100,"end":101,"id":14,"ws":true},{"text":"tetrahydroaminoacridine","start":102,"end":125,"id":15,"ws":true},{"text":"(","start":126,"end":127,"id":16,"ws":true},{"text":"i.p","start":128,"end":131,"id":17,"ws":true},{"text":".","start":132,"end":133,"id":18,"ws":true},{"text":")","start":134,"end":135,"id":19,"ws":true},{"text":",","start":136,"end":137,"id":20,"ws":true},{"text":"and","start":138,"end":141,"id":21,"ws":true},{"text":"a","start":142,"end":143,"id":22,"ws":true},{"text":"glycine-B","start":144,"end":153,"id":23,"ws":true},{"text":"site","start":154,"end":158,"id":24,"ws":true},{"text":"partial","start":159,"end":166,"id":25,"ws":true},{"text":"agonist","start":167,"end":174,"id":26,"ws":true},{"text":",","start":175,"end":176,"id":27,"ws":true},{"text":"D-cycloserine","start":177,"end":190,"id":28,"ws":true},{"text":"(","start":191,"end":192,"id":29,"ws":true},{"text":"i.p","start":193,"end":196,"id":30,"ws":true},{"text":".","start":197,"end":198,"id":31,"ws":true},{"text":";","start":199,"end":200,"id":32,"ws":true},{"text":"a","start":201,"end":202,"id":33,"ws":true},{"text":"positive","start":203,"end":211,"id":34,"ws":true},{"text":"allosteric","start":212,"end":222,"id":35,"ws":true},{"text":"modulator","start":223,"end":232,"id":36,"ws":true},{"text":"of","start":233,"end":235,"id":37,"ws":true},{"text":"NMDA","start":236,"end":240,"id":38,"ws":true},{"text":"receptors","start":241,"end":250,"id":39,"ws":true},{"text":")","start":251,"end":252,"id":40,"ws":true},{"text":",","start":253,"end":254,"id":41,"ws":true},{"text":"in","start":255,"end":257,"id":42,"ws":true},{"text":"alleviating","start":258,"end":269,"id":43,"ws":true},{"text":"the","start":270,"end":273,"id":44,"ws":true},{"text":"deficit","start":274,"end":281,"id":45,"ws":true},{"text":"in","start":282,"end":284,"id":46,"ws":true},{"text":"water","start":285,"end":290,"id":47,"ws":true},{"text":"maze","start":291,"end":295,"id":48,"ws":true},{"text":"spatial","start":296,"end":303,"id":49,"ws":true},{"text":"navigation","start":304,"end":314,"id":50,"ws":true},{"text":"induced","start":315,"end":322,"id":51,"ws":true},{"text":"by","start":323,"end":325,"id":52,"ws":true},{"text":"electrolytic","start":326,"end":338,"id":53,"ws":true},{"text":"lesion","start":339,"end":345,"id":54,"ws":true},{"text":"of","start":346,"end":348,"id":55,"ws":true},{"text":"the","start":349,"end":352,"id":56,"ws":true},{"text":"medial","start":353,"end":359,"id":57,"ws":true},{"text":"septum","start":360,"end":366,"id":58,"ws":true},{"text":"or","start":367,"end":369,"id":59,"ws":true},{"text":"lidocaine","start":370,"end":379,"id":60,"ws":true},{"text":"infusion","start":380,"end":388,"id":61,"ws":true},{"text":"into","start":389,"end":393,"id":62,"ws":true},{"text":"the","start":394,"end":397,"id":63,"ws":true},{"text":"dorsal","start":398,"end":404,"id":64,"ws":true},{"text":"hippocampi","start":405,"end":415,"id":65,"ws":true},{"text":".","start":416,"end":417,"id":66,"ws":false}],"spans":[{"start":177,"end":190,"token_start":28,"token_end":28,"label":"DRUG"},{"start":370,"end":379,"token_start":60,"token_end":60,"label":"DRUG"}],"_input_hash":1944915333,"_task_hash":1724675945,"_session_id":"drug_drug_pilot_shared-hagit","_view_id":"blocks","relations":[{"head":13,"child":15,"head_span":{"start":81,"end":99,"token_start":13,"token_end":13,"label":null},"child_span":{"start":102,"end":125,"token_start":15,"token_end":15,"label":null},"color":"#96e8ce","label":"COMB1"},{"head":28,"child":15,"head_span":{"start":177,"end":190,"token_start":28,"token_end":28,"label":"DRUG"},"child_span":{"start":102,"end":125,"token_start":15,"token_end":15,"label":null},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"He was initially treated with combination chemotherapy regimen of vincristine , actinomycin-D and cyclophosphamide ( VAC therapy ) .","paragraph":"<h3><u>[Rhabdomyosarcoma of the bladder: a case report].</u></h3>A 15-year-old man with the chief complaint of general fatigue was referred to our hospital on November 11, 1993. Bilateral percutaneous nephrostomy was performed for postrenal anuria. X-ray examinations revealed a huge intrapelvic tumor, and it was histopathologically diagnosed as rhabdomyosarcoma by transrectal needle biopsy. <b style='color:DodgerBlue;'><i>He</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>initially</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>actinomycin-D</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>VAC</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Pelvic exenteration was performed on December 15, 1993. Histopathological findings were alveolar rhabdomyosarcoma with degenerative change and partial necrosis. After the operation, he was given two course of VAC therapy. In May, 1994, brain metastasis occurred, so 4 courses of VAC therapy were administered. For a very short period, neurological symptoms improved, but he died of pneumonia on November 15, 1994.","tokens":[{"text":"He","start":0,"end":2,"id":0,"ws":true},{"text":"was","start":3,"end":6,"id":1,"ws":true},{"text":"initially","start":7,"end":16,"id":2,"ws":true},{"text":"treated","start":17,"end":24,"id":3,"ws":true},{"text":"with","start":25,"end":29,"id":4,"ws":true},{"text":"combination","start":30,"end":41,"id":5,"ws":true},{"text":"chemotherapy","start":42,"end":54,"id":6,"ws":true},{"text":"regimen","start":55,"end":62,"id":7,"ws":true},{"text":"of","start":63,"end":65,"id":8,"ws":true},{"text":"vincristine","start":66,"end":77,"id":9,"ws":true},{"text":",","start":78,"end":79,"id":10,"ws":true},{"text":"actinomycin-D","start":80,"end":93,"id":11,"ws":true},{"text":"and","start":94,"end":97,"id":12,"ws":true},{"text":"cyclophosphamide","start":98,"end":114,"id":13,"ws":true},{"text":"(","start":115,"end":116,"id":14,"ws":true},{"text":"VAC","start":117,"end":120,"id":15,"ws":true},{"text":"therapy","start":121,"end":128,"id":16,"ws":true},{"text":")","start":129,"end":130,"id":17,"ws":true},{"text":".","start":131,"end":132,"id":18,"ws":false}],"spans":[{"start":66,"end":77,"token_start":9,"token_end":9,"label":"DRUG"},{"start":98,"end":114,"token_start":13,"token_end":13,"label":"DRUG"}],"_input_hash":1557412523,"_task_hash":-2119098685,"_session_id":"drug_drug_pilot_shared-hagit","_view_id":"blocks","relations":[{"head":9,"child":11,"head_span":{"start":66,"end":77,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":80,"end":93,"token_start":11,"token_end":11,"label":null},"color":"#96e8ce","label":"COMB1"},{"head":13,"child":11,"head_span":{"start":98,"end":114,"token_start":13,"token_end":13,"label":"DRUG"},"child_span":{"start":80,"end":93,"token_start":11,"token_end":11,"label":null},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"However , when a lung mass was noted two months later , he started to receive combination chemotherapy consisting of cyclophosphamide , adriamycin , vincristine , and prednisolone every three months .","paragraph":"<h3><u>[Lymphomatoid granulomatosis (LYG) occurring in a patient with follicular lymphoma during remission].</u></h3>A 49 years-old man presented with dry cough, low grade fever, and abnormal shadow on a chest X-ray. He had suffered from follicular lymphoma of the liver 5 years previously. He received irradiation therapy in combination with chemotherapy for approximately three years and had been in complete remission. Physical and radiological examination revealed pleural effusion and softly dense masses in the right lung. The laboratory data were within normal limits. He was diagnosed as having lymphomatoid granulomatosis (LYG) by open lung biopsy. The lung lesion was mainly infiltrated with T cells. The patient received <b style='color:Tomato;'><i>prednisolone</i></b> and the lung lesions disappeared. <b style='color:DodgerBlue;'><i>However</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>lung</i></b> <b style='color:DodgerBlue;'><i>mass</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>noted</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>later</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>he</i></b> <b style='color:DodgerBlue;'><i>started</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>receive</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>consisting</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>adriamycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>prednisolone</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>three</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>.</i></b> He has not shown relapse of LYG so far. To investigate the association between the preceding follicular lymphoma and subsequent LYG at this time, DNA analysis using the PCR technique was carried out. The LYG lesion did not show a rearranged band for the JH probe, while the paraffin-embedded specimen of the preceding follicular lymphoma had shown rearranged band for the JH band. Southern blot analysis of the LYG lesion, showed no rearrangement for TCR beta, gamma or JH probe. These findings indicate that the LYG was different from the preceding follicular lymphoma in terms of origin. LYG is considered to be induced in the immunosuppressive state due to lymphoma.","tokens":[{"text":"However","start":0,"end":7,"id":0,"ws":true},{"text":",","start":8,"end":9,"id":1,"ws":true},{"text":"when","start":10,"end":14,"id":2,"ws":true},{"text":"a","start":15,"end":16,"id":3,"ws":true},{"text":"lung","start":17,"end":21,"id":4,"ws":true},{"text":"mass","start":22,"end":26,"id":5,"ws":true},{"text":"was","start":27,"end":30,"id":6,"ws":true},{"text":"noted","start":31,"end":36,"id":7,"ws":true},{"text":"two","start":37,"end":40,"id":8,"ws":true},{"text":"months","start":41,"end":47,"id":9,"ws":true},{"text":"later","start":48,"end":53,"id":10,"ws":true},{"text":",","start":54,"end":55,"id":11,"ws":true},{"text":"he","start":56,"end":58,"id":12,"ws":true},{"text":"started","start":59,"end":66,"id":13,"ws":true},{"text":"to","start":67,"end":69,"id":14,"ws":true},{"text":"receive","start":70,"end":77,"id":15,"ws":true},{"text":"combination","start":78,"end":89,"id":16,"ws":true},{"text":"chemotherapy","start":90,"end":102,"id":17,"ws":true},{"text":"consisting","start":103,"end":113,"id":18,"ws":true},{"text":"of","start":114,"end":116,"id":19,"ws":true},{"text":"cyclophosphamide","start":117,"end":133,"id":20,"ws":true},{"text":",","start":134,"end":135,"id":21,"ws":true},{"text":"adriamycin","start":136,"end":146,"id":22,"ws":true},{"text":",","start":147,"end":148,"id":23,"ws":true},{"text":"vincristine","start":149,"end":160,"id":24,"ws":true},{"text":",","start":161,"end":162,"id":25,"ws":true},{"text":"and","start":163,"end":166,"id":26,"ws":true},{"text":"prednisolone","start":167,"end":179,"id":27,"ws":true},{"text":"every","start":180,"end":185,"id":28,"ws":true},{"text":"three","start":186,"end":191,"id":29,"ws":true},{"text":"months","start":192,"end":198,"id":30,"ws":true},{"text":".","start":199,"end":200,"id":31,"ws":false}],"spans":[{"start":117,"end":133,"token_start":20,"token_end":20,"label":"DRUG"},{"start":149,"end":160,"token_start":24,"token_end":24,"label":"DRUG"},{"start":167,"end":179,"token_start":27,"token_end":27,"label":"DRUG"}],"_input_hash":8987266,"_task_hash":528717002,"_session_id":"drug_drug_pilot_shared-hagit","_view_id":"blocks","relations":[{"head":20,"child":22,"head_span":{"start":117,"end":133,"token_start":20,"token_end":20,"label":"DRUG"},"child_span":{"start":136,"end":146,"token_start":22,"token_end":22,"label":null},"color":"#96e8ce","label":"COMB1"},{"head":24,"child":22,"head_span":{"start":149,"end":160,"token_start":24,"token_end":24,"label":"DRUG"},"child_span":{"start":136,"end":146,"token_start":22,"token_end":22,"label":null},"color":"#96e8ce","label":"COMB1"},{"head":27,"child":22,"head_span":{"start":167,"end":179,"token_start":27,"token_end":27,"label":"DRUG"},"child_span":{"start":136,"end":146,"token_start":22,"token_end":22,"label":null},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T1"],"answer":"accept"}
{"text":"Three patients treated initially with propranolol alone have required substitution of amiodarone due to refractory congestive heart failure .","paragraph":"<h3><u>The role of beta-blockade therapy for ventricular tachycardia induced with isoproterenol: a prospective analysis.</u></h3>Isoproterenol is sometimes required for ventricular tachycardia (VT) induction. However, the role of beta-blockade for treatment of such VT has not been critically assessed. The use of beta-blockade was evaluated prospectively in 14 consecutive patients who required isoproterenol 2.4 +/- 1.3 (+/- S.D.) micrograms/min to induce sustained monomorphic VT (greater than 30 seconds, or requiring termination due to hemodynamic collapse) after a negative baseline study. The VT mechanisms were enhanced automaticity (group A, six patients), triggered automaticity (group B, three patients), and reentry (group C, five patients). Groups A and B had serial intravenous electropharmacologic tests with <b style='color:Tomato;'><i>propranolol</i></b> alone (0.2 mg/kg), <b style='color:Tomato;'><i>verapamil</i></b> alone (0.15 mg/kg), and <b style='color:Tomato;'><i>propranolol</i></b> plus <b style='color:Tomato;'><i>verapamil</i></b>, and group C had serial tests with <b style='color:Tomato;'><i>propranolol</i></b> alone, <b style='color:Tomato;'><i>procainamide</i></b> or <b style='color:Tomato;'><i>quinidine</i></b> (class Ia drug) alone, and <b style='color:Tomato;'><i>propranolol</i></b> plus a class Ia drug until VT could no longer be induced. All six patients in group A responded to <b style='color:Tomato;'><i>propranolol</i></b> alone. In group B, one patient responded to <b style='color:Tomato;'><i>verapamil</i></b> alone, and two patients responded to <b style='color:Tomato;'><i>propranolol</i></b> plus <b style='color:Tomato;'><i>verapamil</i></b>. In group C, three patients responded to <b style='color:Tomato;'><i>propranolol</i></b> alone, one patient responded to a class Ia drug alone, and one patient responded to <b style='color:Tomato;'><i>propranolol</i></b> plus a class Ia drug. During a follow-up of 7 to 37 (17.9 +/- 10.7) (+/- S.D.) months, VT has not recurred in any patient. <b style='color:DodgerBlue;'><i>Three</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>initially</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>propranolol</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>required</i></b> <b style='color:DodgerBlue;'><i>substitution</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>amiodarone</i></b> <b style='color:DodgerBlue;'><i>due</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>refractory</i></b> <b style='color:DodgerBlue;'><i>congestive</i></b> <b style='color:DodgerBlue;'><i>heart</i></b> <b style='color:DodgerBlue;'><i>failure</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In patients requiring isoproterenol for VT induction, beta-blockade alone appears to be effective in preventing reinduction of VT caused by enhanced automaticity. A heterogeneous response occurs when the VT mechanisms are triggered automaticity or reentry.","tokens":[{"text":"Three","start":0,"end":5,"id":0,"ws":true},{"text":"patients","start":6,"end":14,"id":1,"ws":true},{"text":"treated","start":15,"end":22,"id":2,"ws":true},{"text":"initially","start":23,"end":32,"id":3,"ws":true},{"text":"with","start":33,"end":37,"id":4,"ws":true},{"text":"propranolol","start":38,"end":49,"id":5,"ws":true},{"text":"alone","start":50,"end":55,"id":6,"ws":true},{"text":"have","start":56,"end":60,"id":7,"ws":true},{"text":"required","start":61,"end":69,"id":8,"ws":true},{"text":"substitution","start":70,"end":82,"id":9,"ws":true},{"text":"of","start":83,"end":85,"id":10,"ws":true},{"text":"amiodarone","start":86,"end":96,"id":11,"ws":true},{"text":"due","start":97,"end":100,"id":12,"ws":true},{"text":"to","start":101,"end":103,"id":13,"ws":true},{"text":"refractory","start":104,"end":114,"id":14,"ws":true},{"text":"congestive","start":115,"end":125,"id":15,"ws":true},{"text":"heart","start":126,"end":131,"id":16,"ws":true},{"text":"failure","start":132,"end":139,"id":17,"ws":true},{"text":".","start":140,"end":141,"id":18,"ws":false}],"spans":[{"start":38,"end":49,"token_start":5,"token_end":5,"label":"DRUG"},{"start":86,"end":96,"token_start":11,"token_end":11,"label":"DRUG"}],"_input_hash":-632828286,"_task_hash":-1526074177,"_session_id":"drug_drug_pilot_shared-hagit","_view_id":"blocks","relations":[{"head":5,"child":11,"head_span":{"start":38,"end":49,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":86,"end":96,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"These studies suggest a slight advantage to the combined approaches that contain flutamide and bicalutamide , but the lack of dramatic differences in outcome makes monotherapy reasonable , especially in patients with more indolent disease .","paragraph":"<h3><u>The selection of hormonal therapy in prostate cancer: who, when, and for how long?</u></h3>Androgen deprivation is the foundation for the systemic therapy of advanced prostate cancer. Multiple trials have tested combined androgen blockade versus androgen deprivation alone in patients with advanced disease. <b style='color:DodgerBlue;'><i>These</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>suggest</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>slight</i></b> <b style='color:DodgerBlue;'><i>advantage</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>approaches</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>contain</i></b> <b style='color:MediumOrchid;'><i>flutamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>bicalutamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>lack</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>dramatic</i></b> <b style='color:DodgerBlue;'><i>differences</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>outcome</i></b> <b style='color:DodgerBlue;'><i>makes</i></b> <b style='color:DodgerBlue;'><i>monotherapy</i></b> <b style='color:DodgerBlue;'><i>reasonable</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>especially</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>indolent</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Intermittent androgen deprivation is an alternative that may allow patients to reduce the total time on androgen suppression as well as possibly delay the onset of androgen independence. A number of secondary hormonal therapies, including deferred and secondary antiandrogens, <b style='color:Tomato;'><i>ketoconazole</i></b>, and estrogens have shown modest response proportions. Patients with less advanced disease such as a rising prostate-specific antigen have varied outcomes, and no standard approach exists. In this group, noncastrating forms of hormonal therapy are being evaluated. Patients undergoing definitive local therapy who have high-risk features may benefit from early, as opposed to deferred, androgen deprivation. This review examines the evidence for the current state of the art in hormonal therapy in patients with prostate cancer and focuses, in particular, on treatment composition and timing as well as the rationale for the use of hormonal therapy in early stage disease.","tokens":[{"text":"These","start":0,"end":5,"id":0,"ws":true},{"text":"studies","start":6,"end":13,"id":1,"ws":true},{"text":"suggest","start":14,"end":21,"id":2,"ws":true},{"text":"a","start":22,"end":23,"id":3,"ws":true},{"text":"slight","start":24,"end":30,"id":4,"ws":true},{"text":"advantage","start":31,"end":40,"id":5,"ws":true},{"text":"to","start":41,"end":43,"id":6,"ws":true},{"text":"the","start":44,"end":47,"id":7,"ws":true},{"text":"combined","start":48,"end":56,"id":8,"ws":true},{"text":"approaches","start":57,"end":67,"id":9,"ws":true},{"text":"that","start":68,"end":72,"id":10,"ws":true},{"text":"contain","start":73,"end":80,"id":11,"ws":true},{"text":"flutamide","start":81,"end":90,"id":12,"ws":true},{"text":"and","start":91,"end":94,"id":13,"ws":true},{"text":"bicalutamide","start":95,"end":107,"id":14,"ws":true},{"text":",","start":108,"end":109,"id":15,"ws":true},{"text":"but","start":110,"end":113,"id":16,"ws":true},{"text":"the","start":114,"end":117,"id":17,"ws":true},{"text":"lack","start":118,"end":122,"id":18,"ws":true},{"text":"of","start":123,"end":125,"id":19,"ws":true},{"text":"dramatic","start":126,"end":134,"id":20,"ws":true},{"text":"differences","start":135,"end":146,"id":21,"ws":true},{"text":"in","start":147,"end":149,"id":22,"ws":true},{"text":"outcome","start":150,"end":157,"id":23,"ws":true},{"text":"makes","start":158,"end":163,"id":24,"ws":true},{"text":"monotherapy","start":164,"end":175,"id":25,"ws":true},{"text":"reasonable","start":176,"end":186,"id":26,"ws":true},{"text":",","start":187,"end":188,"id":27,"ws":true},{"text":"especially","start":189,"end":199,"id":28,"ws":true},{"text":"in","start":200,"end":202,"id":29,"ws":true},{"text":"patients","start":203,"end":211,"id":30,"ws":true},{"text":"with","start":212,"end":216,"id":31,"ws":true},{"text":"more","start":217,"end":221,"id":32,"ws":true},{"text":"indolent","start":222,"end":230,"id":33,"ws":true},{"text":"disease","start":231,"end":238,"id":34,"ws":true},{"text":".","start":239,"end":240,"id":35,"ws":false}],"spans":[{"start":81,"end":90,"token_start":12,"token_end":12,"label":"DRUG"},{"start":95,"end":107,"token_start":14,"token_end":14,"label":"DRUG"}],"_input_hash":137769162,"_task_hash":410888998,"_session_id":"drug_drug_pilot_shared-hagit","_view_id":"blocks","relations":[{"head":12,"child":14,"head_span":{"start":81,"end":90,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":95,"end":107,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T0"],"answer":"accept"}
{"text":"We examined the feasibility and safety of using paclitaxel and trastuzumab as maintenance therapy after high-dose chemotherapy ( HDC ) with autologous hematopoietic stem cell transplantation ( AHST ) for patients with HER2-positive metastatic breast cancer .","paragraph":"<h3><u>Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation.</u></h3> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>examined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>feasibility</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>maintenance</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>HDC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>autologous</i></b> <b style='color:DodgerBlue;'><i>hematopoietic</i></b> <b style='color:DodgerBlue;'><i>stem</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>transplantation</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AHST</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>HER2-positive</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Ten patients (9 women and 1 man) were enrolled in the study. The median age was 46.5 years (range, 27-65 years). The median follow-up time was 1003 days (range, 216-2526 days). All patients had metastatic disease, but 2 had only bone metastasis. One patient had complete response, 6 had partial response and 3 had stable disease to the standard-dose chemotherapy prior to transplantation. The conditioning regimen consisted of <b style='color:Tomato;'><i>cyclophosphamide</i></b>, <b style='color:Tomato;'><i>carmustine</i></b>, and <b style='color:Tomato;'><i>thiotepa</i></b>. After AHST, patients received weekly <b style='color:Tomato;'><i>paclitaxel</i></b> for 12 doses and <b style='color:Tomato;'><i>trastuzumab</i></b> every 3 weeks for 1 year as maintenance therapy. All patients experienced successful engraftment. The only grade 4 toxic effects observed were leukopenia and thrombocytopenia. The most common grade 3 toxic effect was neutropenic fever. No treatment-related deaths were observed. The median progression-free survival time was 441 days, and the median overall survival time was 955 days. Two patients died in accidents while their disease remained in remission. Five patients died with disease progression. At the time of this report, 3 patients are alive with stable disease, 1 of whom has remained free of disease progression for 2526 days since transplantation. Our findings indicate that <b style='color:Tomato;'><i>paclitaxel</i></b> plus <b style='color:Tomato;'><i>trastuzumab</i></b> as maintenance therapy after HDC with AHST for patients with HER2-positive metastatic breast cancer not only is feasible and safe but also results in survival outcomes similar to historical results. ","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"examined","start":3,"end":11,"id":1,"ws":true},{"text":"the","start":12,"end":15,"id":2,"ws":true},{"text":"feasibility","start":16,"end":27,"id":3,"ws":true},{"text":"and","start":28,"end":31,"id":4,"ws":true},{"text":"safety","start":32,"end":38,"id":5,"ws":true},{"text":"of","start":39,"end":41,"id":6,"ws":true},{"text":"using","start":42,"end":47,"id":7,"ws":true},{"text":"paclitaxel","start":48,"end":58,"id":8,"ws":true},{"text":"and","start":59,"end":62,"id":9,"ws":true},{"text":"trastuzumab","start":63,"end":74,"id":10,"ws":true},{"text":"as","start":75,"end":77,"id":11,"ws":true},{"text":"maintenance","start":78,"end":89,"id":12,"ws":true},{"text":"therapy","start":90,"end":97,"id":13,"ws":true},{"text":"after","start":98,"end":103,"id":14,"ws":true},{"text":"high-dose","start":104,"end":113,"id":15,"ws":true},{"text":"chemotherapy","start":114,"end":126,"id":16,"ws":true},{"text":"(","start":127,"end":128,"id":17,"ws":true},{"text":"HDC","start":129,"end":132,"id":18,"ws":true},{"text":")","start":133,"end":134,"id":19,"ws":true},{"text":"with","start":135,"end":139,"id":20,"ws":true},{"text":"autologous","start":140,"end":150,"id":21,"ws":true},{"text":"hematopoietic","start":151,"end":164,"id":22,"ws":true},{"text":"stem","start":165,"end":169,"id":23,"ws":true},{"text":"cell","start":170,"end":174,"id":24,"ws":true},{"text":"transplantation","start":175,"end":190,"id":25,"ws":true},{"text":"(","start":191,"end":192,"id":26,"ws":true},{"text":"AHST","start":193,"end":197,"id":27,"ws":true},{"text":")","start":198,"end":199,"id":28,"ws":true},{"text":"for","start":200,"end":203,"id":29,"ws":true},{"text":"patients","start":204,"end":212,"id":30,"ws":true},{"text":"with","start":213,"end":217,"id":31,"ws":true},{"text":"HER2-positive","start":218,"end":231,"id":32,"ws":true},{"text":"metastatic","start":232,"end":242,"id":33,"ws":true},{"text":"breast","start":243,"end":249,"id":34,"ws":true},{"text":"cancer","start":250,"end":256,"id":35,"ws":true},{"text":".","start":257,"end":258,"id":36,"ws":false}],"spans":[{"start":48,"end":58,"token_start":8,"token_end":8,"label":"DRUG"},{"start":63,"end":74,"token_start":10,"token_end":10,"label":"DRUG"}],"_input_hash":-1578970086,"_task_hash":304060663,"_session_id":"drug_drug_pilot_shared-hagit","_view_id":"blocks","relations":[{"head":8,"child":10,"head_span":{"start":48,"end":58,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":63,"end":74,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"Dual antiplatelet therapy with aspirin and clopidogrel ( the preferred thienopyridine because of its superior hematologic safety ) is recommended for at least 4 weeks to prevent subacute stent thrombosis with bare-metal stents and 3 to 6 months to prevent late-stent thrombosis with drug-eluting stents .","paragraph":"<h3><u>Long-term care after percutaneous coronary intervention: focus on the role of antiplatelet therapy.</u></h3>Arterial wall injury caused by percutaneous coronary intervention (PCI) triggers transient platelet activation and mural thrombosis; these effects are superimposed on the preexisting platelet hyperreactivity associated with underlying atherothrombosis. Platelet activation has been implicated in the major complications of PCI: acute and subacute thrombosis and restenosis. Antithrombotic and anticoagulant therapy minimizes thrombotic complications after PCI. <b style='color:Tomato;'><i>aspirin</i></b> plus a thienopyridine (<b style='color:Tomato;'><i>ticlopidine</i></b> or <b style='color:Tomato;'><i>clopidogrel</i></b>) is more effective than <b style='color:Tomato;'><i>aspirin</i></b> plus <b style='color:Tomato;'><i>heparin</i></b> and extended <b style='color:Tomato;'><i>warfarin</i></b> therapy in preventing periprocedural ischemic events and subsequent stent thrombosis and results in less major and minor bleeding. <b style='color:DodgerBlue;'><i>Dual</i></b> <b style='color:DodgerBlue;'><i>antiplatelet</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>aspirin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>clopidogrel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>preferred</i></b> <b style='color:DodgerBlue;'><i>thienopyridine</i></b> <b style='color:DodgerBlue;'><i>because</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>its</i></b> <b style='color:DodgerBlue;'><i>superior</i></b> <b style='color:DodgerBlue;'><i>hematologic</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>recommended</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>least</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>prevent</i></b> <b style='color:DodgerBlue;'><i>subacute</i></b> <b style='color:DodgerBlue;'><i>stent</i></b> <b style='color:DodgerBlue;'><i>thrombosis</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>bare-metal</i></b> <b style='color:DodgerBlue;'><i>stents</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>prevent</i></b> <b style='color:DodgerBlue;'><i>late-stent</i></b> <b style='color:DodgerBlue;'><i>thrombosis</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>drug-eluting</i></b> <b style='color:DodgerBlue;'><i>stents</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Coronary atherothrombosis is a diffuse vascular disease, and reduction of the risk of future ischemic events requires strategies that extend beyond the focal treatment of stenotic lesions. Optimal long-term care after PCI requires aggressive systemic pharmacotherapy (antiplatelet agents, statins, beta-blockers, and angiotensin-converting enzyme Inhibitors) in conjunction with therapeutic lifestyle changes (smoking cessation, weight reduction, dietary measures, and exercise). In this context, dual antiplatelet therapy (<b style='color:Tomato;'><i>aspirin</i></b> plus <b style='color:Tomato;'><i>clopidogrel</i></b>) is recommended for at least 12 months after PCI for prophylaxis of future atherothrombotic events.","tokens":[{"text":"Dual","start":0,"end":4,"id":0,"ws":true},{"text":"antiplatelet","start":5,"end":17,"id":1,"ws":true},{"text":"therapy","start":18,"end":25,"id":2,"ws":true},{"text":"with","start":26,"end":30,"id":3,"ws":true},{"text":"aspirin","start":31,"end":38,"id":4,"ws":true},{"text":"and","start":39,"end":42,"id":5,"ws":true},{"text":"clopidogrel","start":43,"end":54,"id":6,"ws":true},{"text":"(","start":55,"end":56,"id":7,"ws":true},{"text":"the","start":57,"end":60,"id":8,"ws":true},{"text":"preferred","start":61,"end":70,"id":9,"ws":true},{"text":"thienopyridine","start":71,"end":85,"id":10,"ws":true},{"text":"because","start":86,"end":93,"id":11,"ws":true},{"text":"of","start":94,"end":96,"id":12,"ws":true},{"text":"its","start":97,"end":100,"id":13,"ws":true},{"text":"superior","start":101,"end":109,"id":14,"ws":true},{"text":"hematologic","start":110,"end":121,"id":15,"ws":true},{"text":"safety","start":122,"end":128,"id":16,"ws":true},{"text":")","start":129,"end":130,"id":17,"ws":true},{"text":"is","start":131,"end":133,"id":18,"ws":true},{"text":"recommended","start":134,"end":145,"id":19,"ws":true},{"text":"for","start":146,"end":149,"id":20,"ws":true},{"text":"at","start":150,"end":152,"id":21,"ws":true},{"text":"least","start":153,"end":158,"id":22,"ws":true},{"text":"4","start":159,"end":160,"id":23,"ws":true},{"text":"weeks","start":161,"end":166,"id":24,"ws":true},{"text":"to","start":167,"end":169,"id":25,"ws":true},{"text":"prevent","start":170,"end":177,"id":26,"ws":true},{"text":"subacute","start":178,"end":186,"id":27,"ws":true},{"text":"stent","start":187,"end":192,"id":28,"ws":true},{"text":"thrombosis","start":193,"end":203,"id":29,"ws":true},{"text":"with","start":204,"end":208,"id":30,"ws":true},{"text":"bare-metal","start":209,"end":219,"id":31,"ws":true},{"text":"stents","start":220,"end":226,"id":32,"ws":true},{"text":"and","start":227,"end":230,"id":33,"ws":true},{"text":"3","start":231,"end":232,"id":34,"ws":true},{"text":"to","start":233,"end":235,"id":35,"ws":true},{"text":"6","start":236,"end":237,"id":36,"ws":true},{"text":"months","start":238,"end":244,"id":37,"ws":true},{"text":"to","start":245,"end":247,"id":38,"ws":true},{"text":"prevent","start":248,"end":255,"id":39,"ws":true},{"text":"late-stent","start":256,"end":266,"id":40,"ws":true},{"text":"thrombosis","start":267,"end":277,"id":41,"ws":true},{"text":"with","start":278,"end":282,"id":42,"ws":true},{"text":"drug-eluting","start":283,"end":295,"id":43,"ws":true},{"text":"stents","start":296,"end":302,"id":44,"ws":true},{"text":".","start":303,"end":304,"id":45,"ws":false}],"spans":[{"start":31,"end":38,"token_start":4,"token_end":4,"label":"DRUG"},{"start":43,"end":54,"token_start":6,"token_end":6,"label":"DRUG"}],"_input_hash":1471340217,"_task_hash":-1789027077,"_session_id":"drug_drug_pilot_shared-hagit","_view_id":"blocks","relations":[{"head":4,"child":6,"head_span":{"start":31,"end":38,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":43,"end":54,"token_start":6,"token_end":6,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T1"],"answer":"accept"}
{"text":"Furthermore , in non-metastatic castration-resistant prostate cancer ( M0 CRPC ) , two second-generation anti-androgens , apalutamide and enzalutamide , when used in combination with ADT , have demonstrated a significant benefit in metastasis-free survival .","paragraph":"<h3><u>Recent trends in the management of advanced prostate cancer.</u></h3>Advanced prostate cancer includes a wide spectrum of disease ranging from hormone na\u00efve or hormone sensitive to castration resistant, both containing populations of men who have demonstrable metastatic and non-metastatic states. The mainstay of treatment for metastatic hormone-sensitive prostate cancer is androgen deprivation therapy (ADT). However, recent level 1 evidence demonstrates that the addition of chemotherapy or <b style='color:Tomato;'><i>abiraterone</i></b> acetate to ADT results in significant survival advantage as compared with ADT alone. <b style='color:DodgerBlue;'><i>Furthermore</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>non-metastatic</i></b> <b style='color:DodgerBlue;'><i>castration-resistant</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>M0</i></b> <b style='color:DodgerBlue;'><i>CRPC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>second-generation</i></b> <b style='color:DodgerBlue;'><i>anti-androgens</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>apalutamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>enzalutamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>ADT</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>significant</i></b> <b style='color:DodgerBlue;'><i>benefit</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>metastasis-free</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Here, we review the most recent studies leading to these significant changes in the treatment of advanced prostate cancer.","tokens":[{"text":"Furthermore","start":0,"end":11,"id":0,"ws":true},{"text":",","start":12,"end":13,"id":1,"ws":true},{"text":"in","start":14,"end":16,"id":2,"ws":true},{"text":"non-metastatic","start":17,"end":31,"id":3,"ws":true},{"text":"castration-resistant","start":32,"end":52,"id":4,"ws":true},{"text":"prostate","start":53,"end":61,"id":5,"ws":true},{"text":"cancer","start":62,"end":68,"id":6,"ws":true},{"text":"(","start":69,"end":70,"id":7,"ws":true},{"text":"M0","start":71,"end":73,"id":8,"ws":true},{"text":"CRPC","start":74,"end":78,"id":9,"ws":true},{"text":")","start":79,"end":80,"id":10,"ws":true},{"text":",","start":81,"end":82,"id":11,"ws":true},{"text":"two","start":83,"end":86,"id":12,"ws":true},{"text":"second-generation","start":87,"end":104,"id":13,"ws":true},{"text":"anti-androgens","start":105,"end":119,"id":14,"ws":true},{"text":",","start":120,"end":121,"id":15,"ws":true},{"text":"apalutamide","start":122,"end":133,"id":16,"ws":true},{"text":"and","start":134,"end":137,"id":17,"ws":true},{"text":"enzalutamide","start":138,"end":150,"id":18,"ws":true},{"text":",","start":151,"end":152,"id":19,"ws":true},{"text":"when","start":153,"end":157,"id":20,"ws":true},{"text":"used","start":158,"end":162,"id":21,"ws":true},{"text":"in","start":163,"end":165,"id":22,"ws":true},{"text":"combination","start":166,"end":177,"id":23,"ws":true},{"text":"with","start":178,"end":182,"id":24,"ws":true},{"text":"ADT","start":183,"end":186,"id":25,"ws":true},{"text":",","start":187,"end":188,"id":26,"ws":true},{"text":"have","start":189,"end":193,"id":27,"ws":true},{"text":"demonstrated","start":194,"end":206,"id":28,"ws":true},{"text":"a","start":207,"end":208,"id":29,"ws":true},{"text":"significant","start":209,"end":220,"id":30,"ws":true},{"text":"benefit","start":221,"end":228,"id":31,"ws":true},{"text":"in","start":229,"end":231,"id":32,"ws":true},{"text":"metastasis-free","start":232,"end":247,"id":33,"ws":true},{"text":"survival","start":248,"end":256,"id":34,"ws":true},{"text":".","start":257,"end":258,"id":35,"ws":false}],"spans":[{"start":122,"end":133,"token_start":16,"token_end":16,"label":"DRUG"},{"start":138,"end":150,"token_start":18,"token_end":18,"label":"DRUG"}],"_input_hash":236482726,"_task_hash":-1620523265,"_session_id":"drug_drug_pilot_shared-hagit","_view_id":"blocks","relations":[{"head":16,"child":18,"head_span":{"start":122,"end":133,"token_start":16,"token_end":16,"label":"DRUG"},"child_span":{"start":138,"end":150,"token_start":18,"token_end":18,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":18,"child":25,"head_span":{"start":138,"end":150,"token_start":18,"token_end":18,"label":"DRUG"},"child_span":{"start":183,"end":186,"token_start":25,"token_end":25,"label":null},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T0"],"answer":"accept"}
{"text":"A screening method based on liquid chromatography-electrospray mass spectrometry for the simultaneous determination of six corticosteroids ( betamethasone 17-valerate BM 17-V , beclomethasone BC , beclomethasone dipropionate BCDP , methylprednisolone MP , budesonide BD , flunisolide FN ) was developed in order to control their illegal use in cosmetic and natural products .","paragraph":"<h3><u>LC-MS method for the simultaneous determination of six glucocorticoids in pharmaceutical formulations and counterfeit cosmetic products.</u></h3> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>screening</i></b> <b style='color:DodgerBlue;'><i>method</i></b> <b style='color:DodgerBlue;'><i>based</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>liquid</i></b> <b style='color:DodgerBlue;'><i>chromatography-electrospray</i></b> <b style='color:DodgerBlue;'><i>mass</i></b> <b style='color:DodgerBlue;'><i>spectrometry</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>simultaneous</i></b> <b style='color:DodgerBlue;'><i>determination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>six</i></b> <b style='color:DodgerBlue;'><i>corticosteroids</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>betamethasone</i></b> <b style='color:DodgerBlue;'><i>17-valerate</i></b> <b style='color:DodgerBlue;'><i>BM</i></b> <b style='color:DodgerBlue;'><i>17-V</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>beclomethasone</i></b> <b style='color:DodgerBlue;'><i>BC</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>beclomethasone</i></b> <b style='color:DodgerBlue;'><i>dipropionate</i></b> <b style='color:DodgerBlue;'><i>BCDP</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>methylprednisolone</i></b> <b style='color:DodgerBlue;'><i>MP</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>budesonide</i></b> <b style='color:DodgerBlue;'><i>BD</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>flunisolide</i></b> <b style='color:DodgerBlue;'><i>FN</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>developed</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>order</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>control</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>illegal</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>cosmetic</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>natural</i></b> <b style='color:DodgerBlue;'><i>products</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Indeed, despite corticosteroids are banned in cosmetics, counterfeit products might be present on the market, representing a health hazard. Therefore, effective analytical methods are required to rapidly screen over the counter products in health care shops for counterfeit corticosteroids. The analytical method involves the employment of a Waters Synergy C18 column (150mm\u00d72.0mm I.D.) by using the following mobile phase: A (0.1% formic acid in acetonitrile), B (0.1% formic acid in water) in a linear gradient (from A-B 25:75, v/v to A-B 95:5, v/v in 30min) at the flow rate of 0.3mL/min. The detection was performed with an ion trap (IT) mass spectrometer in positive polarity, total ion current (TIC) and tandem mass modalities for qualitative purpose; single ion monitoring (SIM) mode was used for quantitative analysis on the ESI generated most abundant ion for each steroid. The method was fully validated in terms of precision, detection and quantification limits, linearity, recovery, and it was applied to the identification and quantification of corticosteroids in pharmaceutical formulations and cosmetic products. The mean recovery of BM 17-V, BC, BCDP, MP, BD and FN were found to be 101.3, 101.5, 98.8, 98.9, 98.1, 99.0%, respectively. Limits of quantitation (LOQ) were comprised in the range 29-95ng/mL. To the best of our knowledge, for the first time this mix of glucocorticoids were simultaneously determined in cosmetic products by using a fully validated method. BMV, in its two isomeric forms BM 17-V and BM 21-V, was found to be illegally present in one cream sample (A) with the total concentration level of 0.036% (w/w). ","tokens":[{"text":"A","start":0,"end":1,"id":0,"ws":true},{"text":"screening","start":2,"end":11,"id":1,"ws":true},{"text":"method","start":12,"end":18,"id":2,"ws":true},{"text":"based","start":19,"end":24,"id":3,"ws":true},{"text":"on","start":25,"end":27,"id":4,"ws":true},{"text":"liquid","start":28,"end":34,"id":5,"ws":true},{"text":"chromatography-electrospray","start":35,"end":62,"id":6,"ws":true},{"text":"mass","start":63,"end":67,"id":7,"ws":true},{"text":"spectrometry","start":68,"end":80,"id":8,"ws":true},{"text":"for","start":81,"end":84,"id":9,"ws":true},{"text":"the","start":85,"end":88,"id":10,"ws":true},{"text":"simultaneous","start":89,"end":101,"id":11,"ws":true},{"text":"determination","start":102,"end":115,"id":12,"ws":true},{"text":"of","start":116,"end":118,"id":13,"ws":true},{"text":"six","start":119,"end":122,"id":14,"ws":true},{"text":"corticosteroids","start":123,"end":138,"id":15,"ws":true},{"text":"(","start":139,"end":140,"id":16,"ws":true},{"text":"betamethasone","start":141,"end":154,"id":17,"ws":true},{"text":"17-valerate","start":155,"end":166,"id":18,"ws":true},{"text":"BM","start":167,"end":169,"id":19,"ws":true},{"text":"17-V","start":170,"end":174,"id":20,"ws":true},{"text":",","start":175,"end":176,"id":21,"ws":true},{"text":"beclomethasone","start":177,"end":191,"id":22,"ws":true},{"text":"BC","start":192,"end":194,"id":23,"ws":true},{"text":",","start":195,"end":196,"id":24,"ws":true},{"text":"beclomethasone","start":197,"end":211,"id":25,"ws":true},{"text":"dipropionate","start":212,"end":224,"id":26,"ws":true},{"text":"BCDP","start":225,"end":229,"id":27,"ws":true},{"text":",","start":230,"end":231,"id":28,"ws":true},{"text":"methylprednisolone","start":232,"end":250,"id":29,"ws":true},{"text":"MP","start":251,"end":253,"id":30,"ws":true},{"text":",","start":254,"end":255,"id":31,"ws":true},{"text":"budesonide","start":256,"end":266,"id":32,"ws":true},{"text":"BD","start":267,"end":269,"id":33,"ws":true},{"text":",","start":270,"end":271,"id":34,"ws":true},{"text":"flunisolide","start":272,"end":283,"id":35,"ws":true},{"text":"FN","start":284,"end":286,"id":36,"ws":true},{"text":")","start":287,"end":288,"id":37,"ws":true},{"text":"was","start":289,"end":292,"id":38,"ws":true},{"text":"developed","start":293,"end":302,"id":39,"ws":true},{"text":"in","start":303,"end":305,"id":40,"ws":true},{"text":"order","start":306,"end":311,"id":41,"ws":true},{"text":"to","start":312,"end":314,"id":42,"ws":true},{"text":"control","start":315,"end":322,"id":43,"ws":true},{"text":"their","start":323,"end":328,"id":44,"ws":true},{"text":"illegal","start":329,"end":336,"id":45,"ws":true},{"text":"use","start":337,"end":340,"id":46,"ws":true},{"text":"in","start":341,"end":343,"id":47,"ws":true},{"text":"cosmetic","start":344,"end":352,"id":48,"ws":true},{"text":"and","start":353,"end":356,"id":49,"ws":true},{"text":"natural","start":357,"end":364,"id":50,"ws":true},{"text":"products","start":365,"end":373,"id":51,"ws":true},{"text":".","start":374,"end":375,"id":52,"ws":false}],"spans":[{"start":141,"end":154,"token_start":17,"token_end":17,"label":"DRUG"},{"start":177,"end":191,"token_start":22,"token_end":22,"label":"DRUG"},{"start":197,"end":211,"token_start":25,"token_end":25,"label":"DRUG"},{"start":232,"end":250,"token_start":29,"token_end":29,"label":"DRUG"},{"start":256,"end":266,"token_start":32,"token_end":32,"label":"DRUG"}],"_input_hash":782553464,"_task_hash":-1744775723,"_session_id":"drug_drug_pilot_shared-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"We used MCF-7 and MDA-MB231 breast cancer cells incubated with Curcumin and Quercetin for 24h , in the absence and presence of Somatostatin , at their EC50 concentrations , to evaluate membrane fatty acid-based functional lipidomics together with the follow-up of EGFR and MAPK signaling pathways .","paragraph":"<h3><u>Effects of Somatostatin, Curcumin and Quercetin on the fatty acid profile of breast cancer cell membranes.</u></h3> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>MCF-7</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>MDA-MB231</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>incubated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>Curcumin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Quercetin</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>24h</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>absence</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>presence</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>Somatostatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>EC50</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>membrane</i></b> <b style='color:DodgerBlue;'><i>fatty</i></b> <b style='color:DodgerBlue;'><i>acid-based</i></b> <b style='color:DodgerBlue;'><i>functional</i></b> <b style='color:DodgerBlue;'><i>lipidomics</i></b> <b style='color:DodgerBlue;'><i>together</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>follow-up</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>EGFR</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>MAPK</i></b> <b style='color:DodgerBlue;'><i>signaling</i></b> <b style='color:DodgerBlue;'><i>pathways</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The two cell lines gave different membrane free fatty acid reorganization: in MCF-7 cells, the following changes observed: increase of omega-6 linoleic acid in the cells incubated with <b style='color:Tomato;'><i>somatostatin</i></b>+Quercetin and Quercetin and decrease of omega-3 acids in the cells incubated with <b style='color:Tomato;'><i>somatostatin</i></b>+<b style='color:Tomato;'><i>curcumin</i></b> compared to <b style='color:Tomato;'><i>somatostatin</i></b>, and significant increases of monounsaturated fatty acid (MUFA), mono-trans arachidonic acid levels and docosapentaenoic acid for the cells incubated with <b style='color:Tomato;'><i>somatostatin</i></b>+Quercetin compared to the control cells. In MDA-MB231 cells, incubations with <b style='color:Tomato;'><i>curcumin</i></b>, Quercetin and <b style='color:Tomato;'><i>somatostatin</i></b>+Quercetin induced the most significant membrane remodeling with the increase of stearic acid, diminution of omega-6 linoleic, arachidonic acids and omega-3 (docosapentaenoic and docosahexaenoic acids). Distinct signaling pathway changes were found for these cell lines. In MCF-7 cells, separate or combined incubations with <b style='color:Tomato;'><i>somatostatin</i></b> and Quercetin, significantly decreased EGFR and incubation with <b style='color:Tomato;'><i>curcumin</i></b> decreased MAPK signaling. In MDA-MB231 cells, incubation with <b style='color:Tomato;'><i>curcumin</i></b> decreased AKT1 and p-AKT1(Thr308) levels. Incubation with <b style='color:Tomato;'><i>curcumin</i></b> and Quercetin decreased the EGFR levels.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"used","start":3,"end":7,"id":1,"ws":true},{"text":"MCF-7","start":8,"end":13,"id":2,"ws":true},{"text":"and","start":14,"end":17,"id":3,"ws":true},{"text":"MDA-MB231","start":18,"end":27,"id":4,"ws":true},{"text":"breast","start":28,"end":34,"id":5,"ws":true},{"text":"cancer","start":35,"end":41,"id":6,"ws":true},{"text":"cells","start":42,"end":47,"id":7,"ws":true},{"text":"incubated","start":48,"end":57,"id":8,"ws":true},{"text":"with","start":58,"end":62,"id":9,"ws":true},{"text":"Curcumin","start":63,"end":71,"id":10,"ws":true},{"text":"and","start":72,"end":75,"id":11,"ws":true},{"text":"Quercetin","start":76,"end":85,"id":12,"ws":true},{"text":"for","start":86,"end":89,"id":13,"ws":true},{"text":"24h","start":90,"end":93,"id":14,"ws":true},{"text":",","start":94,"end":95,"id":15,"ws":true},{"text":"in","start":96,"end":98,"id":16,"ws":true},{"text":"the","start":99,"end":102,"id":17,"ws":true},{"text":"absence","start":103,"end":110,"id":18,"ws":true},{"text":"and","start":111,"end":114,"id":19,"ws":true},{"text":"presence","start":115,"end":123,"id":20,"ws":true},{"text":"of","start":124,"end":126,"id":21,"ws":true},{"text":"Somatostatin","start":127,"end":139,"id":22,"ws":true},{"text":",","start":140,"end":141,"id":23,"ws":true},{"text":"at","start":142,"end":144,"id":24,"ws":true},{"text":"their","start":145,"end":150,"id":25,"ws":true},{"text":"EC50","start":151,"end":155,"id":26,"ws":true},{"text":"concentrations","start":156,"end":170,"id":27,"ws":true},{"text":",","start":171,"end":172,"id":28,"ws":true},{"text":"to","start":173,"end":175,"id":29,"ws":true},{"text":"evaluate","start":176,"end":184,"id":30,"ws":true},{"text":"membrane","start":185,"end":193,"id":31,"ws":true},{"text":"fatty","start":194,"end":199,"id":32,"ws":true},{"text":"acid-based","start":200,"end":210,"id":33,"ws":true},{"text":"functional","start":211,"end":221,"id":34,"ws":true},{"text":"lipidomics","start":222,"end":232,"id":35,"ws":true},{"text":"together","start":233,"end":241,"id":36,"ws":true},{"text":"with","start":242,"end":246,"id":37,"ws":true},{"text":"the","start":247,"end":250,"id":38,"ws":true},{"text":"follow-up","start":251,"end":260,"id":39,"ws":true},{"text":"of","start":261,"end":263,"id":40,"ws":true},{"text":"EGFR","start":264,"end":268,"id":41,"ws":true},{"text":"and","start":269,"end":272,"id":42,"ws":true},{"text":"MAPK","start":273,"end":277,"id":43,"ws":true},{"text":"signaling","start":278,"end":287,"id":44,"ws":true},{"text":"pathways","start":288,"end":296,"id":45,"ws":true},{"text":".","start":297,"end":298,"id":46,"ws":false}],"spans":[{"start":63,"end":71,"token_start":10,"token_end":10,"label":"DRUG"},{"start":127,"end":139,"token_start":22,"token_end":22,"label":"DRUG"}],"_input_hash":-1803484576,"_task_hash":288010961,"_session_id":"drug_drug_pilot_shared-hagit","_view_id":"blocks","relations":[{"head":10,"child":12,"head_span":{"start":63,"end":71,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":76,"end":85,"token_start":12,"token_end":12,"label":null},"color":"#96e8ce","label":"COMB1"},{"head":12,"child":22,"head_span":{"start":76,"end":85,"token_start":12,"token_end":12,"label":null},"child_span":{"start":127,"end":139,"token_start":22,"token_end":22,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T1"],"answer":"accept"}
{"text":"Following corneal scrapings and culture , topical 0.5 % moxifloxacin and 0.5 % tobramycin were administered hourly .","paragraph":"<h3><u>A case of Stenotrophomonas maltophilia keratitis effectively treated with moxifloxacin.</u></h3>A 70-year-old man with a long history of diabetes mellitus presented to our hospital (Department of Ophthalmology, Sahm Yook Medical Center, Seoul, Korea) complaining of severe ocular pain and visual disturbance in his left eye that had started three days prior to admission. A round 3.7 \u00d7 5.0 mm dense central stromal infiltrate with an overlying epithelial defect was noted on slit-lamp examination. <b style='color:DodgerBlue;'><i>Following</i></b> <b style='color:DodgerBlue;'><i>corneal</i></b> <b style='color:DodgerBlue;'><i>scrapings</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>culture</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>topical</i></b> <b style='color:DodgerBlue;'><i>0.5</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:MediumOrchid;'><i>moxifloxacin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>0.5</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:MediumOrchid;'><i>tobramycin</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>hourly</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A few days later, Stenotrophomonas maltophilia was isolated in a bacterial culture from a corneal specimen. According to the results of susceptibility tests, topical 0.5% <b style='color:Tomato;'><i>moxifloxacin</i></b> was given every hour and 0.5% <b style='color:Tomato;'><i>tobramycin</i></b> was stopped. The patient's clinical features improved steadily with treatment. The corneal epithelium healed rapidly, and the infiltrate resolved within four weeks of the initiation of treatment. The patient's best corrected visual acuity improved from hand motion to 20 / 25.","tokens":[{"text":"Following","start":0,"end":9,"id":0,"ws":true},{"text":"corneal","start":10,"end":17,"id":1,"ws":true},{"text":"scrapings","start":18,"end":27,"id":2,"ws":true},{"text":"and","start":28,"end":31,"id":3,"ws":true},{"text":"culture","start":32,"end":39,"id":4,"ws":true},{"text":",","start":40,"end":41,"id":5,"ws":true},{"text":"topical","start":42,"end":49,"id":6,"ws":true},{"text":"0.5","start":50,"end":53,"id":7,"ws":true},{"text":"%","start":54,"end":55,"id":8,"ws":true},{"text":"moxifloxacin","start":56,"end":68,"id":9,"ws":true},{"text":"and","start":69,"end":72,"id":10,"ws":true},{"text":"0.5","start":73,"end":76,"id":11,"ws":true},{"text":"%","start":77,"end":78,"id":12,"ws":true},{"text":"tobramycin","start":79,"end":89,"id":13,"ws":true},{"text":"were","start":90,"end":94,"id":14,"ws":true},{"text":"administered","start":95,"end":107,"id":15,"ws":true},{"text":"hourly","start":108,"end":114,"id":16,"ws":true},{"text":".","start":115,"end":116,"id":17,"ws":false}],"spans":[{"start":56,"end":68,"token_start":9,"token_end":9,"label":"DRUG"},{"start":79,"end":89,"token_start":13,"token_end":13,"label":"DRUG"}],"_input_hash":1332991430,"_task_hash":1426603318,"_session_id":"drug_drug_pilot_shared-hagit","_view_id":"blocks","relations":[{"head":9,"child":13,"head_span":{"start":56,"end":68,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":79,"end":89,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T1"],"answer":"accept"}
{"text":"Combination treatment with cetuximab and nystatin selectively increased cetuximab uptake by tumor tissues , translating into potentiated antitumor efficacy of cetuximab in vivo ( A431 and A549 tumors ) .","paragraph":"<h3><u>Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration.</u></h3><b style='color:Tomato;'><i>cetuximab</i></b>, a monoclonal antibody (mAb) targeting the epidermal growth factor receptor (EGFR), has been intensively investigated as a promising cancer treatment strategy. The specific mechanism of <b style='color:Tomato;'><i>cetuximab</i></b> endocytosis and its influence on <b style='color:Tomato;'><i>cetuximab</i></b> uptake, biodistribution and efficacy still remain elusive. Recently, statins have been reported to synergize with EGFR-targeting agents. Our prior work established that <b style='color:Tomato;'><i>nystatin</i></b>, a cholesterol-sequestering antifungal drug, facilitates endocytosis via the clathrin-dependent pathway. This study aimed to investigate whether <b style='color:Tomato;'><i>nystatin</i></b> regulates the uptake and efficacy of <b style='color:Tomato;'><i>cetuximab</i></b> and <b style='color:Tomato;'><i>cetuximab</i></b>-based antibody-drug conjugates (<b style='color:Tomato;'><i>cetuximab</i></b>-ADCs). In vitro and in vivo efficacies of <b style='color:Tomato;'><i>nystatin</i></b> on the uptake and activity of <b style='color:Tomato;'><i>cetuximab</i></b>/<b style='color:Tomato;'><i>cetuximab</i></b>-ADCs were studied in multiple human carcinoma cell lines and xenograft models, respectively. We identified that cholesterol sequestration by <b style='color:Tomato;'><i>nystatin</i></b> enhanced <b style='color:Tomato;'><i>cetuximab</i></b> internalization in EGFR-positive carcinoma cells by regulating EGFR trafficking/turnover and facilitating a switch from lipid rafts to clathrin-mediated endocytosis. <b style='color:DodgerBlue;'><i>Combination</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>nystatin</i></b> <b style='color:DodgerBlue;'><i>selectively</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>uptake</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>tumor</i></b> <b style='color:DodgerBlue;'><i>tissues</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>translating</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>potentiated</i></b> <b style='color:DodgerBlue;'><i>antitumor</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vivo</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>A431</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>A549</i></b> <b style='color:DodgerBlue;'><i>tumors</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>nystatin</i></b>-enhanced internalization of <b style='color:Tomato;'><i>cetuximab</i></b> further improved the uptake and potency of <b style='color:Tomato;'><i>cetuximab</i></b>-<b style='color:Tomato;'><i>doxorubicin</i></b> and <b style='color:Tomato;'><i>cetuximab</i></b>-<b style='color:Tomato;'><i>methotrexate</i></b> conjugates in EGFR-positive <b style='color:Tomato;'><i>cetuximab</i></b>-resistant tumors. Combination therapy with <b style='color:Tomato;'><i>nystatin</i></b> plus either <b style='color:Tomato;'><i>cetuximab</i></b> or <b style='color:Tomato;'><i>cetuximab</i></b>-ADC further prolonged animal survival and significantly suppressed tumor growth, as compared with single-agent <b style='color:Tomato;'><i>cetuximab</i></b> or <b style='color:Tomato;'><i>cetuximab</i></b>-ADC. In summary, our results identify a novel mechanism whereby cholesterol sequestration enhances the uptake of EGFR-targeting mAb and ADCs, therefore providing preclinical proof-of-concept that combination with <b style='color:Tomato;'><i>nystatin</i></b> can potentiate the delivery and efficacy of these EGFR-targeted agents. ","tokens":[{"text":"Combination","start":0,"end":11,"id":0,"ws":true},{"text":"treatment","start":12,"end":21,"id":1,"ws":true},{"text":"with","start":22,"end":26,"id":2,"ws":true},{"text":"cetuximab","start":27,"end":36,"id":3,"ws":true},{"text":"and","start":37,"end":40,"id":4,"ws":true},{"text":"nystatin","start":41,"end":49,"id":5,"ws":true},{"text":"selectively","start":50,"end":61,"id":6,"ws":true},{"text":"increased","start":62,"end":71,"id":7,"ws":true},{"text":"cetuximab","start":72,"end":81,"id":8,"ws":true},{"text":"uptake","start":82,"end":88,"id":9,"ws":true},{"text":"by","start":89,"end":91,"id":10,"ws":true},{"text":"tumor","start":92,"end":97,"id":11,"ws":true},{"text":"tissues","start":98,"end":105,"id":12,"ws":true},{"text":",","start":106,"end":107,"id":13,"ws":true},{"text":"translating","start":108,"end":119,"id":14,"ws":true},{"text":"into","start":120,"end":124,"id":15,"ws":true},{"text":"potentiated","start":125,"end":136,"id":16,"ws":true},{"text":"antitumor","start":137,"end":146,"id":17,"ws":true},{"text":"efficacy","start":147,"end":155,"id":18,"ws":true},{"text":"of","start":156,"end":158,"id":19,"ws":true},{"text":"cetuximab","start":159,"end":168,"id":20,"ws":true},{"text":"in","start":169,"end":171,"id":21,"ws":true},{"text":"vivo","start":172,"end":176,"id":22,"ws":true},{"text":"(","start":177,"end":178,"id":23,"ws":true},{"text":"A431","start":179,"end":183,"id":24,"ws":true},{"text":"and","start":184,"end":187,"id":25,"ws":true},{"text":"A549","start":188,"end":192,"id":26,"ws":true},{"text":"tumors","start":193,"end":199,"id":27,"ws":true},{"text":")","start":200,"end":201,"id":28,"ws":true},{"text":".","start":202,"end":203,"id":29,"ws":false}],"spans":[{"start":27,"end":36,"token_start":3,"token_end":3,"label":"DRUG"},{"start":41,"end":49,"token_start":5,"token_end":5,"label":"DRUG"},{"start":72,"end":81,"token_start":8,"token_end":8,"label":"DRUG"},{"start":159,"end":168,"token_start":20,"token_end":20,"label":"DRUG"}],"_input_hash":-1277491604,"_task_hash":-1965461189,"_session_id":"drug_drug_pilot_shared-hagit","_view_id":"blocks","relations":[{"head":3,"child":5,"head_span":{"start":27,"end":36,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":41,"end":49,"token_start":5,"token_end":5,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T0"],"answer":"accept"}
{"text":"The effects of combination therapy with chenodeoxycholic acid ( CDCA ) and simvastatin on serum cholestanol , low-density lipoprotein ( LDL ) cholesterol , and lathosterol levels were investigated in seven adult patients with cerebrotendinous xanthomatosis ( CTX ) who were on long-term treatment with CDCA .","paragraph":"<h3><u>Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>chenodeoxycholic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CDCA</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>simvastatin</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>serum</i></b> <b style='color:DodgerBlue;'><i>cholestanol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>low-density</i></b> <b style='color:DodgerBlue;'><i>lipoprotein</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>LDL</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>cholesterol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>lathosterol</i></b> <b style='color:DodgerBlue;'><i>levels</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>investigated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>seven</i></b> <b style='color:DodgerBlue;'><i>adult</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>cerebrotendinous</i></b> <b style='color:DodgerBlue;'><i>xanthomatosis</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CTX</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>long-term</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>CDCA</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The patients were treated with a combination of CDCA 750 mg daily and an increasing dose of <b style='color:Tomato;'><i>simvastatin</i></b> from 10 mg to 40 mg daily for a period of 6 months. We found a significant effect of this combination therapy compared with CDCA alone in terms of decreasing the serum cholestanol and LDL cholesterol levels, particularly with a daily dose of 40 mg <b style='color:Tomato;'><i>simvastatin</i></b>. The mean cholestanol level decreased from 9.27 micromol/L (baseline) to 6.69 micromol/L (40 mg <b style='color:Tomato;'><i>simvastatin</i></b>), while the mean LDL cholesterol level decreased from 5.08 mmol/L (baseline) to 3.04 mmol/L (40 mg <b style='color:Tomato;'><i>simvastatin</i></b>). No side effects were reported, and there were no effects on the clinical condition, cerebral magnetic resonance imaging (MRI), visual evoked potentials, and electroencephalographic features. We conclude that a combination of 750 mg CDCA and 40 mg <b style='color:Tomato;'><i>simvastatin</i></b> daily is effective to further reduce serum cholestanol, LDL cholesterol, and lathosterol in adult CTX patients treated with long-term CDCA. Whether this combination treatment will be effective for the long-term prevention of neurological deterioration and atherosclerosis remains to be established.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"effects","start":4,"end":11,"id":1,"ws":true},{"text":"of","start":12,"end":14,"id":2,"ws":true},{"text":"combination","start":15,"end":26,"id":3,"ws":true},{"text":"therapy","start":27,"end":34,"id":4,"ws":true},{"text":"with","start":35,"end":39,"id":5,"ws":true},{"text":"chenodeoxycholic","start":40,"end":56,"id":6,"ws":true},{"text":"acid","start":57,"end":61,"id":7,"ws":true},{"text":"(","start":62,"end":63,"id":8,"ws":true},{"text":"CDCA","start":64,"end":68,"id":9,"ws":true},{"text":")","start":69,"end":70,"id":10,"ws":true},{"text":"and","start":71,"end":74,"id":11,"ws":true},{"text":"simvastatin","start":75,"end":86,"id":12,"ws":true},{"text":"on","start":87,"end":89,"id":13,"ws":true},{"text":"serum","start":90,"end":95,"id":14,"ws":true},{"text":"cholestanol","start":96,"end":107,"id":15,"ws":true},{"text":",","start":108,"end":109,"id":16,"ws":true},{"text":"low-density","start":110,"end":121,"id":17,"ws":true},{"text":"lipoprotein","start":122,"end":133,"id":18,"ws":true},{"text":"(","start":134,"end":135,"id":19,"ws":true},{"text":"LDL","start":136,"end":139,"id":20,"ws":true},{"text":")","start":140,"end":141,"id":21,"ws":true},{"text":"cholesterol","start":142,"end":153,"id":22,"ws":true},{"text":",","start":154,"end":155,"id":23,"ws":true},{"text":"and","start":156,"end":159,"id":24,"ws":true},{"text":"lathosterol","start":160,"end":171,"id":25,"ws":true},{"text":"levels","start":172,"end":178,"id":26,"ws":true},{"text":"were","start":179,"end":183,"id":27,"ws":true},{"text":"investigated","start":184,"end":196,"id":28,"ws":true},{"text":"in","start":197,"end":199,"id":29,"ws":true},{"text":"seven","start":200,"end":205,"id":30,"ws":true},{"text":"adult","start":206,"end":211,"id":31,"ws":true},{"text":"patients","start":212,"end":220,"id":32,"ws":true},{"text":"with","start":221,"end":225,"id":33,"ws":true},{"text":"cerebrotendinous","start":226,"end":242,"id":34,"ws":true},{"text":"xanthomatosis","start":243,"end":256,"id":35,"ws":true},{"text":"(","start":257,"end":258,"id":36,"ws":true},{"text":"CTX","start":259,"end":262,"id":37,"ws":true},{"text":")","start":263,"end":264,"id":38,"ws":true},{"text":"who","start":265,"end":268,"id":39,"ws":true},{"text":"were","start":269,"end":273,"id":40,"ws":true},{"text":"on","start":274,"end":276,"id":41,"ws":true},{"text":"long-term","start":277,"end":286,"id":42,"ws":true},{"text":"treatment","start":287,"end":296,"id":43,"ws":true},{"text":"with","start":297,"end":301,"id":44,"ws":true},{"text":"CDCA","start":302,"end":306,"id":45,"ws":true},{"text":".","start":307,"end":308,"id":46,"ws":false}],"spans":[{"start":40,"end":56,"token_start":6,"token_end":6,"label":"DRUG"},{"start":75,"end":86,"token_start":12,"token_end":12,"label":"DRUG"}],"_input_hash":-475065306,"_task_hash":-2052397739,"_session_id":"drug_drug_pilot_shared-hagit","_view_id":"blocks","relations":[{"head":6,"child":12,"head_span":{"start":40,"end":56,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":75,"end":86,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"Paclitaxel ( Taxol ; Bristol-Myers Squibb Company , Princeton , NJ ) has been demonstrated to be highly effective in treating patients with advanced breast cancer , including those with anthracycline-resistant breast cancer , a fact that has led to efforts to combine paclitaxel and anthracyclines .","paragraph":"<h3><u>Paclitaxel and doxorubicin in metastatic breast cancer.</u></h3>For the past decades the anthracyclines have been regarded as among the most active drugs for the treatment of metastatic breast cancer. However, the 5-year survival rate in patients with stage IV breast cancer continues to be below 20%, and new active drugs and drug combinations clearly must be explored. <b style='color:MediumOrchid;'><i>Paclitaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Taxol</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>Bristol-Myers</i></b> <b style='color:DodgerBlue;'><i>Squibb</i></b> <b style='color:DodgerBlue;'><i>Company</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Princeton</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>NJ</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>highly</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>treating</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>anthracycline-resistant</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>fact</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>led</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>efforts</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>combine</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>anthracyclines</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Several studies aiming to define the optimal dose and schedule of combination <b style='color:Tomato;'><i>paclitaxel</i></b>/<b style='color:Tomato;'><i>doxorubicin</i></b> have now been completed or are ongoing. Phase I/II studies have yielded encouraging preliminary response rates but quite variable toxicity profiles depending on the schedule used. These clinical trials involving combination <b style='color:Tomato;'><i>paclitaxel</i></b>/<b style='color:Tomato;'><i>doxorubicin</i></b> are reviewed, with special emphasis on the short-infusion trials.","tokens":[{"text":"Paclitaxel","start":0,"end":10,"id":0,"ws":true},{"text":"(","start":11,"end":12,"id":1,"ws":true},{"text":"Taxol","start":13,"end":18,"id":2,"ws":true},{"text":";","start":19,"end":20,"id":3,"ws":true},{"text":"Bristol-Myers","start":21,"end":34,"id":4,"ws":true},{"text":"Squibb","start":35,"end":41,"id":5,"ws":true},{"text":"Company","start":42,"end":49,"id":6,"ws":true},{"text":",","start":50,"end":51,"id":7,"ws":true},{"text":"Princeton","start":52,"end":61,"id":8,"ws":true},{"text":",","start":62,"end":63,"id":9,"ws":true},{"text":"NJ","start":64,"end":66,"id":10,"ws":true},{"text":")","start":67,"end":68,"id":11,"ws":true},{"text":"has","start":69,"end":72,"id":12,"ws":true},{"text":"been","start":73,"end":77,"id":13,"ws":true},{"text":"demonstrated","start":78,"end":90,"id":14,"ws":true},{"text":"to","start":91,"end":93,"id":15,"ws":true},{"text":"be","start":94,"end":96,"id":16,"ws":true},{"text":"highly","start":97,"end":103,"id":17,"ws":true},{"text":"effective","start":104,"end":113,"id":18,"ws":true},{"text":"in","start":114,"end":116,"id":19,"ws":true},{"text":"treating","start":117,"end":125,"id":20,"ws":true},{"text":"patients","start":126,"end":134,"id":21,"ws":true},{"text":"with","start":135,"end":139,"id":22,"ws":true},{"text":"advanced","start":140,"end":148,"id":23,"ws":true},{"text":"breast","start":149,"end":155,"id":24,"ws":true},{"text":"cancer","start":156,"end":162,"id":25,"ws":true},{"text":",","start":163,"end":164,"id":26,"ws":true},{"text":"including","start":165,"end":174,"id":27,"ws":true},{"text":"those","start":175,"end":180,"id":28,"ws":true},{"text":"with","start":181,"end":185,"id":29,"ws":true},{"text":"anthracycline-resistant","start":186,"end":209,"id":30,"ws":true},{"text":"breast","start":210,"end":216,"id":31,"ws":true},{"text":"cancer","start":217,"end":223,"id":32,"ws":true},{"text":",","start":224,"end":225,"id":33,"ws":true},{"text":"a","start":226,"end":227,"id":34,"ws":true},{"text":"fact","start":228,"end":232,"id":35,"ws":true},{"text":"that","start":233,"end":237,"id":36,"ws":true},{"text":"has","start":238,"end":241,"id":37,"ws":true},{"text":"led","start":242,"end":245,"id":38,"ws":true},{"text":"to","start":246,"end":248,"id":39,"ws":true},{"text":"efforts","start":249,"end":256,"id":40,"ws":true},{"text":"to","start":257,"end":259,"id":41,"ws":true},{"text":"combine","start":260,"end":267,"id":42,"ws":true},{"text":"paclitaxel","start":268,"end":278,"id":43,"ws":true},{"text":"and","start":279,"end":282,"id":44,"ws":true},{"text":"anthracyclines","start":283,"end":297,"id":45,"ws":true},{"text":".","start":298,"end":299,"id":46,"ws":false}],"spans":[{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},{"start":268,"end":278,"token_start":43,"token_end":43,"label":"DRUG"}],"_input_hash":702583470,"_task_hash":1770101995,"_session_id":"drug_drug_pilot_shared-hagit","_view_id":"blocks","relations":[{"head":43,"child":45,"head_span":{"start":268,"end":278,"token_start":43,"token_end":43,"label":"DRUG"},"child_span":{"start":283,"end":297,"token_start":45,"token_end":45,"label":null},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"The management of EP is challenging : no standardized guidelines exist with literature suggesting cyclosporine or infliximab as first-line therapy .","paragraph":"<h3><u>Erythrodermic psoriasis successfully and rapidly treated with brodalumab: Report of two cases.</u></h3>Erythrodermic psoriasis (EP) is a rare form of the disease clinically characterized by a generalized erythema covering \u226590% of the body surface area (BSA). <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>management</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>EP</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>challenging</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>standardized</i></b> <b style='color:DodgerBlue;'><i>guidelines</i></b> <b style='color:DodgerBlue;'><i>exist</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>literature</i></b> <b style='color:DodgerBlue;'><i>suggesting</i></b> <b style='color:MediumOrchid;'><i>cyclosporine</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>infliximab</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, a recent systematic review showed a positive response in EP patients treated with biologic agents. The most common biologic used for EP up until now has been <b style='color:Tomato;'><i>ustekinumab</i></b>, whereas <b style='color:Tomato;'><i>infliximab</i></b> might represent a first-line option in case of complicated EP (acute, severe, or unstable). Up until now, no case of <b style='color:Tomato;'><i>brodalumab</i></b> (a monoclonal antibody blocking IL-17 receptor) treatment for EP in real-life has ever been described. Here, we report the first two cases of efficacy and safety of <b style='color:Tomato;'><i>brodalumab</i></b> in real-life cases of EP.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"management","start":4,"end":14,"id":1,"ws":true},{"text":"of","start":15,"end":17,"id":2,"ws":true},{"text":"EP","start":18,"end":20,"id":3,"ws":true},{"text":"is","start":21,"end":23,"id":4,"ws":true},{"text":"challenging","start":24,"end":35,"id":5,"ws":true},{"text":":","start":36,"end":37,"id":6,"ws":true},{"text":"no","start":38,"end":40,"id":7,"ws":true},{"text":"standardized","start":41,"end":53,"id":8,"ws":true},{"text":"guidelines","start":54,"end":64,"id":9,"ws":true},{"text":"exist","start":65,"end":70,"id":10,"ws":true},{"text":"with","start":71,"end":75,"id":11,"ws":true},{"text":"literature","start":76,"end":86,"id":12,"ws":true},{"text":"suggesting","start":87,"end":97,"id":13,"ws":true},{"text":"cyclosporine","start":98,"end":110,"id":14,"ws":true},{"text":"or","start":111,"end":113,"id":15,"ws":true},{"text":"infliximab","start":114,"end":124,"id":16,"ws":true},{"text":"as","start":125,"end":127,"id":17,"ws":true},{"text":"first-line","start":128,"end":138,"id":18,"ws":true},{"text":"therapy","start":139,"end":146,"id":19,"ws":true},{"text":".","start":147,"end":148,"id":20,"ws":false}],"spans":[{"start":98,"end":110,"token_start":14,"token_end":14,"label":"DRUG"},{"start":114,"end":124,"token_start":16,"token_end":16,"label":"DRUG"}],"_input_hash":-575753313,"_task_hash":-166345926,"_session_id":"drug_drug_pilot_shared-dana_n","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"As single agents , curcumin and metformin are reported to exhibit chemopreventive properties , in vitro as well as in patients with oral cancer .","paragraph":"<h3><u>Curcumin and metformin-mediated chemoprevention of oral cancer is associated with inhibition of cancer stem cells.</u></h3>Effective chemoprevention is critical for improving outcomes of oral cancer. <b style='color:DodgerBlue;'><i>As</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>curcumin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>metformin</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>reported</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>exhibit</i></b> <b style='color:DodgerBlue;'><i>chemopreventive</i></b> <b style='color:DodgerBlue;'><i>properties</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In this study, the chemopreventive efficacy of this drug combination was tested in a 4-nitro quinoline-1-oxide (4NQO) induced mice oral carcinogenesis model. Molecular analysis revealed a cancer stem cell (CSC)-driven oral carcinogenic progression in this model, wherein a progressive increase in the expression of CSC-specific markers (CD44 and CD133) was observed from 8th to 25th week, at transcript (40-100-fold) and protein levels (P\u2009\u2264\u20090.0001). Chemopreventive treatment of the animals at 17th week with <b style='color:Tomato;'><i>curcumin</i></b> and <b style='color:Tomato;'><i>metformin</i></b> indicated that the combination regimen decreased tumor volume when compared to the control arm (0.69+0.03 vs 6.66+2.4\u2009mm","tokens":[{"text":"As","start":0,"end":2,"id":0,"ws":true},{"text":"single","start":3,"end":9,"id":1,"ws":true},{"text":"agents","start":10,"end":16,"id":2,"ws":true},{"text":",","start":17,"end":18,"id":3,"ws":true},{"text":"curcumin","start":19,"end":27,"id":4,"ws":true},{"text":"and","start":28,"end":31,"id":5,"ws":true},{"text":"metformin","start":32,"end":41,"id":6,"ws":true},{"text":"are","start":42,"end":45,"id":7,"ws":true},{"text":"reported","start":46,"end":54,"id":8,"ws":true},{"text":"to","start":55,"end":57,"id":9,"ws":true},{"text":"exhibit","start":58,"end":65,"id":10,"ws":true},{"text":"chemopreventive","start":66,"end":81,"id":11,"ws":true},{"text":"properties","start":82,"end":92,"id":12,"ws":true},{"text":",","start":93,"end":94,"id":13,"ws":true},{"text":"in","start":95,"end":97,"id":14,"ws":true},{"text":"vitro","start":98,"end":103,"id":15,"ws":true},{"text":"as","start":104,"end":106,"id":16,"ws":true},{"text":"well","start":107,"end":111,"id":17,"ws":true},{"text":"as","start":112,"end":114,"id":18,"ws":true},{"text":"in","start":115,"end":117,"id":19,"ws":true},{"text":"patients","start":118,"end":126,"id":20,"ws":true},{"text":"with","start":127,"end":131,"id":21,"ws":true},{"text":"oral","start":132,"end":136,"id":22,"ws":true},{"text":"cancer","start":137,"end":143,"id":23,"ws":true},{"text":".","start":144,"end":145,"id":24,"ws":false}],"spans":[{"start":19,"end":27,"token_start":4,"token_end":4,"label":"DRUG"},{"start":32,"end":41,"token_start":6,"token_end":6,"label":"DRUG"}],"_input_hash":-1095827099,"_task_hash":-240223432,"_session_id":"drug_drug_pilot_shared-dana_n","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Withdrawal rates were comparable to drug survival rates of other biological therapies and rates of adverse events were similar between brodalumab and ustekinumab .","paragraph":"<h3><u>Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.</u></h3>As part of the National Institute for Health and Care Excellence single technology appraisal process, <b style='color:Tomato;'><i>brodalumab</i></b> was assessed to determine the clinical and cost effectiveness of its use in the treatment of moderate-to-severe plaque psoriasis. The Centre for Reviews and Dissemination and the Centre for Health Economics Technology Assessment Group at the University of York were commissioned to act as the independent Evidence Review Group. This article provides a summary of the Evidence Review Group's review of the company's submission, the Evidence Review Group report and the National Institute for Health and Care Excellence Appraisal Committee's subsequent guidance issued in March 2018. The main clinical effectiveness data were derived from three well-conducted, multicentre, double-blind randomised controlled trials. The trials demonstrated that <b style='color:Tomato;'><i>brodalumab</i></b> statistically significantly reduced the severity of psoriasis and its impact on health-related quality of life, compared with placebo, at 12\u00a0weeks. In comparison with <b style='color:Tomato;'><i>ustekinumab</i></b>, statistically significantly more patients taking <b style='color:Tomato;'><i>brodalumab</i></b> had reduced psoriasis severity at 12\u00a0weeks. Psoriasis severity and quality of life also appeared improved at 52\u00a0weeks, although statistical significance was not assessed. <b style='color:DodgerBlue;'><i>Withdrawal</i></b> <b style='color:DodgerBlue;'><i>rates</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>comparable</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>rates</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>biological</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>rates</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>adverse</i></b> <b style='color:DodgerBlue;'><i>events</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>similar</i></b> <b style='color:DodgerBlue;'><i>between</i></b> <b style='color:MediumOrchid;'><i>brodalumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ustekinumab</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A network meta-analysis was presented, comparing <b style='color:Tomato;'><i>brodalumab</i></b> with other therapies available at the same point in the treatment pathway (i.e. in patients for whom standard systemic therapy or phototherapy is inadequately effective, not tolerated or contraindicated). The network meta-analysis ranked treatments in order of effectiveness, in terms of achieving different levels of Psoriasis Area and Severity Index response. The results indicated that <b style='color:Tomato;'><i>brodalumab</i></b> had a similar probability of response to <b style='color:Tomato;'><i>ixekizumab</i></b>, <b style='color:Tomato;'><i>secukinumab</i></b> and <b style='color:Tomato;'><i>infliximab</i></b> and a higher probability of response than <b style='color:Tomato;'><i>ustekinumab</i></b>, <b style='color:Tomato;'><i>adalimumab</i></b>, <b style='color:Tomato;'><i>etanercept</i></b>, <b style='color:Tomato;'><i>apremilast</i></b>, <b style='color:Tomato;'><i>dimethyl fumarate</i></b> and placebo. The company's economic model compared nine treatment sequences that included three lines of active therapy, consisting of <b style='color:Tomato;'><i>brodalumab</i></b> and other comparators recommended by the National Institute for Health and Care Excellence, followed by best supportive care. The sequence with <b style='color:Tomato;'><i>brodalumab</i></b> in the first-line position dominated sequences that started with <b style='color:Tomato;'><i>adalimumab</i></b>, <b style='color:Tomato;'><i>infliximab</i></b>, <b style='color:Tomato;'><i>secukinumab</i></b> and <b style='color:Tomato;'><i>ustekinumab</i></b>. The incremental cost-effectiveness ratio of the <b style='color:Tomato;'><i>brodalumab</i></b> sequence compared to less effective and non-dominated sequences ranged from \u00a37145 (vs. the <b style='color:Tomato;'><i>etanercept</i></b> sequence) to \u00a313,353 (vs. the <b style='color:Tomato;'><i>dimethyl fumarate</i></b> sequence) per quality-adjusted life-year gained. The incremental cost-effectiveness ratio for the more costly and effective <b style='color:Tomato;'><i>ixekizumab</i></b> sequence was \u00a3894,010 per quality-adjusted life-year gained compared to the <b style='color:Tomato;'><i>brodalumab</i></b> sequence. At a threshold of \u00a320,000 per quality-adjusted life-year gained, the <b style='color:Tomato;'><i>brodalumab</i></b> sequence had the highest probability of being cost effective (96%). The main limitation of the company's economic model was the restrictive nature of the sequences compared. Twelve separate scenarios based on key uncertainties were explored by the Evidence Review Group. The only scenarios where <b style='color:Tomato;'><i>brodalumab</i></b> was ranked lower than first were not considered to be more appropriate or plausible than the assumptions or scenarios included in the company's base case. The treatment rankings identified in the Evidence Review Group's alternative base case were identical to those derived from the company's base case model. At the first National Institute for Health and Care Excellence Appraisal Committee meeting, the Committee concluded that <b style='color:Tomato;'><i>brodalumab</i></b> appears to be as effective as other anti-interleukin-17 agents and is cost effective, based on the discount agreed in the patient access scheme. <b style='color:Tomato;'><i>brodalumab</i></b> is recommended as an option for treating adults with severe plaque psoriasis (defined by a total Psoriasis Area and Severity Index score of 10 or more and a Dermatology Life Quality Index score of more than 10) who have not responded to other systemic non-biological therapies. <b style='color:Tomato;'><i>brodalumab</i></b> should be stopped at 12\u00a0weeks if the psoriasis has not responded adequately.","tokens":[{"text":"Withdrawal","start":0,"end":10,"id":0,"ws":true},{"text":"rates","start":11,"end":16,"id":1,"ws":true},{"text":"were","start":17,"end":21,"id":2,"ws":true},{"text":"comparable","start":22,"end":32,"id":3,"ws":true},{"text":"to","start":33,"end":35,"id":4,"ws":true},{"text":"drug","start":36,"end":40,"id":5,"ws":true},{"text":"survival","start":41,"end":49,"id":6,"ws":true},{"text":"rates","start":50,"end":55,"id":7,"ws":true},{"text":"of","start":56,"end":58,"id":8,"ws":true},{"text":"other","start":59,"end":64,"id":9,"ws":true},{"text":"biological","start":65,"end":75,"id":10,"ws":true},{"text":"therapies","start":76,"end":85,"id":11,"ws":true},{"text":"and","start":86,"end":89,"id":12,"ws":true},{"text":"rates","start":90,"end":95,"id":13,"ws":true},{"text":"of","start":96,"end":98,"id":14,"ws":true},{"text":"adverse","start":99,"end":106,"id":15,"ws":true},{"text":"events","start":107,"end":113,"id":16,"ws":true},{"text":"were","start":114,"end":118,"id":17,"ws":true},{"text":"similar","start":119,"end":126,"id":18,"ws":true},{"text":"between","start":127,"end":134,"id":19,"ws":true},{"text":"brodalumab","start":135,"end":145,"id":20,"ws":true},{"text":"and","start":146,"end":149,"id":21,"ws":true},{"text":"ustekinumab","start":150,"end":161,"id":22,"ws":true},{"text":".","start":162,"end":163,"id":23,"ws":false}],"spans":[{"start":135,"end":145,"token_start":20,"token_end":20,"label":"DRUG"},{"start":150,"end":161,"token_start":22,"token_end":22,"label":"DRUG"}],"_input_hash":-2044054306,"_task_hash":40529012,"_session_id":"drug_drug_pilot_shared-dana_n","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"In patients with NPSLE , the use of high-dose corticosteroids is recommended in combination with immunosuppressants , such as mycophenolate mofetil and intravenous cyclophosphamide pulse therapy .","paragraph":"<h3><u>[Neuropsychiatric Systemic Lupus Erythematosus].</u></h3>Central nervous system damage, a major organ manifestation of systemic lupus erythematosus (SLE), causes significant morbidity and mortality. Designating this condition as neuropsychiatric SLE (NPSLE), the American College of Rheumatology defines it as involving the central and peripheral nervous systems and being characterized by various manifestations including stroke, seizures, and psychosis. NPSLE treatment mainly seeks to reduce damage accrual. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>NPSLE</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:DodgerBlue;'><i>corticosteroids</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>recommended</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>immunosuppressants</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>mycophenolate</i></b> <b style='color:DodgerBlue;'><i>mofetil</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>pulse</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> This can be accomplished by controlling the activity of the disease, minimizing the use of corticosteroids, and optimizing the management of comorbidities, including cardiovascular risk factors. An international task force analysis of a treat-to-target strategy for SLE (T2T/SLE) recommended targeting remission, preventing damage, and improving quality of life. Thus, more effective and less toxic treatments, such as those using biologics or kinase inhibitors, are still being developed for the treatment of SLE/NPSLE.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"patients","start":3,"end":11,"id":1,"ws":true},{"text":"with","start":12,"end":16,"id":2,"ws":true},{"text":"NPSLE","start":17,"end":22,"id":3,"ws":true},{"text":",","start":23,"end":24,"id":4,"ws":true},{"text":"the","start":25,"end":28,"id":5,"ws":true},{"text":"use","start":29,"end":32,"id":6,"ws":true},{"text":"of","start":33,"end":35,"id":7,"ws":true},{"text":"high-dose","start":36,"end":45,"id":8,"ws":true},{"text":"corticosteroids","start":46,"end":61,"id":9,"ws":true},{"text":"is","start":62,"end":64,"id":10,"ws":true},{"text":"recommended","start":65,"end":76,"id":11,"ws":true},{"text":"in","start":77,"end":79,"id":12,"ws":true},{"text":"combination","start":80,"end":91,"id":13,"ws":true},{"text":"with","start":92,"end":96,"id":14,"ws":true},{"text":"immunosuppressants","start":97,"end":115,"id":15,"ws":true},{"text":",","start":116,"end":117,"id":16,"ws":true},{"text":"such","start":118,"end":122,"id":17,"ws":true},{"text":"as","start":123,"end":125,"id":18,"ws":true},{"text":"mycophenolate","start":126,"end":139,"id":19,"ws":true},{"text":"mofetil","start":140,"end":147,"id":20,"ws":true},{"text":"and","start":148,"end":151,"id":21,"ws":true},{"text":"intravenous","start":152,"end":163,"id":22,"ws":true},{"text":"cyclophosphamide","start":164,"end":180,"id":23,"ws":true},{"text":"pulse","start":181,"end":186,"id":24,"ws":true},{"text":"therapy","start":187,"end":194,"id":25,"ws":true},{"text":".","start":195,"end":196,"id":26,"ws":false}],"spans":[{"start":126,"end":139,"token_start":19,"token_end":19,"label":"DRUG"},{"start":164,"end":180,"token_start":23,"token_end":23,"label":"DRUG"}],"_input_hash":438186251,"_task_hash":1532533663,"_session_id":"drug_drug_pilot_shared-dana_n","_view_id":"blocks","relations":[{"head":19,"child":23,"head_span":{"start":126,"end":139,"token_start":19,"token_end":19,"label":"DRUG"},"child_span":{"start":164,"end":180,"token_start":23,"token_end":23,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T0"],"answer":"accept"}
{"text":"Thirty-three women diagnosed with metastatic breast cancer participated in a phase 1 clinical trial of a new combination of cyclophosphamide ( CTX ) and mitoxantrone ( MXT ) , with dose escalation of paclitaxel .","paragraph":"<h3><u>Longitudinal effects of high-dose chemotherapy and autologous stem cell transplantation on quality of life in the treatment of metastatic breast cancer.</u></h3>This study determined the effects of high-dose chemotherapy (HDCT) with autologous blood stem cell transplantation (ASCT) on quality of life (QL) in women with metastatic breast cancer prior to, and during treatment, and up to 1-year post-ASCT. <b style='color:DodgerBlue;'><i>Thirty-three</i></b> <b style='color:DodgerBlue;'><i>women</i></b> <b style='color:DodgerBlue;'><i>diagnosed</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>participated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>new</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CTX</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>mitoxantrone</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>MXT</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>escalation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Longitudinal QL data were collected using the functional living index-cancer (FLIC) and symptom scales at seven time periods: pre-induction chemotherapy (CT), post-induction CT, post-high dose CT (HDCT), and at 3, 6, 9 and 12 months post-ASCT. FLIC scores indicated that the worst problems for patients were feelings of hardship on themselves and their families, followed by psychological functioning and physical functioning problems. The time around diagnosis of the metastatic disease and following HDCT were the worst times for all levels of quality of life, but anxiety and depression symptoms continued to increase in severity across the entire follow-up period. The symptoms that were most problematic were worry about the future, loss of sexual interest, anxiety about the treatment, general worrying, and joint pain. These data highlight the problems that women with metastatic breast cancer encounter at different stages of the disease and treatment process, and can be used to tailor psychosocial interventions appropriate for treating the relevant issues at different points in time.","tokens":[{"text":"Thirty-three","start":0,"end":12,"id":0,"ws":true},{"text":"women","start":13,"end":18,"id":1,"ws":true},{"text":"diagnosed","start":19,"end":28,"id":2,"ws":true},{"text":"with","start":29,"end":33,"id":3,"ws":true},{"text":"metastatic","start":34,"end":44,"id":4,"ws":true},{"text":"breast","start":45,"end":51,"id":5,"ws":true},{"text":"cancer","start":52,"end":58,"id":6,"ws":true},{"text":"participated","start":59,"end":71,"id":7,"ws":true},{"text":"in","start":72,"end":74,"id":8,"ws":true},{"text":"a","start":75,"end":76,"id":9,"ws":true},{"text":"phase","start":77,"end":82,"id":10,"ws":true},{"text":"1","start":83,"end":84,"id":11,"ws":true},{"text":"clinical","start":85,"end":93,"id":12,"ws":true},{"text":"trial","start":94,"end":99,"id":13,"ws":true},{"text":"of","start":100,"end":102,"id":14,"ws":true},{"text":"a","start":103,"end":104,"id":15,"ws":true},{"text":"new","start":105,"end":108,"id":16,"ws":true},{"text":"combination","start":109,"end":120,"id":17,"ws":true},{"text":"of","start":121,"end":123,"id":18,"ws":true},{"text":"cyclophosphamide","start":124,"end":140,"id":19,"ws":true},{"text":"(","start":141,"end":142,"id":20,"ws":true},{"text":"CTX","start":143,"end":146,"id":21,"ws":true},{"text":")","start":147,"end":148,"id":22,"ws":true},{"text":"and","start":149,"end":152,"id":23,"ws":true},{"text":"mitoxantrone","start":153,"end":165,"id":24,"ws":true},{"text":"(","start":166,"end":167,"id":25,"ws":true},{"text":"MXT","start":168,"end":171,"id":26,"ws":true},{"text":")","start":172,"end":173,"id":27,"ws":true},{"text":",","start":174,"end":175,"id":28,"ws":true},{"text":"with","start":176,"end":180,"id":29,"ws":true},{"text":"dose","start":181,"end":185,"id":30,"ws":true},{"text":"escalation","start":186,"end":196,"id":31,"ws":true},{"text":"of","start":197,"end":199,"id":32,"ws":true},{"text":"paclitaxel","start":200,"end":210,"id":33,"ws":true},{"text":".","start":211,"end":212,"id":34,"ws":false}],"spans":[{"start":124,"end":140,"token_start":19,"token_end":19,"label":"DRUG"},{"start":153,"end":165,"token_start":24,"token_end":24,"label":"DRUG"},{"start":200,"end":210,"token_start":33,"token_end":33,"label":"DRUG"}],"_input_hash":1782132717,"_task_hash":189034633,"_session_id":"drug_drug_pilot_shared-dana_n","_view_id":"blocks","relations":[{"head":19,"child":24,"head_span":{"start":124,"end":140,"token_start":19,"token_end":19,"label":"DRUG"},"child_span":{"start":153,"end":165,"token_start":24,"token_end":24,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":24,"child":33,"head_span":{"start":153,"end":165,"token_start":24,"token_end":24,"label":"DRUG"},"child_span":{"start":200,"end":210,"token_start":33,"token_end":33,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"Among the anti-herpesvirus agents , aciclovir , valaciclovir , penciclovir , famciclovir , idoxuridine , trifluridine and brivudin are used in the treatment of herpes simplex virus and varicella-zoster virus infections , and ganciclovir , foscarnet , cidofovir , fomivirsen and maribavir ( the latter in the developmental stage ) are used in the treatment of cytomegalovirus infections .","paragraph":"<h3><u>Antiviral drugs: current state of the art.</u></h3>The chemotherapy of virus infections has definitely come of age. There are now 15 antiviral agents that have been formally licensed for the treatment of human immunodeficiency virus infections (<b style='color:Tomato;'><i>zidovudine</i></b>, <b style='color:Tomato;'><i>didanosine</i></b>, <b style='color:Tomato;'><i>zalcitabine</i></b>, <b style='color:Tomato;'><i>stavudine</i></b>, <b style='color:Tomato;'><i>lamivudine</i></b>, <b style='color:Tomato;'><i>abacavir</i></b>, <b style='color:Tomato;'><i>nevirapine</i></b>, <b style='color:Tomato;'><i>delavirdine</i></b>, <b style='color:Tomato;'><i>efavirenz</i></b>, <b style='color:Tomato;'><i>saquinavir</i></b>, <b style='color:Tomato;'><i>ritonavir</i></b>, <b style='color:Tomato;'><i>indinavir</i></b>, <b style='color:Tomato;'><i>nelfinavir</i></b>, <b style='color:Tomato;'><i>amprenavir</i></b>, <b style='color:Tomato;'><i>lopinavir</i></b>) and several others, such as <b style='color:Tomato;'><i>tenofovir</i></b> disoproxil, <b style='color:Tomato;'><i>emtricitabine</i></b>, capravirine, emivirine, T-20 (pentafuside) and AMD3100 (bicyclam) are under clinical development. <b style='color:Tomato;'><i>lamivudine</i></b> has been approved, and several other compounds (such as <b style='color:Tomato;'><i>adefovir</i></b> dipivoxil, <b style='color:Tomato;'><i>emtricitabine</i></b> and <b style='color:Tomato;'><i>entecavir</i></b>) are under clinical development, for the treatment of hepatitis B virus infections. <b style='color:DodgerBlue;'><i>Among</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>anti-herpesvirus</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>aciclovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>valaciclovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>penciclovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>famciclovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>idoxuridine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>trifluridine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>brivudin</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>herpes</i></b> <b style='color:DodgerBlue;'><i>simplex</i></b> <b style='color:DodgerBlue;'><i>virus</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>varicella-zoster</i></b> <b style='color:DodgerBlue;'><i>virus</i></b> <b style='color:DodgerBlue;'><i>infections</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ganciclovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>foscarnet</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cidofovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>fomivirsen</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>maribavir</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>latter</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>developmental</i></b> <b style='color:DodgerBlue;'><i>stage</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cytomegalovirus</i></b> <b style='color:DodgerBlue;'><i>infections</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Following <b style='color:Tomato;'><i>amantadine</i></b> and <b style='color:Tomato;'><i>rimantadine</i></b>, the neuraminidase inhibitors, <b style='color:Tomato;'><i>zanamivir</i></b> and <b style='color:Tomato;'><i>oseltamivir</i></b>, have now become available for the therapy and prophylaxis of influenza virus infections, and so is <b style='color:Tomato;'><i>ribavirin</i></b> for the treatment of respiratory syncytial virus infections and the combination of <b style='color:Tomato;'><i>ribavirin</i></b> with interferon-alpha for the treatment of hepatitis C virus infections.","tokens":[{"text":"Among","start":0,"end":5,"id":0,"ws":true},{"text":"the","start":6,"end":9,"id":1,"ws":true},{"text":"anti-herpesvirus","start":10,"end":26,"id":2,"ws":true},{"text":"agents","start":27,"end":33,"id":3,"ws":true},{"text":",","start":34,"end":35,"id":4,"ws":true},{"text":"aciclovir","start":36,"end":45,"id":5,"ws":true},{"text":",","start":46,"end":47,"id":6,"ws":true},{"text":"valaciclovir","start":48,"end":60,"id":7,"ws":true},{"text":",","start":61,"end":62,"id":8,"ws":true},{"text":"penciclovir","start":63,"end":74,"id":9,"ws":true},{"text":",","start":75,"end":76,"id":10,"ws":true},{"text":"famciclovir","start":77,"end":88,"id":11,"ws":true},{"text":",","start":89,"end":90,"id":12,"ws":true},{"text":"idoxuridine","start":91,"end":102,"id":13,"ws":true},{"text":",","start":103,"end":104,"id":14,"ws":true},{"text":"trifluridine","start":105,"end":117,"id":15,"ws":true},{"text":"and","start":118,"end":121,"id":16,"ws":true},{"text":"brivudin","start":122,"end":130,"id":17,"ws":true},{"text":"are","start":131,"end":134,"id":18,"ws":true},{"text":"used","start":135,"end":139,"id":19,"ws":true},{"text":"in","start":140,"end":142,"id":20,"ws":true},{"text":"the","start":143,"end":146,"id":21,"ws":true},{"text":"treatment","start":147,"end":156,"id":22,"ws":true},{"text":"of","start":157,"end":159,"id":23,"ws":true},{"text":"herpes","start":160,"end":166,"id":24,"ws":true},{"text":"simplex","start":167,"end":174,"id":25,"ws":true},{"text":"virus","start":175,"end":180,"id":26,"ws":true},{"text":"and","start":181,"end":184,"id":27,"ws":true},{"text":"varicella-zoster","start":185,"end":201,"id":28,"ws":true},{"text":"virus","start":202,"end":207,"id":29,"ws":true},{"text":"infections","start":208,"end":218,"id":30,"ws":true},{"text":",","start":219,"end":220,"id":31,"ws":true},{"text":"and","start":221,"end":224,"id":32,"ws":true},{"text":"ganciclovir","start":225,"end":236,"id":33,"ws":true},{"text":",","start":237,"end":238,"id":34,"ws":true},{"text":"foscarnet","start":239,"end":248,"id":35,"ws":true},{"text":",","start":249,"end":250,"id":36,"ws":true},{"text":"cidofovir","start":251,"end":260,"id":37,"ws":true},{"text":",","start":261,"end":262,"id":38,"ws":true},{"text":"fomivirsen","start":263,"end":273,"id":39,"ws":true},{"text":"and","start":274,"end":277,"id":40,"ws":true},{"text":"maribavir","start":278,"end":287,"id":41,"ws":true},{"text":"(","start":288,"end":289,"id":42,"ws":true},{"text":"the","start":290,"end":293,"id":43,"ws":true},{"text":"latter","start":294,"end":300,"id":44,"ws":true},{"text":"in","start":301,"end":303,"id":45,"ws":true},{"text":"the","start":304,"end":307,"id":46,"ws":true},{"text":"developmental","start":308,"end":321,"id":47,"ws":true},{"text":"stage","start":322,"end":327,"id":48,"ws":true},{"text":")","start":328,"end":329,"id":49,"ws":true},{"text":"are","start":330,"end":333,"id":50,"ws":true},{"text":"used","start":334,"end":338,"id":51,"ws":true},{"text":"in","start":339,"end":341,"id":52,"ws":true},{"text":"the","start":342,"end":345,"id":53,"ws":true},{"text":"treatment","start":346,"end":355,"id":54,"ws":true},{"text":"of","start":356,"end":358,"id":55,"ws":true},{"text":"cytomegalovirus","start":359,"end":374,"id":56,"ws":true},{"text":"infections","start":375,"end":385,"id":57,"ws":true},{"text":".","start":386,"end":387,"id":58,"ws":false}],"spans":[{"start":36,"end":45,"token_start":5,"token_end":5,"label":"DRUG"},{"start":48,"end":60,"token_start":7,"token_end":7,"label":"DRUG"},{"start":63,"end":74,"token_start":9,"token_end":9,"label":"DRUG"},{"start":77,"end":88,"token_start":11,"token_end":11,"label":"DRUG"},{"start":91,"end":102,"token_start":13,"token_end":13,"label":"DRUG"},{"start":105,"end":117,"token_start":15,"token_end":15,"label":"DRUG"},{"start":225,"end":236,"token_start":33,"token_end":33,"label":"DRUG"},{"start":239,"end":248,"token_start":35,"token_end":35,"label":"DRUG"},{"start":251,"end":260,"token_start":37,"token_end":37,"label":"DRUG"}],"_input_hash":1265321677,"_task_hash":1758490147,"_session_id":"drug_drug_pilot_shared-dana_n","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The present study examined the efficacy of single and combined treatment with an anticholinesterase , tetrahydroaminoacridine ( i.p . ) , and a glycine-B site partial agonist , D-cycloserine ( i.p . ; a positive allosteric modulator of NMDA receptors ) , in alleviating the deficit in water maze spatial navigation induced by electrolytic lesion of the medial septum or lidocaine infusion into the dorsal hippocampi .","paragraph":"<h3><u>Tetrahydroaminoacridine and D-cycloserine fail to alleviate the water maze spatial navigation defect induced by hippocampal inactivation.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>examined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>anticholinesterase</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>tetrahydroaminoacridine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>i.p</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>glycine-B</i></b> <b style='color:DodgerBlue;'><i>site</i></b> <b style='color:DodgerBlue;'><i>partial</i></b> <b style='color:DodgerBlue;'><i>agonist</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>D-cycloserine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>i.p</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>positive</i></b> <b style='color:DodgerBlue;'><i>allosteric</i></b> <b style='color:DodgerBlue;'><i>modulator</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>NMDA</i></b> <b style='color:DodgerBlue;'><i>receptors</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>alleviating</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>deficit</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>water</i></b> <b style='color:DodgerBlue;'><i>maze</i></b> <b style='color:DodgerBlue;'><i>spatial</i></b> <b style='color:DodgerBlue;'><i>navigation</i></b> <b style='color:DodgerBlue;'><i>induced</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>electrolytic</i></b> <b style='color:DodgerBlue;'><i>lesion</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>medial</i></b> <b style='color:DodgerBlue;'><i>septum</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>lidocaine</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>dorsal</i></b> <b style='color:DodgerBlue;'><i>hippocampi</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In medial septum-lesioned rats, a combination of tetrahydroaminoacridine 3 mg kg(-1) and <b style='color:Tomato;'><i>d-cycloserine</i></b> 10 mg kg(-1) facilitated acquisition of the water maze test more effectively than either of the drugs alone. Single or combined treatment with tetrahydroaminoacridine 3 mg kg(-1) and <b style='color:Tomato;'><i>d-cycloserine</i></b> 10 mg kg(-1) had no effect on the water maze deficit induced by hippocampal <b style='color:Tomato;'><i>lidocaine</i></b> infusion. These results suggest that combined treatment with tetrahydroaminoacridine and <b style='color:Tomato;'><i>d-cycloserine</i></b> can effectively stimulate water maze spatial navigation, and that functioning of the hippocampus is a prerequisite for this effect.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"present","start":4,"end":11,"id":1,"ws":true},{"text":"study","start":12,"end":17,"id":2,"ws":true},{"text":"examined","start":18,"end":26,"id":3,"ws":true},{"text":"the","start":27,"end":30,"id":4,"ws":true},{"text":"efficacy","start":31,"end":39,"id":5,"ws":true},{"text":"of","start":40,"end":42,"id":6,"ws":true},{"text":"single","start":43,"end":49,"id":7,"ws":true},{"text":"and","start":50,"end":53,"id":8,"ws":true},{"text":"combined","start":54,"end":62,"id":9,"ws":true},{"text":"treatment","start":63,"end":72,"id":10,"ws":true},{"text":"with","start":73,"end":77,"id":11,"ws":true},{"text":"an","start":78,"end":80,"id":12,"ws":true},{"text":"anticholinesterase","start":81,"end":99,"id":13,"ws":true},{"text":",","start":100,"end":101,"id":14,"ws":true},{"text":"tetrahydroaminoacridine","start":102,"end":125,"id":15,"ws":true},{"text":"(","start":126,"end":127,"id":16,"ws":true},{"text":"i.p","start":128,"end":131,"id":17,"ws":true},{"text":".","start":132,"end":133,"id":18,"ws":true},{"text":")","start":134,"end":135,"id":19,"ws":true},{"text":",","start":136,"end":137,"id":20,"ws":true},{"text":"and","start":138,"end":141,"id":21,"ws":true},{"text":"a","start":142,"end":143,"id":22,"ws":true},{"text":"glycine-B","start":144,"end":153,"id":23,"ws":true},{"text":"site","start":154,"end":158,"id":24,"ws":true},{"text":"partial","start":159,"end":166,"id":25,"ws":true},{"text":"agonist","start":167,"end":174,"id":26,"ws":true},{"text":",","start":175,"end":176,"id":27,"ws":true},{"text":"D-cycloserine","start":177,"end":190,"id":28,"ws":true},{"text":"(","start":191,"end":192,"id":29,"ws":true},{"text":"i.p","start":193,"end":196,"id":30,"ws":true},{"text":".","start":197,"end":198,"id":31,"ws":true},{"text":";","start":199,"end":200,"id":32,"ws":true},{"text":"a","start":201,"end":202,"id":33,"ws":true},{"text":"positive","start":203,"end":211,"id":34,"ws":true},{"text":"allosteric","start":212,"end":222,"id":35,"ws":true},{"text":"modulator","start":223,"end":232,"id":36,"ws":true},{"text":"of","start":233,"end":235,"id":37,"ws":true},{"text":"NMDA","start":236,"end":240,"id":38,"ws":true},{"text":"receptors","start":241,"end":250,"id":39,"ws":true},{"text":")","start":251,"end":252,"id":40,"ws":true},{"text":",","start":253,"end":254,"id":41,"ws":true},{"text":"in","start":255,"end":257,"id":42,"ws":true},{"text":"alleviating","start":258,"end":269,"id":43,"ws":true},{"text":"the","start":270,"end":273,"id":44,"ws":true},{"text":"deficit","start":274,"end":281,"id":45,"ws":true},{"text":"in","start":282,"end":284,"id":46,"ws":true},{"text":"water","start":285,"end":290,"id":47,"ws":true},{"text":"maze","start":291,"end":295,"id":48,"ws":true},{"text":"spatial","start":296,"end":303,"id":49,"ws":true},{"text":"navigation","start":304,"end":314,"id":50,"ws":true},{"text":"induced","start":315,"end":322,"id":51,"ws":true},{"text":"by","start":323,"end":325,"id":52,"ws":true},{"text":"electrolytic","start":326,"end":338,"id":53,"ws":true},{"text":"lesion","start":339,"end":345,"id":54,"ws":true},{"text":"of","start":346,"end":348,"id":55,"ws":true},{"text":"the","start":349,"end":352,"id":56,"ws":true},{"text":"medial","start":353,"end":359,"id":57,"ws":true},{"text":"septum","start":360,"end":366,"id":58,"ws":true},{"text":"or","start":367,"end":369,"id":59,"ws":true},{"text":"lidocaine","start":370,"end":379,"id":60,"ws":true},{"text":"infusion","start":380,"end":388,"id":61,"ws":true},{"text":"into","start":389,"end":393,"id":62,"ws":true},{"text":"the","start":394,"end":397,"id":63,"ws":true},{"text":"dorsal","start":398,"end":404,"id":64,"ws":true},{"text":"hippocampi","start":405,"end":415,"id":65,"ws":true},{"text":".","start":416,"end":417,"id":66,"ws":false}],"spans":[{"start":102,"end":125,"token_start":15,"token_end":15,"label":"DRUG"},{"start":177,"end":190,"token_start":28,"token_end":28,"label":"DRUG"},{"start":370,"end":379,"token_start":60,"token_end":60,"label":"DRUG"}],"_input_hash":1944915333,"_task_hash":1724675945,"_session_id":"drug_drug_pilot_shared-dana_n","_view_id":"blocks","relations":[{"head":15,"child":28,"head_span":{"start":102,"end":125,"token_start":15,"token_end":15,"label":"DRUG"},"child_span":{"start":177,"end":190,"token_start":28,"token_end":28,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T0"],"answer":"accept"}
{"text":"He was initially treated with combination chemotherapy regimen of vincristine , actinomycin-D and cyclophosphamide ( VAC therapy ) .","paragraph":"<h3><u>[Rhabdomyosarcoma of the bladder: a case report].</u></h3>A 15-year-old man with the chief complaint of general fatigue was referred to our hospital on November 11, 1993. Bilateral percutaneous nephrostomy was performed for postrenal anuria. X-ray examinations revealed a huge intrapelvic tumor, and it was histopathologically diagnosed as rhabdomyosarcoma by transrectal needle biopsy. <b style='color:DodgerBlue;'><i>He</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>initially</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>actinomycin-D</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>VAC</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Pelvic exenteration was performed on December 15, 1993. Histopathological findings were alveolar rhabdomyosarcoma with degenerative change and partial necrosis. After the operation, he was given two course of VAC therapy. In May, 1994, brain metastasis occurred, so 4 courses of VAC therapy were administered. For a very short period, neurological symptoms improved, but he died of pneumonia on November 15, 1994.","tokens":[{"text":"He","start":0,"end":2,"id":0,"ws":true},{"text":"was","start":3,"end":6,"id":1,"ws":true},{"text":"initially","start":7,"end":16,"id":2,"ws":true},{"text":"treated","start":17,"end":24,"id":3,"ws":true},{"text":"with","start":25,"end":29,"id":4,"ws":true},{"text":"combination","start":30,"end":41,"id":5,"ws":true},{"text":"chemotherapy","start":42,"end":54,"id":6,"ws":true},{"text":"regimen","start":55,"end":62,"id":7,"ws":true},{"text":"of","start":63,"end":65,"id":8,"ws":true},{"text":"vincristine","start":66,"end":77,"id":9,"ws":true},{"text":",","start":78,"end":79,"id":10,"ws":true},{"text":"actinomycin-D","start":80,"end":93,"id":11,"ws":true},{"text":"and","start":94,"end":97,"id":12,"ws":true},{"text":"cyclophosphamide","start":98,"end":114,"id":13,"ws":true},{"text":"(","start":115,"end":116,"id":14,"ws":true},{"text":"VAC","start":117,"end":120,"id":15,"ws":true},{"text":"therapy","start":121,"end":128,"id":16,"ws":true},{"text":")","start":129,"end":130,"id":17,"ws":true},{"text":".","start":131,"end":132,"id":18,"ws":false}],"spans":[{"start":66,"end":77,"token_start":9,"token_end":9,"label":"DRUG"},{"start":80,"end":93,"token_start":11,"token_end":11,"label":"DRUG"},{"start":98,"end":114,"token_start":13,"token_end":13,"label":"DRUG"}],"_input_hash":1557412523,"_task_hash":-2119098685,"_session_id":"drug_drug_pilot_shared-dana_n","_view_id":"blocks","relations":[{"head":9,"child":11,"head_span":{"start":66,"end":77,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":80,"end":93,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":11,"child":13,"head_span":{"start":80,"end":93,"token_start":11,"token_end":11,"label":"DRUG"},"child_span":{"start":98,"end":114,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T0"],"answer":"accept"}
{"text":"However , when a lung mass was noted two months later , he started to receive combination chemotherapy consisting of cyclophosphamide , adriamycin , vincristine , and prednisolone every three months .","paragraph":"<h3><u>[Lymphomatoid granulomatosis (LYG) occurring in a patient with follicular lymphoma during remission].</u></h3>A 49 years-old man presented with dry cough, low grade fever, and abnormal shadow on a chest X-ray. He had suffered from follicular lymphoma of the liver 5 years previously. He received irradiation therapy in combination with chemotherapy for approximately three years and had been in complete remission. Physical and radiological examination revealed pleural effusion and softly dense masses in the right lung. The laboratory data were within normal limits. He was diagnosed as having lymphomatoid granulomatosis (LYG) by open lung biopsy. The lung lesion was mainly infiltrated with T cells. The patient received <b style='color:Tomato;'><i>prednisolone</i></b> and the lung lesions disappeared. <b style='color:DodgerBlue;'><i>However</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>lung</i></b> <b style='color:DodgerBlue;'><i>mass</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>noted</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>later</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>he</i></b> <b style='color:DodgerBlue;'><i>started</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>receive</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>consisting</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>adriamycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>prednisolone</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>three</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>.</i></b> He has not shown relapse of LYG so far. To investigate the association between the preceding follicular lymphoma and subsequent LYG at this time, DNA analysis using the PCR technique was carried out. The LYG lesion did not show a rearranged band for the JH probe, while the paraffin-embedded specimen of the preceding follicular lymphoma had shown rearranged band for the JH band. Southern blot analysis of the LYG lesion, showed no rearrangement for TCR beta, gamma or JH probe. These findings indicate that the LYG was different from the preceding follicular lymphoma in terms of origin. LYG is considered to be induced in the immunosuppressive state due to lymphoma.","tokens":[{"text":"However","start":0,"end":7,"id":0,"ws":true},{"text":",","start":8,"end":9,"id":1,"ws":true},{"text":"when","start":10,"end":14,"id":2,"ws":true},{"text":"a","start":15,"end":16,"id":3,"ws":true},{"text":"lung","start":17,"end":21,"id":4,"ws":true},{"text":"mass","start":22,"end":26,"id":5,"ws":true},{"text":"was","start":27,"end":30,"id":6,"ws":true},{"text":"noted","start":31,"end":36,"id":7,"ws":true},{"text":"two","start":37,"end":40,"id":8,"ws":true},{"text":"months","start":41,"end":47,"id":9,"ws":true},{"text":"later","start":48,"end":53,"id":10,"ws":true},{"text":",","start":54,"end":55,"id":11,"ws":true},{"text":"he","start":56,"end":58,"id":12,"ws":true},{"text":"started","start":59,"end":66,"id":13,"ws":true},{"text":"to","start":67,"end":69,"id":14,"ws":true},{"text":"receive","start":70,"end":77,"id":15,"ws":true},{"text":"combination","start":78,"end":89,"id":16,"ws":true},{"text":"chemotherapy","start":90,"end":102,"id":17,"ws":true},{"text":"consisting","start":103,"end":113,"id":18,"ws":true},{"text":"of","start":114,"end":116,"id":19,"ws":true},{"text":"cyclophosphamide","start":117,"end":133,"id":20,"ws":true},{"text":",","start":134,"end":135,"id":21,"ws":true},{"text":"adriamycin","start":136,"end":146,"id":22,"ws":true},{"text":",","start":147,"end":148,"id":23,"ws":true},{"text":"vincristine","start":149,"end":160,"id":24,"ws":true},{"text":",","start":161,"end":162,"id":25,"ws":true},{"text":"and","start":163,"end":166,"id":26,"ws":true},{"text":"prednisolone","start":167,"end":179,"id":27,"ws":true},{"text":"every","start":180,"end":185,"id":28,"ws":true},{"text":"three","start":186,"end":191,"id":29,"ws":true},{"text":"months","start":192,"end":198,"id":30,"ws":true},{"text":".","start":199,"end":200,"id":31,"ws":false}],"spans":[{"start":117,"end":133,"token_start":20,"token_end":20,"label":"DRUG"},{"start":136,"end":146,"token_start":22,"token_end":22,"label":"DRUG"},{"start":149,"end":160,"token_start":24,"token_end":24,"label":"DRUG"},{"start":167,"end":179,"token_start":27,"token_end":27,"label":"DRUG"}],"_input_hash":8987266,"_task_hash":528717002,"_session_id":"drug_drug_pilot_shared-dana_n","_view_id":"blocks","relations":[{"head":20,"child":22,"head_span":{"start":117,"end":133,"token_start":20,"token_end":20,"label":"DRUG"},"child_span":{"start":136,"end":146,"token_start":22,"token_end":22,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":22,"child":24,"head_span":{"start":136,"end":146,"token_start":22,"token_end":22,"label":"DRUG"},"child_span":{"start":149,"end":160,"token_start":24,"token_end":24,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":24,"child":27,"head_span":{"start":149,"end":160,"token_start":24,"token_end":24,"label":"DRUG"},"child_span":{"start":167,"end":179,"token_start":27,"token_end":27,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T1"],"answer":"accept"}
{"text":"Three patients treated initially with propranolol alone have required substitution of amiodarone due to refractory congestive heart failure .","paragraph":"<h3><u>The role of beta-blockade therapy for ventricular tachycardia induced with isoproterenol: a prospective analysis.</u></h3>Isoproterenol is sometimes required for ventricular tachycardia (VT) induction. However, the role of beta-blockade for treatment of such VT has not been critically assessed. The use of beta-blockade was evaluated prospectively in 14 consecutive patients who required isoproterenol 2.4 +/- 1.3 (+/- S.D.) micrograms/min to induce sustained monomorphic VT (greater than 30 seconds, or requiring termination due to hemodynamic collapse) after a negative baseline study. The VT mechanisms were enhanced automaticity (group A, six patients), triggered automaticity (group B, three patients), and reentry (group C, five patients). Groups A and B had serial intravenous electropharmacologic tests with <b style='color:Tomato;'><i>propranolol</i></b> alone (0.2 mg/kg), <b style='color:Tomato;'><i>verapamil</i></b> alone (0.15 mg/kg), and <b style='color:Tomato;'><i>propranolol</i></b> plus <b style='color:Tomato;'><i>verapamil</i></b>, and group C had serial tests with <b style='color:Tomato;'><i>propranolol</i></b> alone, <b style='color:Tomato;'><i>procainamide</i></b> or <b style='color:Tomato;'><i>quinidine</i></b> (class Ia drug) alone, and <b style='color:Tomato;'><i>propranolol</i></b> plus a class Ia drug until VT could no longer be induced. All six patients in group A responded to <b style='color:Tomato;'><i>propranolol</i></b> alone. In group B, one patient responded to <b style='color:Tomato;'><i>verapamil</i></b> alone, and two patients responded to <b style='color:Tomato;'><i>propranolol</i></b> plus <b style='color:Tomato;'><i>verapamil</i></b>. In group C, three patients responded to <b style='color:Tomato;'><i>propranolol</i></b> alone, one patient responded to a class Ia drug alone, and one patient responded to <b style='color:Tomato;'><i>propranolol</i></b> plus a class Ia drug. During a follow-up of 7 to 37 (17.9 +/- 10.7) (+/- S.D.) months, VT has not recurred in any patient. <b style='color:DodgerBlue;'><i>Three</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>initially</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>propranolol</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>required</i></b> <b style='color:DodgerBlue;'><i>substitution</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>amiodarone</i></b> <b style='color:DodgerBlue;'><i>due</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>refractory</i></b> <b style='color:DodgerBlue;'><i>congestive</i></b> <b style='color:DodgerBlue;'><i>heart</i></b> <b style='color:DodgerBlue;'><i>failure</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In patients requiring isoproterenol for VT induction, beta-blockade alone appears to be effective in preventing reinduction of VT caused by enhanced automaticity. A heterogeneous response occurs when the VT mechanisms are triggered automaticity or reentry.","tokens":[{"text":"Three","start":0,"end":5,"id":0,"ws":true},{"text":"patients","start":6,"end":14,"id":1,"ws":true},{"text":"treated","start":15,"end":22,"id":2,"ws":true},{"text":"initially","start":23,"end":32,"id":3,"ws":true},{"text":"with","start":33,"end":37,"id":4,"ws":true},{"text":"propranolol","start":38,"end":49,"id":5,"ws":true},{"text":"alone","start":50,"end":55,"id":6,"ws":true},{"text":"have","start":56,"end":60,"id":7,"ws":true},{"text":"required","start":61,"end":69,"id":8,"ws":true},{"text":"substitution","start":70,"end":82,"id":9,"ws":true},{"text":"of","start":83,"end":85,"id":10,"ws":true},{"text":"amiodarone","start":86,"end":96,"id":11,"ws":true},{"text":"due","start":97,"end":100,"id":12,"ws":true},{"text":"to","start":101,"end":103,"id":13,"ws":true},{"text":"refractory","start":104,"end":114,"id":14,"ws":true},{"text":"congestive","start":115,"end":125,"id":15,"ws":true},{"text":"heart","start":126,"end":131,"id":16,"ws":true},{"text":"failure","start":132,"end":139,"id":17,"ws":true},{"text":".","start":140,"end":141,"id":18,"ws":false}],"spans":[{"start":38,"end":49,"token_start":5,"token_end":5,"label":"DRUG"},{"start":86,"end":96,"token_start":11,"token_end":11,"label":"DRUG"}],"_input_hash":-632828286,"_task_hash":-1526074177,"_session_id":"drug_drug_pilot_shared-dana_n","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"These studies suggest a slight advantage to the combined approaches that contain flutamide and bicalutamide , but the lack of dramatic differences in outcome makes monotherapy reasonable , especially in patients with more indolent disease .","paragraph":"<h3><u>The selection of hormonal therapy in prostate cancer: who, when, and for how long?</u></h3>Androgen deprivation is the foundation for the systemic therapy of advanced prostate cancer. Multiple trials have tested combined androgen blockade versus androgen deprivation alone in patients with advanced disease. <b style='color:DodgerBlue;'><i>These</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>suggest</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>slight</i></b> <b style='color:DodgerBlue;'><i>advantage</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>approaches</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>contain</i></b> <b style='color:MediumOrchid;'><i>flutamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>bicalutamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>lack</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>dramatic</i></b> <b style='color:DodgerBlue;'><i>differences</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>outcome</i></b> <b style='color:DodgerBlue;'><i>makes</i></b> <b style='color:DodgerBlue;'><i>monotherapy</i></b> <b style='color:DodgerBlue;'><i>reasonable</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>especially</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>indolent</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Intermittent androgen deprivation is an alternative that may allow patients to reduce the total time on androgen suppression as well as possibly delay the onset of androgen independence. A number of secondary hormonal therapies, including deferred and secondary antiandrogens, <b style='color:Tomato;'><i>ketoconazole</i></b>, and estrogens have shown modest response proportions. Patients with less advanced disease such as a rising prostate-specific antigen have varied outcomes, and no standard approach exists. In this group, noncastrating forms of hormonal therapy are being evaluated. Patients undergoing definitive local therapy who have high-risk features may benefit from early, as opposed to deferred, androgen deprivation. This review examines the evidence for the current state of the art in hormonal therapy in patients with prostate cancer and focuses, in particular, on treatment composition and timing as well as the rationale for the use of hormonal therapy in early stage disease.","tokens":[{"text":"These","start":0,"end":5,"id":0,"ws":true},{"text":"studies","start":6,"end":13,"id":1,"ws":true},{"text":"suggest","start":14,"end":21,"id":2,"ws":true},{"text":"a","start":22,"end":23,"id":3,"ws":true},{"text":"slight","start":24,"end":30,"id":4,"ws":true},{"text":"advantage","start":31,"end":40,"id":5,"ws":true},{"text":"to","start":41,"end":43,"id":6,"ws":true},{"text":"the","start":44,"end":47,"id":7,"ws":true},{"text":"combined","start":48,"end":56,"id":8,"ws":true},{"text":"approaches","start":57,"end":67,"id":9,"ws":true},{"text":"that","start":68,"end":72,"id":10,"ws":true},{"text":"contain","start":73,"end":80,"id":11,"ws":true},{"text":"flutamide","start":81,"end":90,"id":12,"ws":true},{"text":"and","start":91,"end":94,"id":13,"ws":true},{"text":"bicalutamide","start":95,"end":107,"id":14,"ws":true},{"text":",","start":108,"end":109,"id":15,"ws":true},{"text":"but","start":110,"end":113,"id":16,"ws":true},{"text":"the","start":114,"end":117,"id":17,"ws":true},{"text":"lack","start":118,"end":122,"id":18,"ws":true},{"text":"of","start":123,"end":125,"id":19,"ws":true},{"text":"dramatic","start":126,"end":134,"id":20,"ws":true},{"text":"differences","start":135,"end":146,"id":21,"ws":true},{"text":"in","start":147,"end":149,"id":22,"ws":true},{"text":"outcome","start":150,"end":157,"id":23,"ws":true},{"text":"makes","start":158,"end":163,"id":24,"ws":true},{"text":"monotherapy","start":164,"end":175,"id":25,"ws":true},{"text":"reasonable","start":176,"end":186,"id":26,"ws":true},{"text":",","start":187,"end":188,"id":27,"ws":true},{"text":"especially","start":189,"end":199,"id":28,"ws":true},{"text":"in","start":200,"end":202,"id":29,"ws":true},{"text":"patients","start":203,"end":211,"id":30,"ws":true},{"text":"with","start":212,"end":216,"id":31,"ws":true},{"text":"more","start":217,"end":221,"id":32,"ws":true},{"text":"indolent","start":222,"end":230,"id":33,"ws":true},{"text":"disease","start":231,"end":238,"id":34,"ws":true},{"text":".","start":239,"end":240,"id":35,"ws":false}],"spans":[{"start":81,"end":90,"token_start":12,"token_end":12,"label":"DRUG"},{"start":95,"end":107,"token_start":14,"token_end":14,"label":"DRUG"}],"_input_hash":137769162,"_task_hash":410888998,"_session_id":"drug_drug_pilot_shared-dana_n","_view_id":"blocks","relations":[{"head":12,"child":14,"head_span":{"start":81,"end":90,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":95,"end":107,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T0"],"answer":"accept"}
{"text":"We examined the feasibility and safety of using paclitaxel and trastuzumab as maintenance therapy after high-dose chemotherapy ( HDC ) with autologous hematopoietic stem cell transplantation ( AHST ) for patients with HER2-positive metastatic breast cancer .","paragraph":"<h3><u>Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation.</u></h3> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>examined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>feasibility</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>maintenance</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>HDC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>autologous</i></b> <b style='color:DodgerBlue;'><i>hematopoietic</i></b> <b style='color:DodgerBlue;'><i>stem</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>transplantation</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AHST</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>HER2-positive</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Ten patients (9 women and 1 man) were enrolled in the study. The median age was 46.5 years (range, 27-65 years). The median follow-up time was 1003 days (range, 216-2526 days). All patients had metastatic disease, but 2 had only bone metastasis. One patient had complete response, 6 had partial response and 3 had stable disease to the standard-dose chemotherapy prior to transplantation. The conditioning regimen consisted of <b style='color:Tomato;'><i>cyclophosphamide</i></b>, <b style='color:Tomato;'><i>carmustine</i></b>, and <b style='color:Tomato;'><i>thiotepa</i></b>. After AHST, patients received weekly <b style='color:Tomato;'><i>paclitaxel</i></b> for 12 doses and <b style='color:Tomato;'><i>trastuzumab</i></b> every 3 weeks for 1 year as maintenance therapy. All patients experienced successful engraftment. The only grade 4 toxic effects observed were leukopenia and thrombocytopenia. The most common grade 3 toxic effect was neutropenic fever. No treatment-related deaths were observed. The median progression-free survival time was 441 days, and the median overall survival time was 955 days. Two patients died in accidents while their disease remained in remission. Five patients died with disease progression. At the time of this report, 3 patients are alive with stable disease, 1 of whom has remained free of disease progression for 2526 days since transplantation. Our findings indicate that <b style='color:Tomato;'><i>paclitaxel</i></b> plus <b style='color:Tomato;'><i>trastuzumab</i></b> as maintenance therapy after HDC with AHST for patients with HER2-positive metastatic breast cancer not only is feasible and safe but also results in survival outcomes similar to historical results. ","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"examined","start":3,"end":11,"id":1,"ws":true},{"text":"the","start":12,"end":15,"id":2,"ws":true},{"text":"feasibility","start":16,"end":27,"id":3,"ws":true},{"text":"and","start":28,"end":31,"id":4,"ws":true},{"text":"safety","start":32,"end":38,"id":5,"ws":true},{"text":"of","start":39,"end":41,"id":6,"ws":true},{"text":"using","start":42,"end":47,"id":7,"ws":true},{"text":"paclitaxel","start":48,"end":58,"id":8,"ws":true},{"text":"and","start":59,"end":62,"id":9,"ws":true},{"text":"trastuzumab","start":63,"end":74,"id":10,"ws":true},{"text":"as","start":75,"end":77,"id":11,"ws":true},{"text":"maintenance","start":78,"end":89,"id":12,"ws":true},{"text":"therapy","start":90,"end":97,"id":13,"ws":true},{"text":"after","start":98,"end":103,"id":14,"ws":true},{"text":"high-dose","start":104,"end":113,"id":15,"ws":true},{"text":"chemotherapy","start":114,"end":126,"id":16,"ws":true},{"text":"(","start":127,"end":128,"id":17,"ws":true},{"text":"HDC","start":129,"end":132,"id":18,"ws":true},{"text":")","start":133,"end":134,"id":19,"ws":true},{"text":"with","start":135,"end":139,"id":20,"ws":true},{"text":"autologous","start":140,"end":150,"id":21,"ws":true},{"text":"hematopoietic","start":151,"end":164,"id":22,"ws":true},{"text":"stem","start":165,"end":169,"id":23,"ws":true},{"text":"cell","start":170,"end":174,"id":24,"ws":true},{"text":"transplantation","start":175,"end":190,"id":25,"ws":true},{"text":"(","start":191,"end":192,"id":26,"ws":true},{"text":"AHST","start":193,"end":197,"id":27,"ws":true},{"text":")","start":198,"end":199,"id":28,"ws":true},{"text":"for","start":200,"end":203,"id":29,"ws":true},{"text":"patients","start":204,"end":212,"id":30,"ws":true},{"text":"with","start":213,"end":217,"id":31,"ws":true},{"text":"HER2-positive","start":218,"end":231,"id":32,"ws":true},{"text":"metastatic","start":232,"end":242,"id":33,"ws":true},{"text":"breast","start":243,"end":249,"id":34,"ws":true},{"text":"cancer","start":250,"end":256,"id":35,"ws":true},{"text":".","start":257,"end":258,"id":36,"ws":false}],"spans":[{"start":48,"end":58,"token_start":8,"token_end":8,"label":"DRUG"},{"start":63,"end":74,"token_start":10,"token_end":10,"label":"DRUG"}],"_input_hash":-1578970086,"_task_hash":304060663,"_session_id":"drug_drug_pilot_shared-dana_n","_view_id":"blocks","relations":[{"head":8,"child":10,"head_span":{"start":48,"end":58,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":63,"end":74,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T1"],"answer":"accept"}
{"text":"Dual antiplatelet therapy with aspirin and clopidogrel ( the preferred thienopyridine because of its superior hematologic safety ) is recommended for at least 4 weeks to prevent subacute stent thrombosis with bare-metal stents and 3 to 6 months to prevent late-stent thrombosis with drug-eluting stents .","paragraph":"<h3><u>Long-term care after percutaneous coronary intervention: focus on the role of antiplatelet therapy.</u></h3>Arterial wall injury caused by percutaneous coronary intervention (PCI) triggers transient platelet activation and mural thrombosis; these effects are superimposed on the preexisting platelet hyperreactivity associated with underlying atherothrombosis. Platelet activation has been implicated in the major complications of PCI: acute and subacute thrombosis and restenosis. Antithrombotic and anticoagulant therapy minimizes thrombotic complications after PCI. <b style='color:Tomato;'><i>aspirin</i></b> plus a thienopyridine (<b style='color:Tomato;'><i>ticlopidine</i></b> or <b style='color:Tomato;'><i>clopidogrel</i></b>) is more effective than <b style='color:Tomato;'><i>aspirin</i></b> plus <b style='color:Tomato;'><i>heparin</i></b> and extended <b style='color:Tomato;'><i>warfarin</i></b> therapy in preventing periprocedural ischemic events and subsequent stent thrombosis and results in less major and minor bleeding. <b style='color:DodgerBlue;'><i>Dual</i></b> <b style='color:DodgerBlue;'><i>antiplatelet</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>aspirin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>clopidogrel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>preferred</i></b> <b style='color:DodgerBlue;'><i>thienopyridine</i></b> <b style='color:DodgerBlue;'><i>because</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>its</i></b> <b style='color:DodgerBlue;'><i>superior</i></b> <b style='color:DodgerBlue;'><i>hematologic</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>recommended</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>least</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>prevent</i></b> <b style='color:DodgerBlue;'><i>subacute</i></b> <b style='color:DodgerBlue;'><i>stent</i></b> <b style='color:DodgerBlue;'><i>thrombosis</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>bare-metal</i></b> <b style='color:DodgerBlue;'><i>stents</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>prevent</i></b> <b style='color:DodgerBlue;'><i>late-stent</i></b> <b style='color:DodgerBlue;'><i>thrombosis</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>drug-eluting</i></b> <b style='color:DodgerBlue;'><i>stents</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Coronary atherothrombosis is a diffuse vascular disease, and reduction of the risk of future ischemic events requires strategies that extend beyond the focal treatment of stenotic lesions. Optimal long-term care after PCI requires aggressive systemic pharmacotherapy (antiplatelet agents, statins, beta-blockers, and angiotensin-converting enzyme Inhibitors) in conjunction with therapeutic lifestyle changes (smoking cessation, weight reduction, dietary measures, and exercise). In this context, dual antiplatelet therapy (<b style='color:Tomato;'><i>aspirin</i></b> plus <b style='color:Tomato;'><i>clopidogrel</i></b>) is recommended for at least 12 months after PCI for prophylaxis of future atherothrombotic events.","tokens":[{"text":"Dual","start":0,"end":4,"id":0,"ws":true},{"text":"antiplatelet","start":5,"end":17,"id":1,"ws":true},{"text":"therapy","start":18,"end":25,"id":2,"ws":true},{"text":"with","start":26,"end":30,"id":3,"ws":true},{"text":"aspirin","start":31,"end":38,"id":4,"ws":true},{"text":"and","start":39,"end":42,"id":5,"ws":true},{"text":"clopidogrel","start":43,"end":54,"id":6,"ws":true},{"text":"(","start":55,"end":56,"id":7,"ws":true},{"text":"the","start":57,"end":60,"id":8,"ws":true},{"text":"preferred","start":61,"end":70,"id":9,"ws":true},{"text":"thienopyridine","start":71,"end":85,"id":10,"ws":true},{"text":"because","start":86,"end":93,"id":11,"ws":true},{"text":"of","start":94,"end":96,"id":12,"ws":true},{"text":"its","start":97,"end":100,"id":13,"ws":true},{"text":"superior","start":101,"end":109,"id":14,"ws":true},{"text":"hematologic","start":110,"end":121,"id":15,"ws":true},{"text":"safety","start":122,"end":128,"id":16,"ws":true},{"text":")","start":129,"end":130,"id":17,"ws":true},{"text":"is","start":131,"end":133,"id":18,"ws":true},{"text":"recommended","start":134,"end":145,"id":19,"ws":true},{"text":"for","start":146,"end":149,"id":20,"ws":true},{"text":"at","start":150,"end":152,"id":21,"ws":true},{"text":"least","start":153,"end":158,"id":22,"ws":true},{"text":"4","start":159,"end":160,"id":23,"ws":true},{"text":"weeks","start":161,"end":166,"id":24,"ws":true},{"text":"to","start":167,"end":169,"id":25,"ws":true},{"text":"prevent","start":170,"end":177,"id":26,"ws":true},{"text":"subacute","start":178,"end":186,"id":27,"ws":true},{"text":"stent","start":187,"end":192,"id":28,"ws":true},{"text":"thrombosis","start":193,"end":203,"id":29,"ws":true},{"text":"with","start":204,"end":208,"id":30,"ws":true},{"text":"bare-metal","start":209,"end":219,"id":31,"ws":true},{"text":"stents","start":220,"end":226,"id":32,"ws":true},{"text":"and","start":227,"end":230,"id":33,"ws":true},{"text":"3","start":231,"end":232,"id":34,"ws":true},{"text":"to","start":233,"end":235,"id":35,"ws":true},{"text":"6","start":236,"end":237,"id":36,"ws":true},{"text":"months","start":238,"end":244,"id":37,"ws":true},{"text":"to","start":245,"end":247,"id":38,"ws":true},{"text":"prevent","start":248,"end":255,"id":39,"ws":true},{"text":"late-stent","start":256,"end":266,"id":40,"ws":true},{"text":"thrombosis","start":267,"end":277,"id":41,"ws":true},{"text":"with","start":278,"end":282,"id":42,"ws":true},{"text":"drug-eluting","start":283,"end":295,"id":43,"ws":true},{"text":"stents","start":296,"end":302,"id":44,"ws":true},{"text":".","start":303,"end":304,"id":45,"ws":false}],"spans":[{"start":31,"end":38,"token_start":4,"token_end":4,"label":"DRUG"},{"start":43,"end":54,"token_start":6,"token_end":6,"label":"DRUG"}],"_input_hash":1471340217,"_task_hash":-1789027077,"_session_id":"drug_drug_pilot_shared-dana_n","_view_id":"blocks","relations":[{"head":4,"child":6,"head_span":{"start":31,"end":38,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":43,"end":54,"token_start":6,"token_end":6,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T1"],"answer":"accept"}
{"text":"Furthermore , in non-metastatic castration-resistant prostate cancer ( M0 CRPC ) , two second-generation anti-androgens , apalutamide and enzalutamide , when used in combination with ADT , have demonstrated a significant benefit in metastasis-free survival .","paragraph":"<h3><u>Recent trends in the management of advanced prostate cancer.</u></h3>Advanced prostate cancer includes a wide spectrum of disease ranging from hormone na\u00efve or hormone sensitive to castration resistant, both containing populations of men who have demonstrable metastatic and non-metastatic states. The mainstay of treatment for metastatic hormone-sensitive prostate cancer is androgen deprivation therapy (ADT). However, recent level 1 evidence demonstrates that the addition of chemotherapy or <b style='color:Tomato;'><i>abiraterone</i></b> acetate to ADT results in significant survival advantage as compared with ADT alone. <b style='color:DodgerBlue;'><i>Furthermore</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>non-metastatic</i></b> <b style='color:DodgerBlue;'><i>castration-resistant</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>M0</i></b> <b style='color:DodgerBlue;'><i>CRPC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>second-generation</i></b> <b style='color:DodgerBlue;'><i>anti-androgens</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>apalutamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>enzalutamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>ADT</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>significant</i></b> <b style='color:DodgerBlue;'><i>benefit</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>metastasis-free</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Here, we review the most recent studies leading to these significant changes in the treatment of advanced prostate cancer.","tokens":[{"text":"Furthermore","start":0,"end":11,"id":0,"ws":true},{"text":",","start":12,"end":13,"id":1,"ws":true},{"text":"in","start":14,"end":16,"id":2,"ws":true},{"text":"non-metastatic","start":17,"end":31,"id":3,"ws":true},{"text":"castration-resistant","start":32,"end":52,"id":4,"ws":true},{"text":"prostate","start":53,"end":61,"id":5,"ws":true},{"text":"cancer","start":62,"end":68,"id":6,"ws":true},{"text":"(","start":69,"end":70,"id":7,"ws":true},{"text":"M0","start":71,"end":73,"id":8,"ws":true},{"text":"CRPC","start":74,"end":78,"id":9,"ws":true},{"text":")","start":79,"end":80,"id":10,"ws":true},{"text":",","start":81,"end":82,"id":11,"ws":true},{"text":"two","start":83,"end":86,"id":12,"ws":true},{"text":"second-generation","start":87,"end":104,"id":13,"ws":true},{"text":"anti-androgens","start":105,"end":119,"id":14,"ws":true},{"text":",","start":120,"end":121,"id":15,"ws":true},{"text":"apalutamide","start":122,"end":133,"id":16,"ws":true},{"text":"and","start":134,"end":137,"id":17,"ws":true},{"text":"enzalutamide","start":138,"end":150,"id":18,"ws":true},{"text":",","start":151,"end":152,"id":19,"ws":true},{"text":"when","start":153,"end":157,"id":20,"ws":true},{"text":"used","start":158,"end":162,"id":21,"ws":true},{"text":"in","start":163,"end":165,"id":22,"ws":true},{"text":"combination","start":166,"end":177,"id":23,"ws":true},{"text":"with","start":178,"end":182,"id":24,"ws":true},{"text":"ADT","start":183,"end":186,"id":25,"ws":true},{"text":",","start":187,"end":188,"id":26,"ws":true},{"text":"have","start":189,"end":193,"id":27,"ws":true},{"text":"demonstrated","start":194,"end":206,"id":28,"ws":true},{"text":"a","start":207,"end":208,"id":29,"ws":true},{"text":"significant","start":209,"end":220,"id":30,"ws":true},{"text":"benefit","start":221,"end":228,"id":31,"ws":true},{"text":"in","start":229,"end":231,"id":32,"ws":true},{"text":"metastasis-free","start":232,"end":247,"id":33,"ws":true},{"text":"survival","start":248,"end":256,"id":34,"ws":true},{"text":".","start":257,"end":258,"id":35,"ws":false}],"spans":[{"start":122,"end":133,"token_start":16,"token_end":16,"label":"DRUG"},{"start":138,"end":150,"token_start":18,"token_end":18,"label":"DRUG"}],"_input_hash":236482726,"_task_hash":-1620523265,"_session_id":"drug_drug_pilot_shared-dana_n","_view_id":"blocks","relations":[{"head":16,"child":25,"head_span":{"start":122,"end":133,"token_start":16,"token_end":16,"label":"DRUG"},"child_span":{"start":183,"end":186,"token_start":25,"token_end":25,"label":null},"color":"#c5bdf4","label":"POS1"},{"head":18,"child":25,"head_span":{"start":138,"end":150,"token_start":18,"token_end":18,"label":"DRUG"},"child_span":{"start":183,"end":186,"token_start":25,"token_end":25,"label":null},"color":"#ffd882","label":"POS2"}],"radio":["POS10","POS1T0","POS20","POS2T0"],"answer":"accept"}
{"text":"A screening method based on liquid chromatography-electrospray mass spectrometry for the simultaneous determination of six corticosteroids ( betamethasone 17-valerate BM 17-V , beclomethasone BC , beclomethasone dipropionate BCDP , methylprednisolone MP , budesonide BD , flunisolide FN ) was developed in order to control their illegal use in cosmetic and natural products .","paragraph":"<h3><u>LC-MS method for the simultaneous determination of six glucocorticoids in pharmaceutical formulations and counterfeit cosmetic products.</u></h3> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>screening</i></b> <b style='color:DodgerBlue;'><i>method</i></b> <b style='color:DodgerBlue;'><i>based</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>liquid</i></b> <b style='color:DodgerBlue;'><i>chromatography-electrospray</i></b> <b style='color:DodgerBlue;'><i>mass</i></b> <b style='color:DodgerBlue;'><i>spectrometry</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>simultaneous</i></b> <b style='color:DodgerBlue;'><i>determination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>six</i></b> <b style='color:DodgerBlue;'><i>corticosteroids</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>betamethasone</i></b> <b style='color:DodgerBlue;'><i>17-valerate</i></b> <b style='color:DodgerBlue;'><i>BM</i></b> <b style='color:DodgerBlue;'><i>17-V</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>beclomethasone</i></b> <b style='color:DodgerBlue;'><i>BC</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>beclomethasone</i></b> <b style='color:DodgerBlue;'><i>dipropionate</i></b> <b style='color:DodgerBlue;'><i>BCDP</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>methylprednisolone</i></b> <b style='color:DodgerBlue;'><i>MP</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>budesonide</i></b> <b style='color:DodgerBlue;'><i>BD</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>flunisolide</i></b> <b style='color:DodgerBlue;'><i>FN</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>developed</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>order</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>control</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>illegal</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>cosmetic</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>natural</i></b> <b style='color:DodgerBlue;'><i>products</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Indeed, despite corticosteroids are banned in cosmetics, counterfeit products might be present on the market, representing a health hazard. Therefore, effective analytical methods are required to rapidly screen over the counter products in health care shops for counterfeit corticosteroids. The analytical method involves the employment of a Waters Synergy C18 column (150mm\u00d72.0mm I.D.) by using the following mobile phase: A (0.1% formic acid in acetonitrile), B (0.1% formic acid in water) in a linear gradient (from A-B 25:75, v/v to A-B 95:5, v/v in 30min) at the flow rate of 0.3mL/min. The detection was performed with an ion trap (IT) mass spectrometer in positive polarity, total ion current (TIC) and tandem mass modalities for qualitative purpose; single ion monitoring (SIM) mode was used for quantitative analysis on the ESI generated most abundant ion for each steroid. The method was fully validated in terms of precision, detection and quantification limits, linearity, recovery, and it was applied to the identification and quantification of corticosteroids in pharmaceutical formulations and cosmetic products. The mean recovery of BM 17-V, BC, BCDP, MP, BD and FN were found to be 101.3, 101.5, 98.8, 98.9, 98.1, 99.0%, respectively. Limits of quantitation (LOQ) were comprised in the range 29-95ng/mL. To the best of our knowledge, for the first time this mix of glucocorticoids were simultaneously determined in cosmetic products by using a fully validated method. BMV, in its two isomeric forms BM 17-V and BM 21-V, was found to be illegally present in one cream sample (A) with the total concentration level of 0.036% (w/w). ","tokens":[{"text":"A","start":0,"end":1,"id":0,"ws":true},{"text":"screening","start":2,"end":11,"id":1,"ws":true},{"text":"method","start":12,"end":18,"id":2,"ws":true},{"text":"based","start":19,"end":24,"id":3,"ws":true},{"text":"on","start":25,"end":27,"id":4,"ws":true},{"text":"liquid","start":28,"end":34,"id":5,"ws":true},{"text":"chromatography-electrospray","start":35,"end":62,"id":6,"ws":true},{"text":"mass","start":63,"end":67,"id":7,"ws":true},{"text":"spectrometry","start":68,"end":80,"id":8,"ws":true},{"text":"for","start":81,"end":84,"id":9,"ws":true},{"text":"the","start":85,"end":88,"id":10,"ws":true},{"text":"simultaneous","start":89,"end":101,"id":11,"ws":true},{"text":"determination","start":102,"end":115,"id":12,"ws":true},{"text":"of","start":116,"end":118,"id":13,"ws":true},{"text":"six","start":119,"end":122,"id":14,"ws":true},{"text":"corticosteroids","start":123,"end":138,"id":15,"ws":true},{"text":"(","start":139,"end":140,"id":16,"ws":true},{"text":"betamethasone","start":141,"end":154,"id":17,"ws":true},{"text":"17-valerate","start":155,"end":166,"id":18,"ws":true},{"text":"BM","start":167,"end":169,"id":19,"ws":true},{"text":"17-V","start":170,"end":174,"id":20,"ws":true},{"text":",","start":175,"end":176,"id":21,"ws":true},{"text":"beclomethasone","start":177,"end":191,"id":22,"ws":true},{"text":"BC","start":192,"end":194,"id":23,"ws":true},{"text":",","start":195,"end":196,"id":24,"ws":true},{"text":"beclomethasone","start":197,"end":211,"id":25,"ws":true},{"text":"dipropionate","start":212,"end":224,"id":26,"ws":true},{"text":"BCDP","start":225,"end":229,"id":27,"ws":true},{"text":",","start":230,"end":231,"id":28,"ws":true},{"text":"methylprednisolone","start":232,"end":250,"id":29,"ws":true},{"text":"MP","start":251,"end":253,"id":30,"ws":true},{"text":",","start":254,"end":255,"id":31,"ws":true},{"text":"budesonide","start":256,"end":266,"id":32,"ws":true},{"text":"BD","start":267,"end":269,"id":33,"ws":true},{"text":",","start":270,"end":271,"id":34,"ws":true},{"text":"flunisolide","start":272,"end":283,"id":35,"ws":true},{"text":"FN","start":284,"end":286,"id":36,"ws":true},{"text":")","start":287,"end":288,"id":37,"ws":true},{"text":"was","start":289,"end":292,"id":38,"ws":true},{"text":"developed","start":293,"end":302,"id":39,"ws":true},{"text":"in","start":303,"end":305,"id":40,"ws":true},{"text":"order","start":306,"end":311,"id":41,"ws":true},{"text":"to","start":312,"end":314,"id":42,"ws":true},{"text":"control","start":315,"end":322,"id":43,"ws":true},{"text":"their","start":323,"end":328,"id":44,"ws":true},{"text":"illegal","start":329,"end":336,"id":45,"ws":true},{"text":"use","start":337,"end":340,"id":46,"ws":true},{"text":"in","start":341,"end":343,"id":47,"ws":true},{"text":"cosmetic","start":344,"end":352,"id":48,"ws":true},{"text":"and","start":353,"end":356,"id":49,"ws":true},{"text":"natural","start":357,"end":364,"id":50,"ws":true},{"text":"products","start":365,"end":373,"id":51,"ws":true},{"text":".","start":374,"end":375,"id":52,"ws":false}],"spans":[{"start":141,"end":154,"token_start":17,"token_end":17,"label":"DRUG"},{"start":177,"end":191,"token_start":22,"token_end":22,"label":"DRUG"},{"start":197,"end":211,"token_start":25,"token_end":25,"label":"DRUG"},{"start":232,"end":250,"token_start":29,"token_end":29,"label":"DRUG"},{"start":256,"end":266,"token_start":32,"token_end":32,"label":"DRUG"},{"start":272,"end":283,"token_start":35,"token_end":35,"label":"DRUG"}],"_input_hash":782553464,"_task_hash":-1744775723,"_session_id":"drug_drug_pilot_shared-dana_n","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"We used MCF-7 and MDA-MB231 breast cancer cells incubated with Curcumin and Quercetin for 24h , in the absence and presence of Somatostatin , at their EC50 concentrations , to evaluate membrane fatty acid-based functional lipidomics together with the follow-up of EGFR and MAPK signaling pathways .","paragraph":"<h3><u>Effects of Somatostatin, Curcumin and Quercetin on the fatty acid profile of breast cancer cell membranes.</u></h3> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>MCF-7</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>MDA-MB231</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>incubated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>Curcumin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Quercetin</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>24h</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>absence</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>presence</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>Somatostatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>EC50</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>membrane</i></b> <b style='color:DodgerBlue;'><i>fatty</i></b> <b style='color:DodgerBlue;'><i>acid-based</i></b> <b style='color:DodgerBlue;'><i>functional</i></b> <b style='color:DodgerBlue;'><i>lipidomics</i></b> <b style='color:DodgerBlue;'><i>together</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>follow-up</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>EGFR</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>MAPK</i></b> <b style='color:DodgerBlue;'><i>signaling</i></b> <b style='color:DodgerBlue;'><i>pathways</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The two cell lines gave different membrane free fatty acid reorganization: in MCF-7 cells, the following changes observed: increase of omega-6 linoleic acid in the cells incubated with <b style='color:Tomato;'><i>somatostatin</i></b>+Quercetin and Quercetin and decrease of omega-3 acids in the cells incubated with <b style='color:Tomato;'><i>somatostatin</i></b>+<b style='color:Tomato;'><i>curcumin</i></b> compared to <b style='color:Tomato;'><i>somatostatin</i></b>, and significant increases of monounsaturated fatty acid (MUFA), mono-trans arachidonic acid levels and docosapentaenoic acid for the cells incubated with <b style='color:Tomato;'><i>somatostatin</i></b>+Quercetin compared to the control cells. In MDA-MB231 cells, incubations with <b style='color:Tomato;'><i>curcumin</i></b>, Quercetin and <b style='color:Tomato;'><i>somatostatin</i></b>+Quercetin induced the most significant membrane remodeling with the increase of stearic acid, diminution of omega-6 linoleic, arachidonic acids and omega-3 (docosapentaenoic and docosahexaenoic acids). Distinct signaling pathway changes were found for these cell lines. In MCF-7 cells, separate or combined incubations with <b style='color:Tomato;'><i>somatostatin</i></b> and Quercetin, significantly decreased EGFR and incubation with <b style='color:Tomato;'><i>curcumin</i></b> decreased MAPK signaling. In MDA-MB231 cells, incubation with <b style='color:Tomato;'><i>curcumin</i></b> decreased AKT1 and p-AKT1(Thr308) levels. Incubation with <b style='color:Tomato;'><i>curcumin</i></b> and Quercetin decreased the EGFR levels.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"used","start":3,"end":7,"id":1,"ws":true},{"text":"MCF-7","start":8,"end":13,"id":2,"ws":true},{"text":"and","start":14,"end":17,"id":3,"ws":true},{"text":"MDA-MB231","start":18,"end":27,"id":4,"ws":true},{"text":"breast","start":28,"end":34,"id":5,"ws":true},{"text":"cancer","start":35,"end":41,"id":6,"ws":true},{"text":"cells","start":42,"end":47,"id":7,"ws":true},{"text":"incubated","start":48,"end":57,"id":8,"ws":true},{"text":"with","start":58,"end":62,"id":9,"ws":true},{"text":"Curcumin","start":63,"end":71,"id":10,"ws":true},{"text":"and","start":72,"end":75,"id":11,"ws":true},{"text":"Quercetin","start":76,"end":85,"id":12,"ws":true},{"text":"for","start":86,"end":89,"id":13,"ws":true},{"text":"24h","start":90,"end":93,"id":14,"ws":true},{"text":",","start":94,"end":95,"id":15,"ws":true},{"text":"in","start":96,"end":98,"id":16,"ws":true},{"text":"the","start":99,"end":102,"id":17,"ws":true},{"text":"absence","start":103,"end":110,"id":18,"ws":true},{"text":"and","start":111,"end":114,"id":19,"ws":true},{"text":"presence","start":115,"end":123,"id":20,"ws":true},{"text":"of","start":124,"end":126,"id":21,"ws":true},{"text":"Somatostatin","start":127,"end":139,"id":22,"ws":true},{"text":",","start":140,"end":141,"id":23,"ws":true},{"text":"at","start":142,"end":144,"id":24,"ws":true},{"text":"their","start":145,"end":150,"id":25,"ws":true},{"text":"EC50","start":151,"end":155,"id":26,"ws":true},{"text":"concentrations","start":156,"end":170,"id":27,"ws":true},{"text":",","start":171,"end":172,"id":28,"ws":true},{"text":"to","start":173,"end":175,"id":29,"ws":true},{"text":"evaluate","start":176,"end":184,"id":30,"ws":true},{"text":"membrane","start":185,"end":193,"id":31,"ws":true},{"text":"fatty","start":194,"end":199,"id":32,"ws":true},{"text":"acid-based","start":200,"end":210,"id":33,"ws":true},{"text":"functional","start":211,"end":221,"id":34,"ws":true},{"text":"lipidomics","start":222,"end":232,"id":35,"ws":true},{"text":"together","start":233,"end":241,"id":36,"ws":true},{"text":"with","start":242,"end":246,"id":37,"ws":true},{"text":"the","start":247,"end":250,"id":38,"ws":true},{"text":"follow-up","start":251,"end":260,"id":39,"ws":true},{"text":"of","start":261,"end":263,"id":40,"ws":true},{"text":"EGFR","start":264,"end":268,"id":41,"ws":true},{"text":"and","start":269,"end":272,"id":42,"ws":true},{"text":"MAPK","start":273,"end":277,"id":43,"ws":true},{"text":"signaling","start":278,"end":287,"id":44,"ws":true},{"text":"pathways","start":288,"end":296,"id":45,"ws":true},{"text":".","start":297,"end":298,"id":46,"ws":false}],"spans":[{"start":63,"end":71,"token_start":10,"token_end":10,"label":"DRUG"},{"start":76,"end":85,"token_start":12,"token_end":12,"label":"DRUG"},{"start":127,"end":139,"token_start":22,"token_end":22,"label":"DRUG"}],"_input_hash":-1803484576,"_task_hash":288010961,"_session_id":"drug_drug_pilot_shared-dana_n","_view_id":"blocks","relations":[{"head":12,"child":22,"head_span":{"start":76,"end":85,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":127,"end":139,"token_start":22,"token_end":22,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":10,"child":12,"head_span":{"start":63,"end":71,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":76,"end":85,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#ffd882","label":"POS2"},{"head":10,"child":22,"head_span":{"start":63,"end":71,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":127,"end":139,"token_start":22,"token_end":22,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["POS11","POS1T0","POS21","POS2T0","COMB1T0"],"answer":"accept"}
{"text":"Following corneal scrapings and culture , topical 0.5 % moxifloxacin and 0.5 % tobramycin were administered hourly .","paragraph":"<h3><u>A case of Stenotrophomonas maltophilia keratitis effectively treated with moxifloxacin.</u></h3>A 70-year-old man with a long history of diabetes mellitus presented to our hospital (Department of Ophthalmology, Sahm Yook Medical Center, Seoul, Korea) complaining of severe ocular pain and visual disturbance in his left eye that had started three days prior to admission. A round 3.7 \u00d7 5.0 mm dense central stromal infiltrate with an overlying epithelial defect was noted on slit-lamp examination. <b style='color:DodgerBlue;'><i>Following</i></b> <b style='color:DodgerBlue;'><i>corneal</i></b> <b style='color:DodgerBlue;'><i>scrapings</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>culture</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>topical</i></b> <b style='color:DodgerBlue;'><i>0.5</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:MediumOrchid;'><i>moxifloxacin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>0.5</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:MediumOrchid;'><i>tobramycin</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>hourly</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A few days later, Stenotrophomonas maltophilia was isolated in a bacterial culture from a corneal specimen. According to the results of susceptibility tests, topical 0.5% <b style='color:Tomato;'><i>moxifloxacin</i></b> was given every hour and 0.5% <b style='color:Tomato;'><i>tobramycin</i></b> was stopped. The patient's clinical features improved steadily with treatment. The corneal epithelium healed rapidly, and the infiltrate resolved within four weeks of the initiation of treatment. The patient's best corrected visual acuity improved from hand motion to 20 / 25.","tokens":[{"text":"Following","start":0,"end":9,"id":0,"ws":true},{"text":"corneal","start":10,"end":17,"id":1,"ws":true},{"text":"scrapings","start":18,"end":27,"id":2,"ws":true},{"text":"and","start":28,"end":31,"id":3,"ws":true},{"text":"culture","start":32,"end":39,"id":4,"ws":true},{"text":",","start":40,"end":41,"id":5,"ws":true},{"text":"topical","start":42,"end":49,"id":6,"ws":true},{"text":"0.5","start":50,"end":53,"id":7,"ws":true},{"text":"%","start":54,"end":55,"id":8,"ws":true},{"text":"moxifloxacin","start":56,"end":68,"id":9,"ws":true},{"text":"and","start":69,"end":72,"id":10,"ws":true},{"text":"0.5","start":73,"end":76,"id":11,"ws":true},{"text":"%","start":77,"end":78,"id":12,"ws":true},{"text":"tobramycin","start":79,"end":89,"id":13,"ws":true},{"text":"were","start":90,"end":94,"id":14,"ws":true},{"text":"administered","start":95,"end":107,"id":15,"ws":true},{"text":"hourly","start":108,"end":114,"id":16,"ws":true},{"text":".","start":115,"end":116,"id":17,"ws":false}],"spans":[{"start":56,"end":68,"token_start":9,"token_end":9,"label":"DRUG"},{"start":79,"end":89,"token_start":13,"token_end":13,"label":"DRUG"}],"_input_hash":1332991430,"_task_hash":1426603318,"_session_id":"drug_drug_pilot_shared-dana_n","_view_id":"blocks","relations":[{"head":9,"child":13,"head_span":{"start":56,"end":68,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":79,"end":89,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T1"],"answer":"accept"}
{"text":"Combination treatment with cetuximab and nystatin selectively increased cetuximab uptake by tumor tissues , translating into potentiated antitumor efficacy of cetuximab in vivo ( A431 and A549 tumors ) .","paragraph":"<h3><u>Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration.</u></h3><b style='color:Tomato;'><i>cetuximab</i></b>, a monoclonal antibody (mAb) targeting the epidermal growth factor receptor (EGFR), has been intensively investigated as a promising cancer treatment strategy. The specific mechanism of <b style='color:Tomato;'><i>cetuximab</i></b> endocytosis and its influence on <b style='color:Tomato;'><i>cetuximab</i></b> uptake, biodistribution and efficacy still remain elusive. Recently, statins have been reported to synergize with EGFR-targeting agents. Our prior work established that <b style='color:Tomato;'><i>nystatin</i></b>, a cholesterol-sequestering antifungal drug, facilitates endocytosis via the clathrin-dependent pathway. This study aimed to investigate whether <b style='color:Tomato;'><i>nystatin</i></b> regulates the uptake and efficacy of <b style='color:Tomato;'><i>cetuximab</i></b> and <b style='color:Tomato;'><i>cetuximab</i></b>-based antibody-drug conjugates (<b style='color:Tomato;'><i>cetuximab</i></b>-ADCs). In vitro and in vivo efficacies of <b style='color:Tomato;'><i>nystatin</i></b> on the uptake and activity of <b style='color:Tomato;'><i>cetuximab</i></b>/<b style='color:Tomato;'><i>cetuximab</i></b>-ADCs were studied in multiple human carcinoma cell lines and xenograft models, respectively. We identified that cholesterol sequestration by <b style='color:Tomato;'><i>nystatin</i></b> enhanced <b style='color:Tomato;'><i>cetuximab</i></b> internalization in EGFR-positive carcinoma cells by regulating EGFR trafficking/turnover and facilitating a switch from lipid rafts to clathrin-mediated endocytosis. <b style='color:DodgerBlue;'><i>Combination</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>nystatin</i></b> <b style='color:DodgerBlue;'><i>selectively</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>uptake</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>tumor</i></b> <b style='color:DodgerBlue;'><i>tissues</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>translating</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>potentiated</i></b> <b style='color:DodgerBlue;'><i>antitumor</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vivo</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>A431</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>A549</i></b> <b style='color:DodgerBlue;'><i>tumors</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>nystatin</i></b>-enhanced internalization of <b style='color:Tomato;'><i>cetuximab</i></b> further improved the uptake and potency of <b style='color:Tomato;'><i>cetuximab</i></b>-<b style='color:Tomato;'><i>doxorubicin</i></b> and <b style='color:Tomato;'><i>cetuximab</i></b>-<b style='color:Tomato;'><i>methotrexate</i></b> conjugates in EGFR-positive <b style='color:Tomato;'><i>cetuximab</i></b>-resistant tumors. Combination therapy with <b style='color:Tomato;'><i>nystatin</i></b> plus either <b style='color:Tomato;'><i>cetuximab</i></b> or <b style='color:Tomato;'><i>cetuximab</i></b>-ADC further prolonged animal survival and significantly suppressed tumor growth, as compared with single-agent <b style='color:Tomato;'><i>cetuximab</i></b> or <b style='color:Tomato;'><i>cetuximab</i></b>-ADC. In summary, our results identify a novel mechanism whereby cholesterol sequestration enhances the uptake of EGFR-targeting mAb and ADCs, therefore providing preclinical proof-of-concept that combination with <b style='color:Tomato;'><i>nystatin</i></b> can potentiate the delivery and efficacy of these EGFR-targeted agents. ","tokens":[{"text":"Combination","start":0,"end":11,"id":0,"ws":true},{"text":"treatment","start":12,"end":21,"id":1,"ws":true},{"text":"with","start":22,"end":26,"id":2,"ws":true},{"text":"cetuximab","start":27,"end":36,"id":3,"ws":true},{"text":"and","start":37,"end":40,"id":4,"ws":true},{"text":"nystatin","start":41,"end":49,"id":5,"ws":true},{"text":"selectively","start":50,"end":61,"id":6,"ws":true},{"text":"increased","start":62,"end":71,"id":7,"ws":true},{"text":"cetuximab","start":72,"end":81,"id":8,"ws":true},{"text":"uptake","start":82,"end":88,"id":9,"ws":true},{"text":"by","start":89,"end":91,"id":10,"ws":true},{"text":"tumor","start":92,"end":97,"id":11,"ws":true},{"text":"tissues","start":98,"end":105,"id":12,"ws":true},{"text":",","start":106,"end":107,"id":13,"ws":true},{"text":"translating","start":108,"end":119,"id":14,"ws":true},{"text":"into","start":120,"end":124,"id":15,"ws":true},{"text":"potentiated","start":125,"end":136,"id":16,"ws":true},{"text":"antitumor","start":137,"end":146,"id":17,"ws":true},{"text":"efficacy","start":147,"end":155,"id":18,"ws":true},{"text":"of","start":156,"end":158,"id":19,"ws":true},{"text":"cetuximab","start":159,"end":168,"id":20,"ws":true},{"text":"in","start":169,"end":171,"id":21,"ws":true},{"text":"vivo","start":172,"end":176,"id":22,"ws":true},{"text":"(","start":177,"end":178,"id":23,"ws":true},{"text":"A431","start":179,"end":183,"id":24,"ws":true},{"text":"and","start":184,"end":187,"id":25,"ws":true},{"text":"A549","start":188,"end":192,"id":26,"ws":true},{"text":"tumors","start":193,"end":199,"id":27,"ws":true},{"text":")","start":200,"end":201,"id":28,"ws":true},{"text":".","start":202,"end":203,"id":29,"ws":false}],"spans":[{"start":27,"end":36,"token_start":3,"token_end":3,"label":"DRUG"},{"start":41,"end":49,"token_start":5,"token_end":5,"label":"DRUG"},{"start":72,"end":81,"token_start":8,"token_end":8,"label":"DRUG"},{"start":159,"end":168,"token_start":20,"token_end":20,"label":"DRUG"}],"_input_hash":-1277491604,"_task_hash":-1965461189,"_session_id":"drug_drug_pilot_shared-dana_n","_view_id":"blocks","relations":[{"head":3,"child":5,"head_span":{"start":27,"end":36,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":41,"end":49,"token_start":5,"token_end":5,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T0"],"answer":"accept"}
{"text":"The effects of combination therapy with chenodeoxycholic acid ( CDCA ) and simvastatin on serum cholestanol , low-density lipoprotein ( LDL ) cholesterol , and lathosterol levels were investigated in seven adult patients with cerebrotendinous xanthomatosis ( CTX ) who were on long-term treatment with CDCA .","paragraph":"<h3><u>Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>chenodeoxycholic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CDCA</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>simvastatin</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>serum</i></b> <b style='color:DodgerBlue;'><i>cholestanol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>low-density</i></b> <b style='color:DodgerBlue;'><i>lipoprotein</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>LDL</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>cholesterol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>lathosterol</i></b> <b style='color:DodgerBlue;'><i>levels</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>investigated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>seven</i></b> <b style='color:DodgerBlue;'><i>adult</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>cerebrotendinous</i></b> <b style='color:DodgerBlue;'><i>xanthomatosis</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CTX</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>long-term</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>CDCA</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The patients were treated with a combination of CDCA 750 mg daily and an increasing dose of <b style='color:Tomato;'><i>simvastatin</i></b> from 10 mg to 40 mg daily for a period of 6 months. We found a significant effect of this combination therapy compared with CDCA alone in terms of decreasing the serum cholestanol and LDL cholesterol levels, particularly with a daily dose of 40 mg <b style='color:Tomato;'><i>simvastatin</i></b>. The mean cholestanol level decreased from 9.27 micromol/L (baseline) to 6.69 micromol/L (40 mg <b style='color:Tomato;'><i>simvastatin</i></b>), while the mean LDL cholesterol level decreased from 5.08 mmol/L (baseline) to 3.04 mmol/L (40 mg <b style='color:Tomato;'><i>simvastatin</i></b>). No side effects were reported, and there were no effects on the clinical condition, cerebral magnetic resonance imaging (MRI), visual evoked potentials, and electroencephalographic features. We conclude that a combination of 750 mg CDCA and 40 mg <b style='color:Tomato;'><i>simvastatin</i></b> daily is effective to further reduce serum cholestanol, LDL cholesterol, and lathosterol in adult CTX patients treated with long-term CDCA. Whether this combination treatment will be effective for the long-term prevention of neurological deterioration and atherosclerosis remains to be established.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"effects","start":4,"end":11,"id":1,"ws":true},{"text":"of","start":12,"end":14,"id":2,"ws":true},{"text":"combination","start":15,"end":26,"id":3,"ws":true},{"text":"therapy","start":27,"end":34,"id":4,"ws":true},{"text":"with","start":35,"end":39,"id":5,"ws":true},{"text":"chenodeoxycholic","start":40,"end":56,"id":6,"ws":true},{"text":"acid","start":57,"end":61,"id":7,"ws":true},{"text":"(","start":62,"end":63,"id":8,"ws":true},{"text":"CDCA","start":64,"end":68,"id":9,"ws":true},{"text":")","start":69,"end":70,"id":10,"ws":true},{"text":"and","start":71,"end":74,"id":11,"ws":true},{"text":"simvastatin","start":75,"end":86,"id":12,"ws":true},{"text":"on","start":87,"end":89,"id":13,"ws":true},{"text":"serum","start":90,"end":95,"id":14,"ws":true},{"text":"cholestanol","start":96,"end":107,"id":15,"ws":true},{"text":",","start":108,"end":109,"id":16,"ws":true},{"text":"low-density","start":110,"end":121,"id":17,"ws":true},{"text":"lipoprotein","start":122,"end":133,"id":18,"ws":true},{"text":"(","start":134,"end":135,"id":19,"ws":true},{"text":"LDL","start":136,"end":139,"id":20,"ws":true},{"text":")","start":140,"end":141,"id":21,"ws":true},{"text":"cholesterol","start":142,"end":153,"id":22,"ws":true},{"text":",","start":154,"end":155,"id":23,"ws":true},{"text":"and","start":156,"end":159,"id":24,"ws":true},{"text":"lathosterol","start":160,"end":171,"id":25,"ws":true},{"text":"levels","start":172,"end":178,"id":26,"ws":true},{"text":"were","start":179,"end":183,"id":27,"ws":true},{"text":"investigated","start":184,"end":196,"id":28,"ws":true},{"text":"in","start":197,"end":199,"id":29,"ws":true},{"text":"seven","start":200,"end":205,"id":30,"ws":true},{"text":"adult","start":206,"end":211,"id":31,"ws":true},{"text":"patients","start":212,"end":220,"id":32,"ws":true},{"text":"with","start":221,"end":225,"id":33,"ws":true},{"text":"cerebrotendinous","start":226,"end":242,"id":34,"ws":true},{"text":"xanthomatosis","start":243,"end":256,"id":35,"ws":true},{"text":"(","start":257,"end":258,"id":36,"ws":true},{"text":"CTX","start":259,"end":262,"id":37,"ws":true},{"text":")","start":263,"end":264,"id":38,"ws":true},{"text":"who","start":265,"end":268,"id":39,"ws":true},{"text":"were","start":269,"end":273,"id":40,"ws":true},{"text":"on","start":274,"end":276,"id":41,"ws":true},{"text":"long-term","start":277,"end":286,"id":42,"ws":true},{"text":"treatment","start":287,"end":296,"id":43,"ws":true},{"text":"with","start":297,"end":301,"id":44,"ws":true},{"text":"CDCA","start":302,"end":306,"id":45,"ws":true},{"text":".","start":307,"end":308,"id":46,"ws":false}],"spans":[{"start":40,"end":56,"token_start":6,"token_end":6,"label":"DRUG"},{"start":75,"end":86,"token_start":12,"token_end":12,"label":"DRUG"}],"_input_hash":-475065306,"_task_hash":-2052397739,"_session_id":"drug_drug_pilot_shared-dana_n","_view_id":"blocks","relations":[{"head":12,"child":6,"head_span":{"start":75,"end":86,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":40,"end":56,"token_start":6,"token_end":6,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"Paclitaxel ( Taxol ; Bristol-Myers Squibb Company , Princeton , NJ ) has been demonstrated to be highly effective in treating patients with advanced breast cancer , including those with anthracycline-resistant breast cancer , a fact that has led to efforts to combine paclitaxel and anthracyclines .","paragraph":"<h3><u>Paclitaxel and doxorubicin in metastatic breast cancer.</u></h3>For the past decades the anthracyclines have been regarded as among the most active drugs for the treatment of metastatic breast cancer. However, the 5-year survival rate in patients with stage IV breast cancer continues to be below 20%, and new active drugs and drug combinations clearly must be explored. <b style='color:MediumOrchid;'><i>Paclitaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Taxol</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>Bristol-Myers</i></b> <b style='color:DodgerBlue;'><i>Squibb</i></b> <b style='color:DodgerBlue;'><i>Company</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Princeton</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>NJ</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>highly</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>treating</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>anthracycline-resistant</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>fact</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>led</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>efforts</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>combine</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>anthracyclines</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Several studies aiming to define the optimal dose and schedule of combination <b style='color:Tomato;'><i>paclitaxel</i></b>/<b style='color:Tomato;'><i>doxorubicin</i></b> have now been completed or are ongoing. Phase I/II studies have yielded encouraging preliminary response rates but quite variable toxicity profiles depending on the schedule used. These clinical trials involving combination <b style='color:Tomato;'><i>paclitaxel</i></b>/<b style='color:Tomato;'><i>doxorubicin</i></b> are reviewed, with special emphasis on the short-infusion trials.","tokens":[{"text":"Paclitaxel","start":0,"end":10,"id":0,"ws":true},{"text":"(","start":11,"end":12,"id":1,"ws":true},{"text":"Taxol","start":13,"end":18,"id":2,"ws":true},{"text":";","start":19,"end":20,"id":3,"ws":true},{"text":"Bristol-Myers","start":21,"end":34,"id":4,"ws":true},{"text":"Squibb","start":35,"end":41,"id":5,"ws":true},{"text":"Company","start":42,"end":49,"id":6,"ws":true},{"text":",","start":50,"end":51,"id":7,"ws":true},{"text":"Princeton","start":52,"end":61,"id":8,"ws":true},{"text":",","start":62,"end":63,"id":9,"ws":true},{"text":"NJ","start":64,"end":66,"id":10,"ws":true},{"text":")","start":67,"end":68,"id":11,"ws":true},{"text":"has","start":69,"end":72,"id":12,"ws":true},{"text":"been","start":73,"end":77,"id":13,"ws":true},{"text":"demonstrated","start":78,"end":90,"id":14,"ws":true},{"text":"to","start":91,"end":93,"id":15,"ws":true},{"text":"be","start":94,"end":96,"id":16,"ws":true},{"text":"highly","start":97,"end":103,"id":17,"ws":true},{"text":"effective","start":104,"end":113,"id":18,"ws":true},{"text":"in","start":114,"end":116,"id":19,"ws":true},{"text":"treating","start":117,"end":125,"id":20,"ws":true},{"text":"patients","start":126,"end":134,"id":21,"ws":true},{"text":"with","start":135,"end":139,"id":22,"ws":true},{"text":"advanced","start":140,"end":148,"id":23,"ws":true},{"text":"breast","start":149,"end":155,"id":24,"ws":true},{"text":"cancer","start":156,"end":162,"id":25,"ws":true},{"text":",","start":163,"end":164,"id":26,"ws":true},{"text":"including","start":165,"end":174,"id":27,"ws":true},{"text":"those","start":175,"end":180,"id":28,"ws":true},{"text":"with","start":181,"end":185,"id":29,"ws":true},{"text":"anthracycline-resistant","start":186,"end":209,"id":30,"ws":true},{"text":"breast","start":210,"end":216,"id":31,"ws":true},{"text":"cancer","start":217,"end":223,"id":32,"ws":true},{"text":",","start":224,"end":225,"id":33,"ws":true},{"text":"a","start":226,"end":227,"id":34,"ws":true},{"text":"fact","start":228,"end":232,"id":35,"ws":true},{"text":"that","start":233,"end":237,"id":36,"ws":true},{"text":"has","start":238,"end":241,"id":37,"ws":true},{"text":"led","start":242,"end":245,"id":38,"ws":true},{"text":"to","start":246,"end":248,"id":39,"ws":true},{"text":"efforts","start":249,"end":256,"id":40,"ws":true},{"text":"to","start":257,"end":259,"id":41,"ws":true},{"text":"combine","start":260,"end":267,"id":42,"ws":true},{"text":"paclitaxel","start":268,"end":278,"id":43,"ws":true},{"text":"and","start":279,"end":282,"id":44,"ws":true},{"text":"anthracyclines","start":283,"end":297,"id":45,"ws":true},{"text":".","start":298,"end":299,"id":46,"ws":false}],"spans":[{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},{"start":268,"end":278,"token_start":43,"token_end":43,"label":"DRUG"},{"start":283,"end":297,"token_start":45,"token_end":45,"label":"DRUG"}],"_input_hash":702583470,"_task_hash":1770101995,"_session_id":"drug_drug_pilot_shared-dana_n","_view_id":"blocks","relations":[{"head":43,"child":45,"head_span":{"start":268,"end":278,"token_start":43,"token_end":43,"label":"DRUG"},"child_span":{"start":283,"end":297,"token_start":45,"token_end":45,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"However , anastrozole , exemestane and letrozole are associated with significantly fewer endometrial cancers , as well as venous and arterial vascular events , when compared with tamoxifen [ 9 , 10 ] .","paragraph":"<h3><u>Erythema nodosum secondary to aromatase inhibitor use in breast cancer patients: case reports and review of the literature.</u></h3>Aromatase inhibitors (AI's) are increasingly being incorporated in the treatment strategy for hormone receptor positive breast cancer either alone or in combination with chemotherapy, biologics in both the adjuvant and metastatic setting [1]. They markedly suppress plasma estrogen levels by inhibiting or inactivating aromatase, the enzyme responsible for the synthesis of estrogens from androgenic substrates [1]. Currently, the three selective aromatase inhibitors that are available are <b style='color:Tomato;'><i>anastrozole</i></b>, <b style='color:Tomato;'><i>letrozole</i></b> and <b style='color:Tomato;'><i>exemestane</i></b> which reduce circulating estrogen to 1 to 10% of pretreatment levels [2]. For advanced breast cancer, aromatase inhibitors appear to be at a minimum, equivalent and perhaps even better than <b style='color:Tomato;'><i>tamoxifen</i></b> in the first line setting [3, 4]. In primary breast cancer, adjuvant therapy with <b style='color:Tomato;'><i>anastrozole</i></b> or <b style='color:Tomato;'><i>letrozole</i></b> appears to be superior to <b style='color:Tomato;'><i>tamoxifen</i></b> in reducing the risk of relapse [5, 6]. Common adverse effects associated with AI's include arthralgias (21%), myalgias (12%), other musculoskeletal disorders (28%) and an up to 60% increased risk of bone fracture [7, 8]. <b style='color:DodgerBlue;'><i>However</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>anastrozole</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>exemestane</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>letrozole</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>fewer</i></b> <b style='color:DodgerBlue;'><i>endometrial</i></b> <b style='color:DodgerBlue;'><i>cancers</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>venous</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>arterial</i></b> <b style='color:DodgerBlue;'><i>vascular</i></b> <b style='color:DodgerBlue;'><i>events</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>9</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Very rarely <b style='color:Tomato;'><i>letrozole</i></b> and <b style='color:Tomato;'><i>anastrozole</i></b> can cause a skin rash; the frequency of its occurrence has not been quantified(. )However, <b style='color:Tomato;'><i>exemestane</i></b> has not been reported to cause a skin rash [11]. To date, erythema nodosum (EN) has not been reported as a dermatologic side effect of AI's. Here, we report three cases of EN which developed in postmenopausal breast cancer patients on AI's.","tokens":[{"text":"However","start":0,"end":7,"id":0,"ws":true},{"text":",","start":8,"end":9,"id":1,"ws":true},{"text":"anastrozole","start":10,"end":21,"id":2,"ws":true},{"text":",","start":22,"end":23,"id":3,"ws":true},{"text":"exemestane","start":24,"end":34,"id":4,"ws":true},{"text":"and","start":35,"end":38,"id":5,"ws":true},{"text":"letrozole","start":39,"end":48,"id":6,"ws":true},{"text":"are","start":49,"end":52,"id":7,"ws":true},{"text":"associated","start":53,"end":63,"id":8,"ws":true},{"text":"with","start":64,"end":68,"id":9,"ws":true},{"text":"significantly","start":69,"end":82,"id":10,"ws":true},{"text":"fewer","start":83,"end":88,"id":11,"ws":true},{"text":"endometrial","start":89,"end":100,"id":12,"ws":true},{"text":"cancers","start":101,"end":108,"id":13,"ws":true},{"text":",","start":109,"end":110,"id":14,"ws":true},{"text":"as","start":111,"end":113,"id":15,"ws":true},{"text":"well","start":114,"end":118,"id":16,"ws":true},{"text":"as","start":119,"end":121,"id":17,"ws":true},{"text":"venous","start":122,"end":128,"id":18,"ws":true},{"text":"and","start":129,"end":132,"id":19,"ws":true},{"text":"arterial","start":133,"end":141,"id":20,"ws":true},{"text":"vascular","start":142,"end":150,"id":21,"ws":true},{"text":"events","start":151,"end":157,"id":22,"ws":true},{"text":",","start":158,"end":159,"id":23,"ws":true},{"text":"when","start":160,"end":164,"id":24,"ws":true},{"text":"compared","start":165,"end":173,"id":25,"ws":true},{"text":"with","start":174,"end":178,"id":26,"ws":true},{"text":"tamoxifen","start":179,"end":188,"id":27,"ws":true},{"text":"[","start":189,"end":190,"id":28,"ws":true},{"text":"9","start":191,"end":192,"id":29,"ws":true},{"text":",","start":193,"end":194,"id":30,"ws":true},{"text":"10","start":195,"end":197,"id":31,"ws":true},{"text":"]","start":198,"end":199,"id":32,"ws":true},{"text":".","start":200,"end":201,"id":33,"ws":false}],"spans":[{"start":10,"end":21,"token_start":2,"token_end":2,"label":"DRUG"},{"start":24,"end":34,"token_start":4,"token_end":4,"label":"DRUG"},{"start":39,"end":48,"token_start":6,"token_end":6,"label":"DRUG"},{"start":179,"end":188,"token_start":27,"token_end":27,"label":"DRUG"}],"_input_hash":155070717,"_task_hash":-411756935,"_session_id":"drug_drug_pilot_shared-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Additivity , synergy , or competition was observed with MIS and rapamycin , AzadC , doxorubicin , cisplatin , and paclitaxel , suggesting that MIS in combination with selective targeted therapies might achieve greater activity against ovarian cancer than the use of each individual agent alone .","paragraph":"<h3><u>Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.</u></h3>Mullerian Inhibiting Substance (MIS), a biological modifier that causes regression of Mullerian ducts in male embryos, is effective as a single agent in vitro and in vivo against human and mouse ovarian cancer cell lines expressing MIS type II receptor; however, little is known about how recombinant human MIS (rhMIS), now being scaled for preclinical trials, could be used in combination with cytotoxic or targeted chemotherapeutic agents. Mouse serous and endometrioid ovarian carcinoma cell lines were tested in vitro against rhMIS alone and with <b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>paclitaxel</i></b>, or cisplatin as agents in clinical use. Because MIS releases FK506 binding protein (FKBP12), which activates the mammalian target of <b style='color:Tomato;'><i>rapamycin</i></b> (mTOR) downstream of Akt, rhMIS and <b style='color:Tomato;'><i>rapamycin</i></b> combinations were tested. MIS increases p16 protein levels, and 5'-Aza-2'-deoxycytidine (AzadC) induces p16 mRNA; therefore, they were used in combination in vitro and in vivo with a human ovarian cancer cell line. A <b style='color:Tomato;'><i>paclitaxel</i></b>-resistant human ovarian cancer cell line and its parental line both respond to rhMIS in vitro. <b style='color:DodgerBlue;'><i>Additivity</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>synergy</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>competition</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>observed</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>MIS</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rapamycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>AzadC</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>suggesting</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>MIS</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>selective</i></b> <b style='color:DodgerBlue;'><i>targeted</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>might</i></b> <b style='color:DodgerBlue;'><i>achieve</i></b> <b style='color:DodgerBlue;'><i>greater</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>ovarian</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>each</i></b> <b style='color:DodgerBlue;'><i>individual</i></b> <b style='color:DodgerBlue;'><i>agent</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> These assays and statistical analyses could be useful in selecting rhMIS and chemotherapeutic agent combinations that enhance clinical efficacy and reduce toxicity.","tokens":[{"text":"Additivity","start":0,"end":10,"id":0,"ws":true},{"text":",","start":11,"end":12,"id":1,"ws":true},{"text":"synergy","start":13,"end":20,"id":2,"ws":true},{"text":",","start":21,"end":22,"id":3,"ws":true},{"text":"or","start":23,"end":25,"id":4,"ws":true},{"text":"competition","start":26,"end":37,"id":5,"ws":true},{"text":"was","start":38,"end":41,"id":6,"ws":true},{"text":"observed","start":42,"end":50,"id":7,"ws":true},{"text":"with","start":51,"end":55,"id":8,"ws":true},{"text":"MIS","start":56,"end":59,"id":9,"ws":true},{"text":"and","start":60,"end":63,"id":10,"ws":true},{"text":"rapamycin","start":64,"end":73,"id":11,"ws":true},{"text":",","start":74,"end":75,"id":12,"ws":true},{"text":"AzadC","start":76,"end":81,"id":13,"ws":true},{"text":",","start":82,"end":83,"id":14,"ws":true},{"text":"doxorubicin","start":84,"end":95,"id":15,"ws":true},{"text":",","start":96,"end":97,"id":16,"ws":true},{"text":"cisplatin","start":98,"end":107,"id":17,"ws":true},{"text":",","start":108,"end":109,"id":18,"ws":true},{"text":"and","start":110,"end":113,"id":19,"ws":true},{"text":"paclitaxel","start":114,"end":124,"id":20,"ws":true},{"text":",","start":125,"end":126,"id":21,"ws":true},{"text":"suggesting","start":127,"end":137,"id":22,"ws":true},{"text":"that","start":138,"end":142,"id":23,"ws":true},{"text":"MIS","start":143,"end":146,"id":24,"ws":true},{"text":"in","start":147,"end":149,"id":25,"ws":true},{"text":"combination","start":150,"end":161,"id":26,"ws":true},{"text":"with","start":162,"end":166,"id":27,"ws":true},{"text":"selective","start":167,"end":176,"id":28,"ws":true},{"text":"targeted","start":177,"end":185,"id":29,"ws":true},{"text":"therapies","start":186,"end":195,"id":30,"ws":true},{"text":"might","start":196,"end":201,"id":31,"ws":true},{"text":"achieve","start":202,"end":209,"id":32,"ws":true},{"text":"greater","start":210,"end":217,"id":33,"ws":true},{"text":"activity","start":218,"end":226,"id":34,"ws":true},{"text":"against","start":227,"end":234,"id":35,"ws":true},{"text":"ovarian","start":235,"end":242,"id":36,"ws":true},{"text":"cancer","start":243,"end":249,"id":37,"ws":true},{"text":"than","start":250,"end":254,"id":38,"ws":true},{"text":"the","start":255,"end":258,"id":39,"ws":true},{"text":"use","start":259,"end":262,"id":40,"ws":true},{"text":"of","start":263,"end":265,"id":41,"ws":true},{"text":"each","start":266,"end":270,"id":42,"ws":true},{"text":"individual","start":271,"end":281,"id":43,"ws":true},{"text":"agent","start":282,"end":287,"id":44,"ws":true},{"text":"alone","start":288,"end":293,"id":45,"ws":true},{"text":".","start":294,"end":295,"id":46,"ws":false}],"spans":[{"start":64,"end":73,"token_start":11,"token_end":11,"label":"DRUG"},{"start":84,"end":95,"token_start":15,"token_end":15,"label":"DRUG"},{"start":114,"end":124,"token_start":20,"token_end":20,"label":"DRUG"}],"_input_hash":1387497584,"_task_hash":991977050,"_session_id":"drug_drug_pilot_shared-maytal","_view_id":"blocks","relations":[{"head":9,"child":11,"head_span":{"start":56,"end":59,"token_start":9,"token_end":9,"label":null},"child_span":{"start":64,"end":73,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":9,"child":13,"head_span":{"start":56,"end":59,"token_start":9,"token_end":9,"label":null},"child_span":{"start":76,"end":81,"token_start":13,"token_end":13,"label":null},"color":"#ffd882","label":"POS2"},{"head":9,"child":15,"head_span":{"start":56,"end":59,"token_start":9,"token_end":9,"label":null},"child_span":{"start":84,"end":95,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#d9fbad","label":"POS3"}],"radio":["POS10","POS1T0","POS20","POS2T0","POS30","POS3T0"],"answer":"accept"}
{"text":"There was no cytotoxic effect of cisplatin , ifosfamide , and etoposide .","paragraph":"<h3><u>Overcoming Chemoresistance of Pediatric Ependymoma by Inhibition of STAT3 Signaling.</u></h3>The long-term clinical outcome of pediatric intracranial epepdymoma is poor with a high rate of recurrence. One of the main reasons for this poor outcome is the tumor's inherent resistance to chemotherapy. Signal transducer and activator of transcription 3 (STAT3) is overactive in many human cancers, and inhibition of STAT3 signaling is an emerging area of interest in oncology. In this study, the possibility of STAT3 inhibition as a treatment was investigated in pediatric intracranial ependymoma tissues and cell lines. STAT3 activation status was checked in ependymoma tissues. The responses to conventional chemotherapeutic agents and a STAT3 inhibitor WP1066 in primarily cultured ependymoma cells were measured by cell viability assay. Apoptosis assays were conducted to reveal the cytotoxic mechanism of applied agents. Knockdown of STAT3 was tried to confirm the effects of STAT3 inhibition in ependymoma cells. High levels of phospho-STAT3 (p-STAT3) expression were observed in ependymoma tissue, especially in the anaplastic histology group. <b style='color:DodgerBlue;'><i>There</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>cytotoxic</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Both brain tumor-initiating cells (BTICs) and bulk tumor cells (BCs) showed considerably decreased viability after WP1066 treatment. However, BTICs had fewer responses than BCs. No additive or synergistic effect was observed for combination therapy of WP1066 and cisplatin. WP1066 effectively abrogated p-STAT3 expression. An increased apoptosis and decreased Survivin expression were observed after WP1066 treatment. Knockdown of STAT3 also decreased cell survival, supporting the critical role of STAT3 in sustaining ependymoma cells. In this study, we observed a cytotoxic effect of STAT3 inhibitor on ependymoma BTICs and BCs. There is urgent need to develop new therapeutic agents for pediatric ependymoma. STAT3 inhibitors may be a new group of drugs for clinical application. ","tokens":[{"text":"There","start":0,"end":5,"id":0,"ws":true},{"text":"was","start":6,"end":9,"id":1,"ws":true},{"text":"no","start":10,"end":12,"id":2,"ws":true},{"text":"cytotoxic","start":13,"end":22,"id":3,"ws":true},{"text":"effect","start":23,"end":29,"id":4,"ws":true},{"text":"of","start":30,"end":32,"id":5,"ws":true},{"text":"cisplatin","start":33,"end":42,"id":6,"ws":true},{"text":",","start":43,"end":44,"id":7,"ws":true},{"text":"ifosfamide","start":45,"end":55,"id":8,"ws":true},{"text":",","start":56,"end":57,"id":9,"ws":true},{"text":"and","start":58,"end":61,"id":10,"ws":true},{"text":"etoposide","start":62,"end":71,"id":11,"ws":true},{"text":".","start":72,"end":73,"id":12,"ws":false}],"spans":[{"start":45,"end":55,"token_start":8,"token_end":8,"label":"DRUG"},{"start":62,"end":71,"token_start":11,"token_end":11,"label":"DRUG"}],"_input_hash":-1352726798,"_task_hash":-274527523,"_session_id":"drug_drug_pilot_shared-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Several first-line phase III trials , as well as ongoing trials for which only preliminary results have been published , have fueled debates on the optimal dose and schedule ; these have focused not only on weekly vs q3-weeks paclitaxel , but also on other modifications and the advisability of adding bevacizumab .","paragraph":"<h3><u>Carboplatin/Paclitaxel Induction in Ovarian Cancer: The Finer Points.</u></h3>The <b style='color:Tomato;'><i>carboplatin</i></b>/<b style='color:Tomato;'><i>paclitaxel</i></b> doublet remains the chemotherapy backbone for the initial treatment of ovarian cancer. This two-drug regimen, with <b style='color:Tomato;'><i>carboplatin</i></b> dosed using the Calvert formula, yielded convincing noninferior outcomes when compared with the prior, more toxic, regimen of cisplatin/<b style='color:Tomato;'><i>paclitaxel</i></b>. <b style='color:Tomato;'><i>carboplatin</i></b>'s dose-limiting toxicity is thrombocytopenia; however, when this drug is properly dosed and combined with <b style='color:Tomato;'><i>paclitaxel</i></b>, the doublet's cycle 1 dose in chemotherapy-naive women is generally safe. <b style='color:Tomato;'><i>carboplatin</i></b> (unlike cisplatin) contributes minimally to the cumulative sensory neuropathy of <b style='color:Tomato;'><i>paclitaxel</i></b>, thus ensuring noticeable reversibility of neuropathy symptoms following completion of 6 cycles and only occasionally requiring cessation or substitution of the taxane. <b style='color:Tomato;'><i>paclitaxel</i></b> is responsible for the hair loss associated with the <b style='color:Tomato;'><i>carboplatin</i></b>/<b style='color:Tomato;'><i>paclitaxel</i></b> doublet; preventive measures must be considered for patients who would otherwise refuse treatment. <b style='color:DodgerBlue;'><i>Several</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>III</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>ongoing</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>which</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>preliminary</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>published</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>fueled</i></b> <b style='color:DodgerBlue;'><i>debates</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>optimal</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>schedule</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>focused</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>weekly</i></b> <b style='color:DodgerBlue;'><i>vs</i></b> <b style='color:DodgerBlue;'><i>q3-weeks</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>also</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>modifications</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>advisability</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>adding</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Our view is that results of this doublet in the first-line treatment of ovarian cancer are driven primarily by <b style='color:Tomato;'><i>carboplatin</i></b>, given that ovarian cancer is a platinum-sensitive disease. Consequently, the roles of the accompanying <b style='color:Tomato;'><i>paclitaxel</i></b> dose and schedule and the addition of <b style='color:Tomato;'><i>bevacizumab</i></b> are currently unsettled, and questions regarding these issues should be decided based on patient tolerance and comorbidities until additional data are available.","tokens":[{"text":"Several","start":0,"end":7,"id":0,"ws":true},{"text":"first-line","start":8,"end":18,"id":1,"ws":true},{"text":"phase","start":19,"end":24,"id":2,"ws":true},{"text":"III","start":25,"end":28,"id":3,"ws":true},{"text":"trials","start":29,"end":35,"id":4,"ws":true},{"text":",","start":36,"end":37,"id":5,"ws":true},{"text":"as","start":38,"end":40,"id":6,"ws":true},{"text":"well","start":41,"end":45,"id":7,"ws":true},{"text":"as","start":46,"end":48,"id":8,"ws":true},{"text":"ongoing","start":49,"end":56,"id":9,"ws":true},{"text":"trials","start":57,"end":63,"id":10,"ws":true},{"text":"for","start":64,"end":67,"id":11,"ws":true},{"text":"which","start":68,"end":73,"id":12,"ws":true},{"text":"only","start":74,"end":78,"id":13,"ws":true},{"text":"preliminary","start":79,"end":90,"id":14,"ws":true},{"text":"results","start":91,"end":98,"id":15,"ws":true},{"text":"have","start":99,"end":103,"id":16,"ws":true},{"text":"been","start":104,"end":108,"id":17,"ws":true},{"text":"published","start":109,"end":118,"id":18,"ws":true},{"text":",","start":119,"end":120,"id":19,"ws":true},{"text":"have","start":121,"end":125,"id":20,"ws":true},{"text":"fueled","start":126,"end":132,"id":21,"ws":true},{"text":"debates","start":133,"end":140,"id":22,"ws":true},{"text":"on","start":141,"end":143,"id":23,"ws":true},{"text":"the","start":144,"end":147,"id":24,"ws":true},{"text":"optimal","start":148,"end":155,"id":25,"ws":true},{"text":"dose","start":156,"end":160,"id":26,"ws":true},{"text":"and","start":161,"end":164,"id":27,"ws":true},{"text":"schedule","start":165,"end":173,"id":28,"ws":true},{"text":";","start":174,"end":175,"id":29,"ws":true},{"text":"these","start":176,"end":181,"id":30,"ws":true},{"text":"have","start":182,"end":186,"id":31,"ws":true},{"text":"focused","start":187,"end":194,"id":32,"ws":true},{"text":"not","start":195,"end":198,"id":33,"ws":true},{"text":"only","start":199,"end":203,"id":34,"ws":true},{"text":"on","start":204,"end":206,"id":35,"ws":true},{"text":"weekly","start":207,"end":213,"id":36,"ws":true},{"text":"vs","start":214,"end":216,"id":37,"ws":true},{"text":"q3-weeks","start":217,"end":225,"id":38,"ws":true},{"text":"paclitaxel","start":226,"end":236,"id":39,"ws":true},{"text":",","start":237,"end":238,"id":40,"ws":true},{"text":"but","start":239,"end":242,"id":41,"ws":true},{"text":"also","start":243,"end":247,"id":42,"ws":true},{"text":"on","start":248,"end":250,"id":43,"ws":true},{"text":"other","start":251,"end":256,"id":44,"ws":true},{"text":"modifications","start":257,"end":270,"id":45,"ws":true},{"text":"and","start":271,"end":274,"id":46,"ws":true},{"text":"the","start":275,"end":278,"id":47,"ws":true},{"text":"advisability","start":279,"end":291,"id":48,"ws":true},{"text":"of","start":292,"end":294,"id":49,"ws":true},{"text":"adding","start":295,"end":301,"id":50,"ws":true},{"text":"bevacizumab","start":302,"end":313,"id":51,"ws":true},{"text":".","start":314,"end":315,"id":52,"ws":false}],"spans":[{"start":226,"end":236,"token_start":39,"token_end":39,"label":"DRUG"},{"start":302,"end":313,"token_start":51,"token_end":51,"label":"DRUG"}],"_input_hash":1252988243,"_task_hash":322511723,"_session_id":"drug_drug_pilot_shared-maytal","_view_id":"blocks","relations":[{"head":39,"child":51,"head_span":{"start":226,"end":236,"token_start":39,"token_end":39,"label":"DRUG"},"child_span":{"start":302,"end":313,"token_start":51,"token_end":51,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T1"],"answer":"accept"}
{"text":"The primary goal was achieve the correct estimation of the target plasma area against the topotecan concentration-time curve ( AUC ) in a 5 day course of cladribine followed by monitored topotecan in pediatric patients with recurrent/refractory AML .","paragraph":"<h3><u>Topotecan exposure estimation in pediatric acute myeloid leukemia supported by LC-MS-based drug monitoring and pharmacokinetic analysis.</u></h3>Individualization of the <b style='color:Tomato;'><i>topotecan</i></b> dosing can reduce inter-patient variability, toxicity, and at the same time increases chemotherapy efficacy. <b style='color:Tomato;'><i>topotecan</i></b> dosing based on simultaneous drug monitoring and pharmacokinetic analysis can yield more accurate and precise estimation of the <b style='color:Tomato;'><i>topotecan</i></b> systemic exposure than that attainable with the fixed dosing approach. Therefore, a combined approach could provide a tool assisting the clinicians in individualization of the <b style='color:Tomato;'><i>topotecan</i></b> dosing. The aim of the study was to estimate the <b style='color:Tomato;'><i>topotecan</i></b> exposure in pediatric patients with acute myeloid leukemia (AML) based on the plasma concentration-time data and using the pharmacokinetic analysis. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>primary</i></b> <b style='color:DodgerBlue;'><i>goal</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>achieve</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>correct</i></b> <b style='color:DodgerBlue;'><i>estimation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>target</i></b> <b style='color:DodgerBlue;'><i>plasma</i></b> <b style='color:DodgerBlue;'><i>area</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:MediumOrchid;'><i>topotecan</i></b> <b style='color:DodgerBlue;'><i>concentration-time</i></b> <b style='color:DodgerBlue;'><i>curve</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AUC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>course</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cladribine</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>monitored</i></b> <b style='color:MediumOrchid;'><i>topotecan</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>pediatric</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>recurrent/refractory</i></b> <b style='color:DodgerBlue;'><i>AML</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A sensitive and selective reversed-phase liquid chromatographic-mass spectrometry (LC-MS) assay was developed to quantify total <b style='color:Tomato;'><i>topotecan</i></b> in the human plasma samples. This method, with its lower quantification limit of 1 ng/ml, was validated over a linear range of 1-150 ng/ml. Under the proposed approach, the <b style='color:Tomato;'><i>topotecan</i></b> dosing was selected so as to achieve the final AUC value of 140\u00b120 ng/ml h. The presented analytical and pharmacokinetic data demonstrate that the proposed approach can be a practical, useful, efficient, and accurate tool for individualizing the <b style='color:Tomato;'><i>topotecan</i></b> dosing in children with AML.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"primary","start":4,"end":11,"id":1,"ws":true},{"text":"goal","start":12,"end":16,"id":2,"ws":true},{"text":"was","start":17,"end":20,"id":3,"ws":true},{"text":"achieve","start":21,"end":28,"id":4,"ws":true},{"text":"the","start":29,"end":32,"id":5,"ws":true},{"text":"correct","start":33,"end":40,"id":6,"ws":true},{"text":"estimation","start":41,"end":51,"id":7,"ws":true},{"text":"of","start":52,"end":54,"id":8,"ws":true},{"text":"the","start":55,"end":58,"id":9,"ws":true},{"text":"target","start":59,"end":65,"id":10,"ws":true},{"text":"plasma","start":66,"end":72,"id":11,"ws":true},{"text":"area","start":73,"end":77,"id":12,"ws":true},{"text":"against","start":78,"end":85,"id":13,"ws":true},{"text":"the","start":86,"end":89,"id":14,"ws":true},{"text":"topotecan","start":90,"end":99,"id":15,"ws":true},{"text":"concentration-time","start":100,"end":118,"id":16,"ws":true},{"text":"curve","start":119,"end":124,"id":17,"ws":true},{"text":"(","start":125,"end":126,"id":18,"ws":true},{"text":"AUC","start":127,"end":130,"id":19,"ws":true},{"text":")","start":131,"end":132,"id":20,"ws":true},{"text":"in","start":133,"end":135,"id":21,"ws":true},{"text":"a","start":136,"end":137,"id":22,"ws":true},{"text":"5","start":138,"end":139,"id":23,"ws":true},{"text":"day","start":140,"end":143,"id":24,"ws":true},{"text":"course","start":144,"end":150,"id":25,"ws":true},{"text":"of","start":151,"end":153,"id":26,"ws":true},{"text":"cladribine","start":154,"end":164,"id":27,"ws":true},{"text":"followed","start":165,"end":173,"id":28,"ws":true},{"text":"by","start":174,"end":176,"id":29,"ws":true},{"text":"monitored","start":177,"end":186,"id":30,"ws":true},{"text":"topotecan","start":187,"end":196,"id":31,"ws":true},{"text":"in","start":197,"end":199,"id":32,"ws":true},{"text":"pediatric","start":200,"end":209,"id":33,"ws":true},{"text":"patients","start":210,"end":218,"id":34,"ws":true},{"text":"with","start":219,"end":223,"id":35,"ws":true},{"text":"recurrent/refractory","start":224,"end":244,"id":36,"ws":true},{"text":"AML","start":245,"end":248,"id":37,"ws":true},{"text":".","start":249,"end":250,"id":38,"ws":false}],"spans":[{"start":90,"end":99,"token_start":15,"token_end":15,"label":"DRUG"},{"start":154,"end":164,"token_start":27,"token_end":27,"label":"DRUG"},{"start":187,"end":196,"token_start":31,"token_end":31,"label":"DRUG"}],"_input_hash":796298966,"_task_hash":-199747777,"_session_id":"drug_drug_pilot_shared-maytal","_view_id":"blocks","relations":[{"head":27,"child":31,"head_span":{"start":154,"end":164,"token_start":27,"token_end":27,"label":"DRUG"},"child_span":{"start":187,"end":196,"token_start":31,"token_end":31,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T1"],"answer":"accept"}
{"text":"The management of EP is challenging : no standardized guidelines exist with literature suggesting cyclosporine or infliximab as first-line therapy .","paragraph":"<h3><u>Erythrodermic psoriasis successfully and rapidly treated with brodalumab: Report of two cases.</u></h3>Erythrodermic psoriasis (EP) is a rare form of the disease clinically characterized by a generalized erythema covering \u226590% of the body surface area (BSA). <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>management</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>EP</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>challenging</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>standardized</i></b> <b style='color:DodgerBlue;'><i>guidelines</i></b> <b style='color:DodgerBlue;'><i>exist</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>literature</i></b> <b style='color:DodgerBlue;'><i>suggesting</i></b> <b style='color:MediumOrchid;'><i>cyclosporine</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>infliximab</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, a recent systematic review showed a positive response in EP patients treated with biologic agents. The most common biologic used for EP up until now has been <b style='color:Tomato;'><i>ustekinumab</i></b>, whereas <b style='color:Tomato;'><i>infliximab</i></b> might represent a first-line option in case of complicated EP (acute, severe, or unstable). Up until now, no case of <b style='color:Tomato;'><i>brodalumab</i></b> (a monoclonal antibody blocking IL-17 receptor) treatment for EP in real-life has ever been described. Here, we report the first two cases of efficacy and safety of <b style='color:Tomato;'><i>brodalumab</i></b> in real-life cases of EP.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"management","start":4,"end":14,"id":1,"ws":true},{"text":"of","start":15,"end":17,"id":2,"ws":true},{"text":"EP","start":18,"end":20,"id":3,"ws":true},{"text":"is","start":21,"end":23,"id":4,"ws":true},{"text":"challenging","start":24,"end":35,"id":5,"ws":true},{"text":":","start":36,"end":37,"id":6,"ws":true},{"text":"no","start":38,"end":40,"id":7,"ws":true},{"text":"standardized","start":41,"end":53,"id":8,"ws":true},{"text":"guidelines","start":54,"end":64,"id":9,"ws":true},{"text":"exist","start":65,"end":70,"id":10,"ws":true},{"text":"with","start":71,"end":75,"id":11,"ws":true},{"text":"literature","start":76,"end":86,"id":12,"ws":true},{"text":"suggesting","start":87,"end":97,"id":13,"ws":true},{"text":"cyclosporine","start":98,"end":110,"id":14,"ws":true},{"text":"or","start":111,"end":113,"id":15,"ws":true},{"text":"infliximab","start":114,"end":124,"id":16,"ws":true},{"text":"as","start":125,"end":127,"id":17,"ws":true},{"text":"first-line","start":128,"end":138,"id":18,"ws":true},{"text":"therapy","start":139,"end":146,"id":19,"ws":true},{"text":".","start":147,"end":148,"id":20,"ws":false}],"spans":[{"start":98,"end":110,"token_start":14,"token_end":14,"label":"DRUG"},{"start":114,"end":124,"token_start":16,"token_end":16,"label":"DRUG"}],"_input_hash":-575753313,"_task_hash":-166345926,"_session_id":"drug_drug_pilot_shared-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"As single agents , curcumin and metformin are reported to exhibit chemopreventive properties , in vitro as well as in patients with oral cancer .","paragraph":"<h3><u>Curcumin and metformin-mediated chemoprevention of oral cancer is associated with inhibition of cancer stem cells.</u></h3>Effective chemoprevention is critical for improving outcomes of oral cancer. <b style='color:DodgerBlue;'><i>As</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>curcumin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>metformin</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>reported</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>exhibit</i></b> <b style='color:DodgerBlue;'><i>chemopreventive</i></b> <b style='color:DodgerBlue;'><i>properties</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In this study, the chemopreventive efficacy of this drug combination was tested in a 4-nitro quinoline-1-oxide (4NQO) induced mice oral carcinogenesis model. Molecular analysis revealed a cancer stem cell (CSC)-driven oral carcinogenic progression in this model, wherein a progressive increase in the expression of CSC-specific markers (CD44 and CD133) was observed from 8th to 25th week, at transcript (40-100-fold) and protein levels (P\u2009\u2264\u20090.0001). Chemopreventive treatment of the animals at 17th week with <b style='color:Tomato;'><i>curcumin</i></b> and <b style='color:Tomato;'><i>metformin</i></b> indicated that the combination regimen decreased tumor volume when compared to the control arm (0.69+0.03 vs 6.66+2.4\u2009mm","tokens":[{"text":"As","start":0,"end":2,"id":0,"ws":true},{"text":"single","start":3,"end":9,"id":1,"ws":true},{"text":"agents","start":10,"end":16,"id":2,"ws":true},{"text":",","start":17,"end":18,"id":3,"ws":true},{"text":"curcumin","start":19,"end":27,"id":4,"ws":true},{"text":"and","start":28,"end":31,"id":5,"ws":true},{"text":"metformin","start":32,"end":41,"id":6,"ws":true},{"text":"are","start":42,"end":45,"id":7,"ws":true},{"text":"reported","start":46,"end":54,"id":8,"ws":true},{"text":"to","start":55,"end":57,"id":9,"ws":true},{"text":"exhibit","start":58,"end":65,"id":10,"ws":true},{"text":"chemopreventive","start":66,"end":81,"id":11,"ws":true},{"text":"properties","start":82,"end":92,"id":12,"ws":true},{"text":",","start":93,"end":94,"id":13,"ws":true},{"text":"in","start":95,"end":97,"id":14,"ws":true},{"text":"vitro","start":98,"end":103,"id":15,"ws":true},{"text":"as","start":104,"end":106,"id":16,"ws":true},{"text":"well","start":107,"end":111,"id":17,"ws":true},{"text":"as","start":112,"end":114,"id":18,"ws":true},{"text":"in","start":115,"end":117,"id":19,"ws":true},{"text":"patients","start":118,"end":126,"id":20,"ws":true},{"text":"with","start":127,"end":131,"id":21,"ws":true},{"text":"oral","start":132,"end":136,"id":22,"ws":true},{"text":"cancer","start":137,"end":143,"id":23,"ws":true},{"text":".","start":144,"end":145,"id":24,"ws":false}],"spans":[{"start":19,"end":27,"token_start":4,"token_end":4,"label":"DRUG"},{"start":32,"end":41,"token_start":6,"token_end":6,"label":"DRUG"}],"_input_hash":-1095827099,"_task_hash":-240223432,"_session_id":"drug_drug_pilot_shared-maytal","_view_id":"blocks","relations":[{"head":4,"child":6,"head_span":{"start":19,"end":27,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":32,"end":41,"token_start":6,"token_end":6,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T1"],"answer":"accept"}
{"text":"Withdrawal rates were comparable to drug survival rates of other biological therapies and rates of adverse events were similar between brodalumab and ustekinumab .","paragraph":"<h3><u>Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.</u></h3>As part of the National Institute for Health and Care Excellence single technology appraisal process, <b style='color:Tomato;'><i>brodalumab</i></b> was assessed to determine the clinical and cost effectiveness of its use in the treatment of moderate-to-severe plaque psoriasis. The Centre for Reviews and Dissemination and the Centre for Health Economics Technology Assessment Group at the University of York were commissioned to act as the independent Evidence Review Group. This article provides a summary of the Evidence Review Group's review of the company's submission, the Evidence Review Group report and the National Institute for Health and Care Excellence Appraisal Committee's subsequent guidance issued in March 2018. The main clinical effectiveness data were derived from three well-conducted, multicentre, double-blind randomised controlled trials. The trials demonstrated that <b style='color:Tomato;'><i>brodalumab</i></b> statistically significantly reduced the severity of psoriasis and its impact on health-related quality of life, compared with placebo, at 12\u00a0weeks. In comparison with <b style='color:Tomato;'><i>ustekinumab</i></b>, statistically significantly more patients taking <b style='color:Tomato;'><i>brodalumab</i></b> had reduced psoriasis severity at 12\u00a0weeks. Psoriasis severity and quality of life also appeared improved at 52\u00a0weeks, although statistical significance was not assessed. <b style='color:DodgerBlue;'><i>Withdrawal</i></b> <b style='color:DodgerBlue;'><i>rates</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>comparable</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>rates</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>biological</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>rates</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>adverse</i></b> <b style='color:DodgerBlue;'><i>events</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>similar</i></b> <b style='color:DodgerBlue;'><i>between</i></b> <b style='color:MediumOrchid;'><i>brodalumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ustekinumab</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A network meta-analysis was presented, comparing <b style='color:Tomato;'><i>brodalumab</i></b> with other therapies available at the same point in the treatment pathway (i.e. in patients for whom standard systemic therapy or phototherapy is inadequately effective, not tolerated or contraindicated). The network meta-analysis ranked treatments in order of effectiveness, in terms of achieving different levels of Psoriasis Area and Severity Index response. The results indicated that <b style='color:Tomato;'><i>brodalumab</i></b> had a similar probability of response to <b style='color:Tomato;'><i>ixekizumab</i></b>, <b style='color:Tomato;'><i>secukinumab</i></b> and <b style='color:Tomato;'><i>infliximab</i></b> and a higher probability of response than <b style='color:Tomato;'><i>ustekinumab</i></b>, <b style='color:Tomato;'><i>adalimumab</i></b>, <b style='color:Tomato;'><i>etanercept</i></b>, <b style='color:Tomato;'><i>apremilast</i></b>, <b style='color:Tomato;'><i>dimethyl fumarate</i></b> and placebo. The company's economic model compared nine treatment sequences that included three lines of active therapy, consisting of <b style='color:Tomato;'><i>brodalumab</i></b> and other comparators recommended by the National Institute for Health and Care Excellence, followed by best supportive care. The sequence with <b style='color:Tomato;'><i>brodalumab</i></b> in the first-line position dominated sequences that started with <b style='color:Tomato;'><i>adalimumab</i></b>, <b style='color:Tomato;'><i>infliximab</i></b>, <b style='color:Tomato;'><i>secukinumab</i></b> and <b style='color:Tomato;'><i>ustekinumab</i></b>. The incremental cost-effectiveness ratio of the <b style='color:Tomato;'><i>brodalumab</i></b> sequence compared to less effective and non-dominated sequences ranged from \u00a37145 (vs. the <b style='color:Tomato;'><i>etanercept</i></b> sequence) to \u00a313,353 (vs. the <b style='color:Tomato;'><i>dimethyl fumarate</i></b> sequence) per quality-adjusted life-year gained. The incremental cost-effectiveness ratio for the more costly and effective <b style='color:Tomato;'><i>ixekizumab</i></b> sequence was \u00a3894,010 per quality-adjusted life-year gained compared to the <b style='color:Tomato;'><i>brodalumab</i></b> sequence. At a threshold of \u00a320,000 per quality-adjusted life-year gained, the <b style='color:Tomato;'><i>brodalumab</i></b> sequence had the highest probability of being cost effective (96%). The main limitation of the company's economic model was the restrictive nature of the sequences compared. Twelve separate scenarios based on key uncertainties were explored by the Evidence Review Group. The only scenarios where <b style='color:Tomato;'><i>brodalumab</i></b> was ranked lower than first were not considered to be more appropriate or plausible than the assumptions or scenarios included in the company's base case. The treatment rankings identified in the Evidence Review Group's alternative base case were identical to those derived from the company's base case model. At the first National Institute for Health and Care Excellence Appraisal Committee meeting, the Committee concluded that <b style='color:Tomato;'><i>brodalumab</i></b> appears to be as effective as other anti-interleukin-17 agents and is cost effective, based on the discount agreed in the patient access scheme. <b style='color:Tomato;'><i>brodalumab</i></b> is recommended as an option for treating adults with severe plaque psoriasis (defined by a total Psoriasis Area and Severity Index score of 10 or more and a Dermatology Life Quality Index score of more than 10) who have not responded to other systemic non-biological therapies. <b style='color:Tomato;'><i>brodalumab</i></b> should be stopped at 12\u00a0weeks if the psoriasis has not responded adequately.","tokens":[{"text":"Withdrawal","start":0,"end":10,"id":0,"ws":true},{"text":"rates","start":11,"end":16,"id":1,"ws":true},{"text":"were","start":17,"end":21,"id":2,"ws":true},{"text":"comparable","start":22,"end":32,"id":3,"ws":true},{"text":"to","start":33,"end":35,"id":4,"ws":true},{"text":"drug","start":36,"end":40,"id":5,"ws":true},{"text":"survival","start":41,"end":49,"id":6,"ws":true},{"text":"rates","start":50,"end":55,"id":7,"ws":true},{"text":"of","start":56,"end":58,"id":8,"ws":true},{"text":"other","start":59,"end":64,"id":9,"ws":true},{"text":"biological","start":65,"end":75,"id":10,"ws":true},{"text":"therapies","start":76,"end":85,"id":11,"ws":true},{"text":"and","start":86,"end":89,"id":12,"ws":true},{"text":"rates","start":90,"end":95,"id":13,"ws":true},{"text":"of","start":96,"end":98,"id":14,"ws":true},{"text":"adverse","start":99,"end":106,"id":15,"ws":true},{"text":"events","start":107,"end":113,"id":16,"ws":true},{"text":"were","start":114,"end":118,"id":17,"ws":true},{"text":"similar","start":119,"end":126,"id":18,"ws":true},{"text":"between","start":127,"end":134,"id":19,"ws":true},{"text":"brodalumab","start":135,"end":145,"id":20,"ws":true},{"text":"and","start":146,"end":149,"id":21,"ws":true},{"text":"ustekinumab","start":150,"end":161,"id":22,"ws":true},{"text":".","start":162,"end":163,"id":23,"ws":false}],"spans":[{"start":135,"end":145,"token_start":20,"token_end":20,"label":"DRUG"},{"start":150,"end":161,"token_start":22,"token_end":22,"label":"DRUG"}],"_input_hash":-2044054306,"_task_hash":40529012,"_session_id":"drug_drug_pilot_shared-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"In patients with NPSLE , the use of high-dose corticosteroids is recommended in combination with immunosuppressants , such as mycophenolate mofetil and intravenous cyclophosphamide pulse therapy .","paragraph":"<h3><u>[Neuropsychiatric Systemic Lupus Erythematosus].</u></h3>Central nervous system damage, a major organ manifestation of systemic lupus erythematosus (SLE), causes significant morbidity and mortality. Designating this condition as neuropsychiatric SLE (NPSLE), the American College of Rheumatology defines it as involving the central and peripheral nervous systems and being characterized by various manifestations including stroke, seizures, and psychosis. NPSLE treatment mainly seeks to reduce damage accrual. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>NPSLE</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:DodgerBlue;'><i>corticosteroids</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>recommended</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>immunosuppressants</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>mycophenolate</i></b> <b style='color:DodgerBlue;'><i>mofetil</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>pulse</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> This can be accomplished by controlling the activity of the disease, minimizing the use of corticosteroids, and optimizing the management of comorbidities, including cardiovascular risk factors. An international task force analysis of a treat-to-target strategy for SLE (T2T/SLE) recommended targeting remission, preventing damage, and improving quality of life. Thus, more effective and less toxic treatments, such as those using biologics or kinase inhibitors, are still being developed for the treatment of SLE/NPSLE.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"patients","start":3,"end":11,"id":1,"ws":true},{"text":"with","start":12,"end":16,"id":2,"ws":true},{"text":"NPSLE","start":17,"end":22,"id":3,"ws":true},{"text":",","start":23,"end":24,"id":4,"ws":true},{"text":"the","start":25,"end":28,"id":5,"ws":true},{"text":"use","start":29,"end":32,"id":6,"ws":true},{"text":"of","start":33,"end":35,"id":7,"ws":true},{"text":"high-dose","start":36,"end":45,"id":8,"ws":true},{"text":"corticosteroids","start":46,"end":61,"id":9,"ws":true},{"text":"is","start":62,"end":64,"id":10,"ws":true},{"text":"recommended","start":65,"end":76,"id":11,"ws":true},{"text":"in","start":77,"end":79,"id":12,"ws":true},{"text":"combination","start":80,"end":91,"id":13,"ws":true},{"text":"with","start":92,"end":96,"id":14,"ws":true},{"text":"immunosuppressants","start":97,"end":115,"id":15,"ws":true},{"text":",","start":116,"end":117,"id":16,"ws":true},{"text":"such","start":118,"end":122,"id":17,"ws":true},{"text":"as","start":123,"end":125,"id":18,"ws":true},{"text":"mycophenolate","start":126,"end":139,"id":19,"ws":true},{"text":"mofetil","start":140,"end":147,"id":20,"ws":true},{"text":"and","start":148,"end":151,"id":21,"ws":true},{"text":"intravenous","start":152,"end":163,"id":22,"ws":true},{"text":"cyclophosphamide","start":164,"end":180,"id":23,"ws":true},{"text":"pulse","start":181,"end":186,"id":24,"ws":true},{"text":"therapy","start":187,"end":194,"id":25,"ws":true},{"text":".","start":195,"end":196,"id":26,"ws":false}],"spans":[{"start":126,"end":139,"token_start":19,"token_end":19,"label":"DRUG"},{"start":164,"end":180,"token_start":23,"token_end":23,"label":"DRUG"}],"_input_hash":438186251,"_task_hash":1532533663,"_session_id":"drug_drug_pilot_shared-maytal","_view_id":"blocks","relations":[{"head":19,"child":23,"head_span":{"start":126,"end":139,"token_start":19,"token_end":19,"label":"DRUG"},"child_span":{"start":164,"end":180,"token_start":23,"token_end":23,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T0","NEG30"],"answer":"accept"}
{"text":"Thirty-three women diagnosed with metastatic breast cancer participated in a phase 1 clinical trial of a new combination of cyclophosphamide ( CTX ) and mitoxantrone ( MXT ) , with dose escalation of paclitaxel .","paragraph":"<h3><u>Longitudinal effects of high-dose chemotherapy and autologous stem cell transplantation on quality of life in the treatment of metastatic breast cancer.</u></h3>This study determined the effects of high-dose chemotherapy (HDCT) with autologous blood stem cell transplantation (ASCT) on quality of life (QL) in women with metastatic breast cancer prior to, and during treatment, and up to 1-year post-ASCT. <b style='color:DodgerBlue;'><i>Thirty-three</i></b> <b style='color:DodgerBlue;'><i>women</i></b> <b style='color:DodgerBlue;'><i>diagnosed</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>participated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>new</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CTX</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>mitoxantrone</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>MXT</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>escalation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Longitudinal QL data were collected using the functional living index-cancer (FLIC) and symptom scales at seven time periods: pre-induction chemotherapy (CT), post-induction CT, post-high dose CT (HDCT), and at 3, 6, 9 and 12 months post-ASCT. FLIC scores indicated that the worst problems for patients were feelings of hardship on themselves and their families, followed by psychological functioning and physical functioning problems. The time around diagnosis of the metastatic disease and following HDCT were the worst times for all levels of quality of life, but anxiety and depression symptoms continued to increase in severity across the entire follow-up period. The symptoms that were most problematic were worry about the future, loss of sexual interest, anxiety about the treatment, general worrying, and joint pain. These data highlight the problems that women with metastatic breast cancer encounter at different stages of the disease and treatment process, and can be used to tailor psychosocial interventions appropriate for treating the relevant issues at different points in time.","tokens":[{"text":"Thirty-three","start":0,"end":12,"id":0,"ws":true},{"text":"women","start":13,"end":18,"id":1,"ws":true},{"text":"diagnosed","start":19,"end":28,"id":2,"ws":true},{"text":"with","start":29,"end":33,"id":3,"ws":true},{"text":"metastatic","start":34,"end":44,"id":4,"ws":true},{"text":"breast","start":45,"end":51,"id":5,"ws":true},{"text":"cancer","start":52,"end":58,"id":6,"ws":true},{"text":"participated","start":59,"end":71,"id":7,"ws":true},{"text":"in","start":72,"end":74,"id":8,"ws":true},{"text":"a","start":75,"end":76,"id":9,"ws":true},{"text":"phase","start":77,"end":82,"id":10,"ws":true},{"text":"1","start":83,"end":84,"id":11,"ws":true},{"text":"clinical","start":85,"end":93,"id":12,"ws":true},{"text":"trial","start":94,"end":99,"id":13,"ws":true},{"text":"of","start":100,"end":102,"id":14,"ws":true},{"text":"a","start":103,"end":104,"id":15,"ws":true},{"text":"new","start":105,"end":108,"id":16,"ws":true},{"text":"combination","start":109,"end":120,"id":17,"ws":true},{"text":"of","start":121,"end":123,"id":18,"ws":true},{"text":"cyclophosphamide","start":124,"end":140,"id":19,"ws":true},{"text":"(","start":141,"end":142,"id":20,"ws":true},{"text":"CTX","start":143,"end":146,"id":21,"ws":true},{"text":")","start":147,"end":148,"id":22,"ws":true},{"text":"and","start":149,"end":152,"id":23,"ws":true},{"text":"mitoxantrone","start":153,"end":165,"id":24,"ws":true},{"text":"(","start":166,"end":167,"id":25,"ws":true},{"text":"MXT","start":168,"end":171,"id":26,"ws":true},{"text":")","start":172,"end":173,"id":27,"ws":true},{"text":",","start":174,"end":175,"id":28,"ws":true},{"text":"with","start":176,"end":180,"id":29,"ws":true},{"text":"dose","start":181,"end":185,"id":30,"ws":true},{"text":"escalation","start":186,"end":196,"id":31,"ws":true},{"text":"of","start":197,"end":199,"id":32,"ws":true},{"text":"paclitaxel","start":200,"end":210,"id":33,"ws":true},{"text":".","start":211,"end":212,"id":34,"ws":false}],"spans":[{"start":124,"end":140,"token_start":19,"token_end":19,"label":"DRUG"},{"start":153,"end":165,"token_start":24,"token_end":24,"label":"DRUG"},{"start":200,"end":210,"token_start":33,"token_end":33,"label":"DRUG"}],"_input_hash":1782132717,"_task_hash":189034633,"_session_id":"drug_drug_pilot_shared-maytal","_view_id":"blocks","relations":[{"head":19,"child":24,"head_span":{"start":124,"end":140,"token_start":19,"token_end":19,"label":"DRUG"},"child_span":{"start":153,"end":165,"token_start":24,"token_end":24,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":33,"child":19,"head_span":{"start":200,"end":210,"token_start":33,"token_end":33,"label":"DRUG"},"child_span":{"start":124,"end":140,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"Among the anti-herpesvirus agents , aciclovir , valaciclovir , penciclovir , famciclovir , idoxuridine , trifluridine and brivudin are used in the treatment of herpes simplex virus and varicella-zoster virus infections , and ganciclovir , foscarnet , cidofovir , fomivirsen and maribavir ( the latter in the developmental stage ) are used in the treatment of cytomegalovirus infections .","paragraph":"<h3><u>Antiviral drugs: current state of the art.</u></h3>The chemotherapy of virus infections has definitely come of age. There are now 15 antiviral agents that have been formally licensed for the treatment of human immunodeficiency virus infections (<b style='color:Tomato;'><i>zidovudine</i></b>, <b style='color:Tomato;'><i>didanosine</i></b>, <b style='color:Tomato;'><i>zalcitabine</i></b>, <b style='color:Tomato;'><i>stavudine</i></b>, <b style='color:Tomato;'><i>lamivudine</i></b>, <b style='color:Tomato;'><i>abacavir</i></b>, <b style='color:Tomato;'><i>nevirapine</i></b>, <b style='color:Tomato;'><i>delavirdine</i></b>, <b style='color:Tomato;'><i>efavirenz</i></b>, <b style='color:Tomato;'><i>saquinavir</i></b>, <b style='color:Tomato;'><i>ritonavir</i></b>, <b style='color:Tomato;'><i>indinavir</i></b>, <b style='color:Tomato;'><i>nelfinavir</i></b>, <b style='color:Tomato;'><i>amprenavir</i></b>, <b style='color:Tomato;'><i>lopinavir</i></b>) and several others, such as <b style='color:Tomato;'><i>tenofovir</i></b> disoproxil, <b style='color:Tomato;'><i>emtricitabine</i></b>, capravirine, emivirine, T-20 (pentafuside) and AMD3100 (bicyclam) are under clinical development. <b style='color:Tomato;'><i>lamivudine</i></b> has been approved, and several other compounds (such as <b style='color:Tomato;'><i>adefovir</i></b> dipivoxil, <b style='color:Tomato;'><i>emtricitabine</i></b> and <b style='color:Tomato;'><i>entecavir</i></b>) are under clinical development, for the treatment of hepatitis B virus infections. <b style='color:DodgerBlue;'><i>Among</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>anti-herpesvirus</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>aciclovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>valaciclovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>penciclovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>famciclovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>idoxuridine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>trifluridine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>brivudin</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>herpes</i></b> <b style='color:DodgerBlue;'><i>simplex</i></b> <b style='color:DodgerBlue;'><i>virus</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>varicella-zoster</i></b> <b style='color:DodgerBlue;'><i>virus</i></b> <b style='color:DodgerBlue;'><i>infections</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ganciclovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>foscarnet</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cidofovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>fomivirsen</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>maribavir</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>latter</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>developmental</i></b> <b style='color:DodgerBlue;'><i>stage</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cytomegalovirus</i></b> <b style='color:DodgerBlue;'><i>infections</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Following <b style='color:Tomato;'><i>amantadine</i></b> and <b style='color:Tomato;'><i>rimantadine</i></b>, the neuraminidase inhibitors, <b style='color:Tomato;'><i>zanamivir</i></b> and <b style='color:Tomato;'><i>oseltamivir</i></b>, have now become available for the therapy and prophylaxis of influenza virus infections, and so is <b style='color:Tomato;'><i>ribavirin</i></b> for the treatment of respiratory syncytial virus infections and the combination of <b style='color:Tomato;'><i>ribavirin</i></b> with interferon-alpha for the treatment of hepatitis C virus infections.","tokens":[{"text":"Among","start":0,"end":5,"id":0,"ws":true},{"text":"the","start":6,"end":9,"id":1,"ws":true},{"text":"anti-herpesvirus","start":10,"end":26,"id":2,"ws":true},{"text":"agents","start":27,"end":33,"id":3,"ws":true},{"text":",","start":34,"end":35,"id":4,"ws":true},{"text":"aciclovir","start":36,"end":45,"id":5,"ws":true},{"text":",","start":46,"end":47,"id":6,"ws":true},{"text":"valaciclovir","start":48,"end":60,"id":7,"ws":true},{"text":",","start":61,"end":62,"id":8,"ws":true},{"text":"penciclovir","start":63,"end":74,"id":9,"ws":true},{"text":",","start":75,"end":76,"id":10,"ws":true},{"text":"famciclovir","start":77,"end":88,"id":11,"ws":true},{"text":",","start":89,"end":90,"id":12,"ws":true},{"text":"idoxuridine","start":91,"end":102,"id":13,"ws":true},{"text":",","start":103,"end":104,"id":14,"ws":true},{"text":"trifluridine","start":105,"end":117,"id":15,"ws":true},{"text":"and","start":118,"end":121,"id":16,"ws":true},{"text":"brivudin","start":122,"end":130,"id":17,"ws":true},{"text":"are","start":131,"end":134,"id":18,"ws":true},{"text":"used","start":135,"end":139,"id":19,"ws":true},{"text":"in","start":140,"end":142,"id":20,"ws":true},{"text":"the","start":143,"end":146,"id":21,"ws":true},{"text":"treatment","start":147,"end":156,"id":22,"ws":true},{"text":"of","start":157,"end":159,"id":23,"ws":true},{"text":"herpes","start":160,"end":166,"id":24,"ws":true},{"text":"simplex","start":167,"end":174,"id":25,"ws":true},{"text":"virus","start":175,"end":180,"id":26,"ws":true},{"text":"and","start":181,"end":184,"id":27,"ws":true},{"text":"varicella-zoster","start":185,"end":201,"id":28,"ws":true},{"text":"virus","start":202,"end":207,"id":29,"ws":true},{"text":"infections","start":208,"end":218,"id":30,"ws":true},{"text":",","start":219,"end":220,"id":31,"ws":true},{"text":"and","start":221,"end":224,"id":32,"ws":true},{"text":"ganciclovir","start":225,"end":236,"id":33,"ws":true},{"text":",","start":237,"end":238,"id":34,"ws":true},{"text":"foscarnet","start":239,"end":248,"id":35,"ws":true},{"text":",","start":249,"end":250,"id":36,"ws":true},{"text":"cidofovir","start":251,"end":260,"id":37,"ws":true},{"text":",","start":261,"end":262,"id":38,"ws":true},{"text":"fomivirsen","start":263,"end":273,"id":39,"ws":true},{"text":"and","start":274,"end":277,"id":40,"ws":true},{"text":"maribavir","start":278,"end":287,"id":41,"ws":true},{"text":"(","start":288,"end":289,"id":42,"ws":true},{"text":"the","start":290,"end":293,"id":43,"ws":true},{"text":"latter","start":294,"end":300,"id":44,"ws":true},{"text":"in","start":301,"end":303,"id":45,"ws":true},{"text":"the","start":304,"end":307,"id":46,"ws":true},{"text":"developmental","start":308,"end":321,"id":47,"ws":true},{"text":"stage","start":322,"end":327,"id":48,"ws":true},{"text":")","start":328,"end":329,"id":49,"ws":true},{"text":"are","start":330,"end":333,"id":50,"ws":true},{"text":"used","start":334,"end":338,"id":51,"ws":true},{"text":"in","start":339,"end":341,"id":52,"ws":true},{"text":"the","start":342,"end":345,"id":53,"ws":true},{"text":"treatment","start":346,"end":355,"id":54,"ws":true},{"text":"of","start":356,"end":358,"id":55,"ws":true},{"text":"cytomegalovirus","start":359,"end":374,"id":56,"ws":true},{"text":"infections","start":375,"end":385,"id":57,"ws":true},{"text":".","start":386,"end":387,"id":58,"ws":false}],"spans":[{"start":36,"end":45,"token_start":5,"token_end":5,"label":"DRUG"},{"start":48,"end":60,"token_start":7,"token_end":7,"label":"DRUG"},{"start":63,"end":74,"token_start":9,"token_end":9,"label":"DRUG"},{"start":77,"end":88,"token_start":11,"token_end":11,"label":"DRUG"},{"start":91,"end":102,"token_start":13,"token_end":13,"label":"DRUG"},{"start":105,"end":117,"token_start":15,"token_end":15,"label":"DRUG"},{"start":225,"end":236,"token_start":33,"token_end":33,"label":"DRUG"},{"start":239,"end":248,"token_start":35,"token_end":35,"label":"DRUG"},{"start":251,"end":260,"token_start":37,"token_end":37,"label":"DRUG"}],"_input_hash":1265321677,"_task_hash":1758490147,"_session_id":"drug_drug_pilot_shared-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The present study examined the efficacy of single and combined treatment with an anticholinesterase , tetrahydroaminoacridine ( i.p . ) , and a glycine-B site partial agonist , D-cycloserine ( i.p . ; a positive allosteric modulator of NMDA receptors ) , in alleviating the deficit in water maze spatial navigation induced by electrolytic lesion of the medial septum or lidocaine infusion into the dorsal hippocampi .","paragraph":"<h3><u>Tetrahydroaminoacridine and D-cycloserine fail to alleviate the water maze spatial navigation defect induced by hippocampal inactivation.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>examined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>anticholinesterase</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>tetrahydroaminoacridine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>i.p</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>glycine-B</i></b> <b style='color:DodgerBlue;'><i>site</i></b> <b style='color:DodgerBlue;'><i>partial</i></b> <b style='color:DodgerBlue;'><i>agonist</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>D-cycloserine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>i.p</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>positive</i></b> <b style='color:DodgerBlue;'><i>allosteric</i></b> <b style='color:DodgerBlue;'><i>modulator</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>NMDA</i></b> <b style='color:DodgerBlue;'><i>receptors</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>alleviating</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>deficit</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>water</i></b> <b style='color:DodgerBlue;'><i>maze</i></b> <b style='color:DodgerBlue;'><i>spatial</i></b> <b style='color:DodgerBlue;'><i>navigation</i></b> <b style='color:DodgerBlue;'><i>induced</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>electrolytic</i></b> <b style='color:DodgerBlue;'><i>lesion</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>medial</i></b> <b style='color:DodgerBlue;'><i>septum</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>lidocaine</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>dorsal</i></b> <b style='color:DodgerBlue;'><i>hippocampi</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In medial septum-lesioned rats, a combination of tetrahydroaminoacridine 3 mg kg(-1) and <b style='color:Tomato;'><i>d-cycloserine</i></b> 10 mg kg(-1) facilitated acquisition of the water maze test more effectively than either of the drugs alone. Single or combined treatment with tetrahydroaminoacridine 3 mg kg(-1) and <b style='color:Tomato;'><i>d-cycloserine</i></b> 10 mg kg(-1) had no effect on the water maze deficit induced by hippocampal <b style='color:Tomato;'><i>lidocaine</i></b> infusion. These results suggest that combined treatment with tetrahydroaminoacridine and <b style='color:Tomato;'><i>d-cycloserine</i></b> can effectively stimulate water maze spatial navigation, and that functioning of the hippocampus is a prerequisite for this effect.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"present","start":4,"end":11,"id":1,"ws":true},{"text":"study","start":12,"end":17,"id":2,"ws":true},{"text":"examined","start":18,"end":26,"id":3,"ws":true},{"text":"the","start":27,"end":30,"id":4,"ws":true},{"text":"efficacy","start":31,"end":39,"id":5,"ws":true},{"text":"of","start":40,"end":42,"id":6,"ws":true},{"text":"single","start":43,"end":49,"id":7,"ws":true},{"text":"and","start":50,"end":53,"id":8,"ws":true},{"text":"combined","start":54,"end":62,"id":9,"ws":true},{"text":"treatment","start":63,"end":72,"id":10,"ws":true},{"text":"with","start":73,"end":77,"id":11,"ws":true},{"text":"an","start":78,"end":80,"id":12,"ws":true},{"text":"anticholinesterase","start":81,"end":99,"id":13,"ws":true},{"text":",","start":100,"end":101,"id":14,"ws":true},{"text":"tetrahydroaminoacridine","start":102,"end":125,"id":15,"ws":true},{"text":"(","start":126,"end":127,"id":16,"ws":true},{"text":"i.p","start":128,"end":131,"id":17,"ws":true},{"text":".","start":132,"end":133,"id":18,"ws":true},{"text":")","start":134,"end":135,"id":19,"ws":true},{"text":",","start":136,"end":137,"id":20,"ws":true},{"text":"and","start":138,"end":141,"id":21,"ws":true},{"text":"a","start":142,"end":143,"id":22,"ws":true},{"text":"glycine-B","start":144,"end":153,"id":23,"ws":true},{"text":"site","start":154,"end":158,"id":24,"ws":true},{"text":"partial","start":159,"end":166,"id":25,"ws":true},{"text":"agonist","start":167,"end":174,"id":26,"ws":true},{"text":",","start":175,"end":176,"id":27,"ws":true},{"text":"D-cycloserine","start":177,"end":190,"id":28,"ws":true},{"text":"(","start":191,"end":192,"id":29,"ws":true},{"text":"i.p","start":193,"end":196,"id":30,"ws":true},{"text":".","start":197,"end":198,"id":31,"ws":true},{"text":";","start":199,"end":200,"id":32,"ws":true},{"text":"a","start":201,"end":202,"id":33,"ws":true},{"text":"positive","start":203,"end":211,"id":34,"ws":true},{"text":"allosteric","start":212,"end":222,"id":35,"ws":true},{"text":"modulator","start":223,"end":232,"id":36,"ws":true},{"text":"of","start":233,"end":235,"id":37,"ws":true},{"text":"NMDA","start":236,"end":240,"id":38,"ws":true},{"text":"receptors","start":241,"end":250,"id":39,"ws":true},{"text":")","start":251,"end":252,"id":40,"ws":true},{"text":",","start":253,"end":254,"id":41,"ws":true},{"text":"in","start":255,"end":257,"id":42,"ws":true},{"text":"alleviating","start":258,"end":269,"id":43,"ws":true},{"text":"the","start":270,"end":273,"id":44,"ws":true},{"text":"deficit","start":274,"end":281,"id":45,"ws":true},{"text":"in","start":282,"end":284,"id":46,"ws":true},{"text":"water","start":285,"end":290,"id":47,"ws":true},{"text":"maze","start":291,"end":295,"id":48,"ws":true},{"text":"spatial","start":296,"end":303,"id":49,"ws":true},{"text":"navigation","start":304,"end":314,"id":50,"ws":true},{"text":"induced","start":315,"end":322,"id":51,"ws":true},{"text":"by","start":323,"end":325,"id":52,"ws":true},{"text":"electrolytic","start":326,"end":338,"id":53,"ws":true},{"text":"lesion","start":339,"end":345,"id":54,"ws":true},{"text":"of","start":346,"end":348,"id":55,"ws":true},{"text":"the","start":349,"end":352,"id":56,"ws":true},{"text":"medial","start":353,"end":359,"id":57,"ws":true},{"text":"septum","start":360,"end":366,"id":58,"ws":true},{"text":"or","start":367,"end":369,"id":59,"ws":true},{"text":"lidocaine","start":370,"end":379,"id":60,"ws":true},{"text":"infusion","start":380,"end":388,"id":61,"ws":true},{"text":"into","start":389,"end":393,"id":62,"ws":true},{"text":"the","start":394,"end":397,"id":63,"ws":true},{"text":"dorsal","start":398,"end":404,"id":64,"ws":true},{"text":"hippocampi","start":405,"end":415,"id":65,"ws":true},{"text":".","start":416,"end":417,"id":66,"ws":false}],"spans":[{"start":177,"end":190,"token_start":28,"token_end":28,"label":"DRUG"},{"start":370,"end":379,"token_start":60,"token_end":60,"label":"DRUG"}],"_input_hash":1944915333,"_task_hash":1724675945,"_session_id":"drug_drug_pilot_shared-maytal","_view_id":"blocks","relations":[{"head":15,"child":28,"head_span":{"start":102,"end":125,"token_start":15,"token_end":15,"label":null},"child_span":{"start":177,"end":190,"token_start":28,"token_end":28,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["POS11","POS1T0","COMB1T0"],"answer":"accept"}
{"text":"He was initially treated with combination chemotherapy regimen of vincristine , actinomycin-D and cyclophosphamide ( VAC therapy ) .","paragraph":"<h3><u>[Rhabdomyosarcoma of the bladder: a case report].</u></h3>A 15-year-old man with the chief complaint of general fatigue was referred to our hospital on November 11, 1993. Bilateral percutaneous nephrostomy was performed for postrenal anuria. X-ray examinations revealed a huge intrapelvic tumor, and it was histopathologically diagnosed as rhabdomyosarcoma by transrectal needle biopsy. <b style='color:DodgerBlue;'><i>He</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>initially</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>actinomycin-D</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>VAC</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Pelvic exenteration was performed on December 15, 1993. Histopathological findings were alveolar rhabdomyosarcoma with degenerative change and partial necrosis. After the operation, he was given two course of VAC therapy. In May, 1994, brain metastasis occurred, so 4 courses of VAC therapy were administered. For a very short period, neurological symptoms improved, but he died of pneumonia on November 15, 1994.","tokens":[{"text":"He","start":0,"end":2,"id":0,"ws":true},{"text":"was","start":3,"end":6,"id":1,"ws":true},{"text":"initially","start":7,"end":16,"id":2,"ws":true},{"text":"treated","start":17,"end":24,"id":3,"ws":true},{"text":"with","start":25,"end":29,"id":4,"ws":true},{"text":"combination","start":30,"end":41,"id":5,"ws":true},{"text":"chemotherapy","start":42,"end":54,"id":6,"ws":true},{"text":"regimen","start":55,"end":62,"id":7,"ws":true},{"text":"of","start":63,"end":65,"id":8,"ws":true},{"text":"vincristine","start":66,"end":77,"id":9,"ws":true},{"text":",","start":78,"end":79,"id":10,"ws":true},{"text":"actinomycin-D","start":80,"end":93,"id":11,"ws":true},{"text":"and","start":94,"end":97,"id":12,"ws":true},{"text":"cyclophosphamide","start":98,"end":114,"id":13,"ws":true},{"text":"(","start":115,"end":116,"id":14,"ws":true},{"text":"VAC","start":117,"end":120,"id":15,"ws":true},{"text":"therapy","start":121,"end":128,"id":16,"ws":true},{"text":")","start":129,"end":130,"id":17,"ws":true},{"text":".","start":131,"end":132,"id":18,"ws":false}],"spans":[{"start":66,"end":77,"token_start":9,"token_end":9,"label":"DRUG"},{"start":98,"end":114,"token_start":13,"token_end":13,"label":"DRUG"}],"_input_hash":1557412523,"_task_hash":-2119098685,"_session_id":"drug_drug_pilot_shared-maytal","_view_id":"blocks","relations":[{"head":9,"child":11,"head_span":{"start":66,"end":77,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":80,"end":93,"token_start":11,"token_end":11,"label":null},"color":"#96e8ce","label":"COMB1"},{"head":13,"child":9,"head_span":{"start":98,"end":114,"token_start":13,"token_end":13,"label":"DRUG"},"child_span":{"start":66,"end":77,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"However , when a lung mass was noted two months later , he started to receive combination chemotherapy consisting of cyclophosphamide , adriamycin , vincristine , and prednisolone every three months .","paragraph":"<h3><u>[Lymphomatoid granulomatosis (LYG) occurring in a patient with follicular lymphoma during remission].</u></h3>A 49 years-old man presented with dry cough, low grade fever, and abnormal shadow on a chest X-ray. He had suffered from follicular lymphoma of the liver 5 years previously. He received irradiation therapy in combination with chemotherapy for approximately three years and had been in complete remission. Physical and radiological examination revealed pleural effusion and softly dense masses in the right lung. The laboratory data were within normal limits. He was diagnosed as having lymphomatoid granulomatosis (LYG) by open lung biopsy. The lung lesion was mainly infiltrated with T cells. The patient received <b style='color:Tomato;'><i>prednisolone</i></b> and the lung lesions disappeared. <b style='color:DodgerBlue;'><i>However</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>lung</i></b> <b style='color:DodgerBlue;'><i>mass</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>noted</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>later</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>he</i></b> <b style='color:DodgerBlue;'><i>started</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>receive</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>consisting</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>adriamycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>prednisolone</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>three</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>.</i></b> He has not shown relapse of LYG so far. To investigate the association between the preceding follicular lymphoma and subsequent LYG at this time, DNA analysis using the PCR technique was carried out. The LYG lesion did not show a rearranged band for the JH probe, while the paraffin-embedded specimen of the preceding follicular lymphoma had shown rearranged band for the JH band. Southern blot analysis of the LYG lesion, showed no rearrangement for TCR beta, gamma or JH probe. These findings indicate that the LYG was different from the preceding follicular lymphoma in terms of origin. LYG is considered to be induced in the immunosuppressive state due to lymphoma.","tokens":[{"text":"However","start":0,"end":7,"id":0,"ws":true},{"text":",","start":8,"end":9,"id":1,"ws":true},{"text":"when","start":10,"end":14,"id":2,"ws":true},{"text":"a","start":15,"end":16,"id":3,"ws":true},{"text":"lung","start":17,"end":21,"id":4,"ws":true},{"text":"mass","start":22,"end":26,"id":5,"ws":true},{"text":"was","start":27,"end":30,"id":6,"ws":true},{"text":"noted","start":31,"end":36,"id":7,"ws":true},{"text":"two","start":37,"end":40,"id":8,"ws":true},{"text":"months","start":41,"end":47,"id":9,"ws":true},{"text":"later","start":48,"end":53,"id":10,"ws":true},{"text":",","start":54,"end":55,"id":11,"ws":true},{"text":"he","start":56,"end":58,"id":12,"ws":true},{"text":"started","start":59,"end":66,"id":13,"ws":true},{"text":"to","start":67,"end":69,"id":14,"ws":true},{"text":"receive","start":70,"end":77,"id":15,"ws":true},{"text":"combination","start":78,"end":89,"id":16,"ws":true},{"text":"chemotherapy","start":90,"end":102,"id":17,"ws":true},{"text":"consisting","start":103,"end":113,"id":18,"ws":true},{"text":"of","start":114,"end":116,"id":19,"ws":true},{"text":"cyclophosphamide","start":117,"end":133,"id":20,"ws":true},{"text":",","start":134,"end":135,"id":21,"ws":true},{"text":"adriamycin","start":136,"end":146,"id":22,"ws":true},{"text":",","start":147,"end":148,"id":23,"ws":true},{"text":"vincristine","start":149,"end":160,"id":24,"ws":true},{"text":",","start":161,"end":162,"id":25,"ws":true},{"text":"and","start":163,"end":166,"id":26,"ws":true},{"text":"prednisolone","start":167,"end":179,"id":27,"ws":true},{"text":"every","start":180,"end":185,"id":28,"ws":true},{"text":"three","start":186,"end":191,"id":29,"ws":true},{"text":"months","start":192,"end":198,"id":30,"ws":true},{"text":".","start":199,"end":200,"id":31,"ws":false}],"spans":[{"start":117,"end":133,"token_start":20,"token_end":20,"label":"DRUG"},{"start":149,"end":160,"token_start":24,"token_end":24,"label":"DRUG"},{"start":167,"end":179,"token_start":27,"token_end":27,"label":"DRUG"}],"_input_hash":8987266,"_task_hash":528717002,"_session_id":"drug_drug_pilot_shared-maytal","_view_id":"blocks","relations":[{"head":20,"child":22,"head_span":{"start":117,"end":133,"token_start":20,"token_end":20,"label":"DRUG"},"child_span":{"start":136,"end":146,"token_start":22,"token_end":22,"label":null},"color":"#96e8ce","label":"COMB1"},{"head":24,"child":22,"head_span":{"start":149,"end":160,"token_start":24,"token_end":24,"label":"DRUG"},"child_span":{"start":136,"end":146,"token_start":22,"token_end":22,"label":null},"color":"#96e8ce","label":"COMB1"},{"head":27,"child":24,"head_span":{"start":167,"end":179,"token_start":27,"token_end":27,"label":"DRUG"},"child_span":{"start":149,"end":160,"token_start":24,"token_end":24,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T1"],"answer":"accept"}
{"text":"Three patients treated initially with propranolol alone have required substitution of amiodarone due to refractory congestive heart failure .","paragraph":"<h3><u>The role of beta-blockade therapy for ventricular tachycardia induced with isoproterenol: a prospective analysis.</u></h3>Isoproterenol is sometimes required for ventricular tachycardia (VT) induction. However, the role of beta-blockade for treatment of such VT has not been critically assessed. The use of beta-blockade was evaluated prospectively in 14 consecutive patients who required isoproterenol 2.4 +/- 1.3 (+/- S.D.) micrograms/min to induce sustained monomorphic VT (greater than 30 seconds, or requiring termination due to hemodynamic collapse) after a negative baseline study. The VT mechanisms were enhanced automaticity (group A, six patients), triggered automaticity (group B, three patients), and reentry (group C, five patients). Groups A and B had serial intravenous electropharmacologic tests with <b style='color:Tomato;'><i>propranolol</i></b> alone (0.2 mg/kg), <b style='color:Tomato;'><i>verapamil</i></b> alone (0.15 mg/kg), and <b style='color:Tomato;'><i>propranolol</i></b> plus <b style='color:Tomato;'><i>verapamil</i></b>, and group C had serial tests with <b style='color:Tomato;'><i>propranolol</i></b> alone, <b style='color:Tomato;'><i>procainamide</i></b> or <b style='color:Tomato;'><i>quinidine</i></b> (class Ia drug) alone, and <b style='color:Tomato;'><i>propranolol</i></b> plus a class Ia drug until VT could no longer be induced. All six patients in group A responded to <b style='color:Tomato;'><i>propranolol</i></b> alone. In group B, one patient responded to <b style='color:Tomato;'><i>verapamil</i></b> alone, and two patients responded to <b style='color:Tomato;'><i>propranolol</i></b> plus <b style='color:Tomato;'><i>verapamil</i></b>. In group C, three patients responded to <b style='color:Tomato;'><i>propranolol</i></b> alone, one patient responded to a class Ia drug alone, and one patient responded to <b style='color:Tomato;'><i>propranolol</i></b> plus a class Ia drug. During a follow-up of 7 to 37 (17.9 +/- 10.7) (+/- S.D.) months, VT has not recurred in any patient. <b style='color:DodgerBlue;'><i>Three</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>initially</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>propranolol</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>required</i></b> <b style='color:DodgerBlue;'><i>substitution</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>amiodarone</i></b> <b style='color:DodgerBlue;'><i>due</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>refractory</i></b> <b style='color:DodgerBlue;'><i>congestive</i></b> <b style='color:DodgerBlue;'><i>heart</i></b> <b style='color:DodgerBlue;'><i>failure</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In patients requiring isoproterenol for VT induction, beta-blockade alone appears to be effective in preventing reinduction of VT caused by enhanced automaticity. A heterogeneous response occurs when the VT mechanisms are triggered automaticity or reentry.","tokens":[{"text":"Three","start":0,"end":5,"id":0,"ws":true},{"text":"patients","start":6,"end":14,"id":1,"ws":true},{"text":"treated","start":15,"end":22,"id":2,"ws":true},{"text":"initially","start":23,"end":32,"id":3,"ws":true},{"text":"with","start":33,"end":37,"id":4,"ws":true},{"text":"propranolol","start":38,"end":49,"id":5,"ws":true},{"text":"alone","start":50,"end":55,"id":6,"ws":true},{"text":"have","start":56,"end":60,"id":7,"ws":true},{"text":"required","start":61,"end":69,"id":8,"ws":true},{"text":"substitution","start":70,"end":82,"id":9,"ws":true},{"text":"of","start":83,"end":85,"id":10,"ws":true},{"text":"amiodarone","start":86,"end":96,"id":11,"ws":true},{"text":"due","start":97,"end":100,"id":12,"ws":true},{"text":"to","start":101,"end":103,"id":13,"ws":true},{"text":"refractory","start":104,"end":114,"id":14,"ws":true},{"text":"congestive","start":115,"end":125,"id":15,"ws":true},{"text":"heart","start":126,"end":131,"id":16,"ws":true},{"text":"failure","start":132,"end":139,"id":17,"ws":true},{"text":".","start":140,"end":141,"id":18,"ws":false}],"spans":[{"start":38,"end":49,"token_start":5,"token_end":5,"label":"DRUG"},{"start":86,"end":96,"token_start":11,"token_end":11,"label":"DRUG"}],"_input_hash":-632828286,"_task_hash":-1526074177,"_session_id":"drug_drug_pilot_shared-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"These studies suggest a slight advantage to the combined approaches that contain flutamide and bicalutamide , but the lack of dramatic differences in outcome makes monotherapy reasonable , especially in patients with more indolent disease .","paragraph":"<h3><u>The selection of hormonal therapy in prostate cancer: who, when, and for how long?</u></h3>Androgen deprivation is the foundation for the systemic therapy of advanced prostate cancer. Multiple trials have tested combined androgen blockade versus androgen deprivation alone in patients with advanced disease. <b style='color:DodgerBlue;'><i>These</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>suggest</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>slight</i></b> <b style='color:DodgerBlue;'><i>advantage</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>approaches</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>contain</i></b> <b style='color:MediumOrchid;'><i>flutamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>bicalutamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>lack</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>dramatic</i></b> <b style='color:DodgerBlue;'><i>differences</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>outcome</i></b> <b style='color:DodgerBlue;'><i>makes</i></b> <b style='color:DodgerBlue;'><i>monotherapy</i></b> <b style='color:DodgerBlue;'><i>reasonable</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>especially</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>indolent</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Intermittent androgen deprivation is an alternative that may allow patients to reduce the total time on androgen suppression as well as possibly delay the onset of androgen independence. A number of secondary hormonal therapies, including deferred and secondary antiandrogens, <b style='color:Tomato;'><i>ketoconazole</i></b>, and estrogens have shown modest response proportions. Patients with less advanced disease such as a rising prostate-specific antigen have varied outcomes, and no standard approach exists. In this group, noncastrating forms of hormonal therapy are being evaluated. Patients undergoing definitive local therapy who have high-risk features may benefit from early, as opposed to deferred, androgen deprivation. This review examines the evidence for the current state of the art in hormonal therapy in patients with prostate cancer and focuses, in particular, on treatment composition and timing as well as the rationale for the use of hormonal therapy in early stage disease.","tokens":[{"text":"These","start":0,"end":5,"id":0,"ws":true},{"text":"studies","start":6,"end":13,"id":1,"ws":true},{"text":"suggest","start":14,"end":21,"id":2,"ws":true},{"text":"a","start":22,"end":23,"id":3,"ws":true},{"text":"slight","start":24,"end":30,"id":4,"ws":true},{"text":"advantage","start":31,"end":40,"id":5,"ws":true},{"text":"to","start":41,"end":43,"id":6,"ws":true},{"text":"the","start":44,"end":47,"id":7,"ws":true},{"text":"combined","start":48,"end":56,"id":8,"ws":true},{"text":"approaches","start":57,"end":67,"id":9,"ws":true},{"text":"that","start":68,"end":72,"id":10,"ws":true},{"text":"contain","start":73,"end":80,"id":11,"ws":true},{"text":"flutamide","start":81,"end":90,"id":12,"ws":true},{"text":"and","start":91,"end":94,"id":13,"ws":true},{"text":"bicalutamide","start":95,"end":107,"id":14,"ws":true},{"text":",","start":108,"end":109,"id":15,"ws":true},{"text":"but","start":110,"end":113,"id":16,"ws":true},{"text":"the","start":114,"end":117,"id":17,"ws":true},{"text":"lack","start":118,"end":122,"id":18,"ws":true},{"text":"of","start":123,"end":125,"id":19,"ws":true},{"text":"dramatic","start":126,"end":134,"id":20,"ws":true},{"text":"differences","start":135,"end":146,"id":21,"ws":true},{"text":"in","start":147,"end":149,"id":22,"ws":true},{"text":"outcome","start":150,"end":157,"id":23,"ws":true},{"text":"makes","start":158,"end":163,"id":24,"ws":true},{"text":"monotherapy","start":164,"end":175,"id":25,"ws":true},{"text":"reasonable","start":176,"end":186,"id":26,"ws":true},{"text":",","start":187,"end":188,"id":27,"ws":true},{"text":"especially","start":189,"end":199,"id":28,"ws":true},{"text":"in","start":200,"end":202,"id":29,"ws":true},{"text":"patients","start":203,"end":211,"id":30,"ws":true},{"text":"with","start":212,"end":216,"id":31,"ws":true},{"text":"more","start":217,"end":221,"id":32,"ws":true},{"text":"indolent","start":222,"end":230,"id":33,"ws":true},{"text":"disease","start":231,"end":238,"id":34,"ws":true},{"text":".","start":239,"end":240,"id":35,"ws":false}],"spans":[{"start":81,"end":90,"token_start":12,"token_end":12,"label":"DRUG"},{"start":95,"end":107,"token_start":14,"token_end":14,"label":"DRUG"}],"_input_hash":137769162,"_task_hash":410888998,"_session_id":"drug_drug_pilot_shared-maytal","_view_id":"blocks","relations":[{"head":12,"child":14,"head_span":{"start":81,"end":90,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":95,"end":107,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T0"],"answer":"accept"}
{"text":"We examined the feasibility and safety of using paclitaxel and trastuzumab as maintenance therapy after high-dose chemotherapy ( HDC ) with autologous hematopoietic stem cell transplantation ( AHST ) for patients with HER2-positive metastatic breast cancer .","paragraph":"<h3><u>Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation.</u></h3> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>examined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>feasibility</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>maintenance</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>HDC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>autologous</i></b> <b style='color:DodgerBlue;'><i>hematopoietic</i></b> <b style='color:DodgerBlue;'><i>stem</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>transplantation</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AHST</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>HER2-positive</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Ten patients (9 women and 1 man) were enrolled in the study. The median age was 46.5 years (range, 27-65 years). The median follow-up time was 1003 days (range, 216-2526 days). All patients had metastatic disease, but 2 had only bone metastasis. One patient had complete response, 6 had partial response and 3 had stable disease to the standard-dose chemotherapy prior to transplantation. The conditioning regimen consisted of <b style='color:Tomato;'><i>cyclophosphamide</i></b>, <b style='color:Tomato;'><i>carmustine</i></b>, and <b style='color:Tomato;'><i>thiotepa</i></b>. After AHST, patients received weekly <b style='color:Tomato;'><i>paclitaxel</i></b> for 12 doses and <b style='color:Tomato;'><i>trastuzumab</i></b> every 3 weeks for 1 year as maintenance therapy. All patients experienced successful engraftment. The only grade 4 toxic effects observed were leukopenia and thrombocytopenia. The most common grade 3 toxic effect was neutropenic fever. No treatment-related deaths were observed. The median progression-free survival time was 441 days, and the median overall survival time was 955 days. Two patients died in accidents while their disease remained in remission. Five patients died with disease progression. At the time of this report, 3 patients are alive with stable disease, 1 of whom has remained free of disease progression for 2526 days since transplantation. Our findings indicate that <b style='color:Tomato;'><i>paclitaxel</i></b> plus <b style='color:Tomato;'><i>trastuzumab</i></b> as maintenance therapy after HDC with AHST for patients with HER2-positive metastatic breast cancer not only is feasible and safe but also results in survival outcomes similar to historical results. ","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"examined","start":3,"end":11,"id":1,"ws":true},{"text":"the","start":12,"end":15,"id":2,"ws":true},{"text":"feasibility","start":16,"end":27,"id":3,"ws":true},{"text":"and","start":28,"end":31,"id":4,"ws":true},{"text":"safety","start":32,"end":38,"id":5,"ws":true},{"text":"of","start":39,"end":41,"id":6,"ws":true},{"text":"using","start":42,"end":47,"id":7,"ws":true},{"text":"paclitaxel","start":48,"end":58,"id":8,"ws":true},{"text":"and","start":59,"end":62,"id":9,"ws":true},{"text":"trastuzumab","start":63,"end":74,"id":10,"ws":true},{"text":"as","start":75,"end":77,"id":11,"ws":true},{"text":"maintenance","start":78,"end":89,"id":12,"ws":true},{"text":"therapy","start":90,"end":97,"id":13,"ws":true},{"text":"after","start":98,"end":103,"id":14,"ws":true},{"text":"high-dose","start":104,"end":113,"id":15,"ws":true},{"text":"chemotherapy","start":114,"end":126,"id":16,"ws":true},{"text":"(","start":127,"end":128,"id":17,"ws":true},{"text":"HDC","start":129,"end":132,"id":18,"ws":true},{"text":")","start":133,"end":134,"id":19,"ws":true},{"text":"with","start":135,"end":139,"id":20,"ws":true},{"text":"autologous","start":140,"end":150,"id":21,"ws":true},{"text":"hematopoietic","start":151,"end":164,"id":22,"ws":true},{"text":"stem","start":165,"end":169,"id":23,"ws":true},{"text":"cell","start":170,"end":174,"id":24,"ws":true},{"text":"transplantation","start":175,"end":190,"id":25,"ws":true},{"text":"(","start":191,"end":192,"id":26,"ws":true},{"text":"AHST","start":193,"end":197,"id":27,"ws":true},{"text":")","start":198,"end":199,"id":28,"ws":true},{"text":"for","start":200,"end":203,"id":29,"ws":true},{"text":"patients","start":204,"end":212,"id":30,"ws":true},{"text":"with","start":213,"end":217,"id":31,"ws":true},{"text":"HER2-positive","start":218,"end":231,"id":32,"ws":true},{"text":"metastatic","start":232,"end":242,"id":33,"ws":true},{"text":"breast","start":243,"end":249,"id":34,"ws":true},{"text":"cancer","start":250,"end":256,"id":35,"ws":true},{"text":".","start":257,"end":258,"id":36,"ws":false}],"spans":[{"start":48,"end":58,"token_start":8,"token_end":8,"label":"DRUG"},{"start":63,"end":74,"token_start":10,"token_end":10,"label":"DRUG"},{"start":140,"end":190,"token_start":21,"token_end":25,"label":"DRUG"}],"_input_hash":-1578970086,"_task_hash":304060663,"_session_id":"drug_drug_pilot_shared-maytal","_view_id":"blocks","relations":[{"head":8,"child":10,"head_span":{"start":48,"end":58,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":63,"end":74,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":25,"child":10,"head_span":{"start":140,"end":190,"token_start":21,"token_end":25,"label":"DRUG"},"child_span":{"start":63,"end":74,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#ffd882","label":"POS2"},{"head":8,"child":25,"head_span":{"start":48,"end":58,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":140,"end":190,"token_start":21,"token_end":25,"label":"DRUG"},"color":"#ffd882","label":"POS2"}],"radio":["POS11","POS1T1","POS21","POS2T1"],"answer":"accept"}
{"text":"Dual antiplatelet therapy with aspirin and clopidogrel ( the preferred thienopyridine because of its superior hematologic safety ) is recommended for at least 4 weeks to prevent subacute stent thrombosis with bare-metal stents and 3 to 6 months to prevent late-stent thrombosis with drug-eluting stents .","paragraph":"<h3><u>Long-term care after percutaneous coronary intervention: focus on the role of antiplatelet therapy.</u></h3>Arterial wall injury caused by percutaneous coronary intervention (PCI) triggers transient platelet activation and mural thrombosis; these effects are superimposed on the preexisting platelet hyperreactivity associated with underlying atherothrombosis. Platelet activation has been implicated in the major complications of PCI: acute and subacute thrombosis and restenosis. Antithrombotic and anticoagulant therapy minimizes thrombotic complications after PCI. <b style='color:Tomato;'><i>aspirin</i></b> plus a thienopyridine (<b style='color:Tomato;'><i>ticlopidine</i></b> or <b style='color:Tomato;'><i>clopidogrel</i></b>) is more effective than <b style='color:Tomato;'><i>aspirin</i></b> plus <b style='color:Tomato;'><i>heparin</i></b> and extended <b style='color:Tomato;'><i>warfarin</i></b> therapy in preventing periprocedural ischemic events and subsequent stent thrombosis and results in less major and minor bleeding. <b style='color:DodgerBlue;'><i>Dual</i></b> <b style='color:DodgerBlue;'><i>antiplatelet</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>aspirin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>clopidogrel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>preferred</i></b> <b style='color:DodgerBlue;'><i>thienopyridine</i></b> <b style='color:DodgerBlue;'><i>because</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>its</i></b> <b style='color:DodgerBlue;'><i>superior</i></b> <b style='color:DodgerBlue;'><i>hematologic</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>recommended</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>least</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>prevent</i></b> <b style='color:DodgerBlue;'><i>subacute</i></b> <b style='color:DodgerBlue;'><i>stent</i></b> <b style='color:DodgerBlue;'><i>thrombosis</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>bare-metal</i></b> <b style='color:DodgerBlue;'><i>stents</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>prevent</i></b> <b style='color:DodgerBlue;'><i>late-stent</i></b> <b style='color:DodgerBlue;'><i>thrombosis</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>drug-eluting</i></b> <b style='color:DodgerBlue;'><i>stents</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Coronary atherothrombosis is a diffuse vascular disease, and reduction of the risk of future ischemic events requires strategies that extend beyond the focal treatment of stenotic lesions. Optimal long-term care after PCI requires aggressive systemic pharmacotherapy (antiplatelet agents, statins, beta-blockers, and angiotensin-converting enzyme Inhibitors) in conjunction with therapeutic lifestyle changes (smoking cessation, weight reduction, dietary measures, and exercise). In this context, dual antiplatelet therapy (<b style='color:Tomato;'><i>aspirin</i></b> plus <b style='color:Tomato;'><i>clopidogrel</i></b>) is recommended for at least 12 months after PCI for prophylaxis of future atherothrombotic events.","tokens":[{"text":"Dual","start":0,"end":4,"id":0,"ws":true},{"text":"antiplatelet","start":5,"end":17,"id":1,"ws":true},{"text":"therapy","start":18,"end":25,"id":2,"ws":true},{"text":"with","start":26,"end":30,"id":3,"ws":true},{"text":"aspirin","start":31,"end":38,"id":4,"ws":true},{"text":"and","start":39,"end":42,"id":5,"ws":true},{"text":"clopidogrel","start":43,"end":54,"id":6,"ws":true},{"text":"(","start":55,"end":56,"id":7,"ws":true},{"text":"the","start":57,"end":60,"id":8,"ws":true},{"text":"preferred","start":61,"end":70,"id":9,"ws":true},{"text":"thienopyridine","start":71,"end":85,"id":10,"ws":true},{"text":"because","start":86,"end":93,"id":11,"ws":true},{"text":"of","start":94,"end":96,"id":12,"ws":true},{"text":"its","start":97,"end":100,"id":13,"ws":true},{"text":"superior","start":101,"end":109,"id":14,"ws":true},{"text":"hematologic","start":110,"end":121,"id":15,"ws":true},{"text":"safety","start":122,"end":128,"id":16,"ws":true},{"text":")","start":129,"end":130,"id":17,"ws":true},{"text":"is","start":131,"end":133,"id":18,"ws":true},{"text":"recommended","start":134,"end":145,"id":19,"ws":true},{"text":"for","start":146,"end":149,"id":20,"ws":true},{"text":"at","start":150,"end":152,"id":21,"ws":true},{"text":"least","start":153,"end":158,"id":22,"ws":true},{"text":"4","start":159,"end":160,"id":23,"ws":true},{"text":"weeks","start":161,"end":166,"id":24,"ws":true},{"text":"to","start":167,"end":169,"id":25,"ws":true},{"text":"prevent","start":170,"end":177,"id":26,"ws":true},{"text":"subacute","start":178,"end":186,"id":27,"ws":true},{"text":"stent","start":187,"end":192,"id":28,"ws":true},{"text":"thrombosis","start":193,"end":203,"id":29,"ws":true},{"text":"with","start":204,"end":208,"id":30,"ws":true},{"text":"bare-metal","start":209,"end":219,"id":31,"ws":true},{"text":"stents","start":220,"end":226,"id":32,"ws":true},{"text":"and","start":227,"end":230,"id":33,"ws":true},{"text":"3","start":231,"end":232,"id":34,"ws":true},{"text":"to","start":233,"end":235,"id":35,"ws":true},{"text":"6","start":236,"end":237,"id":36,"ws":true},{"text":"months","start":238,"end":244,"id":37,"ws":true},{"text":"to","start":245,"end":247,"id":38,"ws":true},{"text":"prevent","start":248,"end":255,"id":39,"ws":true},{"text":"late-stent","start":256,"end":266,"id":40,"ws":true},{"text":"thrombosis","start":267,"end":277,"id":41,"ws":true},{"text":"with","start":278,"end":282,"id":42,"ws":true},{"text":"drug-eluting","start":283,"end":295,"id":43,"ws":true},{"text":"stents","start":296,"end":302,"id":44,"ws":true},{"text":".","start":303,"end":304,"id":45,"ws":false}],"spans":[{"start":31,"end":38,"token_start":4,"token_end":4,"label":"DRUG"},{"start":43,"end":54,"token_start":6,"token_end":6,"label":"DRUG"}],"_input_hash":1471340217,"_task_hash":-1789027077,"_session_id":"drug_drug_pilot_shared-maytal","_view_id":"blocks","relations":[{"head":4,"child":6,"head_span":{"start":31,"end":38,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":43,"end":54,"token_start":6,"token_end":6,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T1"],"answer":"accept"}
{"text":"Furthermore , in non-metastatic castration-resistant prostate cancer ( M0 CRPC ) , two second-generation anti-androgens , apalutamide and enzalutamide , when used in combination with ADT , have demonstrated a significant benefit in metastasis-free survival .","paragraph":"<h3><u>Recent trends in the management of advanced prostate cancer.</u></h3>Advanced prostate cancer includes a wide spectrum of disease ranging from hormone na\u00efve or hormone sensitive to castration resistant, both containing populations of men who have demonstrable metastatic and non-metastatic states. The mainstay of treatment for metastatic hormone-sensitive prostate cancer is androgen deprivation therapy (ADT). However, recent level 1 evidence demonstrates that the addition of chemotherapy or <b style='color:Tomato;'><i>abiraterone</i></b> acetate to ADT results in significant survival advantage as compared with ADT alone. <b style='color:DodgerBlue;'><i>Furthermore</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>non-metastatic</i></b> <b style='color:DodgerBlue;'><i>castration-resistant</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>M0</i></b> <b style='color:DodgerBlue;'><i>CRPC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>second-generation</i></b> <b style='color:DodgerBlue;'><i>anti-androgens</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>apalutamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>enzalutamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>ADT</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>significant</i></b> <b style='color:DodgerBlue;'><i>benefit</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>metastasis-free</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Here, we review the most recent studies leading to these significant changes in the treatment of advanced prostate cancer.","tokens":[{"text":"Furthermore","start":0,"end":11,"id":0,"ws":true},{"text":",","start":12,"end":13,"id":1,"ws":true},{"text":"in","start":14,"end":16,"id":2,"ws":true},{"text":"non-metastatic","start":17,"end":31,"id":3,"ws":true},{"text":"castration-resistant","start":32,"end":52,"id":4,"ws":true},{"text":"prostate","start":53,"end":61,"id":5,"ws":true},{"text":"cancer","start":62,"end":68,"id":6,"ws":true},{"text":"(","start":69,"end":70,"id":7,"ws":true},{"text":"M0","start":71,"end":73,"id":8,"ws":true},{"text":"CRPC","start":74,"end":78,"id":9,"ws":true},{"text":")","start":79,"end":80,"id":10,"ws":true},{"text":",","start":81,"end":82,"id":11,"ws":true},{"text":"two","start":83,"end":86,"id":12,"ws":true},{"text":"second-generation","start":87,"end":104,"id":13,"ws":true},{"text":"anti-androgens","start":105,"end":119,"id":14,"ws":true},{"text":",","start":120,"end":121,"id":15,"ws":true},{"text":"apalutamide","start":122,"end":133,"id":16,"ws":true},{"text":"and","start":134,"end":137,"id":17,"ws":true},{"text":"enzalutamide","start":138,"end":150,"id":18,"ws":true},{"text":",","start":151,"end":152,"id":19,"ws":true},{"text":"when","start":153,"end":157,"id":20,"ws":true},{"text":"used","start":158,"end":162,"id":21,"ws":true},{"text":"in","start":163,"end":165,"id":22,"ws":true},{"text":"combination","start":166,"end":177,"id":23,"ws":true},{"text":"with","start":178,"end":182,"id":24,"ws":true},{"text":"ADT","start":183,"end":186,"id":25,"ws":true},{"text":",","start":187,"end":188,"id":26,"ws":true},{"text":"have","start":189,"end":193,"id":27,"ws":true},{"text":"demonstrated","start":194,"end":206,"id":28,"ws":true},{"text":"a","start":207,"end":208,"id":29,"ws":true},{"text":"significant","start":209,"end":220,"id":30,"ws":true},{"text":"benefit","start":221,"end":228,"id":31,"ws":true},{"text":"in","start":229,"end":231,"id":32,"ws":true},{"text":"metastasis-free","start":232,"end":247,"id":33,"ws":true},{"text":"survival","start":248,"end":256,"id":34,"ws":true},{"text":".","start":257,"end":258,"id":35,"ws":false}],"spans":[{"start":122,"end":133,"token_start":16,"token_end":16,"label":"DRUG"},{"start":138,"end":150,"token_start":18,"token_end":18,"label":"DRUG"}],"_input_hash":236482726,"_task_hash":-1620523265,"_session_id":"drug_drug_pilot_shared-maytal","_view_id":"blocks","relations":[{"head":16,"child":25,"head_span":{"start":122,"end":133,"token_start":16,"token_end":16,"label":"DRUG"},"child_span":{"start":183,"end":186,"token_start":25,"token_end":25,"label":null},"color":"#c5bdf4","label":"POS1"},{"head":18,"child":25,"head_span":{"start":138,"end":150,"token_start":18,"token_end":18,"label":"DRUG"},"child_span":{"start":183,"end":186,"token_start":25,"token_end":25,"label":null},"color":"#ffd882","label":"POS2"}],"radio":["POS10","POS1T0","POS20","POS2T0"],"answer":"accept"}
{"text":"A screening method based on liquid chromatography-electrospray mass spectrometry for the simultaneous determination of six corticosteroids ( betamethasone 17-valerate BM 17-V , beclomethasone BC , beclomethasone dipropionate BCDP , methylprednisolone MP , budesonide BD , flunisolide FN ) was developed in order to control their illegal use in cosmetic and natural products .","paragraph":"<h3><u>LC-MS method for the simultaneous determination of six glucocorticoids in pharmaceutical formulations and counterfeit cosmetic products.</u></h3> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>screening</i></b> <b style='color:DodgerBlue;'><i>method</i></b> <b style='color:DodgerBlue;'><i>based</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>liquid</i></b> <b style='color:DodgerBlue;'><i>chromatography-electrospray</i></b> <b style='color:DodgerBlue;'><i>mass</i></b> <b style='color:DodgerBlue;'><i>spectrometry</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>simultaneous</i></b> <b style='color:DodgerBlue;'><i>determination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>six</i></b> <b style='color:DodgerBlue;'><i>corticosteroids</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>betamethasone</i></b> <b style='color:DodgerBlue;'><i>17-valerate</i></b> <b style='color:DodgerBlue;'><i>BM</i></b> <b style='color:DodgerBlue;'><i>17-V</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>beclomethasone</i></b> <b style='color:DodgerBlue;'><i>BC</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>beclomethasone</i></b> <b style='color:DodgerBlue;'><i>dipropionate</i></b> <b style='color:DodgerBlue;'><i>BCDP</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>methylprednisolone</i></b> <b style='color:DodgerBlue;'><i>MP</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>budesonide</i></b> <b style='color:DodgerBlue;'><i>BD</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>flunisolide</i></b> <b style='color:DodgerBlue;'><i>FN</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>developed</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>order</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>control</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>illegal</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>cosmetic</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>natural</i></b> <b style='color:DodgerBlue;'><i>products</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Indeed, despite corticosteroids are banned in cosmetics, counterfeit products might be present on the market, representing a health hazard. Therefore, effective analytical methods are required to rapidly screen over the counter products in health care shops for counterfeit corticosteroids. The analytical method involves the employment of a Waters Synergy C18 column (150mm\u00d72.0mm I.D.) by using the following mobile phase: A (0.1% formic acid in acetonitrile), B (0.1% formic acid in water) in a linear gradient (from A-B 25:75, v/v to A-B 95:5, v/v in 30min) at the flow rate of 0.3mL/min. The detection was performed with an ion trap (IT) mass spectrometer in positive polarity, total ion current (TIC) and tandem mass modalities for qualitative purpose; single ion monitoring (SIM) mode was used for quantitative analysis on the ESI generated most abundant ion for each steroid. The method was fully validated in terms of precision, detection and quantification limits, linearity, recovery, and it was applied to the identification and quantification of corticosteroids in pharmaceutical formulations and cosmetic products. The mean recovery of BM 17-V, BC, BCDP, MP, BD and FN were found to be 101.3, 101.5, 98.8, 98.9, 98.1, 99.0%, respectively. Limits of quantitation (LOQ) were comprised in the range 29-95ng/mL. To the best of our knowledge, for the first time this mix of glucocorticoids were simultaneously determined in cosmetic products by using a fully validated method. BMV, in its two isomeric forms BM 17-V and BM 21-V, was found to be illegally present in one cream sample (A) with the total concentration level of 0.036% (w/w). ","tokens":[{"text":"A","start":0,"end":1,"id":0,"ws":true},{"text":"screening","start":2,"end":11,"id":1,"ws":true},{"text":"method","start":12,"end":18,"id":2,"ws":true},{"text":"based","start":19,"end":24,"id":3,"ws":true},{"text":"on","start":25,"end":27,"id":4,"ws":true},{"text":"liquid","start":28,"end":34,"id":5,"ws":true},{"text":"chromatography-electrospray","start":35,"end":62,"id":6,"ws":true},{"text":"mass","start":63,"end":67,"id":7,"ws":true},{"text":"spectrometry","start":68,"end":80,"id":8,"ws":true},{"text":"for","start":81,"end":84,"id":9,"ws":true},{"text":"the","start":85,"end":88,"id":10,"ws":true},{"text":"simultaneous","start":89,"end":101,"id":11,"ws":true},{"text":"determination","start":102,"end":115,"id":12,"ws":true},{"text":"of","start":116,"end":118,"id":13,"ws":true},{"text":"six","start":119,"end":122,"id":14,"ws":true},{"text":"corticosteroids","start":123,"end":138,"id":15,"ws":true},{"text":"(","start":139,"end":140,"id":16,"ws":true},{"text":"betamethasone","start":141,"end":154,"id":17,"ws":true},{"text":"17-valerate","start":155,"end":166,"id":18,"ws":true},{"text":"BM","start":167,"end":169,"id":19,"ws":true},{"text":"17-V","start":170,"end":174,"id":20,"ws":true},{"text":",","start":175,"end":176,"id":21,"ws":true},{"text":"beclomethasone","start":177,"end":191,"id":22,"ws":true},{"text":"BC","start":192,"end":194,"id":23,"ws":true},{"text":",","start":195,"end":196,"id":24,"ws":true},{"text":"beclomethasone","start":197,"end":211,"id":25,"ws":true},{"text":"dipropionate","start":212,"end":224,"id":26,"ws":true},{"text":"BCDP","start":225,"end":229,"id":27,"ws":true},{"text":",","start":230,"end":231,"id":28,"ws":true},{"text":"methylprednisolone","start":232,"end":250,"id":29,"ws":true},{"text":"MP","start":251,"end":253,"id":30,"ws":true},{"text":",","start":254,"end":255,"id":31,"ws":true},{"text":"budesonide","start":256,"end":266,"id":32,"ws":true},{"text":"BD","start":267,"end":269,"id":33,"ws":true},{"text":",","start":270,"end":271,"id":34,"ws":true},{"text":"flunisolide","start":272,"end":283,"id":35,"ws":true},{"text":"FN","start":284,"end":286,"id":36,"ws":true},{"text":")","start":287,"end":288,"id":37,"ws":true},{"text":"was","start":289,"end":292,"id":38,"ws":true},{"text":"developed","start":293,"end":302,"id":39,"ws":true},{"text":"in","start":303,"end":305,"id":40,"ws":true},{"text":"order","start":306,"end":311,"id":41,"ws":true},{"text":"to","start":312,"end":314,"id":42,"ws":true},{"text":"control","start":315,"end":322,"id":43,"ws":true},{"text":"their","start":323,"end":328,"id":44,"ws":true},{"text":"illegal","start":329,"end":336,"id":45,"ws":true},{"text":"use","start":337,"end":340,"id":46,"ws":true},{"text":"in","start":341,"end":343,"id":47,"ws":true},{"text":"cosmetic","start":344,"end":352,"id":48,"ws":true},{"text":"and","start":353,"end":356,"id":49,"ws":true},{"text":"natural","start":357,"end":364,"id":50,"ws":true},{"text":"products","start":365,"end":373,"id":51,"ws":true},{"text":".","start":374,"end":375,"id":52,"ws":false}],"spans":[{"start":141,"end":154,"token_start":17,"token_end":17,"label":"DRUG"},{"start":177,"end":191,"token_start":22,"token_end":22,"label":"DRUG"},{"start":197,"end":211,"token_start":25,"token_end":25,"label":"DRUG"},{"start":232,"end":250,"token_start":29,"token_end":29,"label":"DRUG"},{"start":256,"end":266,"token_start":32,"token_end":32,"label":"DRUG"}],"_input_hash":782553464,"_task_hash":-1744775723,"_session_id":"drug_drug_pilot_shared-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"We used MCF-7 and MDA-MB231 breast cancer cells incubated with Curcumin and Quercetin for 24h , in the absence and presence of Somatostatin , at their EC50 concentrations , to evaluate membrane fatty acid-based functional lipidomics together with the follow-up of EGFR and MAPK signaling pathways .","paragraph":"<h3><u>Effects of Somatostatin, Curcumin and Quercetin on the fatty acid profile of breast cancer cell membranes.</u></h3> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>MCF-7</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>MDA-MB231</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>incubated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>Curcumin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Quercetin</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>24h</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>absence</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>presence</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>Somatostatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>EC50</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>membrane</i></b> <b style='color:DodgerBlue;'><i>fatty</i></b> <b style='color:DodgerBlue;'><i>acid-based</i></b> <b style='color:DodgerBlue;'><i>functional</i></b> <b style='color:DodgerBlue;'><i>lipidomics</i></b> <b style='color:DodgerBlue;'><i>together</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>follow-up</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>EGFR</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>MAPK</i></b> <b style='color:DodgerBlue;'><i>signaling</i></b> <b style='color:DodgerBlue;'><i>pathways</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The two cell lines gave different membrane free fatty acid reorganization: in MCF-7 cells, the following changes observed: increase of omega-6 linoleic acid in the cells incubated with <b style='color:Tomato;'><i>somatostatin</i></b>+Quercetin and Quercetin and decrease of omega-3 acids in the cells incubated with <b style='color:Tomato;'><i>somatostatin</i></b>+<b style='color:Tomato;'><i>curcumin</i></b> compared to <b style='color:Tomato;'><i>somatostatin</i></b>, and significant increases of monounsaturated fatty acid (MUFA), mono-trans arachidonic acid levels and docosapentaenoic acid for the cells incubated with <b style='color:Tomato;'><i>somatostatin</i></b>+Quercetin compared to the control cells. In MDA-MB231 cells, incubations with <b style='color:Tomato;'><i>curcumin</i></b>, Quercetin and <b style='color:Tomato;'><i>somatostatin</i></b>+Quercetin induced the most significant membrane remodeling with the increase of stearic acid, diminution of omega-6 linoleic, arachidonic acids and omega-3 (docosapentaenoic and docosahexaenoic acids). Distinct signaling pathway changes were found for these cell lines. In MCF-7 cells, separate or combined incubations with <b style='color:Tomato;'><i>somatostatin</i></b> and Quercetin, significantly decreased EGFR and incubation with <b style='color:Tomato;'><i>curcumin</i></b> decreased MAPK signaling. In MDA-MB231 cells, incubation with <b style='color:Tomato;'><i>curcumin</i></b> decreased AKT1 and p-AKT1(Thr308) levels. Incubation with <b style='color:Tomato;'><i>curcumin</i></b> and Quercetin decreased the EGFR levels.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"used","start":3,"end":7,"id":1,"ws":true},{"text":"MCF-7","start":8,"end":13,"id":2,"ws":true},{"text":"and","start":14,"end":17,"id":3,"ws":true},{"text":"MDA-MB231","start":18,"end":27,"id":4,"ws":true},{"text":"breast","start":28,"end":34,"id":5,"ws":true},{"text":"cancer","start":35,"end":41,"id":6,"ws":true},{"text":"cells","start":42,"end":47,"id":7,"ws":true},{"text":"incubated","start":48,"end":57,"id":8,"ws":true},{"text":"with","start":58,"end":62,"id":9,"ws":true},{"text":"Curcumin","start":63,"end":71,"id":10,"ws":true},{"text":"and","start":72,"end":75,"id":11,"ws":true},{"text":"Quercetin","start":76,"end":85,"id":12,"ws":true},{"text":"for","start":86,"end":89,"id":13,"ws":true},{"text":"24h","start":90,"end":93,"id":14,"ws":true},{"text":",","start":94,"end":95,"id":15,"ws":true},{"text":"in","start":96,"end":98,"id":16,"ws":true},{"text":"the","start":99,"end":102,"id":17,"ws":true},{"text":"absence","start":103,"end":110,"id":18,"ws":true},{"text":"and","start":111,"end":114,"id":19,"ws":true},{"text":"presence","start":115,"end":123,"id":20,"ws":true},{"text":"of","start":124,"end":126,"id":21,"ws":true},{"text":"Somatostatin","start":127,"end":139,"id":22,"ws":true},{"text":",","start":140,"end":141,"id":23,"ws":true},{"text":"at","start":142,"end":144,"id":24,"ws":true},{"text":"their","start":145,"end":150,"id":25,"ws":true},{"text":"EC50","start":151,"end":155,"id":26,"ws":true},{"text":"concentrations","start":156,"end":170,"id":27,"ws":true},{"text":",","start":171,"end":172,"id":28,"ws":true},{"text":"to","start":173,"end":175,"id":29,"ws":true},{"text":"evaluate","start":176,"end":184,"id":30,"ws":true},{"text":"membrane","start":185,"end":193,"id":31,"ws":true},{"text":"fatty","start":194,"end":199,"id":32,"ws":true},{"text":"acid-based","start":200,"end":210,"id":33,"ws":true},{"text":"functional","start":211,"end":221,"id":34,"ws":true},{"text":"lipidomics","start":222,"end":232,"id":35,"ws":true},{"text":"together","start":233,"end":241,"id":36,"ws":true},{"text":"with","start":242,"end":246,"id":37,"ws":true},{"text":"the","start":247,"end":250,"id":38,"ws":true},{"text":"follow-up","start":251,"end":260,"id":39,"ws":true},{"text":"of","start":261,"end":263,"id":40,"ws":true},{"text":"EGFR","start":264,"end":268,"id":41,"ws":true},{"text":"and","start":269,"end":272,"id":42,"ws":true},{"text":"MAPK","start":273,"end":277,"id":43,"ws":true},{"text":"signaling","start":278,"end":287,"id":44,"ws":true},{"text":"pathways","start":288,"end":296,"id":45,"ws":true},{"text":".","start":297,"end":298,"id":46,"ws":false}],"spans":[{"start":63,"end":71,"token_start":10,"token_end":10,"label":"DRUG"},{"start":127,"end":139,"token_start":22,"token_end":22,"label":"DRUG"}],"_input_hash":-1803484576,"_task_hash":288010961,"_session_id":"drug_drug_pilot_shared-maytal","_view_id":"blocks","relations":[{"head":22,"child":12,"head_span":{"start":127,"end":139,"token_start":22,"token_end":22,"label":"DRUG"},"child_span":{"start":76,"end":85,"token_start":12,"token_end":12,"label":null},"color":"#ffd1b2","label":"COMB2"},{"head":22,"child":10,"head_span":{"start":127,"end":139,"token_start":22,"token_end":22,"label":"DRUG"},"child_span":{"start":63,"end":71,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":10,"child":12,"head_span":{"start":63,"end":71,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":76,"end":85,"token_start":12,"token_end":12,"label":null},"color":"#c5bdf4","label":"COMB3"}],"radio":["COMB1T0","COMB2T0","COMB3T0"],"answer":"accept"}
{"text":"Following corneal scrapings and culture , topical 0.5 % moxifloxacin and 0.5 % tobramycin were administered hourly .","paragraph":"<h3><u>A case of Stenotrophomonas maltophilia keratitis effectively treated with moxifloxacin.</u></h3>A 70-year-old man with a long history of diabetes mellitus presented to our hospital (Department of Ophthalmology, Sahm Yook Medical Center, Seoul, Korea) complaining of severe ocular pain and visual disturbance in his left eye that had started three days prior to admission. A round 3.7 \u00d7 5.0 mm dense central stromal infiltrate with an overlying epithelial defect was noted on slit-lamp examination. <b style='color:DodgerBlue;'><i>Following</i></b> <b style='color:DodgerBlue;'><i>corneal</i></b> <b style='color:DodgerBlue;'><i>scrapings</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>culture</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>topical</i></b> <b style='color:DodgerBlue;'><i>0.5</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:MediumOrchid;'><i>moxifloxacin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>0.5</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:MediumOrchid;'><i>tobramycin</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>hourly</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A few days later, Stenotrophomonas maltophilia was isolated in a bacterial culture from a corneal specimen. According to the results of susceptibility tests, topical 0.5% <b style='color:Tomato;'><i>moxifloxacin</i></b> was given every hour and 0.5% <b style='color:Tomato;'><i>tobramycin</i></b> was stopped. The patient's clinical features improved steadily with treatment. The corneal epithelium healed rapidly, and the infiltrate resolved within four weeks of the initiation of treatment. The patient's best corrected visual acuity improved from hand motion to 20 / 25.","tokens":[{"text":"Following","start":0,"end":9,"id":0,"ws":true},{"text":"corneal","start":10,"end":17,"id":1,"ws":true},{"text":"scrapings","start":18,"end":27,"id":2,"ws":true},{"text":"and","start":28,"end":31,"id":3,"ws":true},{"text":"culture","start":32,"end":39,"id":4,"ws":true},{"text":",","start":40,"end":41,"id":5,"ws":true},{"text":"topical","start":42,"end":49,"id":6,"ws":true},{"text":"0.5","start":50,"end":53,"id":7,"ws":true},{"text":"%","start":54,"end":55,"id":8,"ws":true},{"text":"moxifloxacin","start":56,"end":68,"id":9,"ws":true},{"text":"and","start":69,"end":72,"id":10,"ws":true},{"text":"0.5","start":73,"end":76,"id":11,"ws":true},{"text":"%","start":77,"end":78,"id":12,"ws":true},{"text":"tobramycin","start":79,"end":89,"id":13,"ws":true},{"text":"were","start":90,"end":94,"id":14,"ws":true},{"text":"administered","start":95,"end":107,"id":15,"ws":true},{"text":"hourly","start":108,"end":114,"id":16,"ws":true},{"text":".","start":115,"end":116,"id":17,"ws":false}],"spans":[{"start":56,"end":68,"token_start":9,"token_end":9,"label":"DRUG"},{"start":79,"end":89,"token_start":13,"token_end":13,"label":"DRUG"}],"_input_hash":1332991430,"_task_hash":1426603318,"_session_id":"drug_drug_pilot_shared-maytal","_view_id":"blocks","relations":[{"head":9,"child":13,"head_span":{"start":56,"end":68,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":79,"end":89,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T1"],"answer":"accept"}
{"text":"Combination treatment with cetuximab and nystatin selectively increased cetuximab uptake by tumor tissues , translating into potentiated antitumor efficacy of cetuximab in vivo ( A431 and A549 tumors ) .","paragraph":"<h3><u>Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration.</u></h3><b style='color:Tomato;'><i>cetuximab</i></b>, a monoclonal antibody (mAb) targeting the epidermal growth factor receptor (EGFR), has been intensively investigated as a promising cancer treatment strategy. The specific mechanism of <b style='color:Tomato;'><i>cetuximab</i></b> endocytosis and its influence on <b style='color:Tomato;'><i>cetuximab</i></b> uptake, biodistribution and efficacy still remain elusive. Recently, statins have been reported to synergize with EGFR-targeting agents. Our prior work established that <b style='color:Tomato;'><i>nystatin</i></b>, a cholesterol-sequestering antifungal drug, facilitates endocytosis via the clathrin-dependent pathway. This study aimed to investigate whether <b style='color:Tomato;'><i>nystatin</i></b> regulates the uptake and efficacy of <b style='color:Tomato;'><i>cetuximab</i></b> and <b style='color:Tomato;'><i>cetuximab</i></b>-based antibody-drug conjugates (<b style='color:Tomato;'><i>cetuximab</i></b>-ADCs). In vitro and in vivo efficacies of <b style='color:Tomato;'><i>nystatin</i></b> on the uptake and activity of <b style='color:Tomato;'><i>cetuximab</i></b>/<b style='color:Tomato;'><i>cetuximab</i></b>-ADCs were studied in multiple human carcinoma cell lines and xenograft models, respectively. We identified that cholesterol sequestration by <b style='color:Tomato;'><i>nystatin</i></b> enhanced <b style='color:Tomato;'><i>cetuximab</i></b> internalization in EGFR-positive carcinoma cells by regulating EGFR trafficking/turnover and facilitating a switch from lipid rafts to clathrin-mediated endocytosis. <b style='color:DodgerBlue;'><i>Combination</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>nystatin</i></b> <b style='color:DodgerBlue;'><i>selectively</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>uptake</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>tumor</i></b> <b style='color:DodgerBlue;'><i>tissues</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>translating</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>potentiated</i></b> <b style='color:DodgerBlue;'><i>antitumor</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vivo</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>A431</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>A549</i></b> <b style='color:DodgerBlue;'><i>tumors</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>nystatin</i></b>-enhanced internalization of <b style='color:Tomato;'><i>cetuximab</i></b> further improved the uptake and potency of <b style='color:Tomato;'><i>cetuximab</i></b>-<b style='color:Tomato;'><i>doxorubicin</i></b> and <b style='color:Tomato;'><i>cetuximab</i></b>-<b style='color:Tomato;'><i>methotrexate</i></b> conjugates in EGFR-positive <b style='color:Tomato;'><i>cetuximab</i></b>-resistant tumors. Combination therapy with <b style='color:Tomato;'><i>nystatin</i></b> plus either <b style='color:Tomato;'><i>cetuximab</i></b> or <b style='color:Tomato;'><i>cetuximab</i></b>-ADC further prolonged animal survival and significantly suppressed tumor growth, as compared with single-agent <b style='color:Tomato;'><i>cetuximab</i></b> or <b style='color:Tomato;'><i>cetuximab</i></b>-ADC. In summary, our results identify a novel mechanism whereby cholesterol sequestration enhances the uptake of EGFR-targeting mAb and ADCs, therefore providing preclinical proof-of-concept that combination with <b style='color:Tomato;'><i>nystatin</i></b> can potentiate the delivery and efficacy of these EGFR-targeted agents. ","tokens":[{"text":"Combination","start":0,"end":11,"id":0,"ws":true},{"text":"treatment","start":12,"end":21,"id":1,"ws":true},{"text":"with","start":22,"end":26,"id":2,"ws":true},{"text":"cetuximab","start":27,"end":36,"id":3,"ws":true},{"text":"and","start":37,"end":40,"id":4,"ws":true},{"text":"nystatin","start":41,"end":49,"id":5,"ws":true},{"text":"selectively","start":50,"end":61,"id":6,"ws":true},{"text":"increased","start":62,"end":71,"id":7,"ws":true},{"text":"cetuximab","start":72,"end":81,"id":8,"ws":true},{"text":"uptake","start":82,"end":88,"id":9,"ws":true},{"text":"by","start":89,"end":91,"id":10,"ws":true},{"text":"tumor","start":92,"end":97,"id":11,"ws":true},{"text":"tissues","start":98,"end":105,"id":12,"ws":true},{"text":",","start":106,"end":107,"id":13,"ws":true},{"text":"translating","start":108,"end":119,"id":14,"ws":true},{"text":"into","start":120,"end":124,"id":15,"ws":true},{"text":"potentiated","start":125,"end":136,"id":16,"ws":true},{"text":"antitumor","start":137,"end":146,"id":17,"ws":true},{"text":"efficacy","start":147,"end":155,"id":18,"ws":true},{"text":"of","start":156,"end":158,"id":19,"ws":true},{"text":"cetuximab","start":159,"end":168,"id":20,"ws":true},{"text":"in","start":169,"end":171,"id":21,"ws":true},{"text":"vivo","start":172,"end":176,"id":22,"ws":true},{"text":"(","start":177,"end":178,"id":23,"ws":true},{"text":"A431","start":179,"end":183,"id":24,"ws":true},{"text":"and","start":184,"end":187,"id":25,"ws":true},{"text":"A549","start":188,"end":192,"id":26,"ws":true},{"text":"tumors","start":193,"end":199,"id":27,"ws":true},{"text":")","start":200,"end":201,"id":28,"ws":true},{"text":".","start":202,"end":203,"id":29,"ws":false}],"spans":[{"start":27,"end":36,"token_start":3,"token_end":3,"label":"DRUG"},{"start":41,"end":49,"token_start":5,"token_end":5,"label":"DRUG"},{"start":72,"end":81,"token_start":8,"token_end":8,"label":"DRUG"},{"start":159,"end":168,"token_start":20,"token_end":20,"label":"DRUG"}],"_input_hash":-1277491604,"_task_hash":-1965461189,"_session_id":"drug_drug_pilot_shared-maytal","_view_id":"blocks","relations":[{"head":3,"child":5,"head_span":{"start":27,"end":36,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":41,"end":49,"token_start":5,"token_end":5,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":8,"child":5,"head_span":{"start":72,"end":81,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":41,"end":49,"token_start":5,"token_end":5,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T0"],"answer":"accept"}
{"text":"The effects of combination therapy with chenodeoxycholic acid ( CDCA ) and simvastatin on serum cholestanol , low-density lipoprotein ( LDL ) cholesterol , and lathosterol levels were investigated in seven adult patients with cerebrotendinous xanthomatosis ( CTX ) who were on long-term treatment with CDCA .","paragraph":"<h3><u>Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>chenodeoxycholic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CDCA</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>simvastatin</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>serum</i></b> <b style='color:DodgerBlue;'><i>cholestanol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>low-density</i></b> <b style='color:DodgerBlue;'><i>lipoprotein</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>LDL</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>cholesterol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>lathosterol</i></b> <b style='color:DodgerBlue;'><i>levels</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>investigated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>seven</i></b> <b style='color:DodgerBlue;'><i>adult</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>cerebrotendinous</i></b> <b style='color:DodgerBlue;'><i>xanthomatosis</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CTX</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>long-term</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>CDCA</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The patients were treated with a combination of CDCA 750 mg daily and an increasing dose of <b style='color:Tomato;'><i>simvastatin</i></b> from 10 mg to 40 mg daily for a period of 6 months. We found a significant effect of this combination therapy compared with CDCA alone in terms of decreasing the serum cholestanol and LDL cholesterol levels, particularly with a daily dose of 40 mg <b style='color:Tomato;'><i>simvastatin</i></b>. The mean cholestanol level decreased from 9.27 micromol/L (baseline) to 6.69 micromol/L (40 mg <b style='color:Tomato;'><i>simvastatin</i></b>), while the mean LDL cholesterol level decreased from 5.08 mmol/L (baseline) to 3.04 mmol/L (40 mg <b style='color:Tomato;'><i>simvastatin</i></b>). No side effects were reported, and there were no effects on the clinical condition, cerebral magnetic resonance imaging (MRI), visual evoked potentials, and electroencephalographic features. We conclude that a combination of 750 mg CDCA and 40 mg <b style='color:Tomato;'><i>simvastatin</i></b> daily is effective to further reduce serum cholestanol, LDL cholesterol, and lathosterol in adult CTX patients treated with long-term CDCA. Whether this combination treatment will be effective for the long-term prevention of neurological deterioration and atherosclerosis remains to be established.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"effects","start":4,"end":11,"id":1,"ws":true},{"text":"of","start":12,"end":14,"id":2,"ws":true},{"text":"combination","start":15,"end":26,"id":3,"ws":true},{"text":"therapy","start":27,"end":34,"id":4,"ws":true},{"text":"with","start":35,"end":39,"id":5,"ws":true},{"text":"chenodeoxycholic","start":40,"end":56,"id":6,"ws":true},{"text":"acid","start":57,"end":61,"id":7,"ws":true},{"text":"(","start":62,"end":63,"id":8,"ws":true},{"text":"CDCA","start":64,"end":68,"id":9,"ws":true},{"text":")","start":69,"end":70,"id":10,"ws":true},{"text":"and","start":71,"end":74,"id":11,"ws":true},{"text":"simvastatin","start":75,"end":86,"id":12,"ws":true},{"text":"on","start":87,"end":89,"id":13,"ws":true},{"text":"serum","start":90,"end":95,"id":14,"ws":true},{"text":"cholestanol","start":96,"end":107,"id":15,"ws":true},{"text":",","start":108,"end":109,"id":16,"ws":true},{"text":"low-density","start":110,"end":121,"id":17,"ws":true},{"text":"lipoprotein","start":122,"end":133,"id":18,"ws":true},{"text":"(","start":134,"end":135,"id":19,"ws":true},{"text":"LDL","start":136,"end":139,"id":20,"ws":true},{"text":")","start":140,"end":141,"id":21,"ws":true},{"text":"cholesterol","start":142,"end":153,"id":22,"ws":true},{"text":",","start":154,"end":155,"id":23,"ws":true},{"text":"and","start":156,"end":159,"id":24,"ws":true},{"text":"lathosterol","start":160,"end":171,"id":25,"ws":true},{"text":"levels","start":172,"end":178,"id":26,"ws":true},{"text":"were","start":179,"end":183,"id":27,"ws":true},{"text":"investigated","start":184,"end":196,"id":28,"ws":true},{"text":"in","start":197,"end":199,"id":29,"ws":true},{"text":"seven","start":200,"end":205,"id":30,"ws":true},{"text":"adult","start":206,"end":211,"id":31,"ws":true},{"text":"patients","start":212,"end":220,"id":32,"ws":true},{"text":"with","start":221,"end":225,"id":33,"ws":true},{"text":"cerebrotendinous","start":226,"end":242,"id":34,"ws":true},{"text":"xanthomatosis","start":243,"end":256,"id":35,"ws":true},{"text":"(","start":257,"end":258,"id":36,"ws":true},{"text":"CTX","start":259,"end":262,"id":37,"ws":true},{"text":")","start":263,"end":264,"id":38,"ws":true},{"text":"who","start":265,"end":268,"id":39,"ws":true},{"text":"were","start":269,"end":273,"id":40,"ws":true},{"text":"on","start":274,"end":276,"id":41,"ws":true},{"text":"long-term","start":277,"end":286,"id":42,"ws":true},{"text":"treatment","start":287,"end":296,"id":43,"ws":true},{"text":"with","start":297,"end":301,"id":44,"ws":true},{"text":"CDCA","start":302,"end":306,"id":45,"ws":true},{"text":".","start":307,"end":308,"id":46,"ws":false}],"spans":[{"start":40,"end":56,"token_start":6,"token_end":6,"label":"DRUG"},{"start":75,"end":86,"token_start":12,"token_end":12,"label":"DRUG"}],"_input_hash":-475065306,"_task_hash":-2052397739,"_session_id":"drug_drug_pilot_shared-maytal","_view_id":"blocks","relations":[{"head":6,"child":12,"head_span":{"start":40,"end":56,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":75,"end":86,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T1"],"answer":"accept"}
{"text":"Paclitaxel ( Taxol ; Bristol-Myers Squibb Company , Princeton , NJ ) has been demonstrated to be highly effective in treating patients with advanced breast cancer , including those with anthracycline-resistant breast cancer , a fact that has led to efforts to combine paclitaxel and anthracyclines .","paragraph":"<h3><u>Paclitaxel and doxorubicin in metastatic breast cancer.</u></h3>For the past decades the anthracyclines have been regarded as among the most active drugs for the treatment of metastatic breast cancer. However, the 5-year survival rate in patients with stage IV breast cancer continues to be below 20%, and new active drugs and drug combinations clearly must be explored. <b style='color:MediumOrchid;'><i>Paclitaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Taxol</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>Bristol-Myers</i></b> <b style='color:DodgerBlue;'><i>Squibb</i></b> <b style='color:DodgerBlue;'><i>Company</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Princeton</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>NJ</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>highly</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>treating</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>anthracycline-resistant</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>fact</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>led</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>efforts</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>combine</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>anthracyclines</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Several studies aiming to define the optimal dose and schedule of combination <b style='color:Tomato;'><i>paclitaxel</i></b>/<b style='color:Tomato;'><i>doxorubicin</i></b> have now been completed or are ongoing. Phase I/II studies have yielded encouraging preliminary response rates but quite variable toxicity profiles depending on the schedule used. These clinical trials involving combination <b style='color:Tomato;'><i>paclitaxel</i></b>/<b style='color:Tomato;'><i>doxorubicin</i></b> are reviewed, with special emphasis on the short-infusion trials.","tokens":[{"text":"Paclitaxel","start":0,"end":10,"id":0,"ws":true},{"text":"(","start":11,"end":12,"id":1,"ws":true},{"text":"Taxol","start":13,"end":18,"id":2,"ws":true},{"text":";","start":19,"end":20,"id":3,"ws":true},{"text":"Bristol-Myers","start":21,"end":34,"id":4,"ws":true},{"text":"Squibb","start":35,"end":41,"id":5,"ws":true},{"text":"Company","start":42,"end":49,"id":6,"ws":true},{"text":",","start":50,"end":51,"id":7,"ws":true},{"text":"Princeton","start":52,"end":61,"id":8,"ws":true},{"text":",","start":62,"end":63,"id":9,"ws":true},{"text":"NJ","start":64,"end":66,"id":10,"ws":true},{"text":")","start":67,"end":68,"id":11,"ws":true},{"text":"has","start":69,"end":72,"id":12,"ws":true},{"text":"been","start":73,"end":77,"id":13,"ws":true},{"text":"demonstrated","start":78,"end":90,"id":14,"ws":true},{"text":"to","start":91,"end":93,"id":15,"ws":true},{"text":"be","start":94,"end":96,"id":16,"ws":true},{"text":"highly","start":97,"end":103,"id":17,"ws":true},{"text":"effective","start":104,"end":113,"id":18,"ws":true},{"text":"in","start":114,"end":116,"id":19,"ws":true},{"text":"treating","start":117,"end":125,"id":20,"ws":true},{"text":"patients","start":126,"end":134,"id":21,"ws":true},{"text":"with","start":135,"end":139,"id":22,"ws":true},{"text":"advanced","start":140,"end":148,"id":23,"ws":true},{"text":"breast","start":149,"end":155,"id":24,"ws":true},{"text":"cancer","start":156,"end":162,"id":25,"ws":true},{"text":",","start":163,"end":164,"id":26,"ws":true},{"text":"including","start":165,"end":174,"id":27,"ws":true},{"text":"those","start":175,"end":180,"id":28,"ws":true},{"text":"with","start":181,"end":185,"id":29,"ws":true},{"text":"anthracycline-resistant","start":186,"end":209,"id":30,"ws":true},{"text":"breast","start":210,"end":216,"id":31,"ws":true},{"text":"cancer","start":217,"end":223,"id":32,"ws":true},{"text":",","start":224,"end":225,"id":33,"ws":true},{"text":"a","start":226,"end":227,"id":34,"ws":true},{"text":"fact","start":228,"end":232,"id":35,"ws":true},{"text":"that","start":233,"end":237,"id":36,"ws":true},{"text":"has","start":238,"end":241,"id":37,"ws":true},{"text":"led","start":242,"end":245,"id":38,"ws":true},{"text":"to","start":246,"end":248,"id":39,"ws":true},{"text":"efforts","start":249,"end":256,"id":40,"ws":true},{"text":"to","start":257,"end":259,"id":41,"ws":true},{"text":"combine","start":260,"end":267,"id":42,"ws":true},{"text":"paclitaxel","start":268,"end":278,"id":43,"ws":true},{"text":"and","start":279,"end":282,"id":44,"ws":true},{"text":"anthracyclines","start":283,"end":297,"id":45,"ws":true},{"text":".","start":298,"end":299,"id":46,"ws":false}],"spans":[{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},{"start":268,"end":278,"token_start":43,"token_end":43,"label":"DRUG"}],"_input_hash":702583470,"_task_hash":1770101995,"_session_id":"drug_drug_pilot_shared-maytal","_view_id":"blocks","relations":[{"head":43,"child":45,"head_span":{"start":268,"end":278,"token_start":43,"token_end":43,"label":"DRUG"},"child_span":{"start":283,"end":297,"token_start":45,"token_end":45,"label":null},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"However , anastrozole , exemestane and letrozole are associated with significantly fewer endometrial cancers , as well as venous and arterial vascular events , when compared with tamoxifen [ 9 , 10 ] .","paragraph":"<h3><u>Erythema nodosum secondary to aromatase inhibitor use in breast cancer patients: case reports and review of the literature.</u></h3>Aromatase inhibitors (AI's) are increasingly being incorporated in the treatment strategy for hormone receptor positive breast cancer either alone or in combination with chemotherapy, biologics in both the adjuvant and metastatic setting [1]. They markedly suppress plasma estrogen levels by inhibiting or inactivating aromatase, the enzyme responsible for the synthesis of estrogens from androgenic substrates [1]. Currently, the three selective aromatase inhibitors that are available are <b style='color:Tomato;'><i>anastrozole</i></b>, <b style='color:Tomato;'><i>letrozole</i></b> and <b style='color:Tomato;'><i>exemestane</i></b> which reduce circulating estrogen to 1 to 10% of pretreatment levels [2]. For advanced breast cancer, aromatase inhibitors appear to be at a minimum, equivalent and perhaps even better than <b style='color:Tomato;'><i>tamoxifen</i></b> in the first line setting [3, 4]. In primary breast cancer, adjuvant therapy with <b style='color:Tomato;'><i>anastrozole</i></b> or <b style='color:Tomato;'><i>letrozole</i></b> appears to be superior to <b style='color:Tomato;'><i>tamoxifen</i></b> in reducing the risk of relapse [5, 6]. Common adverse effects associated with AI's include arthralgias (21%), myalgias (12%), other musculoskeletal disorders (28%) and an up to 60% increased risk of bone fracture [7, 8]. <b style='color:DodgerBlue;'><i>However</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>anastrozole</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>exemestane</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>letrozole</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>fewer</i></b> <b style='color:DodgerBlue;'><i>endometrial</i></b> <b style='color:DodgerBlue;'><i>cancers</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>venous</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>arterial</i></b> <b style='color:DodgerBlue;'><i>vascular</i></b> <b style='color:DodgerBlue;'><i>events</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>9</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Very rarely <b style='color:Tomato;'><i>letrozole</i></b> and <b style='color:Tomato;'><i>anastrozole</i></b> can cause a skin rash; the frequency of its occurrence has not been quantified(. )However, <b style='color:Tomato;'><i>exemestane</i></b> has not been reported to cause a skin rash [11]. To date, erythema nodosum (EN) has not been reported as a dermatologic side effect of AI's. Here, we report three cases of EN which developed in postmenopausal breast cancer patients on AI's.","tokens":[{"text":"However","start":0,"end":7,"id":0,"ws":true},{"text":",","start":8,"end":9,"id":1,"ws":true},{"text":"anastrozole","start":10,"end":21,"id":2,"ws":true},{"text":",","start":22,"end":23,"id":3,"ws":true},{"text":"exemestane","start":24,"end":34,"id":4,"ws":true},{"text":"and","start":35,"end":38,"id":5,"ws":true},{"text":"letrozole","start":39,"end":48,"id":6,"ws":true},{"text":"are","start":49,"end":52,"id":7,"ws":true},{"text":"associated","start":53,"end":63,"id":8,"ws":true},{"text":"with","start":64,"end":68,"id":9,"ws":true},{"text":"significantly","start":69,"end":82,"id":10,"ws":true},{"text":"fewer","start":83,"end":88,"id":11,"ws":true},{"text":"endometrial","start":89,"end":100,"id":12,"ws":true},{"text":"cancers","start":101,"end":108,"id":13,"ws":true},{"text":",","start":109,"end":110,"id":14,"ws":true},{"text":"as","start":111,"end":113,"id":15,"ws":true},{"text":"well","start":114,"end":118,"id":16,"ws":true},{"text":"as","start":119,"end":121,"id":17,"ws":true},{"text":"venous","start":122,"end":128,"id":18,"ws":true},{"text":"and","start":129,"end":132,"id":19,"ws":true},{"text":"arterial","start":133,"end":141,"id":20,"ws":true},{"text":"vascular","start":142,"end":150,"id":21,"ws":true},{"text":"events","start":151,"end":157,"id":22,"ws":true},{"text":",","start":158,"end":159,"id":23,"ws":true},{"text":"when","start":160,"end":164,"id":24,"ws":true},{"text":"compared","start":165,"end":173,"id":25,"ws":true},{"text":"with","start":174,"end":178,"id":26,"ws":true},{"text":"tamoxifen","start":179,"end":188,"id":27,"ws":true},{"text":"[","start":189,"end":190,"id":28,"ws":true},{"text":"9","start":191,"end":192,"id":29,"ws":true},{"text":",","start":193,"end":194,"id":30,"ws":true},{"text":"10","start":195,"end":197,"id":31,"ws":true},{"text":"]","start":198,"end":199,"id":32,"ws":true},{"text":".","start":200,"end":201,"id":33,"ws":false}],"spans":[{"start":10,"end":21,"token_start":2,"token_end":2,"label":"DRUG"},{"start":24,"end":34,"token_start":4,"token_end":4,"label":"DRUG"},{"start":39,"end":48,"token_start":6,"token_end":6,"label":"DRUG"},{"start":179,"end":188,"token_start":27,"token_end":27,"label":"DRUG"}],"_input_hash":155070717,"_task_hash":-411756935,"_session_id":"drug_drug_pilot_shared-yakir","_view_id":"blocks","relations":[],"answer":"ignore"}
{"text":"Additivity , synergy , or competition was observed with MIS and rapamycin , AzadC , doxorubicin , cisplatin , and paclitaxel , suggesting that MIS in combination with selective targeted therapies might achieve greater activity against ovarian cancer than the use of each individual agent alone .","paragraph":"<h3><u>Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.</u></h3>Mullerian Inhibiting Substance (MIS), a biological modifier that causes regression of Mullerian ducts in male embryos, is effective as a single agent in vitro and in vivo against human and mouse ovarian cancer cell lines expressing MIS type II receptor; however, little is known about how recombinant human MIS (rhMIS), now being scaled for preclinical trials, could be used in combination with cytotoxic or targeted chemotherapeutic agents. Mouse serous and endometrioid ovarian carcinoma cell lines were tested in vitro against rhMIS alone and with <b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>paclitaxel</i></b>, or cisplatin as agents in clinical use. Because MIS releases FK506 binding protein (FKBP12), which activates the mammalian target of <b style='color:Tomato;'><i>rapamycin</i></b> (mTOR) downstream of Akt, rhMIS and <b style='color:Tomato;'><i>rapamycin</i></b> combinations were tested. MIS increases p16 protein levels, and 5'-Aza-2'-deoxycytidine (AzadC) induces p16 mRNA; therefore, they were used in combination in vitro and in vivo with a human ovarian cancer cell line. A <b style='color:Tomato;'><i>paclitaxel</i></b>-resistant human ovarian cancer cell line and its parental line both respond to rhMIS in vitro. <b style='color:DodgerBlue;'><i>Additivity</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>synergy</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>competition</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>observed</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>MIS</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rapamycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>AzadC</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>suggesting</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>MIS</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>selective</i></b> <b style='color:DodgerBlue;'><i>targeted</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>might</i></b> <b style='color:DodgerBlue;'><i>achieve</i></b> <b style='color:DodgerBlue;'><i>greater</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>ovarian</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>each</i></b> <b style='color:DodgerBlue;'><i>individual</i></b> <b style='color:DodgerBlue;'><i>agent</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> These assays and statistical analyses could be useful in selecting rhMIS and chemotherapeutic agent combinations that enhance clinical efficacy and reduce toxicity.","tokens":[{"text":"Additivity","start":0,"end":10,"id":0,"ws":true},{"text":",","start":11,"end":12,"id":1,"ws":true},{"text":"synergy","start":13,"end":20,"id":2,"ws":true},{"text":",","start":21,"end":22,"id":3,"ws":true},{"text":"or","start":23,"end":25,"id":4,"ws":true},{"text":"competition","start":26,"end":37,"id":5,"ws":true},{"text":"was","start":38,"end":41,"id":6,"ws":true},{"text":"observed","start":42,"end":50,"id":7,"ws":true},{"text":"with","start":51,"end":55,"id":8,"ws":true},{"text":"MIS","start":56,"end":59,"id":9,"ws":true},{"text":"and","start":60,"end":63,"id":10,"ws":true},{"text":"rapamycin","start":64,"end":73,"id":11,"ws":true},{"text":",","start":74,"end":75,"id":12,"ws":true},{"text":"AzadC","start":76,"end":81,"id":13,"ws":true},{"text":",","start":82,"end":83,"id":14,"ws":true},{"text":"doxorubicin","start":84,"end":95,"id":15,"ws":true},{"text":",","start":96,"end":97,"id":16,"ws":true},{"text":"cisplatin","start":98,"end":107,"id":17,"ws":true},{"text":",","start":108,"end":109,"id":18,"ws":true},{"text":"and","start":110,"end":113,"id":19,"ws":true},{"text":"paclitaxel","start":114,"end":124,"id":20,"ws":true},{"text":",","start":125,"end":126,"id":21,"ws":true},{"text":"suggesting","start":127,"end":137,"id":22,"ws":true},{"text":"that","start":138,"end":142,"id":23,"ws":true},{"text":"MIS","start":143,"end":146,"id":24,"ws":true},{"text":"in","start":147,"end":149,"id":25,"ws":true},{"text":"combination","start":150,"end":161,"id":26,"ws":true},{"text":"with","start":162,"end":166,"id":27,"ws":true},{"text":"selective","start":167,"end":176,"id":28,"ws":true},{"text":"targeted","start":177,"end":185,"id":29,"ws":true},{"text":"therapies","start":186,"end":195,"id":30,"ws":true},{"text":"might","start":196,"end":201,"id":31,"ws":true},{"text":"achieve","start":202,"end":209,"id":32,"ws":true},{"text":"greater","start":210,"end":217,"id":33,"ws":true},{"text":"activity","start":218,"end":226,"id":34,"ws":true},{"text":"against","start":227,"end":234,"id":35,"ws":true},{"text":"ovarian","start":235,"end":242,"id":36,"ws":true},{"text":"cancer","start":243,"end":249,"id":37,"ws":true},{"text":"than","start":250,"end":254,"id":38,"ws":true},{"text":"the","start":255,"end":258,"id":39,"ws":true},{"text":"use","start":259,"end":262,"id":40,"ws":true},{"text":"of","start":263,"end":265,"id":41,"ws":true},{"text":"each","start":266,"end":270,"id":42,"ws":true},{"text":"individual","start":271,"end":281,"id":43,"ws":true},{"text":"agent","start":282,"end":287,"id":44,"ws":true},{"text":"alone","start":288,"end":293,"id":45,"ws":true},{"text":".","start":294,"end":295,"id":46,"ws":false}],"spans":[{"start":64,"end":73,"token_start":11,"token_end":11,"label":"DRUG"},{"start":84,"end":95,"token_start":15,"token_end":15,"label":"DRUG"},{"start":114,"end":124,"token_start":20,"token_end":20,"label":"DRUG"}],"_input_hash":1387497584,"_task_hash":991977050,"_session_id":"drug_drug_pilot_shared-yakir","_view_id":"blocks","relations":[{"head":9,"child":11,"head_span":{"start":56,"end":59,"token_start":9,"token_end":9,"label":null},"child_span":{"start":64,"end":73,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":9,"child":15,"head_span":{"start":56,"end":59,"token_start":9,"token_end":9,"label":null},"child_span":{"start":84,"end":95,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#ffd882","label":"POS2"},{"head":9,"child":17,"head_span":{"start":56,"end":59,"token_start":9,"token_end":9,"label":null},"child_span":{"start":98,"end":107,"token_start":17,"token_end":17,"label":null},"color":"#d9fbad","label":"POS3"}],"radio":["POS10","POS1T0","POS20","POS2T0","POS30","POS3T0"],"answer":"accept"}
{"text":"There was no cytotoxic effect of cisplatin , ifosfamide , and etoposide .","paragraph":"<h3><u>Overcoming Chemoresistance of Pediatric Ependymoma by Inhibition of STAT3 Signaling.</u></h3>The long-term clinical outcome of pediatric intracranial epepdymoma is poor with a high rate of recurrence. One of the main reasons for this poor outcome is the tumor's inherent resistance to chemotherapy. Signal transducer and activator of transcription 3 (STAT3) is overactive in many human cancers, and inhibition of STAT3 signaling is an emerging area of interest in oncology. In this study, the possibility of STAT3 inhibition as a treatment was investigated in pediatric intracranial ependymoma tissues and cell lines. STAT3 activation status was checked in ependymoma tissues. The responses to conventional chemotherapeutic agents and a STAT3 inhibitor WP1066 in primarily cultured ependymoma cells were measured by cell viability assay. Apoptosis assays were conducted to reveal the cytotoxic mechanism of applied agents. Knockdown of STAT3 was tried to confirm the effects of STAT3 inhibition in ependymoma cells. High levels of phospho-STAT3 (p-STAT3) expression were observed in ependymoma tissue, especially in the anaplastic histology group. <b style='color:DodgerBlue;'><i>There</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>cytotoxic</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Both brain tumor-initiating cells (BTICs) and bulk tumor cells (BCs) showed considerably decreased viability after WP1066 treatment. However, BTICs had fewer responses than BCs. No additive or synergistic effect was observed for combination therapy of WP1066 and cisplatin. WP1066 effectively abrogated p-STAT3 expression. An increased apoptosis and decreased Survivin expression were observed after WP1066 treatment. Knockdown of STAT3 also decreased cell survival, supporting the critical role of STAT3 in sustaining ependymoma cells. In this study, we observed a cytotoxic effect of STAT3 inhibitor on ependymoma BTICs and BCs. There is urgent need to develop new therapeutic agents for pediatric ependymoma. STAT3 inhibitors may be a new group of drugs for clinical application. ","tokens":[{"text":"There","start":0,"end":5,"id":0,"ws":true},{"text":"was","start":6,"end":9,"id":1,"ws":true},{"text":"no","start":10,"end":12,"id":2,"ws":true},{"text":"cytotoxic","start":13,"end":22,"id":3,"ws":true},{"text":"effect","start":23,"end":29,"id":4,"ws":true},{"text":"of","start":30,"end":32,"id":5,"ws":true},{"text":"cisplatin","start":33,"end":42,"id":6,"ws":true},{"text":",","start":43,"end":44,"id":7,"ws":true},{"text":"ifosfamide","start":45,"end":55,"id":8,"ws":true},{"text":",","start":56,"end":57,"id":9,"ws":true},{"text":"and","start":58,"end":61,"id":10,"ws":true},{"text":"etoposide","start":62,"end":71,"id":11,"ws":true},{"text":".","start":72,"end":73,"id":12,"ws":false}],"spans":[{"start":45,"end":55,"token_start":8,"token_end":8,"label":"DRUG"},{"start":62,"end":71,"token_start":11,"token_end":11,"label":"DRUG"}],"_input_hash":-1352726798,"_task_hash":-274527523,"_session_id":"drug_drug_pilot_shared-yakir","_view_id":"blocks","relations":[{"head":6,"child":8,"head_span":{"start":33,"end":42,"token_start":6,"token_end":6,"label":null},"child_span":{"start":45,"end":55,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":6,"child":11,"head_span":{"start":33,"end":42,"token_start":6,"token_end":6,"label":null},"child_span":{"start":62,"end":71,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#ffd882","label":"POS2"}],"radio":["POS10","POS1T0","POS20","POS2T0"],"answer":"accept"}
{"text":"Several first-line phase III trials , as well as ongoing trials for which only preliminary results have been published , have fueled debates on the optimal dose and schedule ; these have focused not only on weekly vs q3-weeks paclitaxel , but also on other modifications and the advisability of adding bevacizumab .","paragraph":"<h3><u>Carboplatin/Paclitaxel Induction in Ovarian Cancer: The Finer Points.</u></h3>The <b style='color:Tomato;'><i>carboplatin</i></b>/<b style='color:Tomato;'><i>paclitaxel</i></b> doublet remains the chemotherapy backbone for the initial treatment of ovarian cancer. This two-drug regimen, with <b style='color:Tomato;'><i>carboplatin</i></b> dosed using the Calvert formula, yielded convincing noninferior outcomes when compared with the prior, more toxic, regimen of cisplatin/<b style='color:Tomato;'><i>paclitaxel</i></b>. <b style='color:Tomato;'><i>carboplatin</i></b>'s dose-limiting toxicity is thrombocytopenia; however, when this drug is properly dosed and combined with <b style='color:Tomato;'><i>paclitaxel</i></b>, the doublet's cycle 1 dose in chemotherapy-naive women is generally safe. <b style='color:Tomato;'><i>carboplatin</i></b> (unlike cisplatin) contributes minimally to the cumulative sensory neuropathy of <b style='color:Tomato;'><i>paclitaxel</i></b>, thus ensuring noticeable reversibility of neuropathy symptoms following completion of 6 cycles and only occasionally requiring cessation or substitution of the taxane. <b style='color:Tomato;'><i>paclitaxel</i></b> is responsible for the hair loss associated with the <b style='color:Tomato;'><i>carboplatin</i></b>/<b style='color:Tomato;'><i>paclitaxel</i></b> doublet; preventive measures must be considered for patients who would otherwise refuse treatment. <b style='color:DodgerBlue;'><i>Several</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>III</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>ongoing</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>which</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>preliminary</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>published</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>fueled</i></b> <b style='color:DodgerBlue;'><i>debates</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>optimal</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>schedule</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>focused</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>weekly</i></b> <b style='color:DodgerBlue;'><i>vs</i></b> <b style='color:DodgerBlue;'><i>q3-weeks</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>also</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>modifications</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>advisability</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>adding</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Our view is that results of this doublet in the first-line treatment of ovarian cancer are driven primarily by <b style='color:Tomato;'><i>carboplatin</i></b>, given that ovarian cancer is a platinum-sensitive disease. Consequently, the roles of the accompanying <b style='color:Tomato;'><i>paclitaxel</i></b> dose and schedule and the addition of <b style='color:Tomato;'><i>bevacizumab</i></b> are currently unsettled, and questions regarding these issues should be decided based on patient tolerance and comorbidities until additional data are available.","tokens":[{"text":"Several","start":0,"end":7,"id":0,"ws":true},{"text":"first-line","start":8,"end":18,"id":1,"ws":true},{"text":"phase","start":19,"end":24,"id":2,"ws":true},{"text":"III","start":25,"end":28,"id":3,"ws":true},{"text":"trials","start":29,"end":35,"id":4,"ws":true},{"text":",","start":36,"end":37,"id":5,"ws":true},{"text":"as","start":38,"end":40,"id":6,"ws":true},{"text":"well","start":41,"end":45,"id":7,"ws":true},{"text":"as","start":46,"end":48,"id":8,"ws":true},{"text":"ongoing","start":49,"end":56,"id":9,"ws":true},{"text":"trials","start":57,"end":63,"id":10,"ws":true},{"text":"for","start":64,"end":67,"id":11,"ws":true},{"text":"which","start":68,"end":73,"id":12,"ws":true},{"text":"only","start":74,"end":78,"id":13,"ws":true},{"text":"preliminary","start":79,"end":90,"id":14,"ws":true},{"text":"results","start":91,"end":98,"id":15,"ws":true},{"text":"have","start":99,"end":103,"id":16,"ws":true},{"text":"been","start":104,"end":108,"id":17,"ws":true},{"text":"published","start":109,"end":118,"id":18,"ws":true},{"text":",","start":119,"end":120,"id":19,"ws":true},{"text":"have","start":121,"end":125,"id":20,"ws":true},{"text":"fueled","start":126,"end":132,"id":21,"ws":true},{"text":"debates","start":133,"end":140,"id":22,"ws":true},{"text":"on","start":141,"end":143,"id":23,"ws":true},{"text":"the","start":144,"end":147,"id":24,"ws":true},{"text":"optimal","start":148,"end":155,"id":25,"ws":true},{"text":"dose","start":156,"end":160,"id":26,"ws":true},{"text":"and","start":161,"end":164,"id":27,"ws":true},{"text":"schedule","start":165,"end":173,"id":28,"ws":true},{"text":";","start":174,"end":175,"id":29,"ws":true},{"text":"these","start":176,"end":181,"id":30,"ws":true},{"text":"have","start":182,"end":186,"id":31,"ws":true},{"text":"focused","start":187,"end":194,"id":32,"ws":true},{"text":"not","start":195,"end":198,"id":33,"ws":true},{"text":"only","start":199,"end":203,"id":34,"ws":true},{"text":"on","start":204,"end":206,"id":35,"ws":true},{"text":"weekly","start":207,"end":213,"id":36,"ws":true},{"text":"vs","start":214,"end":216,"id":37,"ws":true},{"text":"q3-weeks","start":217,"end":225,"id":38,"ws":true},{"text":"paclitaxel","start":226,"end":236,"id":39,"ws":true},{"text":",","start":237,"end":238,"id":40,"ws":true},{"text":"but","start":239,"end":242,"id":41,"ws":true},{"text":"also","start":243,"end":247,"id":42,"ws":true},{"text":"on","start":248,"end":250,"id":43,"ws":true},{"text":"other","start":251,"end":256,"id":44,"ws":true},{"text":"modifications","start":257,"end":270,"id":45,"ws":true},{"text":"and","start":271,"end":274,"id":46,"ws":true},{"text":"the","start":275,"end":278,"id":47,"ws":true},{"text":"advisability","start":279,"end":291,"id":48,"ws":true},{"text":"of","start":292,"end":294,"id":49,"ws":true},{"text":"adding","start":295,"end":301,"id":50,"ws":true},{"text":"bevacizumab","start":302,"end":313,"id":51,"ws":true},{"text":".","start":314,"end":315,"id":52,"ws":false}],"spans":[{"start":226,"end":236,"token_start":39,"token_end":39,"label":"DRUG"},{"start":302,"end":313,"token_start":51,"token_end":51,"label":"DRUG"}],"_input_hash":1252988243,"_task_hash":322511723,"_session_id":"drug_drug_pilot_shared-yakir","_view_id":"blocks","relations":[{"head":39,"child":51,"head_span":{"start":226,"end":236,"token_start":39,"token_end":39,"label":"DRUG"},"child_span":{"start":302,"end":313,"token_start":51,"token_end":51,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"The primary goal was achieve the correct estimation of the target plasma area against the topotecan concentration-time curve ( AUC ) in a 5 day course of cladribine followed by monitored topotecan in pediatric patients with recurrent/refractory AML .","paragraph":"<h3><u>Topotecan exposure estimation in pediatric acute myeloid leukemia supported by LC-MS-based drug monitoring and pharmacokinetic analysis.</u></h3>Individualization of the <b style='color:Tomato;'><i>topotecan</i></b> dosing can reduce inter-patient variability, toxicity, and at the same time increases chemotherapy efficacy. <b style='color:Tomato;'><i>topotecan</i></b> dosing based on simultaneous drug monitoring and pharmacokinetic analysis can yield more accurate and precise estimation of the <b style='color:Tomato;'><i>topotecan</i></b> systemic exposure than that attainable with the fixed dosing approach. Therefore, a combined approach could provide a tool assisting the clinicians in individualization of the <b style='color:Tomato;'><i>topotecan</i></b> dosing. The aim of the study was to estimate the <b style='color:Tomato;'><i>topotecan</i></b> exposure in pediatric patients with acute myeloid leukemia (AML) based on the plasma concentration-time data and using the pharmacokinetic analysis. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>primary</i></b> <b style='color:DodgerBlue;'><i>goal</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>achieve</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>correct</i></b> <b style='color:DodgerBlue;'><i>estimation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>target</i></b> <b style='color:DodgerBlue;'><i>plasma</i></b> <b style='color:DodgerBlue;'><i>area</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:MediumOrchid;'><i>topotecan</i></b> <b style='color:DodgerBlue;'><i>concentration-time</i></b> <b style='color:DodgerBlue;'><i>curve</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AUC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>course</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cladribine</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>monitored</i></b> <b style='color:MediumOrchid;'><i>topotecan</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>pediatric</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>recurrent/refractory</i></b> <b style='color:DodgerBlue;'><i>AML</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A sensitive and selective reversed-phase liquid chromatographic-mass spectrometry (LC-MS) assay was developed to quantify total <b style='color:Tomato;'><i>topotecan</i></b> in the human plasma samples. This method, with its lower quantification limit of 1 ng/ml, was validated over a linear range of 1-150 ng/ml. Under the proposed approach, the <b style='color:Tomato;'><i>topotecan</i></b> dosing was selected so as to achieve the final AUC value of 140\u00b120 ng/ml h. The presented analytical and pharmacokinetic data demonstrate that the proposed approach can be a practical, useful, efficient, and accurate tool for individualizing the <b style='color:Tomato;'><i>topotecan</i></b> dosing in children with AML.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"primary","start":4,"end":11,"id":1,"ws":true},{"text":"goal","start":12,"end":16,"id":2,"ws":true},{"text":"was","start":17,"end":20,"id":3,"ws":true},{"text":"achieve","start":21,"end":28,"id":4,"ws":true},{"text":"the","start":29,"end":32,"id":5,"ws":true},{"text":"correct","start":33,"end":40,"id":6,"ws":true},{"text":"estimation","start":41,"end":51,"id":7,"ws":true},{"text":"of","start":52,"end":54,"id":8,"ws":true},{"text":"the","start":55,"end":58,"id":9,"ws":true},{"text":"target","start":59,"end":65,"id":10,"ws":true},{"text":"plasma","start":66,"end":72,"id":11,"ws":true},{"text":"area","start":73,"end":77,"id":12,"ws":true},{"text":"against","start":78,"end":85,"id":13,"ws":true},{"text":"the","start":86,"end":89,"id":14,"ws":true},{"text":"topotecan","start":90,"end":99,"id":15,"ws":true},{"text":"concentration-time","start":100,"end":118,"id":16,"ws":true},{"text":"curve","start":119,"end":124,"id":17,"ws":true},{"text":"(","start":125,"end":126,"id":18,"ws":true},{"text":"AUC","start":127,"end":130,"id":19,"ws":true},{"text":")","start":131,"end":132,"id":20,"ws":true},{"text":"in","start":133,"end":135,"id":21,"ws":true},{"text":"a","start":136,"end":137,"id":22,"ws":true},{"text":"5","start":138,"end":139,"id":23,"ws":true},{"text":"day","start":140,"end":143,"id":24,"ws":true},{"text":"course","start":144,"end":150,"id":25,"ws":true},{"text":"of","start":151,"end":153,"id":26,"ws":true},{"text":"cladribine","start":154,"end":164,"id":27,"ws":true},{"text":"followed","start":165,"end":173,"id":28,"ws":true},{"text":"by","start":174,"end":176,"id":29,"ws":true},{"text":"monitored","start":177,"end":186,"id":30,"ws":true},{"text":"topotecan","start":187,"end":196,"id":31,"ws":true},{"text":"in","start":197,"end":199,"id":32,"ws":true},{"text":"pediatric","start":200,"end":209,"id":33,"ws":true},{"text":"patients","start":210,"end":218,"id":34,"ws":true},{"text":"with","start":219,"end":223,"id":35,"ws":true},{"text":"recurrent/refractory","start":224,"end":244,"id":36,"ws":true},{"text":"AML","start":245,"end":248,"id":37,"ws":true},{"text":".","start":249,"end":250,"id":38,"ws":false}],"spans":[{"start":90,"end":99,"token_start":15,"token_end":15,"label":"DRUG"},{"start":154,"end":164,"token_start":27,"token_end":27,"label":"DRUG"},{"start":187,"end":196,"token_start":31,"token_end":31,"label":"DRUG"}],"_input_hash":796298966,"_task_hash":-199747777,"_session_id":"drug_drug_pilot_shared-yakir","_view_id":"blocks","relations":[],"answer":"ignore"}
{"text":"The management of EP is challenging : no standardized guidelines exist with literature suggesting cyclosporine or infliximab as first-line therapy .","paragraph":"<h3><u>Erythrodermic psoriasis successfully and rapidly treated with brodalumab: Report of two cases.</u></h3>Erythrodermic psoriasis (EP) is a rare form of the disease clinically characterized by a generalized erythema covering \u226590% of the body surface area (BSA). <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>management</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>EP</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>challenging</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>standardized</i></b> <b style='color:DodgerBlue;'><i>guidelines</i></b> <b style='color:DodgerBlue;'><i>exist</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>literature</i></b> <b style='color:DodgerBlue;'><i>suggesting</i></b> <b style='color:MediumOrchid;'><i>cyclosporine</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>infliximab</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, a recent systematic review showed a positive response in EP patients treated with biologic agents. The most common biologic used for EP up until now has been <b style='color:Tomato;'><i>ustekinumab</i></b>, whereas <b style='color:Tomato;'><i>infliximab</i></b> might represent a first-line option in case of complicated EP (acute, severe, or unstable). Up until now, no case of <b style='color:Tomato;'><i>brodalumab</i></b> (a monoclonal antibody blocking IL-17 receptor) treatment for EP in real-life has ever been described. Here, we report the first two cases of efficacy and safety of <b style='color:Tomato;'><i>brodalumab</i></b> in real-life cases of EP.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"management","start":4,"end":14,"id":1,"ws":true},{"text":"of","start":15,"end":17,"id":2,"ws":true},{"text":"EP","start":18,"end":20,"id":3,"ws":true},{"text":"is","start":21,"end":23,"id":4,"ws":true},{"text":"challenging","start":24,"end":35,"id":5,"ws":true},{"text":":","start":36,"end":37,"id":6,"ws":true},{"text":"no","start":38,"end":40,"id":7,"ws":true},{"text":"standardized","start":41,"end":53,"id":8,"ws":true},{"text":"guidelines","start":54,"end":64,"id":9,"ws":true},{"text":"exist","start":65,"end":70,"id":10,"ws":true},{"text":"with","start":71,"end":75,"id":11,"ws":true},{"text":"literature","start":76,"end":86,"id":12,"ws":true},{"text":"suggesting","start":87,"end":97,"id":13,"ws":true},{"text":"cyclosporine","start":98,"end":110,"id":14,"ws":true},{"text":"or","start":111,"end":113,"id":15,"ws":true},{"text":"infliximab","start":114,"end":124,"id":16,"ws":true},{"text":"as","start":125,"end":127,"id":17,"ws":true},{"text":"first-line","start":128,"end":138,"id":18,"ws":true},{"text":"therapy","start":139,"end":146,"id":19,"ws":true},{"text":".","start":147,"end":148,"id":20,"ws":false}],"spans":[{"start":98,"end":110,"token_start":14,"token_end":14,"label":"DRUG"},{"start":114,"end":124,"token_start":16,"token_end":16,"label":"DRUG"}],"_input_hash":-575753313,"_task_hash":-166345926,"_session_id":"drug_drug_pilot_shared-yakir","_view_id":"blocks","relations":[],"answer":"ignore"}
{"text":"As single agents , curcumin and metformin are reported to exhibit chemopreventive properties , in vitro as well as in patients with oral cancer .","paragraph":"<h3><u>Curcumin and metformin-mediated chemoprevention of oral cancer is associated with inhibition of cancer stem cells.</u></h3>Effective chemoprevention is critical for improving outcomes of oral cancer. <b style='color:DodgerBlue;'><i>As</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>curcumin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>metformin</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>reported</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>exhibit</i></b> <b style='color:DodgerBlue;'><i>chemopreventive</i></b> <b style='color:DodgerBlue;'><i>properties</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In this study, the chemopreventive efficacy of this drug combination was tested in a 4-nitro quinoline-1-oxide (4NQO) induced mice oral carcinogenesis model. Molecular analysis revealed a cancer stem cell (CSC)-driven oral carcinogenic progression in this model, wherein a progressive increase in the expression of CSC-specific markers (CD44 and CD133) was observed from 8th to 25th week, at transcript (40-100-fold) and protein levels (P\u2009\u2264\u20090.0001). Chemopreventive treatment of the animals at 17th week with <b style='color:Tomato;'><i>curcumin</i></b> and <b style='color:Tomato;'><i>metformin</i></b> indicated that the combination regimen decreased tumor volume when compared to the control arm (0.69+0.03 vs 6.66+2.4\u2009mm","tokens":[{"text":"As","start":0,"end":2,"id":0,"ws":true},{"text":"single","start":3,"end":9,"id":1,"ws":true},{"text":"agents","start":10,"end":16,"id":2,"ws":true},{"text":",","start":17,"end":18,"id":3,"ws":true},{"text":"curcumin","start":19,"end":27,"id":4,"ws":true},{"text":"and","start":28,"end":31,"id":5,"ws":true},{"text":"metformin","start":32,"end":41,"id":6,"ws":true},{"text":"are","start":42,"end":45,"id":7,"ws":true},{"text":"reported","start":46,"end":54,"id":8,"ws":true},{"text":"to","start":55,"end":57,"id":9,"ws":true},{"text":"exhibit","start":58,"end":65,"id":10,"ws":true},{"text":"chemopreventive","start":66,"end":81,"id":11,"ws":true},{"text":"properties","start":82,"end":92,"id":12,"ws":true},{"text":",","start":93,"end":94,"id":13,"ws":true},{"text":"in","start":95,"end":97,"id":14,"ws":true},{"text":"vitro","start":98,"end":103,"id":15,"ws":true},{"text":"as","start":104,"end":106,"id":16,"ws":true},{"text":"well","start":107,"end":111,"id":17,"ws":true},{"text":"as","start":112,"end":114,"id":18,"ws":true},{"text":"in","start":115,"end":117,"id":19,"ws":true},{"text":"patients","start":118,"end":126,"id":20,"ws":true},{"text":"with","start":127,"end":131,"id":21,"ws":true},{"text":"oral","start":132,"end":136,"id":22,"ws":true},{"text":"cancer","start":137,"end":143,"id":23,"ws":true},{"text":".","start":144,"end":145,"id":24,"ws":false}],"spans":[{"start":19,"end":27,"token_start":4,"token_end":4,"label":"DRUG"},{"start":32,"end":41,"token_start":6,"token_end":6,"label":"DRUG"}],"_input_hash":-1095827099,"_task_hash":-240223432,"_session_id":"drug_drug_pilot_shared-yakir","_view_id":"blocks","relations":[{"head":4,"child":6,"head_span":{"start":19,"end":27,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":32,"end":41,"token_start":6,"token_end":6,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T0"],"answer":"accept"}
{"text":"Withdrawal rates were comparable to drug survival rates of other biological therapies and rates of adverse events were similar between brodalumab and ustekinumab .","paragraph":"<h3><u>Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.</u></h3>As part of the National Institute for Health and Care Excellence single technology appraisal process, <b style='color:Tomato;'><i>brodalumab</i></b> was assessed to determine the clinical and cost effectiveness of its use in the treatment of moderate-to-severe plaque psoriasis. The Centre for Reviews and Dissemination and the Centre for Health Economics Technology Assessment Group at the University of York were commissioned to act as the independent Evidence Review Group. This article provides a summary of the Evidence Review Group's review of the company's submission, the Evidence Review Group report and the National Institute for Health and Care Excellence Appraisal Committee's subsequent guidance issued in March 2018. The main clinical effectiveness data were derived from three well-conducted, multicentre, double-blind randomised controlled trials. The trials demonstrated that <b style='color:Tomato;'><i>brodalumab</i></b> statistically significantly reduced the severity of psoriasis and its impact on health-related quality of life, compared with placebo, at 12\u00a0weeks. In comparison with <b style='color:Tomato;'><i>ustekinumab</i></b>, statistically significantly more patients taking <b style='color:Tomato;'><i>brodalumab</i></b> had reduced psoriasis severity at 12\u00a0weeks. Psoriasis severity and quality of life also appeared improved at 52\u00a0weeks, although statistical significance was not assessed. <b style='color:DodgerBlue;'><i>Withdrawal</i></b> <b style='color:DodgerBlue;'><i>rates</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>comparable</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>rates</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>biological</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>rates</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>adverse</i></b> <b style='color:DodgerBlue;'><i>events</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>similar</i></b> <b style='color:DodgerBlue;'><i>between</i></b> <b style='color:MediumOrchid;'><i>brodalumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ustekinumab</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A network meta-analysis was presented, comparing <b style='color:Tomato;'><i>brodalumab</i></b> with other therapies available at the same point in the treatment pathway (i.e. in patients for whom standard systemic therapy or phototherapy is inadequately effective, not tolerated or contraindicated). The network meta-analysis ranked treatments in order of effectiveness, in terms of achieving different levels of Psoriasis Area and Severity Index response. The results indicated that <b style='color:Tomato;'><i>brodalumab</i></b> had a similar probability of response to <b style='color:Tomato;'><i>ixekizumab</i></b>, <b style='color:Tomato;'><i>secukinumab</i></b> and <b style='color:Tomato;'><i>infliximab</i></b> and a higher probability of response than <b style='color:Tomato;'><i>ustekinumab</i></b>, <b style='color:Tomato;'><i>adalimumab</i></b>, <b style='color:Tomato;'><i>etanercept</i></b>, <b style='color:Tomato;'><i>apremilast</i></b>, <b style='color:Tomato;'><i>dimethyl fumarate</i></b> and placebo. The company's economic model compared nine treatment sequences that included three lines of active therapy, consisting of <b style='color:Tomato;'><i>brodalumab</i></b> and other comparators recommended by the National Institute for Health and Care Excellence, followed by best supportive care. The sequence with <b style='color:Tomato;'><i>brodalumab</i></b> in the first-line position dominated sequences that started with <b style='color:Tomato;'><i>adalimumab</i></b>, <b style='color:Tomato;'><i>infliximab</i></b>, <b style='color:Tomato;'><i>secukinumab</i></b> and <b style='color:Tomato;'><i>ustekinumab</i></b>. The incremental cost-effectiveness ratio of the <b style='color:Tomato;'><i>brodalumab</i></b> sequence compared to less effective and non-dominated sequences ranged from \u00a37145 (vs. the <b style='color:Tomato;'><i>etanercept</i></b> sequence) to \u00a313,353 (vs. the <b style='color:Tomato;'><i>dimethyl fumarate</i></b> sequence) per quality-adjusted life-year gained. The incremental cost-effectiveness ratio for the more costly and effective <b style='color:Tomato;'><i>ixekizumab</i></b> sequence was \u00a3894,010 per quality-adjusted life-year gained compared to the <b style='color:Tomato;'><i>brodalumab</i></b> sequence. At a threshold of \u00a320,000 per quality-adjusted life-year gained, the <b style='color:Tomato;'><i>brodalumab</i></b> sequence had the highest probability of being cost effective (96%). The main limitation of the company's economic model was the restrictive nature of the sequences compared. Twelve separate scenarios based on key uncertainties were explored by the Evidence Review Group. The only scenarios where <b style='color:Tomato;'><i>brodalumab</i></b> was ranked lower than first were not considered to be more appropriate or plausible than the assumptions or scenarios included in the company's base case. The treatment rankings identified in the Evidence Review Group's alternative base case were identical to those derived from the company's base case model. At the first National Institute for Health and Care Excellence Appraisal Committee meeting, the Committee concluded that <b style='color:Tomato;'><i>brodalumab</i></b> appears to be as effective as other anti-interleukin-17 agents and is cost effective, based on the discount agreed in the patient access scheme. <b style='color:Tomato;'><i>brodalumab</i></b> is recommended as an option for treating adults with severe plaque psoriasis (defined by a total Psoriasis Area and Severity Index score of 10 or more and a Dermatology Life Quality Index score of more than 10) who have not responded to other systemic non-biological therapies. <b style='color:Tomato;'><i>brodalumab</i></b> should be stopped at 12\u00a0weeks if the psoriasis has not responded adequately.","tokens":[{"text":"Withdrawal","start":0,"end":10,"id":0,"ws":true},{"text":"rates","start":11,"end":16,"id":1,"ws":true},{"text":"were","start":17,"end":21,"id":2,"ws":true},{"text":"comparable","start":22,"end":32,"id":3,"ws":true},{"text":"to","start":33,"end":35,"id":4,"ws":true},{"text":"drug","start":36,"end":40,"id":5,"ws":true},{"text":"survival","start":41,"end":49,"id":6,"ws":true},{"text":"rates","start":50,"end":55,"id":7,"ws":true},{"text":"of","start":56,"end":58,"id":8,"ws":true},{"text":"other","start":59,"end":64,"id":9,"ws":true},{"text":"biological","start":65,"end":75,"id":10,"ws":true},{"text":"therapies","start":76,"end":85,"id":11,"ws":true},{"text":"and","start":86,"end":89,"id":12,"ws":true},{"text":"rates","start":90,"end":95,"id":13,"ws":true},{"text":"of","start":96,"end":98,"id":14,"ws":true},{"text":"adverse","start":99,"end":106,"id":15,"ws":true},{"text":"events","start":107,"end":113,"id":16,"ws":true},{"text":"were","start":114,"end":118,"id":17,"ws":true},{"text":"similar","start":119,"end":126,"id":18,"ws":true},{"text":"between","start":127,"end":134,"id":19,"ws":true},{"text":"brodalumab","start":135,"end":145,"id":20,"ws":true},{"text":"and","start":146,"end":149,"id":21,"ws":true},{"text":"ustekinumab","start":150,"end":161,"id":22,"ws":true},{"text":".","start":162,"end":163,"id":23,"ws":false}],"spans":[{"start":135,"end":145,"token_start":20,"token_end":20,"label":"DRUG"},{"start":150,"end":161,"token_start":22,"token_end":22,"label":"DRUG"}],"_input_hash":-2044054306,"_task_hash":40529012,"_session_id":"drug_drug_pilot_shared-yakir","_view_id":"blocks","relations":[],"answer":"ignore"}
{"text":"In patients with NPSLE , the use of high-dose corticosteroids is recommended in combination with immunosuppressants , such as mycophenolate mofetil and intravenous cyclophosphamide pulse therapy .","paragraph":"<h3><u>[Neuropsychiatric Systemic Lupus Erythematosus].</u></h3>Central nervous system damage, a major organ manifestation of systemic lupus erythematosus (SLE), causes significant morbidity and mortality. Designating this condition as neuropsychiatric SLE (NPSLE), the American College of Rheumatology defines it as involving the central and peripheral nervous systems and being characterized by various manifestations including stroke, seizures, and psychosis. NPSLE treatment mainly seeks to reduce damage accrual. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>NPSLE</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:DodgerBlue;'><i>corticosteroids</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>recommended</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>immunosuppressants</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>mycophenolate</i></b> <b style='color:DodgerBlue;'><i>mofetil</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>pulse</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> This can be accomplished by controlling the activity of the disease, minimizing the use of corticosteroids, and optimizing the management of comorbidities, including cardiovascular risk factors. An international task force analysis of a treat-to-target strategy for SLE (T2T/SLE) recommended targeting remission, preventing damage, and improving quality of life. Thus, more effective and less toxic treatments, such as those using biologics or kinase inhibitors, are still being developed for the treatment of SLE/NPSLE.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"patients","start":3,"end":11,"id":1,"ws":true},{"text":"with","start":12,"end":16,"id":2,"ws":true},{"text":"NPSLE","start":17,"end":22,"id":3,"ws":true},{"text":",","start":23,"end":24,"id":4,"ws":true},{"text":"the","start":25,"end":28,"id":5,"ws":true},{"text":"use","start":29,"end":32,"id":6,"ws":true},{"text":"of","start":33,"end":35,"id":7,"ws":true},{"text":"high-dose","start":36,"end":45,"id":8,"ws":true},{"text":"corticosteroids","start":46,"end":61,"id":9,"ws":true},{"text":"is","start":62,"end":64,"id":10,"ws":true},{"text":"recommended","start":65,"end":76,"id":11,"ws":true},{"text":"in","start":77,"end":79,"id":12,"ws":true},{"text":"combination","start":80,"end":91,"id":13,"ws":true},{"text":"with","start":92,"end":96,"id":14,"ws":true},{"text":"immunosuppressants","start":97,"end":115,"id":15,"ws":true},{"text":",","start":116,"end":117,"id":16,"ws":true},{"text":"such","start":118,"end":122,"id":17,"ws":true},{"text":"as","start":123,"end":125,"id":18,"ws":true},{"text":"mycophenolate","start":126,"end":139,"id":19,"ws":true},{"text":"mofetil","start":140,"end":147,"id":20,"ws":true},{"text":"and","start":148,"end":151,"id":21,"ws":true},{"text":"intravenous","start":152,"end":163,"id":22,"ws":true},{"text":"cyclophosphamide","start":164,"end":180,"id":23,"ws":true},{"text":"pulse","start":181,"end":186,"id":24,"ws":true},{"text":"therapy","start":187,"end":194,"id":25,"ws":true},{"text":".","start":195,"end":196,"id":26,"ws":false}],"spans":[{"start":126,"end":139,"token_start":19,"token_end":19,"label":"DRUG"},{"start":140,"end":147,"token_start":20,"token_end":20,"label":"DRUG"},{"start":164,"end":180,"token_start":23,"token_end":23,"label":"DRUG"}],"_input_hash":438186251,"_task_hash":1532533663,"_session_id":"drug_drug_pilot_shared-yakir","_view_id":"blocks","relations":[{"head":19,"child":23,"head_span":{"start":126,"end":139,"token_start":19,"token_end":19,"label":"DRUG"},"child_span":{"start":164,"end":180,"token_start":23,"token_end":23,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T0"],"answer":"accept"}
{"text":"Thirty-three women diagnosed with metastatic breast cancer participated in a phase 1 clinical trial of a new combination of cyclophosphamide ( CTX ) and mitoxantrone ( MXT ) , with dose escalation of paclitaxel .","paragraph":"<h3><u>Longitudinal effects of high-dose chemotherapy and autologous stem cell transplantation on quality of life in the treatment of metastatic breast cancer.</u></h3>This study determined the effects of high-dose chemotherapy (HDCT) with autologous blood stem cell transplantation (ASCT) on quality of life (QL) in women with metastatic breast cancer prior to, and during treatment, and up to 1-year post-ASCT. <b style='color:DodgerBlue;'><i>Thirty-three</i></b> <b style='color:DodgerBlue;'><i>women</i></b> <b style='color:DodgerBlue;'><i>diagnosed</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>participated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>new</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CTX</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>mitoxantrone</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>MXT</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>escalation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Longitudinal QL data were collected using the functional living index-cancer (FLIC) and symptom scales at seven time periods: pre-induction chemotherapy (CT), post-induction CT, post-high dose CT (HDCT), and at 3, 6, 9 and 12 months post-ASCT. FLIC scores indicated that the worst problems for patients were feelings of hardship on themselves and their families, followed by psychological functioning and physical functioning problems. The time around diagnosis of the metastatic disease and following HDCT were the worst times for all levels of quality of life, but anxiety and depression symptoms continued to increase in severity across the entire follow-up period. The symptoms that were most problematic were worry about the future, loss of sexual interest, anxiety about the treatment, general worrying, and joint pain. These data highlight the problems that women with metastatic breast cancer encounter at different stages of the disease and treatment process, and can be used to tailor psychosocial interventions appropriate for treating the relevant issues at different points in time.","tokens":[{"text":"Thirty-three","start":0,"end":12,"id":0,"ws":true},{"text":"women","start":13,"end":18,"id":1,"ws":true},{"text":"diagnosed","start":19,"end":28,"id":2,"ws":true},{"text":"with","start":29,"end":33,"id":3,"ws":true},{"text":"metastatic","start":34,"end":44,"id":4,"ws":true},{"text":"breast","start":45,"end":51,"id":5,"ws":true},{"text":"cancer","start":52,"end":58,"id":6,"ws":true},{"text":"participated","start":59,"end":71,"id":7,"ws":true},{"text":"in","start":72,"end":74,"id":8,"ws":true},{"text":"a","start":75,"end":76,"id":9,"ws":true},{"text":"phase","start":77,"end":82,"id":10,"ws":true},{"text":"1","start":83,"end":84,"id":11,"ws":true},{"text":"clinical","start":85,"end":93,"id":12,"ws":true},{"text":"trial","start":94,"end":99,"id":13,"ws":true},{"text":"of","start":100,"end":102,"id":14,"ws":true},{"text":"a","start":103,"end":104,"id":15,"ws":true},{"text":"new","start":105,"end":108,"id":16,"ws":true},{"text":"combination","start":109,"end":120,"id":17,"ws":true},{"text":"of","start":121,"end":123,"id":18,"ws":true},{"text":"cyclophosphamide","start":124,"end":140,"id":19,"ws":true},{"text":"(","start":141,"end":142,"id":20,"ws":true},{"text":"CTX","start":143,"end":146,"id":21,"ws":true},{"text":")","start":147,"end":148,"id":22,"ws":true},{"text":"and","start":149,"end":152,"id":23,"ws":true},{"text":"mitoxantrone","start":153,"end":165,"id":24,"ws":true},{"text":"(","start":166,"end":167,"id":25,"ws":true},{"text":"MXT","start":168,"end":171,"id":26,"ws":true},{"text":")","start":172,"end":173,"id":27,"ws":true},{"text":",","start":174,"end":175,"id":28,"ws":true},{"text":"with","start":176,"end":180,"id":29,"ws":true},{"text":"dose","start":181,"end":185,"id":30,"ws":true},{"text":"escalation","start":186,"end":196,"id":31,"ws":true},{"text":"of","start":197,"end":199,"id":32,"ws":true},{"text":"paclitaxel","start":200,"end":210,"id":33,"ws":true},{"text":".","start":211,"end":212,"id":34,"ws":false}],"spans":[{"start":124,"end":140,"token_start":19,"token_end":19,"label":"DRUG"},{"start":153,"end":165,"token_start":24,"token_end":24,"label":"DRUG"},{"start":200,"end":210,"token_start":33,"token_end":33,"label":"DRUG"}],"_input_hash":1782132717,"_task_hash":189034633,"_session_id":"drug_drug_pilot_shared-yakir","_view_id":"blocks","relations":[{"head":19,"child":24,"head_span":{"start":124,"end":140,"token_start":19,"token_end":19,"label":"DRUG"},"child_span":{"start":153,"end":165,"token_start":24,"token_end":24,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":24,"child":33,"head_span":{"start":153,"end":165,"token_start":24,"token_end":24,"label":"DRUG"},"child_span":{"start":200,"end":210,"token_start":33,"token_end":33,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"Among the anti-herpesvirus agents , aciclovir , valaciclovir , penciclovir , famciclovir , idoxuridine , trifluridine and brivudin are used in the treatment of herpes simplex virus and varicella-zoster virus infections , and ganciclovir , foscarnet , cidofovir , fomivirsen and maribavir ( the latter in the developmental stage ) are used in the treatment of cytomegalovirus infections .","paragraph":"<h3><u>Antiviral drugs: current state of the art.</u></h3>The chemotherapy of virus infections has definitely come of age. There are now 15 antiviral agents that have been formally licensed for the treatment of human immunodeficiency virus infections (<b style='color:Tomato;'><i>zidovudine</i></b>, <b style='color:Tomato;'><i>didanosine</i></b>, <b style='color:Tomato;'><i>zalcitabine</i></b>, <b style='color:Tomato;'><i>stavudine</i></b>, <b style='color:Tomato;'><i>lamivudine</i></b>, <b style='color:Tomato;'><i>abacavir</i></b>, <b style='color:Tomato;'><i>nevirapine</i></b>, <b style='color:Tomato;'><i>delavirdine</i></b>, <b style='color:Tomato;'><i>efavirenz</i></b>, <b style='color:Tomato;'><i>saquinavir</i></b>, <b style='color:Tomato;'><i>ritonavir</i></b>, <b style='color:Tomato;'><i>indinavir</i></b>, <b style='color:Tomato;'><i>nelfinavir</i></b>, <b style='color:Tomato;'><i>amprenavir</i></b>, <b style='color:Tomato;'><i>lopinavir</i></b>) and several others, such as <b style='color:Tomato;'><i>tenofovir</i></b> disoproxil, <b style='color:Tomato;'><i>emtricitabine</i></b>, capravirine, emivirine, T-20 (pentafuside) and AMD3100 (bicyclam) are under clinical development. <b style='color:Tomato;'><i>lamivudine</i></b> has been approved, and several other compounds (such as <b style='color:Tomato;'><i>adefovir</i></b> dipivoxil, <b style='color:Tomato;'><i>emtricitabine</i></b> and <b style='color:Tomato;'><i>entecavir</i></b>) are under clinical development, for the treatment of hepatitis B virus infections. <b style='color:DodgerBlue;'><i>Among</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>anti-herpesvirus</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>aciclovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>valaciclovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>penciclovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>famciclovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>idoxuridine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>trifluridine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>brivudin</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>herpes</i></b> <b style='color:DodgerBlue;'><i>simplex</i></b> <b style='color:DodgerBlue;'><i>virus</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>varicella-zoster</i></b> <b style='color:DodgerBlue;'><i>virus</i></b> <b style='color:DodgerBlue;'><i>infections</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ganciclovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>foscarnet</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cidofovir</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>fomivirsen</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>maribavir</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>latter</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>developmental</i></b> <b style='color:DodgerBlue;'><i>stage</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cytomegalovirus</i></b> <b style='color:DodgerBlue;'><i>infections</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Following <b style='color:Tomato;'><i>amantadine</i></b> and <b style='color:Tomato;'><i>rimantadine</i></b>, the neuraminidase inhibitors, <b style='color:Tomato;'><i>zanamivir</i></b> and <b style='color:Tomato;'><i>oseltamivir</i></b>, have now become available for the therapy and prophylaxis of influenza virus infections, and so is <b style='color:Tomato;'><i>ribavirin</i></b> for the treatment of respiratory syncytial virus infections and the combination of <b style='color:Tomato;'><i>ribavirin</i></b> with interferon-alpha for the treatment of hepatitis C virus infections.","tokens":[{"text":"Among","start":0,"end":5,"id":0,"ws":true},{"text":"the","start":6,"end":9,"id":1,"ws":true},{"text":"anti-herpesvirus","start":10,"end":26,"id":2,"ws":true},{"text":"agents","start":27,"end":33,"id":3,"ws":true},{"text":",","start":34,"end":35,"id":4,"ws":true},{"text":"aciclovir","start":36,"end":45,"id":5,"ws":true},{"text":",","start":46,"end":47,"id":6,"ws":true},{"text":"valaciclovir","start":48,"end":60,"id":7,"ws":true},{"text":",","start":61,"end":62,"id":8,"ws":true},{"text":"penciclovir","start":63,"end":74,"id":9,"ws":true},{"text":",","start":75,"end":76,"id":10,"ws":true},{"text":"famciclovir","start":77,"end":88,"id":11,"ws":true},{"text":",","start":89,"end":90,"id":12,"ws":true},{"text":"idoxuridine","start":91,"end":102,"id":13,"ws":true},{"text":",","start":103,"end":104,"id":14,"ws":true},{"text":"trifluridine","start":105,"end":117,"id":15,"ws":true},{"text":"and","start":118,"end":121,"id":16,"ws":true},{"text":"brivudin","start":122,"end":130,"id":17,"ws":true},{"text":"are","start":131,"end":134,"id":18,"ws":true},{"text":"used","start":135,"end":139,"id":19,"ws":true},{"text":"in","start":140,"end":142,"id":20,"ws":true},{"text":"the","start":143,"end":146,"id":21,"ws":true},{"text":"treatment","start":147,"end":156,"id":22,"ws":true},{"text":"of","start":157,"end":159,"id":23,"ws":true},{"text":"herpes","start":160,"end":166,"id":24,"ws":true},{"text":"simplex","start":167,"end":174,"id":25,"ws":true},{"text":"virus","start":175,"end":180,"id":26,"ws":true},{"text":"and","start":181,"end":184,"id":27,"ws":true},{"text":"varicella-zoster","start":185,"end":201,"id":28,"ws":true},{"text":"virus","start":202,"end":207,"id":29,"ws":true},{"text":"infections","start":208,"end":218,"id":30,"ws":true},{"text":",","start":219,"end":220,"id":31,"ws":true},{"text":"and","start":221,"end":224,"id":32,"ws":true},{"text":"ganciclovir","start":225,"end":236,"id":33,"ws":true},{"text":",","start":237,"end":238,"id":34,"ws":true},{"text":"foscarnet","start":239,"end":248,"id":35,"ws":true},{"text":",","start":249,"end":250,"id":36,"ws":true},{"text":"cidofovir","start":251,"end":260,"id":37,"ws":true},{"text":",","start":261,"end":262,"id":38,"ws":true},{"text":"fomivirsen","start":263,"end":273,"id":39,"ws":true},{"text":"and","start":274,"end":277,"id":40,"ws":true},{"text":"maribavir","start":278,"end":287,"id":41,"ws":true},{"text":"(","start":288,"end":289,"id":42,"ws":true},{"text":"the","start":290,"end":293,"id":43,"ws":true},{"text":"latter","start":294,"end":300,"id":44,"ws":true},{"text":"in","start":301,"end":303,"id":45,"ws":true},{"text":"the","start":304,"end":307,"id":46,"ws":true},{"text":"developmental","start":308,"end":321,"id":47,"ws":true},{"text":"stage","start":322,"end":327,"id":48,"ws":true},{"text":")","start":328,"end":329,"id":49,"ws":true},{"text":"are","start":330,"end":333,"id":50,"ws":true},{"text":"used","start":334,"end":338,"id":51,"ws":true},{"text":"in","start":339,"end":341,"id":52,"ws":true},{"text":"the","start":342,"end":345,"id":53,"ws":true},{"text":"treatment","start":346,"end":355,"id":54,"ws":true},{"text":"of","start":356,"end":358,"id":55,"ws":true},{"text":"cytomegalovirus","start":359,"end":374,"id":56,"ws":true},{"text":"infections","start":375,"end":385,"id":57,"ws":true},{"text":".","start":386,"end":387,"id":58,"ws":false}],"spans":[{"start":36,"end":45,"token_start":5,"token_end":5,"label":"DRUG"},{"start":48,"end":60,"token_start":7,"token_end":7,"label":"DRUG"},{"start":63,"end":74,"token_start":9,"token_end":9,"label":"DRUG"},{"start":77,"end":88,"token_start":11,"token_end":11,"label":"DRUG"},{"start":91,"end":102,"token_start":13,"token_end":13,"label":"DRUG"},{"start":105,"end":117,"token_start":15,"token_end":15,"label":"DRUG"},{"start":225,"end":236,"token_start":33,"token_end":33,"label":"DRUG"},{"start":239,"end":248,"token_start":35,"token_end":35,"label":"DRUG"},{"start":251,"end":260,"token_start":37,"token_end":37,"label":"DRUG"}],"_input_hash":1265321677,"_task_hash":1758490147,"_session_id":"drug_drug_pilot_shared-yakir","_view_id":"blocks","relations":[],"answer":"ignore"}
{"text":"The present study examined the efficacy of single and combined treatment with an anticholinesterase , tetrahydroaminoacridine ( i.p . ) , and a glycine-B site partial agonist , D-cycloserine ( i.p . ; a positive allosteric modulator of NMDA receptors ) , in alleviating the deficit in water maze spatial navigation induced by electrolytic lesion of the medial septum or lidocaine infusion into the dorsal hippocampi .","paragraph":"<h3><u>Tetrahydroaminoacridine and D-cycloserine fail to alleviate the water maze spatial navigation defect induced by hippocampal inactivation.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>examined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>anticholinesterase</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>tetrahydroaminoacridine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>i.p</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>glycine-B</i></b> <b style='color:DodgerBlue;'><i>site</i></b> <b style='color:DodgerBlue;'><i>partial</i></b> <b style='color:DodgerBlue;'><i>agonist</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>D-cycloserine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>i.p</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>positive</i></b> <b style='color:DodgerBlue;'><i>allosteric</i></b> <b style='color:DodgerBlue;'><i>modulator</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>NMDA</i></b> <b style='color:DodgerBlue;'><i>receptors</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>alleviating</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>deficit</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>water</i></b> <b style='color:DodgerBlue;'><i>maze</i></b> <b style='color:DodgerBlue;'><i>spatial</i></b> <b style='color:DodgerBlue;'><i>navigation</i></b> <b style='color:DodgerBlue;'><i>induced</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>electrolytic</i></b> <b style='color:DodgerBlue;'><i>lesion</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>medial</i></b> <b style='color:DodgerBlue;'><i>septum</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>lidocaine</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>dorsal</i></b> <b style='color:DodgerBlue;'><i>hippocampi</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In medial septum-lesioned rats, a combination of tetrahydroaminoacridine 3 mg kg(-1) and <b style='color:Tomato;'><i>d-cycloserine</i></b> 10 mg kg(-1) facilitated acquisition of the water maze test more effectively than either of the drugs alone. Single or combined treatment with tetrahydroaminoacridine 3 mg kg(-1) and <b style='color:Tomato;'><i>d-cycloserine</i></b> 10 mg kg(-1) had no effect on the water maze deficit induced by hippocampal <b style='color:Tomato;'><i>lidocaine</i></b> infusion. These results suggest that combined treatment with tetrahydroaminoacridine and <b style='color:Tomato;'><i>d-cycloserine</i></b> can effectively stimulate water maze spatial navigation, and that functioning of the hippocampus is a prerequisite for this effect.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"present","start":4,"end":11,"id":1,"ws":true},{"text":"study","start":12,"end":17,"id":2,"ws":true},{"text":"examined","start":18,"end":26,"id":3,"ws":true},{"text":"the","start":27,"end":30,"id":4,"ws":true},{"text":"efficacy","start":31,"end":39,"id":5,"ws":true},{"text":"of","start":40,"end":42,"id":6,"ws":true},{"text":"single","start":43,"end":49,"id":7,"ws":true},{"text":"and","start":50,"end":53,"id":8,"ws":true},{"text":"combined","start":54,"end":62,"id":9,"ws":true},{"text":"treatment","start":63,"end":72,"id":10,"ws":true},{"text":"with","start":73,"end":77,"id":11,"ws":true},{"text":"an","start":78,"end":80,"id":12,"ws":true},{"text":"anticholinesterase","start":81,"end":99,"id":13,"ws":true},{"text":",","start":100,"end":101,"id":14,"ws":true},{"text":"tetrahydroaminoacridine","start":102,"end":125,"id":15,"ws":true},{"text":"(","start":126,"end":127,"id":16,"ws":true},{"text":"i.p","start":128,"end":131,"id":17,"ws":true},{"text":".","start":132,"end":133,"id":18,"ws":true},{"text":")","start":134,"end":135,"id":19,"ws":true},{"text":",","start":136,"end":137,"id":20,"ws":true},{"text":"and","start":138,"end":141,"id":21,"ws":true},{"text":"a","start":142,"end":143,"id":22,"ws":true},{"text":"glycine-B","start":144,"end":153,"id":23,"ws":true},{"text":"site","start":154,"end":158,"id":24,"ws":true},{"text":"partial","start":159,"end":166,"id":25,"ws":true},{"text":"agonist","start":167,"end":174,"id":26,"ws":true},{"text":",","start":175,"end":176,"id":27,"ws":true},{"text":"D-cycloserine","start":177,"end":190,"id":28,"ws":true},{"text":"(","start":191,"end":192,"id":29,"ws":true},{"text":"i.p","start":193,"end":196,"id":30,"ws":true},{"text":".","start":197,"end":198,"id":31,"ws":true},{"text":";","start":199,"end":200,"id":32,"ws":true},{"text":"a","start":201,"end":202,"id":33,"ws":true},{"text":"positive","start":203,"end":211,"id":34,"ws":true},{"text":"allosteric","start":212,"end":222,"id":35,"ws":true},{"text":"modulator","start":223,"end":232,"id":36,"ws":true},{"text":"of","start":233,"end":235,"id":37,"ws":true},{"text":"NMDA","start":236,"end":240,"id":38,"ws":true},{"text":"receptors","start":241,"end":250,"id":39,"ws":true},{"text":")","start":251,"end":252,"id":40,"ws":true},{"text":",","start":253,"end":254,"id":41,"ws":true},{"text":"in","start":255,"end":257,"id":42,"ws":true},{"text":"alleviating","start":258,"end":269,"id":43,"ws":true},{"text":"the","start":270,"end":273,"id":44,"ws":true},{"text":"deficit","start":274,"end":281,"id":45,"ws":true},{"text":"in","start":282,"end":284,"id":46,"ws":true},{"text":"water","start":285,"end":290,"id":47,"ws":true},{"text":"maze","start":291,"end":295,"id":48,"ws":true},{"text":"spatial","start":296,"end":303,"id":49,"ws":true},{"text":"navigation","start":304,"end":314,"id":50,"ws":true},{"text":"induced","start":315,"end":322,"id":51,"ws":true},{"text":"by","start":323,"end":325,"id":52,"ws":true},{"text":"electrolytic","start":326,"end":338,"id":53,"ws":true},{"text":"lesion","start":339,"end":345,"id":54,"ws":true},{"text":"of","start":346,"end":348,"id":55,"ws":true},{"text":"the","start":349,"end":352,"id":56,"ws":true},{"text":"medial","start":353,"end":359,"id":57,"ws":true},{"text":"septum","start":360,"end":366,"id":58,"ws":true},{"text":"or","start":367,"end":369,"id":59,"ws":true},{"text":"lidocaine","start":370,"end":379,"id":60,"ws":true},{"text":"infusion","start":380,"end":388,"id":61,"ws":true},{"text":"into","start":389,"end":393,"id":62,"ws":true},{"text":"the","start":394,"end":397,"id":63,"ws":true},{"text":"dorsal","start":398,"end":404,"id":64,"ws":true},{"text":"hippocampi","start":405,"end":415,"id":65,"ws":true},{"text":".","start":416,"end":417,"id":66,"ws":false}],"spans":[{"start":102,"end":125,"token_start":15,"token_end":15,"label":"DRUG"},{"start":177,"end":190,"token_start":28,"token_end":28,"label":"DRUG"},{"start":370,"end":379,"token_start":60,"token_end":60,"label":"DRUG"}],"_input_hash":1944915333,"_task_hash":1724675945,"_session_id":"drug_drug_pilot_shared-yakir","_view_id":"blocks","relations":[{"head":28,"child":15,"head_span":{"start":177,"end":190,"token_start":28,"token_end":28,"label":"DRUG"},"child_span":{"start":102,"end":125,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#ffd882","label":"POS2"}],"radio":["POS11","POS1T0","POS21","POS2T0"],"answer":"accept"}
{"text":"He was initially treated with combination chemotherapy regimen of vincristine , actinomycin-D and cyclophosphamide ( VAC therapy ) .","paragraph":"<h3><u>[Rhabdomyosarcoma of the bladder: a case report].</u></h3>A 15-year-old man with the chief complaint of general fatigue was referred to our hospital on November 11, 1993. Bilateral percutaneous nephrostomy was performed for postrenal anuria. X-ray examinations revealed a huge intrapelvic tumor, and it was histopathologically diagnosed as rhabdomyosarcoma by transrectal needle biopsy. <b style='color:DodgerBlue;'><i>He</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>initially</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>actinomycin-D</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>VAC</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Pelvic exenteration was performed on December 15, 1993. Histopathological findings were alveolar rhabdomyosarcoma with degenerative change and partial necrosis. After the operation, he was given two course of VAC therapy. In May, 1994, brain metastasis occurred, so 4 courses of VAC therapy were administered. For a very short period, neurological symptoms improved, but he died of pneumonia on November 15, 1994.","tokens":[{"text":"He","start":0,"end":2,"id":0,"ws":true},{"text":"was","start":3,"end":6,"id":1,"ws":true},{"text":"initially","start":7,"end":16,"id":2,"ws":true},{"text":"treated","start":17,"end":24,"id":3,"ws":true},{"text":"with","start":25,"end":29,"id":4,"ws":true},{"text":"combination","start":30,"end":41,"id":5,"ws":true},{"text":"chemotherapy","start":42,"end":54,"id":6,"ws":true},{"text":"regimen","start":55,"end":62,"id":7,"ws":true},{"text":"of","start":63,"end":65,"id":8,"ws":true},{"text":"vincristine","start":66,"end":77,"id":9,"ws":true},{"text":",","start":78,"end":79,"id":10,"ws":true},{"text":"actinomycin-D","start":80,"end":93,"id":11,"ws":true},{"text":"and","start":94,"end":97,"id":12,"ws":true},{"text":"cyclophosphamide","start":98,"end":114,"id":13,"ws":true},{"text":"(","start":115,"end":116,"id":14,"ws":true},{"text":"VAC","start":117,"end":120,"id":15,"ws":true},{"text":"therapy","start":121,"end":128,"id":16,"ws":true},{"text":")","start":129,"end":130,"id":17,"ws":true},{"text":".","start":131,"end":132,"id":18,"ws":false}],"spans":[{"start":66,"end":77,"token_start":9,"token_end":9,"label":"DRUG"},{"start":80,"end":93,"token_start":11,"token_end":11,"label":"DRUG"},{"start":98,"end":114,"token_start":13,"token_end":13,"label":"DRUG"}],"_input_hash":1557412523,"_task_hash":-2119098685,"_session_id":"drug_drug_pilot_shared-yakir","_view_id":"blocks","relations":[{"head":9,"child":11,"head_span":{"start":66,"end":77,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":80,"end":93,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":13,"child":11,"head_span":{"start":98,"end":114,"token_start":13,"token_end":13,"label":"DRUG"},"child_span":{"start":80,"end":93,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"However , when a lung mass was noted two months later , he started to receive combination chemotherapy consisting of cyclophosphamide , adriamycin , vincristine , and prednisolone every three months .","paragraph":"<h3><u>[Lymphomatoid granulomatosis (LYG) occurring in a patient with follicular lymphoma during remission].</u></h3>A 49 years-old man presented with dry cough, low grade fever, and abnormal shadow on a chest X-ray. He had suffered from follicular lymphoma of the liver 5 years previously. He received irradiation therapy in combination with chemotherapy for approximately three years and had been in complete remission. Physical and radiological examination revealed pleural effusion and softly dense masses in the right lung. The laboratory data were within normal limits. He was diagnosed as having lymphomatoid granulomatosis (LYG) by open lung biopsy. The lung lesion was mainly infiltrated with T cells. The patient received <b style='color:Tomato;'><i>prednisolone</i></b> and the lung lesions disappeared. <b style='color:DodgerBlue;'><i>However</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>lung</i></b> <b style='color:DodgerBlue;'><i>mass</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>noted</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>later</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>he</i></b> <b style='color:DodgerBlue;'><i>started</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>receive</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>consisting</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>adriamycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>prednisolone</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>three</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>.</i></b> He has not shown relapse of LYG so far. To investigate the association between the preceding follicular lymphoma and subsequent LYG at this time, DNA analysis using the PCR technique was carried out. The LYG lesion did not show a rearranged band for the JH probe, while the paraffin-embedded specimen of the preceding follicular lymphoma had shown rearranged band for the JH band. Southern blot analysis of the LYG lesion, showed no rearrangement for TCR beta, gamma or JH probe. These findings indicate that the LYG was different from the preceding follicular lymphoma in terms of origin. LYG is considered to be induced in the immunosuppressive state due to lymphoma.","tokens":[{"text":"However","start":0,"end":7,"id":0,"ws":true},{"text":",","start":8,"end":9,"id":1,"ws":true},{"text":"when","start":10,"end":14,"id":2,"ws":true},{"text":"a","start":15,"end":16,"id":3,"ws":true},{"text":"lung","start":17,"end":21,"id":4,"ws":true},{"text":"mass","start":22,"end":26,"id":5,"ws":true},{"text":"was","start":27,"end":30,"id":6,"ws":true},{"text":"noted","start":31,"end":36,"id":7,"ws":true},{"text":"two","start":37,"end":40,"id":8,"ws":true},{"text":"months","start":41,"end":47,"id":9,"ws":true},{"text":"later","start":48,"end":53,"id":10,"ws":true},{"text":",","start":54,"end":55,"id":11,"ws":true},{"text":"he","start":56,"end":58,"id":12,"ws":true},{"text":"started","start":59,"end":66,"id":13,"ws":true},{"text":"to","start":67,"end":69,"id":14,"ws":true},{"text":"receive","start":70,"end":77,"id":15,"ws":true},{"text":"combination","start":78,"end":89,"id":16,"ws":true},{"text":"chemotherapy","start":90,"end":102,"id":17,"ws":true},{"text":"consisting","start":103,"end":113,"id":18,"ws":true},{"text":"of","start":114,"end":116,"id":19,"ws":true},{"text":"cyclophosphamide","start":117,"end":133,"id":20,"ws":true},{"text":",","start":134,"end":135,"id":21,"ws":true},{"text":"adriamycin","start":136,"end":146,"id":22,"ws":true},{"text":",","start":147,"end":148,"id":23,"ws":true},{"text":"vincristine","start":149,"end":160,"id":24,"ws":true},{"text":",","start":161,"end":162,"id":25,"ws":true},{"text":"and","start":163,"end":166,"id":26,"ws":true},{"text":"prednisolone","start":167,"end":179,"id":27,"ws":true},{"text":"every","start":180,"end":185,"id":28,"ws":true},{"text":"three","start":186,"end":191,"id":29,"ws":true},{"text":"months","start":192,"end":198,"id":30,"ws":true},{"text":".","start":199,"end":200,"id":31,"ws":false}],"spans":[{"start":117,"end":133,"token_start":20,"token_end":20,"label":"DRUG"},{"start":136,"end":146,"token_start":22,"token_end":22,"label":"DRUG"},{"start":149,"end":160,"token_start":24,"token_end":24,"label":"DRUG"},{"start":167,"end":179,"token_start":27,"token_end":27,"label":"DRUG"}],"_input_hash":8987266,"_task_hash":528717002,"_session_id":"drug_drug_pilot_shared-yakir","_view_id":"blocks","relations":[{"head":20,"child":22,"head_span":{"start":117,"end":133,"token_start":20,"token_end":20,"label":"DRUG"},"child_span":{"start":136,"end":146,"token_start":22,"token_end":22,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":24,"child":27,"head_span":{"start":149,"end":160,"token_start":24,"token_end":24,"label":"DRUG"},"child_span":{"start":167,"end":179,"token_start":27,"token_end":27,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":22,"child":24,"head_span":{"start":136,"end":146,"token_start":22,"token_end":22,"label":"DRUG"},"child_span":{"start":149,"end":160,"token_start":24,"token_end":24,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"Three patients treated initially with propranolol alone have required substitution of amiodarone due to refractory congestive heart failure .","paragraph":"<h3><u>The role of beta-blockade therapy for ventricular tachycardia induced with isoproterenol: a prospective analysis.</u></h3>Isoproterenol is sometimes required for ventricular tachycardia (VT) induction. However, the role of beta-blockade for treatment of such VT has not been critically assessed. The use of beta-blockade was evaluated prospectively in 14 consecutive patients who required isoproterenol 2.4 +/- 1.3 (+/- S.D.) micrograms/min to induce sustained monomorphic VT (greater than 30 seconds, or requiring termination due to hemodynamic collapse) after a negative baseline study. The VT mechanisms were enhanced automaticity (group A, six patients), triggered automaticity (group B, three patients), and reentry (group C, five patients). Groups A and B had serial intravenous electropharmacologic tests with <b style='color:Tomato;'><i>propranolol</i></b> alone (0.2 mg/kg), <b style='color:Tomato;'><i>verapamil</i></b> alone (0.15 mg/kg), and <b style='color:Tomato;'><i>propranolol</i></b> plus <b style='color:Tomato;'><i>verapamil</i></b>, and group C had serial tests with <b style='color:Tomato;'><i>propranolol</i></b> alone, <b style='color:Tomato;'><i>procainamide</i></b> or <b style='color:Tomato;'><i>quinidine</i></b> (class Ia drug) alone, and <b style='color:Tomato;'><i>propranolol</i></b> plus a class Ia drug until VT could no longer be induced. All six patients in group A responded to <b style='color:Tomato;'><i>propranolol</i></b> alone. In group B, one patient responded to <b style='color:Tomato;'><i>verapamil</i></b> alone, and two patients responded to <b style='color:Tomato;'><i>propranolol</i></b> plus <b style='color:Tomato;'><i>verapamil</i></b>. In group C, three patients responded to <b style='color:Tomato;'><i>propranolol</i></b> alone, one patient responded to a class Ia drug alone, and one patient responded to <b style='color:Tomato;'><i>propranolol</i></b> plus a class Ia drug. During a follow-up of 7 to 37 (17.9 +/- 10.7) (+/- S.D.) months, VT has not recurred in any patient. <b style='color:DodgerBlue;'><i>Three</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>initially</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>propranolol</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>required</i></b> <b style='color:DodgerBlue;'><i>substitution</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>amiodarone</i></b> <b style='color:DodgerBlue;'><i>due</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>refractory</i></b> <b style='color:DodgerBlue;'><i>congestive</i></b> <b style='color:DodgerBlue;'><i>heart</i></b> <b style='color:DodgerBlue;'><i>failure</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In patients requiring isoproterenol for VT induction, beta-blockade alone appears to be effective in preventing reinduction of VT caused by enhanced automaticity. A heterogeneous response occurs when the VT mechanisms are triggered automaticity or reentry.","tokens":[{"text":"Three","start":0,"end":5,"id":0,"ws":true},{"text":"patients","start":6,"end":14,"id":1,"ws":true},{"text":"treated","start":15,"end":22,"id":2,"ws":true},{"text":"initially","start":23,"end":32,"id":3,"ws":true},{"text":"with","start":33,"end":37,"id":4,"ws":true},{"text":"propranolol","start":38,"end":49,"id":5,"ws":true},{"text":"alone","start":50,"end":55,"id":6,"ws":true},{"text":"have","start":56,"end":60,"id":7,"ws":true},{"text":"required","start":61,"end":69,"id":8,"ws":true},{"text":"substitution","start":70,"end":82,"id":9,"ws":true},{"text":"of","start":83,"end":85,"id":10,"ws":true},{"text":"amiodarone","start":86,"end":96,"id":11,"ws":true},{"text":"due","start":97,"end":100,"id":12,"ws":true},{"text":"to","start":101,"end":103,"id":13,"ws":true},{"text":"refractory","start":104,"end":114,"id":14,"ws":true},{"text":"congestive","start":115,"end":125,"id":15,"ws":true},{"text":"heart","start":126,"end":131,"id":16,"ws":true},{"text":"failure","start":132,"end":139,"id":17,"ws":true},{"text":".","start":140,"end":141,"id":18,"ws":false}],"spans":[{"start":38,"end":49,"token_start":5,"token_end":5,"label":"DRUG"},{"start":86,"end":96,"token_start":11,"token_end":11,"label":"DRUG"}],"_input_hash":-632828286,"_task_hash":-1526074177,"_session_id":"drug_drug_pilot_shared-yakir","_view_id":"blocks","relations":[],"answer":"ignore"}
{"text":"These studies suggest a slight advantage to the combined approaches that contain flutamide and bicalutamide , but the lack of dramatic differences in outcome makes monotherapy reasonable , especially in patients with more indolent disease .","paragraph":"<h3><u>The selection of hormonal therapy in prostate cancer: who, when, and for how long?</u></h3>Androgen deprivation is the foundation for the systemic therapy of advanced prostate cancer. Multiple trials have tested combined androgen blockade versus androgen deprivation alone in patients with advanced disease. <b style='color:DodgerBlue;'><i>These</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>suggest</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>slight</i></b> <b style='color:DodgerBlue;'><i>advantage</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>approaches</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>contain</i></b> <b style='color:MediumOrchid;'><i>flutamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>bicalutamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>lack</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>dramatic</i></b> <b style='color:DodgerBlue;'><i>differences</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>outcome</i></b> <b style='color:DodgerBlue;'><i>makes</i></b> <b style='color:DodgerBlue;'><i>monotherapy</i></b> <b style='color:DodgerBlue;'><i>reasonable</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>especially</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>indolent</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Intermittent androgen deprivation is an alternative that may allow patients to reduce the total time on androgen suppression as well as possibly delay the onset of androgen independence. A number of secondary hormonal therapies, including deferred and secondary antiandrogens, <b style='color:Tomato;'><i>ketoconazole</i></b>, and estrogens have shown modest response proportions. Patients with less advanced disease such as a rising prostate-specific antigen have varied outcomes, and no standard approach exists. In this group, noncastrating forms of hormonal therapy are being evaluated. Patients undergoing definitive local therapy who have high-risk features may benefit from early, as opposed to deferred, androgen deprivation. This review examines the evidence for the current state of the art in hormonal therapy in patients with prostate cancer and focuses, in particular, on treatment composition and timing as well as the rationale for the use of hormonal therapy in early stage disease.","tokens":[{"text":"These","start":0,"end":5,"id":0,"ws":true},{"text":"studies","start":6,"end":13,"id":1,"ws":true},{"text":"suggest","start":14,"end":21,"id":2,"ws":true},{"text":"a","start":22,"end":23,"id":3,"ws":true},{"text":"slight","start":24,"end":30,"id":4,"ws":true},{"text":"advantage","start":31,"end":40,"id":5,"ws":true},{"text":"to","start":41,"end":43,"id":6,"ws":true},{"text":"the","start":44,"end":47,"id":7,"ws":true},{"text":"combined","start":48,"end":56,"id":8,"ws":true},{"text":"approaches","start":57,"end":67,"id":9,"ws":true},{"text":"that","start":68,"end":72,"id":10,"ws":true},{"text":"contain","start":73,"end":80,"id":11,"ws":true},{"text":"flutamide","start":81,"end":90,"id":12,"ws":true},{"text":"and","start":91,"end":94,"id":13,"ws":true},{"text":"bicalutamide","start":95,"end":107,"id":14,"ws":true},{"text":",","start":108,"end":109,"id":15,"ws":true},{"text":"but","start":110,"end":113,"id":16,"ws":true},{"text":"the","start":114,"end":117,"id":17,"ws":true},{"text":"lack","start":118,"end":122,"id":18,"ws":true},{"text":"of","start":123,"end":125,"id":19,"ws":true},{"text":"dramatic","start":126,"end":134,"id":20,"ws":true},{"text":"differences","start":135,"end":146,"id":21,"ws":true},{"text":"in","start":147,"end":149,"id":22,"ws":true},{"text":"outcome","start":150,"end":157,"id":23,"ws":true},{"text":"makes","start":158,"end":163,"id":24,"ws":true},{"text":"monotherapy","start":164,"end":175,"id":25,"ws":true},{"text":"reasonable","start":176,"end":186,"id":26,"ws":true},{"text":",","start":187,"end":188,"id":27,"ws":true},{"text":"especially","start":189,"end":199,"id":28,"ws":true},{"text":"in","start":200,"end":202,"id":29,"ws":true},{"text":"patients","start":203,"end":211,"id":30,"ws":true},{"text":"with","start":212,"end":216,"id":31,"ws":true},{"text":"more","start":217,"end":221,"id":32,"ws":true},{"text":"indolent","start":222,"end":230,"id":33,"ws":true},{"text":"disease","start":231,"end":238,"id":34,"ws":true},{"text":".","start":239,"end":240,"id":35,"ws":false}],"spans":[{"start":81,"end":90,"token_start":12,"token_end":12,"label":"DRUG"},{"start":95,"end":107,"token_start":14,"token_end":14,"label":"DRUG"}],"_input_hash":137769162,"_task_hash":410888998,"_session_id":"drug_drug_pilot_shared-yakir","_view_id":"blocks","relations":[],"answer":"ignore"}
{"text":"We examined the feasibility and safety of using paclitaxel and trastuzumab as maintenance therapy after high-dose chemotherapy ( HDC ) with autologous hematopoietic stem cell transplantation ( AHST ) for patients with HER2-positive metastatic breast cancer .","paragraph":"<h3><u>Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation.</u></h3> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>examined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>feasibility</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>maintenance</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>HDC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>autologous</i></b> <b style='color:DodgerBlue;'><i>hematopoietic</i></b> <b style='color:DodgerBlue;'><i>stem</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>transplantation</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AHST</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>HER2-positive</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Ten patients (9 women and 1 man) were enrolled in the study. The median age was 46.5 years (range, 27-65 years). The median follow-up time was 1003 days (range, 216-2526 days). All patients had metastatic disease, but 2 had only bone metastasis. One patient had complete response, 6 had partial response and 3 had stable disease to the standard-dose chemotherapy prior to transplantation. The conditioning regimen consisted of <b style='color:Tomato;'><i>cyclophosphamide</i></b>, <b style='color:Tomato;'><i>carmustine</i></b>, and <b style='color:Tomato;'><i>thiotepa</i></b>. After AHST, patients received weekly <b style='color:Tomato;'><i>paclitaxel</i></b> for 12 doses and <b style='color:Tomato;'><i>trastuzumab</i></b> every 3 weeks for 1 year as maintenance therapy. All patients experienced successful engraftment. The only grade 4 toxic effects observed were leukopenia and thrombocytopenia. The most common grade 3 toxic effect was neutropenic fever. No treatment-related deaths were observed. The median progression-free survival time was 441 days, and the median overall survival time was 955 days. Two patients died in accidents while their disease remained in remission. Five patients died with disease progression. At the time of this report, 3 patients are alive with stable disease, 1 of whom has remained free of disease progression for 2526 days since transplantation. Our findings indicate that <b style='color:Tomato;'><i>paclitaxel</i></b> plus <b style='color:Tomato;'><i>trastuzumab</i></b> as maintenance therapy after HDC with AHST for patients with HER2-positive metastatic breast cancer not only is feasible and safe but also results in survival outcomes similar to historical results. ","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"examined","start":3,"end":11,"id":1,"ws":true},{"text":"the","start":12,"end":15,"id":2,"ws":true},{"text":"feasibility","start":16,"end":27,"id":3,"ws":true},{"text":"and","start":28,"end":31,"id":4,"ws":true},{"text":"safety","start":32,"end":38,"id":5,"ws":true},{"text":"of","start":39,"end":41,"id":6,"ws":true},{"text":"using","start":42,"end":47,"id":7,"ws":true},{"text":"paclitaxel","start":48,"end":58,"id":8,"ws":true},{"text":"and","start":59,"end":62,"id":9,"ws":true},{"text":"trastuzumab","start":63,"end":74,"id":10,"ws":true},{"text":"as","start":75,"end":77,"id":11,"ws":true},{"text":"maintenance","start":78,"end":89,"id":12,"ws":true},{"text":"therapy","start":90,"end":97,"id":13,"ws":true},{"text":"after","start":98,"end":103,"id":14,"ws":true},{"text":"high-dose","start":104,"end":113,"id":15,"ws":true},{"text":"chemotherapy","start":114,"end":126,"id":16,"ws":true},{"text":"(","start":127,"end":128,"id":17,"ws":true},{"text":"HDC","start":129,"end":132,"id":18,"ws":true},{"text":")","start":133,"end":134,"id":19,"ws":true},{"text":"with","start":135,"end":139,"id":20,"ws":true},{"text":"autologous","start":140,"end":150,"id":21,"ws":true},{"text":"hematopoietic","start":151,"end":164,"id":22,"ws":true},{"text":"stem","start":165,"end":169,"id":23,"ws":true},{"text":"cell","start":170,"end":174,"id":24,"ws":true},{"text":"transplantation","start":175,"end":190,"id":25,"ws":true},{"text":"(","start":191,"end":192,"id":26,"ws":true},{"text":"AHST","start":193,"end":197,"id":27,"ws":true},{"text":")","start":198,"end":199,"id":28,"ws":true},{"text":"for","start":200,"end":203,"id":29,"ws":true},{"text":"patients","start":204,"end":212,"id":30,"ws":true},{"text":"with","start":213,"end":217,"id":31,"ws":true},{"text":"HER2-positive","start":218,"end":231,"id":32,"ws":true},{"text":"metastatic","start":232,"end":242,"id":33,"ws":true},{"text":"breast","start":243,"end":249,"id":34,"ws":true},{"text":"cancer","start":250,"end":256,"id":35,"ws":true},{"text":".","start":257,"end":258,"id":36,"ws":false}],"spans":[{"start":48,"end":58,"token_start":8,"token_end":8,"label":"DRUG"},{"start":63,"end":74,"token_start":10,"token_end":10,"label":"DRUG"}],"_input_hash":-1578970086,"_task_hash":304060663,"_session_id":"drug_drug_pilot_shared-yakir","_view_id":"blocks","relations":[{"head":8,"child":10,"head_span":{"start":48,"end":58,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":63,"end":74,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T1"],"answer":"accept"}
{"text":"Dual antiplatelet therapy with aspirin and clopidogrel ( the preferred thienopyridine because of its superior hematologic safety ) is recommended for at least 4 weeks to prevent subacute stent thrombosis with bare-metal stents and 3 to 6 months to prevent late-stent thrombosis with drug-eluting stents .","paragraph":"<h3><u>Long-term care after percutaneous coronary intervention: focus on the role of antiplatelet therapy.</u></h3>Arterial wall injury caused by percutaneous coronary intervention (PCI) triggers transient platelet activation and mural thrombosis; these effects are superimposed on the preexisting platelet hyperreactivity associated with underlying atherothrombosis. Platelet activation has been implicated in the major complications of PCI: acute and subacute thrombosis and restenosis. Antithrombotic and anticoagulant therapy minimizes thrombotic complications after PCI. <b style='color:Tomato;'><i>aspirin</i></b> plus a thienopyridine (<b style='color:Tomato;'><i>ticlopidine</i></b> or <b style='color:Tomato;'><i>clopidogrel</i></b>) is more effective than <b style='color:Tomato;'><i>aspirin</i></b> plus <b style='color:Tomato;'><i>heparin</i></b> and extended <b style='color:Tomato;'><i>warfarin</i></b> therapy in preventing periprocedural ischemic events and subsequent stent thrombosis and results in less major and minor bleeding. <b style='color:DodgerBlue;'><i>Dual</i></b> <b style='color:DodgerBlue;'><i>antiplatelet</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>aspirin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>clopidogrel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>preferred</i></b> <b style='color:DodgerBlue;'><i>thienopyridine</i></b> <b style='color:DodgerBlue;'><i>because</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>its</i></b> <b style='color:DodgerBlue;'><i>superior</i></b> <b style='color:DodgerBlue;'><i>hematologic</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>recommended</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>least</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>prevent</i></b> <b style='color:DodgerBlue;'><i>subacute</i></b> <b style='color:DodgerBlue;'><i>stent</i></b> <b style='color:DodgerBlue;'><i>thrombosis</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>bare-metal</i></b> <b style='color:DodgerBlue;'><i>stents</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>prevent</i></b> <b style='color:DodgerBlue;'><i>late-stent</i></b> <b style='color:DodgerBlue;'><i>thrombosis</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>drug-eluting</i></b> <b style='color:DodgerBlue;'><i>stents</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Coronary atherothrombosis is a diffuse vascular disease, and reduction of the risk of future ischemic events requires strategies that extend beyond the focal treatment of stenotic lesions. Optimal long-term care after PCI requires aggressive systemic pharmacotherapy (antiplatelet agents, statins, beta-blockers, and angiotensin-converting enzyme Inhibitors) in conjunction with therapeutic lifestyle changes (smoking cessation, weight reduction, dietary measures, and exercise). In this context, dual antiplatelet therapy (<b style='color:Tomato;'><i>aspirin</i></b> plus <b style='color:Tomato;'><i>clopidogrel</i></b>) is recommended for at least 12 months after PCI for prophylaxis of future atherothrombotic events.","tokens":[{"text":"Dual","start":0,"end":4,"id":0,"ws":true},{"text":"antiplatelet","start":5,"end":17,"id":1,"ws":true},{"text":"therapy","start":18,"end":25,"id":2,"ws":true},{"text":"with","start":26,"end":30,"id":3,"ws":true},{"text":"aspirin","start":31,"end":38,"id":4,"ws":true},{"text":"and","start":39,"end":42,"id":5,"ws":true},{"text":"clopidogrel","start":43,"end":54,"id":6,"ws":true},{"text":"(","start":55,"end":56,"id":7,"ws":true},{"text":"the","start":57,"end":60,"id":8,"ws":true},{"text":"preferred","start":61,"end":70,"id":9,"ws":true},{"text":"thienopyridine","start":71,"end":85,"id":10,"ws":true},{"text":"because","start":86,"end":93,"id":11,"ws":true},{"text":"of","start":94,"end":96,"id":12,"ws":true},{"text":"its","start":97,"end":100,"id":13,"ws":true},{"text":"superior","start":101,"end":109,"id":14,"ws":true},{"text":"hematologic","start":110,"end":121,"id":15,"ws":true},{"text":"safety","start":122,"end":128,"id":16,"ws":true},{"text":")","start":129,"end":130,"id":17,"ws":true},{"text":"is","start":131,"end":133,"id":18,"ws":true},{"text":"recommended","start":134,"end":145,"id":19,"ws":true},{"text":"for","start":146,"end":149,"id":20,"ws":true},{"text":"at","start":150,"end":152,"id":21,"ws":true},{"text":"least","start":153,"end":158,"id":22,"ws":true},{"text":"4","start":159,"end":160,"id":23,"ws":true},{"text":"weeks","start":161,"end":166,"id":24,"ws":true},{"text":"to","start":167,"end":169,"id":25,"ws":true},{"text":"prevent","start":170,"end":177,"id":26,"ws":true},{"text":"subacute","start":178,"end":186,"id":27,"ws":true},{"text":"stent","start":187,"end":192,"id":28,"ws":true},{"text":"thrombosis","start":193,"end":203,"id":29,"ws":true},{"text":"with","start":204,"end":208,"id":30,"ws":true},{"text":"bare-metal","start":209,"end":219,"id":31,"ws":true},{"text":"stents","start":220,"end":226,"id":32,"ws":true},{"text":"and","start":227,"end":230,"id":33,"ws":true},{"text":"3","start":231,"end":232,"id":34,"ws":true},{"text":"to","start":233,"end":235,"id":35,"ws":true},{"text":"6","start":236,"end":237,"id":36,"ws":true},{"text":"months","start":238,"end":244,"id":37,"ws":true},{"text":"to","start":245,"end":247,"id":38,"ws":true},{"text":"prevent","start":248,"end":255,"id":39,"ws":true},{"text":"late-stent","start":256,"end":266,"id":40,"ws":true},{"text":"thrombosis","start":267,"end":277,"id":41,"ws":true},{"text":"with","start":278,"end":282,"id":42,"ws":true},{"text":"drug-eluting","start":283,"end":295,"id":43,"ws":true},{"text":"stents","start":296,"end":302,"id":44,"ws":true},{"text":".","start":303,"end":304,"id":45,"ws":false}],"spans":[{"start":31,"end":38,"token_start":4,"token_end":4,"label":"DRUG"},{"start":43,"end":54,"token_start":6,"token_end":6,"label":"DRUG"}],"_input_hash":1471340217,"_task_hash":-1789027077,"_session_id":"drug_drug_pilot_shared-yakir","_view_id":"blocks","relations":[{"head":4,"child":6,"head_span":{"start":31,"end":38,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":43,"end":54,"token_start":6,"token_end":6,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T1"],"answer":"accept"}
{"text":"Furthermore , in non-metastatic castration-resistant prostate cancer ( M0 CRPC ) , two second-generation anti-androgens , apalutamide and enzalutamide , when used in combination with ADT , have demonstrated a significant benefit in metastasis-free survival .","paragraph":"<h3><u>Recent trends in the management of advanced prostate cancer.</u></h3>Advanced prostate cancer includes a wide spectrum of disease ranging from hormone na\u00efve or hormone sensitive to castration resistant, both containing populations of men who have demonstrable metastatic and non-metastatic states. The mainstay of treatment for metastatic hormone-sensitive prostate cancer is androgen deprivation therapy (ADT). However, recent level 1 evidence demonstrates that the addition of chemotherapy or <b style='color:Tomato;'><i>abiraterone</i></b> acetate to ADT results in significant survival advantage as compared with ADT alone. <b style='color:DodgerBlue;'><i>Furthermore</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>non-metastatic</i></b> <b style='color:DodgerBlue;'><i>castration-resistant</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>M0</i></b> <b style='color:DodgerBlue;'><i>CRPC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>second-generation</i></b> <b style='color:DodgerBlue;'><i>anti-androgens</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>apalutamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>enzalutamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>ADT</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>significant</i></b> <b style='color:DodgerBlue;'><i>benefit</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>metastasis-free</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Here, we review the most recent studies leading to these significant changes in the treatment of advanced prostate cancer.","tokens":[{"text":"Furthermore","start":0,"end":11,"id":0,"ws":true},{"text":",","start":12,"end":13,"id":1,"ws":true},{"text":"in","start":14,"end":16,"id":2,"ws":true},{"text":"non-metastatic","start":17,"end":31,"id":3,"ws":true},{"text":"castration-resistant","start":32,"end":52,"id":4,"ws":true},{"text":"prostate","start":53,"end":61,"id":5,"ws":true},{"text":"cancer","start":62,"end":68,"id":6,"ws":true},{"text":"(","start":69,"end":70,"id":7,"ws":true},{"text":"M0","start":71,"end":73,"id":8,"ws":true},{"text":"CRPC","start":74,"end":78,"id":9,"ws":true},{"text":")","start":79,"end":80,"id":10,"ws":true},{"text":",","start":81,"end":82,"id":11,"ws":true},{"text":"two","start":83,"end":86,"id":12,"ws":true},{"text":"second-generation","start":87,"end":104,"id":13,"ws":true},{"text":"anti-androgens","start":105,"end":119,"id":14,"ws":true},{"text":",","start":120,"end":121,"id":15,"ws":true},{"text":"apalutamide","start":122,"end":133,"id":16,"ws":true},{"text":"and","start":134,"end":137,"id":17,"ws":true},{"text":"enzalutamide","start":138,"end":150,"id":18,"ws":true},{"text":",","start":151,"end":152,"id":19,"ws":true},{"text":"when","start":153,"end":157,"id":20,"ws":true},{"text":"used","start":158,"end":162,"id":21,"ws":true},{"text":"in","start":163,"end":165,"id":22,"ws":true},{"text":"combination","start":166,"end":177,"id":23,"ws":true},{"text":"with","start":178,"end":182,"id":24,"ws":true},{"text":"ADT","start":183,"end":186,"id":25,"ws":true},{"text":",","start":187,"end":188,"id":26,"ws":true},{"text":"have","start":189,"end":193,"id":27,"ws":true},{"text":"demonstrated","start":194,"end":206,"id":28,"ws":true},{"text":"a","start":207,"end":208,"id":29,"ws":true},{"text":"significant","start":209,"end":220,"id":30,"ws":true},{"text":"benefit","start":221,"end":228,"id":31,"ws":true},{"text":"in","start":229,"end":231,"id":32,"ws":true},{"text":"metastasis-free","start":232,"end":247,"id":33,"ws":true},{"text":"survival","start":248,"end":256,"id":34,"ws":true},{"text":".","start":257,"end":258,"id":35,"ws":false}],"spans":[{"start":122,"end":133,"token_start":16,"token_end":16,"label":"DRUG"},{"start":138,"end":150,"token_start":18,"token_end":18,"label":"DRUG"}],"_input_hash":236482726,"_task_hash":-1620523265,"_session_id":"drug_drug_pilot_shared-yakir","_view_id":"blocks","relations":[{"head":16,"child":25,"head_span":{"start":122,"end":133,"token_start":16,"token_end":16,"label":"DRUG"},"child_span":{"start":183,"end":186,"token_start":25,"token_end":25,"label":null},"color":"#c5bdf4","label":"POS1"},{"head":18,"child":25,"head_span":{"start":138,"end":150,"token_start":18,"token_end":18,"label":"DRUG"},"child_span":{"start":183,"end":186,"token_start":25,"token_end":25,"label":null},"color":"#ffd882","label":"POS2"}],"radio":["POS10","POS1T0","POS20","POS2T0"],"answer":"accept"}
{"text":"A screening method based on liquid chromatography-electrospray mass spectrometry for the simultaneous determination of six corticosteroids ( betamethasone 17-valerate BM 17-V , beclomethasone BC , beclomethasone dipropionate BCDP , methylprednisolone MP , budesonide BD , flunisolide FN ) was developed in order to control their illegal use in cosmetic and natural products .","paragraph":"<h3><u>LC-MS method for the simultaneous determination of six glucocorticoids in pharmaceutical formulations and counterfeit cosmetic products.</u></h3> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>screening</i></b> <b style='color:DodgerBlue;'><i>method</i></b> <b style='color:DodgerBlue;'><i>based</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>liquid</i></b> <b style='color:DodgerBlue;'><i>chromatography-electrospray</i></b> <b style='color:DodgerBlue;'><i>mass</i></b> <b style='color:DodgerBlue;'><i>spectrometry</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>simultaneous</i></b> <b style='color:DodgerBlue;'><i>determination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>six</i></b> <b style='color:DodgerBlue;'><i>corticosteroids</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>betamethasone</i></b> <b style='color:DodgerBlue;'><i>17-valerate</i></b> <b style='color:DodgerBlue;'><i>BM</i></b> <b style='color:DodgerBlue;'><i>17-V</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>beclomethasone</i></b> <b style='color:DodgerBlue;'><i>BC</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>beclomethasone</i></b> <b style='color:DodgerBlue;'><i>dipropionate</i></b> <b style='color:DodgerBlue;'><i>BCDP</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>methylprednisolone</i></b> <b style='color:DodgerBlue;'><i>MP</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>budesonide</i></b> <b style='color:DodgerBlue;'><i>BD</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>flunisolide</i></b> <b style='color:DodgerBlue;'><i>FN</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>developed</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>order</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>control</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>illegal</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>cosmetic</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>natural</i></b> <b style='color:DodgerBlue;'><i>products</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Indeed, despite corticosteroids are banned in cosmetics, counterfeit products might be present on the market, representing a health hazard. Therefore, effective analytical methods are required to rapidly screen over the counter products in health care shops for counterfeit corticosteroids. The analytical method involves the employment of a Waters Synergy C18 column (150mm\u00d72.0mm I.D.) by using the following mobile phase: A (0.1% formic acid in acetonitrile), B (0.1% formic acid in water) in a linear gradient (from A-B 25:75, v/v to A-B 95:5, v/v in 30min) at the flow rate of 0.3mL/min. The detection was performed with an ion trap (IT) mass spectrometer in positive polarity, total ion current (TIC) and tandem mass modalities for qualitative purpose; single ion monitoring (SIM) mode was used for quantitative analysis on the ESI generated most abundant ion for each steroid. The method was fully validated in terms of precision, detection and quantification limits, linearity, recovery, and it was applied to the identification and quantification of corticosteroids in pharmaceutical formulations and cosmetic products. The mean recovery of BM 17-V, BC, BCDP, MP, BD and FN were found to be 101.3, 101.5, 98.8, 98.9, 98.1, 99.0%, respectively. Limits of quantitation (LOQ) were comprised in the range 29-95ng/mL. To the best of our knowledge, for the first time this mix of glucocorticoids were simultaneously determined in cosmetic products by using a fully validated method. BMV, in its two isomeric forms BM 17-V and BM 21-V, was found to be illegally present in one cream sample (A) with the total concentration level of 0.036% (w/w). ","tokens":[{"text":"A","start":0,"end":1,"id":0,"ws":true},{"text":"screening","start":2,"end":11,"id":1,"ws":true},{"text":"method","start":12,"end":18,"id":2,"ws":true},{"text":"based","start":19,"end":24,"id":3,"ws":true},{"text":"on","start":25,"end":27,"id":4,"ws":true},{"text":"liquid","start":28,"end":34,"id":5,"ws":true},{"text":"chromatography-electrospray","start":35,"end":62,"id":6,"ws":true},{"text":"mass","start":63,"end":67,"id":7,"ws":true},{"text":"spectrometry","start":68,"end":80,"id":8,"ws":true},{"text":"for","start":81,"end":84,"id":9,"ws":true},{"text":"the","start":85,"end":88,"id":10,"ws":true},{"text":"simultaneous","start":89,"end":101,"id":11,"ws":true},{"text":"determination","start":102,"end":115,"id":12,"ws":true},{"text":"of","start":116,"end":118,"id":13,"ws":true},{"text":"six","start":119,"end":122,"id":14,"ws":true},{"text":"corticosteroids","start":123,"end":138,"id":15,"ws":true},{"text":"(","start":139,"end":140,"id":16,"ws":true},{"text":"betamethasone","start":141,"end":154,"id":17,"ws":true},{"text":"17-valerate","start":155,"end":166,"id":18,"ws":true},{"text":"BM","start":167,"end":169,"id":19,"ws":true},{"text":"17-V","start":170,"end":174,"id":20,"ws":true},{"text":",","start":175,"end":176,"id":21,"ws":true},{"text":"beclomethasone","start":177,"end":191,"id":22,"ws":true},{"text":"BC","start":192,"end":194,"id":23,"ws":true},{"text":",","start":195,"end":196,"id":24,"ws":true},{"text":"beclomethasone","start":197,"end":211,"id":25,"ws":true},{"text":"dipropionate","start":212,"end":224,"id":26,"ws":true},{"text":"BCDP","start":225,"end":229,"id":27,"ws":true},{"text":",","start":230,"end":231,"id":28,"ws":true},{"text":"methylprednisolone","start":232,"end":250,"id":29,"ws":true},{"text":"MP","start":251,"end":253,"id":30,"ws":true},{"text":",","start":254,"end":255,"id":31,"ws":true},{"text":"budesonide","start":256,"end":266,"id":32,"ws":true},{"text":"BD","start":267,"end":269,"id":33,"ws":true},{"text":",","start":270,"end":271,"id":34,"ws":true},{"text":"flunisolide","start":272,"end":283,"id":35,"ws":true},{"text":"FN","start":284,"end":286,"id":36,"ws":true},{"text":")","start":287,"end":288,"id":37,"ws":true},{"text":"was","start":289,"end":292,"id":38,"ws":true},{"text":"developed","start":293,"end":302,"id":39,"ws":true},{"text":"in","start":303,"end":305,"id":40,"ws":true},{"text":"order","start":306,"end":311,"id":41,"ws":true},{"text":"to","start":312,"end":314,"id":42,"ws":true},{"text":"control","start":315,"end":322,"id":43,"ws":true},{"text":"their","start":323,"end":328,"id":44,"ws":true},{"text":"illegal","start":329,"end":336,"id":45,"ws":true},{"text":"use","start":337,"end":340,"id":46,"ws":true},{"text":"in","start":341,"end":343,"id":47,"ws":true},{"text":"cosmetic","start":344,"end":352,"id":48,"ws":true},{"text":"and","start":353,"end":356,"id":49,"ws":true},{"text":"natural","start":357,"end":364,"id":50,"ws":true},{"text":"products","start":365,"end":373,"id":51,"ws":true},{"text":".","start":374,"end":375,"id":52,"ws":false}],"spans":[{"start":141,"end":154,"token_start":17,"token_end":17,"label":"DRUG"},{"start":177,"end":191,"token_start":22,"token_end":22,"label":"DRUG"},{"start":197,"end":211,"token_start":25,"token_end":25,"label":"DRUG"},{"start":232,"end":250,"token_start":29,"token_end":29,"label":"DRUG"},{"start":256,"end":266,"token_start":32,"token_end":32,"label":"DRUG"}],"_input_hash":782553464,"_task_hash":-1744775723,"_session_id":"drug_drug_pilot_shared-yakir","_view_id":"blocks","relations":[],"answer":"ignore"}
{"text":"We used MCF-7 and MDA-MB231 breast cancer cells incubated with Curcumin and Quercetin for 24h , in the absence and presence of Somatostatin , at their EC50 concentrations , to evaluate membrane fatty acid-based functional lipidomics together with the follow-up of EGFR and MAPK signaling pathways .","paragraph":"<h3><u>Effects of Somatostatin, Curcumin and Quercetin on the fatty acid profile of breast cancer cell membranes.</u></h3> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>MCF-7</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>MDA-MB231</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>incubated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>Curcumin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Quercetin</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>24h</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>absence</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>presence</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>Somatostatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>EC50</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>membrane</i></b> <b style='color:DodgerBlue;'><i>fatty</i></b> <b style='color:DodgerBlue;'><i>acid-based</i></b> <b style='color:DodgerBlue;'><i>functional</i></b> <b style='color:DodgerBlue;'><i>lipidomics</i></b> <b style='color:DodgerBlue;'><i>together</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>follow-up</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>EGFR</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>MAPK</i></b> <b style='color:DodgerBlue;'><i>signaling</i></b> <b style='color:DodgerBlue;'><i>pathways</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The two cell lines gave different membrane free fatty acid reorganization: in MCF-7 cells, the following changes observed: increase of omega-6 linoleic acid in the cells incubated with <b style='color:Tomato;'><i>somatostatin</i></b>+Quercetin and Quercetin and decrease of omega-3 acids in the cells incubated with <b style='color:Tomato;'><i>somatostatin</i></b>+<b style='color:Tomato;'><i>curcumin</i></b> compared to <b style='color:Tomato;'><i>somatostatin</i></b>, and significant increases of monounsaturated fatty acid (MUFA), mono-trans arachidonic acid levels and docosapentaenoic acid for the cells incubated with <b style='color:Tomato;'><i>somatostatin</i></b>+Quercetin compared to the control cells. In MDA-MB231 cells, incubations with <b style='color:Tomato;'><i>curcumin</i></b>, Quercetin and <b style='color:Tomato;'><i>somatostatin</i></b>+Quercetin induced the most significant membrane remodeling with the increase of stearic acid, diminution of omega-6 linoleic, arachidonic acids and omega-3 (docosapentaenoic and docosahexaenoic acids). Distinct signaling pathway changes were found for these cell lines. In MCF-7 cells, separate or combined incubations with <b style='color:Tomato;'><i>somatostatin</i></b> and Quercetin, significantly decreased EGFR and incubation with <b style='color:Tomato;'><i>curcumin</i></b> decreased MAPK signaling. In MDA-MB231 cells, incubation with <b style='color:Tomato;'><i>curcumin</i></b> decreased AKT1 and p-AKT1(Thr308) levels. Incubation with <b style='color:Tomato;'><i>curcumin</i></b> and Quercetin decreased the EGFR levels.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"used","start":3,"end":7,"id":1,"ws":true},{"text":"MCF-7","start":8,"end":13,"id":2,"ws":true},{"text":"and","start":14,"end":17,"id":3,"ws":true},{"text":"MDA-MB231","start":18,"end":27,"id":4,"ws":true},{"text":"breast","start":28,"end":34,"id":5,"ws":true},{"text":"cancer","start":35,"end":41,"id":6,"ws":true},{"text":"cells","start":42,"end":47,"id":7,"ws":true},{"text":"incubated","start":48,"end":57,"id":8,"ws":true},{"text":"with","start":58,"end":62,"id":9,"ws":true},{"text":"Curcumin","start":63,"end":71,"id":10,"ws":true},{"text":"and","start":72,"end":75,"id":11,"ws":true},{"text":"Quercetin","start":76,"end":85,"id":12,"ws":true},{"text":"for","start":86,"end":89,"id":13,"ws":true},{"text":"24h","start":90,"end":93,"id":14,"ws":true},{"text":",","start":94,"end":95,"id":15,"ws":true},{"text":"in","start":96,"end":98,"id":16,"ws":true},{"text":"the","start":99,"end":102,"id":17,"ws":true},{"text":"absence","start":103,"end":110,"id":18,"ws":true},{"text":"and","start":111,"end":114,"id":19,"ws":true},{"text":"presence","start":115,"end":123,"id":20,"ws":true},{"text":"of","start":124,"end":126,"id":21,"ws":true},{"text":"Somatostatin","start":127,"end":139,"id":22,"ws":true},{"text":",","start":140,"end":141,"id":23,"ws":true},{"text":"at","start":142,"end":144,"id":24,"ws":true},{"text":"their","start":145,"end":150,"id":25,"ws":true},{"text":"EC50","start":151,"end":155,"id":26,"ws":true},{"text":"concentrations","start":156,"end":170,"id":27,"ws":true},{"text":",","start":171,"end":172,"id":28,"ws":true},{"text":"to","start":173,"end":175,"id":29,"ws":true},{"text":"evaluate","start":176,"end":184,"id":30,"ws":true},{"text":"membrane","start":185,"end":193,"id":31,"ws":true},{"text":"fatty","start":194,"end":199,"id":32,"ws":true},{"text":"acid-based","start":200,"end":210,"id":33,"ws":true},{"text":"functional","start":211,"end":221,"id":34,"ws":true},{"text":"lipidomics","start":222,"end":232,"id":35,"ws":true},{"text":"together","start":233,"end":241,"id":36,"ws":true},{"text":"with","start":242,"end":246,"id":37,"ws":true},{"text":"the","start":247,"end":250,"id":38,"ws":true},{"text":"follow-up","start":251,"end":260,"id":39,"ws":true},{"text":"of","start":261,"end":263,"id":40,"ws":true},{"text":"EGFR","start":264,"end":268,"id":41,"ws":true},{"text":"and","start":269,"end":272,"id":42,"ws":true},{"text":"MAPK","start":273,"end":277,"id":43,"ws":true},{"text":"signaling","start":278,"end":287,"id":44,"ws":true},{"text":"pathways","start":288,"end":296,"id":45,"ws":true},{"text":".","start":297,"end":298,"id":46,"ws":false}],"spans":[{"start":63,"end":71,"token_start":10,"token_end":10,"label":"DRUG"},{"start":76,"end":85,"token_start":12,"token_end":12,"label":"DRUG"},{"start":127,"end":139,"token_start":22,"token_end":22,"label":"DRUG"}],"_input_hash":-1803484576,"_task_hash":288010961,"_session_id":"drug_drug_pilot_shared-yakir","_view_id":"blocks","relations":[{"head":22,"child":12,"head_span":{"start":127,"end":139,"token_start":22,"token_end":22,"label":"DRUG"},"child_span":{"start":76,"end":85,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#ffd882","label":"POS2"}],"radio":["POS21","POS2T0"],"answer":"accept"}
{"text":"Following corneal scrapings and culture , topical 0.5 % moxifloxacin and 0.5 % tobramycin were administered hourly .","paragraph":"<h3><u>A case of Stenotrophomonas maltophilia keratitis effectively treated with moxifloxacin.</u></h3>A 70-year-old man with a long history of diabetes mellitus presented to our hospital (Department of Ophthalmology, Sahm Yook Medical Center, Seoul, Korea) complaining of severe ocular pain and visual disturbance in his left eye that had started three days prior to admission. A round 3.7 \u00d7 5.0 mm dense central stromal infiltrate with an overlying epithelial defect was noted on slit-lamp examination. <b style='color:DodgerBlue;'><i>Following</i></b> <b style='color:DodgerBlue;'><i>corneal</i></b> <b style='color:DodgerBlue;'><i>scrapings</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>culture</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>topical</i></b> <b style='color:DodgerBlue;'><i>0.5</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:MediumOrchid;'><i>moxifloxacin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>0.5</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:MediumOrchid;'><i>tobramycin</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>hourly</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A few days later, Stenotrophomonas maltophilia was isolated in a bacterial culture from a corneal specimen. According to the results of susceptibility tests, topical 0.5% <b style='color:Tomato;'><i>moxifloxacin</i></b> was given every hour and 0.5% <b style='color:Tomato;'><i>tobramycin</i></b> was stopped. The patient's clinical features improved steadily with treatment. The corneal epithelium healed rapidly, and the infiltrate resolved within four weeks of the initiation of treatment. The patient's best corrected visual acuity improved from hand motion to 20 / 25.","tokens":[{"text":"Following","start":0,"end":9,"id":0,"ws":true},{"text":"corneal","start":10,"end":17,"id":1,"ws":true},{"text":"scrapings","start":18,"end":27,"id":2,"ws":true},{"text":"and","start":28,"end":31,"id":3,"ws":true},{"text":"culture","start":32,"end":39,"id":4,"ws":true},{"text":",","start":40,"end":41,"id":5,"ws":true},{"text":"topical","start":42,"end":49,"id":6,"ws":true},{"text":"0.5","start":50,"end":53,"id":7,"ws":true},{"text":"%","start":54,"end":55,"id":8,"ws":true},{"text":"moxifloxacin","start":56,"end":68,"id":9,"ws":true},{"text":"and","start":69,"end":72,"id":10,"ws":true},{"text":"0.5","start":73,"end":76,"id":11,"ws":true},{"text":"%","start":77,"end":78,"id":12,"ws":true},{"text":"tobramycin","start":79,"end":89,"id":13,"ws":true},{"text":"were","start":90,"end":94,"id":14,"ws":true},{"text":"administered","start":95,"end":107,"id":15,"ws":true},{"text":"hourly","start":108,"end":114,"id":16,"ws":true},{"text":".","start":115,"end":116,"id":17,"ws":false}],"spans":[{"start":56,"end":68,"token_start":9,"token_end":9,"label":"DRUG"},{"start":79,"end":89,"token_start":13,"token_end":13,"label":"DRUG"}],"_input_hash":1332991430,"_task_hash":1426603318,"_session_id":"drug_drug_pilot_shared-yakir","_view_id":"blocks","relations":[{"head":9,"child":13,"head_span":{"start":56,"end":68,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":79,"end":89,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T1"],"answer":"accept"}
{"text":"Combination treatment with cetuximab and nystatin selectively increased cetuximab uptake by tumor tissues , translating into potentiated antitumor efficacy of cetuximab in vivo ( A431 and A549 tumors ) .","paragraph":"<h3><u>Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration.</u></h3><b style='color:Tomato;'><i>cetuximab</i></b>, a monoclonal antibody (mAb) targeting the epidermal growth factor receptor (EGFR), has been intensively investigated as a promising cancer treatment strategy. The specific mechanism of <b style='color:Tomato;'><i>cetuximab</i></b> endocytosis and its influence on <b style='color:Tomato;'><i>cetuximab</i></b> uptake, biodistribution and efficacy still remain elusive. Recently, statins have been reported to synergize with EGFR-targeting agents. Our prior work established that <b style='color:Tomato;'><i>nystatin</i></b>, a cholesterol-sequestering antifungal drug, facilitates endocytosis via the clathrin-dependent pathway. This study aimed to investigate whether <b style='color:Tomato;'><i>nystatin</i></b> regulates the uptake and efficacy of <b style='color:Tomato;'><i>cetuximab</i></b> and <b style='color:Tomato;'><i>cetuximab</i></b>-based antibody-drug conjugates (<b style='color:Tomato;'><i>cetuximab</i></b>-ADCs). In vitro and in vivo efficacies of <b style='color:Tomato;'><i>nystatin</i></b> on the uptake and activity of <b style='color:Tomato;'><i>cetuximab</i></b>/<b style='color:Tomato;'><i>cetuximab</i></b>-ADCs were studied in multiple human carcinoma cell lines and xenograft models, respectively. We identified that cholesterol sequestration by <b style='color:Tomato;'><i>nystatin</i></b> enhanced <b style='color:Tomato;'><i>cetuximab</i></b> internalization in EGFR-positive carcinoma cells by regulating EGFR trafficking/turnover and facilitating a switch from lipid rafts to clathrin-mediated endocytosis. <b style='color:DodgerBlue;'><i>Combination</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>nystatin</i></b> <b style='color:DodgerBlue;'><i>selectively</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>uptake</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>tumor</i></b> <b style='color:DodgerBlue;'><i>tissues</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>translating</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>potentiated</i></b> <b style='color:DodgerBlue;'><i>antitumor</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vivo</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>A431</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>A549</i></b> <b style='color:DodgerBlue;'><i>tumors</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>nystatin</i></b>-enhanced internalization of <b style='color:Tomato;'><i>cetuximab</i></b> further improved the uptake and potency of <b style='color:Tomato;'><i>cetuximab</i></b>-<b style='color:Tomato;'><i>doxorubicin</i></b> and <b style='color:Tomato;'><i>cetuximab</i></b>-<b style='color:Tomato;'><i>methotrexate</i></b> conjugates in EGFR-positive <b style='color:Tomato;'><i>cetuximab</i></b>-resistant tumors. Combination therapy with <b style='color:Tomato;'><i>nystatin</i></b> plus either <b style='color:Tomato;'><i>cetuximab</i></b> or <b style='color:Tomato;'><i>cetuximab</i></b>-ADC further prolonged animal survival and significantly suppressed tumor growth, as compared with single-agent <b style='color:Tomato;'><i>cetuximab</i></b> or <b style='color:Tomato;'><i>cetuximab</i></b>-ADC. In summary, our results identify a novel mechanism whereby cholesterol sequestration enhances the uptake of EGFR-targeting mAb and ADCs, therefore providing preclinical proof-of-concept that combination with <b style='color:Tomato;'><i>nystatin</i></b> can potentiate the delivery and efficacy of these EGFR-targeted agents. ","tokens":[{"text":"Combination","start":0,"end":11,"id":0,"ws":true},{"text":"treatment","start":12,"end":21,"id":1,"ws":true},{"text":"with","start":22,"end":26,"id":2,"ws":true},{"text":"cetuximab","start":27,"end":36,"id":3,"ws":true},{"text":"and","start":37,"end":40,"id":4,"ws":true},{"text":"nystatin","start":41,"end":49,"id":5,"ws":true},{"text":"selectively","start":50,"end":61,"id":6,"ws":true},{"text":"increased","start":62,"end":71,"id":7,"ws":true},{"text":"cetuximab","start":72,"end":81,"id":8,"ws":true},{"text":"uptake","start":82,"end":88,"id":9,"ws":true},{"text":"by","start":89,"end":91,"id":10,"ws":true},{"text":"tumor","start":92,"end":97,"id":11,"ws":true},{"text":"tissues","start":98,"end":105,"id":12,"ws":true},{"text":",","start":106,"end":107,"id":13,"ws":true},{"text":"translating","start":108,"end":119,"id":14,"ws":true},{"text":"into","start":120,"end":124,"id":15,"ws":true},{"text":"potentiated","start":125,"end":136,"id":16,"ws":true},{"text":"antitumor","start":137,"end":146,"id":17,"ws":true},{"text":"efficacy","start":147,"end":155,"id":18,"ws":true},{"text":"of","start":156,"end":158,"id":19,"ws":true},{"text":"cetuximab","start":159,"end":168,"id":20,"ws":true},{"text":"in","start":169,"end":171,"id":21,"ws":true},{"text":"vivo","start":172,"end":176,"id":22,"ws":true},{"text":"(","start":177,"end":178,"id":23,"ws":true},{"text":"A431","start":179,"end":183,"id":24,"ws":true},{"text":"and","start":184,"end":187,"id":25,"ws":true},{"text":"A549","start":188,"end":192,"id":26,"ws":true},{"text":"tumors","start":193,"end":199,"id":27,"ws":true},{"text":")","start":200,"end":201,"id":28,"ws":true},{"text":".","start":202,"end":203,"id":29,"ws":false}],"spans":[{"start":27,"end":36,"token_start":3,"token_end":3,"label":"DRUG"},{"start":41,"end":49,"token_start":5,"token_end":5,"label":"DRUG"},{"start":72,"end":81,"token_start":8,"token_end":8,"label":"DRUG"},{"start":159,"end":168,"token_start":20,"token_end":20,"label":"DRUG"}],"_input_hash":-1277491604,"_task_hash":-1965461189,"_session_id":"drug_drug_pilot_shared-yakir","_view_id":"blocks","relations":[{"head":3,"child":5,"head_span":{"start":27,"end":36,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":41,"end":49,"token_start":5,"token_end":5,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T0"],"answer":"accept"}
{"text":"The effects of combination therapy with chenodeoxycholic acid ( CDCA ) and simvastatin on serum cholestanol , low-density lipoprotein ( LDL ) cholesterol , and lathosterol levels were investigated in seven adult patients with cerebrotendinous xanthomatosis ( CTX ) who were on long-term treatment with CDCA .","paragraph":"<h3><u>Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>chenodeoxycholic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CDCA</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>simvastatin</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>serum</i></b> <b style='color:DodgerBlue;'><i>cholestanol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>low-density</i></b> <b style='color:DodgerBlue;'><i>lipoprotein</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>LDL</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>cholesterol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>lathosterol</i></b> <b style='color:DodgerBlue;'><i>levels</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>investigated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>seven</i></b> <b style='color:DodgerBlue;'><i>adult</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>cerebrotendinous</i></b> <b style='color:DodgerBlue;'><i>xanthomatosis</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CTX</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>long-term</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>CDCA</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The patients were treated with a combination of CDCA 750 mg daily and an increasing dose of <b style='color:Tomato;'><i>simvastatin</i></b> from 10 mg to 40 mg daily for a period of 6 months. We found a significant effect of this combination therapy compared with CDCA alone in terms of decreasing the serum cholestanol and LDL cholesterol levels, particularly with a daily dose of 40 mg <b style='color:Tomato;'><i>simvastatin</i></b>. The mean cholestanol level decreased from 9.27 micromol/L (baseline) to 6.69 micromol/L (40 mg <b style='color:Tomato;'><i>simvastatin</i></b>), while the mean LDL cholesterol level decreased from 5.08 mmol/L (baseline) to 3.04 mmol/L (40 mg <b style='color:Tomato;'><i>simvastatin</i></b>). No side effects were reported, and there were no effects on the clinical condition, cerebral magnetic resonance imaging (MRI), visual evoked potentials, and electroencephalographic features. We conclude that a combination of 750 mg CDCA and 40 mg <b style='color:Tomato;'><i>simvastatin</i></b> daily is effective to further reduce serum cholestanol, LDL cholesterol, and lathosterol in adult CTX patients treated with long-term CDCA. Whether this combination treatment will be effective for the long-term prevention of neurological deterioration and atherosclerosis remains to be established.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"effects","start":4,"end":11,"id":1,"ws":true},{"text":"of","start":12,"end":14,"id":2,"ws":true},{"text":"combination","start":15,"end":26,"id":3,"ws":true},{"text":"therapy","start":27,"end":34,"id":4,"ws":true},{"text":"with","start":35,"end":39,"id":5,"ws":true},{"text":"chenodeoxycholic","start":40,"end":56,"id":6,"ws":true},{"text":"acid","start":57,"end":61,"id":7,"ws":true},{"text":"(","start":62,"end":63,"id":8,"ws":true},{"text":"CDCA","start":64,"end":68,"id":9,"ws":true},{"text":")","start":69,"end":70,"id":10,"ws":true},{"text":"and","start":71,"end":74,"id":11,"ws":true},{"text":"simvastatin","start":75,"end":86,"id":12,"ws":true},{"text":"on","start":87,"end":89,"id":13,"ws":true},{"text":"serum","start":90,"end":95,"id":14,"ws":true},{"text":"cholestanol","start":96,"end":107,"id":15,"ws":true},{"text":",","start":108,"end":109,"id":16,"ws":true},{"text":"low-density","start":110,"end":121,"id":17,"ws":true},{"text":"lipoprotein","start":122,"end":133,"id":18,"ws":true},{"text":"(","start":134,"end":135,"id":19,"ws":true},{"text":"LDL","start":136,"end":139,"id":20,"ws":true},{"text":")","start":140,"end":141,"id":21,"ws":true},{"text":"cholesterol","start":142,"end":153,"id":22,"ws":true},{"text":",","start":154,"end":155,"id":23,"ws":true},{"text":"and","start":156,"end":159,"id":24,"ws":true},{"text":"lathosterol","start":160,"end":171,"id":25,"ws":true},{"text":"levels","start":172,"end":178,"id":26,"ws":true},{"text":"were","start":179,"end":183,"id":27,"ws":true},{"text":"investigated","start":184,"end":196,"id":28,"ws":true},{"text":"in","start":197,"end":199,"id":29,"ws":true},{"text":"seven","start":200,"end":205,"id":30,"ws":true},{"text":"adult","start":206,"end":211,"id":31,"ws":true},{"text":"patients","start":212,"end":220,"id":32,"ws":true},{"text":"with","start":221,"end":225,"id":33,"ws":true},{"text":"cerebrotendinous","start":226,"end":242,"id":34,"ws":true},{"text":"xanthomatosis","start":243,"end":256,"id":35,"ws":true},{"text":"(","start":257,"end":258,"id":36,"ws":true},{"text":"CTX","start":259,"end":262,"id":37,"ws":true},{"text":")","start":263,"end":264,"id":38,"ws":true},{"text":"who","start":265,"end":268,"id":39,"ws":true},{"text":"were","start":269,"end":273,"id":40,"ws":true},{"text":"on","start":274,"end":276,"id":41,"ws":true},{"text":"long-term","start":277,"end":286,"id":42,"ws":true},{"text":"treatment","start":287,"end":296,"id":43,"ws":true},{"text":"with","start":297,"end":301,"id":44,"ws":true},{"text":"CDCA","start":302,"end":306,"id":45,"ws":true},{"text":".","start":307,"end":308,"id":46,"ws":false}],"spans":[{"start":40,"end":56,"token_start":6,"token_end":6,"label":"DRUG"},{"start":75,"end":86,"token_start":12,"token_end":12,"label":"DRUG"}],"_input_hash":-475065306,"_task_hash":-2052397739,"_session_id":"drug_drug_pilot_shared-yakir","_view_id":"blocks","relations":[{"head":6,"child":12,"head_span":{"start":40,"end":56,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":75,"end":86,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T0"],"answer":"accept"}
{"text":"Paclitaxel ( Taxol ; Bristol-Myers Squibb Company , Princeton , NJ ) has been demonstrated to be highly effective in treating patients with advanced breast cancer , including those with anthracycline-resistant breast cancer , a fact that has led to efforts to combine paclitaxel and anthracyclines .","paragraph":"<h3><u>Paclitaxel and doxorubicin in metastatic breast cancer.</u></h3>For the past decades the anthracyclines have been regarded as among the most active drugs for the treatment of metastatic breast cancer. However, the 5-year survival rate in patients with stage IV breast cancer continues to be below 20%, and new active drugs and drug combinations clearly must be explored. <b style='color:MediumOrchid;'><i>Paclitaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Taxol</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>Bristol-Myers</i></b> <b style='color:DodgerBlue;'><i>Squibb</i></b> <b style='color:DodgerBlue;'><i>Company</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Princeton</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>NJ</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>highly</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>treating</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>anthracycline-resistant</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>fact</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>led</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>efforts</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>combine</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>anthracyclines</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Several studies aiming to define the optimal dose and schedule of combination <b style='color:Tomato;'><i>paclitaxel</i></b>/<b style='color:Tomato;'><i>doxorubicin</i></b> have now been completed or are ongoing. Phase I/II studies have yielded encouraging preliminary response rates but quite variable toxicity profiles depending on the schedule used. These clinical trials involving combination <b style='color:Tomato;'><i>paclitaxel</i></b>/<b style='color:Tomato;'><i>doxorubicin</i></b> are reviewed, with special emphasis on the short-infusion trials.","tokens":[{"text":"Paclitaxel","start":0,"end":10,"id":0,"ws":true},{"text":"(","start":11,"end":12,"id":1,"ws":true},{"text":"Taxol","start":13,"end":18,"id":2,"ws":true},{"text":";","start":19,"end":20,"id":3,"ws":true},{"text":"Bristol-Myers","start":21,"end":34,"id":4,"ws":true},{"text":"Squibb","start":35,"end":41,"id":5,"ws":true},{"text":"Company","start":42,"end":49,"id":6,"ws":true},{"text":",","start":50,"end":51,"id":7,"ws":true},{"text":"Princeton","start":52,"end":61,"id":8,"ws":true},{"text":",","start":62,"end":63,"id":9,"ws":true},{"text":"NJ","start":64,"end":66,"id":10,"ws":true},{"text":")","start":67,"end":68,"id":11,"ws":true},{"text":"has","start":69,"end":72,"id":12,"ws":true},{"text":"been","start":73,"end":77,"id":13,"ws":true},{"text":"demonstrated","start":78,"end":90,"id":14,"ws":true},{"text":"to","start":91,"end":93,"id":15,"ws":true},{"text":"be","start":94,"end":96,"id":16,"ws":true},{"text":"highly","start":97,"end":103,"id":17,"ws":true},{"text":"effective","start":104,"end":113,"id":18,"ws":true},{"text":"in","start":114,"end":116,"id":19,"ws":true},{"text":"treating","start":117,"end":125,"id":20,"ws":true},{"text":"patients","start":126,"end":134,"id":21,"ws":true},{"text":"with","start":135,"end":139,"id":22,"ws":true},{"text":"advanced","start":140,"end":148,"id":23,"ws":true},{"text":"breast","start":149,"end":155,"id":24,"ws":true},{"text":"cancer","start":156,"end":162,"id":25,"ws":true},{"text":",","start":163,"end":164,"id":26,"ws":true},{"text":"including","start":165,"end":174,"id":27,"ws":true},{"text":"those","start":175,"end":180,"id":28,"ws":true},{"text":"with","start":181,"end":185,"id":29,"ws":true},{"text":"anthracycline-resistant","start":186,"end":209,"id":30,"ws":true},{"text":"breast","start":210,"end":216,"id":31,"ws":true},{"text":"cancer","start":217,"end":223,"id":32,"ws":true},{"text":",","start":224,"end":225,"id":33,"ws":true},{"text":"a","start":226,"end":227,"id":34,"ws":true},{"text":"fact","start":228,"end":232,"id":35,"ws":true},{"text":"that","start":233,"end":237,"id":36,"ws":true},{"text":"has","start":238,"end":241,"id":37,"ws":true},{"text":"led","start":242,"end":245,"id":38,"ws":true},{"text":"to","start":246,"end":248,"id":39,"ws":true},{"text":"efforts","start":249,"end":256,"id":40,"ws":true},{"text":"to","start":257,"end":259,"id":41,"ws":true},{"text":"combine","start":260,"end":267,"id":42,"ws":true},{"text":"paclitaxel","start":268,"end":278,"id":43,"ws":true},{"text":"and","start":279,"end":282,"id":44,"ws":true},{"text":"anthracyclines","start":283,"end":297,"id":45,"ws":true},{"text":".","start":298,"end":299,"id":46,"ws":false}],"spans":[{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},{"start":268,"end":278,"token_start":43,"token_end":43,"label":"DRUG"}],"_input_hash":702583470,"_task_hash":1770101995,"_session_id":"drug_drug_pilot_shared-yakir","_view_id":"blocks","relations":[],"answer":"ignore"}
